The phosphatidylinositol 3-Kinaseâ€“AKT pathway in h

Nature Reviews Cancer

2, 489-501

DOI: 10.1038/nrc839

Citation Report

#	Article	IF	Citations
2	Molecular targets for epithelial ovarian cancer. , 0, , 606-618.		0
3	Mutation of PIK3CA: Possible risk factor for cervical carcinogenesis in older women. International Journal of Oncology, 1992, 34, 409.	1.4	20
4	Inhibition of Stearoyl-CoA Desaturase 1 expression in human lung adenocarcinoma cells impairs tumorigenesis. International Journal of Oncology, 1992, 33, 839.	1.4	43
5	Beyond Directed Therapeutics: Are Two Drugs Always Better than One?. Cancer Biology and Therapy, 2002, 1, 683-684.	1.5	0
6	Conversion of Drug-Induced Differentiation to Apoptosis by Pharmacologic Cyclin-Dependent Kinase Inhibitors. Cell Cycle, 2002, 1, 383-388.	1.3	15
7	TRAIL-DISC Formation Is Androgen-Dependent in the Human Prostatic Carcinoma Cell Line LNCaP. Cancer Biology and Therapy, 2002, 1, 631-637.	1.5	20
8	Role of Immunohistochemical Expression of AKT Protein in Breast Carcinoma. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, 2002, , 307-319.	0.0	0
9	G Proteinâ€“Coupled Receptors Provide Survival Signals in Prostate Cancer. Clinical Prostate Cancer, 2002, 1, 177-181.	2.1	16
10	Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resistance Updates, 2002, 5, 234-248.	6.5	506
11	Polyoma virus middle T antigen and its role in identifying cancer-related molecules. Nature Reviews Cancer, 2002, 2, 951-956.	12.8	106
12	Flt3 in Acute Myelogenous Leukemia: Biology, Prognosis, and Therapeutic Implications. Medical Oncology, 2003, 20, 311-324.	1.2	6
13	Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways. Journal of Mammary Gland Biology and Neoplasia, 2003, 8, 45-73.	1.0	62
14	The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Molecular and Cellular Biochemistry, 2003, 253, 89-101.	1.4	103
15	Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: Evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology, 2003, 38, 756-768.	3.6	236
16	Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clinical and Experimental Metastasis, 2003, 20, 265-273.	1.7	201
17	RNAi and 2DE, a promising combination for analysis of phospho-signalling and substrate identification. International Journal of Peptide Research and Therapeutics, 2003, 10, 437-445.	0.1	0
18	Fenofibrate inhibits angiogenesis in vitro and in vivo. Cellular and Molecular Life Sciences, 2003, 60, 810-819.	2.4	91
19	Gene therapeutic approaches for medullary thyroid carcinoma treatment. Journal of Molecular Medicine, 2003, 81, 411-419.	1.7	18

#	Article	IF	Citations
20	Inhibition der Signaltransduktion als therapeutisches Prinzip. Onkologe, 2003, 9, 1088-1101.	0.7	0
21	Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell, 2003, 3, 483-495.	7.7	262
22	Mutations and aneuploidy. Cancer Cell, 2003, 4, 89-94.	7.7	94
23	Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell, 2003, 4, 209-221.	7.7	982
24	Targeting the PI3K-Akt pathway in human cancer. Cancer Cell, 2003, 4, 257-262.	7.7	1,230
25	Will mTOR inhibitors make it as cancer drugs?. Cancer Cell, 2003, 4, 343-348.	7.7	184
26	Relevance of Akt phosphorylation in cell transformation induced by Jaagsiekte sheep retrovirus. Virology, 2003, 312, 95-105.	1.1	53
27	Overcoming resistance of cancer cells to apoptosis. Journal of Cellular Physiology, 2003, 196, 9-18.	2.0	112
28	Epstein-Barr virus: Induction and control of cell transformation. Journal of Cellular Physiology, 2003, 196, 207-218.	2.0	69
29	Roles of theNkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Developmental Dynamics, 2003, 228, 767-778.	0.8	92
30	Lipid Metabolism and Signaling in Zebrafish. , 0, , 203-221.		0
32	Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics, 2003, 3, 2085-2090.	1.3	226
33	Induction of hepatocyte proliferation and death by modulation of T-Antigen expression. Oncogene, 2003, 22, 2515-2530.	2.6	8
34	Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene, 2003, 22, 2812-2822.	2.6	449
35	Role of NF-Î²B and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene, 2003, 22, 3243-3251.	2.6	467
36	Inhibitor of apoptosis protein (IAP) survivin is upregulated by oncogenic c-H-Ras. Oncogene, 2003, 22, 4266-4280.	2.6	92
37	Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway. Oncogene, 2003, 22, 6289-6295.	2.6	50
38	Reciprocal regulation of MelCAM and AKT in human melanoma. Oncogene, 2003, 22, 6891-6899.	2.6	82

#	Article	IF	Citations
39	Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene, 2003, 22, 7414-7430.	2.6	253
40	Control of apoptosis by p53. Oncogene, 2003, 22, 9030-9040.	2.6	1,256
41	Microtubule-targeted anticancer agents and apoptosis. Oncogene, 2003, 22, 9075-9086.	2.6	420
42	Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nature Cell Biology, 2003, 5, 87-90.	4.6	585
43	Senescence, apoptosis and therapy â€" cutting the lifelines of cancer. Nature Reviews Cancer, 2003, 3, 286-295.	12.8	276
45	Cannabinoids: potential anticancer agents. Nature Reviews Cancer, 2003, 3, 745-755.	12.8	616
46	Issues and progress with protein kinase inhibitors for cancer treatment. Nature Reviews Drug Discovery, 2003, 2, 296-313.	21.5	471
47	4-Hydroxy-3-Methoxybenzoic Acid Methyl Ester: A Curcumin Derivative Targets Akt/NFÎºB Cell Survival Signaling Pathway: Potential for Prostate Cancer Management. Neoplasia, 2003, 5, 255-266.	2.3	75
48	Biology of common Î² receptorâ€"signaling cytokines IL-3, IL-5, and GM-CSF. Journal of Allergy and Clinical Immunology, 2003, 112, 653-665.	1.5	227
49	Modification of Radiation Response. Medical Radiology, 2003, , .	0.0	7
50	Novel PI Analogues Selectively Block Activation of the Pro-survival Serine/Threonine Kinase Akt. Journal of the American Chemical Society, 2003, 125, 1144-1145.	6.6	206
51	Use of Capillary Electrophoresis and Endogenous Fluorescent Substrate To Monitor Intracellular Activation of Protein Kinase A. Analytical Chemistry, 2003, 75, 3720-3724.	3.2	43
52	Integration of Growth Factor and Nutrient Signaling. Molecular Cell, 2003, 12, 271-280.	4.5	186
53	Multiple Roles of the PI3K/PKB (Akt) Pathway in Cell Cycle Progression. Cell Cycle, 2003, 2, 336-342.	1.3	722
54	Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer. Journal of Clinical Oncology, 2003, 21, 2787-2799.	0.8	1,195
55	RNAi and 2DE, a promising combination for analysis of phospho-signalling and substrate identification. International Journal of Peptide Research and Therapeutics, 2003, 10, 437-445.	0.9	0
56	Phosphoinositide signaling disorders in human diseases. FEBS Letters, 2003, 546, 25-31.	1.3	161
57	Pathological and molecular aspects of prostate cancer. Lancet, The, 2003, 361, 955-964.	6.3	421

#	Article	IF	Citations
58	Regulation of endothelial cell differentiation and transformation by H-Ras. Experimental Cell Research, 2003, 291, 189-200.	1.2	7
59	Systemic and primary cutaneous anaplastic large cell lymphomas. Seminars in Hematology, 2003, 40, 244-256.	1.8	82
60	AngII induces transient phospholipase D activity in the H295R glomerulosa cell model. Molecular and Cellular Endocrinology, 2003, 206, 113-122.	1.6	25
61	Cell-cycle dysregulation and anticancer therapy. Trends in Pharmacological Sciences, 2003, 24, 139-145.	4.0	294
62	Phosphoinositide 3-kinase signalling â€“ which way to target?. Trends in Pharmacological Sciences, 2003, 24, 366-376.	4.0	374
63	Prostate Cancer. New England Journal of Medicine, 2003, 349, 366-381.	13.9	970
64	Drug resistance reversalâ€”are we getting closer?. European Journal of Cancer, 2003, 39, 2450-2461.	1.3	127
65	Recent advances in understanding apoptosis: new therapeutic opportunities in cancer chemotherapy. Trends in Molecular Medicine, 2003, 9, 251-255.	3.5	33
66	Molecular mechanisms modulating muscle mass. Trends in Molecular Medicine, 2003, 9, 344-350.	3.5	342
67	The anti-apoptotic role of PPARÎ² contributes to efficient skin wound healing. Journal of Steroid Biochemistry and Molecular Biology, 2003, 85, 257-265.	1.2	66
68	Protein Kinase B/Akt Binds and Phosphorylates PED/PEA-15, Stabilizing Its Antiapoptotic Action. Molecular and Cellular Biology, 2003, 23, 4511-4521.	1.1	128
69	Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. British Journal of Cancer, 2003, 89, 2110-2115.	2.9	233
70	Akt2: a role in breast cancer metastasis. Breast Cancer Research, 2003, 6, 55-7.	2.2	35
71	Transformation of Mouse Fibroblasts by Jaagsiekte Sheep Retrovirus Envelope Does Not Require Phosphatidylinositol 3-Kinase. Journal of Virology, 2003, 77, 9951-9959.	1.5	39
72	Nuclear Magnetic Resonance Structure of the P395S Mutant of the N-SH2 Domain of the p85 Subunit of PI3 Kinase:Â An SH2 Domain with Altered Specificityâ€. Biochemistry, 2003, 42, 11120-11127.	1.2	5
73	Insulin-like Growth Factor-I Inhibits Transcriptional Responses of Transforming Growth Factor-Î² by Phosphatidylinositol 3-Kinase/Akt-dependent Suppression of the Activation of Smad3 but Not Smad2. Journal of Biological Chemistry, 2003, 278, 38342-38351.	1.6	91
74	Androgen-stimulated DNA synthesis and cytoskeletal changes in fibroblasts by a nontranscriptional receptor action. Journal of Cell Biology, 2003, 161, 547-556.	2.3	128
75	Caveolin-1 Maintains Activated Akt in Prostate CancerCells through Scaffolding Domain Binding Site Interactions with andInhibition of Serine/Threonine Protein Phosphatases PP1 andPP2A. Molecular and Cellular Biology, 2003, 23, 9389-9404.	1.1	270

#	Article	IF	Citations
76	A role for LIM kinase in cancer invasion. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 7247-7252.	3.3	188
77	Epstein-Barr Virus Latent Membrane Protein 1 (LMP1) Activates the Phosphatidylinositol 3-Kinase/Akt Pathway to Promote Cell Survival and Induce Actin Filament Remodeling. Journal of Biological Chemistry, 2003, 278, 3694-3704.	1.6	250
78	Immune Evasion by Murine Melanoma Mediated through CC Chemokine Receptor-10. Journal of Experimental Medicine, 2003, 198, 1337-1347.	4.2	148
79	AKT and the Phosphatidylinositol 3-Kinase/AKT Pathway: Important Molecular Targets for Lung Cancer Prevention and Treatment. Journal of the National Cancer Institute, 2003, 95, 252-253.	3.0	28
80	Molecular Analysis of Glioblastoma: Pathway Profiling and Its Implications for Patient Therapy. Cancer Biology and Therapy, 2003, 2, 242-247.	1.5	57
81	Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis. Journal of Cell Science, 2003, 116, 4409-4417.	1.2	153
82	Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes and Development, 2003, 17, 2998-3010.	2.7	149
83	Akt as a mediator of cell death. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 11712-11717.	3.3	232
84	Negative Regulation of Mixed Lineage Kinase 3 by Protein Kinase B/AKT Leads to Cell Survival. Journal of Biological Chemistry, 2003, 278, 3897-3902.	1.6	123
85	Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. FASEB Journal, 2003, 17, 1162-1164.	0.2	72
86	Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma. Carcinogenesis, 2003, 25, 241-248.	1.3	100
87	Stent Implantation Activates Akt in the Vessel Wall. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 2015-2020.	1.1	52
88	Differing Roles of Akt and Serum- and Glucocorticoid-regulated Kinase in Glucose Metabolism, DNA Synthesis, and Oncogenic Activity. Journal of Biological Chemistry, 2003, 278, 25802-25807.	1.6	108
89	Src Family Protein-tyrosine Kinases Alter the Function of PTEN to Regulate Phosphatidylinositol 3-Kinase/AKT Cascades. Journal of Biological Chemistry, 2003, 278, 40057-40066.	1.6	218
90	Identification of Target Genes of the p16INK4A-pRB-E2F Pathway. Journal of Biological Chemistry, 2003, 278, 46124-46137.	1.6	107
91	Activation of the p70 S6 Kinase and Phosphorylation of the 4E-BP1 Repressor of mRNA Translation by Type I Interferons. Journal of Biological Chemistry, 2003, 278, 27772-27780.	1.6	114
92	Zinc-induced PTEN Protein Degradation through the Proteasome Pathway in Human Airway Epithelial Cells. Journal of Biological Chemistry, 2003, 278, 28258-28263.	1.6	139
93	Hyaluronan-mediated CD44 Interaction with RhoGEF and Rho Kinase Promotes Grb2-associated Binder-1 Phosphorylation and Phosphatidylinositol 3-Kinase Signaling Leading to Cytokine (Macrophage-Colony) Tj ETQq1 1 0.784314 rgBT /Ov 278, 29420-29434.	1.6	212

#	Article	IF	Citations
94	Hsp90 Inhibition Depletes Chk1 and Sensitizes Tumor Cells to Replication Stress. Journal of Biological Chemistry, 2003, 278, 52572-52577.	1.6	155
95	Î”Np63Î± Expression Is Regulated by the Phosphoinositide 3-Kinase Pathway. Journal of Biological Chemistry, 2003, 278, 51408-51414.	1.6	69
96	The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity. Journal of Molecular Endocrinology, 2003, 31, 169-183.	1.1	61
97	Akt activation disrupts mammary acinar architecture and enhances proliferation in an mTOR-dependent manner. Journal of Cell Biology, 2003, 163, 315-326.	2.3	141
98	Pten Dose Dictates Cancer Progression in the Prostate. PLoS Biology, 2003, 1, e59.	2.6	593
99	Recent Advances with Molecular Target Agents in Cancer: Opportunities for Imaging. Cancer Biology and Therapy, 2003, 2, 599-607.	1.5	14
100	The role of functional and molecular imaging in cancer drug discovery and development. British Journal of Radiology, 2003, 76, S128-S138.	1.0	58
101	Development of Radicicol Analogues. Current Cancer Drug Targets, 2003, 3, 359-369.	0.8	128
102	The Role of the IGF-I Receptor in the Regulation of Matrix Metalloproteinases, Tumor Invasion and Metastasis. Hormone and Metabolic Research, 2003, 35, 802-808.	0.7	79
103	Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change. Biochemical Journal, 2003, 375, 531-538.	1.7	243
104	Conditional loss of PTEN leads to testicular teratoma and enhances embryonic germ cell production. Development (Cambridge), 2003, 130, 1691-1700.	1.2	218
105	Role of the Steroid Receptor Coactivator SRC-3 in Cell Growth. Molecular and Cellular Biology, 2003, 23, 7742-7755.	1.1	121
106	Src Family Kinases: Potential Targets for the Treatment of Human Cancer and Leukemia. Current Pharmaceutical Design, 2003, 9, 2043-2059.	0.9	113
107	Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. Blood, 2003, 101, 3436-3443.	0.6	160
108	Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways. Blood, 2003, 102, 1824-1832.	0.6	87
109	Adapter protein with a pleckstrin homology (PH) and an Src homology 2 (SH2) domain (APS) and SH2-B enhance insulin-receptor autophosphorylation, extracellular-signal-regulated kinase and phosphoinositide 3-kinase-dependent signalling. Biochemical Journal, 2003, 371, 405-412.	1.7	58
110	Tuberous sclerosis complex (TSC) gene involvement in sporadic tumours. Biochemical Society Transactions, 2003, 31, 597-602.	1.6	39
111	Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood, 2003, 102, 972-980.	0.6	432

#	Article	IF	Citations
114	Role of PI3K/Akt Pathway in the Activation of IÎºB/NF-Î¹B Pathway in Lung Epithelial Cells. Tuberculosis and Respiratory Diseases, 2003, 54, 551.	0.2	3
115	Apoptotic Pathways in Cancer Progression and Treatment. , 0, , 143-170.		1
116	Focal adhesion kinase signaling activities and their implications in the control of cell survival and motility. Frontiers in Bioscience - Landmark, 2003, 8, d982-996.	3.0	318
117	Tumor Cell Hypoxia and the Hypoxia-Response Signaling System as a Target for Prostate Cancer Therapy. Current Drug Targets, 2003, 4, 191-196.	1.0	14
118	Analysis of apoptotic cells using Beadlyte^{Â®} suspension arrays. BioTechniques, 2003, 35, 624-629.	0.8	7
119	Phosphoinositide 3-Kinase Signalling Pathways in Tumor Progression, Invasion and Angiogenesis. Tumori, 2004, 90, 2-8.	0.6	185
123	Indole-3-Carbinol and Prostate Cancer. Journal of Nutrition, 2004, 134, 3493S-3498S.	1.3	121
124	Angiogenesis and its role in the behavior of astrocytic brain tumors. Frontiers in Bioscience - Landmark, 2004, 9, 3105.	3.0	25
125	Prostaglandin E2 reduces radiation-induced epithelial apoptosis through a mechanism involving AKT activation and bax translocation. Journal of Clinical Investigation, 2004, 114, 1676-1685.	3.9	140
126	Nerve Growth Factor Restores p53 Function in Pituitary Tumor Cell Lines via trkA-Mediated Activation of Phosphatidylinositol 3-Kinase. Molecular Endocrinology, 2004, 18, 162-172.	3.7	18
127	Regulation of Sensitivity to TRAIL by the PTEN Tumor Suppressor. Vitamins and Hormones, 2004, 67, 409-426.	0.7	37
128	Activation of Ras-Ral Pathway Attenuates p53-independent DNA Damage G2 Checkpoint. Journal of Biological Chemistry, 2004, 279, 36382-36389.	1.6	16
129	Early Involvement of the Phosphatidylinositol 3-Kinase/Akt Pathway in Lung Cancer Progression. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 1088-1094.	2.5	128
130	Saw Palmetto Extract Suppresses Insulin-Like Growth Factor-I Signaling and Induces Stress-Activated Protein Kinase/c-Jun N-Terminal Kinase Phosphorylation in Human Prostate Epithelial Cells. Endocrinology, 2004, 145, 3205-3214.	1.4	28
131	Novel targeted agents in the treatment of lung cancer. Expert Opinion on Investigational Drugs, 2004, 13, 609-629.	1.9	2
132	Targeting mTOR-mediated survival signals in anticancer therapeutic strategies. Expert Review of Anticancer Therapy, 2004, 4, 691-701.	1.1	31
133	Glucocorticoid Receptor Counteracts Tumorigenic Activity of Akt in Skin through Interference with the Phosphatidylinositol 3-Kinase Signaling Pathway. Molecular Endocrinology, 2004, 18, 303-311.	3.7	62
134	Targeting Apoptosis Pathways in Cancer Therapy. Current Cancer Drug Targets, 2004, 4, 569-576.	0.8	158

#	Article	IF	Citations
136	Therapeutic potential of phosphoinositide 3-kinase inhibitors. Expert Opinion on Therapeutic Patents, 2004, 14, 703-732.	2.4	34
137	Apigenin Induces Apoptosis through Proteasomal Degradation of HER2/neu in HER2/neu-overexpressing Breast Cancer Cells via the Phosphatidylinositol 3-Kinase/Akt-dependent Pathway. Journal of Biological Chemistry, 2004, 279, 4479-4489.	1.6	206
138	Activation of the Akt/Mammalian Target of Rapamycin/4E-BP1 Pathway by ErbB2 Overexpression Predicts Tumor Progression in Breast Cancers. Clinical Cancer Research, 2004, 10, 6779-6788.	3.2	293
139	Oncogenic Mutations of PIK3CA in Human Cancers. Cell Cycle, 2004, 3, 1221-1224.	1.3	435
140	Antibody-Based Profiling of the Phosphoinositide 3-Kinase Pathway in Clinical Prostate Cancer. Clinical Cancer Research, 2004, 10, 8351-8356.	3.2	60
141	Identification of Nonsteroidal Anti-inflammatory Drug-activated Gene (NAG-1) as a Novel Downstream Target of Phosphatidylinositol 3-Kinase/AKT/GSK-3Î² Pathway. Journal of Biological Chemistry, 2004, 279, 49617-49623.	1.6	93
142	Induction of Stem Cell Factor/c-Kit/Slug Signal Transduction in Multidrug-resistant Malignant Mesothelioma Cells. Journal of Biological Chemistry, 2004, 279, 46706-46714.	1.6	84
143	Inhibition of Chk1 by Activated PKB/Akt. Cell Cycle, 2004, 3, 632-635.	1.3	48
144	Development of a Fluorescence Polarization Bead-Based Coupled Assay to Target Different Activity/Conformation States of a Protein Kinase. Journal of Biomolecular Screening, 2004, 9, 309-321.	2.6	12
145	Persistent Activation of the Akt Pathway in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2004, 10, 4029-4037.	3.2	163
146	Role of MEN2A-Derived RET in Maintenance and Proliferation of Medullary Thyroid Carcinoma. Journal of the National Cancer Institute, 2004, 96, 1231-1239.	3.0	65
147	The NHE1 Na+/H+ Exchanger Recruits Ezrin/Radixin/Moesin Proteins to Regulate Akt-dependent Cell Survival. Journal of Biological Chemistry, 2004, 279, 26280-26286.	1.6	145
148	Phospholipase D Elevates the Level of MDM2 and Suppresses DNA Damage-Induced Increases in p53. Molecular and Cellular Biology, 2004, 24, 5677-5686.	1.1	64
149	Akt and Hypoxia-Inducible Factor-1 Independently Enhance Tumor Growth and Angiogenesis. Cancer Research, 2004, 64, 3500-3507.	0.4	76
150	Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 4821-4826.	3.3	147
151	Activation of Signal Transducer and Activator of Transcription 5 in Human Prostate Cancer Is Associated with High Histological Grade. Cancer Research, 2004, 64, 4774-4782.	0.4	167
152	Mutually exclusive mutations of the Pten and ras pathways in skin tumor progression. Genes and Development, 2004, 18, 1800-1805.	2.7	59
153	Sp1 Is Involved in Akt-mediated Induction of VEGF Expression through an HIF-1â€“independent Mechanism. Molecular Biology of the Cell, 2004, 15, 4841-4853.	0.9	206

#	Article	IF	Citations
154	Involvement of 3-Phosphoinositide-dependent Protein Kinase-1 in the MEK/MAPK Signal Transduction Pathway. Journal of Biological Chemistry, 2004, 279, 33759-33767.	1.6	93
155	Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 13613-13617.	3.3	199
156	More than a Markerâ€¦ Phosphorylated Akt in Prostate Carcinoma. Clinical Cancer Research, 2004, 10, 6407-6410.	3.2	10
157	Does dysregulated expression of a deregulated viral GPCR trigger Kaposi's sarcomagenesis?. FASEB Journal, 2004, 18, 422-427.	0.2	65
158	3-Phosphoinositide-Dependent Protein Kinase-1/Akt Signaling Represents a Major Cyclooxygenase-2-Independent Target for Celecoxib in Prostate Cancer Cells. Cancer Research, 2004, 64, 1444-1451.	0.4	225
159	Pten Loss Causes Hypertrophy and Increased Proliferation of Astrocytes In vivo. Cancer Research, 2004, 64, 7773-7779.	0.4	204
160	Overexpressed eIF4E Is Functionally Active in Surgical Margins of Head and Neck Cancer Patients via Activation of the Akt/Mammalian Target of Rapamycin Pathway. Clinical Cancer Research, 2004, 10, 5820-5827.	3.2	105
161	In vitro Combination Treatment with Perifosine and UCN-01 Demonstrates Synergism against Prostate (PC-3) and Lung (A549) Epithelial Adenocarcinoma Cell Lines. Clinical Cancer Research, 2004, 10, 5242-5252.	3.2	64
162	Phospho-Akt Overexpression in Nonâ€“Small Cell Lung Cancer Confers Significant Stage-Independent Survival Disadvantage. Clinical Cancer Research, 2004, 10, 6865-6871.	3.2	181
163	The signal transduction networks required for phosphorylation of STAT1 at Ser727 in mouse epidermal JB6 cells in the UVB response and inhibitory mechanisms of tea polyphenols. Carcinogenesis, 2004, 26, 331-342.	1.3	39
164	The MUC1 Oncoprotein Activates the Anti-apoptotic Phosphoinositide 3-Kinase/Akt and Bcl-xL Pathways in Rat 3Y1 Fibroblasts. Journal of Biological Chemistry, 2004, 279, 20607-20612.	1.6	149
165	Dexamethasone Suppresses Antigen-Induced Activation of Phosphatidylinositol 3-Kinase and Downstream Responses in Mast Cells. Journal of Immunology, 2004, 172, 7254-7262.	0.4	71
166	A Proline-Rich Motif in the C Terminus of Akt Contributes to Its Localization in the Immunological Synapse. Journal of Immunology, 2004, 172, 5441-5449.	0.4	32
167	Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells. Journal of Cell Biology, 2004, 164, 603-612.	2.3	353
168	Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas. Cancer Research, 2004, 64, 5048-5050.	0.4	318
169	Antisense and Dominant-Negative AKT2 cDNA Inhibits Glioma Cell Invasion. Tumor Biology, 2004, 25, 172-178.	0.8	34
170	Molecular targeting for malignant gliomas (Review). International Journal of Oncology, 2004, 24, 1101.	1.4	16
171	Epidermal Growth Factor and Trail Interactions in Epithelial-Derived Cells. Vitamins and Hormones, 2004, 67, 207-227.	0.7	24

#	Article	IF	Citations
172	Activating FOXO3a, NF-kappaB and p53 by targeting IKKs: An effective multi-faceted targeting of the tumor-cell phenotype?. Cancer Biology and Therapy, 2004, 3, 614-616.	1.5	55
173	Gefitinib (Iressa) in Oncogene-Addictive Cancers and Therapy for Common Cancers. Cancer Biology and Therapy, 2004, 3, 436-440.	1.5	16
174	RNA interference, A potential strategy for isoform-specific phosphatidylinositol 3-kinase targeted therapy in ovarian cancer. Cancer Biology and Therapy, 2004, 3, 1283-1289.	1.5	18
175	On the trail of cell death pathways in prostate cancer. Cancer Biology and Therapy, 2004, 3, 769-771.	1.5	3
176	Control of Tumor Suppressor p53 Function by Endoplasmic Reticulum Stress. Cell Cycle, 2004, 3, 565-568.	1.3	18
177	Reversing Drug Resistance In Vivo. Cell Cycle, 2004, 3, 845-847.	1.3	57
178	Enhanced T Cell Proliferation in Mice Lacking the p85Î² Subunit of Phosphoinositide 3-Kinase. Journal of Immunology, 2004, 172, 6615-6625.	0.4	69
179	Activation of Akt-1 (PKB-Î±) Can Accelerate ErbB-2-Mediated Mammary Tumorigenesis but Suppresses Tumor Invasion. Cancer Research, 2004, 64, 3171-3178.	0.4	235
180	Persistent gene expression in mouse vagina exposed neonatally to diethylstilbestrol. Journal of Molecular Endocrinology, 2004, 32, 663-677.	1.1	30
181	The Cyclin-dependent Kinase Inhibitor CYC202 (R-Roscovitine) Inhibits Retinoblastoma Protein Phosphorylation, Causes Loss of Cyclin D1, and Activates the Mitogen-activated Protein Kinase Pathway. Cancer Research, 2004, 64, 262-272.	0.4	187
182	Targeting the epidermal growth factor receptor. British Journal of Cancer, 2004, 91, 418-424.	2.9	151
183	From the Cyclooxygenase-2 Inhibitor Celecoxib to a Novel Class of 3-Phosphoinositide-Dependent Protein Kinase-1 Inhibitors. Cancer Research, 2004, 64, 4309-4318.	0.4	252
184	Prion Protein Prevents Human Breast Carcinoma Cell Line from Tumor Necrosis Factor Î±-Induced Cell Death. Cancer Research, 2004, 64, 719-727.	0.4	110
185	Arsenite Sensitizes Human Melanomas to Apoptosis via Tumor Necrosis Factor Î±-mediated Pathway. Journal of Biological Chemistry, 2004, 279, 22747-22758.	1.6	56
186	HIFs and tumorsâ€"causes and consequences. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2004, 286, R608-R623.	0.9	416
187	Polyanions and the Proteome. Molecular and Cellular Proteomics, 2004, 3, 746-769.	2.5	93
188	Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells. Journal of Leukocyte Biology, 2004, 76, 338-351.	1.5	26
189	Comparative signaling pathways of insulin-like growth factor-1 and brain-derived neurotrophic factor in hippocampal neurons and the role of the PI3 kinase pathway in cell survival. Journal of Neurochemistry, 2004, 89, 844-852.	2.1	192

#	Article	IF	Citations
190	Tumour-suppressor function in the nervous system. Nature Reviews Cancer, 2004, 4, 184-196.	12.8	23
191	The tor pathway: a target for cancer therapy. Nature Reviews Cancer, 2004, 4, 335-348.	12.8	1,255
192	Development of novel targeted therapies in the treatment of malignant glioma. Nature Reviews Drug Discovery, 2004, 3, 430-446.	21.5	214
193	Akt negatively regulates the in vitro lifespan of human endothelial cells via a p53/p21-dependent pathway. EMBO Journal, 2004, 23, 212-220.	3.5	298
194	14-3-3 suppresses the nuclear localization of threonine 157-phosphorylated p27Kip1. EMBO Journal, 2004, 23, 1934-1942.	3.5	139
195	Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia, 2004, 18, 267-275.	3.3	143
196	Apoptotic mechanisms in the control of erythropoiesis. Leukemia, 2004, 18, 1176-1199.	3.3	205
197	Interleukin-1Î² maintains an apoptosis-resistant phenotype in the blast cells of acute myeloid leukaemia via multiple pathways. Leukemia, 2004, 18, 1662-1670.	3.3	44
198	Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene, 2004, 23, 646-653.	2.6	233
199	Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene, 2004, 23, 2934-2949.	2.6	524
200	Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene, 2004, 23, 3151-3171.	2.6	1,124
201	Postgenomic global analysis of translational control induced by oncogenic signaling. Oncogene, 2004, 23, 3248-3264.	2.6	88
202	The interplay between Src and integrins in normal and tumor biology. Oncogene, 2004, 23, 7928-7946.	2.6	465
203	DNA-microarray analysis of brain cancer: molecular classification for therapy. Nature Reviews Neuroscience, 2004, 5, 782-792.	4.9	189
204	Control of oncogenesis and cancer therapy resistance. British Journal of Cancer, 2004, 90, 573-577.	2.9	42
205	Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases. Modern Pathology, 2004, 17, 15-21.	2.9	83
206	Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature, 2004, 428, 332-337.	13.7	898
207	G1 cell-cycle control and cancer. Nature, 2004, 432, 298-306.	13.7	1,082

#	Article	IF	Citations
208	Intrinsic tumour suppression. Nature, 2004, 432, 307-315.	13.7	1,158
209	Survival pathways meet their end. Nature, 2004, 428, 267-269.	13.7	65
210	Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?. Trends in Cell Biology, 2004, 14, 639-647.	3.6	274
211	Targeting signal transduction pathways by chemopreventive agents. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2004, 555, 33-51.	0.4	112
212	1D-myo-inositol 3-phosphate synthase: conservation, regulation, and putative target of mood stabilizers. Clinical Neuroscience Research, 2004, 4, 181-187.	0.8	17
213	NPM/ALK downregulates p27Kip1 in a PI-3K-dependent manner. Experimental Hematology, 2004, 32, 1265-1271.	0.2	26
214	Regulation of E-cadherin expression and Î²-catenin/Tcf transcriptional activity by the integrin-linked kinase. Biochimica Et Biophysica Acta - Molecular Cell Research, 2004, 1691, 1-15.	1.9	151
215	Molecular mechanisms of deguelin-induced apoptosis in transformed human bronchial epithelial cells. Biochemical Pharmacology, 2004, 68, 1119-1124.	2.0	61
216	Stimulation of proliferation and migration of a colorectal cancer cell line by amidated and glycine-extended gastrin-releasing peptide via the same receptor. Biochemical Pharmacology, 2004, 68, 2129-2142.	2.0	30
217	Lost in translation. Cancer Cell, 2004, 5, 519-523.	7.7	176
218	Tyrosine kinase inhibitors. Cancer Cell, 2004, 5, 525-531.	7.7	89
219	High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell, 2004, 6, 263-274.	7.7	351
220	Potentiation of signal transduction mitogenesis and cellular proliferation upon binding of receptor-recognized forms of Î±2-macroglobulin to 1-LN prostate cancer cells. Cellular Signalling, 2004, 16, 487-496.	1.7	34
221	Tyrosine kinase receptors as attractive targets of cancer therapy. Critical Reviews in Oncology/Hematology, 2004, 50, 23-38.	2.0	164
222	PI3K-Akt pathway: Its functions and alterations in human cancer. Apoptosis: an International Journal on Programmed Cell Death, 2004, 9, 667-676.	2.2	1,036
223	High Frequency of Mutations of the PIK3CA Gene in Human Cancers. Science, 2004, 304, 554-554.	6.0	3,048
224	Oncomodulatory signals by regulatory proteins encoded by human cytomegalovirus: a novel role for viral infection in tumor progression. FEMS Microbiology Reviews, 2004, 28, 59-77.	3.9	104
225	Phosphoinositide 3-kinase and its targets in B-cell and T-cell signaling. Current Opinion in Immunology, 2004, 16, 314-320.	2.4	121

#	Article	IF	Citations
226	Targeting multiple signal transduction pathways through inhibition of Hsp90. Journal of Molecular Medicine, 2004, 82, 488-99.	1.7	325
227	Cytomegalovirus infection blocks apoptosis in cancer cells. Cellular and Molecular Life Sciences, 2004, 61, 1307-1316.	2.4	26
228	Role of Akt/protein kinase B in the activity of transcriptional coactivator p300. Cellular and Molecular Life Sciences, 2004, 61, 1675-83.	2.4	49
229	Lysophosphatidic acid promotes survival of androgen-insensitive prostate cancer PC3 cells via activation of NF-?B. Prostate, 2004, 61, 105-113.	1.2	49
230	Proximal B cell receptor signaling pathways. Signal Transduction, 2004, 4, 173-194.	0.7	10
231	Humanin vivo-activated CD45R0+ CD4+ Tâ€„cells are susceptible to spontaneous apoptosis that can be inhibited by the chemokine CXCL12 and IL-2, -6, -7, and -15. European Journal of Immunology, 2004, 34, 2771-2780.	1.6	34
232	Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. International Journal of Cancer, 2004, 108, 334-341.	2.3	193
233	Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: Therapeutic prospects. International Journal of Cancer, 2004, 108, 358-366.	2.3	61
234	Pathological and molecular mechanisms of prostate carcinogenesis: Implications for diagnosis, detection, prevention, and treatment. Journal of Cellular Biochemistry, 2004, 91, 459-477.	1.2	164
235	Role of protein kinase C in arginine vasopressin-stimulated ERK and p70S6 kinase phosphorylation. Journal of Cellular Biochemistry, 2004, 91, 1109-1129.	1.2	17
236	Molecular pathways involved in the anti-apoptotic effect of 1,25-dihydroxyvitamin D3 in primary human keratinocytes. Journal of Cellular Biochemistry, 2004, 93, 951-967.	1.2	43
237	Targeting c-Kit mutations: basic science to novel therapies. Leukemia Research, 2004, 28, 11-20.	0.4	81
238	Phosphoinositide Signaling. Chemistry and Biology, 2004, 11, 619-637.	6.2	109
239	Synthesis of anti-tumour phosphatidylinositol analogues from glucose by the use of ring-closing olefin metathesis. Organic and Biomolecular Chemistry, 2004, 2, 2951.	1.5	30
240	Mutation of the PIK3CA Gene in Ovarian and Breast Cancer. Cancer Research, 2004, 64, 7678-7681.	0.4	864
241	Preferential Inhibition of Akt and Killing of Akt-Dependent Cancer Cells by Rationally Designed Phosphatidylinositol Ether Lipid Analogues. Cancer Research, 2004, 64, 2782-2792.	0.4	126
242	Molecular targeting: PI3 kinase pathway. Annals of Oncology, 2004, 15, iv233-iv239.	0.6	43
243	Upstream and downstream of mTOR. Genes and Development, 2004, 18, 1926-1945.	2.7	3,638

#	Article	IF	Citations
244	Structure-Based Optimization of Novel Azepane Derivatives as PKB Inhibitors. Journal of Medicinal Chemistry, 2004, 47, 1375-1390.	2.9	107
245	The biology of CML blast crisis. Blood, 2004, 103, 4010-4022.	0.6	514
246	Conditional Activation of Akt in Adult Skeletal Muscle Induces Rapid Hypertrophy. Molecular and Cellular Biology, 2004, 24, 9295-9304.	1.1	369
247	A Quantitative Single-Cell Assay for Protein Kinase B Reveals Important Insights into the Biochemical Behavior of an Intracellular Substrate Peptide. Biochemistry, 2004, 43, 1599-1608.	1.2	41
248	Quantitative methods for the analysis of protein phosphorylation in drug development. Expert Review of Proteomics, 2004, 1, 327-341.	1.3	76
249	Novel Therapeutic Molecular Targets for Prostate Cancer: The mTor Signaling Pathway and Epidermal Growth Factor Receptor. Journal of Urology, 2004, 171, S41-3; discussion S44.	0.2	25
250	The combination of cytotoxic and molecularly targeted therapies â€“ can it be done?. Drug Discovery Today: Therapeutic Strategies, 2004, 1, 445-454.	0.5	8
251	Chemokine receptors and melanoma metastasis. Journal of Dermatological Science, 2004, 36, 71-78.	1.0	170
252	Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Expert Review of Anticancer Therapy, 2004, 4, 105-128.	1.1	138
253	The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt. Expert Opinion on Investigational Drugs, 2004, 13, 787-797.	1.9	43
254	Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors. Expert Opinion on Investigational Drugs, 2004, 13, 1-19.	1.9	48
255	Signalling Pathways Activated by All-trans-Retinoic Acid in Acute Promyelocytic Leukemia Cells. Leukemia and Lymphoma, 2004, 45, 2175-2185.	0.6	26
256	Development of Rationally Designed, Target-Based Agents for the Treatment of Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2004, 4, 107-123.	1.0	4
257	Molecular Markers and Prostate Cancer Prognosis. Clinical Prostate Cancer, 2004, 3, 157-164.	2.1	20
258	Akt Stimulates Aerobic Glycolysis in Cancer Cells. Cancer Research, 2004, 64, 3892-3899.	0.4	1,297
259	CX3CR1-Fractalkine Expression Regulates Cellular Mechanisms Involved in Adhesion, Migration, and Survival of Human Prostate Cancer Cells. Cancer Research, 2004, 64, 4693-4698.	0.4	174
260	Phosphoinositide3-Kinase: Diverse Roles in Immune Cell Activation. Annual Review of Immunology, 2004, 22, 563-598.	9.5	317
261	Applications of eTagâ„¢ assay platform to systems biology approaches in molecular oncology and toxicology studies. Clinical Immunology, 2004, 111, 162-174.	1.4	23

#	Article	IF	Citations
262	Human Î±A- and Î±B-crystallins prevent UVA-induced apoptosis through regulation of PKCÎ±, RAF/MEK/ERK and AKT signaling pathways. Experimental Eye Research, 2004, 79, 393-403.	1.2	120
263	Targeting hypoxia tolerance in cancer. Drug Resistance Updates, 2004, 7, 25-40.	6.5	81
264	Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: implications for therapy. European Journal of Cancer, 2004, 40, 2509-2518.	1.3	53
265	Improving the selectivity of cancer treatments by interfering with cell response pathways. European Journal of Cancer, 2004, 40, 2550-2559.	1.3	25
266	Gene expression microarray technologies in the development of new therapeutic agents. European Journal of Cancer, 2004, 40, 2560-2591.	1.3	77
267	NSAIDs activate PTEN and other phosphatases in human colon cancer cells: novel mechanism for chemopreventive action of NSAIDs. Biochemical and Biophysical Research Communications, 2004, 320, 875-879.	1.0	26
268	Inhibition of phosphatidylinositol 3â€²-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway. Biochemical and Biophysical Research Communications, 2004, 320, 932-938.	1.0	65
269	PTENless means more. Developmental Biology, 2004, 273, 175-184.	0.9	219
270	Rapid signalling pathway activation by androgens in epithelial and stromal cells. Steroids, 2004, 69, 517-522.	0.8	66
271	Signalling pathways in the molecular pathogenesis of ovarian granulosa cell tumours. Trends in Endocrinology and Metabolism, 2004, 15, 122-128.	3.1	68
272	Cloning, expression, purification, and characterization of the human Class Ia phosphoinositide 3-kinase isoforms. Protein Expression and Purification, 2004, 35, 218-224.	0.6	36
273	Involvement of MAP-kinase, PI3-kinase and EGF-receptor in the stimulatory effect of Neurotensin on DNA synthesis in PC3 cells. Regulatory Peptides, 2004, 120, 155-166.	1.9	71
274	Human cancer, PTEN and the PI-3 kinase pathway. Seminars in Cell and Developmental Biology, 2004, 15, 171-176.	2.3	197
275	PI3K signaling controls cell fate at many points in B lymphocyte development and activation. Seminars in Cell and Developmental Biology, 2004, 15, 183-197.	2.3	59
276	The RET proto-oncogene: a potential target for molecular cancer therapy. Trends in Molecular Medicine, 2004, 10, 351-357.	3.5	41
277	Cooperative translational control of gene expression by Ras and Akt in cancer. Trends in Molecular Medicine, 2004, 10, 607-613.	3.5	51
278	Differential regulation of signal transduction pathways in wild type and mutated p53 breast cancer epithelial cells by copper and zinc. Archives of Biochemistry and Biophysics, 2004, 423, 351-361.	1.4	42
279	Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy. Integrative Cancer Therapies, 2004, 3, 349-380.	0.8	155

#	Article	IF	Citations
280	The IGF-1/PI3K/Akt Pathway Prevents Expression of Muscle Atrophy-Induced Ubiquitin Ligases by Inhibiting FOXO Transcription Factors. Molecular Cell, 2004, 14, 395-403.	4.5	1,647
281	Integration of Smad and Forkhead Pathways in the Control of Neuroepithelial and Glioblastoma Cell Proliferation. Cell, 2004, 117, 211-223.	13.5	903
282	ÎºB Kinase Promotes Tumorigenesis through Inhibition of Forkhead FOXO3a. Cell, 2004, 117, 225-237.	13.5	823
283	GÎ²Î³ subunits stimulate p21-activated kinase 1 (PAK1) through activation of PI3-kinase and Akt but act independently of Rac1/Cdc42. FEBS Letters, 2004, 556, 187-192.	1.3	21
284	LY294002 inhibits monocyte chemoattractant proteinâ€1 expression through a phosphatidylinositol 3â€kinaseâ€independent mechanism. FEBS Letters, 2004, 559, 141-144.	1.3	19
285	The STATs of cancer â€" new molecular targets come of age. Nature Reviews Cancer, 2004, 4, 97-105.	12.8	2,084
286	Involvement of JAK2 upstream of the PI 3-kinase in cellâ€"cell adhesion regulation by gastrin. Experimental Cell Research, 2004, 301, 128-138.	1.2	41
287	Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity. Anti-Cancer Drugs, 2004, 15, 411-419.	0.7	71
288	Negative Feedback Regulation of Phosphatidylinositol 3â€Kinase/Akt Pathway by Overâ€Expressed Cyclooxygenaseâ€2 in Human Epidermal Cancer Cells. Journal of Dermatology, 2004, 31, 516-523.	0.6	10
289	The relation between immunosuppressive agents and malignancy. Current Opinion in Organ Transplantation, 2004, 9, 394-399.	0.8	13
291	PTEN function: how normal cells control it and tumour cells lose it. Biochemical Journal, 2004, 382, 1-11.	1.7	448
292	Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review). Oncology Reports, 2004, 12, 955.	1.2	59
293	Non-cytotoxic drugs as potential treatments for gliomas. Current Opinion in Neurology, 2004, 17, 663-673.	1.8	7
294	Integrating basic science and clinical research in bladder cancer: update from the first bladder Specialized Program of Research Excellence (SPORE). Current Opinion in Urology, 2004, 14, 295-300.	0.9	16
295	Optimal B-cell proliferation requires phosphoinositide 3-kinaseâ€"dependent inactivation of FOXO transcription factors. Blood, 2004, 104, 784-787.	0.6	125
296	Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. Blood, 2004, 103, 2727-2737.	0.6	127
297	Phosphoinositide 3-kinase signaling is essential for ABL oncogeneâ€"mediated transformation of B-lineage cells. Blood, 2004, 103, 4268-4275.	0.6	83
298	Kit and FcÏµRI mediate unique and convergent signals for release of inflammatory mediators from human mast cells. Blood, 2004, 104, 2410-2417.	0.6	144

#	Article	IF	Citations
299	Towards an understanding of isoform specificity in phosphoinositide 3-kinase signalling in lymphocytes. Biochemical Society Transactions, 2004, 32, 315-319.	1.6	26
300	Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. Biochemical Society Transactions, 2004, 32, 393-396.	1.6	91
301	Defects in secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2. Journal of Clinical Investigation, 2004, 113, 441-450.	3.9	186
302	Luminal flow induces eNOS activation and translocation in the rat thick ascending limb. II. Role of PI3-kinase and Hsp90. American Journal of Physiology - Renal Physiology, 2004, 287, F281-F288.	1.3	39
303	PTEN and Cancer. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, 2005, , 93-101.	0.0	0
304	Constitutive Activation of Akt by Flt3 Internal Tandem Duplications Is Necessary for Increased Survival, Proliferation, and Myeloid Transformation. Cancer Research, 2005, 65, 9643-9650.	0.4	205
305	Antiestrogen-resistant human breast cancer cells require activated Protein Kinase B/Akt for growth. Endocrine-Related Cancer, 2005, 12, 599-614.	1.6	81
306	A forkhead in the road to longevity: the molecular basis of lifespan becomes clearer. Journal of Hypertension, 2005, 23, 1285-1309.	0.3	89
307	Dissecting Cancer Pathways and Vulnerabilities with RNAi. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 435-444.	2.0	35
308	Drugging the Cancer Kinome: Progress and Challenges in Developing Personalized Molecular Cancer Therapeutics. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 499-515.	2.0	31
309	CAPTURING SIGNAL ANOMALIES OF HUMAN PROSTATE CANCER INTO MOUSE MODELS. , 2005, , 393-421.		1
310	11,11???-Dideoxy-verticillin: a natural compound possessing growth factor receptor tyrosine kinase-inhibitory effect with anti-tumor activity. Anti-Cancer Drugs, 2005, 16, 515-524.	0.7	46
311	The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKTâ€“dependent apoptosis in diffuse large B-cell lymphoma. Blood, 2005, 105, 308-316.	0.6	141
312	The Jab1/COP9 signalosome subcomplex is a downstream mediator of Bcr-Abl kinase activity and facilitates cell-cycle progression. Blood, 2005, 105, 775-783.	0.6	67
313	15-Deoxy-Î”12,14-prostaglandin J2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-ÎºB activity and down-regulation of antiapoptotic proteins. Blood, 2005, 105, 1750-1758.	0.6	87
314	Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. Blood, 2005, 105, 827-829.	0.6	88
315	Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochemical Journal, 2005, 385, 399-408.	1.7	382
316	Reconstitution of the mammalian PI3K/PTEN/Akt pathway in yeast. Biochemical Journal, 2005, 390, 613-623.	1.7	84

#	Article	IF	Citations
317	The Insulin Receptor and Downstream Signalling. , 2005, , 1-62.		0
318	Evolving Molecular-Based Targeted Therapy for Cancer: An Exciting Field. Comprehensive Therapy, 2005, 31, 299-305.	0.2	0
319	Oncogenic Ras in tumour progression and metastasis. Biological Chemistry, 2005, 386, 193-205.	1.2	240
320	Ribozymes targeting serine/threonine kinase Akt1 sensitize cells to anticancer drugs. Cancer Science, 2005, 96, 620-626.	1.7	12
321	Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. British Journal of Haematology, 2005, 132, 051220022257008.	1.2	87
322	Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). British Journal of Cancer, 2005, 92, 1711-1719.	2.9	128
323	Modulating autoimmunity: pick your PI3 kinase. Nature Medicine, 2005, 11, 924-925.	15.2	15
324	Masters of angiogenesis. Nature Medicine, 2005, 11, 925-927.	15.2	61
325	Mechanisms of BCRâ€“ABL in the pathogenesis of chronic myelogenous leukaemia. Nature Reviews Cancer, 2005, 5, 172-183.	12.8	896
326	The role of autophagy in cancer development and response to therapy. Nature Reviews Cancer, 2005, 5, 726-734.	12.8	1,581
327	Modelling glandular epithelial cancers in three-dimensional cultures. Nature Reviews Cancer, 2005, 5, 675-688.	12.8	929
328	Oncogenic PI3K deregulates transcription and translation. Nature Reviews Cancer, 2005, 5, 921-929.	12.8	708
329	Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery. Nature Reviews Drug Discovery, 2005, 4, 988-1004.	21.5	1,853
330	Mechanisms of type-I- and type-II-interferon-mediated signalling. Nature Reviews Immunology, 2005, 5, 375-386.	10.6	2,758
331	Fuel feeds function: energy metabolism and the T-cell response. Nature Reviews Immunology, 2005, 5, 844-852.	10.6	735
332	RNA polymerases I and III, growth control and cancer. Nature Reviews Molecular Cell Biology, 2005, 6, 69-78.	16.1	305
333	p53, apoptosis and axon-guidance molecules. Cell Death and Differentiation, 2005, 12, 1057-1065.	5.0	60
334	BCR/ABL, mRNA translation and apoptosis. Cell Death and Differentiation, 2005, 12, 534-540.	5.0	16

#	Article	IF	Citations
335	Role of poly(ADP-ribose) polymerase activity in imatinib mesylate-induced cell death. Cell Death and Differentiation, 2005, 12, 627-636.	5.0	14
336	The PI3K inhibitor LY294002 prevents p53 induction by DNA damage and attenuates chemotherapy-induced apoptosis. Cell Death and Differentiation, 2005, 12, 1578-1587.	5.0	39
337	PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kB, MAPkinase and p53 pathways. Leukemia, 2005, 19, 586-594.	3.3	269
338	Alternative phospholipase D/mTOR survival signal in human breast cancer cells. Oncogene, 2005, 24, 672-679.	2.6	103
339	Myc regulates VEGF production in B cells by stimulating initiation of VEGF mRNA translation. Oncogene, 2005, 24, 889-901.	2.6	75
340	PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene, 2005, 24, 1477-1480.	2.6	488
341	Paclitaxel induces the phosphorylation of the eukaryotic translation initiation factor 4E-binding protein 1 through a Cdk1-dependent mechanism. Oncogene, 2005, 24, 4851-4860.	2.6	31
342	Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. Oncogene, 2005, 24, 4540-4548.	2.6	111
343	Chronic activation of protein kinase BÎ²/Akt2 leads to multinucleation and cell fusion in human epithelial kidney cells: events associated with tumorigenesis. Oncogene, 2005, 24, 5459-5470.	2.6	31
344	Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene, 2005, 24, 5552-5560.	2.6	523
345	PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene, 2005, 24, 6465-6481.	2.6	383
346	Viruses â€“ seeking and destroying the tumor program. Oncogene, 2005, 24, 7640-7655.	2.6	60
347	The Akt of translational control. Oncogene, 2005, 24, 7426-7434.	2.6	176
348	Mutations in a signalling pathway. Nature, 2005, 436, 792-792.	13.7	510
349	Expression of proline-rich Akt-substrate PRAS40 in cell survival pathway and carcinogenesis1. Acta Pharmacologica Sinica, 2005, 26, 1253-1258.	2.8	45
350	Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell, 2005, 7, 561-573.	7.7	818
351	A new mouse model of pancreatic cancer: PTEN gets its Akt together. Cancer Cell, 2005, 8, 171-172.	7.7	27
352	Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell, 2005, 8, 381-392.	7.7	168

#	Article	IF	Citations
353	The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. Cancer Cell, 2005, 8, 443-454.	7.7	164
354	Recent advances in the protein kinase B signaling pathway. Current Opinion in Cell Biology, 2005, 17, 150-157.	2.6	324
355	Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. Current Opinion in Cell Biology, 2005, 17, 141-149.	2.6	198
356	Neuronal Polarity: Until GSK-3 Do Us Part. Current Biology, 2005, 15, R198-R200.	1.8	14
357	Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma. Biochimica Et Biophysica Acta: Reviews on Cancer, 2005, 1755, 135-150.	3.3	38
358	STI 571 inhibition effect on KITAsn822Lys-mediated signal transduction cascade. Experimental Hematology, 2005, 33, 682-688.	0.2	22
359	Aging alters vascular mechanotransduction: Pressure-induced regulation of p70S6k in the rat aorta. Mechanisms of Ageing and Development, 2005, 126, 1213-1222.	2.2	18
360	Modulation of signal transduction by tea catechins and related phytochemicals. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005, 591, 147-160.	0.4	109
361	Signalling pathways regulating the invasive differentiation of human trophoblasts: a review. Placenta, 2005, 26, S21-S30.	0.7	175
362	Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in nonâ€“small cell lung cancer in vitro and in vivo. Journal of Thoracic and Cardiovascular Surgery, 2005, 130, 1422-1429.	0.4	32
363	Accumulation of cytoplasmic beta-catenin correlates with reduced expression of E-cadherin, but not with phosphorylated Akt in esophageal squamous cell carcinoma: Immunohistochemical study. Pathology International, 2005, 55, 310-317.	0.6	30
364	Mutations of PIK3CAin gastric adenocarcinoma. BMC Cancer, 2005, 5, 29.	1.1	159
365	Akt-induced promotion of cell-cycle progression at G2/M phase involves upregulation of NF-Y binding activity in PC12 cells. Journal of Cellular Physiology, 2005, 205, 270-277.	2.0	62
366	PIK3CA mutations in advanced ovarian carcinomas. Human Mutation, 2005, 25, 322-322.	1.1	94
367	Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (IressaÂ®, ZD1839) in chemotherapy-resistant non-small cell lung cancer. International Journal of Cancer, 2005, 113, 109-115.	2.3	152
368	Loss of stearoyl-CoA desaturase expression is a frequent event in prostate carcinoma. International Journal of Cancer, 2005, 114, 563-571.	2.3	53
369	Functional consequences of mutations in a putative Akt phosphorylation motif of B-raf in human cancers. Molecular Carcinogenesis, 2005, 43, 59-63.	1.3	15
371	Mechanisms of omega-3 fatty acid-induced growth inhibition in MDA-MB-231 human breast cancer cells. Breast Cancer Research and Treatment, 2005, 92, 187-195.	1.1	161

#	Article	IF	Citations
372	Inhibition of Either Phosphatidylinositol 3-kinase/Akt or the Mitogen/Extracellular-regulated Kinase, MEK/ERK, Signaling Pathways Suppress Growth of Breast Cancer Cell Lines, but MEK/ERK Signaling is Critical for Cell Survival. Breast Cancer Research and Treatment, 2005, 93, 177-188.	1.1	34
373	Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer and Metastasis Reviews, 2005, 24, 47-69.	2.7	161
374	Constitutive activation of PI3K-Akt and NF-Î¹B during prostate cancer progression in autochthonous transgenic mouse model. Prostate, 2005, 64, 224-239.	1.2	128
375	Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR. Journal of Pathology, 2005, 205, 498-506.	2.1	164
376	Small Molecule and Monoclonal Antibody Therapies in Neurooncology. Cancer Control, 2005, 12, 116-124.	0.7	22
377	Skin Cancer Prevention. , 2005, , 161-201.		1
378	Brain chemotherapy from the bench to the clinic: targeting neuronal survival with small molecule inhibitors of apoptosis. Frontiers in Bioscience - Landmark, 2005, 10, 552.	3.0	3
379	Targeting of the EGFR As a Modulator of Cancer Chemotherapy. , 2005, , 1-26.		2
380	Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways. Molecular Cancer Therapeutics, 2005, 4, 457-470.	1.9	63
381	Protein Kinases as Targets in Cancer Therapy: Validated and Emerging Approaches. , 2005, , 291-315.		3
382	From Tumorigenesis to Tumor Progression: Signaling Pathways Driving Tumor Invasion and Metastasis. , 2005, , 299-339.		3
383	Targeting Inducible Chemotherapy Resistance Mechanisms in Colon Cancer. , 2005, , 209-228.		1
384	mTOR-dependent Suppression of Protein Phosphatase 2A Is Critical for Phospholipase D Survival Signals in Human Breast Cancer Cells. Journal of Biological Chemistry, 2005, 280, 35829-35835.	1.6	50
385	Development of Farnesyl Transferase Inhibitors: A Review. Oncologist, 2005, 10, 565-578.	1.9	256
386	The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer and Prostatic Diseases, 2005, 8, 108-118.	2.0	113
387	Kinases as Drug Discovery Targets in Hematologic Malignancies. Current Molecular Medicine, 2005, 5, 625-642.	0.6	27
388	Inositol Hexakisphosphate Kinase-2, a Physiologic Mediator of Cell Death. Journal of Biological Chemistry, 2005, 280, 1634-1640.	1.6	115
389	Strain-induced vascular endothelial cell proliferation requires PI3K-dependent mTOR-4E-BP1 signal pathway. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 288, H1591-H1597.	1.5	39

#	Article	IF	Citations
390	The role of insulin-like growth factor-I receptor in the development of Herceptin resistance. Molecular Cancer Therapeutics, 2005, 4, 1136-1136.	1.9	2
391	Blocking the PI3K/PKB Pathway in Tumor Cells. Anti-Cancer Agents in Medicinal Chemistry, 2005, 5, 449-462.	7.0	31
392	Protein Expression and Prognostic Value of Genes in the erb-b Signaling Pathway in Advanced Ovarian Carcinomas. American Journal of Clinical Pathology, 2005, 124, 392-401.	0.4	46
393	Dexamethasone-induced intrauterine growth restriction impacts the placental prolactin family, insulin-like growth factor-II and the Akt signaling pathway. Journal of Endocrinology, 2005, 185, 253-263.	1.2	108
394	Antitumor Activity of Orally Bioavailable Farnesyltransferase Inhibitor, ABT-100, Is Mediated by Antiproliferative, Proapoptotic, and Antiangiogenic Effects in Xenograft Models. Clinical Cancer Research, 2005, 11, 3045-3054.	3.2	21
395	Epithelial to Mesenchymal Transition Is a Determinant of Sensitivity of Nonâ€“Small-Cell Lung Carcinoma Cell Lines and Xenografts to Epidermal Growth Factor Receptor Inhibition. Cancer Research, 2005, 65, 9455-9462.	0.4	599
396	Formylpeptide Receptor FPR and the Rapid Growth of Malignant Human Gliomas. Journal of the National Cancer Institute, 2005, 97, 823-835.	3.0	115
397	Molecular pathology of prostate cancer. Journal of Clinical Pathology, 2005, 58, 673-684.	1.0	112
398	Expression of Activated Akt and PTEN in Malignant Melanomas. American Journal of Clinical Pathology, 2005, 124, 528-536.	0.4	93
399	Tobacco components stimulate Akt-dependent proliferation and NFÎºB-dependent survival in lung cancer cells. Carcinogenesis, 2005, 26, 1182-1195.	1.3	266
400	Different Activation of Mitogen-Activated Protein Kinase and Akt Signaling Is Associated with Aggressive Phenotype of Human Meningiomas. Clinical Cancer Research, 2005, 11, 4074-4082.	3.2	114
401	Insulin-like Growth Factor-1 (IGF-1) Inversely Regulates Atrophy-induced Genes via the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin (PI3K/Akt/mTOR) Pathway. Journal of Biological Chemistry, 2005, 280, 2737-2744.	1.6	444
402	Cyclin D1 Induction through IÎºB Kinase Î²/Nuclear Factor-ÎºB Pathway Is Responsible for Arsenite-Induced Increased Cell Cycle G1-S Phase Transition in Human Keratinocytes. Cancer Research, 2005, 65, 9287-9293.	0.4	84
403	Prognostic value of activated Akt expression in oral squamous cell carcinoma. Journal of Clinical Pathology, 2005, 58, 1199-1205.	1.0	103
404	Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast Cancer. Clinical Cancer Research, 2005, 11, 5319-5328.	3.2	348
405	Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocrine-Related Cancer, 2005, 12, 423-433.	1.6	117
406	Role of Phosphoinositide 3-Kinase Regulatory Isoforms in Development and Actin Rearrangement. Molecular and Cellular Biology, 2005, 25, 2593-2606.	1.1	120
407	Insulin Receptor Substrate Is a Mediator of Phosphoinositide 3-Kinase Activation in Quiescent Pancreatic Cancer Cells. Cancer Research, 2005, 65, 9164-9168.	0.4	47

#	Article	IF	Citations
408	Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers. Clinical Cancer Research, 2005, 11, 2875-2878.	3.2	397
409	PTEN Represses RNA Polymerase I Transcription by Disrupting the SL1 Complex. Molecular and Cellular Biology, 2005, 25, 6899-6911.	1.1	100
410	Erythropoietin receptor spliced forms differentially expressed in blind subterranean mole rats. FASEB Journal, 2005, 19, 1749-1751.	0.2	24
411	PCOTH, a Novel Gene Overexpressed in Prostate Cancers, Promotes Prostate Cancer Cell Growth through Phosphorylation of Oncoprotein TAF-Î²/SET. Cancer Research, 2005, 65, 4578-4586.	0.4	34
412	Human mesothelioma cells exhibit tumor cellâ€“specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase. Molecular Cancer Therapeutics, 2005, 4, 835-842.	1.9	49
413	Tyrosine 729 of the G-CSF receptor controls the duration of receptor signaling: involvement of SOCS3 and SOCS1. Journal of Leukocyte Biology, 2005, 78, 1008-1015.	1.5	25
414	Inhibition of Protein Synthesis by Y Box-Binding Protein 1 Blocks Oncogenic Cell Transformation. Molecular and Cellular Biology, 2005, 25, 2095-2106.	1.1	80
415	Inhibition of the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway but not the MEK/ERK Pathway Attenuates Laminin-Mediated Small Cell Lung Cancer Cellular Survival and Resistance to Imatinib Mesylate or Chemotherapy. Cancer Research, 2005, 65, 8423-8432.	0.4	113
416	Inhibition of Phosphatidylinositol 3â€²-Kinase/AKT Signaling Promotes Apoptosis of Primary Effusion Lymphoma Cells. Clinical Cancer Research, 2005, 11, 3102-3108.	3.2	98
417	Response of Nonâ€“Small Cell Lung Cancer Cells to the Inhibitors of Phosphatidylinositol 3-Kinase/Akt- and MAPK Kinase 4/c-Jun NH2-Terminal Kinase Pathways: An Effective Therapeutic Strategy for Lung Cancer. Clinical Cancer Research, 2005, 11, 6065-6074.	3.2	52
418	Targeting Signal Transduction Pathways in Colorectal Cancerâ€”More Than Skin Deep. Journal of Clinical Oncology, 2005, 23, 5374-5385.	0.8	71
419	Sensitization of Taxol-induced Apoptosis by Curcumin Involves Down-regulation of Nuclear Factor-ÎºB and the Serine/Threonine Kinase Akt and Is Independent of Tubulin Polymerization. Journal of Biological Chemistry, 2005, 280, 6301-6308.	1.6	203
420	Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma. Journal of Clinical Oncology, 2005, 23, 5347-5356.	0.8	509
421	A3 Adenosine Receptor Activation Inhibits Cell Proliferation via Phosphatidylinositol 3-Kinase/Akt-dependent Inhibition of the Extracellular Signal-regulated Kinase 1/2 Phosphorylation in A375 Human Melanoma Cells. Journal of Biological Chemistry, 2005, 280, 19516-19526.	1.6	106
422	Then Negative Regulation of Phosphoinositide 3-Kinase Signaling by p85 and Its Implication in Cancer. Cell Cycle, 2005, 4, 1309-1312.	1.3	92
423	Targeted Biallelic Inactivation of Pten in the Mouse Prostate Leads to Prostate Cancer Accompanied by Increased Epithelial Cell Proliferation but not by Reduced Apoptosis. Cancer Research, 2005, 65, 5730-5739.	0.4	176
426	Functional Analysis of PIK3CA Gene Mutations in Human Colorectal Cancer. Cancer Research, 2005, 65, 4562-4567.	0.4	335
427	New cancer drugs on the horizon. Future Oncology, 2005, 1, 315-318.	1.1	3

#	Article	IF	Citations
428	The Jak/Stat Pathway: A Novel Way to Regulate PI3K Activity. Cell Cycle, 2005, 4, 897-900.	1.3	43
429	Immunosuppressive Drugs and the Risk of Cancer after Organ Transplantation. New England Journal of Medicine, 2005, 352, 1371-1373.	13.9	220
430	AKT Is Highly Phosphorylated in Pheochromocytomas But Not in Benign Adrenocortical Tumors. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4366-4370.	1.8	43
431	Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 10238-10243.	3.3	43
432	The PI3' Kinase Pathway in Interferon Signaling. Journal of Interferon and Cytokine Research, 2005, 25, 780-787.	0.5	71
433	Cyclooxygenase-2 and Epidermal Growth Factor Receptor: Pharmacologic Targets for Chemoprevention. Journal of Clinical Oncology, 2005, 23, 254-266.	0.8	379
434	Signal Transduction Pathways in Cancer Development and as Targets for Cancer Prevention. Progress in Molecular Biology and Translational Science, 2005, 79, 237-297.	1.9	59
435	Phosphotyrosine Signaling Networks in Epidermal Growth Factor Receptor Overexpressing Squamous Carcinoma Cells. Molecular and Cellular Proteomics, 2005, 4, 356-376.	2.5	121
436	Phosphoinositide 3-Kinase Accelerates Postoperative Tumor Growth by Inhibiting Apoptosis and Enhancing Resistance to Chemotherapy-induced Apoptosis. Journal of Biological Chemistry, 2005, 280, 20968-20977.	1.6	36
437	Human Papillomavirus Can Escape Immune Recognition through Langerhans Cell Phosphoinositide 3-Kinase Activation. Journal of Immunology, 2005, 174, 7172-7178.	0.4	74
438	Cyclooxygenase-2-derived Prostaglandin E2 Promotes Human Cholangiocarcinoma Cell Growth and Invasion through EP1 Receptor-mediated Activation of the Epidermal Growth Factor Receptor and Akt. Journal of Biological Chemistry, 2005, 280, 24053-24063.	1.6	127
439	Knockdown of STAT3 Expression by RNA Interference Inhibits the Induction of Breast Tumors in Immunocompetent Mice. Cancer Research, 2005, 65, 2532-2536.	0.4	197
440	Mitochondrial H2O2 Regulates the Angiogenic Phenotype via PTEN Oxidation. Journal of Biological Chemistry, 2005, 280, 16916-16924.	1.6	217
441	Overexpression of NBS1 Contributes to Transformation through the Activation of Phosphatidylinositol 3-Kinase/Akt. Journal of Biological Chemistry, 2005, 280, 32505-32511.	1.6	59
442	IL-6 induces neuroendocrine dedifferentiation and cell proliferation in non-small cell lung cancer cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2005, 289, L446-L453.	1.3	52
443	The oncogenic properties of mutant p110Â and p110Â phosphatidylinositol 3-kinases in human mammary epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18443-18448.	3.3	313
444	Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 802-807.	3.3	757
445	Signaling Intricacies Take Center Stage in Cancer Cells: Figure 1.. Cancer Research, 2005, 65, 2511-2515.	0.4	53

#	Article	IF	Citations
446	Phosphoinositide 3-Kinase Signaling to Akt Promotes Keratinocyte Differentiation Versus Death. Journal of Biological Chemistry, 2005, 280, 32856-32865.	1.6	191
447	Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes and Development, 2005, 19, 1934-1950.	2.7	225
448	Inhibition of Phosphatidylinositol 3-Kinase/Protein Kinase B Signaling Is Not Sufficient to Account for Indole-3-Carbinolâ€“Induced Apoptosis in Some Breast and Prostate Tumor Cells. Clinical Cancer Research, 2005, 11, 8521-8527.	3.2	11
449	ABL Oncogenes and Phosphoinositide 3-Kinase: Mechanism of Activation and Downstream Effectors. Cancer Research, 2005, 65, 2047-2053.	0.4	141
450	Syndecan-1 Is Involved in Osteoprotegerin-Induced Chemotaxis in Human Peripheral Blood Monocytes. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2964-2971.	1.8	83
451	Mammalian Target of Rapamycin Promotes Vincristine Resistance through Multiple Mechanisms Independent of Maintained Glycolytic Rate. Molecular Cancer Research, 2005, 3, 635-644.	1.5	18
452	Phosphatidylinositol 3-Kinase p85Î± Subunit-Dependent Interaction with BCR/ABL-Related Fusion Tyrosine Kinases: Molecular Mechanisms and Biological Consequences. Molecular and Cellular Biology, 2005, 25, 8001-8008.	1.1	27
453	Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. Endocrine-Related Cancer, 2005, 12, S159-S171.	1.6	82
454	Flavivirus Activates Phosphatidylinositol 3-Kinase Signaling To Block Caspase-Dependent Apoptotic Cell Death at the Early Stage of Virus Infection. Journal of Virology, 2005, 79, 8388-8399.	1.5	176
455	Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Molecular Cancer Therapeutics, 2005, 4, 977-986.	1.9	221
456	Survival Signals Generated by Estrogen and Phospholipase D in MCF-7 Breast Cancer Cells Are Dependent on Myc. Molecular and Cellular Biology, 2005, 25, 7917-7925.	1.1	59
457	Identification of N10-Substituted Phenoxazines as Potent and Specific Inhibitors of Akt Signaling. Journal of Biological Chemistry, 2005, 280, 31924-31935.	1.6	86
458	State-dependent Ras signaling and AMPA receptor trafficking. Genes and Development, 2005, 19, 2000-2015.	2.7	144
459	Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Annals of Oncology, 2005, 16, 928-933.	0.6	82
460	Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway by Inositol Pentakisphosphate Results in Antiangiogenic and Antitumor Effects. Cancer Research, 2005, 65, 8339-8349.	0.4	126
461	Proliferation and Polarity in Breast Cancer: Untying the Gordian Knot. Cell Cycle, 2005, 4, 646-649.	1.3	19
462	Crosstalk Between Pten and Ras Signaling Pathways in Tumor Development. Cell Cycle, 2005, 4, 1185-1188.	1.3	23
463	Inhibitors of Epidermoid Growth Factor Receptor Suppress Cell Growth and Enhance Chemosensitivity of Nasopharyngeal Cancer Cells in vitro. Oncology, 2005, 68, 538-547.	0.9	38

#	Article	IF	Citations
464	From XenoMouseÂ® Technology to Panitumumab (ABX-EGF). , 2005, , 647-657.		4
465	GSK-3Î² reactivation with LY294002 sensitizes hepatoma cells to chemotherapy-induced apoptosis. International Journal of Oncology, 2005, 27, 215.	1.4	17
466	Enhancement of the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF-Î¹B inhibitor. International Journal of Oncology, 2005, 27, 1247.	1.4	2
467	Signaling the Junctions in Gut Epithelium. Science Signaling, 2005, 2005, pe13-pe13.	1.6	11
468	Loss of Imprinting of IGF2: A Common Epigenetic Modifier of Intestinal Tumor Risk. Cancer Research, 2005, 65, 11236-11240.	0.4	119
469	Targeting hypoxia and angiogenesis through HIF-1alpha inhibition. Cancer Biology and Therapy, 2005, 4, 1055-1062.	1.5	42
470	Inhibiting phosphoinositide 3-kinases. Cancer Biology and Therapy, 2005, 4, 546-547.	1.5	1
471	PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors. Cancer Biology and Therapy, 2005, 4, 538-545.	1.5	66
472	Lhermitte-Duclos Disease: A Report of 31 Cases with Immunohistochemical Analysis of the PTEN/AKT/mTOR Pathway. Journal of Neuropathology and Experimental Neurology, 2005, 64, 341-349.	0.9	112
473	Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting. Advances in Cancer Research, 2005, 94, 29-86.	1.9	687
474	The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia. Leukemia and Lymphoma, 2005, 46, 247-255.	0.6	75
475	Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer. British Journal of Cancer, 2005, 93, 1372-1381.	2.9	136
476	Inhibition of PI3-kinaseâ€“Akt pathway enhances dexamethasone-induced apoptosis in a human follicular lymphoma cell line. Experimental Cell Research, 2005, 312, 322-30.	1.2	33
477	Oncogenic Ras-mediated downregulation of Gadd153/CHOP is required for Ras-induced cellular transformation. Oncogene, 2005, 24, 4867-4872.	2.6	18
478	ATP citrate lyase is an important component of cell growth and transformation. Oncogene, 2005, 24, 6314-6322.	2.6	463
479	Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Nonâ€“Small-Cell Lung Cancer Patients Treated With Gefitinib. Journal of Clinical Oncology, 2005, 23, 2493-2501.	0.8	736
480	Endothelin-1 Inhibits Apoptosis in Prostate Cancer. Neoplasia, 2005, 7, 631-637.	2.3	86
481	mTOR Promotes Survival and Astrocytic Characteristics Induced by Pten/Akt Signaling in Glioblastoma. Neoplasia, 2005, 7, 356-368.	2.3	165

#	Article	IF	Citations
482	Disruption of Parallel and Converging Signaling Pathways Contributes to the Synergistic Antitumor Effects of Simultaneous mTOR and EGFR Inhibition in GBM Cells. Neoplasia, 2005, 7, 921-929.	2.3	88
483	CF101, An Agonist to the A3 Adenosine Receptor, Enhances the Chemotherapeutic Effect of 5-Fluorouracil in a Colon Carcinoma Murine Model. Neoplasia, 2005, 7, 85-90.	2.3	40
484	Novel therapeutics in adult malignant brain gliomas. Expert Opinion on Investigational Drugs, 2005, 14, 643-658.	1.9	4
485	Type I Transforming Growth Factor Î² Receptor Binds to and Activates Phosphatidylinositol 3-Kinase. Journal of Biological Chemistry, 2005, 280, 10870-10876.	1.6	201
486	Making Progress through Molecular Attacks on Cancer. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 479-482.	2.0	32
487	The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 6942-6947.	3.3	419
488	Genomics and the second golden era of cancer drug development. Molecular BioSystems, 2005, 1, 17.	2.9	48
489	PTEN and p27 expression in mature T-cell and NK-cell neoplasms. Leukemia and Lymphoma, 2005, 46, 1463-1470.	0.6	20
490	Design and Crystal Structures of Protein Kinase B-Selective Inhibitors in Complex with Protein Kinase A and Mutants. Journal of Medicinal Chemistry, 2005, 48, 163-170.	2.9	59
491	Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis. Journal of Clinical Oncology, 2005, 23, 8253-8261.	0.8	932
492	Synthesis and Activity of C11-Modified Wortmannin Probes for PI3 Kinase. Bioconjugate Chemistry, 2005, 16, 669-675.	1.8	17
493	Synthesis and Biological Activity of Anticancer Ether Lipids That Are Specifically Released by Phospholipase A2 in Tumor Tissue. Journal of Medicinal Chemistry, 2005, 48, 7305-7314.	2.9	41
494	Mechanical signal transduction in skeletal muscle growth and adaptation. Journal of Applied Physiology, 2005, 98, 1900-1908.	1.2	133
495	Activation of Akt and eIF4E Survival Pathways by Rapamycin-Mediated Mammalian Target of Rapamycin Inhibition. Cancer Research, 2005, 65, 7052-7058.	0.4	759
496	Akt-Mediated Phosphorylation of EZH2 Suppresses Methylation of Lysine 27 in Histone H3. Science, 2005, 310, 306-310.	6.0	497
497	PHLPP: A Phosphatase that Directly Dephosphorylates Akt, Promotes Apoptosis, and Suppresses Tumor Growth. Molecular Cell, 2005, 18, 13-24.	4.5	796
498	Binding and Phosphorylation of Par-4 by Akt Is Essential for Cancer Cell Survival. Molecular Cell, 2005, 20, 33-44.	4.5	143
499	Akt Blocks Breast Cancer Cell Motility and Invasion through the Transcription Factor NFAT. Molecular Cell, 2005, 20, 539-550.	4.5	390

#	Article	IF	Citations
500	An expanding role for mTOR in cancer. Trends in Molecular Medicine, 2005, 11, 353-361.	3.5	472
501	Aging: gene silencing or gene activation?. Medical Hypotheses, 2005, 64, 201-208.	0.8	50
502	Vitamin E analogs trigger apoptosis in HER2/erbB2-overexpressing breast cancer cells by signaling via the mitochondrial pathway. Biochemical and Biophysical Research Communications, 2005, 326, 282-289.	1.0	69
503	Ganoderma lucidum suppresses angiogenesis through the inhibition of secretion of VEGF and TGF-Î²1 from prostate cancer cells. Biochemical and Biophysical Research Communications, 2005, 330, 46-52.	1.0	150
504	Suppression of PI3K/mTOR pathway rescues LLC cells from cell death induced by hypoxia. Biochemical and Biophysical Research Communications, 2005, 330, 318-326.	1.0	25
505	The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. Biochemical and Biophysical Research Communications, 2005, 331, 295-302.	1.0	66
506	Induction of apoptosis in prostate cancer cells by pachymic acid from Poria cocos. Biochemical and Biophysical Research Communications, 2005, 332, 1153-1161.	1.0	108
507	KIT (c-kit oncogene product) pathway is constitutively activated in human testicular germ cell tumors. Biochemical and Biophysical Research Communications, 2005, 337, 289-296.	1.0	41
508	A Genetic Screen for Candidate Tumor Suppressors Identifies REST. Cell, 2005, 121, 837-848.	13.5	455
509	Phosphoinositide 3-kinases as drug targets in cancer. Current Opinion in Pharmacology, 2005, 5, 357-365.	1.7	100
510	Temporal and Spatial Regulation of Phosphoinositide Signaling Mediates Cytokinesis. Developmental Cell, 2005, 8, 467-477.	3.1	133
511	Akt/PKB Regulates Actin Organization and Cell Motility via Girdin/APE. Developmental Cell, 2005, 9, 389-402.	3.1	381
512	The chemopreventive agent development research program in the Division of Cancer Prevention of the US National Cancer Institute: An overview. European Journal of Cancer, 2005, 41, 1889-1910.	1.3	55
513	The prevalence of PIK3CA mutations in gastric and colon cancer. European Journal of Cancer, 2005, 41, 1649-1654.	1.3	314
514	Inhibition of survival signalling by dietary polyphenols and indole-3-carbinol. European Journal of Cancer, 2005, 41, 1842-1853.	1.3	47
515	The role of carbonic anhydrase IX overexpression in kidney cancer. European Journal of Cancer, 2005, 41, 2935-2947.	1.3	145
516	Stress kinase signaling in cancer: fact or fiction?. Cancer Letters, 2005, 217, 1-9.	3.2	40
517	Comparison of phosphatidylinositol-3-kinase signalling within a panel of human colorectal cancer cell lines with mutant or wild-type PIK3CA. FEBS Letters, 2005, 579, 5123-5128.	1.3	28

#	Article	IF	Citations
518	Membrane Rafts Segregate Pro- from Anti-Apoptotic Insulin-Like Growth Factor-I Receptor Signaling in Colon Carcinoma Cells Stimulated by Members of the Tumor Necrosis Factor Superfamily. American Journal of Pathology, 2005, 167, 761-773.	1.9	64
519	Akt3 overexpression in the heart results in progression from adaptive to maladaptive hypertrophy. Journal of Molecular and Cellular Cardiology, 2005, 38, 375-385.	0.9	80
520	Inhibition of the cell cycle with chemical inhibitors: A targeted approach. Seminars in Cell and Developmental Biology, 2005, 16, 369-381.	2.3	13
521	FOXO Transcription Factors in Cell-Cycle Regulation and the Response to Oxidative Stress. Antioxidants and Redox Signaling, 2005, 7, 752-760.	2.5	204
522	Apoptotic Pathways and Therapy Resistance in Human Malignancies. Advances in Cancer Research, 2005, 94, 143-196.	1.9	85
523	Interleukin-6 Contributes to Mcl-1 Up-regulation and TRAIL Resistance via an Akt-Signaling Pathway in Cholangiocarcinoma Cells. Gastroenterology, 2005, 128, 2054-2065.	0.6	204
524	Cytokines and signal transduction. Best Practice and Research in Clinical Haematology, 2005, 18, 509-524.	0.7	78
525	Accelerating lead development by microwave-enhanced medicinal chemistry. Drug Discovery Today: Technologies, 2005, 2, 155-161.	4.0	53
526	COX-2 Inhibitor, NS398, Enhances Fas-Mediated Apoptosis via Modulation of the PTENâ€“Akt Pathway in Human Gastric Carcinoma Cell Lines. DNA and Cell Biology, 2005, 24, 141-147.	0.9	24
527	Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: A new therapeutic option. Leukemia and Lymphoma, 2005, 46, 11-19.	0.6	33
528	Discovery of 2-Arylthiazolidine-4-carboxylic Acid Amides as a New Class of Cytotoxic Agents for Prostate Cancerâ€. Journal of Medicinal Chemistry, 2005, 48, 2584-2588.	2.9	97
529	Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Research, 2005, 7, R609-16.	2.2	207
530	Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2. Breast Cancer Research, 2005, 7, R394-401.	2.2	54
531	A SURVEY OF NOVEL MOLECULAR TARGETS FOR ANTICANCER DRUG DISCOVERY. , 2006, , 1-35.		0
532	Mutation of the PIK3CA oncogene in human cancers. British Journal of Cancer, 2006, 94, 455-459.	2.9	444
533	Mechanisms of Gliomagenesis. , 2006, , 449-462.		1
536	Akt- and CREB-Mediated Prostate Cancer Cell Proliferation Inhibition by Nexrutine, a Phellodendron amurense Extract. Neoplasia, 2006, 8, 523-533.	2.3	59
537	mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt. Cancer Research, 2006, 66, 1500-1508.	0.4	2,329

#	Article	IF	Citations
538	Differential Roles of Phosphoinositide-Dependent Protein Kinase-1 and Akt1 Expression and Phosphorylation in Breast Cancer Cell Resistance to Paclitaxel, Doxorubicin, and Gemcitabine. Molecular Pharmacology, 2006, 70, 1045-1052.	1.0	48
539	Pharmacodynamic Biomarkers for Molecular Cancer Therapeutics. Advances in Cancer Research, 2006, 96, 213-268.	1.9	141
540	The new era in the treatment of advanced colorectal cancer patients: the role of monoclonal antibodies. Expert Opinion on Emerging Drugs, 2006, 11, 665-683.	1.0	1
541	Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opinion on Investigational Drugs, 2006, 15, 553-561.	1.9	108
542	Culicinin D, an Antitumor Peptaibol Produced by the FungusCulicinomycesclavisporus, StrainLL-12I252. Journal of Natural Products, 2006, 69, 736-741.	1.5	48
543	Pathways involved in sunburn cell formation: deregulation in skin cancer. Photochemical and Photobiological Sciences, 2006, 5, 199-207.	1.6	42
544	Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs. Molecular Cancer Therapeutics, 2006, 5, 2706-2715.	1.9	81
545	Identification of Small-Molecule Inhibitors of Protein Kinase B (PKB/AKT) in an AlphaScreenâ„¢ High-Throughput Screen. Journal of Biomolecular Screening, 2006, 11, 822-827.	2.6	30
546	Autophagy and Cancer Therapy. Autophagy, 2006, 2, 85-90.	4.3	284
547	Inositol Phosphates and Phosphoinositides in Health and Disease. , 2006, 39, 265-292.		42
548	Expression of Pax2 in Human Renal Tumor-Derived Endothelial Cells Sustains Apoptosis Resistance and Angiogenesis. American Journal of Pathology, 2006, 168, 706-713.	1.9	45
549	Activation of Mammalian Target of Rapamycin Signaling Promotes Cell Cycle Progression and Protects Cells from Apoptosis in Mantle Cell Lymphoma. American Journal of Pathology, 2006, 169, 2171-2180.	1.9	109
550	The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy: Fig. 1.. Clinical Cancer Research, 2006, 12, 5268-5272.	3.2	776
551	Mechanisms of Disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy. Nature Clinical Practice Oncology, 2006, 3, 564-574.	4.3	86
552	Increased cytotoxicity of ionizing radiation in combination with membrane-targeted apoptosis modulators involves downregulation of protein kinase B/Akt-mediated survival-signaling. Radiotherapy and Oncology, 2006, 80, 199-206.	0.3	33
553	p63 and epithelial biology. Experimental Cell Research, 2006, 312, 695-706.	1.2	119
554	Sodium arsenite accelerates TRAIL-mediated apoptosis in melanoma cells through upregulation of TRAIL-R1/R2 surface levels and downregulation of cFLIP expression. Experimental Cell Research, 2006, 312, 4120-4138.	1.2	31
555	Recent Advances in the Treatment of Malignant Astrocytoma. Journal of Clinical Oncology, 2006, 24, 1253-1265.	0.8	285

#	Article	IF	Citations
556	Targeting Tyrosine Kinases in Cancer: The Second Wave. Science, 2006, 312, 1175-1178.	6.0	437
557	Novel Targets for Anticancer Treatment Development in Colorectal Cancer. Clinical Colorectal Cancer, 2006, 6, 265-272.	1.0	10
558	Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt/protein kinase B. Molecular Cancer, 2006, 5, 71.	7.9	87
559	Targeting the ERK signaling pathway in cancer therapy. Annals of Medicine, 2006, 38, 200-211.	1.5	357
561	Respiratory Burst: Role in Signal Transduction in Alveolar Macrophages. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2006, 9, 27-39.	2.9	126
562	Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer, 2006, 51, 181-191.	0.9	322
563	Pegylated Wortmannin and 17-Hydroxywortmannin Conjugates as Phosphoinositide 3-Kinase Inhibitors Active in Human Tumor Xenograft Models. Journal of Medicinal Chemistry, 2006, 49, 1373-1378.	2.9	44
564	DNA Damageâ€"Induced Protein 14-3-3 Ïƒ Inhibits Protein Kinase B/Akt Activation and Suppresses Akt-Activated Cancer. Cancer Research, 2006, 66, 3096-3105.	0.4	79
565	Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. Journal of Cell Biology, 2006, 175, 913-923.	2.3	345
566	Genetics and biology of pancreatic ductal adenocarcinoma. Genes and Development, 2006, 20, 1218-1249.	2.7	1,118
567	TOR Signaling in Growth and Metabolism. Cell, 2006, 124, 471-484.	13.5	5,202
568	Inhibition of the PI3 kinase/Akt pathway enhances doxorubicin-induced apoptotic cell death in tumor cells in a p53-dependent manner. Biochemical and Biophysical Research Communications, 2006, 340, 560-566.	1.0	36
569	3,3â€²-Diindolylmethane downregulates pro-survival pathway in hormone independent prostate cancer. Biochemical and Biophysical Research Communications, 2006, 340, 718-725.	1.0	60
570	PI3 kinase is involved in cocaine behavioral sensitization and its reversal with brain area specificity. Biochemical and Biophysical Research Communications, 2006, 340, 1144-1150.	1.0	40
571	High-density lipoprotein is a potential growth factor for adrenocortical cells. Biochemical and Biophysical Research Communications, 2006, 344, 226-232.	1.0	18
572	IFN-Î± induces apoptosis of adipose tissue cells. Biochemical and Biophysical Research Communications, 2006, 345, 669-674.	1.0	22
573	A novel siRNA validation system for functional screening and identification of effective RNAi probes in mammalian cells. Biochemical and Biophysical Research Communications, 2006, 346, 707-720.	1.0	30
574	mTOR and cancer: reason for dancing at the crossroads?. Current Opinion in Genetics and Development, 2006, 16, 78-84.	1.5	75

#	Article	IF	Citations
575	Fra-1 a target for cancer prevention or intervention. Gene, 2006, 379, 1-11.	1.0	117
576	The phosphatidylinositol 3-kinase/Akt pathway regulates the HCCR-1 oncogene expression. Gene, 2006, 384, 18-26.	1.0	27
577	APAF-1 signaling in human melanoma. Cancer Letters, 2006, 238, 168-179.	3.2	37
578	ICAM-3-induced cancer cell proliferation through the PI3K/Akt pathway. Cancer Letters, 2006, 239, 103-110.	3.2	18
579	PTEN function in normal and neoplastic growth. Cancer Letters, 2006, 241, 184-196.	3.2	246
580	Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treatment Reviews, 2006, 32, 28-44.	3.4	112
581	Cross-talk between IGF-I and TGF-Î² signaling pathways. Cytokine and Growth Factor Reviews, 2006, 17, 59-74.	3.2	80
582	The clinical trail of TRAIL. European Journal of Cancer, 2006, 42, 2233-2240.	1.3	162
583	The Redox Regulation of PI 3-Kinaseâ€“Dependent Signaling. Antioxidants and Redox Signaling, 2006, 8, 1765-1774.	2.5	134
584	Dehydrotrametenolic acid selectively inhibits the growth of H-ras transformed rat2 cells and induces apoptosis through caspase-3 pathway. Life Sciences, 2006, 78, 607-613.	2.0	29
585	Enhancement of cytokine-mediated NF-ÎºB activation by phosphatidylinositol 3-kinase inhibitors in monocytic cells. International Immunopharmacology, 2006, 6, 908-915.	1.7	24
586	Novel Gemini-vitamin D3 analog inhibits tumor cell growth and modulates the Akt/mTOR signaling pathway. Journal of Steroid Biochemistry and Molecular Biology, 2006, 100, 107-116.	1.2	37
587	FGF signal transduction and the regulation of Cdx gene expression. Developmental Biology, 2006, 299, 478-488.	0.9	68
588	Epidermal growth factor receptor pathway inhibitors. Update on Cancer Therapeutics, 2006, 1, 299-310.	0.9	6
590	Biomolecular markers of breast cancer. Frontiers in Bioscience - Landmark, 2006, 11, 1818.	3.0	57
591	Predictive and prognostic role of activated mammalian target of rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy. Oncology Reports, 2006, 16, 57.	1.2	20
592	Treating Imatinib-Resistant Leukemia: The Next Generation Targeted Therapies. Scientific World Journal, The, 2006, 6, 918-930.	0.8	22
593	New Frontiers in the Treatment of Multiple Myeloma. Scientific World Journal, The, 2006, 6, 1475-1503.	0.8	10

#	Article	IF	Citations
596	Radiation Therapy and Apoptosis. , 0, , 1049-1086.		2
597	Cell Motility in Prostate Tumor Invasion and Metastasis. , 2006, , 301-338.		1
598	Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood, 2006, 107, 760-768.	0.6	80
599	AKT induces erythroid-cell maturation of JAK2-deficient fetal liver progenitor cells and is required for Epo regulation of erythroid-cell differentiation. Blood, 2006, 107, 1888-1891.	0.6	69
600	Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis. Blood, 2006, 107, 4834-4840.	0.6	79
601	Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood, 2006, 107, 4807-4816.	0.6	246
602	Role of phosphatidylinositol 3â€²-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood, 2006, 108, 4178-4186.	0.6	241
603	Akt phosphorylates and suppresses the transactivation of retinoic acid receptor Î±. Biochemical Journal, 2006, 395, 653-662.	1.7	47
604	Vanillin derivative 6-bromine-5-hydroxy-4-methoxybenzaldehyde-elicited apoptosis and G2/M arrest of Jurkat cells proceeds concurrently with DNA-PKcs cleavage and Akt inactivation. International Journal of Oncology, 2006, 29, 1167.	1.4	1
605	Protein Synthesis and Cancer. , 2006, , 180-194.		0
608	Mouse embryocarcinoma F9 cells and retinoic acid: A model to study the molecular mechanisms of endodermal differentiation. Advances in Developmental Biology (Amsterdam, Netherlands), 2006, 16, 211-253.	0.4	5
609	Targeting Phospholipase D-mediated Survival Signals in Cancer. Current Signal Transduction Therapy, 2006, 1, 295-303.	0.3	18
610	Emerging biomarkers in prostate cancer. Aging Health, 2006, 2, 579-588.	0.3	2
611	Cell Cycle Inhibition in Malignant Lymphoma: Disease Control by Attacking the Cellular Proliferation Machinery. Current Drug Targets, 2006, 7, 1349-1359.	1.0	4
612	Targeting mTOR Signaling for Lung Cancer Therapy. Journal of Thoracic Oncology, 2006, 1, 109-111.	0.5	8
613	The Relevance of Microdialysis for Clinical Oncology. Current Clinical Pharmacology, 2006, 1, 255-263.	0.2	15
614	Oncogenic PI3K and its role in cancer. Current Opinion in Oncology, 2006, 18, 77-82.	1.1	454
615	On our way to targeted therapy for cachexia in cancer?. Current Opinion in Oncology, 2006, 18, 335-340.	1.1	25

#	Article	IF	Citations
616	New drugs in prostate cancer. Current Opinion in Urology, 2006, 16, 138-145.	0.9	25
617	The Targeting of Phosphoinositide-3 Kinase Attenuates Pulmonary Metastatic Tumor Growth Following Laparotomy. Annals of Surgery, 2006, 243, 250-256.	2.1	15
618	Potential of the Akt inhibitor LY294005 to antagonize the efficacy of Cisplatin against HCT116 tumor cells in a DNA mismatch repair-dependent manner. International Journal of Oncology, 2006, 29, 1303.	1.4	1
619	Clinical experience with erlotinib in non-small-cell lung cancer (NSCLC). Drugs of Today, 2006, 42, 147.	0.7	17
620	EGF-induced activation of Akt results in mTOR-dependent p70S6 kinase phosphorylation and inhibition of HC11 cell lactogenic differentiation. BMC Cell Biology, 2006, 7, 34.	3.0	55
621	Akt1 sequentially phosphorylates p27kip1 within a conserved but non-canonical region. Cell Division, 2006, 1, 11.	1.1	23
622	PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. Journal of Pathology, 2006, 208, 350-355.	2.1	99
623	Proteome profile changes that are differentially regulated by lipid and protein phosphatase activities of tumor suppressor PTEN in PTEN-expressing U-87 MG human glioblastoma cells. Proteomics, 2006, 6, 81-93.	1.3	14
624	Signalling mechanisms mediated by the phosphoinositide 3-kinase/Akt cascade in synaptic plasticity and memory in the rat. European Journal of Neuroscience, 2006, 23, 3375-3384.	1.2	243
625	Targeted Molecular Therapy of GBM. Brain Pathology, 2003, 13, 52-61.	2.1	201
626	Genetic Alterations and Aberrant Expression of Genes Related to the Phosphatidylâ€inositolâ€3â€²â€Kinase/Protein Kinase B (Akt) Signal Transduction Pathway in Glioblastomas. Brain Pathology, 2003, 13, 507-518.	2.1	200
627	Genetic Alterations of Phosphoinositide 3â€kinase Subunit Genes in Human Glioblastomas. Brain Pathology, 2004, 14, 372-377.	2.1	116
628	Expression of insulin-like growth factor-1 receptor, p-AKT and p-ERK1/2 protein in extramammary Paget's disease. British Journal of Dermatology, 2006, 155, 586-591.	1.4	19
629	ERK MAP kinase in G1 cell cycle progression and cancer. Cancer Science, 2006, 97, 697-702.	1.7	217
630	PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma. Cancer Science, 2006, 97, 1351-1358.	1.7	137
631	Drugging the PI3 kinome. Nature Biotechnology, 2006, 24, 794-796.	9.4	65
632	RNAi in moderation. Nature Biotechnology, 2006, 24, 796-797.	9.4	31
633	Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nature Cell Biology, 2006, 8, 877-884.	4.6	515

#	Article	IF	Citations
634	Small moleculeâ€“based reversible reprogramming of cellular lifespan. Nature Chemical Biology, 2006, 2, 369-374.	3.9	62
635	Mapping normal and cancer cell signalling networks: towards single-cell proteomics. Nature Reviews Cancer, 2006, 6, 146-155.	12.8	297
636	Current development of mTOR inhibitors as anticancer agents. Nature Reviews Drug Discovery, 2006, 5, 671-688.	21.5	861
637	The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature Reviews Genetics, 2006, 7, 606-619.	7.7	2,833
638	Predicted mechanisms of resistance to mTOR inhibitors. British Journal of Cancer, 2006, 95, 955-960.	2.9	82
639	Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma. Laboratory Investigation, 2006, 86, 748-766.	1.7	28
640	The Akt pathway in human breast cancer: a tissue-array-based analysis. Modern Pathology, 2006, 19, 238-245.	2.9	166
641	Agonists of an ecdysone-inducible mammalian expression system inhibit Fas Ligand- and TRAIL-induced apoptosis in the human colon carcinoma cell line RKO. Cell Death and Differentiation, 2006, 13, 189-201.	5.0	38
642	Adi3 is a Pdk1-interacting AGC kinase that negatively regulates plant cell death. EMBO Journal, 2006, 25, 255-265.	3.5	78
643	Novel roles of Akt and mTOR in suppressing TGF-Î²/ALK5-mediated Smad3 activation. EMBO Journal, 2006, 25, 58-69.	3.5	169
644	Phosphoinositide 3-kinase controls early and late events in mammalian cell division. EMBO Journal, 2006, 25, 655-661.	3.5	118
645	Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway. EMBO Journal, 2006, 25, 3943-3954.	3.5	76
646	The Selective Protein Kinase C Î² Inhibitor Enzastaurin Induces Apoptosis in Cutaneous T-Cell Lymphoma Cell Lines through the AKT Pathway. Journal of Investigative Dermatology, 2006, 126, 1641-1647.	0.3	89
647	Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients. Leukemia, 2006, 20, 230-238.	3.3	96
648	Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C. Leukemia, 2006, 20, 610-619.	3.3	40
649	Activated type I TGFÎ² receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene, 2006, 25, 3408-3423.	2.6	133
650	PTEN and GSK3Î²: key regulators of progression to androgen-independent prostate cancer. Oncogene, 2006, 25, 329-337.	2.6	193
651	Molecular determinants of Akt-induced keratinocyte transformation. Oncogene, 2006, 25, 1174-1185.	2.6	84

#	Article	IF	Citations
652	RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors. Oncogene, 2006, 25, 1340-1348.	2.6	55
653	Elevated levels of ornithine decarboxylase cooperate with Raf/ERK activation to convert normal keratinocytes into invasive malignant cells. Oncogene, 2006, 25, 1543-1553.	2.6	22
654	The phosphoinositide 3-kinase/Akt pathway is essential for the retinoic acid-induced differentiation of F9 cells. Oncogene, 2006, 25, 2040-2047.	2.6	38
655	Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients. Oncogene, 2006, 25, 2950-2952.	2.6	71
656	Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential. Oncogene, 2006, 25, 2860-2872.	2.6	62
657	MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer. Oncogene, 2006, 25, 3335-3345.	2.6	86
658	Negative cell cycle regulator 14-3-3Ïƒ stabilizes p27 Kip1 by inhibiting the activity of PKB/Akt. Oncogene, 2006, 25, 4585-4594.	2.6	47
659	Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase. Oncogene, 2006, 25, 6092-6100.	2.6	89
660	Evaluation of potential mechanisms underlying genotypeâ€“phenotype correlations in multiple endocrine neoplasia type 2. Oncogene, 2006, 25, 6637-6647.	2.6	40
661	A selective inhibitor of the p110Î´ isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene, 2006, 25, 6648-6659.	2.6	149
662	Targeting survivin via PI3K but not c-akt/PKB by anticancer drugs in immature neutrophils. Oncogene, 2006, 25, 6915-6923.	2.6	24
663	Akt signalling through GSK-3Î², mTOR and Foxo1 is involved in human skeletal muscle hypertrophy and atrophy. Journal of Physiology, 2006, 576, 923-933.	1.3	311
664	Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors. Bioorganic and Medicinal Chemistry, 2006, 14, 6832-6846.	1.4	74
665	Synthesis and structureâ€“activity relationship of 3,4â€²-bispyridinylethylenes: Discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 2000-2007.	1.0	36
666	Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3740-3744.	1.0	22
667	Synthesis and biological evaluation of 5-arylamino-6-chloro-1H-indazole-4,7-diones as inhibitors of protein kinase B/Akt. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 6001-6005.	1.0	26
668	Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy. International Journal of Radiation Oncology Biology Physics, 2006, 64, 38-46.	0.4	50
669	A Structurally Optimized Celecoxib Derivative Inhibits Human Pancreatic Cancer Cell Growth. Journal of Gastrointestinal Surgery, 2006, 10, 207-214.	0.9	25

#	Article	IF	Citations
670	Antitumor Activity of ZSTK474, a New Phosphatidylinositol 3-Kinase Inhibitor. Journal of the National Cancer Institute, 2006, 98, 545-556.	3.0	369
671	Girdin, a Novel Actin-Binding Protein, and Its Family of Proteins Possess Versatile Functions in the Akt and Wnt Signaling Pathways. Annals of the New York Academy of Sciences, 2006, 1086, 169-184.	1.8	82
672	Mirk/Dyrk1B: A Multifunctional Dual-Specificity Kinase Involved in Growth Arrest, Differentiation, and Cell Survival. Cell Biochemistry and Biophysics, 2006, 45, 303-315.	0.9	53
673	Prediction of Anticancer Drug Potency from Expression of Genes Involved in Growth Factor Signaling. Pharmaceutical Research, 2006, 23, 336-349.	1.7	25
674	RET and neuroendocrine tumors. Pituitary, 2006, 9, 179-192.	1.6	32
675	Importin KPNA2, NBS1, DNA Repair and Tumorigenesis. Journal of Molecular Histology, 2006, 37, 293-299.	1.0	47
676	Functional Role of Phosphatidylinositol 3-kinase/Akt Pathway on Cell Growth and Lytic Cycle of Epsteinâ€“Barr Virus in the Burkittâ€™s Lymphoma Cell Line, P3HR-1. Virus Genes, 2006, 32, 327-334.	0.7	4
677	Modulation of the Akt/Ras/Raf/MEK/ERK pathway by A3 adenosine receptor. Purinergic Signalling, 2006, 2, 627-632.	1.1	30
678	PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Research and Treatment, 2006, 96, 91-95.	1.1	190
679	Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression. Breast Cancer Research and Treatment, 2006, 95, 185-194.	1.1	74
680	The Effects of Antisense AKT2 RNA on the Inhibition of Malignant Glioma Cell Growth in vitro and in vivo. Journal of Neuro-Oncology, 2006, 76, 1-11.	1.4	46
681	Curcumin induces apoptosis via inhibition of PI3â€²-kinase/AKT pathway in Acute T cell Leukemias. Apoptosis: an International Journal on Programmed Cell Death, 2006, 11, 245-254.	2.2	174
682	Rare mutation of PIK3CA in meningiomas. Acta Neuropathologica, 2006, 111, 284-285.	3.9	19
683	New fundamental resistance exercise determinants of molecular and cellular muscle adaptations. European Journal of Applied Physiology, 2006, 97, 643-663.	1.2	317
684	Inhibition of cytokinesis and akt phosphorylation by chaetoglobosin K in ras-transformed epithelial cells. Cancer Chemotherapy and Pharmacology, 2006, 57, 741-754.	1.1	12
685	Discovery of trans-3,4â€²-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 1679-1685.	1.0	41
686	Isoquinolineâ€“pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3150-3155.	1.0	39
687	Discovery and SAR of oxindoleâ€“pyridine-based protein kinase B/Akt inhibitors for treating cancers. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3424-3429.	1.0	54

#	Article	IF	Citations
688	Insulin-Like Growth Factor (IGF) family and prostate cancer. Critical Reviews in Oncology/Hematology, 2006, 58, 124-145.	2.0	135
689	What signals are generated by anti-CD20 antibody therapy?. Current Hematologic Malignancy Reports, 2006, 1, 205-213.	1.2	8
690	A small molecule compound inhibits AKT pathway in ovarian cancer cell lines. Gynecologic Oncology, 2006, 100, 308-317.	0.6	36
691	Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genetics and Cytogenetics, 2006, 169, 128-137.	1.0	151
692	A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell, 2006, 9, 341-349.	7.7	575
693	NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell, 2006, 9, 367-378.	7.7	155
694	Kinase inhibitors: Vice becomes virtue. Cancer Cell, 2006, 9, 327-328.	7.7	19
695	At the gates of death. Cancer Cell, 2006, 9, 328-330.	7.7	128
696	The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell, 2006, 10, 133-143.	7.7	180
697	Resveratrol modulation of signal transduction in apoptosis and cell survival: A mini-review. Cancer Detection and Prevention, 2006, 30, 217-223.	2.1	132
698	Clozapine, a neuroleptic agent, inhibits Akt by counteracting Ca2+/calmodulin in PTEN-negative U-87MG human glioblastoma cells. Cellular Signalling, 2006, 18, 1876-1886.	1.7	40
699	Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cellular Signalling, 2006, 18, 2262-2271.	1.7	193
700	Regulation of chemotaxis by the orchestrated activation of Ras, PI3K, and TOR. European Journal of Cell Biology, 2006, 85, 873-895.	1.6	114
701	C. elegans DAF-18/PTEN Mediates Nutrient-Dependent Arrest of Cell Cycle and Growth in the Germline. Current Biology, 2006, 16, 773-779.	1.8	176
702	G-Protein Signaling: A New Branch in an Old Pathway. Current Biology, 2006, 16, R853-R855.	1.8	2
703	Inhibition of phosphatidylinositol 3-kinase-mediated glucose metabolism coincides with resveratrol-induced cell cycle arrest in human diffuse large B-cell lymphomas. Biochemical Pharmacology, 2006, 72, 1246-1256.	2.0	67
704	RNA interference targeting Akt promotes apoptosis in hypoxia-exposed human neuroblastoma cells. Brain Research, 2006, 1070, 24-30.	1.1	12
705	S6k1 is not required for Pten-deficient neuronal hypertrophy. Brain Research, 2006, 1100, 32-41.	1.1	20

#	Article	IF	Citations
706	Future Directions in the Treatment of Hormone-Sensitive Advanced Breast Cancer: The RAD001 (Everolimus)-Letrozole Clinical Program. Seminars in Oncology, 2006, 33, 18-25.	0.8	23
707	Epidermal Growth Factor Receptor Targeting in Cancer. Seminars in Oncology, 2006, 33, 369-385.	0.8	645
708	New Paradigms in Anticancer Therapy: Targeting Multiple Signaling Pathways With Kinase Inhibitors. Seminars in Oncology, 2006, 33, 407-420.	0.8	242
709	Mammalian Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Current Status and Future Applications. Seminars in Oncology, 2006, 33, 607-613.	0.8	24
710	Regulation of the p53-MDM2 pathway by 14-3-3 Ïƒ and other proteins. Seminars in Cancer Biology, 2006, 16, 225-234.	4.3	100
711	Autophagy in the control of programmed cell death. Current Opinion in Plant Biology, 2006, 9, 391-396.	3.5	58
712	RET receptor signaling: Dysfunction in thyroid cancer and Hirschsprung's disease. Pathology International, 2006, 56, 164-172.	0.6	72
713	Cell cycle control in breast cancer cells. Journal of Cellular Biochemistry, 2006, 97, 261-274.	1.2	184
714	Ginsenoside Rg1 inhibits tumor necrosis factor-Î± (TNF-Î±)-induced human arterial smooth muscle cells (HASMCs) proliferation. Journal of Cellular Biochemistry, 2006, 98, 1471-1481.	1.2	34
715	c-Myc-dependent etoposide-induced apoptosis involves activation of Bax and caspases, and PKCdelta signaling. Journal of Cellular Biochemistry, 2006, 98, 1597-1614.	1.2	38
716	RNAi-mediated silencing of insulin receptor substrate 1 (IRS-1) enhances tamoxifen-induced cell death in MCF-7 breast cancer cells. Journal of Cellular Biochemistry, 2006, 98, 440-450.	1.2	41
717	Co-overexpression offibroblast growth factor 3 andepidermal growth factor receptor is correlated with the development of nonsmall cell lung carcinoma. Cancer, 2006, 106, 146-155.	2.0	24
718	Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: FrequentPIK3CAamplification and AKT phosphorylation. International Journal of Cancer, 2006, 118, 1877-1883.	2.3	137
719	In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. International Journal of Cancer, 2006, 118, 2337-2343.	2.3	108
720	Vitamin E analogues as anticancer agents: Lessons from studies with Î±-tocopheryl succinate. Molecular Nutrition and Food Research, 2006, 50, 675-685.	1.5	69
721	The role of histone H3 phosphorylation (Ser10 and Ser28) in cell growth and cell transformation. Molecular Carcinogenesis, 2006, 45, 416-421.	1.3	39
722	Molecular and cellular targets. Molecular Carcinogenesis, 2006, 45, 422-430.	1.3	41
723	Roles of reactive oxygen species in hepatocarcinogenesis and drug resistance gene expression in liver cancers. Molecular Carcinogenesis, 2006, 45, 701-709.	1.3	75

#	Article	IF	Citations
724	Pathophysiology Defined by Altered Signal Transduction Pathways: The Role of JAK-STAT and PI3K Signaling in Leukemic Large Granular Lymphocytes. Cell Cycle, 2006, 5, 2571-2574.	1.3	47
725	Comparative study of gene expression by cDNA microarray in human colorectal cancer tissues and normal mucosa. International Journal of Oncology, 2006, 29, 83.	1.4	43
726	EGFR Tyrosine Kinase Inhibitors Decrease VEGF Expression by Both Hypoxia-Inducible Factor (HIF)-1â€“Independent and HIF-1â€“Dependent Mechanisms. Cancer Research, 2006, 66, 3197-3204.	0.4	256
727	Inhibition of the phosphatidylinositol 3-kinase/Akt pathway sensitizes MDA-MB468 human breast cancer cells to cerulenin-induced apoptosis. Molecular Cancer Therapeutics, 2006, 5, 494-501.	1.9	55
728	Mutational hotspot in Exon 20 of PIK3CA in breast cancer among singapore chinese. Cancer Biology and Therapy, 2006, 5, 544-548.	1.5	19
729	Regulation of the RAP1/RAF-1/Extracellularly Regulated Kinase-1/2 Cascade and Prolactin Release by the Phosphoinositide 3-Kinase/AKT Pathway in Pituitary Cells. Endocrinology, 2006, 147, 6036-6045.	1.4	33
730	Human Tumor Mutants in PI3K p110α Subunit. Cell Cycle, 2006, 5, 675-677.	1.3	48
731	Akt/PKB Signaling in Cancer: A Function in Cell Motility and Invasion. Cell Cycle, 2006, 5, 603-605.	1.3	142
732	Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14477-14482.	3.3	120
733	Activating Transcription Factor 3 and Early Growth Response 1 Are the Novel Targets of LY294002 in a Phosphatidylinositol 3-Kinaseâ€“Independent Pathway. Cancer Research, 2006, 66, 2376-2384.	0.4	65
734	Determinants of Sensitivity and Resistance to Rapamycin-Chemotherapy Drug Combinations In vivo. Cancer Research, 2006, 66, 7639-7646.	0.4	96
735	Recent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain. Expert Opinion on Investigational Drugs, 2006, 15, 669-690.	1.9	19
736	Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells. Molecular Cancer Therapeutics, 2006, 5, 187-196.	1.9	84
737	Celecoxib Inhibits Interleukin-12 Î±Î² and Î²2 Folding and Secretion by a Novel COX2-Independent Mechanism Involving Chaperones of the Endoplasmic Reticulum. Molecular Pharmacology, 2006, 69, 1579-1587.	1.0	40
738	High-throughput mutational analysis of the human cancer genome. Pharmacogenomics, 2006, 7, 597-612.	0.6	15
739	Therapeutic targets: MTOR and related pathways. Cancer Biology and Therapy, 2006, 5, 1065-1073.	1.5	179
740	Deactivation of phosphatidylinositol 3,4,5-trisphosphate/Akt signaling mediates neutrophil spontaneous death. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14836-14841.	3.3	78
741	Protein Kinase B/Akt-Dependent Phosphorylation of Glycogen Synthase Kinase-3Î² in Irradiated Vascular Endothelium. Cancer Research, 2006, 66, 2320-2327.	0.4	43

#	Article	IF	Citations
742	Role of AKT in cyclic strain-induced endothelial cell proliferation and survival. American Journal of Physiology - Cell Physiology, 2006, 290, C812-C821.	2.1	49
743	IGF-1 is downregulated in experimental cancer cachexia. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2006, 291, R674-R683.	0.9	149
744	Combined Signaling through ERK, PI3K/AKT, and RAC1/p38 Is Required for Met-triggered Cortical Neuron Migration. Journal of Biological Chemistry, 2006, 281, 4771-4778.	1.6	97
745	Akt1 Activation Can Augment Hypoxia-Inducible Factor-1Î± Expression by Increasing Protein Translation through a Mammalian Target of Rapamycinâ€"Independent Pathway. Molecular Cancer Research, 2006, 4, 471-479.	1.5	167
746	Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Molecular Cancer Therapeutics, 2006, 5, 1197-1208.	1.9	93
747	Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Molecular Cancer Therapeutics, 2006, 5, 637-644.	1.9	95
748	Violacein synergistically increases 5-fluorouracil cytotoxicity, induces apoptosis and inhibits Akt-mediated signal transduction in human colorectal cancer cells. Carcinogenesis, 2006, 27, 508-516.	1.3	129
749	CARMA1 Is Required for Akt-Mediated NF-ÎºB Activation in T Cells. Molecular and Cellular Biology, 2006, 26, 2327-2336.	1.1	78
750	Regulation of epidermal homeostasis and repair by phosphoinositide 3-kinase. Journal of Cell Science, 2006, 119, 4033-4046.	1.2	51
751	Peptide Aptamers with Binding Specificity for the Intracellular Domain of the ErbB2 Receptor Interfere with AKT Signaling and Sensitize Breast Cancer Cells to Taxol. Molecular Cancer Research, 2006, 4, 983-998.	1.5	34
752	PTEN Loss Promotes rasHa-Mediated Papillomatogenesis via Dual Up-Regulation of AKT Activity and Cell Cycle Deregulation but Malignant Conversion Proceeds via PTEN-Associated Pathways. Cancer Research, 2006, 66, 1302-1312.	0.4	29
753	The Akt inhibitor deguelin, is an angiopreventive agent also acting on the NF-ÂB pathway. Carcinogenesis, 2006, 28, 404-413.	1.3	59
754	FOXO1A Is a Candidate for the 13q14 Tumor Suppressor Gene Inhibiting Androgen Receptor Signaling in Prostate Cancer. Cancer Research, 2006, 66, 6998-7006.	0.4	124
755	Epidermal Growth Factor Receptorâ€"Mediated Signal Transduction in the Development and Therapy of Gliomas. Clinical Cancer Research, 2006, 12, 7261-7270.	3.2	193
756	Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway. Clinical Cancer Research, 2006, 12, 679-689.	3.2	178
757	Involvement of Protein Kinase Cîµ in the Negative Regulation of Akt Activation Stimulated by Granulocyte Colony-Stimulating Factor. Journal of Immunology, 2006, 176, 2407-2413.	0.4	15
758	Increased NBS1 Expression Is a Marker of Aggressive Head and Neck Cancer and Overexpression of NBS1 Contributes to Transformation. Clinical Cancer Research, 2006, 12, 507-515.	3.2	73
759	Conjugated linoleic acid stimulates an anti-tumorigenic protein NAG-1 in an isomer specific manner. Carcinogenesis, 2006, 27, 972-981.	1.3	111

#	Article	IF	Citations
760	Downregulation of PIK3CB by siRNA Suppresses Malignant Glioma Cell Growth In Vitro and In Vivo. Technology in Cancer Research and Treatment, 2006, 5, 271-280.	0.8	51
761	Role for Akt/Protein Kinase B and Activator Protein-1 in Cellular Proliferation Induced by the Human T-cell Leukemia Virus Type 1 Tax Oncoprotein. Journal of Biological Chemistry, 2006, 281, 8927-8938.	1.6	78
762	The Phosphoinositide 3-Kinase/Akt1/Par-4 Axis: A Cancer-Selective Therapeutic Target: Figure 1.. Cancer Research, 2006, 66, 2889-2892.	0.4	87
763	RNA Interferenceâ€“Mediated Depletion of Phosphoinositide 3-Kinase Activates Forkhead Box Class O Transcription Factors and Induces Cell Cycle Arrest and Apoptosis in Breast Carcinoma Cells. Cancer Research, 2006, 66, 1062-1069.	0.4	46
764	Genetics of Lung Cancer: Current Thinking on Genetic Predisposition to the Disease and Response to Treatment. , 2006, , 57-66.		0
765	Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts. Molecular Cancer Therapeutics, 2006, 5, 2494-2502.	1.9	26
766	A Novel Function of Plasminogen Activator Inhibitor-1 in Modulation of the AKT Pathway in Wild-type and Plasminogen Activator Inhibitor-1-deficient Endothelial Cells. Journal of Biological Chemistry, 2006, 281, 22527-22536.	1.6	52
767	Silibinin inhibits UVB- and epidermal growth factorâ€“induced mitogenic and cell survival signaling involving activator protein-1 and nuclear factor-Î°B in mouse epidermal JB6 cells. Molecular Cancer Therapeutics, 2006, 5, 1145-1153.	1.9	41
768	A Specific Role for AKT3 in the Genesis of Ovarian Cancer through Modulation of G2-M Phase Transition. Cancer Research, 2006, 66, 11718-11725.	0.4	85
769	Hodgkinâ€™s lymphoma: molecular targets and novel treatment strategies. Future Oncology, 2006, 2, 533-551.	1.1	5
770	Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 1492-1497.	3.3	257
771	Mutations in the PI3K/PTEN/TSC2 Pathway Contribute to Mammalian Target of Rapamycin Activity and Increased Translation under Hypoxic Conditions. Cancer Research, 2006, 66, 1561-1569.	0.4	77
772	Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma. Clinical Cancer Research, 2006, 12, 860-868.	3.2	187
773	Chemokines, chemokine receptors, and cancer metastasis. Journal of Leukocyte Biology, 2006, 79, 639-651.	1.5	289
774	Nelfinavir Down-regulates Hypoxia-Inducible Factor 1Î± and VEGF Expression and Increases Tumor Oxygenation: Implications for Radiotherapy. Cancer Research, 2006, 66, 9252-9259.	0.4	147
775	Role of Nongenomic Activation of Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase/Extracellular Signal-Regulated Kinase 1/2 Pathways in 1,25D3-Mediated Apoptosis in Squamous Cell Carcinoma Cells. Cancer Research, 2006, 66, 8131-8138.	0.4	46
776	Phosphatidylinositol 3â€²-Kinase/AKT Signaling Is Activated in Medulloblastoma Cell Proliferation and Is Associated with Reduced Expression of PTEN. Clinical Cancer Research, 2006, 12, 3019-3027.	3.2	140
777	Peroxisome Proliferatorâ€“Activated Receptor Î± Activation Decreases Metastatic Potential of Melanoma Cells In vitro via Down-Regulation of Akt. Clinical Cancer Research, 2006, 12, 3028-3036.	3.2	142

#	Article	IF	Citations
778	Expression of the Gene Encoding Poly(ADP-ribose) Polymerase-1 Is Modulated by Fibronectin during Corneal Wound Healing. , 2006, 47, 4199.		12
779	The Insulin-Like Growth Factor I Receptor Is Required for Akt Activation and Suppression of Anoikis in Cells Transformed by the ETV6-NTRK3 Chimeric Tyrosine Kinase. Molecular and Cellular Biology, 2006, 26, 1754-1769.	1.1	65
780	Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts. Human Reproduction Update, 2006, 13, 121-141.	5.2	434
781	A FoxO-Smad synexpression group in human keratinocytes. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 12747-12752.	3.3	221
782	A Phosphatidylinositol 3-Kinase-regulated Akt-Independent Signaling Promotes Cigarette Smoke-induced FRA-1 Expression. Journal of Biological Chemistry, 2006, 281, 10174-10181.	1.6	42
783	The Mucin Muc4 Potentiates Neuregulin Signaling by Increasing the Cell-surface Populations of ErbB2 and ErbB3. Journal of Biological Chemistry, 2006, 281, 19310-19319.	1.6	79
784	Hedgehog/Ras interactions regulate early stages of pancreatic cancer. Genes and Development, 2006, 20, 3161-3173.	2.7	270
785	PIK3CA Mutations in Intraductal Papillary Mucinous Neoplasm/Carcinoma of the Pancreas. Clinical Cancer Research, 2006, 12, 3851-3855.	3.2	155
786	From Melanocytes to Melanoma. , 2006, , .		21
787	Regulation of Survivin by ErbB2 Signaling: Therapeutic Implications for ErbB2-Overexpressing Breast Cancers. Cancer Research, 2006, 66, 1640-1647.	0.4	139
788	RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors. Endocrine Reviews, 2006, 27, 535-560.	8.9	311
789	Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme. Expert Review of Anticancer Therapy, 2006, 6, 1313-1322.	1.1	22
790	The Regulation of Self-Renewal in Human Embryonic Stem Cells. Stem Cells and Development, 2006, 15, 729-740.	1.1	75
791	Phospholipase D Couples Survival and Migration Signals in Stress Response of Human Cancer Cells. Journal of Biological Chemistry, 2006, 281, 15862-15868.	1.6	126
792	Only Akt1 Is Required for Proliferation, while Akt2 Promotes Cell Cycle Exit through p21 Binding. Molecular and Cellular Biology, 2006, 26, 8267-8280.	1.1	153
793	Suppression of Insulin Receptor Substrate 1 (IRS-1) Promotes Mammary Tumor Metastasis. Molecular and Cellular Biology, 2006, 26, 9338-9351.	1.1	79
794	Pharmacodynamic Studies of Gefitinib in Tumor Biopsy Specimens From Patients With Advanced Gastric Carcinoma. Journal of Clinical Oncology, 2006, 24, 4309-4316.	0.8	129
795	Opioids Trigger Î±5Î²1 Integrin-Mediated Monocyte Adhesion. Journal of Immunology, 2006, 176, 1675-1685.	0.4	26

#	Article	IF	Citations
796	PTEN Deletion Leads to Up-regulation of a Secreted Growth Factor Pleiotrophin. Journal of Biological Chemistry, 2006, 281, 10663-10668.	1.6	28
798	Transcriptional Profiles in Liver from Rats Treated with Tumorigenic and Non-tumorigenic Triazole Conazole Fungicides: Propiconazole, Triadimefon, and Myclobutanil. Toxicologic Pathology, 2006, 34, 879-894.	0.9	53
799	TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt. British Journal of Cancer, 2006, 94, 398-406.	2.9	31
800	Increased expression of pAKT is associated with radiation resistance in cervical cancer. British Journal of Cancer, 2006, 94, 1678-1682.	2.9	108
801	Emergence of Androgen Independence at Early Stages of Prostate Cancer Progression in Nkx3.1; Pten Mice. Cancer Research, 2006, 66, 7929-7933.	0.4	80
802	Activation of Mammalian Target of Rapamycin Signaling Pathway Contributes to Tumor Cell Survival in Anaplastic Lymphoma Kinaseâ€“Positive Anaplastic Large Cell Lymphoma. Cancer Research, 2006, 66, 6589-6597.	0.4	187
803	Frequent Alterations in the Expression of Serine/Threonine Kinases in Human Cancers. Cancer Research, 2006, 66, 8147-8154.	0.4	168
804	Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Molecular Cancer Therapeutics, 2006, 5, 1559-1570.	1.9	92
805	Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 4134-4139.	3.3	173
806	Activation of Î²-Catenin Signaling in Prostate Cancer by Peptidyl-Prolyl Isomerase Pin1-Mediated Abrogation of the Androgen Receptor-Î²-Catenin Interaction. Molecular and Cellular Biology, 2006, 26, 929-939.	1.1	65
807	Phospholipase D Prevents Etoposide-Induced Apoptosis by Inhibiting the Expression of Early Growth Response-1 and Phosphatase and Tensin Homologue Deleted on Chromosome 10. Cancer Research, 2006, 66, 784-793.	0.4	38
809	The connection between splicing and cancer. Journal of Cell Science, 2006, 119, 2635-2641.	1.2	318
810	A Peptide Conjugate of Vitamin E Succinate Targets Breast Cancer Cells with High ErbB2 Expression. Cancer Research, 2007, 67, 3337-3344.	0.4	84
811	Protein kinase B/Akt: a nexus of growth factor and cytokine signaling in determining muscle mass. Journal of Applied Physiology, 2007, 103, 378-387.	1.2	157
812	Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives. Expert Review of Molecular Diagnostics, 2007, 7, 821-836.	1.5	12
813	Twist Transcriptionally Up-regulates AKT2 in Breast Cancer Cells Leading to Increased Migration, Invasion, and Resistance to Paclitaxel. Cancer Research, 2007, 67, 1979-1987.	0.4	506
814	STAT5 Is Essential for Akt/p70S6 Kinase Activity during IL-2-Induced Lymphocyte Proliferation. Journal of Immunology, 2007, 179, 5301-5308.	0.4	49
815	S100B and S100A6 Differentially Modulate Cell Survival by Interacting with Distinct RAGE (Receptor) Tj ETQq1 1 0.784314 rgBT /Ove 2007, 282, 31317-31331.	1.6	234

#	Article	IF	Citations
816	Down-regulation of Phosphoglucose Isomerase/Autocrine Motility Factor Expression Sensitizes Human Fibrosarcoma Cells to Oxidative Stress Leading to Cellular Senescence. Journal of Biological Chemistry, 2007, 282, 36362-36369.	1.6	27
817	The Energy Sensor AMP-activated Protein Kinase Directly Regulates the Mammalian FOXO3 Transcription Factor. Journal of Biological Chemistry, 2007, 282, 30107-30119.	1.6	691
818	Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 11736-11741.	3.3	125
819	Protein Kinase C-mediated Down-regulation of Cyclin D1 Involves Activation of the Translational Repressor 4E-BP1 via a Phosphoinositide 3-Kinase/Akt-independent, Protein Phosphatase 2A-dependent Mechanism in Intestinal Epithelial Cells. Journal of Biological Chemistry, 2007, 282, 14213-14225.	1.6	78
820	Tissue-specific Autophagy Alterations and Increased Tumorigenesis in Mice Deficient in Atg4C/Autophagin-3. Journal of Biological Chemistry, 2007, 282, 18573-18583.	1.6	360
821	FoxO transcription factors suppress Myc-driven lymphomagenesis via direct activation of Arf. Genes and Development, 2007, 21, 2775-2787.	2.7	116
822	Phosphatidylinositol Ether Lipid Analogues That Inhibit AKT Also Independently Activate the Stress Kinase, p38Î±, through MKK3/6-independent and -dependent Mechanisms. Journal of Biological Chemistry, 2007, 282, 27020-27029.	1.6	49
823	Lapatinib Antitumor Activity Is Not Dependent upon Phosphatase and Tensin Homologue Deleted on Chromosome 10 in ErbB2-Overexpressing Breast Cancers. Cancer Research, 2007, 67, 1170-1175.	0.4	143
824	The Phosphoinositide-Dependent Kinase-1 Inhibitor 2-Amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) Prevents Y-Box Binding Protein-1 from Inducing Epidermal Growth Factor Receptor. Molecular Pharmacology, 2007, 72, 641-652.	1.0	32
825	Targeting Protein Translation in Human Nonâ€“Small Cell Lung Cancer via Combined MEK and Mammalian Target of Rapamycin Suppression. Cancer Research, 2007, 67, 11300-11308.	0.4	88
826	Emerging drugs for the treatment of pancreatic cancer. Expert Opinion on Emerging Drugs, 2007, 12, 301-311.	1.0	3
827	Direct Evidence for the Action of Phosphatidylinositol (3,4,5)-Trisphosphate-Mediated Signal Transduction in the 2-Cell Mouse Embryo1. Biology of Reproduction, 2007, 77, 813-821.	1.2	32
828	Novel small-molecule therapy of Hodgkin lymphoma. Expert Review of Anticancer Therapy, 2007, 7, 735-740.	1.1	11
829	Emerging therapies for colorectal cancer. Expert Opinion on Investigational Drugs, 2007, 16, 867-876.	1.9	4
830	Hypoxic preconditioning protects human brain endothelium from ischemic apoptosis by Akt-dependent survivin activation. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 292, H2573-H2581.	1.5	104
831	Thioredoxin and Thioredoxin Reductase As Redox-Sensitive Molecular Targets for Cancer Therapy. Current Pharmaceutical Design, 2007, 13, 3368-3377.	0.9	60
832	A Novel Function of eIF2Î± Kinases as Inducers of the Phosphoinositide-3 Kinase Signaling Pathway. Molecular Biology of the Cell, 2007, 18, 3635-3644.	0.9	79
833	Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Annals of Oncology, 2007, 18, 1043-1050.	0.6	58

#	Article	IF	Citations
834	Akt in Ischemia and Reperfusion. Journal of Investigative Surgery, 2007, 20, 195-203.	0.6	161
835	Roles of mTOR and STAT3 in Autophagy Induced by Telomere 3' Overhang-Specific DNA Oligonucleotides. Autophagy, 2007, 3, 496-498.	4.3	41
836	PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors. Clinical Cancer Research, 2007, 13, 378-381.	3.2	114
837	The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-Î¹B inhibition and enhanced by the presence of PTEN. Molecular Cancer Therapeutics, 2007, 6, 2477-2486.	1.9	74
838	Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro-Oncology, 2007, 9, 271-279.	0.6	144
839	Inhibition of the PI3K-Akt Signaling Pathway Reduces Tumor Necrosis Factor-Î± Production in Response to Titanium Particles in Vitro. Journal of Bone and Joint Surgery - Series A, 2007, 89, 1019-1027.	1.4	42
840	New Functions for PI3K in the Control of Cell Division. Cell Cycle, 2007, 6, 1696-1698.	1.3	26
841	Molecular Biology of Colon Cancer. , 2007, , 1-31.		2
842	Protease-Activated Receptor-1 (hPar1), A Survival Factor Eliciting Tumor Progression. Molecular Cancer Research, 2007, 5, 229-240.	1.5	31
843	Met acts on Mdm2 via mTOR to signal cell survival during development. Development (Cambridge), 2007, 134, 1443-1451.	1.2	85
844	A Translational View of the Molecular Pathogenesis of Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 327-343.	0.5	274
845	Following the tracks of AKT1 gene. Cancer Biology and Therapy, 2007, 6, 1521-1524.	1.5	17
846	Manipulation of Plant Programmed Cell Death Pathways During Plant-Pathogen Interactions. Plant Signaling and Behavior, 2007, 2, 188-190.	1.2	13
847	Oridonin induced apoptosis through Akt and MAPKs signaling pathways in human osteosarcoma cells. Cancer Biology and Therapy, 2007, 6, 261-268.	1.5	62
848	Akt/TSC/mTOR Activation by the KSHV G Protein-Coupled Receptor: Emerging Insights into the Molecular Oncogenesis and Treatment of Kaposiâ€™s Sarcoma. Cell Cycle, 2007, 6, 438-443.	1.3	60
849	Spectral Decomposition of Signaling Networks. , 2007, , .		1
850	Targeting Akt to increase the sensitivity of neuroblastoma to chemotherapy: lessons learned from the brain-derived neurotrophic factor/TrkB signal transduction pathway. Expert Opinion on Therapeutic Targets, 2007, 11, 1611-1621.	1.5	41
852	Nicotine Stimulates Human Lung Cancer Cell Growth by Inducing Fibronectin Expression. American Journal of Respiratory Cell and Molecular Biology, 2007, 37, 681-690.	1.4	106

#	Article	IF	Citations
853	EGFR-Activated Signaling and Actin Remodeling Regulate Cyclic Stretchâ€“Induced NRF2-ARE Activation. American Journal of Respiratory Cell and Molecular Biology, 2007, 36, 304-312.	1.4	61
854	p63, Cellular Senescence and Tumor Development. Cell Cycle, 2007, 6, 305-311.	1.3	33
855	Panitumumab a novel drug in cancer treatment. Annals of Oncology, 2007, 18, vi16-vi21.	0.6	30
856	Akt1 Ablation Inhibits, whereas Akt2 Ablation Accelerates, the Development of Mammary Adenocarcinomas in Mouse Mammary Tumor Virus (MMTV)-ErbB2/Neu and MMTV-Polyoma Middle T Transgenic Mice. Cancer Research, 2007, 67, 167-177.	0.4	238
857	Genetic Screening Reveals an Essential Role of p27kip1 in Restriction of Breast Cancer Progression. Cancer Research, 2007, 67, 8032-8042.	0.4	27
858	Antiproliferative activity of sulforaphane in Akt-overexpressing ovarian cancer cells. Molecular Cancer Therapeutics, 2007, 6, 334-345.	1.9	93
859	Essential role of PDK1 in regulating endothelial cell migration. Journal of Cell Biology, 2007, 176, 1035-1047.	2.3	75
860	Metallothionein Expression Is Suppressed in Primary Human Hepatocellular Carcinomas and Is Mediated through Inactivation of CCAAT/Enhancer Binding Protein Î± by Phosphatidylinositol 3-Kinase Signaling Cascade. Cancer Research, 2007, 67, 2736-2746.	0.4	119
861	Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 5563-5568.	3.3	173
862	The Biology Behind mTOR Inhibition in Sarcoma. Oncologist, 2007, 12, 1007-1018.	1.9	163
863	Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway. Endocrine-Related Cancer, 2007, 14, 995-1005.	1.6	56
864	Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines. Molecular Cancer Research, 2007, 5, 195-201.	1.5	271
865	Bevacizumab plus 5-fluorouracil induce growth suppression in the CWR-22 and CWR-22R prostate cancer xenografts. Molecular Cancer Therapeutics, 2007, 6, 2149-2157.	1.9	11
866	Phosphorylated Galectin-3 Mediates Tumor Necrosis Factor-related Apoptosis-inducing Ligand Signaling by Regulating Phosphatase and Tensin Homologue Deleted on Chromosome 10 in Human Breast Carcinoma Cells. Journal of Biological Chemistry, 2007, 282, 21337-21348.	1.6	41
867	Integrative Genomic Analysis of Phosphatidylinositol 3â€²-Kinase Family Identifies PIK3R3 as a Potential Therapeutic Target in Epithelial Ovarian Cancer. Clinical Cancer Research, 2007, 13, 5314-5321.	3.2	111
868	Blockade of the phosphatidylinositol-3-kinaseâ€“Akt signaling pathway enhances the induction of apoptosis by microtubule-destabilizing agents in tumor cells in which the pathway is constitutively activated. Molecular Cancer Therapeutics, 2007, 6, 1133-1142.	1.9	38
869	Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases. Cancer Research, 2007, 67, 5840-5850.	0.4	337
870	CTGF enhances the motility of breast cancer cells via an integrin-Î±vÎ²3â€“ERK1/2-dependent S100A4-upregulated pathway. Journal of Cell Science, 2007, 120, 2053-2065.	1.2	135

#	Article	IF	Citations
871	Mutant PIK3CA-Bearing Colon Cancer Cells Display Increased Metastasis in an Orthotopic Model. Cancer Research, 2007, 67, 5851-5858.	0.4	57
872	Protein Expression Profiles in Renal Cell Carcinoma: Staging, Prognosis, and Patient Selection for Clinical Trials: Fig. 1.. Clinical Cancer Research, 2007, 13, 703s-708s.	3.2	31
873	Targeting the Phosphatidylinositol 3-Kinase Pathway in Multiple Myeloma. Clinical Cancer Research, 2007, 13, 3771-3775.	3.2	71
874	Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer. Molecular Cancer Therapeutics, 2007, 6, 2959-2966.	1.9	47
875	Energy Balance and Carcinogenesis: Underlying Pathways and Targets for Intervention. Current Cancer Drug Targets, 2007, 7, 484-491.	0.8	55
876	Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors. Current Cancer Therapy Reviews, 2007, 3, 276-283.	0.2	0
878	Chemoresistant KM12C Colon Cancer Cells Are Addicted to Low Cyclic AMP Levels in a Phosphodiesterase 4â€“Regulated Compartment via Effects on Phosphoinositide 3-Kinase. Cancer Research, 2007, 67, 5248-5257.	0.4	68
879	Regulation of Mammalian Target of Rapamycin Activity in PTEN-Inactive Prostate Cancer Cells by Ĩºß Kinase Î±. Cancer Research, 2007, 67, 6263-6269.	0.4	67
880	Genetic Alterations and Their Relationship in the Phosphatidylinositol 3-Kinase/Akt Pathway in Thyroid Cancer. Clinical Cancer Research, 2007, 13, 1161-1170.	3.2	362
881	RAD001 Inhibits Human Ovarian Cancer Cell Proliferation, Enhances Cisplatin-Induced Apoptosis, and Prolongs Survival in an Ovarian Cancer Model. Clinical Cancer Research, 2007, 13, 4261-4270.	3.2	216
882	Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs. Molecular Cancer Therapeutics, 2007, 6, 844-855.	1.9	54
883	A platelet biomarker for assessing phosphoinositide 3-kinase inhibition during cancer chemotherapy. Molecular Cancer Therapeutics, 2007, 6, 2600-2607.	1.9	5
884	Targeting the AKT protein kinase for cancer chemoprevention. Molecular Cancer Therapeutics, 2007, 6, 2139-2148.	1.9	153
885	Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT/PKB: mechanistic involvement of AKT catalytic activation loop cysteines. Molecular Cancer Therapeutics, 2007, 6, 3028-3038.	1.9	59
886	Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. Annals of Oncology, 2007, 18, 421-430.	0.6	40
887	Epstein-Barr Virus Latent Membrane Protein 2A Mediates Transformation through Constitutive Activation of the Ras/PI3-K/Akt Pathway. Journal of Virology, 2007, 81, 9299-9306.	1.5	103
888	Lipid Rafts of Primary Endothelial Cells Are Essential for Kaposi's Sarcoma-Associated Herpesvirus/Human Herpesvirus 8-Induced Phosphatidylinositol 3-Kinase and RhoA-GTPases Critical for Microtubule Dynamics and Nuclear Delivery of Viral DNA but Dispensable for Binding and Entry. Journal of Virology, 2007, 81, 7941-7959.	1.5	81
889	Pravastatin Induces Rat Aortic Endothelial Cell Proliferation and Migration via Activation of PI3K/Akt/mTOR/p70 S6 Kinase Signaling. Journal of Pharmacological Sciences, 2007, 105, 334-341.	1.1	28

#	Article	IF	Citations
890	Expression of phospholipase D2 in human colorectal carcinoma. Oncology Reports, 2007, 18, 1329.	1.2	17
892	Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer drug development. Biomarkers in Medicine, 2007, 1, 399-417.	0.6	29
893	Absolute Quantification of Four Isoforms of the Class I Phosphoinositide-3-kinase Catalytic Subunit by Real-Time RT-PCR. Biological and Pharmaceutical Bulletin, 2007, 30, 1181-1184.	0.6	6
895	Role of the highly structured 5â€²-end region of MDR1 mRNA in P-glycoprotein expression. Biochemical Journal, 2007, 406, 445-455.	1.7	26
896	Lymphocyte cell motility: the twisting, turning tale of phosphoinositide 3-kinase. Biochemical Society Transactions, 2007, 35, 1109-1113.	1.6	13
897	Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. Blood, 2007, 109, 1678-1686.	0.6	108
898	Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells. Blood, 2007, 110, 1942-1949.	0.6	133
899	The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood, 2007, 110, 4417-4426.	0.6	141
900	Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. Blood, 2007, 110, 1291-1300.	0.6	115
901	Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood, 2007, 110, 2259-2267.	0.6	236
902	Enhanced susceptibility to apoptosis of oral squamous cell carcinoma cells subjected to combined treatment with anticancer drugs and phosphatidylinositol 3-kinase inhibitors. International Journal of Oncology, 0, , .	1.4	4
903	Enhanced susceptibility to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in oral squamous cell carcinoma cells treated with phosphatidylinositol 3-kinase inhibitors. International Journal of Oncology, 2007, , .	1.4	3
904	Molecular targeted therapies and chemotherapy in malignant gliomas. Current Opinion in Oncology, 2007, 19, 598-605.	1.1	46
905	New molecular targets in malignant gliomas. Current Opinion in Neurology, 2007, 20, 712-718.	1.8	32
906	Receptor Tyrosine Kinases as Therapeutic Targets in Malignant Glioma. Reviews on Recent Clinical Trials, 2007, 2, 87-101.	0.4	25
907	Advances in Molecular Therapeutic Approaches to Patients with Malignant Gliomas. Current Signal Transduction Therapy, 2007, 2, 57-76.	0.3	0
908	Recent Patents of Gene Sequences Relative to the Phosphatidylinositol 3-kinase / Akt Pathway and their Relevance to Drug Discovery. Recent Patents on DNA & Gene Sequences, 2007, 1, 9-23.	0.7	1
909	PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors. International Journal of Oncology, 2007, , .	1.4	10

#	Article	IF	Citations
910	Constitutive activation of MAPK/ERK inhibits prostate cancer cell proliferation through upregulation of BRCA2. International Journal of Oncology, 2007, 30, 217-24.	1.4	20
911	Bortezomib sensitizes human head and neck carcinoma cells SQ20B to radiation. Cancer Biology and Therapy, 2007, 6, 156-159.	1.5	18
912	Activation of growth factor receptors in pancreatic cancer. American Journal of Surgery, 2007, 194, S76-S83.	0.9	1
913	Cell survival, cell death and cell cycle pathways are interconnected: Implications for cancer therapy. Drug Resistance Updates, 2007, 10, 13-29.	6.5	381
914	Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resistance Updates, 2007, 10, 81-100.	6.5	74
915	Proteomics-based identification of biomarkers for predicting sensitivity to a PI3-kinase inhibitor in cancer. Biochemical and Biophysical Research Communications, 2007, 352, 514-521.	1.0	20
916	Quantitative analysis of Akt phosphorylation and activity in response to EGF and insulin treatment. Biochemical and Biophysical Research Communications, 2007, 354, 14-20.	1.0	24
917	A component of green tea, (â˜')-epigallocatechin-3-gallate, promotes apoptosis in T24 human bladder cancer cells via modulation of the PI3K/Akt pathway and Bcl-2 family proteins. Biochemical and Biophysical Research Communications, 2007, 354, 852-857.	1.0	130
918	Leptin restores plasma cholesterol, glucose and weight loss induced by IFNÎ± treatment. Biochemical and Biophysical Research Communications, 2007, 355, 626-631.	1.0	2
919	Sensitization of TNF-induced cytotoxicity in lung cancer cells by concurrent suppression of the NF-ÎºB and Akt pathways. Biochemical and Biophysical Research Communications, 2007, 355, 807-812.	1.0	39
920	Real-time imaging nuclear translocation of Akt1 in HCC cells. Biochemical and Biophysical Research Communications, 2007, 356, 1038-1043.	1.0	14
921	Interlinking interleukin-7. Cytokine, 2007, 39, 75-83.	1.4	83
922	Inhibition of phosphatidylinositol 3-kinase causes cell death in rat osteoblasts through inactivation of Akt. Biomedicine and Pharmacotherapy, 2007, 61, 277-284.	2.5	12
923	Application and interpretation of FISH in biomarker studies. Cancer Letters, 2007, 249, 97-109.	3.2	27
924	Bioinformatics-based discovery and characterization of an AKT-selective inhibitor 9-chloro-2-methylellipticinium acetate (CMEP) in breast cancer cells. Cancer Letters, 2007, 252, 244-258.	3.2	10
925	Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Letters, 2007, 254, 165-177.	3.2	143
926	Protein expression and intracellular localization of prostate apoptosis response-4 (Par-4) are associated with apoptosis induction in nasopharyngeal carcinoma cell lines. Cancer Letters, 2007, 257, 252-262.	3.2	20
927	Proanthocyanidin from grape seeds inactivates the PI3-kinase/PKB pathway and induces apoptosis in a colon cancer cell line. Cancer Letters, 2007, 258, 144-153.	3.2	122

#	Article	IF	Citations
928	A Structural Comparison of Inhibitor Binding to PKB, PKA and PKA-PKB Chimera. Journal of Molecular Biology, 2007, 367, 882-894.	2.0	80
929	Vitamin E analogues as a novel group of mitocans: Anti-cancer agents that act by targeting mitochondria. Molecular Aspects of Medicine, 2007, 28, 607-645.	2.7	96
930	Inositol 1,3,4,5-Tetrakisphosphate Negatively Regulates Phosphatidylinositol-3,4,5- Trisphosphate Signaling in Neutrophils. Immunity, 2007, 27, 453-467.	6.6	62
931	PHLPP and a Second Isoform, PHLPP2, Differentially Attenuate the Amplitude of Akt Signaling by Regulating Distinct Akt Isoforms. Molecular Cell, 2007, 25, 917-931.	4.5	527
932	mTOR Complex1â€“S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends in Molecular Medicine, 2007, 13, 252-259.	3.5	431
933	Association of cooking oil fumes exposure with lung cancer: Involvement of inhibitor of apoptosis proteins in cell survival and proliferation in vitro. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2007, 628, 107-116.	0.9	47
934	Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: Possible role for thrombosis. Radiotherapy and Oncology, 2007, 82, 96-104.	0.3	43
935	Hepatocyte Growth Factor Exerts Multiple Biological Functions on Bovine Mammary Epithelial Cells. Journal of Dairy Science, 2007, 90, 4289-4296.	1.4	7
936	Autophagic Cell Death of Human Pancreatic Tumor Cells Mediated by Oleandrin, a Lipid-Soluble Cardiac Glycoside. Integrative Cancer Therapies, 2007, 6, 354-364.	0.8	128
937	Kinase Inhibitors for Cancer. , 2007, , 183-220.		1
938	The Mammalian Target of Rapamycin Pathway as a Potential Target for Cancer Chemoprevention. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1330-1340.	1.1	55
939	Apoptosis, Senescence, and Cancer. , 2007, , .		8
940	Vitamin E Analogues and Immune Response in Cancer Treatment. Vitamins and Hormones, 2007, 76, 463-491.	0.7	18
941	The involvement of lipid rafts in epidermal growth factor-induced chemotaxis of breast cancer cells. Molecular Membrane Biology, 2007, 24, 91-101.	2.0	32
942	Breast Cancer Chemosensitivity. Advances in Experimental Medicine and Biology, 2007, , .	0.8	2
943	Apoptosis: A Review of Programmed Cell Death. Toxicologic Pathology, 2007, 35, 495-516.	0.9	10,063
944	The Intrinsic Pathway of Apoptosis. , 2007, , 3-30.		3
945	PTEN, more than the AKT pathway. Carcinogenesis, 2007, 28, 1379-1386.	1.3	355

#	Article	IF	Citations
946	Cell Division and Survival. , 2007, , 45-191.		1
947	Roles of androgen-dependent and -independent activation of signal transduction pathways for cell proliferation of prostate cancer cells. Expert Review of Endocrinology and Metabolism, 2007, 2, 689-704.	1.2	7
948	Application of Meso Scale Technology for the Measurement of Phosphoproteins in Human Tumor Xenografts. Assay and Drug Development Technologies, 2007, 5, 391-402.	0.6	49
949	Targeting the Phosphatidylinositol 3-Kinase Pathway in Airway Smooth Muscle. BioDrugs, 2007, 21, 85-95.	2.2	27
950	Regulation of the Phosphatidylinositol 3-Kinase-Akt and the Mitogen-Activated Protein Kinase Pathways by Ursolic Acid in Human Endometrial Cancer Cells. Bioscience, Biotechnology and Biochemistry, 2007, 71, 31-37.	0.6	42
951	Molecular mechanisms of drug resistance in acute myeloid leukaemia. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 363-377.	1.5	15
952	Effects of Collagen IV on Cisplatin-Induced Apoptosis of Non-Small Cell Lung Cancer Cells. Cancer Investigation, 2007, 25, 542-549.	0.6	8
953	PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast Cancer. Clinical Cancer Research, 2007, 13, 3577-3584.	3.2	268
954	Role of Type 2C Protein Phosphatases in Growth Regulation and in Cellular Stress Signaling. Critical Reviews in Biochemistry and Molecular Biology, 2007, 42, 437-461.	2.3	143
955	E-Cadherin Cell-Cell Adhesion in Ewing Tumor Cells Mediates Suppression of Anoikis through Activation of the ErbB4 Tyrosine Kinase. Cancer Research, 2007, 67, 3094-3105.	0.4	157
956	Nerve Growth Factor Induces Endothelial Cell Invasion and Cord Formation by Promoting Matrix Metalloproteinase-2 Expression through the Phosphatidylinositol 3-Kinase/Akt Signaling Pathway and AP-2 Transcription Factor. Journal of Biological Chemistry, 2007, 282, 30485-30496.	1.6	84
957	The Structure of a Human p110Î±/p85Î± Complex Elucidates the Effects of Oncogenic PI3KÎ± Mutations. Science, 2007, 318, 1744-1748.	6.0	504
958	Activation of Akt Predicts Poor Outcome in Neuroblastoma. Cancer Research, 2007, 67, 735-745.	0.4	218
959	A Novel Substrate Mimetic Inhibitor of PKB/Akt Inhibits Prostate Cancer Tumor Growth in Mice by Blocking the PKB Pathway. Biochemistry, 2007, 46, 4716-4724.	1.2	36
960	Smooth muscle cell signal transduction: Implications of vascular biology for vascular surgeons. Journal of Vascular Surgery, 2007, 45, A15-A24.	0.6	95
961	The HIV Protease Inhibitor Nelfinavir Downregulates Akt Phosphorylation by Inhibiting Proteasomal Activity and Inducing the Unfolded Protein Response. Neoplasia, 2007, 9, 271-278.	2.3	110
962	Effects of celecoxib on voltage-gated calcium channel currents in rat pheochromocytoma (PC12) cells. Pharmacological Research, 2007, 56, 267-274.	3.1	28
963	Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-Î²-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. Molecular Cancer, 2007, 6, 46.	7.9	102

#	Article	IF	Citations
964	Exogenous mycoplasmal p37 protein alters gene expression, growth and morphology of prostate cancer cells. Cytogenetic and Genome Research, 2007, 118, 204-213.	0.6	33
965	TOR (target of rapamycin) as an anti-cancer target. Drug Discovery Today: Therapeutic Strategies, 2007, 4, 211-217.	0.5	2
966	Significance of the expression of phosphorylated-STAT3, -Akt, and -ERK1/2 in several tumors of the epidermis. Journal of Dermatological Science, 2007, 48, 71-73.	1.0	15
967	Identification of Inhibitors of Protein Kinase B Using Fragment-Based Lead Discoveryâ€. Journal of Medicinal Chemistry, 2007, 50, 2293-2296.	2.9	128
968	Discovery of 3,3â€˜-(2,4-Diaminopteridine-6,7-diyl)diphenol as an Isozyme-Selective Inhibitor of PI3K for the Treatment of Ischemia Reperfusion Injury Associated with Myocardial Infarction. Journal of Medicinal Chemistry, 2007, 50, 4279-4294.	2.9	43
969	An EGFR and AKT Signaling Pathway was Identified with Mediation Model in Osteosarcomas Clinical Study. Biomarker Insights, 2007, 2, 117727190700200.	1.0	4
970	The Role of Glucose Metabolism and Glucose-Associated Signalling in Cancer. Perspectives in Medicinal Chemistry, 2007, 1, 1177391X0700100.	4.6	13
971	Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. International Journal of Cancer, 2007, 120, 1284-1292.	2.3	113
972	Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. International Journal of Cancer, 2007, 120, 719-733.	2.3	209
973	The aberrant coexpression of several receptor tyrosine kinases is largely restricted to EBV-negative cases of classical Hodgkin's lymphoma. International Journal of Cancer, 2007, 120, 2504-2509.	2.3	29
974	Patterns ofPIK3CA alterations in familial colorectal and endometrial carcinoma. International Journal of Cancer, 2007, 121, 915-920.	2.3	61
975	Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. International Journal of Cancer, 2007, 121, 1424-1432.	2.3	304
976	PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. International Journal of Cancer, 2007, 121, 1771-1778.	2.3	129
977	Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase. International Journal of Cancer, 2007, 121, 2095-2104.	2.3	37
978	2â€Methoxyestradiol attenuates phosphatidylinositol 3â€kinase/Akt pathwayâ€mediated metastasis of gastric cancer. International Journal of Cancer, 2007, 121, 2547-2555.	2.3	39
979	PI-3K/Akt signal pathway plays a crucial role in arsenite-induced cell proliferation of human keratinocytes through induction of cyclin D1. Journal of Cellular Biochemistry, 2007, 101, 969-978.	1.2	26
980	Why is PTEN an important tumor suppressor?. Journal of Cellular Biochemistry, 2007, 102, 1368-1374.	1.2	103
981	Design and synthesis of pyridineâ€“pyrazolopyridine-based inhibitors of protein kinase B/Akt. Bioorganic and Medicinal Chemistry, 2007, 15, 2441-2452.	1.4	59

#	Article	IF	Citations
982	Synthesis and biological evaluation of pyrido[3â€²,2â€²:4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110Î± inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 2438-2442.	1.0	127
983	PTEN hamartomatous tumor syndromes (PHTS): Rare syndromes with great relevance to common cancers and targeted drug development. Critical Reviews in Oncology/Hematology, 2007, 63, 203-214.	2.0	19
984	Pediatric oncology. Current Opinion in Chemical Biology, 2007, 11, 424-432.	2.8	13
985	A polysaccharide of the marine alga Capsosiphon fulvescens induces apoptosis in AGS gastric cancer cells via an IGF-IR-mediated PI3K/Akt pathway. Cell Biology International, 2007, 31, 768-775.	1.4	98
986	Treatment Combining X-Irradiation and a Ribonucleoside Anticancer Drug, TAS106, Effectively Suppresses the Growth of Tumor Cells Transplanted in Mice. International Journal of Radiation Oncology Biology Physics, 2007, 68, 218-228.	0.4	14
987	Simulating non-small cell lung cancer with a multiscale agent-based model. Theoretical Biology and Medical Modelling, 2007, 4, 50.	2.1	81
988	The heatâ€shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epsteinâ€“Barr virusâ€positive NK/Tâ€cell lymphoma by Akt downâ€regulation. Journal of Pathology, 2007, 213, 170-179.	2.1	48
989	Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase. Prostate, 2007, 67, 782-789.	1.2	47
990	Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene, 2007, 26, 1840-1851.	2.6	139
991	eEF1A2 activates Akt and stimulates Akt-dependent actin remodeling, invasion and migration. Oncogene, 2007, 26, 3027-3040.	2.6	125
992	â€˜Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventionsâ€™. Oncogene, 2007, 26, 3629-3636.	2.6	187
993	Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis. Oncogene, 2007, 26, 6184-6193.	2.6	76
994	The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene, 2007, 26, 6469-6487.	2.6	867
995	Homeostatic chemokines increase survival of B-chronic lymphocytic leukemia cells through inactivation of transcription factor FOXO3a. Oncogene, 2007, 26, 7081-7091.	2.6	90
996	Functional inhibition of PI3K by the Î²GBP molecule suppresses Rasâ€“MAPK signalling to block cell proliferation. Oncogene, 2007, 26, 7709-7714.	2.6	26
997	Uniaxial stretch-induced regulation of mitogen-activated protein kinase, Akt and p70 S6 kinase in the ageing Fischer 344 Ã— Brown Norway rat aorta. Experimental Physiology, 2007, 92, 963-970.	0.9	12
998	Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nature Medicine, 2007, 13, 84-88.	15.2	1,177
999	The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nature Medicine, 2007, 13, 748-753.	15.2	275

#	Article	IF	Citations
1000	Molecular imaging of Akt kinase activity. Nature Medicine, 2007, 13, 1114-1119.	15.2	133
1001	Inflammation in prostate carcinogenesis. Nature Reviews Cancer, 2007, 7, 256-269.	12.8	1,352
1002	Hyperactive Ras in developmental disorders and cancer. Nature Reviews Cancer, 2007, 7, 295-308.	12.8	1,422
1003	Proteins, drug targets and the mechanisms they control: the simple truth about complex networks. Nature Reviews Drug Discovery, 2007, 6, 871-880.	21.5	153
1004	Aerosol delivery of Akt controls protein translation in the lungs of dual luciferase reporter mice. Gene Therapy, 2007, 14, 451-458.	2.3	21
1005	Lentivirus-mediated carboxyl-terminal modulator protein gene transfection via aerosol in lungs of K-ras null mice. Gene Therapy, 2007, 14, 1721-1730.	2.3	36
1006	Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia, 2007, 21, 333-339.	3.3	152
1007	High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma. Leukemia, 2007, 21, 780-787.	3.3	61
1008	Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts. British Journal of Cancer, 2007, 97, 65-72.	2.9	60
1009	Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma. Modern Pathology, 2007, 20, 936-946.	2.9	41
1010	A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature, 2007, 448, 439-444.	13.7	1,117
1011	Multiple Components of Photodynamic Therapy Can Phosphorylate Akt?. Photochemistry and Photobiology, 2007, 83, 1029-1033.	1.3	20
1012	Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. Differentiation, 2007, 75, 788-799.	1.0	72
1013	Akt is transferred to the nucleus of cells treated with apoptin, and it participates in apoptin-induced cell death. Cell Proliferation, 2007, 40, 835-848.	2.4	45
1014	Induction of matrix metalloproteinase gene expression in an endothelial cell line by direct interaction with malignant cells. Cancer Science, 2007, 98, 58-67.	1.7	18
1015	Restoration of RUNX3 enhances transforming growth factor-?-dependent p21 expression in a biliary tract cancer cell line. Cancer Science, 2007, 98, 838-843.	1.7	16
1016	von Willebrand factor type D domain mutant of SVS-1/SUSD2, vWDm, induces apoptosis in HeLa cells. Cancer Science, 2007, 98, 909-915.	1.7	12
1017	Simultaneous inhibition of the mitogenâ€activated protein kinase kinase and phosphatidylinositol 3â€²â€kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma. Cancer Science, 2007, 98, 2002-2008.	1.7	14

#	Article	IF	Citations
1018	3-Phosphoinositide-dependent protein kinase-1/Akt signalling and inhibition in a canine prostate carcinoma cell line. Veterinary and Comparative Oncology, 2007, 5, 47-58.	0.8	8
1019	NBS1, the Nijmegen breakage syndrome gene product, regulates neuronal proliferation and differentiation. Journal of Neurochemistry, 2007, 102, 141-152.	2.1	9
1020	Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions. Journal of Cutaneous Pathology, 2007, 34, 220-225.	0.7	17
1021	Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells. Acta Pharmacologica Sinica, 2007, 28, 879-887.	2.8	51
1022	Synaptic plasticity, AMPA-R trafficking, and Ras-MAPK signaling. Acta Pharmacologica Sinica, 2007, 28, 928-936.	2.8	21
1023	Oridonin induces apoptosis via PI3K/Akt pathway in cervical carcinoma HeLa cell line. Acta Pharmacologica Sinica, 2007, 28, 1819-1826.	2.8	75
1024	Choline Transporters in Human Lung Adenocarcinoma: Expression and Functional Implications. Acta Biochimica Et Biophysica Sinica, 2007, 39, 668-674.	0.9	55
1025	Switch activation of PI-PLC downstream signals in activated macrophages with wortmannin. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 869-879.	1.9	10
1026	Neural stem cells, tumour stem cells and brain tumours: Dangerous relationships?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2007, 1776, 125-137.	3.3	16
1027	Blockade of AKT activation in prostate cancer cells with a small molecule inhibitor, 9-chloro-2-methylellipticinium acetate (CMEP). Biochemical Pharmacology, 2007, 73, 15-24.	2.0	15
1028	Identification of the JNK Signaling Pathway as a Functional Target of the Tumor Suppressor PTEN. Cancer Cell, 2007, 11, 555-569.	7.7	214
1029	Negative regulation of Akt activity by p38Î±ÂMAP kinase in cardiomyocytes involves membrane localization of PP2A through interaction with caveolin-1. Cellular Signalling, 2007, 19, 62-74.	1.7	57
1030	The PI3 kinase-Akt pathway mediates Wnt3a-induced proliferation. Cellular Signalling, 2007, 19, 511-518.	1.7	65
1031	Combinatorial activation of FAK and AKT by transforming growth factor-Î²1 confers an anoikis-resistant phenotype to myofibroblasts. Cellular Signalling, 2007, 19, 761-771.	1.7	220
1032	Mechanism of apoptosis induced by IFN-Î± in human myeloma cells: Role of Jak1 and Bim and potentiation by rapamycin. Cellular Signalling, 2007, 19, 844-854.	1.7	38
1033	Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib. Experimental Cell Research, 2007, 313, 1361-1372.	1.2	46
1034	Switching from Tacrolimus to Sirolimus Halts the Appearance of New Sebaceous Neoplasms in Muir-Torre Syndrome. American Journal of Transplantation, 2007, 7, 476-479.	2.6	48
1035	Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin?proteasome system and Cox-2. Journal of Cellular and Molecular Medicine, 2007, 11, 252-285.	1.6	69

#	Article	IF	Citations
1036	The role of intracellular signaling in insulin-mediated regulation of drug metabolizing enzyme gene and protein expression. , 2007, 113, 88-120.		140
1037	Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: Two approaches with therapeutic potential in the treatment of neurodegenerative disease. , 2007, 114, 261-277.		99
1038	Thermal sensitization through ROS modulation: A strategy to improve the efficacy of hyperthermic intraperitoneal chemotherapy. Surgery, 2007, 142, 384-392.	1.0	31
1039	Gene expression profiling reveals underlying molecular mechanisms of the early stages of tamoxifen-induced rat hepatocarcinogenesisâ˜†. Toxicology and Applied Pharmacology, 2007, 225, 61-69.	1.3	26
1040	Effects of 7â€hydroxyâ€3â€methoxycadalene on cell cycle, apoptosis and protein translation in A549 lung cancer cells. BioFactors, 2007, 29, 67-75.	2.6	4
1041	High-Throughput Screening of Gene Function in Stem Cells Using Clonal Microarrays. Stem Cells, 2007, 25, 2928-2935.	1.4	22
1042	Carcinogenesis. , 2007, , 97-118.		2
1043	Alternative Use of Signaling by the Î²GBP Cytokine in Cell Growth and Cancer Control. , 2007, , 203-216.		2
1044	TIMP-3 and Phosphatidylinositol 3-kinase Genes Were Found to Be Related to the Progression of Colon Cancer in a Comparison of Pneumoperitoneum and Laparotomy in a Murine Model. Surgery Today, 2007, 37, 220-225.	0.7	2
1045	Activity of the Akt-dependent anabolic and catabolic pathways in muscle and liver samples in cancer-related cachexia. Journal of Molecular Medicine, 2007, 85, 647-654.	1.7	63
1046	Interferon-Î³ attenuates the survival activity of G-CSF through PI3K/Akt signaling pathway in mouse multipotent progenitor cells. Annals of Hematology, 2007, 86, 547-555.	0.8	8
1047	Promise and Progress for Functional and Molecular Imaging of Response to Targeted Therapies. Pharmaceutical Research, 2007, 24, 1172-1185.	1.7	66
1048	Grifolin induces apoptosis via inhibition of PI3K/AKT signalling pathway in human osteosarcoma cells. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 1317-1326.	2.2	78
1049	Signaling Pathways in Cancer and Embryonic Stem Cells. Stem Cell Reviews and Reports, 2007, 3, 7-17.	5.6	324
1050	Tumour cells resistance in cancer therapy. Clinical and Translational Oncology, 2007, 9, 13-20.	1.2	24
1051	Toxicogenomics of A375 human malignant melanoma cells treated with arbutin. Journal of Biomedical Science, 2007, 14, 87-105.	2.6	62
1052	Mechanisms of resistance to EGFR inhibitors. Targeted Oncology, 2007, 2, 31-37.	1.7	10
1053	Epithelial growth factor receptor (EGFR) pathway and renal cell carcinoma. Targeted Oncology, 2007, 2, 99-105.	1.7	6

#	Article	IF	Citations
1054	Reversal of multidrug resistance and inhibition of phosphorylation of AKT in human ovarian cancer cell line by wild-type PTEN gene. Journal of Huazhong University of Science and Technology [Medical Sciences], 2007, 27, 713-716.	1.0	1
1055	Overexpression of cyclin D1 is associated with elevated levels of MAP kinases, Akt and Pak1 during diethylnitrosamine-induced progressive liver carcinogenesis. Cell Biology International, 2007, 31, 35-43.	1.4	39
1056	The potential for treatment with dietary long-chain polyunsaturated n-3 fatty acids during chemotherapy. Journal of Nutritional Biochemistry, 2008, 19, 787-796.	1.9	119
1057	Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells. Breast Cancer Research and Treatment, 2008, 112, 217-227.	1.1	57
1058	Akt1/protein Kinase BÎ± is Involved in Gastric Cancer Progression and Cell Proliferation. Digestive Diseases and Sciences, 2008, 53, 1801-1810.	1.1	31
1059	Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemotherapy and Pharmacology, 2008, 62, 305-313.	1.1	97
1060	Activation of phosphoinositide 3-kinase by the NBS1 DNA repair protein through a novel activation motif. Journal of Molecular Medicine, 2008, 86, 401-412.	1.7	22
1061	Mammalian target of rapamycin pathway inhibition enhances the effects of 5-aza-dC on suppressing cell proliferation in human gastric cancer cell lines. Science in China Series C: Life Sciences, 2008, 51, 640-647.	1.3	15
1062	Can we predict the response to epidermal growth factor receptor targeted therapy?. Targeted Oncology, 2008, 3, 87-99.	1.7	1
1063	Pharmacogenetics in lung cancer for the lay doctor. Targeted Oncology, 2008, 3, 161-171.	1.7	4
1064	Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease. Immunologic Research, 2008, 42, 84-105.	1.3	35
1065	Genetic modelling of the PTEN/AKT pathway in cancer research. Clinical and Translational Oncology, 2008, 10, 618-627.	1.2	19
1066	Differential induction of apoptosis and inhibition of the PI3-kinase pathway by saturated, monounsaturated and polyunsaturated fatty acids in a colon cancer cell model. Apoptosis: an International Journal on Programmed Cell Death, 2008, 13, 1368-1377.	2.2	34
1067	PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas. Langenbeck's Archives of Surgery, 2008, 393, 289-296.	0.8	67
1068	Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 453, 133-139.	1.4	34
1069	Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib. Cancer Cell International, 2008, 8, 1.	1.8	23
1070	Phosphoproteomics: A possible route to novel biomarkers of breast cancer. Proteomics - Clinical Applications, 2008, 2, 181-194.	0.8	9
1071	Genetic changes and DNA damage responses in the prostate. Prostate, 2008, 68, 902-918.	1.2	27

#	Article	IF	Citations
1072	Amyloid Î²â€peptide activates nuclear factorâ€ÎºB through an Nâ€methylâ€Dâ€aspartate signaling pathway in cultured cerebellar cells. Journal of Neuroscience Research, 2008, 86, 845-860.	1.3	39
1073	Bone marrow stromal cells protect oligodendrocytes from oxygenâ€glucose deprivation injury. Journal of Neuroscience Research, 2008, 86, 1501-1510.	1.3	30
1074	Lycopene inhibits growth of human colon cancer cells via suppression of the Akt signaling pathway. Molecular Nutrition and Food Research, 2008, 52, 646-654.	1.5	112
1075	Inhibition of HIFâ€1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3â€M cells. Molecular Carcinogenesis, 2008, 47, 686-700.	1.3	86
1076	A Caged PhosphopeptideâBased Approach for Photochemical Activation of Kinases in Living Cells. ChemBioChem, 2008, 9, 1583-1586.	1.3	25
1077	Identification of survivalâ€related genes of the phosphatidylinositol 3â€²â€kinase signaling pathway in glioblastoma multiforme. Cancer, 2008, 112, 1575-1584.	2.0	67
1078	Novel mutations of the suppressor genePTENin colorectal carcinomas stratified by microsatellite instability- andTP53mutation- status. Human Mutation, 2008, 29, E252-E262.	1.1	34
1079	Phosphoinositide 3â€kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. International Journal of Cancer, 2008, 122, 433-443.	2.3	180
1080	Akt1 inhibition by RNA interference sensitizes human nonâ€small cell lung cancer cells to cisplatin. International Journal of Cancer, 2008, 122, 2380-2384.	2.3	46
1081	Vitamin E and cancer: An insight into the anticancer activities of vitamin E isomers and analogs. International Journal of Cancer, 2008, 123, 739-752.	2.3	237
1082	An activating mutation in AKT1 in human prostate cancer. International Journal of Cancer, 2008, 123, 2725-2726.	2.3	17
1083	Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities. Journal of Cellular Biochemistry, 2008, 104, 1124-1149.	1.2	186
1084	Involvement of PI3K in HCVâ€related lymphoproliferative disorders. Journal of Cellular Physiology, 2008, 214, 396-404.	2.0	17
1085	Distinct roles of the three Akt isoforms in lactogenic differentiation and involution. Journal of Cellular Physiology, 2008, 217, 468-477.	2.0	75
1086	Constitutive neutrophil apoptosis: Mechanisms and regulation. American Journal of Hematology, 2008, 83, 288-295.	2.0	244
1087	Increased Rac activity is required for the progression of T-lymphomas induced by Pten-deficiency. Leukemia Research, 2008, 32, 113-120.	0.4	7
1088	Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: Role of COX-2 and MDR-1. Leukemia Research, 2008, 32, 855-864.	0.4	70
1089	PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2008, 1784, 150-158.	1.1	282

#	Article	IF	Citations
1090	Targeting phosphoinositide 3-kinaseâ€"Moving towards therapy. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2008, 1784, 159-185.	1.1	491
1091	The biological properties of cetuximab. Critical Reviews in Oncology/Hematology, 2008, 68, 93-106.	2.0	113
1092	Cross-scale sensitivity analysis of a non-small cell lung cancer model: Linking molecular signaling properties to cellular behavior. BioSystems, 2008, 92, 249-258.	0.9	31
1093	Eupalinin A isolated from Eupatorium chinense L. induces autophagocytosis in human leukemia HL60 cells. Bioorganic and Medicinal Chemistry, 2008, 16, 721-731.	1.4	35
1094	Inhibitory effect of xanthones isolated from the pericarp of Garcinia mangostana L. on rat basophilic leukemia RBL-2H3 cell degranulation. Bioorganic and Medicinal Chemistry, 2008, 16, 4500-4508.	1.4	55
1095	The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine. Bioorganic and Medicinal Chemistry, 2008, 16, 7888-7893.	1.4	57
1096	Discovery of potent and cell-active allosteric dual Akt 1 and 2 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4186-4190.	1.0	16
1097	4-(1,3-Thiazol-2-yl)morpholine derivatives as inhibitors of phosphoinositide 3-kinase. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4316-4320.	1.0	46
1098	Allosteric inhibitors of Akt1 and Akt2: A naphthyridinone with efficacy in an A2780 tumor xenograft model. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3178-3182.	1.0	78
1099	PIK3CA Exon 20 Mutation is Independently Associated with a Poor Prognosis in Breast Cancer Patients. Annals of Surgical Oncology, 2008, 15, 1064-1069.	0.7	93
1100	Potential Inhibition of PDK1/Akt Signaling by Phenothiazines Suppresses Cancer Cell Proliferation and Survival. Annals of the New York Academy of Sciences, 2008, 1138, 393-403.	1.8	48
1101	LY294002 induces p53-dependent apoptosis of SGC7901 gastric cancer cells. Acta Pharmacologica Sinica, 2008, 29, 489-498.	2.8	23
1102	Absence of E17K mutation in the pleckstrin homology domain of AKT1 in gastrointestinal and liver cancers in the Korean population. Apmis, 2008, 116, 530-533.	0.9	2
1103	Absence of the AKT1 pleckstrin homology domain mutation in Japanese gastrointestinal and liver cancer patients. Apmis, 2008, 116, 931-933.	0.9	1
1104	Expression of phosphorylated Akt in oral carcinogenesis and its induction by nicotine and alkaline stimulation. Journal of Oral Pathology and Medicine, 2009, 38, 206-213.	1.4	37
1105	Expression and alterations of the PTENâ€Š/â€ŠAKTâ€Š/â€ŠmTOR pathway in ameloblastomas. Oral Diseases, 2008, 14, 561-568.	1.5	35
1106	Spindle assembly checkpoint gene mdf-1 regulates germ cell proliferation in response to nutrition signals in C. elegans. EMBO Journal, 2008, 27, 1085-1096.	3.5	22
1107	Lack of Cytoplasmic ERK Activation Is an Independent Adverse Prognostic Factor in Primary Cutaneous Melanoma. Journal of Investigative Dermatology, 2008, 128, 2696-2704.	0.3	34

#	Article	IF	Citations
1108	Essential roles of PI(3)Kâ€“p110Î² in cell growth, metabolism and tumorigenesis. Nature, 2008, 454, 776-779.	13.7	654
1109	CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene, 2008, 27, 1749-1758.	2.6	720
1110	Activation of the p53â€“p21Cip1 pathway is required for CDK2 activation and S-phase entry in primary rat hepatocytes. Oncogene, 2008, 27, 2763-2771.	2.6	20
1111	Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene, 2008, 27, 3539-3545.	2.6	85
1112	The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Oncogene, 2008, 27, 5182-5194.	2.6	128
1113	FOXOs, cancer and regulation of apoptosis. Oncogene, 2008, 27, 2312-2319.	2.6	509
1114	Class I PI3K in oncogenic cellular transformation. Oncogene, 2008, 27, 5486-5496.	2.6	528
1115	The PTENâ€“PI3K pathway: of feedbacks and cross-talks. Oncogene, 2008, 27, 5527-5541.	2.6	778
1116	The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene, 2008, 27, 6207-6215.	2.6	184
1117	Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells. Oncogene, 2008, 27, 4096-4106.	2.6	47
1118	Simultaneous blockade of AP-1 and phosphatidylinositol 3-kinase pathway in non-small cell lung cancer cells. British Journal of Cancer, 2008, 99, 2013-2019.	2.9	19
1119	Epithelial Pten is dispensable for intestinal homeostasis but suppresses adenoma development and progression after Apc mutation. Nature Genetics, 2008, 40, 1436-1444.	9.4	101
1120	The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nature Reviews Cancer, 2008, 8, 253-267.	12.8	869
1121	Structural comparisons of class I phosphoinositide 3-kinases. Nature Reviews Cancer, 2008, 8, 665-669.	12.8	82
1122	Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-Î²B pathways. Nature Reviews Drug Discovery, 2008, 7, 1031-1040.	21.5	135
1123	Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation. Nature Reviews Genetics, 2008, 9, 115-128.	7.7	755
1124	Outside-in Signaling through Integrins and Cadherins: A Central Mechanism to Control Epidermal Growth and Differentiation?. Journal of Investigative Dermatology, 2008, 128, 501-516.	0.3	138
1125	Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia, 2008, 22, 147-160.	3.3	105

#	Article	IF	Citations
1126	Programmed cell death and new discoveries in the genetics of parkinsonism. Journal of Neurochemistry, 2008, 104, 875-890.	2.1	33
1127	Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin. Transplant International, 2008, 21, 207-217.	0.8	46
1128	Focal adhesion kinase mediates the interferon-Î³-inducible GTPase-induced phosphatidylinositol 3-kinase/Akt survival pathway and further initiates a positive feedback loop of NF-ÎºB activation. Cellular Microbiology, 2008, 10, 1787-1800.	1.1	29
1129	A comprehensive analysis of transcript signatures of the phosphatidylinositol-3 kinase/protein kinase B signal-transduction pathway in prostate cancer. BJU International, 2008, 101, 1454-1460.	1.3	23
1130	Analysis of complex protein kinase B signalling pathways in human prostate cancer samples. BJU International, 2008, 102, 371-382.	1.3	20
1131	Integrating differentiation and cancer: The Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Differentiation, 2008, 76, 717-727.	1.0	113
1132	Chronic lymphocytic leukaemia and acute myeloid leukaemia are not associated with AKT1 pleckstrin homology domain (E17K) mutations. British Journal of Haematology, 2008, 141, 742-743.	1.2	17
1133	A large animal model to evaluate the effects of Hsp90 inhibitors for the treatment of lung adenocarcinoma. Virology, 2008, 371, 206-215.	1.1	17
1134	The reduced catalase expression in TrkA-induced cells leads to autophagic cell death via ROS accumulation. Experimental Cell Research, 2008, 314, 3094-3106.	1.2	134
1135	In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecologic Oncology, 2008, 110, 246-250.	0.6	249
1136	Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma. BMC Cancer, 2008, 8, 163.	1.1	92
1137	Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting. BMC Research Notes, 2008, 1, 14.	0.6	42
1138	HER2-Positive Breast Cancer: From Trastuzumab to Innovatory Anti-HER2 Strategies. Clinical Breast Cancer, 2008, 8, 38-49.	1.1	46
1139	Resistance to TRAIL-induced apoptosis caused by constitutional phosphorylation of Akt and PTEN in acute lymphoblastic leukemia cells. Experimental Hematology, 2008, 36, 1343-1353.	0.2	27
1140	Alphaâ€lipoic acid induces apoptosis in hepatoma cells via the PTEN/Akt pathway. FEBS Letters, 2008, 582, 1667-1671.	1.3	56
1141	The functional implications of Akt activity and TGF-Î² signaling in tamoxifen-resistant breast cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2008, 1783, 438-447.	1.9	28
1142	FoxO tumor suppressors and BCRâ€“ABL-induced leukemia: A matter of evasion of apoptosis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2008, 1785, 63-84.	3.3	51
1143	Taxanes, microtubules and chemoresistant breast cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2008, 1785, 96-132.	3.3	313

#	Article	IF	Citations
1144	Role of p53, PUMA, and Bax in wogonin-induced apoptosis in human cancer cells. Biochemical Pharmacology, 2008, 75, 2020-2033.	2.0	119
1145	Fifty years of Biochemical Pharmacology: The discipline and the journal. Biochemical Pharmacology, 2008, 76, 1-10.	2.0	3
1146	PIK3CA gene mutations in breast carcinoma in Malaysian patients. Cancer Genetics and Cytogenetics, 2008, 187, 74-79.	1.0	8
1147	PKB and the mitochondria: AKTing on apoptosis. Cellular Signalling, 2008, 20, 21-30.	1.7	192
1148	Mutation of Y179 on phospholipase D2 (PLD2) upregulates DNA synthesis in a PI3K-and Akt-dependent manner. Cellular Signalling, 2008, 20, 176-185.	1.7	19
1149	Raptor-rictor axis in TGFÎ²-induced protein synthesis. Cellular Signalling, 2008, 20, 409-423.	1.7	60
1150	Cytotoxic activity of nemorosone in neuroblastoma cells. Journal of Cellular and Molecular Medicine, 2008, 12, 2598-2608.	1.6	28
1151	The microfilament system and malignancy. Seminars in Cancer Biology, 2008, 18, 2-11.	4.3	69
1152	Lipopolysaccharide induces VCAM-1 expression and neutrophil adhesion to human tracheal smooth muscle cells: Involvement of Src/EGFR/PI3-K/Akt pathway. Toxicology and Applied Pharmacology, 2008, 228, 256-268.	1.3	63
1153	The câ€¢myc Promoter: Still MysterY and Challenge. Advances in Cancer Research, 2008, 99, 113-333.	1.9	179
1154	Promising Newer Molecular-Targeted Therapies in Head and Neck Cancer. Drugs, 2008, 68, 1609-1619.	4.9	10
1155	The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer. Journal of Medicinal Chemistry, 2008, 51, 5522-5532.	2.9	710
1156	Membrane androgen receptor activation triggers down-regulation of PI-3K/Akt/NF-kappaB activity and induces apoptotic responses via Bad, FasL and caspase-3 in DU145 prostate cancer cells. Molecular Cancer, 2008, 7, 88.	7.9	57
1157	Chapter 3 Poxvirus Host Range Genes. Advances in Virus Research, 2008, 71, 135-171.	0.9	65
1158	E2F1 Inhibits c-Myc-Driven Apoptosis via PIK3CA/Akt/mTOR and COX-2 in a Mouse Model of Human Liver Cancer. Gastroenterology, 2008, 135, 1322-1332.	0.6	109
1159	Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma. Gastroenterology, 2008, 135, 1972-1983.e11.	0.6	644
1160	Molecular targets and biological modifiers in gastric cancer. Seminars in Diagnostic Pathology, 2008, 25, 274-287.	1.0	30
1161	Nutrition, metabolic factors and cancer risk. Best Practice and Research in Clinical Endocrinology and Metabolism, 2008, 22, 551-571.	2.2	64

#	Article	IF	Citations
1162	Lipocalin 2 promotes lung metastasis of murine breast cancer cells. Journal of Experimental and Clinical Cancer Research, 2008, 27, 83.	3.5	78
1163	Silencing of GM3 synthase suppresses lung metastasis of murine breast cancer cells. Breast Cancer Research, 2008, 10, R1.	2.2	69
1164	EGFR Signaling Networks in Cancer Therapy. , 2008, , .		11
1166	Eicosanoids and Resistance of Cancer Cells to Chemotherapeutic Agents. , 2008, , 133-156.		2
1167	Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy. , 2008, , .		3
1168	Targeted Cancer Therapy. , 2008, , .		11
1169	Experimental models of hepatocellular carcinoma. Journal of Hepatology, 2008, 48, 858-879.	1.8	203
1170	Novel advancements in the management of hepatocellular carcinoma in 2008. Journal of Hepatology, 2008, 48, S20-S37.	1.8	739
1171	Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. Journal of Hepatology, 2008, 49, 52-60.	1.8	84
1172	mTOR-Raptor Binds and Activates SGK1 to Regulate p27 Phosphorylation. Molecular Cell, 2008, 30, 701-711.	4.5	236
1173	Resveratrol and its analogs: Defense against cancer, coronary disease and neurodegenerative maladies or just a fad?. Mutation Research - Reviews in Mutation Research, 2008, 658, 68-94.	2.4	383
1174	Phosphatase and tensin homolog, deleted on chromosome 10 deficiency in brain causes defects in synaptic structure, transmission and plasticity, and myelination abnormalities. Neuroscience, 2008, 151, 476-488.	1.1	170
1175	New drug development in metastatic prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 430-437.	0.8	19
1176	PHLiPPing the switch on Akt and protein kinase C signaling. Trends in Endocrinology and Metabolism, 2008, 19, 223-230.	3.1	169
1177	Inhibition of the PI3K-Akt/PKB survival pathway enhanced an ethanol extract of Rhus verniciflua Stokes-induced apoptosis via a mitochondrial pathway in AGS gastric cancer cell lines. Cancer Letters, 2008, 265, 197-205.	3.2	61
1178	The heat shock protein antagonist 17-AAG potentiates the activity of enzastaurin against malignant human glioma cells. Cancer Letters, 2008, 268, 46-55.	3.2	17
1179	Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms. Cancer Letters, 2008, 271, 260-271.	3.2	53
1180	Reversal of the malignant phenotype of ovarian cancer A2780 cells through transfection with wild-type PTEN gene. Cancer Letters, 2008, 271, 205-214.	3.2	21

#	Article	IF	Citations
1181	The ubiquitin-proteasome system in colorectal cancer. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2008, 1782, 800-808.	1.8	62
1182	Role of Akt isoforms in HGF-induced invasive growth of human salivary gland cancer cells. Biochemical and Biophysical Research Communications, 2008, 370, 123-128.	1.0	25
1183	LY294002 inhibits leukemia cell invasion and migration through early growth response gene 1 induction independent of phosphatidylinositol 3-kinase-Akt pathway. Biochemical and Biophysical Research Communications, 2008, 377, 187-190.	1.0	29
1184	A new evaluation method for quantifying PI3K activity by HTRF assay. Biochemical and Biophysical Research Communications, 2008, 377, 941-945.	1.0	13
1185	Inhibition of PI-3 kinase for treating respiratory disease: good idea or bad idea?. Current Opinion in Pharmacology, 2008, 8, 267-274.	1.7	29
1186	Targeting the PI3Kâ€“AKTâ€“mTOR pathway: progress, pitfalls, and promises. Current Opinion in Pharmacology, 2008, 8, 393-412.	1.7	488
1187	Involvement of PI3K/Akt Pathway in TGF-Î²2₂-Mediated Epithelial Mesenchymal Transition in Human Lens Epithelial Cells. Ophthalmic Research, 2008, 40, 69-76.	1.0	59
1188	Current View: Intestinal Stem Cells and Signaling. Gastroenterology, 2008, 134, 849-864.	0.6	365
1189	Cancer Gene Pathways. , 2008, , 173-226.		2
1190	mTOR inhibitors in the treatment of cancer. Expert Opinion on Investigational Drugs, 2008, 17, 1717-1734.	1.9	127
1191	Adaptation to ER stress as a driver of malignancy and resistance to therapy in human melanoma. Pigment Cell and Melanoma Research, 2008, 21, 358-367.	1.5	98
1192	Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncology, The, 2008, 9, 288-296.	5.1	306
1193	PI3K/Akt Pathway Activation Attenuates the Cytotoxic Effect of Methyl Jasmonate Toward Sarcoma Cells. Neoplasia, 2008, 10, 1303-1313.	2.3	31
1195	Causes and Consequences of Increased Glucose Metabolism of Cancers. Journal of Nuclear Medicine, 2008, 49, 24S-42S.	2.8	560
1196	Recent Advances in Molecular Biology of Thyroid Cancer and Their Clinical Implications. Otolaryngologic Clinics of North America, 2008, 41, 1135-1146.	0.5	70
1197	PIK3CA, HRAS and KRAS Gene Mutations in Human Penile Cancer. Journal of Urology, 2008, 179, 2030-2034.	0.2	51
1198	Pancreatic Carcinogenesis. Pancreatology, 2008, 8, 110-125.	0.5	155
1199	PI(3)Kâ€“Aktâ€“mTOR pathway as a potential therapeutic target in neuroendocrine tumors. Expert Review of Endocrinology and Metabolism, 2008, 3, 207-222.	1.2	3

#	Article	IF	Citations
1200	Akt as a therapeutic target in cancer. Expert Opinion on Therapeutic Targets, 2008, 12, 1139-1165.	1.5	125
1201	Augmentation by Carnosic Acid of Apoptosis in Human Leukaemia Cells Induced by Arsenic Trioxide via Upregulation of the Tumour Suppressor PTEN. Journal of International Medical Research, 2008, 36, 682-690.	0.4	17
1202	Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis, 2008, 29, 2289-2297.	1.3	142
1203	Combination therapy for malignant glioma based on PTEN status. Expert Review of Anticancer Therapy, 2008, 8, 1767-1779.	1.1	14
1204	A Global Metabolite Profiling Approach to Identify Proteinâ^'Metabolite Interactions. Journal of the American Chemical Society, 2008, 130, 14111-14113.	6.6	41
1205	Structure-Based Design of an Organoruthenium Phosphatidyl-inositol-3-kinase Inhibitor Reveals a Switch Governing Lipid Kinase Potency and Selectivity. ACS Chemical Biology, 2008, 3, 305-316.	1.6	51
1206	Insights into the Structural Specificity of the Cytotoxicity of 3-Deoxyphosphatidylinositols. Journal of the American Chemical Society, 2008, 130, 7746-7755.	6.6	29
1207	Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment. Biochemical Journal, 2008, 409, 635-649.	1.7	238
1208	Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes and Development, 2008, 22, 2178-2188.	2.7	100
1209	Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 20315-20320.	3.3	155
1210	Regulation of Phosphorylation of Thr-308 of Akt, Cell Proliferation, and Survival by the B55Î± Regulatory Subunit Targeting of the Protein Phosphatase 2A Holoenzyme to Akt. Journal of Biological Chemistry, 2008, 283, 1882-1892.	1.6	311
1211	Mechanism of Influenza A Virus NS1 Protein Interaction with the p85Î², but Not the p85Î±, Subunit of Phosphatidylinositol 3-Kinase (PI3K) and Up-regulation of PI3K Activity. Journal of Biological Chemistry, 2008, 283, 23397-23409.	1.6	54
1212	Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover. Carcinogenesis, 2008, 29, 25-34.	1.3	71
1213	The ubiquitin ligase Nedd4-1 is dispensable for the regulation of PTEN stability and localization. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8585-8590.	3.3	160
1214	Decoy Receptor 3 Expression in AsPC-1 Human Pancreatic Adenocarcinoma Cells via the Phosphatidylinositol 3-Kinase-, Akt-, and NF-ÎºB-Dependent Pathway. Journal of Immunology, 2008, 181, 8441-8449.	0.4	34
1215	Insights into the oncogenic effects of /PIK3CA/ mutations from the structure of p110α/p85α. Cell Cycle, 2008, 7, 1151-1156.	1.3	73
1217	Skin Cancer Prevention. , 2008, , 239-289.		0
1218	Multistep regulation of telomerase during differentiation of HL60 cells. Journal of Leukocyte Biology, 2008, 83, 1240-1248.	1.5	22

#	Article	IF	Citations
1219	Cancer Cell-Derived Clusterin Modulates the Phosphatidylinositol 3â€²-Kinase-Akt Pathway through Attenuation of Insulin-Like Growth Factor 1 during Serum Deprivation. Molecular and Cellular Biology, 2008, 28, 4285-4299.	1.1	56
1220	Multidrug Resistance-Associated Proteinâ€“Overexpressing Teniposide-Resistant Human Lymphomas Undergo Apoptosis by a Tubulin-Binding Agent. Cancer Research, 2008, 68, 1495-1503.	0.4	31
1221	Spontaneous Squamous Cell Carcinoma Induced by the Somatic Inactivation of Retinoblastoma and Trp53 Tumor Suppressors. Cancer Research, 2008, 68, 683-692.	0.4	60
1222	An Actin-Binding Protein Girdin Regulates the Motility of Breast Cancer Cells. Cancer Research, 2008, 68, 1310-1318.	0.4	162
1223	Activation of Phosphatidylinositol 3-Kinase by Membrane Localization of p110Î± Predisposes Mammary Glands to Neoplastic Transformation. Cancer Research, 2008, 68, 9643-9653.	0.4	47
1224	Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Molecular Cancer Therapeutics, 2008, 7, 670-678.	1.9	171
1225	Regulation of innate immunity by inositol 1,3,4,5-tetrakisphosphate. Cell Cycle, 2008, 7, 2803-2808.	1.3	13
1226	Akt and mRNA translation by interferons. Cell Cycle, 2008, 7, 2112-2116.	1.3	28
1227	Autocrine regulation of glioblastoma cell-cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay. Cell Cycle, 2008, 7, 2553-2561.	1.3	127
1228	Hexamethylene Bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF-ÎºB activity: Implications for cancer therapy. Cell Cycle, 2008, 7, 3759-3767.	1.3	72
1229	Targeting Apoptosis Resistance in Rhabdomyosarcoma. Current Cancer Drug Targets, 2008, 8, 536-544.	0.8	18
1230	Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells. Cell Cycle, 2008, 7, 1769-1775.	1.3	54
1231	Fission yeast TOR complex 2 activates the AGC-family Gad8 kinase essential for stress resistance and cell cycle control. Cell Cycle, 2008, 7, 358-364.	1.3	75
1232	Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas. International Journal of Oncology, 2008, , .	1.4	36
1233	Underlying principles of cell fate determination during G1 phase of the mammalian cell cycle. Cell Cycle, 2008, 7, 3246-3257.	1.3	37
1234	Akt-dependent regulation of NF-ÎºB is controlled by mTOR and Raptor in association with IKK. Genes and Development, 2008, 22, 1490-1500.	2.7	524
1235	Hypoxia-Induced Signaling in the Cardiovascular System. Annual Review of Physiology, 2008, 70, 51-71.	5.6	64
1236	Laminin-332 promotes the invasion of oesophageal squamous cell carcinoma via PI3K activation. British Journal of Cancer, 2008, 98, 974-980.	2.9	39

#	Article	IF	Citations
1237	Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. British Journal of Cancer, 2008, 98, 923-930.	2.9	131
1238	Statins and prostate cancer prevention: where we are now, and future directions. Nature Reviews Urology, 2008, 5, 376-387.	1.4	62
1239	Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis. Journal of Cell Science, 2008, 121, 979-988.	1.2	160
1240	A peptide inhibitor derived from p55PIK phosphatidylinositol 3-kinase regulatory subunit: a novel cancer therapy. Molecular Cancer Therapeutics, 2008, 7, 3719-3728.	1.9	38
1241	Phosphatidylinositol 3-Kinase Inhibition Broadly Sensitizes Glioblastoma Cells to Death Receptorâ€“ and Drug-Induced Apoptosis. Cancer Research, 2008, 68, 6271-6280.	0.4	137
1242	Leptin-enhanced neointimal hyperplasia is reduced by mTOR and PI3K inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 19006-19011.	3.3	55
1243	Mel-18 Negatively Regulates INK4a/ARF-Independent Cell Cycle Progression via Akt Inactivation in Breast Cancer. Cancer Research, 2008, 68, 4201-4209.	0.4	45
1244	Differential Involvement of Iº B Kinases Î± and Î² in Cytokine- and Insulin-Induced Mammalian Target of Rapamycin Activation Determined by Akt. Journal of Immunology, 2008, 180, 7582-7589.	0.4	68
1245	Î´-Catenin-induced Dendritic Morphogenesis. Journal of Biological Chemistry, 2008, 283, 977-987.	1.6	67
1246	TLR9-Activating DNA Up-Regulates ZAP70 via Sustained PKB Induction in IgM+ B Cells. Journal of Immunology, 2008, 181, 8267-8277.	0.4	29
1247	Makorin-2 Is a Neurogenesis Inhibitor Downstream of Phosphatidylinositol 3-Kinase/Akt (PI3K/Akt) Signal. Journal of Biological Chemistry, 2008, 283, 8486-8495.	1.6	26
1248	Macrophage Migration Inhibitory Factor Induces B Cell Survival by Activation of a CD74-CD44 Receptor Complex. Journal of Biological Chemistry, 2008, 283, 2784-2792.	1.6	222
1249	Activation of Human Peripheral IgM+ B Cells Is Transiently Inhibited by BCR-Independent Aggregation of FcÎ³RIIB. Journal of Immunology, 2008, 181, 5350-5359.	0.4	13
1250	Epidermal growth factor receptor exposed to cigarette smoke is aberrantly activated and undergoes perinuclear trafficking. FASEB Journal, 2008, 22, 910-917.	0.2	84
1251	Potential for Molecular Targeted Therapy for Adult T-Cell Leukemia/Lymphoma. International Reviews of Immunology, 2008, 27, 71-78.	1.5	6
1252	The Genomic Analysis of Lactic Acidosis and Acidosis Response in Human Cancers. PLoS Genetics, 2008, 4, e1000293.	1.5	188
1253	Plant flavonoid apigenin inactivates Akt to trigger apoptosis in human prostate cancer: an in vitro and in vivo study. Carcinogenesis, 2008, 29, 2210-2217.	1.3	80
1254	Oncogenes and Signal Transduction. , 2008, , 17-30.		0

#	Article	IF	Citations
1255	Apoptosis and tumor resistance conferred by Par-4. Cancer Biology and Therapy, 2008, 7, 1867-1874.	1.5	47
1256	Dietary Energy Balance Modulates Signaling through the Akt/Mammalian Target of Rapamycin Pathways in Multiple Epithelial Tissues. Cancer Prevention Research, 2008, 1, 65-76.	0.7	153
1257	New Aspects of Regulatory Signaling Pathways and Novel Therapies in Pancreatic Cancer. Current Molecular Medicine, 2008, 8, 12-37.	0.6	24
1258	Targeting Ras in Myeloid Leukemias. Clinical Cancer Research, 2008, 14, 2249-2252.	3.2	57
1260	PTEN Expression in Endometrial Biopsies as a Marker of Progression to Endometrial Carcinoma. Cancer Research, 2008, 68, 6014-6020.	0.4	70
1261	Poly(ester amine)-mediated, Aerosol-delivered Akt1 Small Interfering RNA Suppresses Lung Tumorigenesis. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 60-73.	2.5	97
1262	The Forkhead Transcription Factor FOXO3a Increases Phosphoinositide-3 Kinase/Akt Activity in Drug-Resistant Leukemic Cells through Induction of PIK3CA Expression. Molecular and Cellular Biology, 2008, 28, 5886-5898.	1.1	150
1263	Enhancing Mammalian Target of Rapamycin (mTOR)â€“Targeted Cancer Therapy by Preventing mTOR/Raptor Inhibition-Initiated, mTOR/Rictor-Independent Akt Activation. Cancer Research, 2008, 68, 7409-7418.	0.4	152
1264	A novel combination: ranpirnase and rosiglitazone induce a synergistic apoptotic effect by down-regulating Fra-1 and Survivin in cancer cells. Molecular Cancer Therapeutics, 2008, 7, 1871-1879.	1.9	16
1265	Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment. Clinical Cancer Research, 2008, 14, 865-874.	3.2	59
1266	Nitric Oxide Is a Key Component in Inflammation-Accelerated Tumorigenesis. Cancer Research, 2008, 68, 7130-7136.	0.4	97
1267	HER3 Is a Determinant for Poor Prognosis in Melanoma. Clinical Cancer Research, 2008, 14, 5188-5197.	3.2	142
1268	The eIF4E RNA regulon promotes the Akt signaling pathway. Journal of Cell Biology, 2008, 181, 51-63.	2.3	90
1269	Constitutive PtdIns(3,4,5)P3 synthesis promotes the development and survival of early mammalian embryos. Development (Cambridge), 2008, 135, 425-429.	1.2	37
1270	ICAM-1 Has a Critical Role in the Regulation of Metastatic Melanoma Tumor Susceptibility to CTL Lysis by Interfering with PI3K/AKT Pathway. Cancer Research, 2008, 68, 9854-9864.	0.4	59
1271	Chemoprevention and Treatment of Experimental Cowden's Disease by mTOR Inhibition with Rapamycin. Cancer Research, 2008, 68, 7066-7072.	0.4	92
1272	Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism. Molecular Cancer Therapeutics, 2008, 7, 2609-2620.	1.9	163
1273	Spatiotemporal Analysis of Differential Akt Regulation in Plasma Membrane Microdomains. Molecular Biology of the Cell, 2008, 19, 4366-4373.	0.9	139

#	Article	IF	Citations
1274	Response and determinants of cancer cell susceptibility to PI3K inhibitors: Combined targeting of PI3K and Mek1 as an effective anticancer strategy. Cancer Biology and Therapy, 2008, 7, 310-318.	1.5	74
1275	Association between Phosphatidylinositol 3-Kinase Regulatory Subunit p85Î± Met326Ile Genetic Polymorphism and Colon Cancer Risk. Clinical Cancer Research, 2008, 14, 633-637.	3.2	42
1276	The anandamide analog, Met-F-AEA, controls human breast cancer cell migration via the RHOA/RHO kinase signaling pathway. Endocrine-Related Cancer, 2008, 15, 965-974.	1.6	38
1277	Inhibition of apoptosis by MAD1 is mediated by repression of the PTEN tumor suppressor gene. FASEB Journal, 2008, 22, 1124-1134.	0.2	7
1278	Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2008, 26, 1603-1610.	0.8	519
1279	Localization of Fas/CD95 into the Lipid Rafts on Down-Modulation of the Phosphatidylinositol 3-Kinase Signaling Pathway. Molecular Cancer Research, 2008, 6, 604-613.	1.5	45
1280	Freud-1/Aki1, a Novel PDK1-Interacting Protein, Functions as a Scaffold To Activate the PDK1/Akt Pathway in Epidermal Growth Factor Signaling. Molecular and Cellular Biology, 2008, 28, 5996-6009.	1.1	59
1281	IP6K2 is a client for HSP90 and a target for cancer therapeutics development. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 1389-1390.	3.3	21
1282	PIK3CA Mutations and Copy Number Gains in Human Lung Cancers. Cancer Research, 2008, 68, 6913-6921.	0.4	399
1283	Prolactin Does Not Require Insulin-Like Growth Factor Intermediates but Synergizes with Insulin-Like Growth Factor I in Human Breast Cancer Cells. Molecular Cancer Research, 2008, 6, 634-643.	1.5	16
1284	Phosphatidylinositol 3-Kinase/Akt and Ras/Raf-Mitogen-Activated Protein Kinase Pathway Mutations in Anaplastic Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 278-284.	1.8	177
1285	Clinicopathological Analysis of Papillary Thyroid Cancer withPIK3CAAlterations in a Middle Eastern Population. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 611-618.	1.8	169
1286	Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways. Leukemia and Lymphoma, 2008, 49, 798-808.	0.6	53
1287	Substrate-Bound Insulin-Like Growth Factor (IGF)-I-IGF Binding Protein-Vitronectin-Stimulated Breast Cell Migration Is Enhanced by Coactivation of the Phosphatidylinositide 3-Kinase/AKT Pathway by Î±v-Integrins and the IGF-I Receptor. Endocrinology, 2008, 149, 1075-1090.	1.4	38
1288	Signaling in Human B-Lymphoma Rafts. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2008, 8, 366-374.	0.5	0
1289	Synergistic effects of Pten loss and WNT/CTNNB1 signaling pathway activation in ovarian granulosa cell tumor development and progression. Carcinogenesis, 2008, 29, 2062-2072.	1.3	78
1290	Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans. Cancer Biology and Therapy, 2008, 7, 628-635.	1.5	43
1291	Immunosuppressive therapy and post-transplant malignancy. Nephrology Dialysis Transplantation, 2008, 24, 1097-1103.	0.4	26

#	Article	IF	Citations
1292	Immune Expression and Inhibition of Heat Shock Protein 90 in Uveal Melanoma. Clinical Cancer Research, 2008, 14, 847-855.	3.2	20
1293	Chromatin-modifying enzymes as therapeutic targets â€“ Part 2. Expert Opinion on Therapeutic Targets, 2008, 12, 1457-1467.	1.5	34
1294	Translational control and cancer therapy. Cell Cycle, 2008, 7, 2791-2794.	1.3	22
1295	The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications. Current Cancer Drug Targets, 2008, 8, 187-198.	0.8	685
1296	Fatty Acid Synthase and AKT Pathway Signaling in a Subset of Papillary Thyroid Cancers. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4088-4097.	1.8	65
1297	The Role of PI3/Akt Pathway in the Protective Effect of Insulin against Corticosterone Cell Death Induction in Hippocampal Cell Culture. Neuroendocrinology, 2008, 88, 293-298.	1.2	20
1298	Targeting NF-ÎºB in Waldenstrom macroglobulinemia. Blood, 2008, 111, 5068-5077.	0.6	106
1299	Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood, 2008, 112, 2463-2473.	0.6	97
1300	Igbp1 is part of a positive feedback loop in stem cell factorâ€“dependent, selective mRNA translation initiation inhibiting erythroid differentiation. Blood, 2008, 112, 2750-2760.	0.6	36
1301	AKT1 and AKT2 mutations in lung cancer in a Japanese population. Molecular Medicine Reports, 2008, 1, 663-6.	1.1	2
1302	Effect of exercise on biological pathways in ApcMin/+ mouse intestinal polyps. Journal of Applied Physiology, 2008, 104, 1137-1143.	1.2	42
1303	Illuminating the phosphatidylinositol 3-kinase/Akt pathway. Proceedings of SPIE, 2008, , .	0.8	0
1304	mTOR Pathway and mTOR Inhibitors as Agents for Cancer Therapy. Current Cancer Drug Targets, 2008, 8, 647-665.	0.8	94
1305	In-vivo effects and mechanisms of celecoxib-reduced growth of cyclooxygenase-2 (COX-2)-expressing versus COX-2-deleted human HCC xenografts in nude mice. Anti-Cancer Drugs, 2008, 19, 891-897.	0.7	9
1306	Enhancing the Cytotoxic Activity of Novel Targeted Therapies â€“ Is There a Role for a Combinatorial Approach?. Current Clinical Pharmacology, 2008, 3, 108-117.	0.2	20
1307	Molecular Alterations in Prostate Cancer as Diagnostic, Prognostic, and Therapeutic Targets. Advances in Anatomic Pathology, 2008, 15, 319-331.	2.4	55
1308	The Probiotic Lactobacillus acidophilus Stimulates Chloride/Hydroxyl Exchange Activity in Human Intestinal Epithelial Cells. Journal of Nutrition, 2008, 138, 1355-1359.	1.3	80
1309	Gastrin-Releasing Peptide Receptors Regulate Proliferation of C6 Glioma Cells through a Phosphatidylinositol 3-Kinase-Dependent Mechanism. Current Neurovascular Research, 2008, 5, 99-105.	0.4	30

#	Article	IF	Citations
1310	New targets for therapy of sarcoma. Current Opinion in Oncology, 2008, 20, 400-406.	1.1	16
1311	Mutations of the PIK3CA Gene in Diffuse Large B Cell Lymphoma. Diagnostic Molecular Pathology, 2008, 17, 159-165.	2.1	50
1313	Targeting Receptor Tyrosine Kinases for Chemoprevention by Green Tea Catechin, EGCG. International Journal of Molecular Sciences, 2008, 9, 1034-1049.	1.8	91
1314	Comparisons of Robustness and Sensitivity between Cancer and Normal Cells by Microarray Data. Cancer Informatics, 2008, 6, CIN.S386.	0.9	16
1315	The Role of Inhibitors of the Epidermal Growth Factor in Management of Head and Neck Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 696-706.	2.3	12
1316	Article Commentary: Molecular Targets of Breast Cancer: AKTing in Concert. Breast Cancer: Basic and Clinical Research, 2008, 2, BCBCR.S787.	0.6	6
1317	The Potential Role of Akt Phosphorylation in Human Cancers. International Journal of Biological Markers, 2008, 23, 1-9.	0.7	102
1318	Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling. PLoS ONE, 2008, 3, e3065.	1.1	248
1319	PI-3K/Akt Pathway-Dependent Cyclin D1 Expression Is Responsible for Arsenite-Induced Human Keratinocyte Transformation. Environmental Health Perspectives, 2008, 116, 1-6.	2.8	52
1320	Anticancer Properties of PPARÎ±-Effects on Cellular Metabolism and Inflammation. PPAR Research, 2008, 2008, 1-9.	1.1	52
1321	Enhancing Akt Imaging through Targeted Reporter Expression. Molecular Imaging, 2008, 7, 7290.2008.00017.	0.7	12
1322	Integrin Signaling Through Focal Adhesion Kinase. , 0, , 25-46.		0
1323	Acute, Muscle-Type Specific Insulin Resistance Following Injury. Molecular Medicine, 2008, 14, 715-723.	1.9	33
1324	Targeted therapy in the treatment of malignant gliomas. OncoTargets and Therapy, 2009, 2, 115.	1.0	5
1325	Multiple roles and therapeutic implications of Akt signaling in cancer. OncoTargets and Therapy, 2009, 2, 135.	1.0	14
1326	Inhibitory effects of adenovirus mediated COX-2, Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo. International Journal of Oncology, 2009, 35, 583-91.	1.4	33
1327	PI3K/Akt Pathway Mutations in Retinoblastoma. , 2009, 50, 5054.		16
1328	Activation of PI3K-AKT Pathway in Oral Epithelial Dysplasia and Early Cancer of Tongue. Bulletin of Tokyo Dental College, The, 2009, 50, 125-133.	0.1	38

#	Article	IF	Citations
1329	Expression of Activated PIK3CA in Ovarian Surface Epithelium Results in Hyperplasia but Not Tumor Formation. PLoS ONE, 2009, 4, e4295.	1.1	30
1330	Single-Cell Profiling Reveals the Origin of Phenotypic Variability in Adipogenesis. PLoS ONE, 2009, 4, e5189.	1.1	51
1331	Apoptosis in Carcinogenesis and Chemotherapy. , 2009, , .		10
1332	Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro. Endocrine-Related Cancer, 2009, 16, 1017-1027.	1.6	67
1333	Evaluating the Utility of a Bioluminescent ADP-Detecting Assay for Lipid Kinases. Assay and Drug Development Technologies, 2009, 7, 585-597.	0.6	16
1334	Blocking Phosphoinositide 3-Kinase Activity in Colorectal Cancer Cells Reduces Proliferation but Does Not Increase Apoptosis Alone or in Combination with Cytotoxic Drugs. Molecular Cancer Research, 2009, 7, 955-965.	1.5	22
1335	Autophagy Provides Nutrients but Can Lead to Chop-dependent Induction of Bim to Sensitize Growth Factorâ€“deprived Cells to Apoptosis. Molecular Biology of the Cell, 2009, 20, 1180-1191.	0.9	51
1336	A frequent kinase domain mutation that changes the interaction between PI3KÎ± and the membrane. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 16996-17001.	3.3	255
1337	Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis, 2009, 30, 2047-2052.	1.3	85
1338	Abrogation of Mitogen-Activated Protein Kinase and Akt Signaling by Vandetanib Synergistically Potentiates Histone Deacetylase Inhibitor-Induced Apoptosis in Human Glioma Cells. Journal of Pharmacology and Experimental Therapeutics, 2009, 331, 327-337.	1.3	25
1339	Chemical Interrogation of FOXO3a Nuclear Translocation Identifies Potent and Selective Inhibitors of Phosphoinositide 3-Kinases. Journal of Biological Chemistry, 2009, 284, 28392-28400.	1.6	77
1340	mTOR in renal cell cancer: modulator of tumor biology and therapeutic target. Expert Review of Molecular Diagnostics, 2009, 9, 231-241.	1.5	64
1341	Î²-TrCP-Mediated Ubiquitination and Degradation of PHLPP1 Are Negatively Regulated by Akt. Molecular and Cellular Biology, 2009, 29, 6192-6205.	1.1	94
1342	Activation of Phosphatidylinositol-3â€²-kinase/AKT Signaling Is Essential in Hepatoblastoma Survival. Clinical Cancer Research, 2009, 15, 4538-4545.	3.2	76
1343	The Alkylphospholipid Perifosine Induces Apoptosis and p21-Mediated Cell Cycle Arrest in Medulloblastoma. Molecular Cancer Research, 2009, 7, 1813-1821.	1.5	22
1344	p27 as Jekyll and Hyde: Regulation of cell cycle and cell motility. Cell Cycle, 2009, 8, 3455-3461.	1.3	107
1345	Silencing of ErbB3/ErbB2 Signaling by Immunoglobulin-like Necl-2. Journal of Biological Chemistry, 2009, 284, 23793-23805.	1.6	52
1346	Brain-Derived Neurotrophic Factor Promotes Implantation and Subsequent Placental Development by Stimulating Trophoblast Cell Growth and Survival. Endocrinology, 2009, 150, 3774-3782.	1.4	111

#	Article	IF	Citations
1347	Endothelin-1 Inhibits Thick Ascending Limb Transport via Akt-stimulated Nitric Oxide Production. Journal of Biological Chemistry, 2009, 284, 1454-1460.	1.6	57
1349	Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer. Clinical Cancer Research, 2009, 15, 4799-4805.	3.2	324
1350	(-)-Epigallocatechin-3-Gallate (EGCG) Increases the Viability of Serum-Starved A549 Cells Through Its Effect on Akt. The American Journal of Chinese Medicine, 2009, 37, 723-734.	1.5	16
1351	The Regulation of Liver Cell Survival by Complement. Journal of Immunology, 2009, 182, 5412-5418.	0.4	91
1352	The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. British Journal of Cancer, 2009, 101, 145-148.	2.9	141
1353	Association of LETM1 and MRPL36 Contributes to the Regulation of Mitochondrial ATP Production and Necrotic Cell Death. Cancer Research, 2009, 69, 3397-3404.	0.4	77
1354	The Expression of Phospho-AKT, Phospho-mTOR, and PTEN in Extrahepatic Cholangiocarcinoma. Clinical Cancer Research, 2009, 15, 660-667.	3.2	103
1355	Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors. Molecular Cancer Research, 2009, 7, 601-613.	1.5	105
1356	High Dietary Inorganic Phosphate Increases Lung Tumorigenesis and Alters Akt Signaling. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 59-68.	2.5	120
1357	Striking the balance between PTEN and PDK1: it all depends on the cell context. Genes and Development, 2009, 23, 1699-1704.	2.7	19
1358	Delphinidin suppresses ultraviolet B-induced cyclooxygenases-2 expression through inhibition of MAPKK4 and PI-3 kinase. Carcinogenesis, 2009, 30, 1932-1940.	1.3	95
1359	Loss of Tsc1, but not Pten, in renal tubular cells causes polycystic kidney disease by activating mTORC1. Human Molecular Genetics, 2009, 18, 4428-4441.	1.4	58
1360	RSK1 drives p27^{Kip1}phosphorylation at T198 to promote RhoA inhibition and increase cell motility. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9268-9273.	3.3	142
1361	The Glycolytic Inhibitor 2-Deoxyglucose Activates Multiple Prosurvival Pathways through IGF1R. Journal of Biological Chemistry, 2009, 284, 23225-23233.	1.6	103
1362	Activated Platelet-Derived Growth Factor Î² Receptor Expression, P13K-AKT Pathway Molecular Analysis, and Transforming Signals in Equine Sarcoids. Veterinary Pathology, 2009, 46, 589-597.	0.8	29
1363	Profiling of mismatch discrimination in RNAi enabled rational design of allele-specific siRNAs. Nucleic Acids Research, 2009, 37, 7560-7569.	6.5	51
1364	Targeted Inhibition of Mammalian Target of Rapamycin Signaling Inhibits Tumorigenesis of Colorectal Cancer. Clinical Cancer Research, 2009, 15, 7207-7216.	3.2	151
1365	RhoG Promotes Neural Progenitor Cell Proliferation in Mouse Cerebral Cortex. Molecular Biology of the Cell, 2009, 20, 4941-4950.	0.9	25

#	Article	IF	Citations
1366	The Murine GL261 Glioma Experimental Model to Assess Novel Brain Tumor Treatments. , 2009, , 227-241.		23
1367	Phosphorylated 4E-BP1 Is Associated with Poor Survival in Melanoma. Clinical Cancer Research, 2009, 15, 2872-2878.	3.2	62
1368	Down-Regulation of 3-Phosphoinositideâ€“Dependent Protein Kinase-1 Levels Inhibits Migration and Experimental Metastasis of Human Breast Cancer Cells. Molecular Cancer Research, 2009, 7, 944-954.	1.5	57
1369	Functional Analysis of Secreted Caveolin-1 in Mouse Models of Prostate Cancer Progression. Molecular Cancer Research, 2009, 7, 1446-1455.	1.5	36
1370	Phytochemicals as Modulators of Neoplastic Phenotypes. Pathobiology, 2009, 76, 55-63.	1.9	7
1371	Lysophosphatidic Acid Stimulates Cell Growth by Different Mechanisms in SKOV-3 and Caov-3 Ovarian Cancer Cells: Distinct Roles for Gi- and Rho-Dependent Pathways. Pharmacology, 2009, 83, 333-347.	0.9	15
1372	RNA Interference-Mediated Silencing of the Phosphatidylinositol 3-Kinase Catalytic Subunit Attenuates Growth of Human Ovarian Cancer Cells in vitroand in vivo. Oncology, 2009, 77, 22-32.	0.9	18
1373	Inhibitory effects of adenovirus mediated Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo. Cancer Biology and Therapy, 2009, 8, 1002-1009.	1.5	18
1374	Repeated Aerosol Delivery of Carboxyl-terminal Modulator Protein Suppresses Tumor in the Lungs of K-ras^{LA1} Mice. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 1131-1140.	2.5	14
1375	Stat1 is an inhibitor of Ras-MAPK signaling and Rho small GTPase expression with implications in the transcriptional signature of Ras transformed cells. Cell Cycle, 2009, 8, 2070-2079.	1.3	24
1376	A new link between epigenetic progenitor lesions in cancer and the dynamics of signal transduction. Cell Cycle, 2009, 8, 383-390.	1.3	33
1377	Activation of the AKT/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD). Nephrology Dialysis Transplantation, 2009, 24, 1819-1827.	0.4	76
1378	Intercepting Akt with DNAzyme: a nasopharyngeal carcinoma story. Cancer Biology and Therapy, 2009, 8, 372-374.	1.5	1
1379	The PI3K/Akt/mTOR Pathway as Therapeutic Target in Neuroblastoma. Current Cancer Drug Targets, 2009, 9, 729-737.	0.8	81
1380	Chapter 17 Regulation of Gene Transcription and Keratinocyte Differentiation by Anandamide. Vitamins and Hormones, 2009, 81, 441-467.	0.7	15
1381	Emerging therapies for multiple myeloma. Expert Opinion on Emerging Drugs, 2009, 14, 99-127.	1.0	48
1382	Targeting Epidermal Growth Factor Receptor in Solid Tumors: Critical Evaluation of the Biological Importance of Therapeutic Monoclonal Antibodies. Current Medicinal Chemistry, 2009, 16, 3797-3804.	1.2	26
1383	Metabolic Targeting of Cancers: From Molecular Mechanisms to Therapeutic Strategies. Current Medicinal Chemistry, 2009, 16, 1561-1587.	1.2	30

#	Article	IF	Citations
1384	The AKT Axis as a Therapeutic Target in Autoimmune Diseases. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2009, 9, 145-150.	0.6	62
1385	Cancer Stem Cells and the Biology of Brain Tumors. Current Stem Cell Research and Therapy, 2009, 4, 306-313.	0.6	19
1386	Focal Adhesion Kinase Regulates Pathogen-Killing Capability and Life Span of Neutrophils via Mediating Both Adhesion-Dependent and -Independent Cellular Signals. Journal of Immunology, 2009, 183, 1032-1043.	0.4	40
1387	New trends in epidermal growth factor receptor-directed monoclonal antibodies. Immunotherapy, 2009, 1, 965-982.	1.0	10
1388	Activation of the PI3 Kinase Pathway By Retinoic Acid Mediates Sodium/Iodide Symporter Induction and Iodide Transport in MCF-7 Breast Cancer Cells. Cancer Research, 2009, 69, 3443-3450.	0.4	43
1389	PI3K Inhibitors for Cancer Therapy: What has been Achieved So Far?. Current Medicinal Chemistry, 2009, 16, 916-930.	1.2	38
1390	Recent Advances in Molecular Targets and Treatment of Idiopathic Pulmonary Fibrosis: Focus on TGFβ Signaling and the Myofibroblast. Current Medicinal Chemistry, 2009, 16, 1400-1417.	1.2	126
1391	On the Origin of Epidermal Cancers. Current Molecular Medicine, 2009, 9, 355-364.	0.6	7
1392	Chorionic Gonadotropin Regulates Prostaglandin E Synthase via a Phosphatidylinositol 3-Kinase-Extracellular Regulatory Kinase Pathway in a Human Endometrial Epithelial Cell Line: Implications for Endometrial Responses for Embryo Implantation. Endocrinology, 2009, 150, 4326-4337.	1.4	39
1393	Unique Roles of p160 Coactivators for Regulation of Breast Cancer Cell Proliferation and Estrogen Receptor-Î± Transcriptional Activity. Endocrinology, 2009, 150, 1588-1596.	1.4	59
1394	Predicting Recurrence of Nonfunctioning Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4406-4413.	1.8	87
1395	Molecular therapy in head and neck oncology. Nature Reviews Clinical Oncology, 2009, 6, 266-277.	12.5	86
1396	Adenomatous Polyposis Coli and Asef Function Downstream of Hepatocyte Growth Factor and Phosphatidylinositol 3-Kinase. Journal of Biological Chemistry, 2009, 284, 22436-22443.	1.6	21
1397	Epidermal Growth Factor Receptor and PTEN Modulate Tissue Factor Expression in Glioblastoma through JunD/Activator Protein-1 Transcriptional Activity. Cancer Research, 2009, 69, 2540-2549.	0.4	114
1398	Platinum Complexes. , 2008, , 2358-2363.		0
1399	PtenDeletion in Adult Neural Stem/Progenitor Cells Enhances Constitutive Neurogenesis. Journal of Neuroscience, 2009, 29, 1874-1886.	1.7	245
1400	Psoralidin, an Herbal Molecule, Inhibits Phosphatidylinositol 3-Kinaseâ€“Mediated Akt Signaling in Androgen-Independent Prostate Cancer Cells. Cancer Prevention Research, 2009, 2, 234-243.	0.7	31
1401	Natural Sphingadienes Inhibit Akt-Dependent Signaling and Prevent Intestinal Tumorigenesis. Cancer Research, 2009, 69, 9457-9464.	0.4	55

#	Article	IF	Citations
1402	Gene Expression Patterns in Mismatch Repair-Deficient Colorectal Cancers Highlight the Potential Therapeutic Role of Inhibitors of the Phosphatidylinositol 3-Kinase-AKT-Mammalian Target of Rapamycin Pathway. Clinical Cancer Research, 2009, 15, 2829-2839.	3.2	57
1403	mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary. Clinical Cancer Research, 2009, 15, 5404-5413.	3.2	151
1404	Targeting autophagy potentiates tyrosine kinase inhibitorâ€“induced cell death in Philadelphia chromosomeâ€“positive cells, including primary CML stem cells. Journal of Clinical Investigation, 2009, 119, 1109-1123.	3.9	503
1405	Phosphatidylinositol 3â€²-Kinase Catalytic Subunit Î± Gene Amplification Contributes to the Pathogenesis of Mantle Cell Lymphoma. Clinical Cancer Research, 2009, 15, 5724-5732.	3.2	99
1406	Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processes. Journal of Endocrinology, 2009, 203, 99-110.	1.2	24
1407	Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells. Molecular Cancer Therapeutics, 2009, 8, 1547-1556.	1.9	28
1408	Depletion of Pleckstrin Homology Domain Leucine-rich Repeat Protein Phosphatases 1 and 2 by Bcr-Abl Promotes Chronic Myelogenous Leukemia Cell Proliferation through Continuous Phosphorylation of Akt Isoforms. Journal of Biological Chemistry, 2009, 284, 22155-22165.	1.6	23
1409	Inhibition of Tumor Growth Progression by Antiandrogens and mTOR Inhibitor in aPten-Deficient Mouse Model of Prostate Cancer. Cancer Research, 2009, 69, 7466-7472.	0.4	73
1410	A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells. Human Molecular Genetics, 2009, 18, 1951-1961.	1.4	16
1411	Proteasome Inactivation Promotes p38 Mitogen-activated Protein Kinase-dependent Phosphatidylinositol 3-kinase Activation and Increases Interleukin-8 Production in Retinal Pigment Epithelial Cells. Molecular Biology of the Cell, 2009, 20, 3690-3699.	0.9	30
1412	Unscheduled Akt-Triggered Activation of Cyclin-Dependent Kinase 2 as a Key Effector Mechanism of Apoptin's Anticancer Toxicity. Molecular and Cellular Biology, 2009, 29, 1235-1248.	1.1	68
1413	Interaction of Molecular Markers and Physical Activity on Mortality in Patients with Colon Cancer. Clinical Cancer Research, 2009, 15, 5931-5936.	3.2	66
1414	Nicotine Stimulates PPARÎ²/Î´ Expression in Human Lung Carcinoma Cells through Activation of PI3K/mTOR and Suppression of AP-2Î±. Cancer Research, 2009, 69, 6445-6453.	0.4	54
1415	Coordinate integrin and c-Met signaling regulate Wnt gene expression during epithelial morphogenesis. Development (Cambridge), 2009, 136, 843-853.	1.2	74
1416	Perifosine Inhibits Mammalian Target of Rapamycin Signaling through Facilitating Degradation of Major Components in the mTOR Axis and Induces Autophagy. Cancer Research, 2009, 69, 8967-8976.	0.4	137
1417	DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 19878-19883.	3.3	177
1418	Target-based therapies in breast cancer: current status and future perspectives. Endocrine-Related Cancer, 2009, 16, 675-702.	1.6	62
1419	Phospho-p70S6K/p85S6K and cdc2/cdk1 Are Novel Targets for Diffuse Large B-Cell Lymphoma Combination Therapy. Clinical Cancer Research, 2009, 15, 1708-1720.	3.2	38

#	Article	IF	Citations
1420	Phosphoinositide 3-Kinase Mutations in Breast Cancer: A â€œGoodâ€•Activating Mutation?. Clinical Cancer Research, 2009, 15, 5017-5019.	3.2	29
1421	Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncology, 2009, 45, 324-334.	0.8	317
1422	Cell regulation: determined to signal discrete cooperation. Trends in Biochemical Sciences, 2009, 34, 471-482.	3.7	162
1423	A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene. BMC Research Notes, 2009, 2, 66.	0.6	90
1424	The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Experimental Cell Research, 2009, 315, 485-497.	1.2	115
1425	A novel Drosophila Girdin-like protein is involved in Akt pathway control of cell size. Experimental Cell Research, 2009, 315, 3370-3380.	1.2	15
1426	RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. Journal of Cellular and Molecular Medicine, 2009, 13, 1371-1380.	1.6	128
1427	Multiple defects in negative regulation of the PKB/Akt pathway sensitise human cancer cells to the antiproliferative effect of non-steroidal anti-inflammatory drugs. Biochemical Pharmacology, 2009, 78, 561-572.	2.0	13
1428	Characteristic response of astrocytes to plasminogen/plasmin to upregulate transforming growth factor beta 3 (TGFÎ²3) production/secretion through proteinase-activated receptor-1 (PAR-1) and the downstream phosphatidylinositol 3-kinase (PI3K)-Akt/PKB signaling cascade. Brain Research, 2009, 1305, 1-13.	1.1	24
1429	Activation of SHIP via a small molecule agonist kills multiple myeloma cells. Experimental Hematology, 2009, 37, 1274-1283.	0.2	32
1430	EphA2 Mediates Ligand-Dependent Inhibition and Ligand-Independent Promotion of Cell Migration and Invasion via a Reciprocal Regulatory Loop with Akt. Cancer Cell, 2009, 16, 9-20.	7.7	436
1431	AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer. Cancer Cell, 2009, 16, 21-32.	7.7	472
1432	Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K Signaling. Cancer Cell, 2009, 16, 115-125.	7.7	411
1433	Should individual PI3 kinase isoforms be targeted in cancer?. Current Opinion in Cell Biology, 2009, 21, 199-208.	2.6	106
1434	Insulin regulates P-glycoprotein in rat brain microvessel endothelial cells via an insulin receptor-mediated PKC/NF-ÎºB pathway but not a PI3K/Akt pathway. European Journal of Pharmacology, 2009, 602, 277-282.	1.7	33
1435	Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues. European Journal of Pharmacology, 2009, 625, 6-22.	1.7	22
1436	EGFR protein overexpression and mutation in areca quidâ€“associated oral cavity squamous cell carcinoma in Taiwan. Head and Neck, 2009, 31, 1068-1077.	0.9	28
1437	S6K1 deficiency protects against apoptosis in hepatocytes. Hepatology, 2009, 50, 216-229.	3.6	37

#	Article	IF	Citations
1438	Reduction of Akt2 inhibits migration and invasion of glioma cells. International Journal of Cancer, 2009, 125, 585-595.	2.3	83
1439	A novel anticancer effect of Astragalus saponins: Transcriptional activation of NSAIDâ€activated gene. International Journal of Cancer, 2009, 125, 1082-1091.	2.3	71
1440	Multiple pathways in the FGF signaling network are frequently deregulated by gene amplification in oral dysplasias. International Journal of Cancer, 2009, 125, 2219-2228.	2.3	57
1441	Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyperâ€CVAD and rituximab, alternating with rituximab, highâ€dose methotrexate, and cytarabine. Cancer, 2009, 115, 4727-4736.	2.0	19
1442	Targeted inhibition of the EGFR pathways enhances Znâ€BCâ€AM PDTâ€induced apoptosis in wellâ€differentiated nasopharyngeal carcinoma cells. Journal of Cellular Biochemistry, 2009, 108, 1356-1363.	1.2	20
1443	MAPK pathway activation and the origins of pediatric lowâ€grade astrocytomas. Journal of Cellular Physiology, 2010, 222, 509-514.	2.0	87
1444	Polyporenic acid C induces caspaseâ€8â€mediated apoptosis in human lung cancer A549 cells. Molecular Carcinogenesis, 2009, 48, 498-507.	1.3	38
1445	Activation of p53/p21/PUMA alliance and disruption of PIâ€3/Akt in multimodal targeting of apoptotic signaling cascades in cervical cancer cells by a pentacyclic triterpenediol from Boswellia serrata. Molecular Carcinogenesis, 2009, 48, 1093-1108.	1.3	41
1446	Mitochondria as targets for cancer therapy. Molecular Nutrition and Food Research, 2009, 53, 9-28.	1.5	83
1447	Switching Akt: from survival signaling to deadly response. BioEssays, 2009, 31, 492-495.	1.2	130
1448	The impact of microRNAs on colorectal cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 454, 359-367.	1.4	71
1449	Simultaneous inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways augment the sensitivity to actinomycin D in Ewing sarcoma. Journal of Cancer Research and Clinical Oncology, 2009, 135, 1125-1136.	1.2	22
1450	Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis. Angiogenesis, 2009, 12, 325-338.	3.7	83
1451	Radiation Response in Two HPV-Infected Head-and-Neck Cancer Cell Lines in Comparison to a Nonâ€“HPV-Infected Cell Line and Relationship to Signaling Through AKT. International Journal of Radiation Oncology Biology Physics, 2009, 74, 928-933.	0.4	93
1452	Fish oil targets PTEN to regulate NFÎºB for downregulation of anti-apoptotic genes in breast tumor growth. Breast Cancer Research and Treatment, 2009, 118, 213-228.	1.1	92
1453	Inhibiting PI3K as a therapeutic strategy against cancer. Clinical and Translational Oncology, 2009, 11, 572-579.	1.2	28
1455	Drug development in advanced colorectal cancer: Challenges and opportunities. Current Oncology Reports, 2009, 11, 175-185.	1.8	4
1456	Molecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumors. Targeted Oncology, 2009, 4, 287-296.	1.7	16

#	Article	IF	Citations
1457	Molecular Analysis of PIK3CA, BRAF, and RAS Oncogenes in Periampullary and Ampullary Adenomas and Carcinomas. Journal of Gastrointestinal Surgery, 2009, 13, 1510-1516.	0.9	52
1458	The NF-Î²B/AKT-dependent Induction of Wnt Signaling in Colon Cancer Cells by Macrophages and IL-1Î². Cancer Microenvironment, 2009, 2, 69-80.	3.1	118
1459	Angiogenic effect of saponin extract from Panax notoginseng on HUVECs in vitro and zebrafish in vivo. Phytotherapy Research, 2009, 23, 677-686.	2.8	88
1460	Oleanane Triterpenoid CDDOâ€Me inhibits growth and induces apoptosis in prostate cancer cells by independently targeting proâ€survival Akt and mTOR. Prostate, 2009, 69, 851-860.	1.2	58
1461	Distinct population of highly malignant cells in a head and neck squamous cell carcinoma cell line established by xenograft model. Journal of Biomedical Science, 2009, 16, 100.	2.6	27
1462	cMyc increases cell number through uncoupling of cell division from cell size in CHO cells. BMC Biotechnology, 2009, 9, 76.	1.7	27
1463	Loss of heterozygosity on 10q23 is involved in metastatic recurrence of hepatocellular carcinoma. Cancer Science, 2009, 100, 520-528.	1.7	7
1464	Resveratrol and quercetin cooperate to induce senescenceâ€like growth arrest in C6 rat glioma cells. Cancer Science, 2009, 100, 1655-1662.	1.7	123
1465	Involvement of Pin1 induction in epithelialâ€“mesenchymal transition of tamoxifenâ€resistant breast cancer cells. Cancer Science, 2009, 100, 1834-1841.	1.7	88
1466	Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Pagetâ€™s disease. British Journal of Dermatology, 2009, 161, 357-363.	1.4	21
1467	The heat shock protein 90 inhibitor IPIâ€504 induces apoptosis of AKTâ€dependent diffuse large Bâ€cell lymphomas. British Journal of Haematology, 2009, 144, 358-366.	1.2	30
1468	Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma. Journal of Internal Medicine, 2009, 266, 99-113.	2.7	43
1469	Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO Journal, 2009, 28, 1505-1517.	3.5	302
1470	Inhibition of PI3K-AKT-mTOR Signaling Sensitizes Melanoma Cells to Cisplatin and Temozolomide. Journal of Investigative Dermatology, 2009, 129, 1500-1515.	0.3	116
1471	The endogenous inhibitor of Akt, CTMP, is critical to ischemia-induced neuronal death. Nature Neuroscience, 2009, 12, 618-626.	7.1	98
1472	Beyond chemotherapy: targeted therapies in ovarian cancer. Nature Reviews Cancer, 2009, 9, 167-181.	12.8	452
1473	Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature Reviews Cancer, 2009, 9, 463-475.	12.8	993
1474	Targeting the phosphoinositide 3-kinase pathway in cancer. Nature Reviews Drug Discovery, 2009, 8, 627-644.	21.5	2,218

#	Article	IF	Citations
1475	E-cadherin directly contributes to PI3K/AKT activation by engaging the PI3K-p85 regulatory subunit to adherens junctions of ovarian carcinoma cells. Oncogene, 2009, 28, 1206-1217.	2.6	85
1476	Akt2, but not Akt1, is required for cell survival by inhibiting activation of JNK and p38 after UV irradiation. Oncogene, 2009, 28, 1241-1247.	2.6	20
1477	Rapamycin induces transactivation of the EGFR and increases cell survival. Oncogene, 2009, 28, 1187-1196.	2.6	47
1478	Overexpressing PKIB in prostate cancer promotes its aggressiveness by linking between PKA and Akt pathways. Oncogene, 2009, 28, 2849-2859.	2.6	39
1479	Astrocyte elevated gene-1 contributes to the pathogenesis of neuroblastoma. Oncogene, 2009, 28, 2476-2484.	2.6	102
1481	Osteoprotegerin induces osteopontin via syndecanâ€1 and phosphoinositol 3â€kinase/Akt in human periodontal ligament cells. Journal of Periodontal Research, 2009, 44, 776-783.	1.4	6
1482	The novel molecule 2â€[5â€(2â€chloroethyl)â€2â€acetoxyâ€benzyl]â€4â€(2â€chloroethyl)â€phenyl acetate inhibits phosphoinositide 3â€kinase/Akt/mammalian target of rapamycin signalling through JNK activation in cancer cells. FEBS Journal, 2009, 276, 4037-4050.	2.2	6
1483	Antiâ€gastric cancer effects of celecoxib, a selective COXâ€2 inhibitor, through inhibition of Akt signaling. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 480-487.	1.4	38
1484	Implications of insulinâ€like growth factorâ€I for prostate cancer therapies. International Journal of Urology, 2009, 16, 161-167.	0.5	55
1485	Helicobacter pyloriactivate epidermal growth factor receptor- and phosphatidylinositol 3-OH kinase-dependent Akt and glycogen synthase kinase 3Î² phosphorylation. Cellular Microbiology, 2009, 11, 70-82.	1.1	90
1486	Adhesion molecules Î±, Î² and Î³â€catenin as prognostic factors of tumour progression in upper urinary tract urothelial tumours: the role of AKTâ€P/GSKâ€3Î²/Î²â€catenin pathway. BJU International, 2009, 104, 100-106.	1.3	11
1487	Regulatory Effect of the AMPKâ€"COXâ€2 Signaling Pathway in Curcuminâ€Induced Apoptosis in HTâ€29 Colon Cancer Cells. Annals of the New York Academy of Sciences, 2009, 1171, 489-494.	1.8	83
1488	Methyl jasmonate: A plant stress hormone as an anti-cancer drug. Phytochemistry, 2009, 70, 1600-1609.	1.4	120
1489	Concomitant supplementation of lycopene and eicosapentaenoic acid inhibits the proliferation of human colon cancer cells. Journal of Nutritional Biochemistry, 2009, 20, 426-434.	1.9	70
1490	PI3K/Akt inhibition modulates multidrug resistance and activates NF-ÎºB in murine lymphoma cell lines. Leukemia Research, 2009, 33, 288-296.	0.4	74
1491	Non-peptidic substrate-mimetic inhibitors of Akt as potential anti-cancer agents. Bioorganic and Medicinal Chemistry, 2009, 17, 1764-1771.	1.4	25
1492	Allosteric inhibitors of Akt1 and Akt2: Discovery of [1,2,4]triazolo[3,4-f][1,6]naphthyridines with potent and balanced activity. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 834-836.	1.0	54
1493	Extracellular signalâ€regulated kinase (ERK) activation in chicken heterophils stimulated with phorbol 12â€myristate 13â€acetate (PMA), Formylâ€methionylleucylâ€phenylalanine (fMLP) and lipopolysaccharide (LPS). Animal Science Journal, 2009, 80, 577-584.	0.6	9

#	Article	IF	Citations
1494	Rapamycin Inhibits Hepatectomy-Induced Stimulation of Metastatic Tumor Growth by Reduction of Angiogenesis, Microvascular Blood Perfusion, and Tumor Cell Proliferation. Annals of Surgical Oncology, 2009, 16, 2629-2637.	0.7	14
1495	Mammalian NDR/LATS protein kinases in hippo tumor suppressor signaling. BioFactors, 2009, 35, 338-345.	2.6	78
1496	Polyunsaturated fatty acids inhibit PI3K activity in a yeastâ€based model system. Biotechnology Journal, 2009, 4, 1190-1197.	1.8	20
1497	Computational Tools and Resources for Systems Biology Approaches in Cancer. , 2009, , 227-242.		2
1498	Pyranonaphthoquinone Lactones: A New Class of AKT Selective Kinase Inhibitors Alkylate a Regulatory Loop Cysteine. Journal of Medicinal Chemistry, 2009, 52, 2181-2184.	2.9	63
1499	Enamel Matrix Derivative Protein Stimulated Wound Healing via Phosphoinositide 3-Kinase. Journal of Periodontology, 2009, 80, 1631-1637.	1.7	7
1500	Effect of Dietary Fatty Acids on Inflammatory Gene Expression in Healthy Humans. Journal of Biological Chemistry, 2009, 284, 15400-15407.	1.6	136
1501	The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis, 2009, 30, 377-386.	1.3	1,058
1502	PI(3,4,5)P3 Interactome. Journal of Proteome Research, 2009, 8, 3712-3726.	1.8	50
1503	Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer Treatment Reviews, 2009, 35, 354-363.	3.4	120
1504	Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. European Journal of Cancer, 2009, 45, 1117-1128.	1.3	77
1505	Activation of phosphatidylinositol 3-kinase is required for tumor necrosis factor-Î±-induced upregulation of matrix metalloproteinase-9: Its direct inhibition by quercetin. International Journal of Biochemistry and Cell Biology, 2009, 41, 1592-1600.	1.2	78
1506	The involvement of the fractalkine receptor in the transmigration of neuroblastoma cells through bone-marrow endothelial cells. Cancer Letters, 2009, 273, 127-139.	3.2	42
1507	NM23H2 inhibits EGF- and Ras-induced proliferation of NIH3T3 cells by blocking the ERK pathway. Cancer Letters, 2009, 275, 221-226.	3.2	30
1508	MKP1 repression is required for the chemosensitizing effects of NF-ÎºB and PI3K inhibitors to cisplatin in non-small cell lung cancer. Cancer Letters, 2009, 286, 206-216.	3.2	22
1509	Helicobacter pylori CagA Phosphorylation-Independent Function in Epithelial Proliferation and Inflammation. Cell Host and Microbe, 2009, 5, 23-34.	5.1	282
1510	Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest. Biochemical and Biophysical Research Communications, 2009, 379, 104-109.	1.0	44
1511	UV light induces premature senescence in Akt1-null mouse embryonic fibroblasts by increasing intracellular levels of ROS. Biochemical and Biophysical Research Communications, 2009, 383, 358-362.	1.0	24

#	Article	IF	Citations
1512	Activation of PH-domain leucine-rich protein phosphatase 2 (PHLPP2) by agonist stimulation in cardiac myocytes expressing adenylyl cyclase type 6. Biochemical and Biophysical Research Communications, 2009, 384, 193-198.	1.0	24
1513	Ablation of phosphoinositide-3-kinase class II alpha suppresses hepatoma cell proliferation. Biochemical and Biophysical Research Communications, 2009, 387, 310-315.	1.0	19
1514	PI 3-kinase and cancer: changing accents. Current Opinion in Genetics and Development, 2009, 19, 12-17.	1.5	78
1516	Cell migration and activated PI3K/AKT-directed elongation in the developing rat MÃ¼llerian duct. Developmental Biology, 2009, 325, 351-362.	0.9	38
1517	Phosphoinositide 3-kinase is required for bombesin-induced enhancement of fear memory consolidation in the hippocampus. Peptides, 2009, 30, 1192-1196.	1.2	19
1518	Angiogenesis in cutaneous disease: Part I. Journal of the American Academy of Dermatology, 2009, 61, 921-942.	0.6	38
1519	Combination of 2-methoxyestradiol (2-ME2) and eugenol for apoptosis induction synergistically in androgen independent prostate cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 2009, 113, 25-35.	1.2	54
1520	The Effect of Different Frequencies of Stretch on Human Dermal Keratinocyte Proliferation and Survival. Journal of Surgical Research, 2009, 155, 125-131.	0.8	16
1521	Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma. Human Pathology, 2009, 40, 1408-1417.	1.1	44
1522	PRK1 distribution in normal tissues and carcinomas: overexpression and activation in ovarian serous carcinoma. Human Pathology, 2009, 40, 1434-1440.	1.1	26
1523	Complex prolactin crosstalk in breast cancer: New therapeutic implications. Molecular and Cellular Endocrinology, 2009, 307, 1-7.	1.6	40
1524	Akt and 14-3-3 Control a PACS-2 Homeostatic Switch that Integrates Membrane Traffic with TRAIL-Induced Apoptosis. Molecular Cell, 2009, 34, 497-509.	4.5	61
1525	Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management. Molecular Oncology, 2009, 3, 97-137.	2.1	171
1526	Never Say Die: Survival Signaling in Large Granular Lymphocyte Leukemia. Clinical Lymphoma and Myeloma, 2009, 9, S244-S253.	1.4	18
1527	Vanillin Suppresses Metastatic Potential of Human Cancer Cells through PI3K Inhibition and Decreases Angiogenesis in Vivo. Journal of Agricultural and Food Chemistry, 2009, 57, 3055-3063.	2.4	123
1528	Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells. Molecular Cancer, 2009, 8, 26.	7.9	75
1529	PIK3CA alterations in Middle Eastern ovarian cancers. Molecular Cancer, 2009, 8, 51.	7.9	36
1530	Elongation Factor 1 alpha interacts with phospho-Akt in breast cancer cells and regulates their proliferation, survival and motility. Molecular Cancer, 2009, 8, 58.	7.9	39

#	Article	IF	Citations
1531	Identification of glucocorticoid-induced leucine zipper as a key regulator of tumor cell proliferation in epithelial ovarian cancer. Molecular Cancer, 2009, 8, 83.	7.9	24
1532	Protein kinase CÎµ: an oncogene and emerging tumor biomarker. Molecular Cancer, 2009, 8, 9.	7.9	124
1533	Aurora-A down-regulates IkappaBÎ± via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival. Molecular Cancer, 2009, 8, 95.	7.9	53
1534	Main roads to melanoma. Journal of Translational Medicine, 2009, 7, 86.	1.8	157
1535	Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. Journal of Hematology and Oncology, 2009, 2, 45.	6.9	204
1536	Molecular Genetics of Acute Lymphoblastic Leukemia. Annual Review of Pathology: Mechanisms of Disease, 2009, 4, 175-198.	9.6	69
1537	Degradable polyethylenimines as DNA and small interfering RNA carriers. Expert Opinion on Drug Delivery, 2009, 6, 827-834.	2.4	113
1538	Novel inhibitors of the PI3K family. Expert Opinion on Investigational Drugs, 2009, 18, 1265-1277.	1.9	36
1539	p16. , 2008, , 2221-2221.		0
1540	Progress in the Design and Development of Phosphoinositide 3-Kinase (PI3K) Inhibitors for the Treatment of Chronic Diseases. Progress in Medicinal Chemistry, 2009, 48, 81-131.	4.1	12
1541	The drug-resistance to gefitinib in PTEN low expression cancer cells is reversed by irradiation in vitro. Journal of Experimental and Clinical Cancer Research, 2009, 28, 123.	3.5	16
1542	Controversies in breast cancer: the mammalian target of rapamycin as a target for breast cancer therapy. Breast Cancer Research, 2009, 11, S25.	2.2	5
1543	Phosphoinositide 3-kinase targeting by the Î² galactoside binding protein cytokine negates akt gene expression and leads aggressive breast cancer cells to apoptotic death. Breast Cancer Research, 2009, 11, R2.	2.2	15
1544	PTEN in Hematopoietic and Intestinal Stem Cells and Cancer. , 2009, , 59-73.		0
1547	PTEN and the PI3-Kinase Pathway in Cancer. Annual Review of Pathology: Mechanisms of Disease, 2009, 4, 127-150.	9.6	992
1548	PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2009, 27, 2622-2629.	0.8	402
1549	Antioxidants in the prevention of myocardial ischemia/reperfusion injury. Expert Review of Clinical Pharmacology, 2009, 2, 673-695.	1.3	20
1550	Targeted Therapies for Malignant Glioma. BioDrugs, 2009, 23, 25-35.	2.2	45

#	Article	IF	Citations
1551	Phosphorylation of Telomeric Repeat Binding Factor 1 (TRF1) by Akt Causes Telomere Shortening. Cancer Investigation, 2009, 27, 24-28.	0.6	13
1552	Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells. Journal of Receptor and Signal Transduction Research, 2009, 29, 182-194.	1.3	17
1553	Cell signalling and radiation survival: The impact of protein phosphatases. International Journal of Radiation Biology, 2009, 85, 937-942.	1.0	5
1554	PTEN Deficiency Is Fully Penetrant for Prostate Adenocarcinoma in C57BL/6 Mice via mTOR-Dependent Growth. American Journal of Pathology, 2009, 174, 1869-1879.	1.9	43
1555	Gab2-Mediated Signaling Promotes Melanoma Metastasis. American Journal of Pathology, 2009, 174, 1524-1533.	1.9	67
1556	New approaches and targets in advanced colorectal cancer. European Journal of Cancer, 2009, 45, 79-88.	1.3	4
1557	Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMPâ€9. Hepatology Research, 2009, 39, 177-186.	1.8	308
1558	Inhibitors of phosphoinositide-3-kinase: a structure-based approach to understanding potency and selectivity. Organic and Biomolecular Chemistry, 2009, 7, 840.	1.5	44
1559	EGFR Signaling and Drug Discovery. Oncology, 2009, 77, 400-410.	0.9	387
1560	The E3 Ligase TRAF6 Regulates Akt Ubiquitination and Activation. Science, 2009, 325, 1134-1138.	6.0	527
1561	Drug Targeting of Oncogenic Pathways in Melanoma. Hematology/Oncology Clinics of North America, 2009, 23, 599-618.	0.9	6
1562	Cross talk Initiated by Endothelial Cells Enhances Migration and Inhibits Anoikis of Squamous Cell Carcinoma Cells through STAT3/Akt/ERK Signaling. Neoplasia, 2009, 11, 583-IN14.	2.3	122
1563	Downregulation of survivin and activation of caspase-3 through the PI3K/Akt pathway in ursolic acid-induced HepG2 cell apoptosis. Anti-Cancer Drugs, 2009, 20, 249-258.	0.7	84
1564	Interaction of ionizing radiation and ZRBA1, a mixed EGFR/DNA-targeting molecule. Anti-Cancer Drugs, 2009, 20, 659-667.	0.7	6
1565	Heat Shock Proteins in Cancer: Signaling Pathways, Tumor Markers and Molecular Targets in Liver Malignancy. Protein and Peptide Letters, 2009, 16, 508-516.	0.4	17
1566	Two Diseases with One Hit: Inhibiting a Potential Diabetes Target to Reduce Cancer Risk and to Improve Anti-Cancer Therapy. Current Cancer Therapy Reviews, 2009, 5, 111-121.	0.2	4
1568	Oncolytic adenoviral vectors which employ the survivin promoter induce glioma oncolysis via a process of beclin-dependent autophagy. International Journal of Oncology, 2009, 34, 729-42.	1.4	30
1569	Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing tyrosine kinase inhibitors in small cell lung cancer cells: Implication of c-Src and its inhibitor. International Journal of Oncology, 2009, 34, 689-96.	1.4	11

#	Article	IF	Citations
1570	A 3Dâ€QSAR Study of Celebrexâ€Based Pdk1 Inhibitors Using Comfa Method. Journal of the Chinese Chemical Society, 2009, 56, 59-64.	0.8	0
1571	Isoform-selective phosphoinositide 3â€²-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cellâ€"mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood, 2009, 113, 5549-5557.	0.6	135
1572	Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML. Blood, 2009, 114, 4859-4870.	0.6	52
1573	Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood, 2009, 114, 2926-2935.	0.6	152
1574	Overexpression of PIK3CA is associated with lymph node metastasis in esophageal squamous cell carcinoma. International Journal of Oncology, 2009, 34, 767-75.	1.4	45
1575	The PI3-K/AKT-Pathway and Radiation Resistance Mechanisms in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 761-767.	0.5	134
1576	Expression and localization of FOXO1 in non-small cell lung cancer. Oncology Reports, 2009, 22, .	1.2	15
1577	The expression of epidermal growth factor receptor and its downstream signaling molecules in osteosarcoma. International Journal of Oncology, 2009, 34, 797-803.	1.4	20
1578	Advances in targeted therapies for metastatic colorectal cancer. Therapy: Open Access in Clinical Medicine, 2009, 6, 321-333.	0.2	2
1579	Mouse Models to Decipher the PI3K Signaling Network in Human Cancer. Current Molecular Medicine, 2009, 9, 612-625.	0.6	19
1580	Lapatinib as a Chemotherapeutic Drug. Recent Patents on Anti-Cancer Drug Discovery, 2009, 4, 216-226.	0.8	1
1581	Targeted Inhibition of AKT in Pancreatic Cancer. Current Cancer Therapy Reviews, 2009, 5, 288-295.	0.2	6
1582	Coordination of Ribosomal Protein and Ribosomal RNA Gene Expression in Response to TOR Signaling. Current Genomics, 2009, 10, 198-205.	0.7	65
1583	Role of the Akt Pathway in Prostate Cancer. Current Cancer Drug Targets, 2009, 9, 163-175.	0.8	19
1584	Integration of Anti-Epidermal Growth Factor Receptor Therapies With Cytotoxic Chemotherapy. Cancer Journal (Sudbury, Mass), 2010, 16, 226-234.	1.0	5
1585	Development of Inhibitors of the IGF-IR/PI3K/Akt/mTOR Pathway. Reviews on Recent Clinical Trials, 2010, 5, 189-208.	0.4	39
1586	Quantification of Intracellular Proteins and Monitoring Therapy Using Flow Cytometry. Current Drug Targets, 2010, 11, 994-999.	1.0	7
1587	MEK1 and AKT2 Mutations in Japanese Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 597-600.	0.5	11

#	Article	IF	Citations
1588	CETUXIMAB: From Bench to Bedside. Current Cancer Drug Targets, 2010, 10, 80-95.	0.8	107
1589	Allosteric AKT inhibitors as a targeted cancer therapy. Cancer Biology and Therapy, 2010, 9, 504-506.	1.5	9
1590	Bladder cancer in patients after organ transplantation. Current Opinion in Urology, 2010, 20, 432-436.	0.9	13
1591	Biology of Colorectal Cancer. Cancer Journal (Sudbury, Mass), 2010, 16, 196-201.	1.0	129
1592	PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer. International Journal of Oncology, 2010, 38, .	1.4	18
1593	Evaluation of systemic external microwave hyperthermia for treatment of pleural metastasis in orthotopic lung cancer model. Oncology Reports, 2010, 24, 591-8.	1.2	10
1594	Implication of necrosis-linked p53 aggregation in acquired apoptotic resistance to 5-FU in MCF-7 multicellular tumour spheroids. Oncology Reports, 2010, 24, .	1.2	6
1595	PI3K/p110Î´ is a novel therapeutic target in multiple myeloma. Blood, 2010, 116, 1460-1468.	0.6	177
1596	Pediatric mastocytosisâ€“associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations. Blood, 2010, 116, 1114-1123.	0.6	52
1597	AKT1 and AKT2 maintain hematopoietic stem cell function by regulating reactive oxygen species. Blood, 2010, 115, 4030-4038.	0.6	246
1598	Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia. Blood, 2010, 116, 2513-2521.	0.6	102
1599	Akt inhibitors reduce glucose uptake independently of their effects on Akt. Biochemical Journal, 2010, 432, 191-198.	1.7	22
1600	2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways. International Journal of Oncology, 2010, 37, .	1.4	5
1601	Role of extracellular signal-regulated kinase (ERK)1/2 in multicellular resistance to docetaxel in MCF-7 cells. International Journal of Oncology, 2010, 37, 655-61.	1.4	23
1602	Downregulation of Dicer enhances tumor cell proliferation and invasion. International Journal of Oncology, 2010, 37, 299-305.	1.4	31
1603	Phosphorylated mTOR Expression is Associated with Poor Prognosis for Patients with Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2010, 17, 2486-2493.	0.7	60
1604	Role of RAS in the Regulation of PI 3-Kinase. Current Topics in Microbiology and Immunology, 2010, 346, 143-169.	0.7	99
1605	Crossing paths: interactions between the cell death machinery and growth factor survival signals. Cellular and Molecular Life Sciences, 2010, 67, 1619-1630.	2.4	60

#	Article	IF	Citations
1606	Akt and PKC are involved not only in upregulation of telomerase activity but also in cell differentiation-related function via mTORC2 in leukemia cells. Histochemistry and Cell Biology, 2010, 134, 555-563.	0.8	14
1607	PIKing the right isoform: the emergent role of the p110Î² subunit in breast cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 456, 235-243.	1.4	37
1608	Bilobalide prevents apoptosis through activation of the PI3K/Akt pathway in SH-SY5Y cells. Apoptosis: an International Journal on Programmed Cell Death, 2010, 15, 715-727.	2.2	55
1609	Glutamate Promotes Cell Growth by EGFR Signaling on U-87MG Human Glioblastoma Cell Line. Pathology and Oncology Research, 2010, 16, 285-293.	0.9	25
1610	Arsenic Trioxide Inhibits Cholangiocarcinoma Cell Growth and induces Apoptosis. Pathology and Oncology Research, 2010, 16, 413-420.	0.9	6
1611	G protein-coupled receptor 30 in tumor development. Endocrine, 2010, 38, 29-37.	1.1	73
1612	Mutational and Immunohistochemical Study of the PI3K/Akt Pathway in Papillary Thyroid Carcinoma in Greece. Endocrine Pathology, 2010, 21, 90-100.	5.2	13
1613	Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer. Medical Oncology, 2010, 27, 91-97.	1.2	15
1614	Chemotherapy Foundation Symposium XXVIII Innovative Cancer Therapy For Tomorrow Abstracts 2010. Current Treatment Options in Oncology, 2010, 11, 1-104.	1.3	9
1615	RACK1 promotes breast carcinoma proliferation and invasion/metastasis in vitro and in vivo. Breast Cancer Research and Treatment, 2010, 123, 375-386.	1.1	57
1616	Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Research and Treatment, 2010, 123, 271-279.	1.1	179
1617	Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. Journal of Neuro-Oncology, 2010, 96, 219-230.	1.4	208
1618	Effect of Combination Treatment of Rapamycin and Isoflavones on mTOR Pathway in Human Glioblastoma (U87) Cells. Neurochemical Research, 2010, 35, 986-993.	1.6	30
1619	Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer. Familial Cancer, 2010, 9, 125-129.	0.9	52
1620	Phosphatidylinositol-3-Kinase-AKT Pathway, Phospho-JUN and Phospho-JNK Expression in Spontaneously Arising Bovine Urinary Bladder Tumours. Journal of Comparative Pathology, 2010, 143, 173-178.	0.1	16
1621	Diallyl trisulfide induces Bcl-2 and caspase-3-dependent apoptosis via downregulation of Akt phosphorylation in human T24 bladder cancer cells. Phytomedicine, 2010, 17, 363-368.	2.3	67
1622	A synthetic analog of 15-epi-lipoxin A4 inhibits human monocyte apoptosis: Involvement of ERK-2 and PI3-kinase. Prostaglandins and Other Lipid Mediators, 2010, 91, 10-17.	1.0	10
1623	Signal transduction pathways and transcription factors triggered by arsenic trioxide in leukemia cells. Toxicology and Applied Pharmacology, 2010, 244, 385-392.	1.3	50

#	Article	IF	Citations
1624	Genome-wide sequence-based prediction of peripheral proteins using a novel semi-supervised learning technique. BMC Bioinformatics, 2010, 11, S6.	1.2	15
1625	Clinical significance of Phosphatidyl Inositol Synthase overexpression in oral cancer. BMC Cancer, 2010, 10, 168.	1.1	16
1626	Characterization of AKT independent effects of the synthetic AKT inhibitors SH-5 and SH-6 using an integrated approach combining transcriptomic profiling and signaling pathway perturbations. BMC Cancer, 2010, 10, 287.	1.1	12
1627	Establishment and characterization of a new human pancreatic adenocarcinoma cell line with high metastatic potential to the lung. BMC Cancer, 2010, 10, 295.	1.1	44
1628	Inhibitory effects of andrographolide on migration and invasion in human non-small cell lung cancer A549 cells via down-regulation of PI3K/Akt signaling pathway. European Journal of Pharmacology, 2010, 632, 23-32.	1.7	146
1629	Antagonistic effect of flavonoids on NSC-741909-mediated antitumor activity via scavenging of reactive oxygen species. European Journal of Pharmacology, 2010, 649, 51-58.	1.7	14
1630	Autophagy is a therapeutic target in anticancer drug resistance. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1806, 220-229.	3.3	223
1631	Oleanane triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells through a ROS-dependent mechanism. Biochemical Pharmacology, 2010, 79, 350-360.	2.0	97
1632	Molecularly targeted therapy in hepatocellular carcinoma. Biochemical Pharmacology, 2010, 80, 550-560.	2.0	110
1633	Targeting inflammatory pathways for tumor radiosensitization. Biochemical Pharmacology, 2010, 80, 1904-1914.	2.0	129
1634	3Î²-Hydroxylup-20(29)-ene-27,28-dioic acid dimethyl ester, a novel natural product from Plumbago zeylanica inhibits the proliferation and migration of MDA-MB-231 cells. Chemico-Biological Interactions, 2010, 188, 412-420.	1.7	25
1635	4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors. Cancer Cell, 2010, 18, 39-51.	7.7	360
1636	c-Cbl acts as a mediator of Src-induced activation of the PI3K-Akt signal transduction pathway during TRAIL treatment. Cellular Signalling, 2010, 22, 377-385.	1.7	39
1637	Simvastatin induces derepression of PTEN expression via NFÎºB to inhibit breast cancer cell growth. Cellular Signalling, 2010, 22, 749-758.	1.7	146
1638	Kinases as targets in the treatment of solid tumors. Cellular Signalling, 2010, 22, 984-1002.	1.7	88
1639	Radiation-induced bystander signaling pathways in human fibroblasts: A role for interleukin-33 in the signal transmission. Cellular Signalling, 2010, 22, 1076-1087.	1.7	104
1640	Eriocalyxin B induces apoptosis in lymphoma cells through multiple cellular signaling pathways. Experimental Hematology, 2010, 38, 191-201.	0.2	35
1641	Inhibition of mTORC1 by RAD001 (everolimus) potentiates the effects of 1,25-dihydroxyvitamin D3 to induce growth arrest and differentiation of AML cells in vitro and in vivo. Experimental Hematology, 2010, 38, 666-676.	0.2	40

#	Article	IF	Citations
1642	BMP2 accelerates the motility and invasiveness of gastric cancer cells via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Experimental Cell Research, 2010, 316, 24-37.	1.2	129
1643	Fibroblast growth factor 8 increases breast cancer cell growth by promoting cell cycle progression and by protecting against cell death. Experimental Cell Research, 2010, 316, 800-812.	1.2	21
1644	Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression. Experimental Cell Research, 2010, 316, 3197-3206.	1.2	35
1645	PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast. Experimental and Molecular Pathology, 2010, 88, 150-155.	0.9	41
1646	Chronic myeloid leukemia and BCR/ABL signal pathways are not associated with AKT1 pleckstrin homology domain (E17K) mutations. European Journal of Haematology, 2010, 84, 87-88.	1.1	3
1647	Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrixâ€metalloproteinase expression. Cytoskeleton, 2010, 67, 535-544.	1.0	32
1648	Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. Cancer, 2010, 116, 3903-3909.	2.0	36
1649	Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advancedâ€stage head and neck squamous cell carcinoma. Head and Neck, 2010, 32, 1619-1628.	0.9	24
1650	Cytotoxic effects of antipsychotic drugs implicate cholesterol homeostasis as a novel chemotherapeutic target. International Journal of Cancer, 2010, 126, 28-40.	2.3	101
1651	Concomitant inhibition of AKT and autophagy is required for efficient cisplatinâ€induced apoptosis of metastatic skin carcinoma. International Journal of Cancer, 2010, 127, 2790-2803.	2.3	75
1652	Control of intestinal promoter activity of the cellular migratory regulator gene ELMO3 by CDX2 and SP1. Journal of Cellular Biochemistry, 2010, 109, 1118-1128.	1.2	25
1653	Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: The cellular mechanism. Journal of Cellular Biochemistry, 2010, 111, 1426-1436.	1.2	245
1655	Selective Inhibition of Human Brain Tumor Cells through Multifunctional Quantumâ€Dotâ€Based siRNA Delivery. Angewandte Chemie - International Edition, 2010, 49, 103-107.	7.2	136
1656	Involvement of Akt/NFâ€ºB pathway in N⁶â€isopentenyladenosineâ€induced apoptosis in human breast cancer cells. Molecular Carcinogenesis, 2010, 49, 892-901.	1.3	30
1657	Isosilybin A induces apoptosis in human prostate cancer cells via targeting Akt, NFâ€ºB, and androgen receptor signaling. Molecular Carcinogenesis, 2010, 49, 902-912.	1.3	28
1658	Cell death of prostate cancer cells by specific amino acid restriction depends on alterations of glucose metabolism. Journal of Cellular Physiology, 2010, 224, 491-500.	2.0	23
1659	Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma. Leukemia Research, 2010, 34, 824-826.	0.4	30
1660	Understanding the stereospecific interactions of 3-deoxyphosphatidylinositol derivatives with the PTEN phosphatase domain. Journal of Molecular Graphics and Modelling, 2010, 29, 102-114.	1.3	9

#	Article	IF	Citations
1661	Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 653-656.	1.0	28
1662	Straightforward synthesis of novel Akt inhibitors based on a glucose scaffold. Carbohydrate Research, 2010, 345, 1291-1298.	1.1	7
1663	Synthetic and computational studies on liphagal: a natural product inhibitor of PI-3K. Tetrahedron Letters, 2010, 51, 6120-6122.	0.7	14
1664	Analysis of cellular phosphatidylinositol (3,4,5)-trisphosphate levels and distribution using confocal fluorescent microscopy. Analytical Biochemistry, 2010, 406, 41-50.	1.1	8
1665	3,5-Diaryl-1H-pyrazole as a molecular scaffold for the synthesis of apoptosis-inducing agents. Bioorganic and Medicinal Chemistry, 2010, 18, 3270-3278.	1.4	27
1666	Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2408-2411.	1.0	81
1667	A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells. European Journal of Medicinal Chemistry, 2010, 45, 705-709.	2.6	29
1668	Akt regulates the expression of MafK, synaptotagmin I, and syntenin-1, which play roles in neuronal function. Journal of Biomedical Science, 2010, 17, 18.	2.6	12
1669	The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation. Radiation Oncology, 2010, 5, 108.	1.2	53
1670	Peroxisome proliferator-activated receptor gamma ligand-mediated apoptosis of hepatocellular carcinoma cells depends upon modulation of PI3Kinase pathway independent of Akt. Journal of Molecular Signaling, 2010, 5, 20.	0.5	10
1671	The role of PI 3â€kinase p110Î² in AKT signally, cell survival, and proliferation in human prostate cancer cells. Prostate, 2010, 70, 755-764.	1.2	41
1672	Chloride intracellular channel 1 identified using proteomic analysis plays an important role in the radiosensitivity of HEpâ€2 cells via reactive oxygen species production. Proteomics, 2010, 10, 2589-2604.	1.3	50
1673	SZâ€685C, a marine anthraquinone, is a potent inducer of apoptosis with anticancer activity by suppression of the Akt/FOXO pathway. British Journal of Pharmacology, 2010, 159, 689-697.	2.7	102
1674	Disruption of gap junctions attenuates aminoglycosideâ€elicited renal tubular cell injury. British Journal of Pharmacology, 2010, 160, 2055-2068.	2.7	23
1675	Role of PI3K in the generation and survival of B cells. Immunological Reviews, 2010, 237, 55-71.	2.8	100
1676	Identification of increased NBS1 expression as a prognostic marker of squamous cell carcinoma of the oral cavity. Cancer Science, 2010, 101, 1029-1037.	1.7	22
1677	Girding for migratory cues: roles of the Akt substrate Girdin in cancer progression and angiogenesis. Cancer Science, 2010, 101, 836-842.	1.7	59
1678	Interaction of integrin Î±₆Î²₄ with ErbB3 and implication in heregulinâ€induced ErbB3/ErbB2â€mediated DNA synthesis. Genes To Cells, 2010, 15, 995-1001.	0.5	12

#	Article	IF	Citations
1679	Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMDâ€2076, against multiple myeloma. British Journal of Haematology, 2010, 150, 313-325.	1.2	42
1680	Apigenin induces apoptosis via downregulation of Sâ€phase kinaseâ€associated protein 2â€mediated induction of p27Kip1 in primary effusion lymphoma cells. Cell Proliferation, 2010, 43, 170-183.	2.4	45
1681	CNK1 is a novel Akt interaction partner that promotes cell proliferation through the Akt-FoxO signalling axis. Oncogene, 2010, 29, 3575-3582.	2.6	26
1682	Essential role of PI3-kinase pathway in p53-mediated transcription: Implications in cancer chemotherapy. Oncogene, 2010, 29, 3605-3618.	2.6	13
1683	Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells. Oncogene, 2010, 29, 3845-3853.	2.6	33
1684	Recent advances in the molecular pathogenesis of Ewing's sarcoma. Oncogene, 2010, 29, 4504-4516.	2.6	176
1685	H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene, 2010, 29, 5193-5203.	2.6	93
1686	Analysis of the genome to personalize therapy for melanoma. Oncogene, 2010, 29, 5545-5555.	2.6	125
1687	A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate. British Journal of Cancer, 2010, 102, 104-114.	2.9	54
1688	Hierarchical clustering of immunohistochemical analysis of the activated ErbB/PI3K/Akt/NF-Î¹B signalling pathway and prognostic significance in prostate cancer. British Journal of Cancer, 2010, 102, 1163-1173.	2.9	45
1689	E17K substitution in AKT1 in prostate cancer. British Journal of Cancer, 2010, 102, 1491-1494.	2.9	35
1690	Bcl-2 and Î²1-integrin predict survival in a tissue microarray of small cell lung cancer. British Journal of Cancer, 2010, 103, 1710-1715.	2.9	39
1691	Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways. Leukemia, 2010, 24, 13-21.	3.3	106
1692	The BioPAX community standard for pathway data sharing. Nature Biotechnology, 2010, 28, 935-942.	9.4	613
1693	Biochemical polymorphism of the growth hormone system proteins and its manifestations in human prostate cells. Biochemistry (Moscow), 2010, 75, 1547-1562.	0.7	0
1694	Protein phosphatase-1 regulates Akt1 signal transduction pathway to control gene expression, cell survival and differentiation. Cell Death and Differentiation, 2010, 17, 1448-1462.	5.0	85
1695	Cytoskeletal keratin glycosylation protects epithelial tissue from injury. Nature Cell Biology, 2010, 12, 876-885.	4.6	111
1696	ABC transporters in cancer: more than just drug efflux pumps. Nature Reviews Cancer, 2010, 10, 147-156.	12.8	920

#	Article	IF	Citations
1697	Degradation of HER2 Receptor Through Hypericinâ€mediated Photodynamic Therapy. Photochemistry and Photobiology, 2010, 86, 200-205.	1.3	17
1698	Novel systemic approaches to treatment of HCC. Wspolczesna Onkologia, 2010, 1, 23-30.	0.7	0
1699	Predictive molecular markers for EGFR-TKI in non-small cell lung cancer patients: new insights and critical aspects. Journal of Nucleic Acids Investigation, 2010, 1, 10.	0.5	1
1700	Update and developments in the treatment of glioblastoma multiforme – focus on bevacizumab. Pharmacogenomics and Personalized Medicine, 2010, 3, 79.	0.4	4
1701	Molecular Genetic Markers in Female Reproductive Cancers. Journal of Oncology, 2010, 2010, 1-2.	0.6	1
1702	The Synergistic Effect of ConditionalPtenLoss and OncogenicK-rasMutation on Endometrial Cancer Development Occurs via Decreased Progesterone Receptor Action. Journal of Oncology, 2010, 2010, 1-9.	0.6	48
1703	Mesenchymal Migration as a Therapeutic Target in Glioblastoma. Journal of Oncology, 2010, 2010, 1-17.	0.6	70
1704	Exploring the Gain of Function Contribution of AKT to Mammary Tumorigenesis in Mouse Models. PLoS ONE, 2010, 5, e9305.	1.1	28
1705	Ack1 Mediated AKT/PKB Tyrosine 176 Phosphorylation Regulates Its Activation. PLoS ONE, 2010, 5, e9646.	1.1	136
1706	Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma. PLoS ONE, 2010, 5, e12711.	1.1	24
1707	Phosphoinositide 3-Kinases. , 2010, , 1049-1060.		5
1708	Molecular Biology of Lung Cancer. Japanese Journal of Lung Cancer, 2010, 50, 329-341.	0.0	0
1709	dGirdin a new player of Akt /PKB signaling in Drosophila Melanogaster. Frontiers in Bioscience - Landmark, 2010, 15, 1164.	3.0	7
1710	Brain Tumor Stem Cells as Therapeutic Targets in Models of Glioma. Yonsei Medical Journal, 2010, 51, 633.	0.9	32
1712	Roles of protein kinase B Akt in lung cancer. Frontiers in Bioscience - Elite, 2010, E2, 1472-1484.	0.9	27
1713	Phosphoinositide 3-Kinase/Akt Inhibits MST1-Mediated Pro-apoptotic Signaling through Phosphorylation of Threonine 120. Journal of Biological Chemistry, 2010, 285, 3815-3824.	1.6	70
1714	Disulfiram Treatment Facilitates Phosphoinositide 3-Kinase Inhibition in Human Breast Cancer Cells In vitro and In vivo. Cancer Research, 2010, 70, 3996-4004.	0.4	87
1715	Early T Cell Differentiation. Progress in Molecular Biology and Translational Science, 2010, 92, 121-156.	0.9	16

#	Article	IF	Citations
1716	The PI3Kâ€“Akt mediates oncogenic Met-induced centrosome amplification and chromosome instability. Carcinogenesis, 2010, 31, 1531-1540.	1.3	49
1717	Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis, 2010, 31, 1387-1391.	1.3	53
1718	Insulin-Like Growth Factor I Suppresses Bone Morphogenetic Protein Signaling in Prostate Cancer Cells by Activating mTOR Signaling. Cancer Research, 2010, 70, 9106-9117.	0.4	25
1719	WJD008, a Dual Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin Inhibitor, Prevents PI3K Signaling and Inhibits the Proliferation of Transformed Cells with Oncogenic PI3K Mutant. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 830-838.	1.3	37
1720	Inhibition of the phosphatidylinositol 3-kinase-Akt pathway enhances gamma-2 herpesvirus lytic replication and facilitates reactivation from latency. Journal of General Virology, 2010, 91, 463-469.	1.3	41
1721	Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR , PTEN , STK11 , RPKAA1 , PRKAG2 , TSC1 , TSC2 , PI3K and Akt1. Carcinogenesis, 2010, 31, 1604-1611.	1.3	88
1722	Oncogenic Potential of Retinoic Acid Receptor-Î³ in Hepatocellular Carcinoma. Cancer Research, 2010, 70, 2285-2295.	0.4	64
1723	L1 Cell Adhesion Molecule Is a Novel Therapeutic Target in Intrahepatic Cholangiocarcinoma. Clinical Cancer Research, 2010, 16, 3571-3580.	3.2	41
1724	Cancer and the Complement Cascade. Molecular Cancer Research, 2010, 8, 1453-1465.	1.5	206
1725	Correlating Phosphatidylinositol 3-Kinase Inhibitor Efficacy with Signaling Pathway Status: In silico and Biological Evaluations. Cancer Research, 2010, 70, 4982-4994.	0.4	108
1726	Pooled Analysis of Phosphatidylinositol 3-Kinase Pathway Variants and Risk of Prostate Cancer. Cancer Research, 2010, 70, 2389-2396.	0.4	43
1727	AT7867 Is a Potent and Oral Inhibitor of AKT and p70 S6 Kinase That Induces Pharmacodynamic Changes and Inhibits Human Tumor Xenograft Growth. Molecular Cancer Therapeutics, 2010, 9, 1100-1110.	1.9	59
1728	Coordination between Cell Cycle Progression and Cell Fate Decision by the p53 and E2F1 Pathways in Response to DNA Damage. Journal of Biological Chemistry, 2010, 285, 31571-31580.	1.6	56
1729	Phosphatidylinositol 3-kinase, a novel target molecule for the inhibitory effects of kaempferol on neoplastic cell transformation. Carcinogenesis, 2010, 31, 1338-1343.	1.3	50
1730	The Akt isoforms, their unique functions and potential as anticancer therapeutic targets. Biomolecular Concepts, 2010, 1, 389-401.	1.0	10
1731	Phosphorylation of the Immunomodulator FTY720 Inhibits Programmed Cell Death of Fibroblasts Via the S1P₃ Receptor Subtype and Bcl-2 Activation. Cellular Physiology and Biochemistry, 2010, 26, 67-78.	1.1	18
1732	An ATPase promotes autophosphorylation of the pattern recognition receptor XA21 and inhibits XA21-mediated immunity. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 8029-8034.	3.3	104
1733	Genetic Alterations in the Phosphatidylinositol-3 Kinase/Akt Pathway in Thyroid Cancer. Thyroid, 2010, 20, 697-706.	2.4	258

#	Article	IF	Citations
1734	The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. Carcinogenesis, 2010, 31, 1726-1733.	1.3	216
1735	Mass spectrometry based cellular phosphoinositides profiling and phospholipid analysis: A brief review. Experimental and Molecular Medicine, 2010, 42, 1.	3.2	47
1736	Current and emerging molecular targets in glioma. Expert Review of Anticancer Therapy, 2010, 10, 1735-1751.	1.1	31
1737	MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivity. Cancer Biology and Therapy, 2010, 9, 717-724.	1.5	54
1738	Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opinion on Therapeutic Targets, 2010, 14, 1073-1090.	1.5	140
1739	Therapeutic targeting of EGFR in malignant gliomas. Expert Opinion on Therapeutic Targets, 2010, 14, 303-316.	1.5	23
1740	Protein Kinase B (AKT) Mediates Phospholipase D Activation via ERK1/2 and Promotes Respiratory Burst Parameters in Formylpeptide-stimulated Neutrophil-like HL-60 Cells. Journal of Biological Chemistry, 2010, 285, 32055-32063.	1.6	10
1741	B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 12747-12754.	3.3	143
1742	mTOR Signaling as a Target of Amino Acid Treatment of the Age-Related Sarcopenia. Interdisciplinary Topics in Gerontology, 2010, 37, 115-141.	3.6	21
1743	Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 20126-20131.	3.3	118
1745	Toxicological Disruption of Signaling Homeostasis: Tyrosine Phosphatases as Targets. Annual Review of Pharmacology and Toxicology, 2010, 50, 215-235.	4.2	32
1746	Oncogenic Mutations of PIK3CA in Human Cancers. Current Topics in Microbiology and Immunology, 2010, 347, 21-41.	0.7	202
1747	Thymosin Î²4 targeting impairs tumorigenic activity of colon cancer stem cells. FASEB Journal, 2010, 24, 4291-4301.	0.2	33
1748	Attenuation of PI3K/Akt-Mediated Tumorigenic Signals through PTEN Activation by DNA Vaccine-Induced Anti-ErbB2 Antibodies. Journal of Immunology, 2010, 184, 4170-4177.	0.4	19
1749	TGF-Î²1 Protects against Mesangial Cell Apoptosis via Induction of Autophagy. Journal of Biological Chemistry, 2010, 285, 37909-37919.	1.6	120
1750	Activation of Akt and MAPK pathways enhances the tumorigenicity of CD133+ primary colon cancer cells. Carcinogenesis, 2010, 31, 1376-1380.	1.3	103
1751	Molecular Genetics of Thyroid Cancer. , 2010, , 117-138.		3
1752	Effects of HIV Protease Inhibitors on Progression of Monocrotaline- and Hypoxia-Induced Pulmonary Hypertension in Rats. Circulation, 2010, 122, 1937-1947.	1.6	51

#	Article	IF	Citations
1753	Fibroblast growth factor receptorâ€“3 expression in meningiomas with stimulation of proliferation by the phosphoinositide 3 kinaseâ€“Akt pathway. Journal of Neurosurgery, 2010, 112, 934-939.	0.9	25
1754	Inhibition of Cell Proliferation and MAP Kinase and Akt Pathways in Oral Squamous Cell Carcinoma by Genistein and Biochanin A. Evidence-based Complementary and Alternative Medicine, 2010, 7, 351-358.	0.5	35
1755	In Utero Exposure to Bisphenol A Shifts the Window of Susceptibility for Mammary Carcinogenesis in the Rat. Environmental Health Perspectives, 2010, 118, 1614-1619.	2.8	95
1756	PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress. Current Medicinal Chemistry, 2010, 17, 4326-4341.	1.2	89
1757	An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo. Cancer Biology and Therapy, 2010, 9, 493-503.	1.5	61
1758	The mTOR Pathway: A New Target in Cancer Therapy. Current Cancer Drug Targets, 2010, 10, 484-495.	0.8	152
1759	Decoupling of Receptor and Downstream Signals in the Akt Pathway by Its Low-Pass Filter Characteristics. Science Signaling, 2010, 3, ra56.	1.6	79
1760	A Mutated Soluble Neuropilin-2 B Domain Antagonizes Vascular Endothelial Growth Factor Bioactivity and Inhibits Tumor Progression. Molecular Cancer Research, 2010, 8, 1063-1073.	1.5	48
1761	Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status. International Journal of Oncology, 2010, 37, 1001-10.	1.4	42
1762	Expression profiling of 22 genes involved in the PI3Kâ€“AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations. Modern Pathology, 2010, 23, 694-702.	2.9	47
1764	The PKB/AKT Pathway in Cancer. Current Pharmaceutical Design, 2010, 16, 34-44.	0.9	252
1765	Clinical Significance of Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway in Korean Patients with Colorectal Cancer. Oncology, 2010, 79, 278-282.	0.9	12
1766	Cell Death and Survival Signaling in Oncogenesis. Klinische Padiatrie, 2010, 222, 340-344.	0.2	14
1767	PI3K/AKT/mTOR Inhibitors In Ovarian Cancer. Current Medicinal Chemistry, 2010, 17, 4433-4447.	1.2	41
1768	Kinase signaling pathways as targets for intervention in pancreatic cancer. Cancer Biology and Therapy, 2010, 9, 754-763.	1.5	26
1769	Physiological and Molecular Role of Ranpirnase on Cancer Treatment. Current Cancer Therapy Reviews, 2010, 6, 26-33.	0.2	0
1770	Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers. Cancer Biology and Therapy, 2010, 10, 1137-1146.	1.5	22
1771	Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery. Oncologist, 2010, 15, 390-404.	1.9	155

#	Article	IF	Citations
1772	Development of New Fluorescent Xanthines as Kinase Inhibitors. Organic Letters, 2010, 12, 1212-1215.	2.4	37
1773	Novel Targeted Therapies for Prostate Cancer. Urologic Clinics of North America, 2010, 37, 105-119.	0.8	9
1774	Signaling Mechanisms in Neuroendocrine Tumors as Targets for Therapy. Endocrinology and Metabolism Clinics of North America, 2010, 39, 801-810.	1.2	15
1775	Nanoparticle-Mediated Cytoplasmic Delivery of Proteins To Target Cellular Machinery. ACS Nano, 2010, 4, 1493-1500.	7.3	119
1776	Tyrosine kinase inhibitors to treat liver cancer. Expert Opinion on Emerging Drugs, 2010, 15, 13-26.	1.0	20
1777	Targeted therapy of hepatocellular cancer. Expert Opinion on Investigational Drugs, 2010, 19, 265-274.	1.9	50
1778	Overview of the Molecular Genetics and Molecular Chemotherapy of GBM. , 2010, , 1-42.		3
1779	The Genetics of Colorectal Cancer. Cancer Metastasis - Biology and Treatment, 2010, , 65-100.	0.1	0
1780	Inhibition of NF-Î¹B and Akt pathways by an antibody-avidin fusion protein sensitizes malignant B-cells to cisplatin-induced apoptosis. International Journal of Oncology, 2010, 36, 1299-307.	1.4	11
1781	Protein kinase networks regulating glucocorticoid-induced apoptosis of hematopoietic cancer cells: fundamental aspects and practical considerations. Leukemia and Lymphoma, 2010, 51, 1968-2005.	0.6	53
1782	Coordination of the Nuclear and Cytoplasmic Activities of p53 in Response to DNA Damage. Biophysical Journal, 2010, 99, 1696-1705.	0.2	22
1783	Dexamethasone protects human fibroblasts from apoptosis via an S1P3-receptor subtype dependent activation of PKB/Akt and BclXL. Pharmacological Research, 2010, 61, 449-459.	3.1	18
1784	HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: Outlook and recent implications in nanomedical approaches. Pharmacological Research, 2010, 62, 150-165.	3.1	63
1785	PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer, 2010, 69, 279-283.	0.9	161
1786	Characterization of side population cells in human malignant mesothelioma cell lines. Lung Cancer, 2010, 70, 146-151.	0.9	31
1787	PTEN, PIK3CA, p-AKT, and p-p70S6K Status. American Journal of Pathology, 2010, 177, 1647-1656.	1.9	276
1788	Roles of Tetrahydrobiopterin in Promoting Tumor Angiogenesis. American Journal of Pathology, 2010, 177, 2671-2680.	1.9	32
1789	MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Molecular Cancer, 2010, 9, 83.	7.9	139

#	Article	IF	Citations
1790	The Role of Phosphoinositide 3-Kinase in Breast Cancer: An Overview. Clinical Breast Cancer, 2010, 10, S56-S58.	1.1	1
1791	Does the PI3K Pathway Play a Role in Basal Breast Cancer?. Clinical Breast Cancer, 2010, 10, S66-S71.	1.1	22
1792	The Chromosomal Instability Pathway in Colon Cancer. Gastroenterology, 2010, 138, 2059-2072.	0.6	681
1793	The anti-apoptotic function of human Î±A-crystallin is directly related to its chaperone activity. Cell Death and Disease, 2010, 1, e31-e31.	2.7	67
1794	Discovery of (Thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer. Journal of Medicinal Chemistry, 2010, 53, 1086-1097.	2.9	116
1795	mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro-Oncology, 2010, 12, 882-889.	0.6	159
1796	Stoichiometric Quantification of Akt Phosphorylation Using LC-MS/MS. Journal of Proteome Research, 2010, 9, 743-751.	1.8	24
1797	Class I Phospho-inositide-3-kinases (PI3Ks) Isoform-Specific Inhibition Study by the Combination of Docking and Molecular Dynamics Simulation. Journal of Chemical Information and Modeling, 2010, 50, 136-145.	2.5	30
1798	A Link between mir-100 and FRAP1/mTOR in Clear Cell Ovarian Cancer. Molecular Endocrinology, 2010, 24, 447-463.	3.7	225
1799	The Biology of the HER Family and Her2/neu Directed-Antibody Therapy. , 2010, , 437-464.		1
1800	Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design. MedChemComm, 2010, 1, 139.	3.5	68
1801	MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted DrugsIn vitroandIn vivo. Molecular Cancer Therapeutics, 2010, 9, 1956-1967.	1.9	821
1802	Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood, 2010, 115, 559-569.	0.6	93
1803	Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma. Human Pathology, 2010, 41, 794-804.	1.1	46
1804	The epidermal growth factor receptor pathway in relation to pelvic lymph node metastasis and survival in early-stage cervical cancer. Human Pathology, 2010, 41, 1735-1741.	1.1	22
1805	Targeting the PI3K signaling pathway in cancer. Current Opinion in Genetics and Development, 2010, 20, 87-90.	1.5	494
1806	Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Letters, 2010, 291, 1-13.	3.2	78
1807	Abrogation of Akt signaling by Isobavachalcone contributes to its anti-proliferative effects towards human cancer cells. Cancer Letters, 2010, 294, 167-177.	3.2	80

#	Article	IF	Citations
1808	Overexpression of LAPTM4B-35 promotes growth and metastasis of hepatocellular carcinoma in vitro and in vivo. Cancer Letters, 2010, 294, 236-244.	3.2	69
1809	Concurrent blockade of the NF-Î¹B and Akt pathways potently sensitizes cancer cells to chemotherapeutic-induced cytotoxicity. Cancer Letters, 2010, 295, 38-43.	3.2	10
1810	Retinoic acid and its binding protein modulate apoptotic signals in hypoxic hepatocellular carcinoma cells. Cancer Letters, 2010, 295, 229-235.	3.2	11
1811	Molecular networks in respiratory epithelium carcinomas. Cancer Letters, 2010, 295, 1-6.	3.2	0
1812	Targets for cancer therapy in childhood sarcomas. Cancer Treatment Reviews, 2010, 36, 318-327.	3.4	93
1813	The long road to colorectal cancer therapy: Searching for the right signals. Drug Resistance Updates, 2010, 13, 44-56.	6.5	25
1814	Absence of activating somatic mutations of PI3KCA and AKT1 genes in South Indian women with endometriosis. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2010, 152, 78-82.	0.5	5
1815	The death effector domain-containing DEDD forms a complex with Akt and Hsp90, and supports their stability. Biochemical and Biophysical Research Communications, 2010, 391, 1708-1713.	1.0	9
1816	Modulation of curcumin-induced Akt phosphorylation and apoptosis by PI3K inhibitor in MCF-7 cells. Biochemical and Biophysical Research Communications, 2010, 394, 476-481.	1.0	48
1817	Knockdown of Akt isoforms by RNA silencing suppresses the growth of human prostate cancer cells in vitro and in vivo. Biochemical and Biophysical Research Communications, 2010, 399, 79-83.	1.0	35
1818	Flaxseed oilâ€“trastuzumab interaction in breast cancer. Food and Chemical Toxicology, 2010, 48, 2223-2226.	1.8	29
1819	The role of genetic variants in human longevity. Ageing Research Reviews, 2010, 9, S67-S78.	5.0	43
1820	Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 5â€²-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound 26 (PKI-587), a Highly Efficacious Dual Inhibitor. Journal of Medicinal Chemistry, 2010, 53, 2636-2645.	2.9	182
1821	Microsatellite instability in colorectal cancerâ€”the stable evidence. Nature Reviews Clinical Oncology, 2010, 7, 153-162.	12.5	736
1822	Synthesis and SAR of Novel 4-Morpholinopyrrolopyrimidine Derivatives as Potent Phosphatidylinositol 3-Kinase Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 3169-3182.	2.9	48
1823	Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin. Expert Review of Molecular Diagnostics, 2010, 10, 509-519.	1.5	60
1824	The T-loop Extension of the Tomato Protein Kinase AvrPto-dependent Pto-interacting Protein 3 (Adi3) Directs Nuclear Localization for Suppression of Plant Cell Death. Journal of Biological Chemistry, 2010, 285, 17584-17594.	1.6	32
1825	AKT Signaling in Physiology and Disease. Current Topics in Microbiology and Immunology, 2010, 347, 105-133.	0.7	99

#	Article	IF	Citations
1827	Signaling Targets in Myeloid Leukemias. , 2010, , 2821-2829.		0
1828	Sphingolipids as Signaling and Regulatory Molecules. Advances in Experimental Medicine and Biology, 2010, , .	0.8	23
1831	Regulation of Gene Expression in the Intestinal Epithelium. Progress in Molecular Biology and Translational Science, 2010, 96, 207-229.	0.9	43
1832	Neutrophil spontaneous death is mediated by down-regulation of autocrine signaling through GPCR, PI3KÎ³, ROS, and actin. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2950-2955.	3.3	62
1833	Low Dietary Inorganic Phosphate Stimulates Lung Tumorigenesis Through Altering Protein Translation and Cell Cycle in K-ras^{LA1}Mice. Nutrition and Cancer, 2010, 62, 525-532.	0.9	15
1834	Elimination of Human Lung Cancer Stem Cells through Targeting of the Stem Cell Factorâ€“c-kit Autocrine Signaling Loop. Cancer Research, 2010, 70, 338-346.	0.4	142
1835	Second AKT: The rise of SGK in cancer signalling. Growth Factors, 2010, 28, 394-408.	0.5	127
1836	Programmed Cell Death 4 (PDCD4) Enhances the Sensitivity of Gastric Cancer Cells to TRAIL-Induced Apoptosis by Inhibiting the PI3K/Akt Signaling Pathway. Molecular Diagnosis and Therapy, 2010, 14, 155-161.	1.6	31
1837	Arsenic trioxide cooperates with alltransretinoic acid to enhance mitogen-activated protein kinase activation and differentiation in PMLâ€“RARÎ± negative human myeloblastic leukemia cells. Leukemia and Lymphoma, 2010, 51, 1-14.	0.6	43
1838	EGFR and KRAS in Colorectal Cancer. Advances in Clinical Chemistry, 2010, 51, 71-119.	1.8	103
1839	The Levels of H11/HspB8 DNA Methylation in Human Melanoma Tissues and Xenografts Are a Critical Molecular Marker for 5-Aza-2â€²-Deoxycytidine Therapy. Cancer Investigation, 2011, 29, 383-395.	0.6	17
1840	Modeling and analysis of retinoic acid induced differentiation of uncommitted precursor cells. Integrative Biology (United Kingdom), 2011, 3, 578.	0.6	21
1841	Sulforaphane Potentiates the Efficacy of 17-Allylamino 17-Demethoxygeldanamycin Against Pancreatic Cancer Through Enhanced Abrogation of Hsp90 Chaperone Function. Nutrition and Cancer, 2011, 63, 1151-1159.	0.9	34
1842	Growth Inhibition of Human Lung Cancer Cells via Down-regulation of Epidermal Growth Factor Receptor Signaling by Yuanhuadine, a Daphnane Diterpene from Daphne genkwa. Journal of Natural Products, 2011, 74, 2102-2108.	1.5	56
1843	Structureâ€“Activity Relationships of Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Investigations of Various 6,5-Heterocycles to Improve Metabolic Stability. Journal of Medicinal Chemistry, 2011, 54, 5174-5184.	2.9	40
1844	Neurotensin Signaling Activates MicroRNAs-21 and -155 and Akt, Promotes Tumor Growth in Mice, and Is Increased in Human Colon Tumors. Gastroenterology, 2011, 141, 1749-1761.e1.	0.6	115
1845	DNA-PK Mediates AKT Activation and Apoptosis Inhibition in Clinically Acquired Platinum Resistance. Neoplasia, 2011, 13, 1069-IN35.	2.3	108
1846	Multistep Phosphorylation by Oncogenic Kinases Enhances the Degradation of the NF2 Tumor Suppressor Merlin. Neoplasia, 2011, 13, 643-652.	2.3	25

#	Article	IF	Citations
1847	Cooperation between Stat3 and Akt Signaling Leads to Prostate Tumor Development in Transgenic Mice. Neoplasia, 2011, 13, 254-IN12.	2.3	40
1848	Targeted Therapy for Melanoma: A Primer. Surgical Oncology Clinics of North America, 2011, 20, 165-180.	0.6	25
1849	Ha-ras Oncogene and Anticancer Drug Resistance. Genomic Medicine, Biomarkers, and Health Sciences, 2011, 3, 39-48.	0.3	3
1850	Capitalizing on tumor genotyping: Towards the design of mutation specific inhibitors of phosphoinsitide-3-kinase. Advances in Enzyme Regulation, 2011, 51, 273-279.	2.9	4
1851	Molecular Biology of Lung Cancer: Clinical Implications. Clinics in Chest Medicine, 2011, 32, 703-740.	0.8	194
1852	Cucurmosin induces apoptosis of BxPC-3 human pancreatic cancer cells via inactivation of the EGFR signaling pathway. Oncology Reports, 2011, 27, 891-7.	1.2	23
1853	The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt Pathway. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E577-E585.	1.8	93
1854	Autophagy as a therapeutic target in cancer. Cancer Biology and Therapy, 2011, 11, 157-168.	1.5	287
1855	Iterative in Situ Click Chemistry Assembles a Branched Capture Agent and Allosteric Inhibitor for Akt1. Journal of the American Chemical Society, 2011, 133, 18280-18288.	6.6	46
1856	Molecular mechanism of size control in development and human diseases. Cell Research, 2011, 21, 715-729.	5.7	60
1857	Molecular Pathways for Cancer Chemoprevention by Dietary Phytochemicals. Nutrition and Cancer, 2011, 63, 495-505.	0.9	129
1858	Invasiveness and anchorage independent growth ability augmented by PTEN inactivation through the PI3K/AKT/NFkB pathway in lung cancer cells. Lung Cancer, 2011, 73, 302-309.	0.9	60
1859	A theoretical investigation of inositol 1,3,4,5-tetrakisphosphate. Physical Chemistry Chemical Physics, 2011, 13, 1070-1081.	1.3	9
1860	Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC). BMC Cancer, 2011, 11, 147.	1.1	86
1861	Osthole induces G2/M arrest and apoptosis in lung cancer A549 cells by modulating PI3K/Akt pathway. Journal of Experimental and Clinical Cancer Research, 2011, 30, 33.	3.5	123
1862	Blockade of Her2/neu Binding to Hsp90 by Emodin Azide Methyl Anthraquinone Derivative Induces Proteasomal Degradation of Her2/neu. Molecular Pharmaceutics, 2011, 8, 1687-1697.	2.3	41
1863	Phosphoinositide 3-kinase in Health and Disease. Current Topics in Microbiology and Immunology, 2011, , .	0.7	1
1864	Panzem. , 2011, , 2781-2781.		0

#	Article	IF	Citations
1865	RAEB. , 2011, , 3160-3160.		0
1866	From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma. Expert Opinion on Investigational Drugs, 2011, 20, 1015-1028.	1.9	5
1867	Ras and Rap Signaling in Synaptic Plasticity and Mental Disorders. Neuroscientist, 2011, 17, 54-78.	2.6	131
1868	Cancer Stem Cells in Solid Tumors. , 2011, , .		7
1872	Receptor Tyrosine Kinases. , 2011, , 3198-3203.		0
1874	Androgen Action. Methods in Molecular Biology, 2011, , .	0.4	2
1875	Rational Design of Phosphoinositide 3-Kinase Î± Inhibitors That Exhibit Selectivity over the Phosphoinositide 3-Kinase Î² Isoform. Journal of Medicinal Chemistry, 2011, 54, 7815-7833.	2.9	60
1876	Phage Display. , 2011, , 2836-2839.		0
1877	Platelet-Derived Growth Factor. , 2011, , 2908-2910.		0
1878	Lung-Residing Metastatic and Dormant Neuroblastoma Cells. American Journal of Pathology, 2011, 179, 524-536.	1.9	17
1879	Phosphatase and Tensin Homolog on Chromosome 10 Is Phosphorylated in Primary Effusion Lymphoma and Kaposi's Sarcoma. American Journal of Pathology, 2011, 179, 2108-2119.	1.9	24
1880	Emerging Therapies for Advanced Gastroenteropancreatic Neuroendocrine Tumors. Clinical Colorectal Cancer, 2011, 10, 298-309.	1.0	5
1881	Modulation of YY1 and p53 expression by transforming growth factor-Î²3 in prostate cell lines. Cytokine, 2011, 56, 403-410.	1.4	12
1882	MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Cancer Letters, 2011, 307, 211-220.	3.2	129
1883	RasGAP-derived peptide 38GAP potentiates the cytotoxicity of cisplatin through inhibitions of Akt, ERK and NF-Î¹ºB in colon carcinoma HCT116 cells. Cancer Letters, 2011, 308, 62-70.	3.2	23
1884	Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST). Cancer Letters, 2011, 312, 43-54.	3.2	125
1885	Kaempferol protects MC3T3-E1 cells through antioxidant effect and regulation of mitochondrial function. Food and Chemical Toxicology, 2011, 49, 1800-1805.	1.8	59
1886	Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001. European Journal of Cancer, 2011, 47, 1244-1257.	1.3	17

#	Article	IF	Citations
1887	Decrease in transient receptor potential melastatin 6 mRNA stability caused by rapamycin in renal tubular epithelial cells. Biochimica Et Biophysica Acta - Biomembranes, 2011, 1808, 1502-1508.	1.4	22
1888	Centchroman inhibits proliferation of head and neck cancer cells through the modulation of PI3K/mTOR Pathway. Biochemical and Biophysical Research Communications, 2011, 404, 40-45.	1.0	31
1889	Peptidoglycan enhances secretion of monocyte chemoattractants via multiple signaling pathways. Biochemical and Biophysical Research Communications, 2011, 408, 132-138.	1.0	21
1890	NOTCH and phosphatidylinositide 3-kinase/phosphatase and tensin homolog deleted on chromosome ten/AKT/mammalian target of rapamycin (mTOR) signaling in T-cell development and T-cell acute lymphoblastic leukemia. Leukemia and Lymphoma, 2011, 52, 1200-1210.	0.6	31
1891	The good oncogene: When bad genes identify good outcome in cancer. Medical Hypotheses, 2011, 76, 259-263.	0.8	6
1892	Co-expression of erythropoietin receptor with human epidermal growth factor 2 may counteract trastuzumab inhibition in gastric cancer. Medical Hypotheses, 2011, 77, 948-952.	0.8	1
1893	Thyroid hormones protect astrocytes from morphine-induced apoptosis by regulating nitric oxide and pERK 1/2 pathways. Neurochemistry International, 2011, 58, 861-871.	1.9	17
1894	Advances in the understanding of the structure and function of ER-Î±36,a novel variant of human estrogen receptor-alpha. Journal of Steroid Biochemistry and Molecular Biology, 2011, 127, 231-237.	1.2	33
1895	Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway. Journal of Hepatology, 2011, 55, 1400-1408.	1.8	57
1896	Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2011, 14, 206-218.	2.0	25
1897	Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors. Steroids, 2011, 76, 750-752.	0.8	42
1898	Neurotoxicity induced by dexamethasone in the human neuroblastoma SH-SY5Y cell line can be prevented by folic acid. Neuroscience, 2011, 190, 346-353.	1.1	23
1899	Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncology, The, 2011, 12, 361-368.	5.1	151
1900	Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer. Journal of Medicinal Chemistry, 2011, 54, 7579-7587.	2.9	184
1901	The impact of PTEN regulation by CK2 on PI3K-dependent signaling and leukemia cell survival. Advances in Enzyme Regulation, 2011, 51, 37-49.	2.9	63
1902	Discovery and Optimization of a Series of Benzothiazole Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors. Journal of Medicinal Chemistry, 2011, 54, 1789-1811.	2.9	103
1903	Phospholipase D: Enzymology, Functionality, and Chemical Modulation. Chemical Reviews, 2011, 111, 6064-6119.	23.0	314
1904	PI3K Inhibitors in Cardiovascular Disease. Cardiovascular Therapeutics, 2011, 29, 29-36.	1.1	63

#	Article	IF	Citations
1905	Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases. Breast Cancer Research, 2011, 13, R125.	2.2	87
1906	Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncology, 2011, 7, 1149-1167.	1.1	191
1907	Spatial relationship of phosphorylated epidermal growth factor receptor and activated AKT in head and neck squamous cell carcinoma. Radiotherapy and Oncology, 2011, 101, 165-170.	0.3	24
1908	Targeting Receptor Tyrosine Kinase Pathways in Hepatocellular Carcinoma. Anti-Cancer Agents in Medicinal Chemistry, 2011, 11, 560-575.	0.9	24
1909	ErbB2/HER2: Its Contribution to Basic Cancer Biology and the Development of Molecular Targeted Therapy. , 2011, , .		2
1910	Contribution of PKB/AKT signaling to thyroid cancer. Frontiers in Bioscience - Landmark, 2011, 16, 1461.	3.0	26
1911	Signaling Pathways in Pancreatic Cancer. Critical Reviews in Eukaryotic Gene Expression, 2011, 21, 115-129.	0.4	34
1912	Targeting therapies in cancer: opportunities in ovarian cancer. , 0, , 167-182.		0
1913	Promising Experimental Therapies for Metastatic Melanoma. , 2011, , .		0
1914	Cigarette Smoke and Cancer. Journal of Oncology, 2011, 2011, 1-2.	0.6	2
1915	Epigenetic Effects and Molecular Mechanisms of Tumorigenesis Induced by Cigarette Smoke: An Overview. Journal of Oncology, 2011, 2011, 1-14.	0.6	57
1916	Molecular Mechanisms of Cigarette Smoke-Induced Proliferation of Lung Cells and Prevention by Vitamin C. Journal of Oncology, 2011, 2011, 1-16.	0.6	11
1917	Acquired Radioresistance of Cancer and the AKT/GSK3Î²/cyclin D1 Overexpression Cycle. Journal of Radiation Research, 2011, 52, 539-544.	0.8	88
1918	Carbon Ion Irradiation Suppresses Metastatic Potential of Human Non-small Cell Lung Cancer A549 Cells through the Phosphatidylinositol-3-Kinase/Akt Signaling Pathway. Journal of Radiation Research, 2011, 52, 374-379.	0.8	53
1919	The HGF-Met Signaling Axis: Emerging Themes and Targets of Inhibition. Current Protein and Peptide Science, 2011, 12, 12-22.	0.7	22
1920	Chamaejasmine Inactivates Akt To Trigger Apoptosis in Human HEp-2 Larynx Carcinoma Cells. Molecules, 2011, 16, 8152-8164.	1.7	14
1921	Opposite Effects of HIV-1 p17 Variants on PTEN Activation and Cell Growth in B Cells. PLoS ONE, 2011, 6, e17831.	1.1	47
1922	Autophagy Interplay with Apoptosis and Cell Cycle Regulation in the Growth Inhibiting Effect of Resveratrol in Glioma Cells. PLoS ONE, 2011, 6, e20849.	1.1	144

#	Article	IF	Citations
1923	Differential Impact of EGFR-Targeted Therapies on Hypoxia Responses: Implications for Treatment Sensitivity in Triple-Negative Metastatic Breast Cancer. PLoS ONE, 2011, 6, e25080.	1.1	30
1924	Irreversible EGFR Inhibitor EKB-569 Targets Low-LET Î³-Radiation-Triggered Rel Orchestration and Potentiates Cell Death in Squamous Cell Carcinoma. PLoS ONE, 2011, 6, e29705.	1.1	14
1925	The Phosphatidylinositol 3â€² Kinase-Akt-mammalian Target of Rapamycin Pathway in Smooth Muscle Tumors of the Uterus. International Journal of Gynecological Pathology, 2011, 33, 244-251.	0.9	3
1926	Regulation and Function of FoxO Transcription Factors in Normal and Cancer Stem Cells: What Have We Learned?. Current Drug Targets, 2011, 12, 1267-1283.	1.0	33
1927	Antiproteasomal agents in rectal cancer. Anti-Cancer Drugs, 2011, 22, 341-350.	0.7	9
1928	Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors. Current Medicinal Chemistry, 2011, 18, 2686-2714.	1.2	105
1929	Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets. Current Drug Targets, 2011, 12, 1056-1081.	1.0	38
1930	Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines. Oncology Reports, 2011, 26, 1273-9.	1.2	28
1931	Multi-step process of human breast carcinogenesis: A role for BRCA1, BECN1, CCND1, PTEN and UVRAG. Molecular Medicine Reports, 2012, 5, 305-12.	1.1	14
1932	Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. Blood, 2011, 118, 2035-2043.	0.6	106
1933	Pretreatment with phosphatase and tensin homolog deleted on chromosome 10 (PTEN) inhibitor SF1670 augments the efficacy of granulocyte transfusion in a clinically relevant mouse model. Blood, 2011, 117, 6702-6713.	0.6	63
1934	Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia. Blood, 2011, 117, 6650-6659.	0.6	72
1935	Next-generation Akt inhibitors provide greater specificity: effects on glucose metabolism in adipocytes. Biochemical Journal, 2011, 435, 539-544.	1.7	50
1936	AKT inhibition by triciribine alone or as combination therapy for growth control of gastroenteropancreatic neuroendocrine tumors. International Journal of Oncology, 2011, 40, 876-88.	1.4	14
1937	Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia. Oncology Reports, 2012, 27, 461-6.	1.2	17
1938	Anti-angiogenic activity of cranberry proanthocyanidins and cytotoxic properties in ovarian cancer cells. International Journal of Oncology, 2012, 40, 227-35.	1.4	34
1939	Statins exhibit anticancer effects through modifications of the pAkt signaling pathway. International Journal of Oncology, 2011, 40, 867-75.	1.4	23
1940	Reverse-phase protein microarrays (RPPA) as a diagnostic and therapeutic guide in multidrug resistant leukemia. International Journal of Oncology, 2011, 38, 427-35.	1.4	12

#	Article	IF	Citations
1941	Deltonin Isolated from Dioscorea zingiberensis Inhibits Cancer Cell Growth through Inducing Mitochondrial Apoptosis and Suppressing Akt and Mitogen Activated Protein Kinase Signals. Biological and Pharmaceutical Bulletin, 2011, 34, 1231-1239.	0.6	25
1942	Targeting the Extracellular Signal-Regulated Kinase Pathway in Cancer Therapy. Biological and Pharmaceutical Bulletin, 2011, 34, 1781-1784.	0.6	54
1943	Inhibition of Akt (ser473) Phosphorylation and Rapamycin-Resistant Cell Growth by Knockdown of Mammalian Target of Rapamycin with Small Interfering RNA in Vascular Endothelial Growth Factor Receptor-1-Targeting Vector. Biological and Pharmaceutical Bulletin, 2011, 34, 602-608.	0.6	26
1944	Carboxyl-terminal modulator protein induces apoptosis by regulating mitochondrial function in lung cancer cells. International Journal of Oncology, 2011, 40, 1515-24.	1.4	2
1945	Angiotensin-(1-7) inhibits the migration and invasion of A549 human lung adenocarcinoma cells through inactivation of the PI3K/Akt and MAPK signaling pathways. Oncology Reports, 2012, 27, 783-90.	1.2	69
1946	Tobacco-specific carcinogen nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induces AKT activation in head and neck epithelia. International Journal of Oncology, 2011, 39, 1193-8.	1.4	7
1947	Transforming growth factor-Î²-induced protein (TGFBI) suppresses mesothelioma progression through the Akt/mTOR pathway. International Journal of Oncology, 2011, 39, 1001-9.	1.4	20
1949	Pathogenesis of early leukemia and lymphoma. Cancer Biomarkers, 2011, 9, 341-374.	0.8	6
1950	Possible involvement of NEDD4 in keloid formation; its critical role in fibroblast proliferation and collagen production. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 2011, 87, 563-573.	1.6	36
1951	The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU International, 2011, 108, E84-90.	1.3	29
1952	Epigenetic regulation of signaling pathways in cancer: Role of the histone methyltransferase EZH2. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 19-27.	1.4	121
1953	Enhanced antitumor efficacy by blocking activation of the phosphatidylinositol 3â€kinase/Akt pathway during antiâ€angiogenesis therapy. Cancer Science, 2011, 102, 1469-1475.	1.7	6
1954	Antitumor effects of Î±â€bisabolol against pancreatic cancer. Cancer Science, 2011, 102, 2199-2205.	1.7	55
1955	Î±7 Nicotinic receptor activation reduces Î²â€amyloidâ€induced apoptosis by inhibiting caspaseâ€independent death through phosphatidylinositol 3â€kinase signaling. Journal of Neurochemistry, 2011, 119, 848-858.	2.1	57
1956	Postâ€transcriptional regulation of IGF1R by key microRNAs in longâ€“lived mutant mice. Aging Cell, 2011, 10, 1080-1088.	3.0	44
1957	Protocatechuic acid inhibits cancer cell metastasis involving the downâ€regulation of Ras/Akt/NFâ€ÎºB pathway and MMPâ€2 production by targeting RhoB activation. British Journal of Pharmacology, 2011, 162, 237-254.	2.7	107
1958	Epidermal Growth Factor Receptor Inhibitors in the Treatment of Nonmelanoma Skin Cancers. Dermatologic Surgery, 2011, 37, 1199-1209.	0.4	12
1959	c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase. Oncogene, 2011, 30, 2003-2016.	2.6	98

#	Article	IF	Citations
1960	PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene, 2011, 30, 2547-2557.	2.6	471
1961	The role of microRNA-150 as a tumor suppressor in malignant lymphoma. Leukemia, 2011, 25, 1324-1334.	3.3	156
1962	Dietary energy balance modulation of epithelial carcinogenesis: a role for IGFâ€1 receptor signaling and crosstalk. Annals of the New York Academy of Sciences, 2011, 1229, 7-17.	1.8	6
1963	Rapid Upregulation of Cytoprotective Nitric Oxide in Breast Tumor Cells Subjected to a Photodynamic Therapyâ€like Oxidative Challenge. Photochemistry and Photobiology, 2011, 87, 378-386.	1.3	36
1964	The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximabâ€“bevacizumabâ€“irradiation combination on head and neck cancer xenografts. Oral Oncology, 2011, 47, 340-344.	0.8	34
1965	Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma. Oral Oncology, 2011, 47, 946-950.	0.8	54
1966	Modelling and analysis of an ensemble of eukaryotic translation initiation models. IET Systems Biology, 2011, 5, 2-14.	0.8	19
1967	Membrane-associated signaling in human B-lymphoma lines. Experimental Cell Research, 2011, 317, 151-162.	1.2	17
1968	Soluble E-cadherin promotes cell survival by activating epidermal growth factor receptorâ˜†. Experimental Cell Research, 2011, 317, 838-848.	1.2	47
1969	A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecologic Oncology, 2011, 121, 455-461.	0.6	48
1970	Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: Cytoplasmic sequestration of CDK2 by p27. Gynecologic Oncology, 2011, 122, 641-647.	0.6	19
1971	Role of HCV Core gene of genotype 1a and 3a and host gene Cox-2 in HCV-induced pathogenesis. Virology Journal, 2011, 8, 155.	1.4	28
1972	Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations. Diagnostic Pathology, 2011, 6, 118.	0.9	33
1973	A cyano analogue of boswellic acid induces crosstalk between p53/PUMA/Bax and telomerase that stages the human papillomavirus type 18 positive HeLa cells to apoptotic death. European Journal of Pharmacology, 2011, 660, 241-248.	1.7	29
1974	Ellagic acid prevents rat colon carcinogenesis induced by 1, 2 dimethyl hydrazine through inhibition of AKT-phosphoinositide-3 kinase pathway. European Journal of Pharmacology, 2011, 660, 249-258.	1.7	93
1975	Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors. Experimental Hematology, 2011, 39, 457-472.e3.	0.2	44
1976	Shikonin, a Chinese plant-derived naphthoquinone, induces apoptosis in hepatocellular carcinoma cells through reactive oxygen species: A potential new treatment for hepatocellular carcinoma. Free Radical Biology and Medicine, 2011, 51, 2259-2271.	1.3	129
1977	Cell metabolism: An essential link between cell growth and apoptosis. Biochimica Et Biophysica Acta - Molecular Cell Research, 2011, 1813, 645-654.	1.9	133

#	Article	IF	Citations
1978	Synthesis and biological evaluation of a novel class of isatin analogs as dual inhibitors of tubulin polymerization and Akt pathway. Bioorganic and Medicinal Chemistry, 2011, 19, 6006-6014.	1.4	53
1979	Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6793-6799.	1.0	31
1980	AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity. Cancer Cell, 2011, 19, 58-71.	7.7	867
1981	Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth. Cancer Cell, 2011, 19, 792-804.	7.7	449
1982	Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells. Cellular Signalling, 2011, 23, 201-212.	1.7	95
1983	Akt phosphorylation at Thr308 and Ser473 is required for CHIP-mediated ubiquitination of the kinase. Cellular Signalling, 2011, 23, 1824-1830.	1.7	48
1984	Efficacy and Comparative Effectiveness of Sirolimus (Rapamune) as an Anticancer Drug. Laryngoscope, 2011, 121, S123-S123.	1.1	0
1985	Synthesis and Biological Evaluation of Novel Analogues of the Pan Class I Phosphatidylinositol 3-Kinase (PI3K) Inhibitor 2-(Difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474). Journal of Medicinal Chemistry, 2011, 54, 7105-7126.	2.9	97
1986	Celecoxib Promotes c-FLIP Degradation through Akt-Independent Inhibition of GSK3. Cancer Research, 2011, 71, 6270-6281.	0.4	35
1987	PI3KÎ´ Inhibitors in Cancer: Rationale and Serendipity Merge in the Clinic. Cancer Discovery, 2011, 1, 562-572.	7.7	126
1988	High Expression of Y-Box-Binding Protein-1 is Associated with Poor Survival in Resectable Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2011, 18, 3370-3376.	0.7	8
1989	Different effects of corticotropin-releasing factor and urocortin 2 on apoptosis of prostate cancer cells in vitro. Journal of Molecular Endocrinology, 2011, 47, 219-227.	1.1	23
1990	Targeting PI3K/Akt/HSP90 Signaling Sensitizes Gastric Cancer Cells to Deoxycholate-Induced Apoptosis. Digestive Diseases and Sciences, 2011, 56, 323-329.	1.1	25
1991	Mutational Analysis of the PTEN Gene and Its Effects in Esophageal Squamous Cell Carcinoma. Digestive Diseases and Sciences, 2011, 56, 1315-1322.	1.1	11
1992	Mechanisms for the activity of heterocyclic cyclohexanone curcumin derivatives in estrogen receptor negative human breast cancer cell lines. Investigational New Drugs, 2011, 29, 87-97.	1.2	64
1993	The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study. Breast Cancer Research and Treatment, 2011, 128, 725-734.	1.1	45
1994	Combined activity of oridonin and wogonin in advanced-stage ovarian cancer cells. Cell Biology and Toxicology, 2011, 27, 133-147.	2.4	25
1995	RhoA/ROCK signaling mediates plasticity of scirrhous gastric carcinoma motility. Clinical and Experimental Metastasis, 2011, 28, 627-636.	1.7	33

#	Article	IF	Citations
1996	PI3Kinase signaling in glioblastoma. Journal of Neuro-Oncology, 2011, 103, 417-427.	1.4	66
1997	PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts. Journal of Neuro-Oncology, 2011, 104, 155-167.	1.4	37
1998	Involvement of PTEN/Akt signaling in capsular invasive carcinomas developed in a rat two-stage thyroid carcinogenesis model after promotion with sulfadimethoxine. Journal of Cancer Research and Clinical Oncology, 2011, 137, 723-732.	1.2	7
1999	Gastrokine 1 functions as a tumor suppressor by inhibition of epithelialâ€“mesenchymal transition in gastric cancers. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1697-1704.	1.2	48
2000	The microtubule depolymerizing agent naphthazarin induces both apoptosis and autophagy in A549 lung cancer cells. Apoptosis: an International Journal on Programmed Cell Death, 2011, 16, 924-939.	2.2	68
2001	Honokiol protects osteoblastic MC3T3-E1 cells against antimycin A-induced cytotoxicity. Inflammation Research, 2011, 60, 1005-1012.	1.6	12
2002	CD34 antigen: Determination of specific sites of phosphorylation in vitro and in vivo. International Journal of Mass Spectrometry, 2011, 301, 12-21.	0.7	6
2003	H2S Protects Hippocampal Neurons from Anoxiaâ€“Reoxygenation Through cAMP-Mediated PI3K/Akt/p70S6K Cell-Survival Signaling Pathways. Journal of Molecular Neuroscience, 2011, 43, 453-460.	1.1	44
2004	Mammalian target of rapamycin as a target in hematological malignancies. Targeted Oncology, 2011, 6, 53-61.	1.7	18
2005	Molecular oncology of lung cancer. General Thoracic and Cardiovascular Surgery, 2011, 59, 527-537.	0.4	60
2006	Predictive and Prognostic Markers in Colorectal Cancer. Current Oncology Reports, 2011, 13, 206-215.	1.8	48
2007	Targeting the PI3K/AKT/mTOR Pathway in Non-Hodgkinâ€™s Lymphoma: Results, Biology, and Development Strategies. Current Oncology Reports, 2011, 13, 398-406.	1.8	38
2008	Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer. BMC Cancer, 2011, 11, 399.	1.1	58
2009	Role of protein kinase C and epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon carcinoma cells. BMC Cancer, 2011, 11, 421.	1.1	39
2010	Protein secretion in human mammary epithelial cells following HER1 receptor activation: influence of HER2 and HER3 expression. BMC Cancer, 2011, 11, 69.	1.1	9
2011	An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells. Molecular Cancer, 2011, 10, 135.	7.9	90
2012	Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers. Cell Communication and Signaling, 2011, 9, 13.	2.7	110
2013	Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer. Journal of Translational Medicine, 2011, 9, 133.	1.8	49

#	Article	IF	Citations
2014	Molecular interplay between leptin, insulin-like growth factor-1, and Î²-amyloid in organotypic slices from rabbit hippocampus. Molecular Neurodegeneration, 2011, 6, 41.	4.4	34
2015	Astrocyte elevated gene 1: biological functions and molecular mechanism in cancer and beyond. Cell and Bioscience, 2011, 1, 36.	2.1	36
2016	Cellular stress-induced up-regulation of FMRP promotes cell survival by modulating PI3K-Akt phosphorylation cascades. Journal of Biomedical Science, 2011, 18, 17.	2.6	26
2017	Neutrophils promote motility of cancer cells via a hyaluronanâ€mediated TLR4/PI3K activation loop. Journal of Pathology, 2011, 225, 438-447.	2.1	118
2018	Human prostate cancer xenografts in lit/lit mice exhibit reduced growth and androgenâ€independent progression. Prostate, 2011, 71, 525-537.	1.2	19
2019	Efficacy and comparative effectiveness of sirolimus as an anticancer drug. Laryngoscope, 2011, 121, 978-982.	1.1	13
2020	Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis. Molecular Carcinogenesis, 2011, 50, 264-279.	1.3	62
2021	Constitutive overexpression of Idâ€1 in mammary glands of transgenic mice results in precocious and increased formation of terminal end buds, enhanced alveologenesis, delayed involution. Journal of Cellular Physiology, 2011, 226, 1340-1352.	2.0	8
2022	Nanoscale Materials for Tackling Brain Cancer: Recent Progress and Outlook. Advanced Materials, 2011, 23, H136-50.	11.1	52
2023	MR evaluation of response to targeted treatment in cancer cells. NMR in Biomedicine, 2011, 24, 648-672.	1.6	58
2024	Synthesis of Oxacycles Employing the Oxaâ€Pictetâ€“Spengler Reaction: Recent Developments and New Prospects. European Journal of Organic Chemistry, 2011, 2011, 5195-5231.	1.2	95
2025	Activation of CD47 receptors causes proliferation of human astrocytoma but not normal astrocytes via an Aktâ€dependent pathway. Glia, 2011, 59, 308-319.	2.5	51
2026	Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosomes and Cancer, 2011, 50, 606-618.	1.5	90
2027	The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer, 2011, 117, 290-300.	2.0	48
2028	Alphaâ€fetoprotein: A new member of intracellular signal molecules in regulation of the PI3K/AKT signaling in human hepatoma cell lines. International Journal of Cancer, 2011, 128, 524-532.	2.3	99
2029	VEGFRâ€2 expression in carcinoid cancer cells and its role in tumor growth and metastasis. International Journal of Cancer, 2011, 128, 1045-1056.	2.3	66
2030	Phosphatidylinositolâ€3â€²â€kinase/AKT signaling is essential in synovial sarcoma. International Journal of Cancer, 2011, 129, 1564-1575.	2.3	47
2031	Comparison of intracellular signalling by insulin and the hypermitogenic AspB10 analogue in MCFâ€7 breast adenocarcinoma cells. Journal of Applied Toxicology, 2011, 31, 329-341.	1.4	16

#	Article	IF	Citations
2033	Smallâ€Moleculeâ€Based Nanoassemblies as Inducible Nanoprobes for Monitoring Dynamic Molecular Interactions Inside Live Cells. Angewandte Chemie - International Edition, 2011, 50, 8709-8713.	7.2	13
2034	Cytosolic phospholipase A2induction and prostaglandin E2release by interleukin-1Î² via the myeloid differentiation factor 88-dependent pathway and cooperation of p300, Akt, and NF-Î²B activity in human rheumatoid arthritis synovial fibroblasts. Arthritis and Rheumatism, 2011, 63, 2905-2917.	6.7	26
2035	Chemostatâ€based transcriptional analysis of growth rate change and BCLâ€2 overâ€expression in NS0 cells. Biotechnology and Bioengineering, 2011, 108, 1603-1615.	1.7	6
2036	Epigenomic reprogramming of the developing reproductive tract and disease susceptibility in adulthood. Birth Defects Research Part A: Clinical and Molecular Teratology, 2011, 91, 666-671.	1.6	36
2037	Targeting the AKT/GSK3Î²/Cyclin D1/Cdk4 Survival Signaling Pathway for Eradication of Tumor Radioresistance Acquired by Fractionated Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2011, 80, 540-548.	0.4	47
2038	Preparation and evaluation of trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors. 3-Hydroxyphenol analogues and bioisosteric replacements. Bioorganic and Medicinal Chemistry, 2011, 19, 836-851.	1.4	17
2039	Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma. Clinical Cancer Research, 2011, 17, 2373-2384.	3.2	104
2040	Regulation of PI 3-K, PTEN, p53, and mTOR in Malignant and Benign Tumors Deficient in Tuberin. Genes and Cancer, 2011, 2, 1051-1060.	0.6	20
2041	Role of Sp Transcription Factors in the Regulation of Cancer Cell Metabolism. Genes and Cancer, 2011, 2, 712-719.	0.6	46
2042	The Changing Role of Pathology in Breast Cancer Diagnosis and Treatment. Pathobiology, 2011, 78, 99-114.	1.9	101
2043	Nerve growth factor induces cord formation of mesenchymal stem cell by promoting proliferation and activating the PI3K/Akt signaling pathway. Acta Pharmacologica Sinica, 2011, 32, 1483-1490.	2.8	20
2044	Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?. Current Medicinal Chemistry, 2011, 18, 5528-5544.	1.2	51
2045	The Phosphoinositide 3-Kinase Signaling Pathway as a Therapeutic Target in Grade IV Brain Tumors. Current Cancer Drug Targets, 2011, 11, 894-918.	0.8	30
2046	Autophagy modulation for cancer therapy. Cancer Biology and Therapy, 2011, 11, 169-176.	1.5	130
2047	Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis. Modern Pathology, 2011, 24, 846-854.	2.9	26
2048	Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside. Expert Opinion on Investigational Drugs, 2011, 20, 1685-1705.	1.9	4
2049	Foxp3+IL-17+ T cells promote development of cancer-initiating cells in colorectal cancer. Journal of Leukocyte Biology, 2010, 89, 85-91.	1.5	120
2050	Cyclic Strain Delays the Expression of Tissue Factor Induced by Thrombin in Human Umbilical Vein Endothelial Cells. International Journal of Angiology, 2011, 20, 157-166.	0.2	0

#	Article	IF	Citations
2051	Protein Kinase B/AKT and Focal Adhesion Kinase: Two Close Signaling Partners in Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2011, 11, 993-1002.	0.9	20
2052	Evolving Molecular Mechanism-Based Strategies for Control of Hepatocellular Carcinoma. Current Medicinal Chemistry, 2011, 18, 4375-4388.	1.2	7
2054	The metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 1535-1546.	1.5	7
2055	RAS Interaction with PI3K: More Than Just Another Effector Pathway. Genes and Cancer, 2011, 2, 261-274.	0.6	580
2056	Targeted Therapies for Lung Cancer. Cancer Journal (Sudbury, Mass), 2011, 17, 512-527.	1.0	91
2057	Novel function of keratins 5 and 14 in proliferation and differentiation of stratified epithelial cells. Molecular Biology of the Cell, 2011, 22, 4068-4078.	0.9	241
2058	Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors. Clinical Cancer Research, 2011, 17, 871-879.	3.2	150
2059	Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocrine-Related Cancer, 2011, 18, R253-R276.	1.6	299
2060	Genetic Polymorphisms in Inflammation Pathway Genes and Prostate Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 923-933.	1.1	54
2061	Human Cytomegalovirus-Regulated Paxillin in Monocytes Links Cellular Pathogenic Motility to the Process of Viral Entry. Journal of Virology, 2011, 85, 1360-1369.	1.5	50
2062	Inhibiting the mTOR Pathway Synergistically Enhances Cytotoxicity in Ovarian Cancer Cells Induced by Etoposide through Upregulation of c-Jun. Clinical Cancer Research, 2011, 17, 4742-4750.	3.2	27
2063	mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling. Cancer Discovery, 2011, 1, 248-259.	7.7	385
2064	Resveratrol inhibits mTOR signaling by targeting DEPTOR. Communicative and Integrative Biology, 2011, 4, 382-384.	0.6	19
2065	High-Resolution Melting Analysis for Mutation Screening of RGSL1, RGS16, and RGS8 in Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 397-407.	1.1	12
2066	Melanoma update: diagnostic and prognostic factors that can effectively shape and personalize management. Biomarkers in Medicine, 2011, 5, 333-360.	0.6	6
2068	Combination of PI3K/mTOR Inhibitors: Antitumor Activity and Molecular Correlates. Cancer Research, 2011, 71, 4573-4584.	0.4	68
2069	The Tumor Suppressor Protein Menin Inhibits AKT Activation by Regulating Its Cellular Localization. Cancer Research, 2011, 71, 371-382.	0.4	95
2070	Downregulation of PTEN at Corneal Wound Sites Accelerates Wound Healing through Increased Cell Migration. , 2011, 52, 2272.		30

#	Article	IF	Citations
2071	PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer. Clinical Cancer Research, 2011, 17, 667-677.	3.2	180
2072	Epigenetic Silencing Mediated through Activated PI3K/AKT Signaling in Breast Cancer. Cancer Research, 2011, 71, 1752-1762.	0.4	56
2073	AKT Activation by Pdcd4 Knockdown Up-Regulates Cyclin D1 Expression and Promotes Cell Proliferation. Genes and Cancer, 2011, 2, 818-828.	0.6	43
2074	Thyroid Function and Growth Regulation under Normal and Abnormal Conditions. Journal of Thyroid Research, 2011, 2011, 1-2.	0.5	2
2075	Delay of cell cycle progression and induction of death of cancer cells on type I collagen fibrils. Connective Tissue Research, 2011, 52, 167-177.	1.1	10
2076	Deciphering Squamous Cell Carcinoma Using Multidimensional Genomic Approaches. Journal of Skin Cancer, 2011, 2011, 1-16.	0.5	9
2077	Relative Expression Levels Rather Than Specific Activity Plays the Major Role in DeterminingIn VivoAKT Isoform Substrate Specificity. Enzyme Research, 2011, 2011, 1-18.	1.8	16
2078	Myocardial injury after ischemia-reperfusion in mice deficient in Akt2 is associated with increased cardiac macrophage density. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 301, H1932-H1940.	1.5	30
2079	Small Molecule Inhibition of GDC-0449 Refractory Smoothened Mutants and Downstream Mechanisms of Drug Resistance. Cancer Research, 2011, 71, 435-444.	0.4	339
2080	Phytochemicals in Cancer Prevention. , 2011, , 2882-2885.		0
2081	Antitumor and anti-angiogenic activities of Scutellaria barbata extracts in vitro are partially mediated by inhibition of Akt/protein kinase B. Molecular Medicine Reports, 2012, 5, 788-92.	1.1	10
2082	In Situ Phosphorylation of Akt and ERK1/2 in Rat Mammary Gland, Colon, and Liver Following Treatment with Human Insulin and IGF-1. Toxicologic Pathology, 2011, 39, 623-640.	0.9	16
2083	Phosphoinositide-3-Kinase Inhibition Enhances Radiosensitization of Cervical Cancer In Vivo. International Journal of Gynecological Cancer, 2011, 21, 100-105.	1.2	24
2084	Interaction of Nectin-like Molecule 2 with Integrin Î±6Î²4 and Inhibition of Disassembly of Integrin Î±6Î²4 from Hemidesmosomes. Journal of Biological Chemistry, 2011, 286, 36667-36676.	1.6	35
2085	Pancreatic Tumor Suppression by Benzyl Isothiocyanate Is Associated with Inhibition of PI3K/AKT/FOXO Pathway. Clinical Cancer Research, 2011, 17, 1784-1795.	3.2	157
2086	The Actin-Binding Protein Girdin and Its Akt-Mediated Phosphorylation Regulate Neointima Formation After Vascular Injury. Circulation Research, 2011, 108, 1170-1179.	2.0	61
2087	Epithelial Phosphatidylinositol-3-Kinase Signaling Is Required for Î²-Catenin Activation and Host Defense against Citrobacter rodentium Infection. Infection and Immunity, 2011, 79, 1863-1872.	1.0	41
2088	Expression, signaling proficiency, and stimulatory function of the NKG2D lymphocyte receptor in human cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 4081-4086.	3.3	47

#	Article	IF	Citations
2089	Regulation of Nur77 expression by Î²â€catenin and its mitogenic effect in colon cancer cells. FASEB Journal, 2011, 25, 192-205.	0.2	105
2090	Molecular alterations associated with liver metastases development in colorectal cancer patients. British Journal of Cancer, 2011, 105, 281-287.	2.9	28
2091	Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells. British Journal of Cancer, 2011, 105, 513-522.	2.9	14
2092	Structured Feature Selection and Task Relationship Inference for Multi-task Learning. , 2011, , .		13
2093	EGFRâ€“PI3Kâ€“AKTâ€“mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Expert Opinion on Therapeutic Targets, 2011, 15, 63-74.	1.5	134
2094	Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomideâ€“CCI-779 Interaction via P-Glycoprotein. Journal of Clinical Oncology, 2011, 29, 3427-3434.	0.8	77
2096	FATP4 contributes as an enzyme to the basal and insulin-mediated fatty acid uptake of C₂C₁₂muscle cells. American Journal of Physiology - Endocrinology and Metabolism, 2011, 301, E785-E796.	1.8	29
2097	mTOR Inhibitors in Cancer Treatment. , 2011, , .		0
2098	Recent Advances in Molecular Diagnosis of Thyroid Cancer. Journal of Thyroid Research, 2011, 2011, 1-8.	0.5	13
2099	Enhanced Urinary Bladder, Liver and Colon Carcinogenesis in Zucker Diabetic Fatty Rats in a Multiorgan Carcinogenesis Bioassay: Evidence for Mechanisms Involving Activation of PI3K Signaling and Impairment of P53 on Urinary Bladder Carcinogenesis. Journal of Toxicologic Pathology, 2011, 24, 25-36.	0.3	12
2100	The Microenvironment and Molecular Biology of the Multiple Myeloma Tumor. Advances in Cancer Research, 2011, 110, 19-42.	1.9	61
2101	Targeted Therapy for Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: Can There Be Too Many Active Drugs?. Journal of Clinical Oncology, 2011, 29, 3111-3113.	0.8	3
2102	PDP-1 Links the TGF-Î² and IIS Pathways to Regulate Longevity, Development, and Metabolism. PLoS Genetics, 2011, 7, e1001377.	1.5	70
2103	SGK3 Is an Estrogen-Inducible Kinase Promoting Estrogen-Mediated Survival of Breast Cancer Cells. Molecular Endocrinology, 2011, 25, 72-82.	3.7	60
2104	Aberrant Signaling Pathways in Glioma. Cancers, 2011, 3, 3242-3278.	1.7	178
2105	Combination of Farnesyltransferase and Akt Inhibitors Is Synergistic in Breast Cancer Cells and Causes Significant Breast Tumor Regression in ErbB2 Transgenic Mice. Clinical Cancer Research, 2011, 17, 2852-2862.	3.2	55
2106	Intracellular signalling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary (CUP): a study of 100 CUP cases. Annals of Oncology, 2012, 23, 2725-2730.	0.6	16
2107	Inhibition of AKT2 Enhances Sensitivity to Gemcitabine via Regulating PUMA and NF-ÎºB Signaling Pathway in Human Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences, 2012, 13, 1186-1208.	1.8	33

#	Article	IF	Citations
2108	A pleckstrin homologyâ€•related domain in SHIP1 mediates membrane localization during FcÎ³ receptorâ€•induced phagocytosis. FASEB Journal, 2012, 26, 3163-3177.	0.2	28
2109	Oral infusion of pomegranate fruit extract inhibits prostate carcinogenesis in the TRAMP model. Carcinogenesis, 2012, 33, 644-651.	1.3	69
2110	Watching tumours gasp and die with MRI: the promise of hyperpolarised¹³C MR spectroscopic imaging. British Journal of Radiology, 2012, 85, 697-708.	1.0	31
2111	Computational Modeling of the Metabolic States Regulated by the Kinase Akt. Frontiers in Physiology, 2012, 3, 418.	1.3	20
2112	Design and Development of Degradable Polyethylenimines for Delivery of DNA and Small Interfering RNA: An Updated Review. ISRN Materials Science, 2012, 2012, 1-24.	1.0	25
2113	Quantitative Immunofluorescence Reveals the Signature of Active B-cell Receptor Signaling in Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2012, 18, 6122-6135.	3.2	48
2114	Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells. Cancer Biology and Therapy, 2012, 13, 1325-1338.	1.5	26
2115	Sarcospan-dependent Akt activation is required for utrophin expression and muscle regeneration. Journal of Cell Biology, 2012, 197, 1009-1027.	2.3	54
2116	Cigarette Smoke Induces Aberrant EGF Receptor Activation That Mediates Lung Cancer Development and Resistance to Tyrosine Kinase Inhibitors. Molecular Cancer Therapeutics, 2012, 11, 795-804.	1.9	79
2117	Involvement of Phosphoinositide 3-Kinase and PTEN Protein in Mechanism of Activation of TRPC6 Protein in Vascular Smooth Muscle Cells. Journal of Biological Chemistry, 2012, 287, 17672-17681.	1.6	40
2118	P90 RSK arranges Chk1 in the nucleus for monitoring of genomic integrity during cell proliferation. Molecular Biology of the Cell, 2012, 23, 1582-1592.	0.9	48
2119	Molecular targets and targeted therapeutics in endometrial cancer. Current Opinion in Oncology, 2012, 24, 554-563.	1.1	53
2120	Molecular Classification of Estrogen Receptor-positive/Luminal Breast Cancers. Advances in Anatomic Pathology, 2012, 19, 39-53.	2.4	68
2121	Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro-Oncology, 2012, 14, 819-829.	0.6	117
2122	Protein Kinase C Inhibitor AEB071 Targets Ocular Melanoma Harboring GNAQ Mutations via Effects on the PKC/Erk1/2 and PKC/NF-ÎºB Pathways. Molecular Cancer Therapeutics, 2012, 11, 1905-1914.	1.9	75
2123	An Introduction to Phosphoinositides. Current Topics in Microbiology and Immunology, 2012, 362, 1-42.	0.7	17
2124	Retinoblastoma and Phosphate and Tensin Homolog Tumor Suppressors: Impact on Ductal Carcinoma In Situ Progression. Journal of the National Cancer Institute, 2012, 104, 1825-1836.	3.0	24
2125	Linker for Activation of T-cell Family Member2 (LAT2) a Lipid Raft Adaptor Protein for AKT Signaling, Is an Early Mediator of Alkylphospholipid Anti-leukemic Activity. Molecular and Cellular Proteomics, 2012, 11, 1898-1912.	2.5	24

#	Article	IF	Citations
2126	Mice Expressing Activated PI3K Rapidly Develop Advanced Colon Cancer. Cancer Research, 2012, 72, 2931-2936.	0.4	52
2127	Specific delivery of kinase inhibitors in nonmalignant and malignant diseases. Expert Opinion on Drug Delivery, 2012, 9, 59-70.	2.4	5
2128	Molecular Link Mechanisms between Inflammation and Cancer. Current Pharmaceutical Design, 2012, 18, 3831-3852.	0.9	344
2129	Pitfalls in Lung Cancer Molecular Pathology: How to Limit them in Routine Practice?. Current Medicinal Chemistry, 2012, 19, 2638-2651.	1.2	28
2130	Perifosine induces protective autophagy and upregulation of ATG5 in human chronic myelogenous leukemia cells in vitro. Acta Pharmacologica Sinica, 2012, 33, 542-550.	2.8	41
2131	Phosphorylation is the switch that turns PEA-15 from tumor suppressor to tumor promoter. Small GTPases, 2012, 3, 173-177.	0.7	36
2132	Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma. Modern Pathology, 2012, 25, 212-221.	2.9	81
2133	The Regulation of Multiple p53 Stress Responses is Mediated through MDM2. Genes and Cancer, 2012, 3, 199-208.	0.6	128
2134	Targeted Therapy for Brain Tumours: Role of PARP Inhibitors. Current Cancer Drug Targets, 2012, 12, 218-236.	0.8	23
2135	HER2-Akt signaling in regulating COP9 signalsome subunit 6 and p53. Cell Cycle, 2012, 11, 4181-4190.	1.3	37
2136	Identification of inositol polyphosphate 4-phosphatase type II as a novel tumor resistance biomarker in human laryngeal cancer HEp-2 cells. Cancer Biology and Therapy, 2012, 13, 1307-1318.	1.5	21
2137	The roles of REIC gene and its encoding product in gastric carcinoma. Cell Cycle, 2012, 11, 1414-1431.	1.3	20
2138	Molecular Pathogenesis of Granulosa Cell Tumors of the Ovary. Endocrine Reviews, 2012, 33, 109-144.	8.9	164
2139	Girdin maintains the stemness of glioblastoma stem cells. Oncogene, 2012, 31, 2715-2724.	2.6	67
2140	Targeting the PI3K pathway for cancer therapy. Future Medicinal Chemistry, 2012, 4, 1153-1169.	1.1	53
2141	Dyslipidemia, statins and prostate cancer. Expert Review of Anticancer Therapy, 2012, 12, 981-990.	1.1	9
2142	Physical Activity as a Standard Cancer Treatment. Journal of the National Cancer Institute, 2012, 104, 797-799.	3.0	15
2143	The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer. Clinical Cancer Research, 2012, 18, 2316-2325.	3.2	382

#	Article	IF	Citations
2144	PI3K/Akt signalling is required for the attachment and spreading, and growth in vivo of metastatic scirrhous gastric carcinoma. British Journal of Cancer, 2012, 106, 1535-1542.	2.9	41
2145	The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells. Oncogene, 2012, 31, 2049-2061.	2.6	65
2146	Inhibition of cell migration by PITENINs: the role of ARF6. Oncogene, 2012, 31, 4317-4332.	2.6	25
2147	Regulation of Airway and Alveolar Epithelial Cell Apoptosis by p53-Induced Plasminogen Activator Inhibitor-1 during Cigarette Smoke Exposure Injury. American Journal of Respiratory Cell and Molecular Biology, 2012, 47, 474-483.	1.4	39
2148	A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine. Journal of Clinical Oncology, 2012, 30, 3234-3241.	0.8	319
2149	Advances in Ovarian Cancer Management. , 2012, , .		1
2150	Evidence of aberrant DNA damage response signalling but normal rates of DNA repair in dividing lymphoblasts from patients with schizophrenia. World Journal of Biological Psychiatry, 2012, 13, 114-125.	1.3	23
2151	PI3Ksâ€”Drug Targets in Inflammation and Cancer. Sub-Cellular Biochemistry, 2012, 58, 111-181.	1.0	9
2152	Monitoring the development of xenograft triple-negative breast cancer models using diffusion-weighted magnetic resonance imaging. Experimental Biology and Medicine, 2012, 237, 1273-1280.	1.1	9
2153	Nuclear import of hTERT requires a bipartite nuclear localization signal mediated by Akt phosphorylation. Journal of Cell Science, 2012, 125, 2684-97.	1.2	81
2154	Killing of Kras-Mutant Colon Cancer Cells via Rac-Independent Actin Remodeling by the Î²GBP Cytokine, a Physiological PI3K Inhibitor Therapeutically Effective In Vivo. Molecular Cancer Therapeutics, 2012, 11, 1884-1893.	1.9	4
2155	TIEG1 Inhibits Breast Cancer Invasion and Metastasis by Inhibition of Epidermal Growth Factor Receptor (EGFR) Transcription and the EGFR Signaling Pathway. Molecular and Cellular Biology, 2012, 32, 50-63.	1.1	56
2156	Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway. Advances in Urology, 2012, 2012, 1-12.	0.6	14
2157	The essential role of PIM kinases in sarcoma growth and bone invasion. Carcinogenesis, 2012, 33, 1479-1486.	1.3	34
2158	Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2718-2723.	3.3	313
2159	Protein kinase N1, a cell inhibitor of Akt kinase, has a central role in quality control of germinal center formation. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 21022-21027.	3.3	26
2160	The Î²-Subunit of the SnRK1 Complex Is Phosphorylated by the Plant Cell Death Suppressor Adi3 Â Â Â. Plant Physiology, 2012, 159, 1277-1290.	2.3	35
2161	Haploinsufficiency of the genes encoding the tumor suppressor Pten predisposes zebrafish to hemangiosarcoma. DMM Disease Models and Mechanisms, 2012, 5, 241-247.	1.2	40

#	Article	IF	Citations
2162	Alpha-Crystallins and Tumorigenesis. Current Molecular Medicine, 2012, 12, 1164-1173.	0.6	22
2163	A Novel Tumor suppressor network in squamous malignancies. Scientific Reports, 2012, 2, 828.	1.6	11
2164	Epigenetic Deregulation of MicroRNAs: New Opportunities to Target Oncogenic Signaling Pathways in Hepatocellular Carcinoma. Current Pharmaceutical Design, 2012, 19, 1192-1200.	0.9	11
2165	TGF-Î²1 Signalling, Connecting Aberrant Inflammation and Colorectal Tumorigenesis. Current Pharmaceutical Design, 2012, 18, 3874-3888.	0.9	30
2166	Novel Targets and Derived Small Molecule Inhibitors in Multiple Myeloma. Current Cancer Drug Targets, 2012, 12, 797-813.	0.8	8
2167	Light Fluorous-Tagged Traceless One-Pot Synthesis of Benzimidazoles Facilitated by Microwave Irradiation. Combinatorial Chemistry and High Throughput Screening, 2012, 15, 411-417.	0.6	2
2168	Recent Developments in Targeted Therapies of the RAF-MEK and PI3KAKT Pathways in Cancer Treatment. Current Cancer Therapy Reviews, 2012, 8, 205-217.	0.2	0
2169	Phosphatidylinositol-3-kinase Î± catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours. Oncology Reports, 2012, 28, 1559-1566.	1.2	19
2170	An antitumor peptide from Musca domestica pupae (MATP) induces apoptosis in HepG2 cells through a JNK-mediated and Akt-mediated NF-ÎºB pathway. Anti-Cancer Drugs, 2012, 23, 827-835.	0.7	6
2171	Role of Oncogenic Pathways and KRAS/BRAF Mutations in the Behavior of Colon Adenocarcinoma in Renal Transplant Patients. Transplantation, 2012, 93, 509-517.	0.5	7
2172	RL71, a second-generation curcumin analog, induces apoptosis and downregulates Akt in ER-negative breast cancer cells. International Journal of Oncology, 2012, 41, 1119-1127.	1.4	24
2173	Targeting PI3 Kinase/AKT/mTOR Signaling in Cancer. Critical Reviews in Oncogenesis, 2012, 17, 69-95.	0.2	204
2174	Cerulenin-induced apoptosis is mediated by disrupting the interaction between AIF and hexokinase II. International Journal of Oncology, 2012, 40, 1949-56.	1.4	6
2175	Antiproliferative effect of oleuropein in prostate cell lines. International Journal of Oncology, 2012, 41, 31-8.	1.4	54
2176	Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-ÎºB pathways. Oncology Reports, 2012, 28, 501-510.	1.2	83
2177	Molecular pathogenesis of Waldenstrom's macroglobulinemia. Haematologica, 2012, 97, 1281-1290.	1.7	35
2178	RL66 a second-generation curcumin analog has potent in vivo and in vitro anticancer activity in ER-negative breast cancer models. International Journal of Oncology, 2012, 41, 1723-1732.	1.4	23
2179	Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. International Journal of Oncology, 2012, 41, 1204-1212.	1.4	20

#	Article	IF	Citations
2180	Therapeutic strategies for head and neck cancer based on p53 status. Experimental and Therapeutic Medicine, 2012, 3, 585-591.	0.8	7
2181	The heat shock protein 90 inhibitor SNX-2112 inhibits B16 melanoma cell growth in vitro and in vivo. Oncology Reports, 2012, 27, 1904-10.	1.2	21
2182	Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies. Future Oncology, 2012, 8, 273-292.	1.1	36
2183	Attractor Landscape Analysis Reveals Feedback Loops in the p53 Network That Control the Cellular Response to DNA Damage. Science Signaling, 2012, 5, ra83.	1.6	146
2184	Combined targeting of <scp>MEK</scp>/<scp>MAPK</scp> and <scp>PI</scp>3<scp>K</scp>/<scp>A</scp>kt signalling in multiple myeloma. British Journal of Haematology, 2012, 159, 430-440.	1.2	41
2185	<scp>SB</scp>365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of <scp>PI</scp>3<scp>K</scp>/<scp>A</scp>kt/<scp>mTOR</scp> signaling pathway. Cancer Science, 2012, 103, 1929-1937.	1.7	47
2186	Positive feedback regulation of Aktâ€FMRP pathway protects neurons from cell death. Journal of Neurochemistry, 2012, 123, 226-238.	2.1	19
2187	Glioblastoma Multiforme. Hematology/Oncology Clinics of North America, 2012, 26, 825-853.	0.9	125
2188	Quinazoline derivatives as potential anticancer agents: a patent review (2007 â€“ 2010). Expert Opinion on Therapeutic Patents, 2012, 22, 223-252.	2.4	104
2189	Inhibition of p85, the non-catalytic subunit of phosphatidylinositol 3-kinase, exerts potent antitumor activity in human breast cancer cells. Cell Death and Disease, 2012, 3, e440-e440.	2.7	10
2190	Molecular Pathogenesis of Melanoma: Established and Novel Pathways. , 2012, , 19-37.		0
2191	Binding Selectivity Studies of Phosphoinositide 3-Kinases Using Free Energy Calculations. Journal of Chemical Information and Modeling, 2012, 52, 3213-3224.	2.5	28
2192	Synthesis and antitumor activity of inositol phosphotriester analogues. Organic and Biomolecular Chemistry, 2012, 10, 3642.	1.5	13
2193	Environmental factors in causing human cancers: emphasis on tumorigenesis. Tumor Biology, 2012, 33, 1265-1274.	0.8	60
2194	Oncogenes in Cell Survival and Cell Death. Cold Spring Harbor Perspectives in Biology, 2012, 4, a009829-a009829.	2.3	99
2195	Simvastatin Inhibits Glucoseâ€Stimulated Vascular Smooth Muscle Cell Migration Involving Increased Expression of RhoB and a Block of Ras/Akt Signal. Cardiovascular Therapeutics, 2012, 30, 75-84.	1.1	20
2196	AKT1 polymorphisms and survival of early stage nonâ€small cell lung cancer. Journal of Surgical Oncology, 2012, 105, 167-174.	0.8	40
2197	Anti-leukemic effect of 2-pyrone derivatives via MAPK and PI3 kinase pathways. Investigational New Drugs, 2012, 30, 2284-2293.	1.2	9

#	Article	IF	Citations
2198	The Protein Kinase C Inhibitor Enzastaurin Exhibits Antitumor Activity against Uveal Melanoma. PLoS ONE, 2012, 7, e29622.	1.1	60
2199	Clinical trials and future potential of targeted therapy for ovarian cancer. International Journal of Clinical Oncology, 2012, 17, 430-440.	1.0	36
2200	Balance between apoptosis or survival induced by changes in extracellular-matrix composition in human mesangial cells: a key role for ILK-NFÎºB pathway. Apoptosis: an International Journal on Programmed Cell Death, 2012, 17, 1261-1274.	2.2	18
2201	Plausible role of naringenin against cerebrally implanted C6 glioma cells in rats. Molecular and Cellular Biochemistry, 2013, 375, 171-8.	1.4	11
2202	Selective small molecule inhibitors of p110Î± and Î´ isoforms of phosphoinosityl-3-kinase are cytotoxic to human acute myeloid leukemia progenitors. Experimental Hematology, 2012, 40, 922-933.	0.2	7
2203	NOK/STYK1 interacts with GSKâ€3Î² and mediates Ser9 phosphorylation through activated Akt. FEBS Letters, 2012, 586, 3787-3792.	1.3	25
2204	Nicotine stimulates proliferation and inhibits apoptosis in colon cancer cell lines through activation of survival pathways. Journal of Surgical Research, 2012, 178, 233-241.	0.8	73
2205	Gambogic acid inhibits TNF-Î±-induced invasion of human prostate cancer PC3 cells in vitro through PI3K/Akt and NF-ÎºB signaling pathways. Acta Pharmacologica Sinica, 2012, 33, 531-541.	2.8	62
2206	Chemotherapy and autophagy-mediated cell death in pancreatic cancer cells. Pancreatology, 2012, 12, 1-7.	0.5	23
2207	TGF-Î²/BMP Pathways and the Podocyte. Seminars in Nephrology, 2012, 32, 368-376.	0.6	19
2208	EGFR and c-Met Cross Talk in Glioblastoma and Its Regulation by Human Cord Blood Stem Cells. Translational Oncology, 2012, 5, 379-IN18.	1.7	38
2209	Identification of Druggable Targets for Radiation Mitigation Using a Small Interfering RNA Screening Assay. Radiation Research, 2012, 178, 150.	0.7	12
2210	Akt/PKB-Mediated Phosphorylation of Twist1 Promotes Tumor Metastasis via Mediating Cross-Talk between PI3K/Akt and TGF-Î² Signaling Axes. Cancer Discovery, 2012, 2, 248-259.	7.7	182
2211	Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer. Therapeutic Advances in Gastroenterology, 2012, 5, 319-337.	1.4	24
2212	Hepatic Vitamin A Preloading Reduces Colorectal Cancer Metastatic Multiplicity in a Mouse Xenograft Model. Nutrition and Cancer, 2012, 64, 732-740.	0.9	10
2213	Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511. Journal of Medicinal Chemistry, 2012, 55, 7796-7816.	2.9	42
2214	Current and Future Management Strategies for Relapsed or Progressive Hepatoblastoma. Paediatric Drugs, 2012, 14, 221-232.	1.3	20
2215	Signaling regulation of fetoplacental angiogenesis. Journal of Endocrinology, 2012, 212, 243-255.	1.2	48

#	Article	IF	Citations
2216	Discovery of a Novel Series of Potent and Orally Bioavailable Phosphoinositide 3-Kinase Î³ Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 5467-5482.	2.9	42
2217	Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors. Journal of Medicinal Chemistry, 2012, 55, 8110-8127.	2.9	149
2218	Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors. Molecular BioSystems, 2012, 8, 2645.	2.9	11
2219	Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. British Journal of Cancer, 2012, 107, 1093-1099.	2.9	116
2220	Activation of the AKT/cyclin D1/Cdk4 survival signaling pathway in radioresistant cancer stem cells. Oncogenesis, 2012, 1, e12-e12.	2.1	71
2221	Inhibition of nuclear factor kappa B activation reduces Coxsackievirus B3 replication in lymphoid cells. Virus Research, 2012, 163, 495-502.	1.1	3
2222	In vitro mechanisms involved in the regulation of cell survival by lithium chloride and IGF-1 in human hormone-dependent breast cancer cells (MCF-7). Toxicology Letters, 2012, 214, 182-191.	0.4	12
2223	S-Allylcysteine inhibits tumour progression and the epithelialâ€“mesenchymal transition in a mouse xenograft model of oral cancer. British Journal of Nutrition, 2012, 108, 28-38.	1.2	29
2224	Unraveling the Complex Regulatory Relationships Between Metabolism and Signal Transduction in Cancer. Advances in Experimental Medicine and Biology, 2012, 736, 179-189.	0.8	8
2225	Molecular-targeted therapies for ovarian cancer: prospects for the future. International Journal of Clinical Oncology, 2012, 17, 424-429.	1.0	28
2226	Stearoyl-CoA desaturase activity modulates the activation of epidermal growth factor receptor in human lung cancer cells. Experimental Biology and Medicine, 2012, 237, 1007-1017.	1.1	46
2227	Targeting the PI3K/mTOR Axis, Alone and in Combination with Autophagy Blockade, for the Treatment of Malignant Peripheral Nerve Sheath Tumors. Molecular Cancer Therapeutics, 2012, 11, 1758-1769.	1.9	41
2228	Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway. Carcinogenesis, 2012, 33, 2391-2397.	1.3	161
2229	Ack1 Tyrosine Kinase Activation Correlates with Pancreatic Cancer Progression. American Journal of Pathology, 2012, 180, 1386-1393.	1.9	64
2230	Inhibition of c-Met activation sensitizes osteosarcoma cells to cisplatin via suppression of the PI3Kâ€“Akt signaling. Archives of Biochemistry and Biophysics, 2012, 526, 38-43.	1.4	38
2231	Prediction in the face of uncertainty: A Monte Carlo-based approach for systems biology of cancer treatment. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2012, 746, 163-170.	0.9	29
2232	Focal adhesion kinase regulation of neovascularization. Microvascular Research, 2012, 83, 64-70.	1.1	24
2233	PIK3CA mutations in endometrial carcinomas in Chinese women: phosphatidylinositol 3â€²-kinase pathway alterations might be associated with favorable prognosis. Human Pathology, 2012, 43, 1197-1205.	1.1	9

#	Article	IF	Citations
2234	Wogonin induces apoptosis and down-regulates survivin in human breast cancer MCF-7 cells by modulating PI3Kâ€“AKT pathway. International Immunopharmacology, 2012, 12, 334-341.	1.7	89
2235	Oleanane triterpenoid CDDO-Me inhibits Akt activity without affecting PDK1 kinase or PP2A phosphatase activity in cancer cells. Biochemical and Biophysical Research Communications, 2012, 417, 570-575.	1.0	25
2236	Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation. Biochemical and Biophysical Research Communications, 2012, 419, 584-589.	1.0	29
2237	Mechanism of apoptotosis induced by ortho-topolin riboside in human hepatoma cell line SMMC-7721. Food and Chemical Toxicology, 2012, 50, 1962-1968.	1.8	12
2238	miRâ€376a suppresses proliferation and induces apoptosis in hepatocellular carcinoma. FEBS Letters, 2012, 586, 2396-2403.	1.3	70
2239	Tyrosines 303/343/353 within the Sprouty-related domain of Spred2 are essential for its interaction with p85 and inhibitory effect on Ras/ERK activation. International Journal of Biochemistry and Cell Biology, 2012, 44, 748-758.	1.2	9
2240	Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Kl± and mTOR. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5098-5103.	1.0	23
2241	Synthesis and structureâ€“activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5714-5720.	1.0	24
2242	SNX-2112, an Hsp90 inhibitor, induces apoptosis and autophagy via degradation of Hsp90 client proteins in human melanoma A-375 cells. Cancer Letters, 2012, 318, 180-188.	3.2	64
2243	Autophagy in tumorigenesis and cancer therapy: Dr. Jekyll or Mr. Hyde?. Cancer Letters, 2012, 323, 115-127.	3.2	115
2244	Inhibition of DNA-dependent protein kinase promotes ultrasound-induced cell death including apoptosis in human leukemia cells. Cancer Letters, 2012, 322, 107-112.	3.2	18
2245	ESM-1 regulates cell growth and metastatic process through activation of NF-ÎºB in colorectal cancer. Cellular Signalling, 2012, 24, 1940-1949.	1.7	69
2246	Oncogenic PI3K Mutations Lead to NF-ÎºBâ€“Dependent Cytokine Expression following Growth Factor Deprivation. Cancer Research, 2012, 72, 3260-3269.	0.4	74
2247	Akt Phosphorylates the Transcriptional Repressor Bmi1 to Block Its Effects on the Tumor-Suppressing Ink4a-Arf Locus. Science Signaling, 2012, 5, ra77.	1.6	53
2248	PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacologica Sinica, 2012, 33, 1441-1458.	2.8	141
2249	Oncogene-specific formation of chemoresistant murine hepatic cancer stem cells. Hepatology, 2012, 56, 1331-1341.	3.6	87
2250	Identifying dysregulated pathways in cancers from pathway interaction networks. BMC Bioinformatics, 2012, 13, 126.	1.2	109
2251	Transforming growth factor-Î² suppresses metastasis in a subset of human colon carcinoma cells. BMC Cancer, 2012, 12, 221.	1.1	16

#	Article	IF	Citations
2252	Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck. BMC Cancer, 2012, 12, 463.	1.1	58
2253	Role of hepatitis B virus X protein in regulating LIM and SH3 protein 1 (LASP-1) expression to mediate proliferation and migration of hepatoma cells. Virology Journal, 2012, 9, 163.	1.4	36
2254	GPR30 regulates the EGFR-Akt cascade and predicts lower survival in patients with ovarian cancer. Journal of Ovarian Research, 2012, 5, 35.	1.3	65
2255	Mathematical Investigation of How Oncogenic Ras Mutants Promote Ras Signaling. Methods in Molecular Biology, 2012, 880, 69-85.	0.4	13
2256	The Role of Protein Phosphorylation in Therapy Resistance and Disease Progression in Chronic Myelogenous Leukemia. Progress in Molecular Biology and Translational Science, 2012, 106, 107-142.	0.9	8
2257	Establishment of phosphatidylinositol 3â€kinase inhibitorâ€resistant cancer cell lines and therapeutic strategies for overcoming the resistance. Cancer Science, 2012, 103, 1955-1960.	1.7	17
2258	Hepatic stem cells and transforming growth factor Î² in hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 530-538.	8.2	124
2259	Fresh Surgical Specimens Yield Breast Stem/Progenitor Cells and Reveal Their Oncogenic Abnormalities. Annals of Surgical Oncology, 2012, 19, 527-535.	0.7	12
2260	Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum. Annals of the New York Academy of Sciences, 2012, 1271, 58-67.	1.8	76
2261	Abnormal development of NG2+PDGFR-Î±+ neural progenitor cells leads to neonatal hydrocephalus in a ciliopathy mouse model. Nature Medicine, 2012, 18, 1797-1804.	15.2	106
2262	Targeted Therapy for Gastric Adenocarcinoma. Advances in Pharmacology, 2012, 65, 437-470.	1.2	10
2263	Phosphoinositol 3-kinase, a novel target molecule for the inhibitory effects of juglone on TPA-induced cell transformation. International Journal of Molecular Medicine, 2012, 30, 8-14.	1.8	11
2264	Development and evaluation of PIK75 nanosuspension, a phosphatidylinositol-3-kinase inhibitor. European Journal of Pharmaceutical Sciences, 2012, 47, 824-833.	1.9	23
2265	Cancer Chemoprevention and Nutri-Epigenetics: State of the Art and Future Challenges. Topics in Current Chemistry, 2012, 329, 73-132.	4.0	143
2266	Main signal pathways underlying the molecular mechanisms of the antitumor effects of wogonin. Chinese Journal of Natural Medicines, 2012, 10, 401-407.	0.7	6
2267	Immunohistochemical Evaluation of AKT Protein Activation in Canine Mast Cell Tumours. Journal of Comparative Pathology, 2012, 147, 171-176.	0.1	8
2268	Prognostic markers in renal cell carcinoma: A focus on the â€˜mammalian target of rapamycinâ€™ pathway. Arab Journal of Urology Arab Association of Urology, 2012, 10, 110-117.	0.7	3
2269	miR-1297 mediates PTEN expression and contributes to cell progression in LSCC. Biochemical and Biophysical Research Communications, 2012, 427, 254-260.	1.0	51

#	Article	IF	Citations
2270	Absence of evidence for epidermal growth factor receptor and human homolog of the Kirsten rat sarcoma-2 virus oncogene mutations in breast cancer. Cancer Epidemiology, 2012, 36, 341-346.	0.8	8
2271	Gonadotropin signalling in epithelial ovarian cancer. Cancer Letters, 2012, 324, 152-159.	3.2	50
2272	A new protoapigenone analog RY10-4 induces apoptosis and suppresses invasion through the PI3K/Akt pathway in human breast cancer. Cancer Letters, 2012, 324, 210-220.	3.2	21
2273	Phosphorylated AKT Protein Is Overexpressed in Human Peripheral T-cell Lymphomas and Predicts Decreased Patient Survival. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 106-112.	0.2	13
2274	Neuroendocrine tumors: The age of targeted therapies. EndocrinologÃa Y NutriciÃ³n (English Edition), 2012, 59, 438-451.	0.5	2
2275	JNK-dependent Atg4 upregulation mediates asperphenamate derivative BBP-induced autophagy in MCF-7 cells. Toxicology and Applied Pharmacology, 2012, 263, 21-31.	1.3	47
2276	Expression of midkine in ameloblastomas and its correlation with clinicopathologic parameters. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2012, 114, 497-502.	0.2	8
2277	The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation. Oral Oncology, 2012, 48, 822-830.	0.8	51
2278	The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in mice. Pharmacological Research, 2012, 65, 365-371.	3.1	22
2279	Sulforaphane inhibits pancreatic cancer through disrupting Hsp90â€“p50Cdc37 complex and direct interactions with amino acids residues of Hsp90. Journal of Nutritional Biochemistry, 2012, 23, 1617-1626.	1.9	49
2280	Exploratory analysis of activation of PTENâ€“PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). Lung Cancer, 2012, 77, 192-198.	0.9	64
2281	Relaxin induces matrix-metalloproteinases-9 and -13 via RXFP1: Induction of MMP-9 involves the PI3K, ERK, Akt and PKC-Î¶ pathways. Molecular and Cellular Endocrinology, 2012, 363, 46-61.	1.6	62
2282	Reciprocal Regulation of Akt and Oct4 Promotes the Self-Renewal and Survival of Embryonal Carcinoma Cells. Molecular Cell, 2012, 48, 627-640.	4.5	155
2283	The Antitumor Effect of GDC-0941 Alone and in Combination with Rapamycin in Breast Cancer Cells. Chemotherapy, 2012, 58, 273-281.	0.8	7
2284	Synergism between carnosic acid and arsenic trioxide on induction of acute myeloid leukemia cell apoptosis is associated with modulation of PTEN/Akt signaling pathway. Chinese Journal of Integrative Medicine, 2012, 18, 934-941.	0.7	24
2285	The Role of the Insulin-like Growth Factor-1 Receptor (IGF-1R), Phosphatase and Tensin Homolog (PTEN), c-Met, and the PI3-Kinase Pathway in Colorectal Cancer. Current Colorectal Cancer Reports, 2012, 8, 243-253.	1.0	0
2286	PI3K/Akt/mTOR and Raf/MEK/ERK signaling pathways perturbations in non-functioning pituitary adenomas. Endocrine, 2012, 42, 285-291.	1.1	31
2287	3-Phosphoinositide-Dependent Kinase 1 Controls Breast Tumor Growth in a Kinase-Dependent but Akt-Independent Manner. Neoplasia, 2012, 14, 719-IN19.	2.3	57

#	Article	IF	Citations
2288	Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors. Translational Oncology, 2012, 5, 422-429.	1.7	26
2289	The Chalcone Flavokawain B Induces G₂/M Cell-Cycle Arrest and Apoptosis in Human Oral Carcinoma HSC-3 Cells through the Intracellular ROS Generation and Downregulation of the Akt/p38 MAPK Signaling Pathway. Journal of Agricultural and Food Chemistry, 2012, 60, 2385-2397.	2.4	97
2290	Novel Apoptotic Regulators in Carcinogenesis. , 2012, , .		4
2291	Heat Shock Protein 90B1 Plays an Oncogenic Role and is a Target of microRNA-223 in Human Osteosarcoma. Cellular Physiology and Biochemistry, 2012, 30, 1481-1490.	1.1	83
2292	The mTOR Signalling Pathway in Human Cancer. International Journal of Molecular Sciences, 2012, 13, 1886-1918.	1.8	662
2293	Effect of diallyl disulfide on insulin-like growth factor signaling molecules involved in cell survival and proliferation of human prostate cancer cells in vitro and in silico approach through docking analysis. Phytomedicine, 2012, 19, 912-923.	2.3	38
2295	Serous Effusions. , 2012, , .		9
2296	Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nature Communications, 2012, 3, 876.	5.8	307
2297	Phosphoinositides I: Enzymes of Synthesis and Degradation. Sub-Cellular Biochemistry, 2012, , .	1.0	6
2298	TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer. Oncogene, 2012, 31, 2389-2400.	2.6	164
2299	Therapeutic Efficacy of Silibinin on Human Neuroblastoma Cells: Akt and NF-Î¹B Expressions May Play an Important Role in Silibinin-Induced Response. Neurochemical Research, 2012, 37, 2053-2063.	1.6	16
2300	Prediction of functional phosphorylation sites by incorporating evolutionary information. Protein and Cell, 2012, 3, 675-690.	4.8	14
2301	Signaling Networks Associated with AKT Activation in Non-Small Cell Lung Cancer (NSCLC): New Insights on the Role of Phosphatydil-Inositol-3 kinase. PLoS ONE, 2012, 7, e30427.	1.1	119
2302	FOXO3 Is a Glucocorticoid Receptor Target and Regulates LKB1 and Its Own Expression Based on Cellular AMP Levels via a Positive Autoregulatory Loop. PLoS ONE, 2012, 7, e42166.	1.1	70
2303	XB130 Mediates Cancer Cell Proliferation and Survival through Multiple Signaling Events Downstream of Akt. PLoS ONE, 2012, 7, e43646.	1.1	36
2304	Regulation of Epidermal Growth Factor Receptor Signaling and Erlotinib Sensitivity in Head and Neck Cancer Cells by miR-7. PLoS ONE, 2012, 7, e47067.	1.1	68
2305	Apocrine-Eccrine Carcinomas: Molecular and Immunohistochemical Analyses. PLoS ONE, 2012, 7, e47290.	1.1	45
2306	Pleckstrin Homology Domain of Akt Kinase: A Proof of Principle for Highly Specific and Effective Non-Enzymatic Anti-Cancer Target. PLoS ONE, 2012, 7, e50424.	1.1	8

#	Article	IF	Citations
2307	Mutation and genomic amplification of the PIK3CA proto-oncogene in pituitary adenomas. Brazilian Journal of Medical and Biological Research, 2012, 45, 851-855.	0.7	33
2308	Targeting mTOR Pathways in Human Malignancies. Current Pharmaceutical Design, 2012, 18, 2766-2777.	0.9	99
2309	Dietary Agents in Cancer Chemoprevention and Treatment. Journal of Oncology, 2012, 2012, 1-2.	0.6	20
2310	Overexpression of S6 Kinase 1 in Brain Tumours Is Associated with Induction of Hypoxia-Responsive Genes and Predicts Patients' Survival. Journal of Oncology, 2012, 2012, 1-10.	0.6	25
2311	Akt: A Double-Edged Sword in Cell Proliferation and Genome Stability. Journal of Oncology, 2012, 2012, 1-15.	0.6	224
2312	Sensitization of Cervical Cancer Cells to Cisplatin by Genistein: The Role of NFB and Akt/mTOR Signaling Pathways. Journal of Oncology, 2012, 2012, 1-6.	0.6	42
2313	PI3K Pathway in NSCLC. Frontiers in Oncology, 2012, 1, 55.	1.3	7
2314	PI3Kâ€“AKTâ€“mTOR inhibitors for the systemic treatment of endometrial cancer. Expert Review of Obstetrics and Gynecology, 2012, 7, 421-430.	0.4	1
2315	PTEN Gene: A Model for Genetic Diseases in Dermatology. Scientific World Journal, The, 2012, 2012, 1-8.	0.8	18
2316	The New Model of Carcinogenesis: The Cancer Stem Cell Hypothesis. , 0, , .		1
2317	Analysis of Cellular Signaling Events by Flow Cytometry. , 0, , .		0
2318	Cell Death and Cancer, Novel Therapeutic Strategies. , 0, , .		8
2319	Molecular biomarkers of glioblastoma: current targets and clinical implications. Current Biomarker Findings, 0, , 63.	0.4	4
2320	Treatment of Recurrent Metastatic Head and Neck Cancer: Focus on Cetuximab. Clinical Medicine Insights Ear, Nose and Throat, 2012, 5, CMENT.S5129.	1.5	17
2321	Cetuximab and biomarkers in non-small-cell lung carcinoma. Biologics: Targets and Therapy, 2012, 6, 221.	3.0	10
2322	Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine. OncoTargets and Therapy, 2012, 5, 21.	1.0	15
2323	The Gain of Function of p53 Mutant p53S in Promoting Tumorigenesis by Cross-talking with H-RasV12. International Journal of Biological Sciences, 2012, 8, 596-605.	2.6	21
2324	Dietary Phenolic Acids Act as Effective Antioxidants in Membrane Models and in Cultured Cells, Exhibiting Proapoptotic Effects in Leukaemia Cells. Oxidative Medicine and Cellular Longevity, 2012, 2012, 1-12.	1.9	43

#	Article	IF	Citations
2325	Multiple Signaling Molecules are Involved in Expression of CCL2 and IL-1Î² in Response to FSL-1, a Toll-Like Receptor 6 Agonist, in Macrophages. Korean Journal of Physiology and Pharmacology, 2012, 16, 447.	0.6	6
2326	Small molecules targeting phosphoinositide 3-kinases. MedChemComm, 2012, 3, 1337.	3.5	54
2327	Cadherin switch from E- to N-cadherin in melanoma progression is regulated by the PI3K/PTEN pathway through Twist and Snail. British Journal of Dermatology, 2012, 166, 1184-1197.	1.4	100
2328	Overexpression of RhoGDI2 Correlates with Tumor Progression and Poor Prognosis in Colorectal Carcinoma. Annals of Surgical Oncology, 2012, 19, 145-153.	0.7	17
2329	Negative Feedback and Adaptive Resistance to the Targeted Therapy of Cancer. Cancer Discovery, 2012, 2, 311-319.	7.7	188
2330	Curcumin potentiates antitumor activity of<scp>l</scp>-asparaginase via inhibition of the AKT signaling pathway in acute lymphoblastic leukemia. Leukemia and Lymphoma, 2012, 53, 1376-1382.	0.6	26
2331	A Novel cyano derivative of 11â€Ketoâ€Îî²â€Boswellic acid causes apoptotic death by disrupting PI3K/AKT/Hspâ€90 cascade, mitochondrial integrity, and other cell survival signaling events in HLâ€60 cells. Molecular Carcinogenesis, 2012, 51, 679-695.	1.3	22
2332	The diagnostic and research applications of flow cytometry in cytopathology. Diagnostic Cytopathology, 2012, 40, 525-535.	0.5	10
2333	Differential effects of AKT1(p.E17K) expression on human mammary luminal epithelial and myoepithelial cells. Human Mutation, 2012, 33, 1216-1227.	1.1	14
2334	Oncogenic PIK3CA mutations in colorectal cancers and polyps. International Journal of Cancer, 2012, 131, 813-820.	2.3	73
2335	Î±â€Tocopheryloxyacetic acid is superior to Î±â€tocopheryl succinate in suppressing HER2â€high breast carcinomas due to its higher stability. International Journal of Cancer, 2012, 131, 1052-1058.	2.3	22
2336	Colorectal serrated adenocarcinoma shows a different profile of oncogene mutations, MSI status and DNA repair protein expression compared to conventional and sporadic MSIâ€H carcinomas. International Journal of Cancer, 2012, 131, 1790-1799.	2.3	44
2337	Insulin-Like Growth Factors and Insulin: At the Crossroad Between Tumor Development and Longevity. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2012, 67A, 640-651.	1.7	37
2338	Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochemical Society Transactions, 2012, 40, 139-146.	1.6	385
2339	Staying alive. Cell Cycle, 2012, 11, 1680-1696.	1.3	211
2340	Role of intracellular tyrosines in activating KIT-induced myeloproliferative disease. Leukemia, 2012, 26, 1499-1506.	3.3	12
2341	Alteration in methylation pattern of oncogene Akt1 promoter region in bladder cancer. Molecular Biology Reports, 2012, 39, 5631-5636.	1.0	11
2342	Combined effect of sCD40L and PI3K siRNA on transplanted tumours growth and microenvironment in nude mice with gastric cancer. Molecular Biology Reports, 2012, 39, 8755-8761.	1.0	7

#	Article	IF	Citations
2343	Systemic rapamycin alone may not be a treatment option for malignant glioma: evidence from an in vivo study. Journal of Neuro-Oncology, 2012, 108, 53-58.	1.4	6
2344	Isobavachalcone: An overview. Chinese Journal of Integrative Medicine, 2012, 18, 543-547.	0.7	80
2345	Molecular Therapies for Tuberous Sclerosis and Neurofibromatosis. Current Neurology and Neuroscience Reports, 2012, 12, 294-301.	2.0	48
2346	Differential DNA Methylation Status Between Human Preadipocytes and Mature Adipocytes. Cell Biochemistry and Biophysics, 2012, 63, 1-15.	0.9	29
2347	Modern Trends into the Epidemiology and Screening of Ovarian Cancer. Genetic Substrate of the Sporadic Form. Pathology and Oncology Research, 2012, 18, 135-148.	0.9	9
2348	Ursolic acid-induced apoptosis in K562 cells involving upregulation of PTEN gene expression and inactivation of the PI3K/Akt pathway. Archives of Pharmacal Research, 2012, 35, 543-548.	2.7	34
2349	Roles of the PI3K/Akt pathway and autophagy in TLR3 signaling-induced apoptosis and growth arrest of human prostate cancer cells. Cancer Immunology, Immunotherapy, 2012, 61, 667-676.	2.0	80
2350	USP1 regulates AKT phosphorylation by modulating the stability of PHLPP1 in lung cancer cells. Journal of Cancer Research and Clinical Oncology, 2012, 138, 1231-1238.	1.2	37
2351	Characterization of molecular recognition of Phosphoinositide-3-kinase Î± inhibitor through molecular dynamics simulation. Journal of Molecular Modeling, 2012, 18, 1907-1916.	0.8	9
2352	Carnosic acid modulates Akt/IKK/NF-ÎºB signaling by PP2A and induces intrinsic and extrinsic pathway mediated apoptosis in human prostate carcinoma PC-3 cells. Apoptosis: an International Journal on Programmed Cell Death, 2012, 17, 735-747.	2.2	114
2353	Neuroglobin attenuates Alzheimerâ€like tau hyperphosphorylation by activating Akt signaling. Journal of Neurochemistry, 2012, 120, 157-164.	2.1	64
2354	Ursolic acid induces apoptosis in human leukaemia cells and exhibits antiâ€leukaemic activity in nude mice through the PKB pathway. British Journal of Pharmacology, 2012, 165, 1813-1826.	2.7	53
2355	Growth hormone modulation of EGF-induced PI3K-Akt pathway in mice liver. Cellular Signalling, 2012, 24, 514-523.	1.7	34
2356	Akt2 inhibits the activation of NFAT in lymphocytes by modulating calcium release from intracellular stores. Cellular Signalling, 2012, 24, 1064-1073.	1.7	12
2357	14â€3â€3Ïƒ regulation by p53 mediates a chemotherapy response to 5â€fluorouracil in MCFâ€7 breast cancer cells via Akt inactivation. FEBS Letters, 2012, 586, 163-168.	1.3	19
2358	Expression screening of 17q12â€“21 amplicon reveals GRB7 as an ERBB2â€dependent oncogene. FEBS Letters, 2012, 586, 1708-1714.	1.3	23
2359	Tehranolide inhibits proliferation of MCF-7 human breast cancer cells by inducing G0/G1 arrest and apoptosis. Free Radical Biology and Medicine, 2012, 52, 1987-1999.	1.3	42
2360	MAD1 and its life as a MYC antagonist: An update. European Journal of Cell Biology, 2012, 91, 506-514.	1.6	36

#	Article	IF	Citations
2361	Synthesis and biological evaluation of cyclopentane-linked alkyl phosphocholines as potential anticancer agents that act by inhibiting Akt phosphorylation. European Journal of Medicinal Chemistry, 2012, 47, 485-492.	2.6	19
2362	Autophagy inhibition enhances ursolic acid-induced apoptosis in PC3 cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2012, 1823, 451-457.	1.9	86
2363	Prolactin and epidermal growth factor stimulate adipophilin synthesis in HC11 mouse mammary epithelial cells via the PI3-kinase/Akt/mTOR pathway. Biochimica Et Biophysica Acta - Molecular Cell Research, 2012, 1823, 987-996.	1.9	28
2364	Skp2: A novel potential therapeutic target for prostate cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1825, 11-17.	3.3	81
2365	Synergistic effects of Akt1 shRNA and paclitaxel-incorporated conjugated linoleic acid-coupled poloxamer thermosensitive hydrogel on breast cancer. Biomaterials, 2012, 33, 2272-2281.	5.7	42
2366	Computational model of EGFR and IGF1R pathways in lung cancer: A Systems Biology approach for Translational Oncology. Biotechnology Advances, 2012, 30, 142-153.	6.0	34
2367	Imidazo[1,2-a]pyrazines as novel PI3K inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1874-1878.	1.0	29
2368	Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2283-2286.	1.0	22
2369	2-Anilino-4-aryl-8H-purine derivatives as inhibitors of PDK1. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2880-2884.	1.0	9
2370	Pyrazolopyrimidines as dual Akt/p70S6K inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2693-2697.	1.0	22
2371	Identification of ETP-46321, a potent and orally bioavailable PI3K Î±, Î´ inhibitor. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3460-3466.	1.0	24
2372	Thieno[3,2-d]pyrimidin-4(3H)-one derivatives as PDK1 inhibitors discovered by fragment-based screening. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4023-4027.	1.0	8
2373	Cyclic diâ€nucleotides: new era for small molecules as adjuvants. Microbial Biotechnology, 2012, 5, 168-176.	2.0	44
2374	Post-translational modifications of TRF1 and TRF2 and their roles in telomere maintenance. Mechanisms of Ageing and Development, 2012, 133, 421-434.	2.2	55
2375	Relationship between epidermal growth factor receptor gene copy number and protein expression in oral cavity squamous cell carcinoma. Oral Oncology, 2012, 48, 67-72.	0.8	39
2376	Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib. Experimental Cell Research, 2012, 318, 641-652.	1.2	11
2377	PTEN regulates apoptotic cell death through PI3-K/Akt/GSK3Î² signaling pathway in DMH induced early colon carcinogenesis in rat. Experimental and Molecular Pathology, 2012, 93, 135-146.	0.9	32
2378	PTEN in colorectal cancer: a report on two Cowden syndrome patients. Clinical Genetics, 2012, 81, 555-562.	1.0	13

#	Article	IF	Citations
2379	Targeted therapy of hepatocellular carcinoma: Present and future. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 862-872.	1.4	72
2380	Targeting Gene-Viro-Therapy with AFP driving Apoptin gene shows potent antitumor effect in hepatocarcinoma. Journal of Biomedical Science, 2012, 19, 20.	2.6	22
2381	Fascin overexpression promotes neoplastic progression in oral squamous cell carcinoma. BMC Cancer, 2012, 12, 32.	1.1	65
2382	Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer. BMC Cancer, 2012, 12, 50.	1.1	115
2383	Hepatitis C virus to hepatocellular carcinoma. Infectious Agents and Cancer, 2012, 7, 2.	1.2	29
2384	Regulation of cigarette smokeâ€mediated mucin expression by hypoxiaâ€inducible factorâ€1 Î± via epidermal growth factor receptorâ€mediated signaling pathways. Journal of Applied Toxicology, 2012, 32, 282-292.	1.4	40
2385	The efficacy of a novel, dual PI3K/mTOR inhibitor NVPâ€BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer. Journal of Cellular Biochemistry, 2012, 113, 784-791.	1.2	78
2386	AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene) Tj ETQq1 1 0.784314 rgBT /Ov 55, 833-845.	3.6	183
2387	Dual inhibition of phosphatidylinositol 3â€kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin. International Journal of Cancer, 2012, 130, 1695-1705.	2.3	144
2388	Metabolic consequences of treatment with AKT inhibitor perifosine in breast cancer cells. NMR in Biomedicine, 2012, 25, 379-388.	1.6	23
2389	ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective. Medicinal Research Reviews, 2012, 32, 166-215.	5.0	72
2390	Therapeutic potential of hyaluronan oligosaccharides for bone metastasis of breast cancer. Journal of Orthopaedic Research, 2012, 30, 662-672.	1.2	43
2391	Apigenin, a chemopreventive bioflavonoid, induces AMPâ€activated protein kinase activation in human keratinocytes. Molecular Carcinogenesis, 2012, 51, 268-279.	1.3	54
2392	USP22 Acts as an Oncogene by the Activation of BMI-1-Mediated INK4a/ARF Pathway and Akt Pathway. Cell Biochemistry and Biophysics, 2012, 62, 229-235.	0.9	70
2393	Activation of AKT is associated with metastasis of nasopharyngeal carcinoma. Tumor Biology, 2012, 33, 241-245.	0.8	27
2394	Deoxyactein Isolated from Cimicifuga racemosa protects osteoblastic MC3T3â€E1 cells against antimycin Aâ€induced cytotoxicity. Journal of Applied Toxicology, 2013, 33, 488-494.	1.4	15
2395	The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001. Molecular Carcinogenesis, 2013, 52, 446-458.	1.3	48
2396	Comparative proteomic analysis implicates eEF2 as a novel target of PI3KÎ³ in the MDA-MB-231 metastatic breast cancer cell line. Proteome Science, 2013, 11, 4.	0.7	6

#	Article	IF	Citations
2398	Nicotinamide N-methyltransferase overexpression is associated with Akt phosphorylation and indicates worse prognosis in patients with nasopharyngeal carcinoma. Tumor Biology, 2013, 34, 3923-3931.	0.8	35
2399	Report of the JDS/JCA Joint Committee on Diabetes and Cancer. Diabetology International, 2013, 4, 81-96.	0.7	32
2400	Cancer cachexia prevention via physical exercise: molecular mechanisms. Journal of Cachexia, Sarcopenia and Muscle, 2013, 4, 111-124.	2.9	149
2401	Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene. Human Cell, 2013, 26, 121-127.	1.2	12
2402	Stromal cell-derived factor-1 (SDF-1) enhances cells invasion by Î±vÎ²6 integrin-mediated signaling in ovarian cancer. Molecular and Cellular Biochemistry, 2013, 380, 177-184.	1.4	35
2403	Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma. Metabolic Brain Disease, 2013, 28, 355-366.	1.4	18
2404	T11TS impedes glioma angiogenesis by inhibiting VEGF signaling and pro-survival PI3K/Akt/eNOS pathway with concomitant upregulation of PTEN in brain endothelial cells. Journal of Neuro-Oncology, 2013, 113, 13-25.	1.4	27
2405	Slow Regulated Release of H2S Inhibits Oxidative Stress Induced Cell Death by Influencing Certain Key Signaling Molecules. Neurochemical Research, 2013, 38, 1375-1393.	1.6	31
2406	The PI(3)P interactome from a colon cancer cell. Journal of Proteomics, 2013, 82, 35-51.	1.2	27
2408	The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-Î²B and disruption of mitochondria-dependent pathways. Chemico-Biological Interactions, 2013, 205, 1-10.	1.7	37
2409	Mechanical and Chemical Signaling in Angiogenesis. Studies in Mechanobiology, Tissue Engineering and Biomaterials, 2013, , .	0.7	1
2410	Calix[6]arene bypasses human pancreatic cancer aggressiveness: Downregulation of receptor tyrosine kinases and induction of cell death by reticulum stress and autophagy. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 2856-2865.	1.9	30
2411	Investigating New Therapeutic Strategies Targeting Hyperinsulinemia's Mitogenic Effects in a Female Mouse Breast Cancer Model. Endocrinology, 2013, 154, 1701-1710.	1.4	30
2413	Induction of apoptotic death and retardation of neuronal differentiation of human neural stem cells by sodium arsenite treatment. Experimental Cell Research, 2013, 319, 875-887.	1.2	35
2414	Rapamycin Reverses Pulmonary Artery Smooth Muscle Cell Proliferation in Pulmonary Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2013, 48, 568-577.	1.4	127
2415	On the genetic control of planar growth during tissue morphogenesis in plants. Protoplasma, 2013, 250, 651-661.	1.0	10
2416	Resistance to Immunotherapeutic Antibodies in Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2013, , .	0.1	2
2417	Odontogenic ameloblast-associated protein (ODAM) inhibits growth and migration of human melanoma cells and elicits PTEN elevation and inactivation of PI3K/AKT signaling. BMC Cancer, 2013, 13, 227.	1.1	13

#	Article	IF	Citations
2418	TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages. BMC Cancer, 2013, 13, 140.	1.1	13
2419	Apigenin promotes apoptosis, inhibits invasion and induces cell cycle arrest of T24 human bladder cancer cells. Cancer Cell International, 2013, 13, 54.	1.8	65
2420	Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia. Molecular Cancer, 2013, 12, 46.	7.9	48
2421	Robustness of complex feedback systems: application to oncological biochemical networks. International Journal of Control, 2013, 86, 1304-1321.	1.2	6
2422	Molecular recognition with boronic acidsâ€"applications in chemical biology. Journal of Chemical Biology, 2013, 6, 161-174.	2.2	88
2423	Amyloid beta-induced glycogen synthase kinase 3Î² phosphorylated VDAC1 in Alzheimer's disease: Implications for synaptic dysfunction and neuronal damage. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1913-1921.	1.8	114
2424	Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. Biochimica Et Biophysica Acta: Reviews on Cancer, 2013, 1835, 46-60.	3.3	169
2425	AEG-1/MTDH/LYRIC. Advances in Cancer Research, 2013, 120, 75-111.	1.9	87
2426	Perifosine Induces Cell Apoptosis in Human Osteosarcoma Cells: New Implication for Osteosarcoma Therapy?. Cell Biochemistry and Biophysics, 2013, 65, 217-227.	0.9	47
2427	CoMFA and CoMSIA analysis of protein kinase B (PKBÎ²) inhibitors using various alignment methods. Medicinal Chemistry Research, 2013, 22, 6046-6062.	1.1	2
2428	B7-H4 enhances oncogenicity and inhibits apoptosis in pancreatic cancer cells. Cell and Tissue Research, 2013, 353, 139-151.	1.5	44
2429	Ribosomal Protein S6 Phosphorylation is Associated with Epithelial Dysplasia and Squamous Cell Carcinoma of the Oral Cavity. Pathology and Oncology Research, 2013, 19, 189-193.	0.9	27
2430	Anti-metastatic effect of cantharidin in A549 human lung cancer cells. Archives of Pharmacal Research, 2013, 36, 479-484.	2.7	38
2431	Reversal of boswellic acid analog BA145 induced caspase dependent apoptosis by PI3K inhibitor LY294002 and MEK inhibitor PD98059. Apoptosis: an International Journal on Programmed Cell Death, 2013, 18, 1561-1573.	2.2	16
2432	Signal transduction disturbance related to hepatocarcinogenesis in mouse by prolonged exposure to Nanjing drinking water. Environmental Science and Pollution Research, 2013, 20, 6468-6481.	2.7	3
2433	Autophagy. Advances in Cancer Research, 2013, 118, 61-95.	1.9	161
2434	Promising New Molecular Targeted Therapies in Head and Neck Cancer. Drugs, 2013, 73, 315-325.	4.9	81
2435	Reactive oxygen species mediate Cr(VI)-induced carcinogenesis through PI3K/AKT-dependent activation of GSK-3Î²/Î²-catenin signaling. Toxicology and Applied Pharmacology, 2013, 271, 239-248.	1.3	36

#	Article	IF	Citations
2436	Altered Ca2+ signaling in cancer cells: Proto-oncogenes and tumor suppressors targeting IP3 receptors. Biochimica Et Biophysica Acta: Reviews on Cancer, 2013, 1835, 180-193.	3.3	65
2437	Knockdown of the cochaperone SGTA results in the suppression of androgen and PI3K/Akt signaling and inhibition of prostate cancer cell proliferation. International Journal of Cancer, 2013, 133, 2812-2823.	2.3	21
2438	Role of Phosphatidylinositol 3,4,5-Trisphosphate in Cell Signaling. Advances in Experimental Medicine and Biology, 2013, 991, 105-139.	0.8	36
2439	Inhibition of formyl peptide receptor in high-grade astrocytoma by CHemotaxis Inhibitory Protein of S. aureus. British Journal of Cancer, 2013, 108, 587-596.	2.9	22
2440	Effects of Nicorandil in Neuroprotective Activation of PI3K/AKT Pathways in a Cellular Model of Alzheimer's Disease. European Neurology, 2013, 70, 233-241.	0.6	39
2441	Lipid-mediated Protein Signaling. Advances in Experimental Medicine and Biology, 2013, , .	0.8	11
2442	Knockdown of creatine kinase B inhibits ovarian cancer progression by decreasing glycolysis. International Journal of Biochemistry and Cell Biology, 2013, 45, 979-986.	1.2	60
2443	Tissue microarray analysis reveals the expression and prognostic significance of phosphorylated AktThr308 in oral squamous cell carcinoma. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2013, 116, 591-597.	0.2	15
2444	Protein kinase B/Akt1 inhibits autophagy by down-regulating UVRAG expression. Experimental Cell Research, 2013, 319, 122-133.	1.2	34
2445	Abnormal expression of PI3K isoforms in patients with tobacco-related oral squamous cell carcinoma. Clinica Chimica Acta, 2013, 416, 100-106.	0.5	10
2446	Akt2 expression is associated with good long-term prognosis in oestrogen receptor positive breast cancer. European Journal of Cancer, 2013, 49, 1196-1204.	1.3	9
2447	Stemness of T cells and the hematopoietic stem cells: Fate, memory, niche, cytokines. Cytokine and Growth Factor Reviews, 2013, 24, 485-501.	3.2	8
2448	A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1. Journal of Molecular Cell Biology, 2013, 5, 3-13.	1.5	242
2449	Current Understanding on EGFR and Wnt/Â-Catenin Signaling in Glioma and Their Possible Crosstalk. Genes and Cancer, 2013, 4, 427-446.	0.6	124
2450	Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment. Cancer Letters, 2013, 329, 45-58.	3.2	17
2451	Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas. Cell Death and Differentiation, 2013, 20, 396-407.	5.0	53
2452	gp130: a promising drug target for cancer therapy. Expert Opinion on Therapeutic Targets, 2013, 17, 1303-1328.	1.5	59
2453	CK2 inhibitor CX4945 induces sequential inactivation of proteins in the signaling pathways related with cell migration and suppresses metastasis of A549 human lung cancer cells. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5609-5613.	1.0	29

#	Article	IF	Citations
2454	Phosphatase and Tensin Homolog Deleted on Chromosome 10 (PTEN) Signaling Regulates Mitochondrial Biogenesis and Respiration via Estrogen-related Receptor Î± (ERRÎ±). Journal of Biological Chemistry, 2013, 288, 25007-25024.	1.6	51
2455	Protein Expression of PTEN, Insulin-Like Growth Factor I Receptor (IGF-IR), and Lethal Prostate Cancer: A Prospective Study. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1984-1993.	1.1	41
2456	Cancer Chemoprevention and Treatment by Diet Therapy. Evidence-based Anticancer Complementary and Alternative Medicine, 2013, , .	0.1	1
2457	What a Tangled Web We Weave: Emerging Resistance Mechanisms to Inhibition of the Phosphoinositide 3-Kinase Pathway. Cancer Discovery, 2013, 3, 1345-1354.	7.7	131
2458	Carboxyl-Terminal Modulator Protein Positively Regulates Akt Phosphorylation and Acts as an Oncogenic Driver in Breast Cancer. Cancer Research, 2013, 73, 6194-6205.	0.4	25
2459	Characterization of a Chemical Affinity Probe Targeting Akt Kinases. Journal of Proteome Research, 2013, 12, 3792-3800.	1.8	31
2460	A Review of Applications of Metabolomics in Cancer. Metabolites, 2013, 3, 552-574.	1.3	217
2461	Korean mistletoe lectin promotes proliferation and invasion of trophoblast cells through regulation of Akt signaling. Reproductive Toxicology, 2013, 39, 33-39.	1.3	8
2462	A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Research and Treatment, 2013, 141, 437-446.	1.1	70
2463	The tumor suppressor gastrokine-1 is expressed in placenta andÂcontributes to the regulation of trophoblast migration. Placenta, 2013, 34, 1027-1035.	0.7	16
2464	Ribosomal proteins as novel players in tumorigenesis. Cancer and Metastasis Reviews, 2014, 33, 115-41.	2.7	63
2465	Synergistic growth inhibition by acyclic retinoid and phosphatidylinositol 3-kinase inhibitor in human hepatoma cells. BMC Cancer, 2013, 13, 465.	1.1	7
2466	Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. Journal of Hematology and Oncology, 2013, 6, 88.	6.9	211
2467	Tumour-associated mutant p53 drives the Warburg effect. Nature Communications, 2013, 4, 2935.	5.8	329
2469	The expression of fatty acid metabolismâ€associated proteins is correlated with the prognosis of meningiomas. Apmis, 2013, 121, 997-1003.	0.9	5
2470	Murine models of atrophy, cachexia, and sarcopenia in skeletal muscle. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1410-1420.	1.8	77
2471	Report of the <scp>J</scp>apan Diabetes Society/<scp>J</scp>apanese Cancer Association joint committee on diabetes and cancer. Cancer Science, 2013, 104, 965-976.	1.7	71
2472	Capsaicin induces apoptosis in human osteosarcoma cells through AMPK-dependent and AMPK-independent signaling pathways. Molecular and Cellular Biochemistry, 2013, 384, 229-237.	1.4	24

#	Article	IF	Citations
2473	Scavenger receptor class B type I regulates cellular cholesterol metabolism and cell signaling associated with breast cancer development. Breast Cancer Research, 2013, 15, R87.	2.2	108
2474	Metallothionein 1G functions as a tumor suppressor in thyroid cancer through modulating the PI3K/Akt signaling pathway. BMC Cancer, 2013, 13, 462.	1.1	55
2475	VRK2 identifies a subgroup of primary high-grade astrocytomas with a better prognosis. BMC Clinical Pathology, 2013, 13, 23.	1.8	12
2476	Characterization and identification of PARM-1 as a new potential oncogene. Molecular Cancer, 2013, 12, 84.	7.9	17
2477	Dual modulation of JNK and Akt signaling pathways by chaetoglobosin K in human lung carcinoma and ras-transformed epithelial cells. Investigational New Drugs, 2013, 31, 525-534.	1.2	12
2478	Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study. Investigational New Drugs, 2013, 31, 677-684.	1.2	34
2479	Tumor glycolysis as a target for cancer therapy: progress and prospects. Molecular Cancer, 2013, 12, 152.	7.9	837
2480	QChIPat: a quantitative method to identify distinct binding patterns for two biological ChIP-seq samples in different experimental conditions. BMC Genomics, 2013, 14, S3.	1.2	31
2481	The effects of silencing of PI3K p85Î± on 5-FU-induced colorectal cancer cells apoptosis. Medical Oncology, 2013, 30, 704.	1.2	5
2482	Translating Imaging Results into Tumor Biology: FDG-PET and The Response to Chemoradiation in Human Cervical Carcinoma. Radiation Research, 2013, 180, 223-230.	0.7	1
2483	Novel self-assembled lithocholic acid nanoparticles for drug delivery in cancer. RSC Advances, 2013, 3, 19760.	1.7	16
2484	Targeting the PI3-Kinase/Akt/mTOR Signaling Pathway. Surgical Oncology Clinics of North America, 2013, 22, 641-664.	0.6	161
2485	Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest. Gynecologic Oncology, 2013, 131, 207-212.	0.6	10
2486	Zinc ions as effectors of environmental oxidative lung injury. Free Radical Biology and Medicine, 2013, 65, 57-69.	1.3	79
2487	Noncanonical control of C. elegans germline apoptosis by the insulin/IGF-1 and Ras/MAPK signaling pathways. Cell Death and Differentiation, 2013, 20, 97-107.	5.0	43
2488	Inositol Hexaphosphate Inhibits Tumor Growth, Vascularity, and Metabolism in TRAMP Mice: A Multiparametric Magnetic Resonance Study. Cancer Prevention Research, 2013, 6, 40-50.	0.7	38
2489	A Chemical Epitopeâ€Targeting Strategy for Protein Capture Agents: The Serine 474 Epitope of the Kinase Akt2. Angewandte Chemie - International Edition, 2013, 52, 13975-13979.	7.2	20
2490	Targeted therapy with kinase inhibitors in aggressive endocrine tumors. Expert Opinion on Pharmacotherapy, 2013, 14, 1187-1203.	0.9	16

#	Article	IF	Citations
2491	The novel phosphoinositide 3â€kinaseâ€“mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor. International Journal of Cancer, 2013, 133, 505-513.	2.3	28
2492	Combination of TNF-Î± and graphene oxide-loaded BEZ235 to enhance apoptosis of PIK3CA mutant colorectal cancer cells. Journal of Materials Chemistry B, 2013, 1, 5602.	2.9	14
2493	The costimulatory molecule B7-H4 promote tumor progression and cell proliferation through translocating into nucleus. Oncogene, 2013, 32, 5347-5358.	2.6	78
2494	miRNA-34b Inhibits Prostate Cancer through Demethylation, Active Chromatin Modifications, and AKT Pathways. Clinical Cancer Research, 2013, 19, 73-84.	3.2	110
2495	Initial testing (stage 1) of the phosphatidylinositol 3â€² kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2013, 60, 791-798.	0.8	19
2496	Reactive oxygen species generated in different compartments induce cell death, survival, or senescence. Free Radical Biology and Medicine, 2013, 57, 176-187.	1.3	121
2497	ADAMTS9 is a functional tumor suppressor through inhibiting AKT/mTOR pathway and associated with poor survival in gastric cancer. Oncogene, 2013, 32, 3319-3328.	2.6	108
2498	Inhibition of microRNA-21 increases radiosensitivity of esophageal cancer cells through phosphatase and tensin homolog deleted on chromosome 10 activation. Ecological Management and Restoration, 2013, 26, 823-831.	0.2	41
2499	The transcription factor NFâ€E2â€related Factor 2 (Nrf2): a protooncogene?. FASEB Journal, 2013, 27, 414-423.	0.2	166
2500	IPD-196, a novel phosphatidylinositol 3-kinase inhibitor with potent anticancer activity against hepatocellular carcinoma. Cancer Letters, 2013, 329, 99-108.	3.2	11
2501	QSAR and pharmacophore modeling of N-acetyl-2-aminobenzothiazole class of phosphoinositide-3-kinase-Î± inhibitors. Medicinal Chemistry Research, 2013, 22, 890-899.	1.1	7
2502	Sodium arsenite exposure inhibits AKT and Stat3 activation, suppresses self-renewal and induces apoptotic death of embryonic stem cells. Apoptosis: an International Journal on Programmed Cell Death, 2013, 18, 188-200.	2.2	18
2503	Combination of the PI3K Inhibitor ZSTK474 with a PSMA-Targeted Immunotoxin Accelerates Apoptosis and Regression of Prostate Cancer. Neoplasia, 2013, 15, 1172-IN32.	2.3	21
2504	Wogonin induces apoptosis in RPMI 8226, a human myeloma cell line, by downregulating phospho-Akt and overexpressing Bax. Life Sciences, 2013, 92, 55-62.	2.0	25
2505	The evolving landscape of therapeutic drug development for hepatocellular carcinoma. Contemporary Clinical Trials, 2013, 36, 605-615.	0.8	7
2506	Radiosensitization of Glioblastoma Cell Lines by the Dual PI3K and mTOR Inhibitor NVP-BEZ235 Depends on Drug-Irradiation Schedule. Translational Oncology, 2013, 6, 169-IN16.	1.7	51
2507	Differential sensitivity of p44/p42-MAPK- and PI3K/Akt-targeted neuroblastoma subtypes to arsenic trioxide. Neurochemistry International, 2013, 63, 809-817.	1.9	4
2508	Downregulation of Erbin in Her2-overexpressing breast cancer cells promotes cell migration and induces trastuzumab resistance. Molecular Immunology, 2013, 56, 104-112.	1.0	17

#	Article	IF	Citations
2509	Silencing of mitochondrial NADP+-dependent isocitrate dehydrogenase gene enhances glioma radiosensitivity. Biochemical and Biophysical Research Communications, 2013, 433, 260-265.	1.0	13
2510	Expression of platelet derived growth factor Î² receptor, its activation and downstream signals in bovine cutaneous fibropapillomas. Research in Veterinary Science, 2013, 94, 596-601.	0.9	11
2511	Neferine induces reactive oxygen species mediated intrinsic pathway of apoptosis in HepG2 cells. Food Chemistry, 2013, 136, 659-667.	4.2	81
2512	Cyclin G1 Expands Liver Tumor-Initiating Cells by Sox2 Induction via Akt/mTOR Signaling. Molecular Cancer Therapeutics, 2013, 12, 1796-1804.	1.9	45
2513	Glucagon-like peptide 2 in colon carcinogenesis: Possible target for anti-cancer therapy?. , 2013, 139, 87-94.		17
2514	Reactivation of AKT signaling following treatment of cancer cells with PI3K inhibitors attenuates their antitumor effects. Biochemical and Biophysical Research Communications, 2013, 438, 32-37.	1.0	19
2515	Antitumor activity of methyl gallate by inhibition of focal adhesion formation and Akt phosphorylation in glioma cells. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 4017-4029.	1.1	46
2516	Integrin-linked kinase mediates the hydrogen peroxide-dependent transforming growth factor-Î²1 up-regulation. Free Radical Biology and Medicine, 2013, 61, 416-427.	1.3	22
2517	Phase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancer. Radiotherapy and Oncology, 2013, 107, 184-188.	0.3	42
2518	Ferulic acid attenuates focal cerebral ischemia-induced decreases in p70S6 kinase and S6 phosphorylation. Neuroscience Letters, 2013, 555, 7-11.	1.0	34
2519	Differential regulation of CC chemokine ligand 2 and CXCL8 by antifungal agent nystatin in macrophages. Biochemical and Biophysical Research Communications, 2013, 437, 392-396.	1.0	7
2520	A novel antitumor activity of deguelin targeting the insulin-like growth factor (IGF) receptor pathway via up-regulation of IGF-binding protein-3 expression in breast cancer. Cancer Letters, 2013, 332, 102-109.	3.2	31
2521	Glutathione S-transferase class mu regulation of apoptosis signal-regulating kinase 1 protein during VCD-induced ovotoxicity in neonatal rat ovaries. Toxicology and Applied Pharmacology, 2013, 267, 49-56.	1.3	28
2522	Lead optimization of a dihydropyrrolopyrimidine inhibitor against phosphoinositide 3-kinase (PI3K) to improve the phenol glucuronic acid conjugation. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 673-678.	1.0	16
2523	â€œThe Infinite Mazeâ€•of breast cancer, signaling pathways and radioresistance. Breast, 2013, 22, 411-418.	0.9	13
2524	Activation of the Akt/mTOR pathway in dentigerous cysts, odontogenic keratocysts, and ameloblastomas. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2013, 116, 336-342.	0.2	10
2525	A novel function of protein kinase B as an inducer of the mismatch repair gene hPMS2 degradation. Cellular Signalling, 2013, 25, 1498-1504.	1.7	13
2526	Gankyrin plays an essential role in estrogen-driven and GPR30-mediated endometrial carcinoma cell proliferation via the PTEN/PI3K/AKT signaling pathway. Cancer Letters, 2013, 339, 279-287.	3.2	47

#	Article	IF	Citations
2527	Atrogin-1, MuRF-1, and sarcopenia. Endocrine, 2013, 43, 12-21.	1.1	258
2528	AEG-1 expression characteristics in human non-small cell lung cancer and its relationship with apoptosis. Medical Oncology, 2013, 30, 383.	1.2	45
2529	Head and neck cancer: from anatomy to biology. International Journal of Cancer, 2013, 133, 2013-2023.	2.3	130
2530	Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nature Medicine, 2013, 19, 209-216.	15.2	421
2531	Modulation of mitochondrial apoptosis by PI3K inhibitors. Mitochondrion, 2013, 13, 195-198.	1.6	63
2532	Reprogramming of the MicroRNA Transcriptome Mediates Resistance to Rapamycin. Journal of Biological Chemistry, 2013, 288, 6034-6044.	1.6	41
2533	MicroRNA-137, an HMGA1 Target, Suppresses Colorectal Cancer Cell Invasion and Metastasis in Mice by Directly Targeting FMNL2. Gastroenterology, 2013, 144, 624-635.e4.	0.6	123
2534	Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1588-1591.	1.0	26
2535	Micellar formulations of pro-apoptotic DM-PIT-1 analogs and TRAILin vitroandin vivo. Drug Delivery, 2013, 20, 78-85.	2.5	13
2536	The evolution of the TOR pathway and its role in cancer. Oncogene, 2013, 32, 3923-3932.	2.6	136
2537	Everolimus in colorectal cancer. Expert Opinion on Pharmacotherapy, 2013, 14, 505-513.	0.9	22
2538	mTOR Inhibition Elicits a Dramatic Response in PI3K-Dependent Colon Cancers. PLoS ONE, 2013, 8, e60709.	1.1	21
2539	Computational Models of Vascularization and Therapy in Tumor Growth. Studies in Mechanobiology, Tissue Engineering and Biomaterials, 2013, , 227-246.	0.7	0
2540	Interactions of Everolimus and Sorafenib in Pancreatic Cancer Cells. AAPS Journal, 2013, 15, 78-84.	2.2	15
2541	Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB Î²) inhibitors. Journal of Molecular Graphics and Modelling, 2013, 42, 17-25.	1.3	61
2542	The role of insulin and IGF system in pancreatic cancer. Journal of Molecular Endocrinology, 2013, 50, R67-R74.	1.1	70
2543	Complete genomic landscape of a recurring sporadic parathyroid carcinoma. Journal of Pathology, 2013, 230, 249-260.	2.1	57
2544	Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding. Tumor Biology, 2013, 34, 1991-2002.	0.8	121

#	Article	IF	Citations
2545	Cell survival and metastasis regulation by Akt signaling in colorectal cancer. Cellular Signalling, 2013, 25, 1711-1719.	1.7	137
2546	Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. Breast Cancer Research and Treatment, 2013, 139, 39-49.	1.1	49
2547	Attenuation of Multifocal Cell Survival Signaling by Bioactive Phytochemicals in the Prevention and Therapy of Cancer. Evidence-based Anticancer Complementary and Alternative Medicine, 2013, , 269-310.	0.1	2
2548	Genetics/Genomics/Proteomics of Gastric Adenocarcinoma. Gastroenterology Clinics of North America, 2013, 42, 241-260.	1.0	16
2549	Pharmacophore models generation by catalyst and phase consensus-based virtual screening protocol against PI3KÎ± inhibitors. Molecular Simulation, 2013, 39, 529-544.	0.9	4
2550	A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: Correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features. Oncology Reports, 2013, 30, 623-636.	1.2	41
2551	<scp>SOX</scp>2 promotes tumor growth of esophageal squamous cell carcinoma through the <scp>AKT</scp>/mammalian target of rapamycin complex 1 signaling pathway. Cancer Science, 2013, 104, 810-816.	1.7	67
2552	Kinase Inhibitors of Marine Origin. Chemical Reviews, 2013, 113, 6761-6815.	23.0	112
2553	PTEN in Prostate Cancer. , 2013, , 87-137.		2
2554	Role of Par-4 in Prostate Cancer. , 2013, , 481-495.		1
2555	A comparative perspective on lipid storage in animals. Journal of Cell Science, 2013, 126, 1541-1552.	1.2	112
2556	Membrane Polar Lipids. , 2013, , 57-83.		3
2557	NK4 Gene Therapy Inhibits HGF/Met-Induced Growth of Human Cholangiocarcinoma Cells. Digestive Diseases and Sciences, 2013, 58, 1636-1643.	1.1	5
2558	Therapeutic targeting of EGFR-activated metabolic pathways in glioblastoma. Expert Opinion on Investigational Drugs, 2013, 22, 1023-1040.	1.9	32
2559	Transcriptional and Functional Adaptations of Human Endothelial Cells to Physiological Chronic Low Oxygen1. Biology of Reproduction, 2013, 88, 114.	1.2	26
2560	FOXP1 acts through a negative feedback loop to suppress FOXO-induced apoptosis. Cell Death and Differentiation, 2013, 20, 1219-1229.	5.0	51
2561	Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2â€“4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyr (GDC-0032): A Î²-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity. Journal of Medicinal Chemistry, 2013, 56, 4597-4610.	2.9	161
2562	Synthesis and biological evaluation of novel phosphatidylinositol 3-kinase inhibitors: Solubilized 4-substituted benzimidazole analogs of 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474). European Journal of Medicinal Chemistry, 2013, 64, 137-147.	2.6	17

#	Article	IF	Citations
2563	Anticancer Property of Bromelain With Therapeutic Potential in Malignant Peritoneal Mesothelioma. Cancer Investigation, 2013, 31, 241-250.	0.6	43
2564	PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment. Journal of Molecular Medicine, 2013, 91, 1383-1397.	1.7	12
2565	Structured feature selection and task relationship inference for multi-task learning. Knowledge and Information Systems, 2013, 35, 345-364.	2.1	27
2566	Targeted inhibition of phosphatidyl inositol-3-kinase p110Î², but not p110Î±, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers. Apoptosis: an International Journal on Programmed Cell Death, 2013, 18, 509-520.	2.2	25
2567	Cancer-related marketing centrality motifs acting as pivot units in the human signaling network and mediating cross-talk between biological pathways. Molecular BioSystems, 2013, 9, 3026.	2.9	13
2568	Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6829-6834.	3.3	232
2569	Secretome analysis of Glioblastoma cell line - HNGC-2. Molecular BioSystems, 2013, 9, 1390.	2.9	12
2570	External Qi of Yan Xin Qigong Inhibits Activation of Akt, Erk/12 and NF-Ä¸B and Induces Cell Cycle Arrest and Apoptosis in Colorectal Cancer Cells. Cellular Physiology and Biochemistry, 2013, 31, 113-122.	1.1	21
2571	Assessing colorectal cancer heterogeneity: one step closer to tailored medicine. Journal of Applied Biomedicine, 2013, 11, 115-129.	0.6	2
2572	Differential expression and activation of Epidermal Growth Factor Receptor 1 (EGFR1), ERK, AKT, STAT3, and TWIST1 in nonsmall cell lung cancer (NSCLC). Experimental Lung Research, 2013, 39, 387-398.	0.5	6
2573	Targeting the <scp>ABCG</scp>2â€overexpressing multidrug resistant (<scp>MDR</scp>) cancer cells by <scp>PPAR</scp>Î³ agonists. British Journal of Pharmacology, 2013, 170, 1137-1151.	2.7	38
2574	Thioredoxin and Thioredoxin Target Proteins: From Molecular Mechanisms to Functional Significance. Antioxidants and Redox Signaling, 2013, 18, 1165-1207.	2.5	311
2575	Signaling Pathways as Specific Pharmacologic Targets for Neuroendocrine Tumor Therapy: RET, PI3K, MEK, Growth Factors, and Notch. Neuroendocrinology, 2013, 97, 57-66.	1.2	17
2576	RACK1 promotes prostate cancer cell proliferation, invasion and metastasis. Molecular Medicine Reports, 2013, 8, 999-1004.	1.1	21
2577	Naturally Occurring Hydroxytyrosol: Synthesis and Anticancer Potential. Current Medicinal Chemistry, 2013, 20, 655-670.	1.2	83
2578	Piceatannol suppresses the metastatic potential of MCF10A human breast epithelial cells harboring mutated H-ras by inhibiting MMP-2 expression. International Journal of Molecular Medicine, 2013, 32, 775-784.	1.8	23
2579	Sea urchin akt activity is Runx-dependent and required for post-cleavage stage cell division. Biology Open, 2013, 2, 472-478.	0.6	6
2580	Vitamin E Facilitates the Inactivation of the Kinase Akt by the Phosphatase PHLPP1. Science Signaling, 2013, 6, ra19.	1.6	47

#	Article	IF	Citations
2581	MK-2206, an AKT Inhibitor, Promotes Caspase-Independent Cell Death and Inhibits Leiomyoma Growth. Endocrinology, 2013, 154, 4046-4057.	1.4	41
2582	Akt Signaling Accelerates Tumor Recurrence Following Ras Inhibition in the Context of Ink4a/Arf Loss. Genes and Cancer, 2013, 4, 476-485.	0.6	5
2583	Identification of gene sets and pathways associated with lactation performance in mice. Physiological Genomics, 2013, 45, 171-181.	1.0	15
2584	Overcoming resistance to mTOR inhibition for enhanced strategies in clinical trials. Expert Opinion on Investigational Drugs, 2013, 22, 679-685.	1.9	8
2585	The gene dosage of class Ia PI3K dictates the development of PTEN hamartoma tumor syndrome. Cell Cycle, 2013, 12, 3589-3593.	1.3	3
2586	An overview of ABC and SLC Drug Transporter Gene Regulation. Current Drug Metabolism, 2013, 14, 253-264.	0.7	0
2587	Phase II Study of Everolimus in Patients with Metastatic Colorectal Adenocarcinoma Previously Treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens. Clinical Cancer Research, 2013, 19, 3987-3995.	3.2	57
2588	ANT2 suppression by shRNA restores miR-636 expression, thereby downregulating Ras and inhibiting tumorigenesis of hepatocellular carcinoma. Experimental and Molecular Medicine, 2013, 45, e3-e3.	3.2	36
2589	mTOR signaling pathway and mTOR inhibitors in the treatment of cancer. Dicle Medical Journal, 2013, 40, 156-160.	0.2	3
2590	H. pylori CagL-Y58/E59 Prime Higher Integrin Î±5Î²1 in Adverse pH Condition to Enhance Hypochlorhydria Vicious Cycle for Gastric Carcinogenesis. PLoS ONE, 2013, 8, e72735.	1.1	19
2591	Akt2 and acid ceramidase cooperate to induce cell invasion and resistance to apoptosis. Cell Cycle, 2013, 12, 2024-2032.	1.3	6
2592	p55PIK Transcriptionally Activated by MZF1 Promotes Colorectal Cancer Cell Proliferation. BioMed Research International, 2013, 2013, 1-10.	0.9	38
2593	Influence of alpha lipoic acid on epithelial apoptosis in experimental periodontitis. Turkish Journal of Medical Sciences, 2013, 43, 747-755.	0.4	3
2594	p110Î´ PI3 kinase pathway: emerging roles in cancer. Frontiers in Oncology, 2013, 3, 40.	1.3	52
2595	Targeting Genomic Alterations in Squamous Cell Lung Cancer. Frontiers in Oncology, 2013, 3, 195.	1.3	16
2596	ADAM15 Adds to Apoptosis Resistance of Synovial Fibroblasts by Modulating Focal Adhesion Kinase Signaling. Arthritis and Rheumatism, 2013, 65, 2826-2834.	6.7	18
2597	Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer. Prostate Cancer, 2013, 2013, 1-23.	0.4	48
2598	miR-205 Targets PTEN and PHLPP2 to Augment AKT Signaling and Drive Malignant Phenotypes in Nonâ€“Small Cell Lung Cancer. Cancer Research, 2013, 73, 5402-5415.	0.4	178

#	Article	IF	Citations
2599	Intrinsic Disorder in PTEN and its Interactome Confers Structural Plasticity and Functional Versatility. Scientific Reports, 2013, 3, 2035.	1.6	69
2600	Reduction of the ST6 Î²-Galactosamide Î±-2,6-Sialyltransferase 1 (ST6GAL1)-catalyzed Sialylation of Nectin-like Molecule 2/Cell Adhesion Molecule 1 and Enhancement of ErbB2/ErbB3 Signaling by MicroRNA-199a. Journal of Biological Chemistry, 2013, 288, 11845-11853.	1.6	31
2601	Carcinogenesis of Pancreatic Adenocarcinoma: Precursor Lesions. International Journal of Molecular Sciences, 2013, 14, 19731-19762.	1.8	59
2602	Competition for growth factors: a lot more death with a little less Aktion. Cell Death and Differentiation, 2013, 20, 1291-1292.	5.0	1
2603	An Efficient Synthesis of an AKT Inhibitor-IV Analog Labeled with Biotin. Advanced Materials Research, 0, 859, 349-352.	0.3	0
2604	Targeted therapy for hepatocellular carcinoma: current status and future direction. Clinical Investigation, 2013, 3, 83-93.	0.0	0
2605	Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E2572-81.	3.3	56
2606	Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma Identifies CDK4 and IGF1R as Synergistic Drug Targets. Science Signaling, 2013, 6, ra85.	1.6	97
2607	Genomics of Squamous Cell Lung Cancer. Oncologist, 2013, 18, 707-716.	1.9	27
2608	Atypical Intradermal Smooth Muscle Neoplasms (Formerly Cutaneous Leiomyosarcomas). Applied Immunohistochemistry and Molecular Morphology, 2013, 21, 132-138.	0.6	18
2609	PAK1 Mediates Resistance to PI3K Inhibition in Lymphomas. Clinical Cancer Research, 2013, 19, 1106-1115.	3.2	47
2610	Loss of PTEN Expression Is Associated with Poor Prognosis in Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas. Clinical Cancer Research, 2013, 19, 6830-6841.	3.2	60
2611	The role of cyclin D1 in response to long-term exposure to ionizing radiation. Cell Cycle, 2013, 12, 2738-2743.	1.3	29
2612	Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?. Therapeutic Advances in Medical Oncology, 2013, 5, 51-72.	1.4	11
2613	Molecular Pathways: Environmental Estrogens Activate Nongenomic Signaling to Developmentally Reprogram the Epigenome. Clinical Cancer Research, 2013, 19, 3732-3737.	3.2	44
2614	WD Repeat Protein WDR48 in Complex with Deubiquitinase USP12 Suppresses Akt-dependent Cell Survival Signaling by Stabilizing PH Domain Leucine-rich Repeat Protein Phosphatase 1 (PHLPP1). Journal of Biological Chemistry, 2013, 288, 34545-34554.	1.6	59
2615	Rapamycin regulates connective tissue growth factor expression of lung epithelial cells via phosphoinositide 3-kinase. Experimental Biology and Medicine, 2013, 238, 1082-1094.	1.1	23
2616	Cardiac hormones for the treatment of cancer. Endocrine-Related Cancer, 2013, 20, R113-R125.	1.6	17

#	Article	IF	Citations
2617	The antiproliferative effect of indomethacin-loaded lipid-core nanocapsules in glioma cells is mediated by cell cycle regulation, differentiation, and the inhibition of survival pathways. International Journal of Nanomedicine, 2013, 8, 711.	3.3	31
2618	Suppressive oligodeoxynucleotides synergistically enhance antiproliferative effects of anticancer drugs in A549 human lung cancer cells. International Journal of Oncology, 2013, 42, 429-436.	1.4	3
2619	Scutellaria barbata D. Don induces G1/S arrest via modulation of p53 and Akt pathways in human colon carcinoma cells. Oncology Reports, 2013, 29, 1623-1628.	1.2	34
2620	Synthesis of a Biotinylated AKT Inhibitor Analogue. Advanced Materials Research, 0, 848, 203-206.	0.3	0
2621	Major Signaling Pathways Involved in Breast Cancer. , 2013, , 47-64.		3
2622	ART1 Silencing Enhances Apoptosis of Mouse CT26 Cells via the PI3K/Akt/NF-κB Pathway. Cellular Physiology and Biochemistry, 2013, 32, 1587-1599.	1.1	24
2623	mTOR Inhibitors Block Kaposi Sarcoma Growth by Inhibiting Essential Autocrine Growth Factors and Tumor Angiogenesis. Cancer Research, 2013, 73, 2235-2246.	0.4	65
2624	Inhibition of Rapamycin-Induced AKT Activation Elicits Differential Antitumor Response in Head and Neck Cancers. Cancer Research, 2013, 73, 1118-1127.	0.4	19
2625	Elevation of Receptor Tyrosine Kinases by Small Molecule AKT Inhibitors in Prostate Cancer Is Mediated by Pim-1. Cancer Research, 2013, 73, 3402-3411.	0.4	58
2626	Correlation between the expression of Id-1 and hyperthermia-associated molecules in oral squamous cell carcinoma. Journal of Clinical Pathology, 2013, 66, 758-763.	1.0	10
2627	XPLN is an endogenous inhibitor of mTORC2. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 15979-15984.	3.3	38
2628	Rapid Screening of Novel Agents for Combination Therapy in Sarcomas. Sarcoma, 2013, 2013, 1-12.	0.7	12
2629	Targeted Therapies in the Treatment of Advanced Hepatocellular Carcinoma. Clinical Medicine Insights: Oncology, 2013, 7, CMO.S7633.	0.6	22
2630	Overexpression of cyclin B1 antagonizes chemotherapeutic-induced apoptosis through PTEN/Akt pathway in human esophageal squamous cell carcinoma cells. Cancer Biology and Therapy, 2013, 14, 45-55.	1.5	32
2631	Pertuzumab: new hope for patients with HER2-positive breast cancer. Annals of Oncology, 2013, 24, 273-282.	0.6	128
2632	Distinct pattern of chromosomal alterations and pathways in tongue and cheek squamous cell carcinoma. Head and Neck, 2013, 36, n/a-n/a.	0.9	0
2633	Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the Bloodâ€“Brain Barrier without restriction by ABCB1 and ABCG2. International Journal of Cancer, 2013, 133, 1222-1233.	2.3	26
2634	Abundant expression of m<scp>TOR</scp> kinase in salivary gland tumors â€“ potentials as therapy target?. Journal of Oral Pathology and Medicine, 2013, 42, 769-773.	1.4	10

#	Article	IF	Citations
2635	Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux. CNS Oncology, 2013, 2, 271-288.	1.2	21
2636	Interrogating Tumor Metabolism and Tumor Microenvironments Using Molecular Positron Emission Tomography Imaging. Theranostic Approaches to Improve Therapeutics. Pharmacological Reviews, 2013, 65, 1214-1256.	7.1	42
2637	Cyproheptadineâ€induced myeloma cell apoptosis is associated with inhibition of the <scp>PI</scp>3K/<scp>AKT</scp> signaling. European Journal of Haematology, 2013, 91, 514-521.	1.1	12
2638	Energy deprivation by silibinin in colorectal cancer cells. Autophagy, 2013, 9, 697-713.	4.3	80
2639	Thrombin-mediated activation of Akt signaling contributes to pulmonary vascular remodeling in pulmonary hypertension. Physiological Reports, 2013, 1, e00190.	0.7	24
2640	Genes Related to Suppression of Malignant Phenotype Induced by Maitake D-Fraction in Breast Cancer Cells. Journal of Medicinal Food, 2013, 16, 602-617.	0.8	22
2641	Genetic variations of mTORC1 genes and risk of gastric cancer in an eastern chinese population. Molecular Carcinogenesis, 2013, 52, 70-79.	1.3	118
2642	Optimization of oncogene expression through intraâ€population competition. Biotechnology Journal, 2013, 8, 1476-1484.	1.8	3
2643	the 11q13â€q14 amplicon: Clinicopathological correlations and potential drivers. Genes Chromosomes and Cancer, 2013, 52, 333-355.	1.5	70
2644	Exploring the biology of cancer of unknown primary: breakthroughs and drawbacks. European Journal of Clinical Investigation, 2013, 43, 491-500.	1.7	50
2645	Perifosine â€“ a new option in treatment of acute myeloid leukemia?. Expert Opinion on Investigational Drugs, 2013, 22, 1315-1327.	1.9	13
2646	Effects of Isoform-selective Phosphatidylinositol 3-Kinase Inhibitors on Osteoclasts. Journal of Biological Chemistry, 2013, 288, 35346-35357.	1.6	35
2647	Mechanical Properties of Respiratory Muscles. , 2013, 3, 1533-1567.		70
2648	Blocked Autophagy Using Lysosomotropic Agents Sensitizes Resistant Prostate Tumor Cells to the Novel Akt Inhibitor AZD5363. Clinical Cancer Research, 2013, 19, 833-844.	3.2	86
2649	New Strategies in Prostate Cancer: Translating Genomics into the Clinic. Clinical Cancer Research, 2013, 19, 517-523.	3.2	50
2650	PIK3CA and PTEN Gene and Exon Mutation-Specific Clinicopathologic and Molecular Associations in Colorectal Cancer. Clinical Cancer Research, 2013, 19, 3285-3296.	3.2	107
2651	CDK inhibitor p57^{Kip2} is downregulated by Akt during HER2-mediated tumorigenicity. Cell Cycle, 2013, 12, 935-943.	1.3	34
2652	Type I interferons induce autophagy in certain human cancer cell lines. Autophagy, 2013, 9, 683-696.	4.3	79

#	Article	IF	Citations
2653	Glucose restriction induces cell death in parental but not in homeodomain-interacting protein kinase 2-depleted RKO colon cancer cells: molecular mechanisms and implications for tumor therapy. Cell Death and Disease, 2013, 4, e639-e639.	2.7	38
2654	EMP2 regulates angiogenesis in endometrial cancer cells through induction of VEGF. Oncogene, 2013, 32, 5369-5376.	2.6	49
2655	Minor cell-death defects but reduced tumor latency in mice lacking the BH3-only proteins Bad and Bmf. Oncogene, 2013, 32, 621-630.	2.6	15
2656	Cyclin D1 overexpression perturbs DNA replication and induces replication-associated DNA double-strand breaks in acquired radioresistant cells. Cell Cycle, 2013, 12, 773-782.	1.3	46
2657	Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome. Genes and Development, 2013, 27, 1568-1580.	2.7	19
2658	Induction of apoptosis and suppression of angiogenesis of hepatocellular carcinoma by HS-159, a novel phosphatidylinositol 3-kinase inhibitor. International Journal of Oncology, 2013, 43, 201-209.	1.4	4
2659	miR-708 acts as a tumor suppressor in human glioblastoma cells. Oncology Reports, 2013, 30, 870-876.	1.2	44
2660	Inhibitory effect of atorvastatin on the cell growth of cardiac myxomas via the PTEN and PHLPP2 phosphatase signaling pathway. Oncology Reports, 2013, 30, 757-762.	1.2	6
2661	Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy. International Journal of Molecular Medicine, 2013, 31, 1449-1456.	1.8	52
2662	Natriuretic Peptidesâ€™ Metabolic Targets for Treatment of Cancer. Journal of Investigative Medicine, 2013, 61, 816-822.	0.7	6
2663	Predictive Biomarkers for Epidermal Growth Factor Receptor Agents in Non-Small Cell Lung Cancer. , 2013, , 155-182.		0
2664	Melanoma Mutagenesis and Aberrant Cell Signaling. Cancer Control, 2013, 20, 261-281.	0.7	29
2666	Genetic and Epigenetic Regulation of Phosphoinositide 3-kinase Isoforms. Current Pharmaceutical Design, 2013, 19, 680-686.	0.9	8
2667	Overexpression of Bmi-1 contributes to the invasion and metastasis of hepatocellular carcinoma by increasing the expression of matrix metalloproteinase (MMP)-2, MMP-9 and vascular endothelial growth factor via the PTEN/PI3K/Akt pathway. International Journal of Oncology, 2013, 43, 793-802.	1.4	90
2669	Induction of Apoptosis by 4-(3-(tert-butylamino)imidazo[1,2-Î±]pyridine-2-yl) Benzoic Acid in Breast Cancer Cells via Upregulation of PTEN. Oncology Research, 2013, 21, 1-13.	0.6	16
2670	Regulation of YAP through an Akt-dependent process by 3, 3â€²-diindolylmethane in human colon cancer cells. International Journal of Oncology, 2013, 43, 1992-1998.	1.4	26
2671	miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling. Molecular Medicine Reports, 2013, 7, 1579-1584.	1.1	72
2672	Activation of mammalian target of rapamycin complex 1 (mTORC1) and Raf/Pyk2 by growth factor-mediated Eph receptor 2 (EphA2) is required for cholangiocarcinoma growth and metastasis. Hepatology, 2013, 57, 2248-2260.	3.6	32

#	Article	IF	Citations
2673	Cytotoxic effects of mistletoe (Viscum album L.) in head and neck squamous cell carcinoma cell lines. Oncology Reports, 2013, 30, 2316-2322.	1.2	26
2674	Knockdown of DEPTOR induces apoptosis, increases chemosensitivity to doxorubicin and suppresses autophagy in RPMI-8226 human multiple myeloma cells in vitro. International Journal of Molecular Medicine, 2013, 31, 1127-1134.	1.8	26
2675	The flavonoid glabridin attenuates 2-deoxy-D-ribose-induced oxidative damage and cellular dysfunction in MC3T3-E1 osteoblastic cells. International Journal of Molecular Medicine, 2013, 31, 243-251.	1.8	27
2676	Chrysanthemum zawadskii extract protects osteoblastic cells from highly reducing sugar-induced oxidative damage. International Journal of Molecular Medicine, 2013, 32, 241-250.	1.8	17
2677	Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer. Breast Cancer: Targets and Therapy, 2013, 5, 27.	1.0	2
2678	Analgesic-antitumor peptide induces apoptosis and inhibits the proliferation of SW480 human colon cancer cells. Oncology Letters, 2013, 5, 483-488.	0.8	31
2679	Deltonin induces apoptosis in MDA-MB-231 human breast cancer cells via reactive oxygen species-mediated mitochondrial dysfunction and ERK/AKT signaling pathways. Molecular Medicine Reports, 2013, 7, 1038-1044.	1.1	24
2680	The function of human epidermal growth factor receptor-3 and its role in tumors (Review). Oncology Reports, 2013, 30, 2563-2570.	1.2	14
2681	AKT-independent PI3-K signaling in cancer – emerging role for SGK3. Cancer Management and Research, 2013, 5, 281.	0.9	73
2682	In Vitro Biomechanical Strain Regulation of Fibroblast Wound Healing. Journal of Osteopathic Medicine, 2013, 113, 806-818.	0.4	13
2683	New Insights Into Biology of Chronic Myeloid Leukemia: Implications in Therapy. Current Cancer Drug Targets, 2013, 13, 711-723.	0.8	10
2684	High-efficiency liposomal encapsulation of a tyrosine kinase inhibitor leads to improved in vivo toxicity and tumor response profile. International Journal of Nanomedicine, 2013, 8, 3991.	3.3	23
2685	Biologic Impact and Clinical Implication of mTOR Inhibition in Metastatic Breast Cancer. International Journal of Biological Markers, 2013, 28, 233-241.	0.7	3
2686	Prostate Cancer Progression to Androgen Independent Disease: The Role of the PI3K/AKT Pathway. , 0, , .		0
2687	Endoglin Haploinsufficiency Promotes Fibroblast Accumulation during Wound Healing through Akt Activation. PLoS ONE, 2013, 8, e54687.	1.1	20
2688	Multiple Genetic Alterations within the PI3K Pathway Are Responsible for AKT Activation in Patients with Ovarian Carcinoma. PLoS ONE, 2013, 8, e55362.	1.1	33
2689	Non-Invasive Imaging of Phosphoinositide-3-Kinase-Catalytic-Subunit-Alpha (PIK3CA) Promoter Modulation in Small Animal Models. PLoS ONE, 2013, 8, e55971.	1.1	21
2690	Curcumin Enhances the Effect of Chemotherapy against Colorectal Cancer Cells by Inhibition of NF-ÎºB and Src Protein Kinase Signaling Pathways. PLoS ONE, 2013, 8, e57218.	1.1	178

#	Article	IF	Citations
2691	Pathway Analysis for Genome-Wide Association Study of Lung Cancer in Han Chinese Population. PLoS ONE, 2013, 8, e57763.	1.1	9
2692	CG0009, a Novel Glycogen Synthase Kinase 3 Inhibitor, Induces Cell Death through Cyclin D1 Depletion in Breast Cancer Cells. PLoS ONE, 2013, 8, e60383.	1.1	22
2693	Metformin Downregulates the Insulin/IGF-I Signaling Pathway and Inhibits Different Uterine Serous Carcinoma (USC) Cells Proliferation and Migration in p53-Dependent or -Independent Manners. PLoS ONE, 2013, 8, e61537.	1.1	129
2694	Cancer Associated E17K Mutation Causes Rapid Conformational Drift in AKT1 Pleckstrin Homology (PH) Domain. PLoS ONE, 2013, 8, e64364.	1.1	49
2695	Hypoxiaâ€“Induced Cytotoxic Drug Resistance in Osteosarcoma Is Independent of HIF-1Alpha. PLoS ONE, 2013, 8, e65304.	1.1	59
2696	Efficacy of Histone Deacetylase and Estrogen Receptor Inhibition in Breast Cancer Cells Due to Concerted down Regulation of Akt. PLoS ONE, 2013, 8, e68973.	1.1	22
2697	Reappraisal of the Therapeutic Role of Celecoxib in Cholangiocarcinoma. PLoS ONE, 2013, 8, e69928.	1.1	10
2698	The Role of Chromosome Missegregation in Cancer Development: A Theoretical Approach Using Agent-Based Modelling. PLoS ONE, 2013, 8, e72206.	1.1	13
2699	MicroRNA-26a Inhibits Angiogenesis by Down-Regulating VEGFA through the PIK3C2Î±/Akt/HIF-1Î± Pathway in Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e77957.	1.1	105
2700	The Prognostic Value of Phosphorylated AKT Expression in Non-Small Cell Lung Cancer: A Meta-Analysis. PLoS ONE, 2013, 8, e81451.	1.1	19
2701	13-Methyltetradecanoic Acid Exhibits Anti-Tumor Activity on T-Cell Lymphomas In Vitro and In Vivo by Down-Regulating p-AKT and Activating Caspase-3. PLoS ONE, 2013, 8, e65308.	1.1	24
2702	Targeted Apoptotic Effects of Thymoquinone and Tamoxifen on XIAP Mediated Akt Regulation in Breast Cancer. PLoS ONE, 2013, 8, e61342.	1.1	100
2703	Interaction between NBS1 and the mTOR/Rictor/SIN1 Complex through Specific Domains. PLoS ONE, 2013, 8, e65586.	1.1	10
2704	MiR-133b Is Down-Regulated in Human Osteosarcoma and Inhibits Osteosarcoma Cells Proliferation, Migration and Invasion, and Promotes Apoptosis. PLoS ONE, 2013, 8, e83571.	1.1	96
2705	Direct Association of Heat Shock Protein 20 (HSPB6) with Phosphoinositide 3-kinase (PI3K) in Human Hepatocellular Carcinoma: Regulation of the PI3K Activity. PLoS ONE, 2013, 8, e78440.	1.1	20
2706	VEGF in Tumor Progression and Targeted Therapy. Current Cancer Drug Targets, 2013, 13, 423-443.	0.8	70
2707	Targeting the PI3K-AKT-mTOR signaling network in cancer. Chinese Journal of Cancer, 2013, 32, 253-265.	4.9	173
2710	Impact of Quercetin, Diallyl Disulfide and Nimbolide on the Regulation of Nuclear Factor Kappa B Expression in Prostate and Breast Cancer Cell Lines. Natural Products Chemistry & Research, 2013, 1, .	0.2	2

#	Article	IF	Citations
2711	The Roles of AMP-Activated Protein Kinase-Related Kinase 5 as a Novel Therapeutic Target of Human T-Cell Leukaemia Virus Type 1-Infected T-Cells. , 2013, , .		0
2712	Apoptosis and Clearance of the Secretory Mammary Epithelium. , 0, , .		1
2713	Targeted Therapies in Melanoma: Successes and Pitfalls. , 0, , .		1
2714	Human Serum Proteins Recognized by CA215 and Cancerous Immunoglobulins and Implications in Cancer Immunology. Cancer and Clinical Oncology, 2014, 3, .	0.2	1
2715	Novel Biomarkers in Determining Prostate Cancer Diagnosis and Prognosis. OnLine Journal of Biological Sciences, 2014, 14, 277-285.	0.2	1
2716	Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer. Journal of Gynecologic Oncology, 2014, 25, 249.	1.0	31
2717	Evaluation of PTEN, PI3K, MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinoma. Wspolczesna Onkologia, 2014, 4, 234-240.	0.7	12
2718	Impact of Soy Isoflavones on the Epigenome in Cancer Prevention. Nutrients, 2014, 6, 4218-4272.	1.7	83
2719	LFG-500 Inhibits the Invasion of Cancer Cells via Down-Regulation of PI3K/AKT/NF-Î²B Signaling Pathway. PLoS ONE, 2014, 9, e91332.	1.1	27
2720	Novel Secondary Somatic Mutations in Ewing's Sarcoma and Desmoplastic Small Round Cell Tumors. PLoS ONE, 2014, 9, e93676.	1.1	32
2721	Biochemical and Cellular Evidence Demonstrating AKT-1 as a Binding Partner for Resveratrol Targeting Protein NQO2. PLoS ONE, 2014, 9, e101070.	1.1	30
2722	Abieslactone Induces Cell Cycle Arrest and Apoptosis in Human Hepatocellular Carcinomas through the Mitochondrial Pathway and the Generation of Reactive Oxygen Species. PLoS ONE, 2014, 9, e115151.	1.1	20
2723	Delivery-Corrected Imaging of Fluorescently-Labeled Glucose Reveals Distinct Metabolic Phenotypes in Murine Breast Cancer. PLoS ONE, 2014, 9, e115529.	1.1	23
2724	The Influence of the CHIEF Pathway on Colorectal Cancer-Specific Mortality. PLoS ONE, 2014, 9, e116169.	1.1	16
2725	Expression of Thrombospondin-1 Modulates the Angioinflammatory Phenotype of Choroidal Endothelial Cells. PLoS ONE, 2014, 9, e116423.	1.1	25
2726	Molecular Alterations of PI3K/Akt/mTOR Pathway: A Therapeutic Target in Endometrial Cancer. Scientific World Journal, The, 2014, 2014, 1-9.	0.8	56
2727	Squamosamide Derivative FLZ Protects Retinal Pigment Epithelium Cells from Oxidative Stress through Activation of Epidermal Growth Factor Receptor (EGFR)-AKT Signaling. International Journal of Molecular Sciences, 2014, 15, 18762-18775.	1.8	16
2728	PIK3CA in Colorectal Cancer. Frontiers in Oncology, 2014, 4, 35.	1.3	87

#	Article	IF	Citations
2729	Revealing Biological Pathways Implicated in Lung Cancer from TCGA Gene Expression Data Using Gene Set Enrichment Analysis. Cancer Informatics, 2014, 13s1, CIN.S13882.	0.9	8
2730	Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer. World Journal of Gastroenterology, 2014, 20, 9862.	1.4	18
2731	Activation of the PI3K/Akt/mTOR/p70S6K Pathway is Involved in S100A4-induced Viability and Migration in Colorectal Cancer Cells. International Journal of Medical Sciences, 2014, 11, 841-849.	1.1	53
2732	Down Regulation of FOXO1 Promotes Cell Proliferation in Cervical Cancer. Journal of Cancer, 2014, 5, 655-662.	1.2	42
2733	The Role of TGF-Î² Signaling in Î²-Cell Dysfunction and Type 2 Diabetes: A Review. Journal of Cytology & Histology, 2014, 05, .	0.1	7
2734	Additive effect by combination of Akt inhibitor, MK-2206, and PDGFR inhibitor, tyrphostin AG 1296, in suppressing anaplastic thyroid carcinoma cell viability and motility. OncoTargets and Therapy, 2014, 7, 425.	1.0	10
2735	Molecular Biology of Non-small-cell Lung Cancer. Hanyang Medical Reviews, 2014, 34, 4.	0.4	2
2736	ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer. Oncotarget, 2014, 5, 6633-6646.	0.8	66
2737	Antiausterity Activity of Arctigenin Enantiomers: Importance of (2R,3R)-Absolute Configuration. Natural Product Communications, 2014, 9, 1934578X1400900.	0.2	4
2738	Druggable Targets in Pancreatic Adenocarcinoma. Forum on Immunopathological Diseases and Therapeutics, 2014, 5, 195-214.	0.1	0
2739	Nuclear receptor-induced transcription is driven by spatially and timely restricted waves of ROS. Nucleus, 2014, 5, 482-491.	0.6	20
2740	Diabetes Mellitus and Liver Cancer Risk: An Evaluation Based on a Systematic Review of Epidemiologic Evidence among the Japanese Population. Japanese Journal of Clinical Oncology, 2014, 44, 986-999.	0.6	28
2741	Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition. Cancer Research, 2014, 74, 4458-4469.	0.4	63
2742	Selective and potent small-molecule inhibitors of PI3Ks. Future Medicinal Chemistry, 2014, 6, 737-756.	1.1	12
2743	The Diarylheptanoid Hirsutenone Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin via Modulation of Apoptosis-inducing Factor and X-linked Inhibitor of Apoptosis. Journal of Biological Chemistry, 2014, 289, 1723-1731.	1.6	28
2744	Biphasic Modulation of Paracellular Claudin-5 Expression in Mouse Brain Endothelial Cells Is Mediated through the Phosphoinositide-3-Kinase/AKT Pathway. Journal of Pharmacology and Experimental Therapeutics, 2014, 351, 654-662.	1.3	25
2745	Inhibition of lewis lung cancer cell growth and migration by fucoidan. Molecular and Cellular Toxicology, 2014, 10, 269-276.	0.8	3
2746	Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in 12 V-Ha-Ras transgenic mouse glioma model. Cancer Cell International, 2014, 14, 105.	1.8	16

#	Article	IF	Citations
2747	Attenuation of enoyl coenzyme A hydratase short chain 1 expression in gastric cancer cells inhibits cell proliferation and migration in vitro. Cellular and Molecular Biology Letters, 2014, 19, 576-89.	2.7	10
2748	Inhibition of Cullin-RING E3 ubiquitin ligase 7 by simian virus 40 large T antigen. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 3371-3376.	3.3	16
2749	Role of erbB3 receptors in cancer therapeutic resistance. Acta Biochimica Et Biophysica Sinica, 2014, 46, 190-198.	0.9	37
2750	Coordinated Regulation of Serum- and Glucocorticoid-inducible Kinase 3 by a C-terminal Hydrophobic Motif and Hsp90-Cdc37 Chaperone Complex. Journal of Biological Chemistry, 2014, 289, 4815-4826.	1.6	12
2751	Akt-dependent Activation of mTORC1 Complex Involves Phosphorylation of mTOR (Mammalian Target of) Tj ETQq0 0 0 rgBT /Overlock 1	1.6	118
2752	DNA damage signaling guards against perturbation of cyclin D1 expression triggered by low-dose long-term fractionated radiation. Oncogenesis, 2014, 3, e132-e132.	2.1	14
2753	MCT-1 expression and PTEN deficiency synergistically promote neoplastic multinucleation through the Src/p190B signaling activation. Oncogene, 2014, 33, 5109-5120.	2.6	21
2754	Exploiting the therapeutic potential of the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies. Expert Review of Clinical Pharmacology, 2014, 7, 847-858.	1.3	17
2755	Follistatin could promote the proliferation of duck primary myoblasts by activating PI3K/Akt/mTOR signalling. Bioscience Reports, 2014, 34, .	1.1	16
2756	Dysregulated Estrogen Receptor Signaling in the Hypothalamic-Pituitary-Ovarian Axis Leads to Ovarian Epithelial Tumorigenesis in Mice. PLoS Genetics, 2014, 10, e1004230.	1.5	14
2757	Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment. Molecular and Cellular Oncology, 2014, 1, e963447.	0.3	9
2758	ER-α36: a novel biomarker and potential therapeutic target in breast cancer. OncoTargets and Therapy, 2014, 7, 1525.	1.0	27
2759	Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmacogenomics and Personalized Medicine, 2014, 7, 203.	0.4	83
2760	mTOR pathway: A current, up-to-date mini-review (Review). Oncology Letters, 2014, 8, 2367-2370.	0.8	87
2761	A Cell-Cell Communication Marker for Identifying Targeted Tumor Therapies. Current Bioactive Compounds, 2014, 9, 255-262.	0.2	6
2762	Robustness and Evolvability of the Human Signaling Network. PLoS Computational Biology, 2014, 10, e1003763.	1.5	23
2763	Protective effect of apigenin against oxidative stress-induced damage in osteoblastic cells. International Journal of Molecular Medicine, 2014, 33, 1327-1334.	1.8	72
2764	Data-Derived Modeling Characterizes Plasticity of MAPK Signaling in Melanoma. PLoS Computational Biology, 2014, 10, e1003795.	1.5	20

#	Article	IF	Citations
2765	Effect of NK4 Transduction in Bone Marrow-Derived Mesenchymal Stem Cells on Biological Characteristics of Pancreatic Cancer Cells. International Journal of Molecular Sciences, 2014, 15, 3729-3745.	1.8	14
2766	â€˜Druggableâ€™ alterations detected by Ion Torrent in metastatic colorectal cancer patients. Oncology Letters, 2014, 7, 1761-1766.	0.8	10
2767	The Role of STAT3 in Non-Small Cell Lung Cancer. Cancers, 2014, 6, 708-722.	1.7	154
2768	PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways. Bioscience Reports, 2014, 34, .	1.1	75
2769	An Unexpected Synthesis of 2H-Benzimidazole Derivatives. Advanced Materials Research, 2014, 1023, 43-46.	0.3	0
2770	Efficacy of Everolimus in Patients with Advanced Renal Cell Carcinoma Refractory or Intolerant to VEGFR-TKIs and Safety Compared with Prior VEGFR-TKI Treatment. Japanese Journal of Clinical Oncology, 2014, 44, 479-485.	0.6	9
2771	Mechanisms of T-Cell Immunosuppression by Mesenchymal Stromal Cells: What Do We Know So Far?. BioMed Research International, 2014, 2014, 1-14.	0.9	140
2772	Isocudraxanthone K Induces Growth Inhibition and Apoptosis in Oral Cancer Cells via Hypoxia Inducible Factor-1Î±. BioMed Research International, 2014, 2014, 1-14.	0.9	18
2773	TRAIL combinations: The new â€˜trailâ€™ for cancer therapy (Review). Oncology Letters, 2014, 7, 1327-1332.	0.8	66
2774	HIV-1 Nef and KSHV oncogene K1 synergistically promote angiogenesis by inducing cellular miR-718 to regulate the PTEN/AKT/mTOR signaling pathway. Nucleic Acids Research, 2014, 42, 9862-9879.	6.5	85
2775	Prostaglandin E2 receptor EP2 mediates Snail expression in hepatocellular carcinoma cells. Oncology Reports, 2014, 31, 2099-2106.	1.2	25
2776	The molecular background of mucinous carcinoma beyond MUC2. The Clinical Journal of Pathology, 2014, , n/a-n/a.	0.0	1
2777	Acacetin (5,7-dihydroxy-4â€²-methoxyflavone) exhibits in vitro and in vivo anticancer activity through the suppression of NF-ÎºB/Akt signaling in prostate cancer cells. International Journal of Molecular Medicine, 2014, 33, 317-324.	1.8	77
2778	Ubiquitin-specific protease 22-induced autophagy is correlated with poor prognosis of pancreatic cancer. Oncology Reports, 2014, 32, 2726-2734.	1.2	41
2779	Protein kinase C Î¶ regulates survivin expression and inhibits apoptosis in colon cancer. International Journal of Oncology, 2014, 45, 1043-1050.	1.4	7
2780	Akt: a new activation mechanism. Cell Research, 2014, 24, 785-786.	5.7	47
2781	Nuclear accumulation of cyclin D1 following long-term fractionated exposures to low-dose ionizing radiation in normal human diploid cells. Cell Cycle, 2014, 13, 1248-1255.	1.3	20
2782	Mig-6 Suppresses Endometrial Cancer Associated with Pten Deficiency and ERK Activation. Cancer Research, 2014, 74, 7371-7382.	0.4	40

#	Article	IF	Citations
2783	Akt induces down regulation of MUC5AC production in NCI-H292 human airway epithelial cells cultured on extracellular matrix. Bioscience, Biotechnology and Biochemistry, 2014, 78, 212-221.	0.6	7
2784	Down-modulation of Bcl-2 sensitizes PTEN-mutated prostate cancer cells to starvation and taxanes. Prostate, 2014, 74, 1411-1422.	1.2	14
2785	Cyclin <scp>D</scp>1â€induced proliferation is independent of betaâ€catenin in <scp>H</scp>ead and <scp>N</scp>eck <scp>C</scp>ancer. Oral Diseases, 2014, 20, e42-8.	1.5	6
2786	Population pharmacokinetics and pharmacodynamics of <scp>BYL</scp>719, a phosphoinositide 3â€kinase antagonist, in adult patients with advanced solid malignancies. British Journal of Clinical Pharmacology, 2014, 78, 543-555.	1.1	27
2787	TREMâ€2 Promotes Macrophageâ€Mediated Eradication of Pseudomonas aeruginosa via a PI3K/Akt Pathway. Scandinavian Journal of Immunology, 2014, 79, 187-196.	1.3	47
2788	Unique microRNAâ€profiles in EGFR â€mutated lung adenocarcinomas. International Journal of Cancer, 2014, 135, 1812-1821.	2.3	61
2789	Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung. Cancer Medicine, 2014, 3, 337-348.	1.3	31
2790	Deflection of vascular endothelial growth factor action by <scp>SS</scp>18â€“<scp>SSX</scp> and composite vascular endothelial growth factorâ€and chemokine (Câ€Xâ€C motif) receptor 4â€targeted therapy in synovial sarcoma. Cancer Science, 2014, 105, 1124-1134.	1.7	14
2791	<scp>PI</scp>3K/Akt pathway regulates retinoic acidâ€induced Hox gene expression in F9 cells. Development Growth and Differentiation, 2014, 56, 518-525.	0.6	16
2792	The Role of Signaling Pathways in Cervical Cancer and Molecular Therapeutic Targets. Archives of Medical Research, 2014, 45, 525-539.	1.5	75
2793	Decreased Muc5AC expression is associated with poor prognosis in gastric cancer. International Journal of Cancer, 2014, 134, 114-124.	2.3	23
2794	DW09849, a Selective Phosphatidylinositol 3-Kinase (PI3K) Inhibitor, Prevents PI3K Signaling and Preferentially Inhibits Proliferation of Cells Containing the Oncogenic Mutation p110Î± (H1047R). Journal of Pharmacology and Experimental Therapeutics, 2014, 348, 432-441.	1.3	14
2795	Impact of mTORC1 inhibition on keratinocyte proliferation during skin tumor promotion in wildâ€type and BK5.Akt^{WT} mice. Molecular Carcinogenesis, 2014, 53, 871-882.	1.3	8
2796	Modulating Autophagy and the â€œReverse Warburg Effectâ€ Cancer Drug Discovery and Development, 2014, , 131-156.	0.2	2
2797	Use of mTOR inhibitors in the treatment of malignancies. Expert Opinion on Pharmacotherapy, 2014, 15, 979-990.	0.9	5
2798	MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer. BMC Cancer, 2014, 14, 656.	1.1	64
2799	Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism. Journal of Inflammation, 2014, 11, 23.	1.5	96
2800	Nck1 depletion induces activation of the PI3K/Akt pathway by attenuating PTP1B protein expression. Cell Communication and Signaling, 2014, 12, 71.	2.7	15

#	Article	IF	Citations
2801	A novel phosphatidylinositol 3-kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genes. Breast Cancer Research, 2014, 16, 482.	2.2	41
2802	Context-Dependent Antagonism between Akt Inhibitors and Topoisomerase Poisons. Molecular Pharmacology, 2014, 85, 723-734.	1.0	6
2803	Phosphoinositide 3-kinase inhibitors in lymphoma. Current Opinion in Oncology, 2014, 26, 469-475.	1.1	34
2804	Dual Inhibition of Phosphatidylinositol 3â€²-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach for Mucinous Adenocarcinoma of the Ovary. International Journal of Gynecological Cancer, 2014, 24, 444-453.	1.2	19
2805	PIK3CA Mutations in Mucinous Cystic Neoplasms of the Pancreas. Pancreas, 2014, 43, 245-249.	0.5	55
2806	LKB1 Loss Induces Characteristic Patterns of Gene Expression in Human Tumors Associated with NRF2 Activation and Attenuation of PI3K-AKT. Journal of Thoracic Oncology, 2014, 9, 794-804.	0.5	65
2807	In situassessment of PI3K and PTEN alterations in mycosis fungoides: correlation with clinicopathological features. Experimental Dermatology, 2014, 23, 931-933.	1.4	15
2808	Mimic of manganese superoxide dismutase induces apoptosis in human acute myeloid leukemia cells. Leukemia and Lymphoma, 2014, 55, 1166-1175.	0.6	3
2809	AKT as a therapeutic target in multiple myeloma. Expert Opinion on Therapeutic Targets, 2014, 18, 897-915.	1.5	44
2810	Principles of the Warburg Effect and Cancer Cell Metabolism. , 2014, , 355-369.		0
2811	Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and Efficacy. Clinical Cancer Research, 2014, 20, 6071-6082.	3.2	45
2812	Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RASâ€“ERK Signaling. Cancer Discovery, 2014, 4, 334-347.	7.7	169
2813	Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors. Clinical Cancer Research, 2014, 20, 1212-1222.	3.2	51
2814	Tumor Metabolome Targeting and Drug Development. Cancer Drug Discovery and Development, 2014, , .	0.2	0
2815	Down-Regulated MAC30 Expression Inhibits Proliferation and Mobility of Human Gastric Cancer Cells. Cellular Physiology and Biochemistry, 2014, 33, 1359-1368.	1.1	34
2816	The Lipid Kinase PI4KIIIÎ² Is Highly Expressed in Breast Tumors and Activates Akt in Cooperation with Rab11a. Molecular Cancer Research, 2014, 12, 1492-1508.	1.5	32
2817	Correlation between the expression levels of miR-1 and PIK3CA in non-small-cell lung cancer and their relationship with clinical characteristics and prognosis. Future Oncology, 2014, 10, 49-57.	1.1	23
2818	Synthesis of an Akt Inhibitor-IV Analogue via an Amine-Exchange Reaction. Advanced Materials Research, 0, 1023, 47-50.	0.3	0

#	Article	IF	Citations
2819	mTOR Signaling in Protein Translation Regulation: Implications in Cancer Genesis and Therapeutic Interventions. Molecular Biology International, 2014, 2014, 1-14.	1.7	149
2820	The PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models. Frontiers in Oncology, 2014, 4, 252.	1.3	166
2821	Autophagy, Warburg, and Warburg Reverse Effects in Human Cancer. BioMed Research International, 2014, 2014, 1-10.	0.9	58
2822	Hormone Resistance in Two MCF-7 Breast Cancer Cell Lines is Associated with Reduced mTOR Signaling, Decreased Glycolysis, and Increased Sensitivity to Cytotoxic Drugs. Frontiers in Oncology, 2014, 4, 221.	1.3	23
2823	Marine Compounds. , 2014, , 209-250.		0
2824	Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status. Molecular Cancer, 2014, 13, 21.	7.9	29
2825	Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization. Journal of Hematology and Oncology, 2014, 7, 9.	6.9	52
2826	Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer. Journal of Ovarian Research, 2014, 7, 38.	1.3	24
2827	The Adherens Junction Protein Afadin Is an AKT Substrate that Regulates Breast Cancer Cell Migration. Molecular Cancer Research, 2014, 12, 464-476.	1.5	44
2828	The Prolyl Peptidases PRCP/PREP Regulate IRS-1 Stability Critical for Rapamycin-induced Feedback Activation of PI3K and AKT. Journal of Biological Chemistry, 2014, 289, 21694-21705.	1.6	17
2829	MicroRNA-21 Affects Proliferation and Apoptosis by Regulating Expression of PTEN in Human Keloid Fibroblasts. Plastic and Reconstructive Surgery, 2014, 134, 561e-573e.	0.7	58
2830	Clinicopathological significance of PI3K, Akt and survivin expression in gastric cancer. Biomedicine and Pharmacotherapy, 2014, 68, 471-475.	2.5	21
2831	Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT. Toxicology Letters, 2014, 224, 7-15.	0.4	38
2832	GABARBP down-regulates HIF-1Î± expression through the VEGFR-2 and PI3K/mTOR/4E-BP1 pathways. Cellular Signalling, 2014, 26, 1506-1513.	1.7	19
2833	Interleukin 7 and thymic stromal lymphopoietin: from immunity to leukemia. Cellular and Molecular Life Sciences, 2014, 71, 365-378.	2.4	42
2834	Quercetin suppresses invasion and migration of H-Ras-transformed MCF10A human epithelial cells by inhibiting phosphatidylinositol 3-kinase. Food Chemistry, 2014, 142, 66-71.	4.2	36
2835	PDK1 controls upstream PI3K expression and PIP3 generation. Oncogene, 2014, 33, 3043-3053.	2.6	30
2836	Mapping protein signal pathway interaction in sarcoma bone metastasis: linkage between rank, metalloproteinases turnover and growth factor signaling pathways. Clinical and Experimental Metastasis, 2014, 31, 15-24.	1.7	20

#	Article	IF	Citations
2837	Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy. Cancer and Metastasis Reviews, 2014, 33, 469-496.	2.7	100
2838	The novel miR-9500 regulates the proliferation and migration of human lung cancer cells by targeting Akt1. Cell Death and Differentiation, 2014, 21, 1150-1159.	5.0	29
2839	AKT signaling is involved in fucoidan-induced inhibition of growth and migration of human bladder cancer cells. Food and Chemical Toxicology, 2014, 64, 344-352.	1.8	56
2840	The pathogenesis and treatment of large granular lymphocyte leukemia. Blood Reviews, 2014, 28, 87-94.	2.8	69
2841	Increased expression of S100A6 promotes cell proliferation and migration in human hepatocellular carcinoma. Journal of Molecular Medicine, 2014, 92, 291-303.	1.7	39
2842	Platycodin D, a triterpenoid saponin from Platycodon grandiflorum, induces G2/M arrest and apoptosis in human hepatoma HepG2 cells by modulating the PI3K/Akt pathway. Tumor Biology, 2014, 35, 1267-1274.	0.8	50
2843	The novel arylindolylmaleimide PDA-66 displays pronounced antiproliferative effects in acute lymphoblastic leukemia cells. BMC Cancer, 2014, 14, 71.	1.1	14
2844	PI3K/Akt pathway involving into apoptosis and invasion in human colon cancer cells LoVo. Molecular Biology Reports, 2014, 41, 3359-3367.	1.0	43
2845	Interleukin-6 inhibition of peroxisome proliferator-activated receptor alpha expression is mediated by JAK2- and PI3K-induced STAT1/3 in HepG2 hepatocyte cells. Molecular and Cellular Biochemistry, 2014, 388, 25-37.	1.4	20
2846	The PI3K/AKT/MTOR Signaling Pathway: The Role of PI3K and AKT Inhibitors in Breast Cancer. Current Breast Cancer Reports, 2014, 6, 59-70.	0.5	7
2847	Synthesis and antitumor activities of novel 4-morpholinothieno[3,2-d]pyrimidine derivatives. Chemical Research in Chinese Universities, 2014, 30, 75-81.	1.3	6
2848	The novel IGF-IR/Aktâ€“dependent anticancer activities of glucosamine. BMC Cancer, 2014, 14, 31.	1.1	16
2849	TGF-Â: Duality of Function Between Tumor Prevention and Carcinogenesis. Journal of the National Cancer Institute, 2014, 106, djt369-djt369.	3.0	413
2850	Novel thiazole derivatives: a patent review (2008 â€“ 2012; Part 1). Expert Opinion on Therapeutic Patents, 2014, 24, 201-216.	2.4	42
2851	Mesenchymal stem cells and cancer: Friends or enemies?. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2014, 768, 98-106.	0.4	64
2852	Molecular Targets and Mechanisms of Cancer Prevention and Treatment by Withaferin A, A Naturally Occurring Steroidal Lactone. AAPS Journal, 2014, 16, 1-10.	2.2	91
2853	Identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives as potent PI3K/mTOR dual inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 790-793.	1.0	7
2854	Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110Î´ result in T cell senescence and human immunodeficiency. Nature Immunology, 2014, 15, 88-97.	7.0	575

#	Article	IF	Citations
2855	Cholesteryl Ester Accumulation Induced by PTEN Loss and PI3K/AKT Activation Underlies Human Prostate Cancer Aggressiveness. Cell Metabolism, 2014, 19, 393-406.	7.2	671
2856	Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 335-342.	0.2	72
2857	I Prostanoid Receptorâ€"Mediated Inflammatory Pathway Promotes Hepatic Gluconeogenesis Through Activation of PKA and Inhibition of AKT. Diabetes, 2014, 63, 2911-2923.	0.3	23
2858	Molecular Testing in Cancer. , 2014, , .		2
2859	[6]-Shogaol inhibits growth and induces apoptosis of non-small cell lung cancer cells by directly regulating Akt1/2. Carcinogenesis, 2014, 35, 683-691.	1.3	71
2860	Hypoxia as a biomarker for radioresistant cancer stem cells. International Journal of Radiation Biology, 2014, 90, 636-652.	1.0	115
2861	Long-term immunosuppression and malignancy in thoracic transplantation: Where is the balance?. Journal of Heart and Lung Transplantation, 2014, 33, 461-467.	0.3	29
2862	Expression of molecules related to <scp>AKT</scp> pathway as putative regulators of ameloblastoma local invasiveness. Journal of Oral Pathology and Medicine, 2014, 43, 143-147.	1.4	10
2863	Fibroblast Growth Factor-2 Signaling in Neurogenesis and Neurodegeneration. Journal of NeuroImmune Pharmacology, 2014, 9, 92-101.	2.1	202
2864	Role of AKT signaling in DNA repair and clinical response to cancer therapy. Neuro-Oncology, 2014, 16, 1313-1323.	0.6	110
2865	<scp>PI</scp>3Kâ€dependent multiple myeloma cell survival is mediated by the <scp>PIK</scp>3<scp>CA</scp> isoform. British Journal of Haematology, 2014, 166, 529-539.	1.2	17
2866	⁹⁹Tc NMR as a promising technique for structural investigation of biomolecules: theoretical studies on the solvent and thermal effects of phenylbenzothiazole complex. Magnetic Resonance in Chemistry, 2014, 52, 129-137.	1.1	21
2867	Guggulsterone of Commiphora mukul resin reverses drug resistance in imatinib-resistant leukemic cells by inhibiting cyclooxygenase-2 and P-glycoprotein. Phytomedicine, 2014, 21, 1004-1009.	2.3	10
2868	Breast cancer: Current and future endocrine therapies. Molecular and Cellular Endocrinology, 2014, 382, 695-723.	1.6	81
2869	Down-regulation of lipid raft-associated onco-proteins via cholesterol-dependent lipid raft internalization in docosahexaenoic acid-induced apoptosis. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2014, 1841, 190-203.	1.2	51
2870	The Molecular Basis for the Pharmacokinetics and Pharmacodynamics of Curcumin and Its Metabolites in Relation to Cancer. Pharmacological Reviews, 2014, 66, 222-307.	7.1	418
2871	Dietary phytochemicals alter epigenetic events and signaling pathways for inhibition of metastasis cascade. Cancer and Metastasis Reviews, 2014, 33, 41-85.	2.7	56
2872	The multiple layers of non-genetic regulation of PTEN tumour suppressor activity. European Journal of Cancer, 2014, 50, 216-225.	1.3	69

#	Article	IF	Citations
2873	MiR-1 targets PIK3CA and inhibits tumorigenic properties of A549 cells. Biomedicine and Pharmacotherapy, 2014, 68, 155-161.	2.5	43
2874	Bradykinin promotes vascular endothelial growth factor expression and increases angiogenesis in human prostate cancer cells. Biochemical Pharmacology, 2014, 87, 243-253.	2.0	38
2875	Multimodal Therapies for Pancreatic Cancer. , 2014, , 39-73.		0
2876	Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. Nature Genetics, 2014, 46, 1258-1263.	9.4	269
2877	Signaling Cascades Driving the Malignant Phenotype of Glioma Cells. , 2014, , 47-75.		2
2878	Akt Suppression of TGFÎ² Signaling Contributes to the Maintenance of Vascular Identity in Embryonic Stem Cell-Derived Endothelial Cells. Stem Cells, 2014, 32, 177-190.	1.4	20
2879	Improving chemoradiation efficacy by PI3-K/AKT inhibition. Cancer Treatment Reviews, 2014, 40, 1182-1191.	3.4	39
2880	Pre-B-cell leukemia homeobox interacting protein 1 is overexpressed in astrocytoma and promotes tumor cell growth and migration. Neuro-Oncology, 2014, 16, 946-959.	0.6	31
2881	Caspase-activated phosphoinositide binding by CNT-1 promotes apoptosis by inhibiting the AKT pathway. Nature Structural and Molecular Biology, 2014, 21, 1082-1090.	3.6	18
2882	The Role of the PTEN/PI3K/Akt Pathway on Prognosis in Epithelial Ovarian Cancer: A Meta-Analysis. Oncologist, 2014, 19, 528-535.	1.9	48
2883	Class IA Phosphatidylinositol 3-Kinase Inhibition Inhibits Cell Growth and Proliferation in Mantle Cell Lymphoma. Acta Haematologica, 2014, 131, 59-69.	0.7	21
2884	Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis. Leukemia, 2014, 28, 2197-2205.	3.3	60
2885	Discovery and synthesis of a novel series of potent, selective inhibitors of the PI3KÎ±: 2-alkyl-chromeno[4,3-c]pyrazol-4(2H)-one derivatives. Organic and Biomolecular Chemistry, 2014, 12, 9157-9165.	1.5	14
2886	Targeting Myristoylated Alanine-Rich C Kinase Substrate Phosphorylation Site Domain in Lung Cancer. Mechanisms and Therapeutic Implications. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 1127-1138.	2.5	62
2887	Inhibition of triple-negative and Herceptin-resistant breast cancer cell proliferation and migration by Annexin A2 antibodies. British Journal of Cancer, 2014, 111, 2328-2341.	2.9	46
2888	Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1Î±-mediated VEGF-dependent angiogenesis. Oncogene, 2014, 33, 2053-2064.	2.6	110
2889	Clinical delineation and natural history of the PIK3CAâ€related overgrowth spectrum. American Journal of Medical Genetics, Part A, 2014, 164, 1713-1733.	0.7	249
2890	Naproxen Induces Cell-Cycle Arrest and Apoptosis in Human Urinary Bladder Cancer Cell Lines and Chemically Induced Cancers by Targeting PI3K. Cancer Prevention Research, 2014, 7, 236-245.	0.7	75

#	Article	IF	Citations
2891	Anticancer activity of HS-527, a novel inhibitor targeting PI3-kinase in human pancreatic cancer cells. Cancer Letters, 2014, 353, 68-77.	3.2	11
2892	Insulin Receptor Substrate 2-mediated Phosphatidylinositol 3-kinase Signaling Selectively Inhibits Glycogen Synthase Kinase 3Î² to Regulate Aerobic Glycolysis. Journal of Biological Chemistry, 2014, 289, 18603-18613.	1.6	43
2893	A Novel Small-Molecule YLT205 Induces Apoptosis in Human Colorectal CellsviaMitochondrial Apoptosis PathwayIn Vitroand Inhibits Tumor GrowthIn Vivo. Cellular Physiology and Biochemistry, 2014, 33, 933-944.	1.1	22
2894	Postulated Mechanisms of Resistance of B-Cell Non-Hodgkin Lymphoma to Rituximab Treatment Regimens: Strategies to Overcome Resistance. Seminars in Oncology, 2014, 41, 667-677.	0.8	43
2895	T-box transcription factors in cancer biology. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 380-391.	3.3	50
2896	Salvianolic acid A reverses paclitaxel resistance in human breast cancer MCF-7 cells via targeting the expression of transgelin 2 and attenuating PI3 K/Akt pathway. Phytomedicine, 2014, 21, 1725-1732.	2.3	48
2897	Blockade of epidermal growth factor receptor/mammalian target of rapamycin pathway by Icariside II results in reduced cell proliferation of osteosarcoma cells. Food and Chemical Toxicology, 2014, 73, 7-16.	1.8	38
2898	KU004 induces G1 cell cycle arrest in human breast cancer SKBR-3 cells by modulating PI3K/Akt pathway. Biomedicine and Pharmacotherapy, 2014, 68, 625-630.	2.5	7
2899	PTEN. Annual Review of Biochemistry, 2014, 83, 641-669.	5.0	427
2900	miR-508 sustains phosphoinositide signalling and promotes aggressive phenotype of oesophageal squamous cell carcinoma. Nature Communications, 2014, 5, 4620.	5.8	57
2901	Targeted Systemic Delivery of Therapeutic siRNA. , 2014, , 47-65.		5
2902	TIPE3 Is the Transfer Protein of Lipid Second Messengers that Promote Cancer. Cancer Cell, 2014, 26, 465-478.	7.7	93
2903	Crosstalk between kinases, phosphatases and miRNAs in cancer. Biochimie, 2014, 107, 167-187.	1.3	10
2904	Molecular Approaches Toward Targeted Cancer Prevention with Some Food Plants and Their Products: Inflammatory and Other Signal Pathways. Nutrition and Cancer, 2014, 66, 194-205.	0.9	72
2905	Down-regulation of miR-29c in human bladder cancer and the inhibition of proliferation in T24 cell via PI3K-AKT pathway. Medical Oncology, 2014, 31, 65.	1.2	30
2906	Constitutive AKT activation in follicular lymphoma. BMC Cancer, 2014, 14, 565.	1.1	19
2907	Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma. Molecular Cancer, 2014, 13, 185.	7.9	37
2908	Whole genome sequencing reveals potential targets for therapy in patients with refractory KRASmutated metastatic colorectal cancer. BMC Medical Genomics, 2014, 7, 36.	0.7	18

#	Article	IF	Citations
2909	A GG allele of 3â€²-side AKT1 SNP is associated with decreased AKT1 activation and better prognosis of gastric cancer. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1399-1411.	1.2	20
2910	Radiosensitizing activity of a novel Benzoxazine through the promotion of apoptosis and inhibition of DNA repair. Investigational New Drugs, 2014, 32, 424-435.	1.2	5
2911	Matrine inhibits proliferation and induces apoptosis of human colon cancer LoVo cells by inactivating Akt pathway. Molecular Biology Reports, 2014, 41, 2101-2108.	1.0	30
2912	Vitamin D Inhibits COX-2 Expression and Inflammatory Response by Targeting Thioesterase Superfamily Member 4. Journal of Biological Chemistry, 2014, 289, 11681-11694.	1.6	107
2913	PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients. Breast Cancer Research, 2014, 16, R13.	2.2	54
2914	PI3K pathway inhibitor LY294002 alters Jurkat T cell biobehaviours via ERK1/2-ICBP90 mediation. Open Life Sciences, 2014, 9, 739-748.	0.6	0
2915	An update on molecular biology of thyroid cancers. Critical Reviews in Oncology/Hematology, 2014, 90, 233-252.	2.0	83
2916	PTEN and leukemia stem cells. Advances in Biological Regulation, 2014, 56, 22-29.	1.4	33
2917	A New Chemical Probe for Phosphatidylinositol Kinase Activity. ChemBioChem, 2014, 15, 1253-1256.	1.3	25
2918	PTEN Deficiency Mediates a Reciprocal Response to IGFI and mTOR Inhibition. Molecular Cancer Research, 2014, 12, 1610-1620.	1.5	25
2919	The novel PI3 kinase inhibitor, BAY 80â€6946, impairs melanoma growth in vivo and in vitro. Experimental Dermatology, 2014, 23, 579-584.	1.4	13
2920	Gene Expression Analysis in MCF-7 Breast Cancer Cells Treated with Recombinant Bromelain. Applied Biochemistry and Biotechnology, 2014, 173, 1618-1639.	1.4	12
2921	Association between the lengths of GT dinucleotide repeat in the PIK3CA gene with breast cancer risk. Medical Oncology, 2014, 31, 29.	1.2	1
2922	Efficacy of rapamycin against glioblastoma cancer stem cells. Clinical and Translational Oncology, 2014, 16, 495-502.	1.2	36
2923	PP121, a dual inhibitor of tyrosine and phosphoinositide kinases, inhibits anaplastic thyroid carcinoma cell proliferation and migration. Tumor Biology, 2014, 35, 8659-8664.	0.8	18
2924	Epalrestat induces cell proliferation and migration in endothelial cells via mTOR activation through PI3/Akt signaling. Diabetology International, 2014, 5, 105-111.	0.7	1
2925	Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells. BMC Cancer, 2014, 14, 373.	1.1	21
2926	Endothelial cell-derived interleukin-6 regulates tumor growth. BMC Cancer, 2014, 14, 99.	1.1	27

#	Article	IF	Citations
2927	Acylglycerol kinase promotes cell proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor. Molecular Cancer, 2014, 13, 106.	7.9	51
2928	Prostate cancer ETS rearrangements switch a cell migration gene expression program from RAS/ERK to PI3K/AKT regulation. Molecular Cancer, 2014, 13, 61.	7.9	31
2929	Deoxynivalenol induced mouse skin cell proliferation and inflammation via MAPK pathway. Toxicology and Applied Pharmacology, 2014, 279, 186-197.	1.3	57
2930	The links between AKT and two intracellular proteolytic cascades: Ubiquitination and autophagy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 342-352.	3.3	58
2931	HtrA1 Downregulation Induces Cisplatin Resistance in Lung Adenocarcinoma by Promoting Cancer Stem Cellâ€Like Properties. Journal of Cellular Biochemistry, 2014, 115, 1112-1121.	1.2	19
2932	Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours. British Journal of Cancer, 2014, 111, 858-865.	2.9	20
2933	Safety profile and treatment response of everolimus in different solid tumors: an observational study. Future Oncology, 2014, 10, 1611-1617.	1.1	8
2934	<scp>MicroRNA</scp>â€221 targeting <scp>PI3â€K/Akt</scp> signaling axis induces cell proliferation and <scp>BCNU</scp> resistance in human glioblastoma. Neuropathology, 2014, 34, 455-464.	0.7	40
2935	Herpes Simplex Virus Protein Kinases US3 and UL13 Modulate VP11/12 Phosphorylation, Virion Packaging, and Phosphatidylinositol 3-Kinase/Akt Signaling Activity. Journal of Virology, 2014, 88, 7379-7388.	1.5	38
2936	Synthesis and structureâ€“activity relationships of PI3K/mTOR dual inhibitors from a series of 2-amino-4-methylpyrido[2,3- d]pyrimidine derivatives. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4538-4541.	1.0	17
2937	Therapeutic Melting Pot of Never in Mitosis Gene A Related Kinase 2 (Nek2): A Perspective on Nek2 as an Oncology Target and Recent Advancements in Nek2 Small Molecule Inhibition. Journal of Medicinal Chemistry, 2014, 57, 5835-5844.	2.9	21
2938	The end of KRAS, and other, cancers? A new way forward. Drug Discovery Today, 2014, 19, 383-387.	3.2	5
2939	A novel PI3K inhibitor displays potent preclinical activity against an androgen-independent and PTEN-deficient prostate cancer model established from the cell line PC3. Toxicology Letters, 2014, 228, 133-139.	0.4	16
2940	Hydroxytyrosol, a natural molecule from olive oil, suppresses the growth of human hepatocellular carcinoma cells via inactivating AKT and nuclear factor-kappa B pathways. Cancer Letters, 2014, 347, 79-87.	3.2	82
2941	SPOP Promotes Tumorigenesis by Acting as a Key Regulatory Hub in Kidney Cancer. Cancer Cell, 2014, 25, 455-468.	7.7	154
2942	Inhibition of phosphoinositide 3-kinase is associated with reduced angiogenesis and an altered expression of angiogenic markers in endothelioma cells. Biomedicine and Pharmacotherapy, 2014, 68, 611-617.	2.5	5
2943	The role of NAD+-dependent isocitrate dehydrogenase 3 subunit Î± in AFB1 induced liver lesion. Toxicology Letters, 2014, 224, 371-379.	0.4	7
2944	Elucidation of different inhibition mechanism of small chemicals on PtdInsP-binding domains using in silico docking experiments. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2256-2262.	1.0	4

#	Article	IF	Citations
2945	Small chemicals with inhibitory effects on PtdIns(3,4,5)P3 binding of Btk PH domain. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2334-2339.	1.0	16
2946	BMX Acts Downstream of PI3K to Promote Colorectal Cancer Cell Survival and Pathway Inhibition Sensitizes to the BH3 Mimetic ABT-737. Neoplasia, 2014, 16, 147-W16.	2.3	22
2947	The Role of Src in Colon Cancer and Its Therapeutic Implications. Clinical Colorectal Cancer, 2014, 13, 5-13.	1.0	106
2948	Update on Prognostic Markers for Endometrial Cancer. Women's Health, 2014, 10, 277-288.	0.7	34
2949	PI3K/AKT signaling pathway and cancer: an updated review. Annals of Medicine, 2014, 46, 372-383.	1.5	887
2950	BI-69A11 enhances susceptibility of colon cancer cells to mda-7/IL-24-induced growth inhibition by targeting Akt. British Journal of Cancer, 2014, 111, 101-111.	2.9	10
2951	PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E2404-13.	3.3	85
2952	Molecular mechanisms and physiology of disease. , 2014, , .		1
2953	Theoretical studies on beta and delta isoform-specific binding mechanisms of phosphoinositide 3-kinase inhibitors. Molecular BioSystems, 2014, 10, 454-466.	2.9	17
2954	Synthesis and biological evaluation of substituted 2-anilino-7H-pyrrolopyrimidines as PDK1 inhibitors. Tetrahedron, 2014, 70, 4947-4956.	1.0	7
2955	Targeted therapy for gastric cancer: Molecular pathways and ongoing investigations. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 232-237.	3.3	59
2956	Transcriptional and posttranslational regulation of insulin-like growth factor binding protein-3 by Akt3. Carcinogenesis, 2014, 35, 2232-2243.	1.3	10
2957	Short Linear Motifs: Ubiquitous and Functionally Diverse Protein Interaction Modules Directing Cell Regulation. Chemical Reviews, 2014, 114, 6733-6778.	23.0	389
2958	Shikonin inhibits prostate cancer cells metastasis by reducing matrix metalloproteinase-2/-9 expression via AKT/mTOR and ROS/ERK1/2 pathways. International Immunopharmacology, 2014, 21, 447-455.	1.7	74
2959	Alpha-melanocyte stimulating hormone protects retinal pigment epithelium cells from oxidative stress through activation of melanocortin 1 receptorâ€“Aktâ€“mTOR signaling. Biochemical and Biophysical Research Communications, 2014, 443, 447-452.	1.0	47
2960	Studying the enhancement of programmed cell death by combined AG1024 and paclitaxel in a model of chronic myelogenous leukemia. Life Sciences, 2014, 102, 118-126.	2.0	1
2961	Dysregulation of the IGFâ€‰/PI3K/AKT/mTOR signaling pathway in autism spectrum disorders. International Journal of Developmental Neuroscience, 2014, 35, 35-41.	0.7	120
2962	Arachidonic acid promotes migration and invasion through a PI3K/Akt-dependent pathway in MDA-MB-231 breast cancer cells. Prostaglandins Leukotrienes and Essential Fatty Acids, 2014, 90, 169-177.	1.0	30

#	Article	IF	Citations
2963	Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing agents in K-ras mutation-harboring lung adenocarcinoma cells: Implication of EGFR tyrosine kinase inhibitors. International Journal of Oncology, 2014, 44, 685-692.	1.4	6
2964	Farnesol induces apoptosis of DU145 prostate cancer cells through the PI3K/Akt and MAPK pathways. International Journal of Molecular Medicine, 2014, 33, 1169-1176.	1.8	26
2965	A novel derivative of quinazoline, WYK431 induces G2/M phase arrest and apoptosis in human gastric cancer BGC823 cells through the PI3K/Akt pathway. International Journal of Oncology, 2014, 45, 771-781.	1.4	12
2966	The Role of n-3 Polyunsaturated Fatty Acids in the Prevention and Treatment of Breast Cancer. Nutrients, 2014, 6, 5184-5223.	1.7	152
2967	Significance of AKT in gastric cancer (Review). International Journal of Oncology, 2014, 45, 2187-2192.	1.4	48
2968	Activation of EGFR-PI3K-AKT signaling is required for Mycoplasma hyorhinis-promoted gastric cancer cell migration. Cancer Cell International, 2014, 14, 135.	1.8	37
2969	Significance of p85 expression as a prognostic factor for patients with breast cancer. Oncology Letters, 2014, 8, 1657-1661.	0.8	3
2970	Dual targeting of glioblastoma multiforme with a proteasome inhibitor (Velcade) and a phosphatidylinositol 3-kinase inhibitor (ZSTK474). International Journal of Oncology, 2014, 44, 557-562.	1.4	14
2971	SIPL1 enhances the proliferation, attachment, and migration of CHO cells by inhibiting PTEN function. International Journal of Molecular Medicine, 2014, 34, 835-841.	1.8	11
2972	Genetic screen identifies suppressor of morphogenesis in genitalia-1 (SMG-1) as a modulator of sorafenib resistance in hepatocellular carcinoma cell lines. International Journal of Oncology, 2014, 45, 1450-1456.	1.4	8
2973	CD38 is highly expressed and affects the PI3K/Akt signaling pathway in cervical cancer. Oncology Reports, 2014, 32, 2703-2709.	1.2	28
2974	Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma. Oncology Reports, 2014, 32, 1465-1472.	1.2	33
2975	Bayesian sparse graphical models for classification with application to protein expression data. Annals of Applied Statistics, 2014, 8, 1443-1468.	0.5	23
2976	Design and Synthesis of Novel Quinazoline Derivatives and Their Evaluation as PI3Ks Inhibitors. Chemical and Pharmaceutical Bulletin, 2014, 62, 1166-1172.	0.6	1
2977	A key to the quest?. Blood, 2014, 124, 2162-2163.	0.6	1
2978	PP2A inactivation by ROS accumulation. Blood, 2014, 124, 2163-2165.	0.6	13
2979	Distinct regulatory effect of the p34SEI-1 oncoprotein on cancer metastasis in HER2/neu-positive and -negative cells. International Journal of Oncology, 2014, 45, 189-196.	1.4	11
2980	HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer. International Journal of Oncology, 2014, 45, 311-321.	1.4	10

#	Article	IF	Citations
2981	EphA3, induced by PC-1/PrLZ, contributes to the malignant progression of prostate cancer. Oncology Reports, 2014, 32, 2657-2665.	1.2	25
2982	Skin mast cells develop nonâ€synchronized changes in typical lineage characteristics upon culture. Experimental Dermatology, 2014, 23, 933-935.	1.4	32
2983	Constitutive Photomorphogensis Protein1 (COP1) mediated p53 pathway and its oncogenic role. Biomedical Research and Therapy, 2014, 1, .	0.3	2
2984	Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines under Normoxic and Hypoxic Conditions. Breast Cancer: Basic and Clinical Research, 2014, 8, BCBCR.S13693.	0.6	35
2985	Akt Goes Cycling. Cancer Control, 2014, 21, 239-241.	0.7	0
2986	TRAF4 Enhances Osteosarcoma Cell Proliferation and Invasion by Akt Signaling Pathway. Oncology Research, 2014, 22, 21-28.	0.6	24
2987	Effect of StarD13 on colorectal cancer proliferation, motility and invasion. Oncology Reports, 2014, 31, 505-515.	1.2	31
2988	Thymoquinone induces G2/M arrest, inactivates PI3K/Akt and nuclear factor-Î°B pathways in human cholangiocarcinomas both in vitro and in vivo. Oncology Reports, 2014, 31, 2063-2070.	1.2	64
2989	Apigenin-induced apoptosis is enhanced by inhibition of autophagy formation in HCT116 human colon cancer cells. International Journal of Oncology, 2014, 44, 1599-1606.	1.4	116
2990	Effect of PTEN and KAI1 gene overexpression on the proliferation, metastasis and radiosensitivity of ASPC-1 pancreatic cancer cells under hypoxic conditions. Molecular Medicine Reports, 2014, 10, 1973-1977.	1.1	5
2991	1,25-Dihydroxyvitamin D3 and cisplatin synergistically induce apoptosis and cell cycle arrest in gastric cancer cells. International Journal of Molecular Medicine, 2014, 33, 1177-1184.	1.8	33
2992	Fisetin targets phosphatidylinositol-3-kinase and induces apoptosis of human B lymphoma Raji cells. Toxicology Reports, 2015, 2, 984-989.	1.6	16
2993	Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone I in human breast cancer cell lines. Molecular Medicine Reports, 2015, 11, 931-939.	1.1	56
2994	Dysregulation of the PI3K/Akt signaling pathway affects cell cycle and apoptosis of side population cells in nasopharyngeal carcinoma. Oncology Letters, 2015, 10, 182-188.	0.8	23
2995	Hsp90 inhibitor induces autophagy and apoptosis in osteosarcoma cells. International Journal of Oncology, 2015, 46, 47-54.	1.4	77
2996	Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability. Molecular Carcinogenesis, 2015, 54, 1301-1314.	1.3	27
2997	PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer. Cancer Medicine, 2015, 4, 371-382.	1.3	25
2998	On comparing heterogeneity across biomarkers. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2015, 87, 558-567.	1.1	12

#	Article	IF	Citations
2999	Nonâ€hormonal targets underlying endometriosis: A focus on molecular mechanisms. Molecular Reproduction and Development, 2015, 82, 410-431.	1.0	2
3000	The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines. Hematological Oncology, 2015, 33, 166-175.	0.8	15
3001	Basal expression of insulinâ€like growth factor 1 receptor determines intrinsic resistance of cancer cells to a phosphatidylinositol 3â€kinase inhibitor ZSTK474. Cancer Science, 2015, 106, 171-178.	1.7	12
3002	Proteomics and Prostate Cancer. , 2015, , 143-174.		0
3003	Paxillin regulates vascular endothelial growth factor A-induced in vitro angiogenesis of human umbilical vein endothelial cells. Molecular Medicine Reports, 2015, 11, 1784-1792.	1.1	10
3004	Reactive oxygen species-mediated activation of the Src-epidermal growth factor receptor-Akt signaling cascade prevents bortezomib-induced apoptosis in hepatocellular carcinoma cells. Molecular Medicine Reports, 2015, 11, 712-718.	1.1	23
3005	Fucoidan inhibits the migration and proliferation of HT-29 human colon cancer cells via the phosphoinositide-3 kinase/Akt/mechanistic target of rapamycin pathways. Molecular Medicine Reports, 2015, 12, 3446-3452.	1.1	67
3006	Myristoylated p110Î± Causes Embryonic Death Due to Developmental and Vascular Defects. Open Life Sciences, 2015, 10, 461-478.	0.6	5
3007	Pseudolaric acid B exerts antitumor activity via suppression of the Akt signaling pathway in HeLa cervical cancer cells. Molecular Medicine Reports, 2015, 12, 2021-2026.	1.1	8
3009	Associations of PI3KR1 and mTOR Polymorphisms with Esophageal Squamous Cell Carcinoma Risk and Gene-Environment Interactions in Eastern Chinese Populations. Scientific Reports, 2015, 5, 8250.	1.6	48
3010	Highly-accurate metabolomic detection of early-stage ovarian cancer. Scientific Reports, 2015, 5, 16351.	1.6	65
3011	Akt2 knock-down reveals its contribution to human lung cancer cell proliferation, growth, motility, invasion and endothelial cell tube formation. Scientific Reports, 2015, 5, 12759.	1.6	32
3012	The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia. Scientific Reports, 2015, 5, 18137.	1.6	28
3013	IRX2-mediated upregulation of MMP-9 and VEGF in a PI3K/AKT-dependent manner. Molecular Medicine Reports, 2015, 12, 4346-4351.	1.1	15
3014	A novel analysis strategy for integrating methylation and expression data reveals core pathways for thyroid cancer aetiology. BMC Genomics, 2015, 16, S7.	1.2	3
3015	Polymorphic GT dinucleotide repeat in the PIK3CA gene and risk of colorectal cancer. Cancer Biomarkers, 2015, 15, 397-403.	0.8	3
3016	AKT is translocated to the mitochondria during etoposide-induced apoptosis of HeLa cells. Molecular Medicine Reports, 2015, 12, 7577-7581.	1.1	4
3017	Multiple Roles of MicroRNA-100 in Human Cancer and its Therapeutic Potential. Cellular Physiology and Biochemistry, 2015, 37, 2143-2159.	1.1	67

#	Article	IF	Citations
3018	DNA methylation Landscape of body size variation in sheep. Scientific Reports, 2015, 5, 13950.	1.6	24
3019	Superoxide Dismutase 1 Regulation of CXCR4-Mediated Signaling in Prostate Cancer Cells is Dependent on Cellular Oxidative State. Cellular Physiology and Biochemistry, 2015, 37, 2071-2084.	1.1	23
3020	PTEN regulates lung endodermal morphogenesis through MEK/ERK pathway. Developmental Biology, 2015, 408, 56-65.	0.9	9
3021	Forkhead Box Transcription Factor (FOXO3a) mediates the cytotoxic effect of vernodalin in vitro and inhibits the breast tumor growth in vivo. Journal of Experimental and Clinical Cancer Research, 2015, 34, 147.	3.5	34
3022	Activin and TGFÎ² use diverging mitogenic signaling in advanced colon cancer. Molecular Cancer, 2015, 14, 182.	7.9	52
3023	<scp>HSP</scp>60 overexpression increases the protein levels of the p110Î± subunit ofÂÂphosphoinositide 3â€kinase and câ€Myc. Clinical and Experimental Pharmacology and Physiology, 2015, 42, 1092-1097.	0.9	13
3025	Current mechanistic insights into the roles of matrix metalloproteinases in tumour invasion and metastasis. Journal of Pathology, 2015, 237, 273-281.	2.1	201
3026	Expression of focal adhesion kinase in mouse cumulusâ€oocyte complexes, and effect of phosphorylation at Tyr397 on cumulus expansion. Molecular Reproduction and Development, 2015, 82, 218-231.	1.0	4
3027	Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. British Journal of Haematology, 2015, 171, 463-470.	1.2	81
3028	Ovarian actions of resveratrol. Annals of the New York Academy of Sciences, 2015, 1348, 86-96.	1.8	55
3029	Leishmania mexicana amastigotes inhibit p38 and JNK and activate PI3K/AKT: role in the inhibition of apoptosis of dendritic cells. Parasite Immunology, 2015, 37, 579-589.	0.7	16
3031	Targeting Glioma Stem Cells for Therapy: Perspectives and Challenges. Journal of Cell Science & Therapy, 2015, 06, .	0.3	1
3032	A Systematic Review on Antitumor Agents with 1, 3, 5-triazines. , 2015, 5, .		27
3033	The expression of the PI3K/AKT/mTOR pathway in gastric cancer and its role in gastric cancer prognosis. OncoTargets and Therapy, 2015, 8, 2427.	1.0	50
3034	Biomarkers for determination prostate cancer: implication for diagnosis and prognosis. Neoplasma, 2015, 62, 683-691.	0.7	18
3035	MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A. Oncotarget, 2015, 6, 3211-3224.	0.8	145
3036	Tyrphostin AG1296, a platelet-derived growth factor receptor inhibitor, induces apoptosis, and reduces viability and migration of PLX4032-resistant melanoma cells. OncoTargets and Therapy, 2015, 8, 1043.	1.0	10
3037	Design, Synthesis and Biological Evaluation of Novel 1,3,5-triazines Derivatives as Potent Antitumor Agents. , 2015, , .		0

#	Article	IF	Citations
3038	Antitumor Effects of Fucoidan on Human Colon Cancer Cells via Activation of Akt Signaling. Biomolecules and Therapeutics, 2015, 23, 225-232.	1.1	56
3039	Von Hippel-Lindau status influences phenotype of liver cancers arising from PTEN loss. Gastrointestinal Cancer: Targets and Therapy, 2015, 5, 61.	5.5	1
3040	PI3K pathway in cancer. , 0, , 193-203.		0
3041	Genetic variations in the mTOR gene contribute toward gastric adenocarcinoma susceptibility in an Eastern Chinese population. Pharmacogenetics and Genomics, 2015, 25, 521-530.	0.7	11
3042	Sinulariolide Suppresses Human Hepatocellular Carcinoma Cell Migration and Invasion by Inhibiting Matrix Metalloproteinase-2/-9 through MAPKs and PI3K/Akt Signaling Pathways. International Journal of Molecular Sciences, 2015, 16, 16469-16482.	1.8	74
3043	The Role of the PI3K Pathway in the Regeneration of the Damaged Brain by Neural Stem Cells after		

#	Article	IF	Citations
3056	Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells. PLoS ONE, 2015, 10, e0129663.	1.1	30
3057	Precise Classification of Cervical Carcinomas Combined with Somatic Mutation Profiling Contributes to Predicting Disease Outcome. PLoS ONE, 2015, 10, e0133670.	1.1	48
3058	Hormetic Effect of Berberine Attenuates the Anticancer Activity of Chemotherapeutic Agents. PLoS ONE, 2015, 10, e0139298.	1.1	47
3059	A Panel of Genetic Polymorphism for the Prediction of Prognosis in Patients with Early Stage Non-Small Cell Lung Cancer after Surgical Resection. PLoS ONE, 2015, 10, e0140216.	1.1	11
3060	Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092. PLoS ONE, 2015, 10, e0140479.	1.1	93
3061	Association between Time on Protease Inhibitors and the Incidence of Squamous Cell Carcinoma of the Anus among U.S. Male Veterans. PLoS ONE, 2015, 10, e0142966.	1.1	21
3063	The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells. Drug Design, Development and Therapy, 2015, 9, 1627.	2.0	63
3064	Splicing Regulators and Their Roles in Cancer Biology and Therapy. BioMed Research International, 2015, 2015, 1-12.	0.9	39
3065	Drug Repositioning for Gynecologic Tumors: A New Therapeutic Strategy for Cancer. Scientific World Journal, The, 2015, 2015, 1-10.	0.8	28
3066	Association betweenAKT1Gene Polymorphism rs2498794 and Smoking-Related Traits with reference to Cancer Susceptibility. BioMed Research International, 2015, 2015, 1-12.	0.9	8
3069	MicroRNA-3127 promotes cell proliferation and tumorigenicity in hepatocellular carcinoma by disrupting of PI3K/AKT negative regulation. Oncotarget, 2015, 6, 6359-6372.	0.8	36
3070	Deregulation ofARID1A,CDH1,cMETandPIK3CAand target-related microRNA expression in gastric cancer. Oncotarget, 2015, 6, 26935-26945.	0.8	35
3071	Systems Biology of Glioblastoma Multiforme. , 2015, , .		0
3072	Cellular adaptation to nutrient deprivation: crosstalk between the mTORC1 and eIF2Î± signaling pathways and implications for autophagy. Cell Cycle, 2015, 14, 2571-2577.	1.3	34
3073	Personalized Therapies for Cancer Treatment. , 2015, , 317-346.		0
3074	New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials. Cancer Treatment Reviews, 2015, 41, 614-622.	3.4	19
3075	Toll-Like Receptor Pathway and its Targeting in Treatment of Cancers. , 2015, , 329-339.		2
3076	ShRNA-mediated silencing of the ubiquitin-specific protease 22 gene restrained cell progression and affected the Akt pathway in nasopharyngeal carcinoma. Cancer Biology and Therapy, 2015, 16, 88-96.	1.5	15

#	Article	IF	Citations
3077	The critical role of Akt in cardiovascular function. Vascular Pharmacology, 2015, 74, 38-48.	1.0	299
3078	CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization. Molecular Cancer Therapeutics, 2015, 14, 1295-1305.	1.9	48
3079	Extracellular signal-regulated kinases 1/2 and Akt contribute to triclosan-stimulated proliferation of JB6 Cl 41-5a cells. Archives of Toxicology, 2015, 89, 1297-1311.	1.9	19
3080	miRNA-150 downregulation promotes pertuzumab resistance in ovarian cancer cells via AKT activation. Archives of Gynecology and Obstetrics, 2015, 292, 1109-1116.	0.8	41
3081	Microenvironment involved in FPR1 expression by human glioblastomas. Journal of Neuro-Oncology, 2015, 123, 53-63.	1.4	9
3082	PIM kinase (and Akt) biology and signaling in tumors. , 2015, 151, 41-49.		154
3083	Design of selective PI3KÎ± inhibitors starting from a promiscuous pan kinase scaffold. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2679-2685.	1.0	9
3084	Emerging kinase inhibitors of the treatment of gastric cancer. Expert Opinion on Emerging Drugs, 2015, 20, 479-493.	1.0	13
3085	Tumor-Targeted Synergistic Blockade of MAPK and PI3K from a Layer-by-Layer Nanoparticle. Clinical Cancer Research, 2015, 21, 4410-4419.	3.2	55
3086	Proline-rich AKT substrate of 40-kDa (PRAS40) in the pathophysiology of cancer. Biochemical and Biophysical Research Communications, 2015, 463, 161-166.	1.0	44
3087	Uterine Histotroph and Conceptus Development. I. Cooperative Effects of Arginine and Secreted Phosphoprotein 1 on Proliferation of Ovine Trophectoderm Cells via Activation of the PDK1-Akt/PKB-TSC2-MTORC1 Signaling Cascade1. Biology of Reproduction, 2015, 92, 51.	1.2	24
3088	Constitutive control of AKT1 gene expression by JUNB/CJUN in ALK+ anaplastic large-cell lymphoma: a novel crosstalk mechanism. Leukemia, 2015, 29, 2162-2172.	3.3	18
3089	Chronic inorganic arsenic exposure in vitro induces a cancer cell phenotype in human peripheral lung epithelial cells. Toxicology and Applied Pharmacology, 2015, 286, 36-43.	1.3	36
3090	The molecular background of mucinous carcinoma beyond MUC2. Journal of Pathology: Clinical Research, 2015, 1, 3-17.	1.3	69
3091	microRNA-93 promotes cell proliferation via targeting of PTEN in Osteosarcoma cells. Journal of Experimental and Clinical Cancer Research, 2015, 34, 76.	3.5	68
3092	Apelin-13 promotes cardiomyocyte hypertrophy via PI3K-Akt-ERK1/2-p70S6K and PI3K-induced autophagy. Acta Biochimica Et Biophysica Sinica, 2015, 47, 969-980.	0.9	48
3093	Network-level effects of kinase inhibitors modulate TNF-Î±â€“induced apoptosis in the intestinal epithelium. Science Signaling, 2015, 8, ra129.	1.6	19
3094	Nuclear Pore Complexes and Nucleocytoplasmic Transport. International Review of Cell and Molecular Biology, 2015, 320, 171-233.	1.6	68

#	Article	IF	Citations
3095	MicroRNA profiling of the pubertal mouse mammary gland identifies miR-184 as a candidate breast tumour suppressor gene. Breast Cancer Research, 2015, 17, 83.	2.2	44
3096	Hsp27 Acts as a Master Molecular Chaperone and Plays an Essential Role in Hepatocellular Carcinoma Progression. Digestion, 2015, 92, 192-202.	1.2	18
3097	PH motifs in PAR1&2 endow breast cancer growth. Nature Communications, 2015, 6, 8853.	5.8	27
3098	Modification of a dihydropyrrolopyrimidine phosphoinositide 3-kinase (PI3K) inhibitor to improve oral bioavailability. Bioorganic and Medicinal Chemistry, 2015, 23, 7650-7660.	1.4	9
3099	Bitter melon juice targets molecular mechanisms underlying gemcitabine resistance in pancreatic cancer cells. International Journal of Oncology, 2015, 46, 1849-1857.	1.4	22
3100	Sedanolide induces autophagy through the PI3K, p53 and NF-Î¹B signaling pathways in human liver cancer cells. International Journal of Oncology, 2015, 47, 2240-2246.	1.4	22
3101	GDC-0152 attenuates the malignant progression of osteosarcoma promoted by ANGPTL2 via PI3K/AKT but not p38MAPK signaling pathway. International Journal of Oncology, 2015, 46, 1651-1658.	1.4	29
3102	Identification of Akt1 as a potent therapeutic target for oral squamous cell carcinoma. International Journal of Oncology, 2015, 47, 1273-1281.	1.4	16
3103	Fra-1 is upregulated in gastric cancer tissues and affects the PI3K/Akt and p53 signaling pathway in gastric cancer. International Journal of Oncology, 2015, 47, 1725-1734.	1.4	40
3104	The role of targeting kinase activity by natural products in cancer chemoprevention and chemotherapy (Review). Oncology Reports, 2015, 34, 547-554.	1.2	37
3105	Energy metabolism determines the sensitivity of human hepatocellular carcinoma cells to mitochondrial inhibitors and biguanide drugs. Oncology Reports, 2015, 34, 1620-1628.	1.2	27
3106	The JAK/STAT signaling cascade in gastric carcinoma (Review). International Journal of Oncology, 2015, 47, 1617-1626.	1.4	74
3107	Combined treatment of XIAP-targeting shRNA and celecoxib synergistically inhibits the tumor growth of non-small cell lung cancer cells in vitro and in vivo. Oncology Reports, 2015, 33, 1079-1088.	1.2	6
3108	miRNA-542-3p downregulation promotes trastuzumab resistance in breast cancer cells via AKT activation. Oncology Reports, 2015, 33, 1215-1220.	1.2	38
3109	The phosphatidylinositol 3-kinase/Akt and c-Jun N-terminal kinase signaling in cancer: Alliance or contradiction? (Review). International Journal of Oncology, 2015, 47, 429-436.	1.4	95
3110	Circadian gene hClock enhances proliferation and inhibits apoptosis of human colorectal carcinoma cells in vitro and in vivo. Molecular Medicine Reports, 2015, 11, 4204-4210.	1.1	23
3111	Therapeutic targeting of tumor suppressor genes. Cancer, 2015, 121, 1357-1368.	2.0	132
3112	Selectivity Mechanism of <scp>ATP</scp>â€Competitive Inhibitors for <scp>PKB</scp> and <scp>PKA</scp>. Chemical Biology and Drug Design, 2015, 86, 9-18.	1.5	5

#	Article	IF	Citations
3113	MLN0128, an ATP-Competitive mTOR Kinase Inhibitor with Potent In Vitro and In Vivo Antitumor Activity, as Potential Therapy for Bone and Soft-Tissue Sarcoma. Molecular Cancer Therapeutics, 2015, 14, 395-406.	1.9	83
3114	Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma. Expert Opinion on Therapeutic Targets, 2015, 19, 795-805.	1.5	82
3115	mTOR Signaling in Endometrial Cancer: From a Molecular and Therapeutic Point of View. Current Obstetrics and Gynecology Reports, 2015, 4, 1-10.	0.3	11
3116	Gene and protein expression in pituitary corticotroph adenomas: a systematic review of the literature. Neurosurgical Focus, 2015, 38, E17.	1.0	26
3117	Expression of astrocyte elevated gene-1 (AEG-1) in human meningiomas and its roles in cell proliferation and survival. Journal of Neuro-Oncology, 2015, 121, 31-39.	1.4	11
3118	PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2â€“Targeted Therapies in Breast Cancer. Journal of Clinical Oncology, 2015, 33, 1334-1339.	0.8	201
3119	Cytotoxicity of obacunone and obacunone glucoside in human prostate cancer cells involves Akt-mediated programmed cell death. Toxicology, 2015, 329, 88-97.	2.0	27
3120	Profiling of Phosphatidylinositol 3-Kinase (PI3K) Proteins in Insulin Signaling Pathway. Applied Biochemistry and Biotechnology, 2015, 175, 3431-3446.	1.4	3
3121	Exploitation of the Ability of Î³-Tocopherol to Facilitate Membrane Co-localization of Akt and PHLPP1 to Develop PHLPP1-Targeted Akt Inhibitors. Journal of Medicinal Chemistry, 2015, 58, 2290-2298.	2.9	9
3122	Differential metabolomic analysis of the potential antiproliferative mechanism of olive leaf extract on the JIMT-1 breast cancer cell line. Journal of Pharmaceutical and Biomedical Analysis, 2015, 105, 156-162.	1.4	35
3123	Targeting drivers of melanoma with synthetic small molecules and phytochemicals. Cancer Letters, 2015, 359, 20-35.	3.2	67
3124	PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy. Endocrine, 2015, 48, 363-370.	1.1	94
3125	The route to personalized medicine in bladder cancer: where do we stand?. Targeted Oncology, 2015, 10, 325-336.	1.7	14
3126	Downregulation of PI3-K/Akt/PTEN pathway and activation of mitochondrial intrinsic apoptosis by Diclofenac and Curcumin in colon cancer. Molecular and Cellular Biochemistry, 2015, 402, 225-241.	1.4	69
3127	Understanding cancer and the anticancer activities of naphthoquinones â€“ a review. RSC Advances, 2015, 5, 20309-20338.	1.7	240
3128	Sirolimus plus gemcitabine: a new therapeutic combination for resistant sarcomas?. Expert Review of Anticancer Therapy, 2015, 15, 257-259.	1.1	5
3130	The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubuleâ€Targeting Drugs in Prostate Cancer. Journal of Cellular Biochemistry, 2015, 116, 1341-1349.	1.2	97
3131	New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions. Hepatology Research, 2015, 45, E1-E11.	1.8	67

#	Article	IF	Citations
3132	Cutaneous adverse effects of targeted therapies. Journal of the American Academy of Dermatology, 2015, 72, 221-236.	0.6	150
3133	Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary. Molecular Cancer Research, 2015, 13, 795-806.	1.5	25
3134	A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer. Investigational New Drugs, 2015, 33, 187-193.	1.2	35
3135	6,7-Dihydrobenzo[f]benzo[4,5]imidazo[1,2-d][1,4]oxazepine derivatives as selective inhibitors of PI3KÎ±. Bioorganic and Medicinal Chemistry, 2015, 23, 1231-1240.	1.4	26
3136	Akt phosphorylates Prohibitin 1 to mediate its mitochondrial localization and promote proliferation of bladder cancer cells. Cell Death and Disease, 2015, 6, e1660-e1660.	2.7	51
3137	Quercetin ameliorates dysregulation of lipid metabolism genes via the PI3K/AKT pathway in a dietâ€induced mouse model of nonalcoholic fatty liver disease. Molecular Nutrition and Food Research, 2015, 59, 879-893.	1.5	102
3138	Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. Cancer Chemotherapy and Pharmacology, 2015, 75, 183-189.	1.1	136
3139	Paracrine regulation of glioma cells invasion by astrocytes is mediated by glialâ€derived neurotrophic factor. International Journal of Cancer, 2015, 137, 1012-1020.	2.3	42
3140	Ionizing radiationâ€inducible miRâ€30e promotes glioma cell invasion through <scp>EGFR</scp> stabilization by directly targeting <scp>CBL</scp>â€B. FEBS Journal, 2015, 282, 1512-1525.	2.2	32
3141	Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas. Journal of Translational Medicine, 2015, 13, 37.	1.8	15
3142	The DEAD box protein p68: a crucial regulator of AKT/FOXO3a signaling axis in oncogenesis. Oncogene, 2015, 34, 5843-5856.	2.6	53
3143	Discovery of a Novel Series of Thienopyrimidine as Highly Potent and Selective PI3K Inhibitors. ACS Medicinal Chemistry Letters, 2015, 6, 434-438.	1.3	34
3144	Novel Candidate Key Drivers in the Integrative Network of Genes, MicroRNAs, Methylations, and Copy Number Variations in Squamous Cell Lung Carcinoma. BioMed Research International, 2015, 2015, 1-11.	0.9	31
3145	Discovery of Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor CC-223. Journal of Medicinal Chemistry, 2015, 58, 5323-5333.	2.9	29
3146	Critical Role for the DNA Sensor AIM2 in Stem Cell Proliferation and Cancer. Cell, 2015, 162, 45-58.	13.5	266
3147	Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma. Cancer Biology and Therapy, 2015, 16, 325-335.	1.5	12
3148	Immune biomarkers of anti-EGFR monoclonal antibody therapy. Annals of Oncology, 2015, 26, 40-47.	0.6	51
3149	Molecular biomarkers in colorectal carcinoma. Pharmacogenomics, 2015, 16, 1189-1222.	0.6	14

#	Article	IF	Citations
3150	Platelet endothelial aggregation receptor-1: a novel modifier of neoangiogenesis. Cardiovascular Research, 2015, 108, 124-138.	1.8	36
3151	A Phase I Study of Everolimus and Docetaxel inÂPatients With Castration-Resistant ProstateÂCancer. Clinical Genitourinary Cancer, 2015, 13, 113-123.	0.9	33
3152	Snail promotes cell migration through PI3K/AKT-dependent Rac1 activation as well as PI3K/AKT-independent pathways during prostate cancer progression. Cell Adhesion and Migration, 2015, 9, 255-264.	1.1	58
3153	Xyloglucan from Tropaeolum majus Seeds Induces Cellular Differentiation of Human Keratinocytes by Inhibition of EGFR Phosphorylation and Decreased Activity of Transcription Factor CREB. Biomacromolecules, 2015, 16, 2157-2167.	2.6	12
3154	Large granular lymphocyte leukemia: clinical background, molecular pathogenesis and treatment. Expert Opinion on Orphan Drugs, 2015, 3, 859-867.	0.5	0
3155	Platelet-Derived Growth Factor Signaling in the Lung. From Lung Development and Disease to Clinical Studies. American Journal of Respiratory Cell and Molecular Biology, 2015, 52, 263-284.	1.4	76
3156	Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives. Future Oncology, 2015, 11, 1809-1828.	1.1	19
3157	Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115. Journal of Medicinal Chemistry, 2015, 58, 5599-5608.	2.9	60
3158	Feasibility of global miRNA analysis from fine-needle biopsy FFPE material in patients with hepatocellular carcinoma treated with sorafenib. Clinical Science, 2015, 128, 29-37.	1.8	10
3159	MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine. Medical Oncology, 2015, 32, 206.	1.2	18
3160	Discovery of Akt Kinase Inhibitors through Structure-Based Virtual Screening and Their Evaluation as Potential Anticancer Agents. International Journal of Molecular Sciences, 2015, 16, 3202-3212.	1.8	44
3161	The acetyl-CoA carboxylase enzyme: a target for cancer therapy?. Expert Review of Anticancer Therapy, 2015, 15, 667-676.	1.1	80
3162	Girdin/GIV is upregulated by cyclic tension, propagates mechanical signal transduction, and is required for the cellular proliferation and migration of MG-63 cells. Biochemical and Biophysical Research Communications, 2015, 464, 493-499.	1.0	16
3163	EGFR negates the proliferative effect of oncogenic HER2 in MDA-MB-231 cells. Archives of Biochemistry and Biophysics, 2015, 575, 69-76.	1.4	7
3164	NVP-BEZ235, a novel dual PI3Kâ€“mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. Cancer Letters, 2015, 367, 58-68.	3.2	102
3165	Genetic architecture of colorectal cancer. Gut, 2015, 64, 1623-1636.	6.1	152
3166	LYG-202 exerts antitumor effect on PI3K/Akt signaling pathway in human breast cancer cells. Apoptosis: an International Journal on Programmed Cell Death, 2015, 20, 1253-1269.	2.2	18
3167	Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression. EBioMedicine, 2015, 2, 808-824.	2.7	219

#	Article	IF	Citations
3168	Sphingosine kinase 2 deficiency increases proliferation and migration of renal mouse mesangial cells and fibroblasts. Biological Chemistry, 2015, 396, 813-825.	1.2	17
3169	Class I PI 3-kinases: Function and evolution. Advances in Biological Regulation, 2015, 59, 53-64.	1.4	66
3170	Integrated Akt/PKB Signaling in Immunomodulation and Its Potential Role in Cancer Immunotherapy. Journal of the National Cancer Institute, 2015, 107, djv171-djv171.	3.0	78
3171	MicroRNA-374b Suppresses Proliferation and Promotes Apoptosis in T-cell Lymphoblastic Lymphoma by Repressing AKT1 and Wnt-16. Clinical Cancer Research, 2015, 21, 4881-4891.	3.2	51
3172	Molecular modeling based approach, synthesis, and cytotoxic activity of novel benzoin derivatives targeting phosphoinostide 3-kinase (PI3KÎ±). Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3120-3124.	1.0	26
3173	Assessment of microtubule depolymerization property of flavonoids isolated from Tanacetum gracile in breast cancer cells by biochemical and molecular docking approach. Chemico-Biological Interactions, 2015, 239, 1-11.	1.7	17
3174	Novel therapeutic strategies for multiple myeloma. Experimental Hematology, 2015, 43, 732-741.	0.2	98
3175	Metformin inhibits the proliferation of A431 cells by modulating the PI3K/Akt signaling pathway. Experimental and Therapeutic Medicine, 2015, 9, 1401-1406.	0.8	30
3176	PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 8638-8643.	3.3	174
3177	NVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/ mTOR phosphorylation. OncoTargets and Therapy, 2015, 8, 269.	1.0	22
3178	Licochalcone A, a Polyphenol Present in Licorice, Suppresses UV-Induced COX-2 Expression by Targeting PI3K, MEK1, and B-Raf. International Journal of Molecular Sciences, 2015, 16, 4453-4470.	1.8	34
3179	A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Investigational New Drugs, 2015, 33, 710-719.	1.2	24
3180	Diagnosing phenotypes of single-sample individuals by edge biomarkers. Journal of Molecular Cell Biology, 2015, 7, 231-241.	1.5	69
3181	Adaptive Mitochondrial Reprogramming and Resistance to PI3K Therapy. Journal of the National Cancer Institute, 2015, 107, .	3.0	91
3182	Di-(2-ethylhexyl)-phthalate induces oxidative stress in human endometrial stromal cells in vitro. Molecular and Cellular Endocrinology, 2015, 407, 9-17.	1.6	86
3183	Mechanisms of aromatase inhibitor resistance. Nature Reviews Cancer, 2015, 15, 261-275.	12.8	319
3184	Prognosis of women with early breast cancer and PIK3CA mutations. Breast, 2015, 24, 283-284.	0.9	3
3185	IKKÎ²/NF-Î°B mediated the low doses of bisphenol A induced migration of cervical cancer cells. Archives of Biochemistry and Biophysics, 2015, 573, 52-58.	1.4	58

#	Article	IF	Citations
3186	Loss of ARID1A expression is associated with poor prognosis in patients with stage I/II clear cell carcinoma of the ovary. International Journal of Clinical Oncology, 2015, 20, 967-973.	1.0	40
3187	In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response. Breast Cancer Research and Treatment, 2015, 149, 669-680.	1.1	46
3188	Methylation status of insulin-like growth factor-binding protein 7 concurs with the malignance of oral tongue cancer. Journal of Experimental and Clinical Cancer Research, 2015, 34, 20.	3.5	13
3189	The <scp>PI</scp>3<scp>K</scp>/<scp>A</scp>kt/m<scp>TOR</scp> axis in head and neck cancer: functions, aberrations, crossâ€talk, and therapies. Oral Diseases, 2015, 21, 815-825.	1.5	132
3190	Cochinchina MomordicaSeed Suppresses Proliferation and Metastasis in Human Lung Cancer Cells by Regulating Multiple Molecular Targets. The American Journal of Chinese Medicine, 2015, 43, 149-166.	1.5	16
3191	Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas. Expert Opinion on Investigational Drugs, 2015, 24, 345-362.	1.9	1
3192	Notch signaling in hepatocellular carcinoma: molecular targeting in an advanced disease. Hepatoma Research, 2015, 1, 11.	0.6	10
3193	Stimulus-dependent differences in signalling regulate epithelial-mesenchymal plasticity and change the effects of drugs in breast cancer cell lines. Cell Communication and Signaling, 2015, 13, 26.	2.7	47
3194	Prodrug Conjugate Strategies in Targeted Anticancer Drug Delivery Systems. Advances in Delivery Science and Technology, 2015, , 367-387.	0.4	1
3196	Autophagy and Necroptosis in Cancer. , 2015, , 243-273.		0
3197	Analysis of fast protein phosphorylation kinetics in single cells on a microfluidic chip. Lab on A Chip, 2015, 15, 726-734.	3.1	57
3199	The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206. Cell Cycle, 2015, 14, 232-242.	1.3	10
3200	PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs). Medical Oncology, 2015, 32, 111.	1.2	36
3201	Targeting PI3KÎ´: Emerging Therapy for Chronic Lymphocytic Leukemia and Beyond. Medicinal Research Reviews, 2015, 35, 720-752.	5.0	22
3203	Kinases, tails and more: Regulation of PTEN function by phosphorylation. Methods, 2015, 77-78, 75-81.	1.9	64
3204	Proteus syndrome: Report of a case with AKT1 mutation in a dental cyst. European Journal of Medical Genetics, 2015, 58, 300-304.	0.7	9
3205	PTEN Deficiency as a Predictive Biomarker of Resistance to HER2-Targeted Therapy in Advanced Gastric Cancer. Oncology, 2015, 88, 76-85.	0.9	27
3206	Identification of potential therapeutic target genes, key miRNAs and mechanisms in acute myeloid leukemia based on bioinformatics analysis. Medical Oncology, 2015, 32, 152.	1.2	9

#	Article	IF	Citations
3207	Mesenchymal Stem Cellâ€“Conditioned Medium Improves the Proliferation and Migration of Keratinocytes in a Diabetes-Like Microenvironment. International Journal of Lower Extremity Wounds, 2015, 14, 73-86.	0.6	55
3208	Deficiency of Akt1, but not Akt2, attenuates the development of pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 308, L208-L220.	1.3	75
3209	Interplay between receptor tyrosine kinases and hypoxia signaling in cancer. International Journal of Biochemistry and Cell Biology, 2015, 62, 101-114.	1.2	23
3210	(â^')-Liriopein B Suppresses Breast Cancer Progression via Inhibition of Multiple Kinases. Chemical Research in Toxicology, 2015, 28, 897-906.	1.7	10
3211	p85Î± is a microRNA target and affects chemosensitivity in pancreatic cancer. Journal of Surgical Research, 2015, 196, 285-293.	0.8	26
3212	AXL Mediates Resistance to PI3KÎ± Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas. Cancer Cell, 2015, 27, 533-546.	7.7	263
3213	A protein-targeting strategy used to develop a selective inhibitor of the E17K point mutation in the PH domain of Akt1. Nature Chemistry, 2015, 7, 455-462.	6.6	25
3214	Targeting Glutamatergic Signaling and the PI3 Kinase Pathway to Halt Melanoma Progression. Translational Oncology, 2015, 8, 1-9.	1.7	23
3215	Further screening of the resin glycosides in the edible water spinach and characterisation on their mechanism of anticancer potential. Journal of Functional Foods, 2015, 19, 141-154.	1.6	15
3216	Selective inhibition of cancer cells' proliferation by compounds included in extracts from Baltic Sea cyanobacteria. Toxicon, 2015, 108, 1-10.	0.8	24
3217	Nicotine Induces Tumor Growth and Chemoresistance through Activation of the PI3K/Akt/mTOR Pathway in Bladder Cancer. Molecular Cancer Therapeutics, 2015, 14, 2112-2120.	1.9	83
3218	Surviving at a Distance: Organ-Specific Metastasis. Trends in Cancer, 2015, 1, 76-91.	3.8	419
3219	Bisphenol A stimulates the epithelial mesenchymal transition of estrogen negative breast cancer cells via FOXA1 signals. Archives of Biochemistry and Biophysics, 2015, 585, 10-16.	1.4	46
3220	Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 2015, 76, 257-267.	1.1	5
3222	Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo. Molecular Cancer Therapeutics, 2015, 14, 2519-2526.	1.9	30
3223	Cigarette Smoke Exposure Triggers the Autophagic Cascade via Activation of the AMPK Pathway in Mice1. Biology of Reproduction, 2015, 93, 93.	1.2	44
3224	Recurrent inactivating RASA2 mutations in melanoma. Nature Genetics, 2015, 47, 1408-1410.	9.4	90
3225	MicroRNA-587 antagonizes 5-FU-induced apoptosis and confers drug resistance by regulating PPP2R1B expression in colorectal cancer. Cell Death and Disease, 2015, 6, e1845-e1845.	2.7	82

#	Article	IF	Citations
3226	A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors. Investigational New Drugs, 2015, 33, 1225-1231.	1.2	46
3227	The Actual Role of Receptors as Cancer Markers, Biochemical and Clinical Aspects: Receptors in Breast Cancer. Advances in Experimental Medicine and Biology, 2015, 867, 327-337.	0.8	13
3228	Evaluation of novel Akt1 inhibitors as anticancer agents using virtual co-crystallized pharmacophore generation. Journal of Molecular Graphics and Modelling, 2015, 62, 213-225.	1.3	17
3229	Advances in small-molecule drug discovery for triple-negative breast cancer. Future Medicinal Chemistry, 2015, 7, 2019-2039.	1.1	14
3230	Targeted therapy and promising novel agents for the treatment of advanced soft tissue sarcomas. Expert Opinion on Investigational Drugs, 2015, 24, 1409-1418.	1.9	4
3231	Lysosomal cysteine peptidases â€“ Molecules signaling tumor cell death and survival. Seminars in Cancer Biology, 2015, 35, 168-179.	4.3	51
3232	Effect of uraemia on endothelial cell damage is mediated by the integrin linked kinase pathway. Journal of Physiology, 2015, 593, 601-618.	1.3	27
3233	Epidermal growth factorâ€“stimulated Akt phosphorylation requires clathrin or ErbB2 but not receptor endocytosis. Molecular Biology of the Cell, 2015, 26, 3504-3519.	0.9	75
3234	The imidazo[1,2-a]pyridine ring system as a scaffold for potent dual phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4136-4142.	1.0	19
3235	AMP-activated Protein Kinase (AMPK) Control of mTORC1 Is p53- and TSC2-independent in Pemetrexed-treated Carcinoma Cells. Journal of Biological Chemistry, 2015, 290, 27473-27486.	1.6	66
3236	DNA-PKcs interference sensitizes colorectal cancer cells to a mTOR kinase inhibitor WAY-600. Biochemical and Biophysical Research Communications, 2015, 466, 547-553.	1.0	18
3237	S-Nitrosylation in Cancer Cells: To Prevent or to Cause?. , 2015, , 97-109.		0
3238	Histone methylation modifiers in cellular signaling pathways. Cellular and Molecular Life Sciences, 2015, 72, 4577-4592.	2.4	92
3239	Inhibition of phosphatidylinositol-3,4,5-trisphosphate binding to the AKT pleckstrin homology domain by 4-amino-1,2,5-oxadiazole derivatives. MedChemComm, 2015, 6, 1798-1808.	3.5	7
3240	Nuclear Localization of DNAJB6 Is Associated With Survival of Patients With Esophageal Cancer and Reduces AKT Signaling and Proliferation of Cancer Cells. Gastroenterology, 2015, 149, 1825-1836.e5.	0.6	46
3241	Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer. Expert Opinion on Investigational Drugs, 2015, 24, 1185-1198.	1.9	4
3242	Amino acid management in cancer. Seminars in Cell and Developmental Biology, 2015, 43, 22-32.	2.3	96
3243	Activating Mutations in PIK3CA Lead to Widespread Modulation of the Tyrosine Phosphoproteome. Journal of Proteome Research, 2015, 14, 3882-3891.	1.8	7

#	Article	IF	Citations
3244	The Mechanism of ATP-Dependent Allosteric Protection of Akt Kinase Phosphorylation. Structure, 2015, 23, 1725-1734.	1.6	58
3245	Protein Modifications in Pathogenic Dysregulation of Signaling. , 2015, , .		0
3246	Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma. Cancer Biology and Therapy, 2015, 16, 602-609.	1.5	33
3247	Aschantin targeting on the kinase domain of mammalian target of rapamycin suppresses epidermal growth factor-induced neoplastic cell transformation. Carcinogenesis, 2015, 36, 1223-1234.	1.3	17
3248	Akt Phosphorylates Wnt Coactivator and Chromatin Effector Pygo2 at Serine 48 to Antagonize Its Ubiquitin/Proteasome-mediated Degradation. Journal of Biological Chemistry, 2015, 290, 21553-21567.	1.6	10
3249	Noncatalytic PTEN missense mutation predisposes to organ-selective cancer development in vivo. Genes and Development, 2015, 29, 1707-1720.	2.7	29
3250	PI3K/Akt/mTOR: A promising therapeutic target for non-medullary thyroid carcinoma. Cancer Treatment Reviews, 2015, 41, 707-713.	3.4	95
3251	Telomere Dysfunction and Cell Senescence in Chronic Lung Diseases: Therapeutic Potential. , 2015, 153, 125-134.		45
3252	AMIGO2, a novel membrane anchor of PDK1, controls cell survival and angiogenesis via Akt activation. Journal of Cell Biology, 2015, 211, 619-637.	2.3	49
3253	Design and synthesis of 2-oxindole based multi-targeted inhibitors of PDK1/Akt signaling pathway for the treatment of glioblastoma multiforme. European Journal of Medicinal Chemistry, 2015, 105, 274-288.	2.6	37
3254	Advances in Cancer Biomarkers. Advances in Experimental Medicine and Biology, 2015, , .	0.8	14
3255	In vitro study of normoxic epidermal growth factor receptorâ€“induced hypoxiaâ€inducible factorâ€1â€alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for antiâ€“epidermal growth factor receptor therapy. Head and Neck, 2015, 37, 1150-1162.	0.9	11
3256	Clinical implication of Sox9 and activated Akt expression in pancreatic ductal adenocarcinoma. Medical Oncology, 2015, 32, 358.	1.2	29
3257	Exploring a Non-ATP Pocket for Potential Allosteric Modulation of PI3KÎ±. Journal of Physical Chemistry B, 2015, 119, 1002-1016.	1.2	30
3258	Influence of Rictor and Raptor Expression of mTOR Signaling on Long-Term Outcomes of Patients with Hepatocellular Carcinoma. Digestive Diseases and Sciences, 2015, 60, 919-928.	1.1	28
3259	Inhibitory effects of kaempferol on the invasion of human breast carcinoma cells by downregulating the expression and activity of matrix metalloproteinase-9. Biochemistry and Cell Biology, 2015, 93, 16-27.	0.9	85
3260	Helicobacter pylori Infection Activates the Aktâ€“Mdm2â€“p53 Signaling Pathway in Gastric Epithelial Cells. Digestive Diseases and Sciences, 2015, 60, 876-886.	1.1	21
3261	4-Acetylantroquinonol B Suppresses Tumor Growth and Metastasis of Hepatoma Cells via Blockade of Translation-Dependent Signaling Pathway and VEGF Production. Journal of Agricultural and Food Chemistry, 2015, 63, 208-215.	2.4	13

#	Article	IF	Citations
3262	Phospho-flow detection of constitutive and cytokine-induced pSTAT3/5, pAKT and pERK expression highlights novel prognostic biomarkers for patients with multiple myeloma. Leukemia, 2015, 29, 483-490.	3.3	17
3263	Herbal product silibinin-induced programmed cell death is enhanced by metformin in cervical cancer cells at the dose without influence on nonmalignant cells. Journal of Applied Biomedicine, 2015, 13, 113-121.	0.6	7
3264	The interplay of NR4A receptors and the oncogeneâ€“tumor suppressor networks in cancer. Cellular Signalling, 2015, 27, 257-266.	1.7	76
3265	Vps4A functions as a tumor suppressor by regulating the secretion and uptake of exosomal microRNAs in human hepatoma cells. Hepatology, 2015, 61, 1284-1294.	3.6	138
3266	The molecular mechanisms of a novel multi-kinase inhibitor ZLJ33 in suppressing pancreatic cancer growth. Cancer Letters, 2015, 356, 392-403.	3.2	4
3267	Nanomaterials for Theranostics: Recent Advances and Future Challenges. Chemical Reviews, 2015, 115, 327-394.	23.0	1,063
3268	Respiratory Muscle Plasticity. , 2015, 2, 1441-1462.		26
3269	Treatment deâ€escalation in HPVâ€positive oropharyngeal carcinoma: Ongoing trials, critical issues and perspectives. International Journal of Cancer, 2015, 136, 1494-1503.	2.3	199
3270	Divergence of P53, PTEN, PI3K, Akt and mTOR expression in tonsillar cancer. Head and Neck, 2015, 37, 636-643.	0.9	15
3271	Integrated analysis of cancer-related pathways affected by genetic and epigenetic alterations in gastric cancer. Gastric Cancer, 2015, 18, 65-76.	2.7	97
3272	The impact of Girdin expression on recurrence-free survival in patients with luminal-type breast cancer. Breast Cancer, 2015, 22, 445-451.	1.3	13
3273	Susceptibility of PTEN-positive metastatic tumors to small interfering RNA targeting the mammalian target of rapamycin. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 185-194.	1.7	15
3274	Phosphatidylinositol 3-Kinase (PI3K) and Phosphatidylinositol 3-Kinase-Related Kinase (PIKK) Inhibitors: Importance of the Morpholine Ring. Journal of Medicinal Chemistry, 2015, 58, 41-71.	2.9	122
3275	Design, synthesis and biological evaluation of acylhydrazone derivatives as PI3K inhibitors. Chinese Chemical Letters, 2015, 26, 118-120.	4.8	9
3276	Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2015, 1853, 254-263.	1.9	100
3277	Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model. FASEB Journal, 2015, 29, 464-476.	0.2	43
3278	Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial. Clinical Cancer Research, 2015, 21, 49-59.	3.2	49
3279	Multifunctional polyamidoamine-modified selenium nanoparticles dual-delivering siRNA and cisplatin to A549/DDP cells for reversal multidrug resistance. Acta Biomaterialia, 2015, 11, 368-380.	4.1	118

#	Article	IF	Citations
3280	Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer. Journal of Cancer Research and Clinical Oncology, 2015, 141, 671-689.	1.2	132
3282	Targeting PI3 kinase in cancer. , 2015, 146, 53-60.		129
3283	Genomic Applications in Pathology. , 2015, , .		1
3284	Analysing Molecular Mechanism Related to Therapy- Resistance in In-vitro Models of Ovarian Cancer. , 2016, , .		0
3285	mTOR: An attractive therapeutic target for osteosarcoma?. Oncotarget, 2016, 7, 50805-50813.	0.8	39
3286	Huaier extract synergizes with tamoxifen to induce autophagy and apoptosis in ER-positive breast cancer cells. Oncotarget, 2016, 7, 26003-26015.	0.8	23
3287	Mechanisms and Therapeutic Targets of microRNA-associated Chemoresistance in Epithelial Ovarian Cancer. Current Cancer Drug Targets, 2016, 16, 429-441.	0.8	17
3288	Inhibition of miR301 enhances Akt-mediated cell proliferation by accumulation of PTEN in nucleus and its effects on cell-cycle regulatory proteins. Oncotarget, 2016, 7, 20953-20965.	0.8	15
3289	New advances in targeted gastric cancer treatment. World Journal of Gastroenterology, 2016, 22, 6776.	1.4	74
3290	Up-regulation of REG3A in colorectal cancer cells confers proliferation and correlates with colorectal cancer risk. Oncotarget, 2016, 7, 3921-3933.	0.8	40
3291	Hypoxia-induced apoptosis and mitochondrial dysfunction in chondrocytes arising from CREB phosphorylation reduction. Genetics and Molecular Research, 2016, 15, .	0.3	3
3292	Exogenous hydrogen sulfide exerts proliferation, anti-apoptosis, migration effects and accelerates cell cycle progression in multiple myeloma cells via activating the Akt pathway. Oncology Reports, 2016, 36, 1909-1916.	1.2	20
3293	Transplantation of mononuclear cells from bone marrow in a rat model of Huntington’s disease. Journal of Neurorestoratology, 2016, Volume 4, 95-105.	1.1	2
3294	TDRG1 functions in testicular seminoma are dependent on the PI3K/Akt/mTOR signaling pathway. OncoTargets and Therapy, 2016, 9, 409.	1.0	22
3295	A personalized Approach for Targeting the Melanoma: Inhibition of Oncogenic Signaling in Combination with Small Molecules. General Medicine (Los Angeles, Calif), 2016, 04, .	0.2	1
3296	Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e40-e54.	1.8	29
3297	A four-gene signature predicts survival in clear-cell renal-cell carcinoma. Oncotarget, 2016, 7, 82712-82726.	0.8	30
3298	Clinicopathological Significance of Elevated PIK3CA Expression in Gastric Cancer. Journal of Gastric Cancer, 2016, 16, 85.	0.9	13

#	Article	IF	Citations
3299	Post-translational regulation of the cleaved fragment of Par-4 in ovarian and endometrial cancer cells. Oncotarget, 2016, 7, 36971-36987.	0.8	11
3300	Infiltrating macrophages increase RCC epithelial mesenchymal transition (EMT) and stem cell-like populations via AKT and mTOR signaling. Oncotarget, 2016, 7, 44478-44491.	0.8	49
3301	PAEDERUS ALFIERI EXTRACT INDUCES APOPTOSIS IN HUMAN MYELOID LEUKEMIA K562 CELLS. Asian Journal of Pharmaceutical and Clinical Research, 2016, 10, 72.	0.3	1
3302	In vivo genetic dissection of tumor growth and the Warburg effect. ELife, 2016, 5, .	2.8	78
3303	Juglanthraquinone C Induces Intracellular ROS Increase and Apoptosis by Activating the Akt/Foxo Signal Pathway in HCC Cells. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-18.	1.9	36
3304	The PI3K AKT pathway in the pathogenesis of prostate cancer. Frontiers in Bioscience - Landmark, 2016, 21, 1084-1091.	3.0	191
3305	The association of PTEN hypermethylation and breast cancer: a meta-analysis. OncoTargets and Therapy, 2016, Volume 9, 5643-5650.	1.0	27
3306	TGF-Î²and Hypoxia/Reoxygenation Promote Radioresistance of A549 Lung Cancer Cells through Activation of Nrf2 and EGFR. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-11.	1.9	21
3307	Andrographolide inhibits growth of human T-cell acute lymphoblastic leukemia Jurkat cells by downregulation of PI3K/AKT and upregulation of p38 MAPK pathways. Drug Design, Development and Therapy, 2016, 10, 1389.	2.0	29
3308	Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation. Journal of Korean Medical Science, 2016, 31, 360.	1.1	11
3309	Integrins in the Spotlight of Cancer. International Journal of Molecular Sciences, 2016, 17, 2037.	1.8	111
3310	Synthesis of Pelorol and Its Analogs and Their Inhibitory Effects on Phosphatidylinositol 3-Kinase. Marine Drugs, 2016, 14, 118.	2.2	7
3311	A Probabilistic Boolean Network Approach for the Analysis of Cancer-Specific Signalling: A Case Study of Deregulated PDGF Signalling in GIST. PLoS ONE, 2016, 11, e0156223.	1.1	12
3312	Mammalian Target of Rapamycin (mTOR), Aging, Neuroscience, and Their Association with Aging-Related Diseases. , 2016, , 185-203.		0
3313	A Comprehensive and System Review for the Pharmacological Mechanism of Action of Rhein, an Active Anthraquinone Ingredient. Frontiers in Pharmacology, 2016, 7, 247.	1.6	105
3314	Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives. Frontiers in Pharmacology, 2016, 7, 395.	1.6	131
3315	Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Frontiers in Pharmacology, 2016, 7, 431.	1.6	5
3316	Repeated PM2.5 exposure inhibits BEAS-2B cell P53 expression through ROS-Akt-DNMT3B pathway-mediated promoter hypermethylation. Oncotarget, 2016, 7, 20691-20703.	0.8	92

#	Article	IF	Citations
3317	Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics. Translational Oncogenomics, 2016, Suppl. 1, 33-49.	1.7	25
3318	Therapeutic potential of mTOR inhibitors for targeting cancer stem cells. British Journal of Clinical Pharmacology, 2016, 82, 1180-1188.	1.1	27
3319	AKT in cancer: new molecular insights and advances in drug development. British Journal of Clinical Pharmacology, 2016, 82, 943-956.	1.1	209
3320	The preclinical evaluation of TIC10/ONC201 as an anti-pancreatic cancer agent. Biochemical and Biophysical Research Communications, 2016, 476, 260-266.	1.0	27
3321	HSP27 Knockdown Increases Cytoplasmic p21 and Cisplatin Sensitivity in Ovarian Carcinoma Cells. Oncology Research, 2016, 23, 119-128.	0.6	18
3322	Noncoding RNAs Regulating Cancer Signaling Network. Advances in Experimental Medicine and Biology, 2016, 927, 297-315.	0.8	3
3323	Tumor suppressor RIZ1 in obesity and the PI3K/AKT/mTOR pathway. Obesity, 2016, 24, 389-397.	1.5	9
3324	Resveratrol Increases Antiâ€Proliferative Activity of Bestatin Through Downregulating Pâ€Glycoprotein Expression Via Inhibiting PI3K/Akt/mTOR Pathway in K562/ADR Cells. Journal of Cellular Biochemistry, 2016, 117, 1233-1239.	1.2	49
3325	Dynamics of GFPâ€Fusion p110Î± and p110Î² Isoforms of PI3K Signaling Pathway in Normal and Cancer Cells. Journal of Cellular Biochemistry, 2016, 117, 2864-2874.	1.2	8
3326	Dehydroglyasperin C suppresses TPA-induced cell transformation through direct inhibition of MKK4 and PI3K. Molecular Carcinogenesis, 2016, 55, 552-562.	1.3	12
3327	Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19â€784 Diverse Solid Tumors. JAMA Oncology, 2016, 2, 1565.	3.4	195
3328	The Long and Short Non-coding RNAs in Cancer Biology. Advances in Experimental Medicine and Biology, 2016, , .	0.8	4
3329	AKT activation controls cell survival in response to HDAC6 inhibition. Cell Death and Disease, 2016, 7, e2286-e2286.	2.7	22
3330	Abrus agglutinin is a potent antiâ€proliferative and antiâ€angiogenic agent in human breast cancer. International Journal of Cancer, 2016, 139, 457-466.	2.3	24
3331	Wild-type phosphatase and tensin homolog deleted on chromosome 10 improved the sensitivity of cells to rapamycin through regulating phosphorylation of Akt in esophageal squamous cell carcinoma. Ecological Management and Restoration, 2016, 30, n/a-n/a.	0.2	1
3332	Protease-activated receptors (PARs) inÂcancer. Methods in Cell Biology, 2016, 132, 341-358.	0.5	15
3334	Platycodin D potentiates proliferation inhibition and apoptosis induction upon AKT inhibition via feedback blockade in non-small cell lung cancer cells. Scientific Reports, 2016, 6, 37997.	1.6	31
3335	NLS-RARÎ± modulates acute promyelocytic leukemia NB4 cell proliferation and differentiation via the PI3K/AKT pathway. Molecular Medicine Reports, 2016, 14, 5495-5500.	1.1	4

#	Article	IF	Citations
3336	A Fucus vesiculosus extract inhibits estrogen receptor activation and induces cell death in female cancer cell lines. BMC Complementary and Alternative Medicine, 2016, 16, 151.	3.7	24
3337	MicroRNA-195 targets VEGFR2 and has a tumor suppressive role in ACHN cells via PI3K/Akt and Raf/MEK/ERK signaling pathways. International Journal of Oncology, 2016, 49, 1155-1163.	1.4	42
3338	Depletion of the triggering receptor expressed on myeloid cells 2 inhibits progression of renal cell carcinoma via regulating related protein expression and PTEN-PI3K/Akt pathway. International Journal of Oncology, 2016, 49, 2498-2506.	1.4	22
3339	Grifolin induces autophagic cell death by inhibiting the Akt/mTOR/S6K pathway in human ovarian cancer cells. Oncology Reports, 2016, 36, 1041-1047.	1.2	27
3340	Preliminary results of a non-invasive method to measure tumor size and distribution in vivo. Experimental and Therapeutic Medicine, 2016, 12, 3614-3620.	0.8	2
3341	AKT1 E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection. BMC Cancer, 2016, 16, 622.	1.1	65
3342	Pristimerin demonstrates anticancer potential in colorectal cancer cells by inducing G1 phase arrest and apoptosis and suppressing various pro-survival signaling proteins. Oncology Reports, 2016, 35, 1091-1100.	1.2	29
3343	Knockdown of SLC34A2 Inhibits Hepatocellular Carcinoma Cell Proliferation and Invasion. Oncology Research, 2016, 24, 511-519.	0.6	15
3344	The inhibition of cell proliferation and induction of apoptosis in pancreatic ductal adenocarcinoma cells by verrucarin A, a macrocyclic trichothecene, is associated with the inhibition of Akt/NF-Î²B/mTOR prosurvival signaling. International Journal of Oncology, 2016, 49, 1139-1147.	1.4	18
3345	Molecular status ofPI3KCA,KRASandBRAFin ovarian clear cell carcinoma: an analysis of 63 patients. Journal of Clinical Pathology, 2016, 69, 1088-1092.	1.0	19
3346	Salidroside induces apoptosis and autophagy in human colorectal cancer cells through inhibition of PI3K/Akt/mTOR pathway. Oncology Reports, 2016, 36, 3559-3567.	1.2	97
3347	A Functional Polymorphism (rs2494752) in the AKT1 Promoter Region and Gastric Adenocarcinoma Risk in an Eastern Chinese Population. Scientific Reports, 2016, 6, 20008.	1.6	20
3348	Sestrin-3 modulation is essential for therapeutic efficacy of cucurbitacin B in lung cancer cells. Carcinogenesis, 2017, 38, bgw124.	1.3	19
3349	Leukocyte immunoglobulin-like receptor B4 regulates key signalling molecules involved in FcÎ³RI-mediated clathrin-dependent endocytosis and phagocytosis. Scientific Reports, 2016, 6, 35085.	1.6	28
3350	Akt-dependent activation of Erk by cyclin D1b contributes to cell invasiveness and tumorigenicity. Oncology Letters, 2016, 12, 4850-4856.	0.8	8
3351	TPX2 promotes glioma cell proliferation and invasion via activation of the AKT signaling pathway. Oncology Letters, 2016, 12, 5015-5022.	0.8	20
3352	BAG-1/SODD, HSP70, and HSP90 are potential prognostic markers of poor survival in node-negative breast carcinoma. Human Pathology, 2016, 54, 64-73.	1.1	12
3353	Curcumin inhibits intracellular fatty acid synthase and induces apoptosis in human breast cancer MDA-MB-231 cells. Oncology Reports, 2016, 35, 2651-2656.	1.2	53

#	Article	IF	Citations
3354	The role of microRNA-26a in human cancer progression and clinical application. Tumor Biology, 2016, 37, 7095-7108.	0.8	45
3355	Hepatitis C Virus RNA-Dependent RNA Polymerase Interacts with the Akt/PKB Kinase and Induces Its Subcellular Relocalization. Antimicrobial Agents and Chemotherapy, 2016, 60, 3540-3550.	1.4	7
3356	Avian reovirus ÏƒA and ÏƒNS proteins activate the phosphatidylinositol 3-kinase-dependent Akt signalling pathway. Archives of Virology, 2016, 161, 2243-2248.	0.9	6
3357	Therapeutic Benefit of Selective Inhibition of p110Î± PI3-Kinase in Pancreatic Neuroendocrine Tumors. Clinical Cancer Research, 2016, 22, 5805-5817.	3.2	35
3358	Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature, 2016, 534, 272-276.	13.7	358
3359	A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast Cancers. Clinical Breast Cancer, 2016, 16, e57-e59.	1.1	4
3360	Development of novel PET probes targeting phosphatidylinositol 3-kinase (PI3K) in tumors. Nuclear Medicine and Biology, 2016, 43, 101-107.	0.3	6
3361	AT13148, a first-in-class multi-AGC kinase inhibitor, potently inhibitsÂgastric cancer cells both inÂvitro and inÂvivo. Biochemical and Biophysical Research Communications, 2016, 478, 330-336.	1.0	11
3362	Missing link between microRNA and prostate cancer. Tumor Biology, 2016, 37, 5683-5704.	0.8	17
3363	Astaxanthin down-regulates Rad51 expression via inactivation of AKT kinase to enhance mitomycin C-induced cytotoxicity in human non-small cell lung cancer cells. Biochemical Pharmacology, 2016, 105, 91-100.	2.0	51
3364	Shift of microRNA profile upon orthotopic xenografting of glioblastoma spheroid cultures. Journal of Neuro-Oncology, 2016, 128, 395-404.	1.4	6
3365	Upregulation of miR-34a by diallyl disulfide suppresses invasion and induces apoptosis in SGC-7901 cells through inhibition of the PI3K/Akt signaling pathway. Oncology Letters, 2016, 11, 2661-2667.	0.8	27
3366	Gene-expression profiles in lung adenocarcinomas related to chronic wood smoke or tobacco exposure. Respiratory Research, 2016, 17, 42.	1.4	16
3367	Molecular Signaling in Oral Cancer Invasion and Metastasis. , 2016, , 71-99.		1
3368	Targeting PI3K Signaling in Cancer: A Cautionary Tale of Two AKTs. Cancer Cell, 2016, 29, 429-431.	7.7	23
3369	XB130: A novel adaptor protein in cancer signal transduction. Biomedical Reports, 2016, 4, 300-306.	0.9	18
3370	Perifosine and ABT-737 synergistically inhibit lung cancer cells inÂvitro and inÂvivo. Biochemical and Biophysical Research Communications, 2016, 473, 1170-1176.	1.0	32
3371	EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway. Tumor Biology, 2016, 37, 11959-11971.	0.8	33

#	Article	IF	Citations
3372	Carcinoma of the colon and rectum with deregulation of insulin-like growth factor 2 signaling: clinical and molecular implications. Journal of Gastroenterology, 2016, 51, 971-984.	2.3	19
3373	Genetics of Melanoma. , 2016, , .		3
3374	d -3-Deoxy-dioctanoylphosphatidylinositol induces cytotoxicity in human MCF-7 breast cancer cells via a mechanism that involves downregulation of the D-type cyclin-retinoblastoma pathway. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 1808-1815.	1.2	4
3375	Clinical significance of serum protease-activated receptor 1 (PAR1) level in patients with breast cancer. Journal of Oncological Science, 2016, 2, 7-11.	0.1	0
3376	Korean Red Ginseng water extract arrests growth of xenografted lymphoma cells. Journal of Ginseng Research, 2016, 40, 431-436.	3.0	28
3377	Gamma-synuclein binds to AKT and promotes cancer cell survival and proliferation. Tumor Biology, 2016, 37, 14999-15005.	0.8	6
3378	Lentivirus-mediated silencing of HSDL2 suppresses cell proliferation in human gliomas. Tumor Biology, 2016, 37, 15065-15077.	0.8	28
3379	Octyl Ester of Ginsenoside Rh2 Induces Apoptosis and G1 Cell Cycle Arrest in Human HepG2 Cells by Activating the Extrinsic Apoptotic Pathway and Modulating the Akt/p38 MAPK Signaling Pathway. Journal of Agricultural and Food Chemistry, 2016, 64, 7520-7529.	2.4	18
3380	Correlations of PTEN genetic polymorphisms with the risk of depression and depressive symptoms in a Chinese population. Gene, 2016, 595, 77-82.	1.0	7
3381	Odontogenic ameloblast-associated protein (ODAM) inhibits human colorectal cancer growth by promoting PTEN elevation and inactivating PI3K/AKT signaling. Biomedicine and Pharmacotherapy, 2016, 84, 601-607.	2.5	12
3382	Genomic insights into head and neck cancer. Cancers of the Head & Neck, 2016, 1, .	6.2	65
3383	Sporoderm-Broken Spores of Ganoderma lucidum Inhibit the Growth of Lung Cancer: Involvement of the Akt/mTOR Signaling Pathway. Nutrition and Cancer, 2016, 68, 1151-1160.	0.9	21
3384	Propranolol sensitizes thyroid cancer cells to cytotoxic effect of vemurafenib. Oncology Reports, 2016, 36, 1576-1584.	1.2	21
3385	Experimental verification of a predicted novel microRNA located in human PIK3CA gene with a potential oncogenic function in colorectal cancer. Tumor Biology, 2016, 37, 14089-14101.	0.8	11
3386	A novel Smac mimetic APG-1387 demonstrates potent antitumor activity in nasopharyngeal carcinoma cells by inducing apoptosis. Cancer Letters, 2016, 381, 14-22.	3.2	21
3387	IKBB tumor suppressive role in nasopharyngeal carcinomaviaNF-Î°B-mediated signalling. International Journal of Cancer, 2016, 138, 160-170.	2.3	12
3388	Depletion of UBA protein 2-like protein inhibits growth and induces apoptosis of human colorectal carcinoma cells. Tumor Biology, 2016, 37, 13225-13235.	0.8	19
3389	Metabolic Reprogramming by the PI3K-Akt-mTOR Pathway in Cancer. Recent Results in Cancer Research, 2016, 207, 39-72.	1.8	143

#	Article	IF	Citations
3390	p110Î± and p110Î² isoforms of <scp>PI</scp>3K signaling: are they two sides of the same coin?. FEBS Letters, 2016, 590, 3071-3082.	1.3	20
3391	Genetic and epigenetic cancer chemoprevention on molecular targets during multistage carcinogenesis. Archives of Toxicology, 2016, 90, 2389-2404.	1.9	14
3392	Quantifying pulsed electric field-induced membrane nanoporation in single cells. Biochimica Et Biophysica Acta - Biomembranes, 2016, 1858, 2795-2803.	1.4	16
3393	GOLM1 Modulates EGFR/RTK Cell-Surface Recycling to Drive Hepatocellular Carcinoma Metastasis. Cancer Cell, 2016, 30, 444-458.	7.7	174
3394	Developmental Therapeutics for Gynecologic Cancers: An Overview. , 2016, , 99-125.		0
3395	Discovery of Chromeno[4,3-<i>c</i>]pyrazol-4(2<i>H</i>)-one Containing Carbonyl or Oxime Derivatives as Potential, Selective Inhibitors PI3KÎ±. Chemical and Pharmaceutical Bulletin, 2016, 64, 1576-1581.	0.6	15
3396	Cancer Stem Cells as New Therapeutic Targets for Ovarian Cancer. , 2016, , 231-259.		0
3397	Î²-Cryptoxanthin Reduced Lung Tumor Multiplicity and Inhibited Lung Cancer Cell Motility by Downregulating Nicotinic Acetylcholine Receptor Î±7 Signaling. Cancer Prevention Research, 2016, 9, 875-886.	0.7	42
3398	Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer. Cancer Discovery, 2016, 6, 1134-1147.	7.7	106
3399	The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR. Journal of Experimental and Clinical Cancer Research, 2016, 35, 97.	3.5	36
3400	Stearoyl CoA desaturase-1: New insights into a central regulator of cancer metabolism. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 1865-1880.	1.2	123
3401	Prostate Cancer in African American Men: The Effect of Androgens and microRNAs on Epidermal Growth Factor Signaling. Hormones and Cancer, 2016, 7, 296-304.	4.9	5
3402	Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 7268-7274.	2.9	35
3403	Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1. Cancer Immunology Research, 2016, 4, 779-788.	1.6	80
3404	Plum polyphenols inhibit colorectal aberrant crypt foci formation in rats: potential role of the miR-143/protein kinase B/mammalian target of rapamycin axis. Nutrition Research, 2016, 36, 1105-1113.	1.3	22
3405	HTLV-1 Viral Factor HBZ Induces CCR4 to Promote T-cell Migration and Proliferation. Cancer Research, 2016, 76, 5068-5079.	0.4	60
3406	Gynecological Cancers. , 2016, , .		0
3407	The association of Phosphatase and tensin homolog (PTEN) deletion and prostate cancer risk: A meta-analysis. Biomedicine and Pharmacotherapy, 2016, 83, 114-121.	2.5	14

#	Article	IF	Citations
3408	Eupatilin inhibits EGF-induced JB6 cell transformation by targeting PI3K. International Journal of Oncology, 2016, 49, 1148-1154.	1.4	6
3409	Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2016, 172, 402-421.	0.7	195
3410	G protein-coupled receptors (GPCRs) That Signal via Protein Kinase A (PKA) Cross-talk at Insulin Receptor Substrate 1 (IRS1) to Activate the phosphatidylinositol 3-kinase (PI3K)/AKT Pathway. Journal of Biological Chemistry, 2016, 291, 27160-27169.	1.6	50
3411	Dysfunctional MnSOD leads to redox dysregulation and activation of prosurvival AKT signaling in uterine leiomyomas. Science Advances, 2016, 2, e1601132.	4.7	24
3412	Modeling synovial sarcoma metastasis in the mouse: PI3â€²-lipid signaling and inflammation. Journal of Experimental Medicine, 2016, 213, 2989-3005.	4.2	29
3413	Aliskiren attenuates the effects of interleukin-6 on endothelial nitric oxide synthase and caveolin-1 in human aortic endothelial cells. Nitric Oxide - Biology and Chemistry, 2016, 61, 45-54.	1.2	1
3414	Autophagy prevention sensitizes AKTi-1/2-induced anti-hepatocellular carcinoma cell activity inÂvitro and inÂvivo. Biochemical and Biophysical Research Communications, 2016, 480, 334-340.	1.0	18
3415	Overexpression of microRNA-634 suppresses survival and matrix synthesis of human osteoarthritis chondrocytes by targeting PIK3R1. Scientific Reports, 2016, 6, 23117.	1.6	46
3416	Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway. Journal of Hematology and Oncology, 2016, 9, 114.	6.9	47
3417	Adipose tissue at the nexus of systemic and cellular immunometabolism. Seminars in Immunology, 2016, 28, 431-440.	2.7	55
3418	Salinomycin causes migration and invasion of human fibrosarcoma cells by inducing MMP-2 expression via PI3-kinase, ERK-1/2 and p38 kinase pathways. International Journal of Oncology, 2016, 48, 2686-2692.	1.4	12
3419	The endosomal transcriptional regulator RNF11 integrates degradation and transport of EGFR. Journal of Cell Biology, 2016, 215, 543-558.	2.3	51
3420	Whole-exome sequencing identifies recurrent AKT1 mutations in sclerosing hemangioma of lung. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10672-10677.	3.3	42
3421	Roxarsone induces angiogenesis via PI3K/Akt signaling. Cell and Bioscience, 2016, 6, 54.	2.1	19
3422	PI3K/Akt signaling pathway triggers P2X7 receptor expression as a pro-survival factor of neuroblastoma cells under limiting growth conditions. Scientific Reports, 2016, 5, 18417.	1.6	62
3423	The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care. Therapeutic Advances in Gastroenterology, 2016, 9, 861-886.	1.4	44
3424	CWF-145, a novel synthetic quinolone derivative exerts potent antimitotic activity against human prostate cancer: Rapamycin enhances antimitotic drug-induced apoptosis through the inhibition of Akt/mTOR pathway. Chemico-Biological Interactions, 2016, 260, 1-12.	1.7	5
3425	Knockdown of UBE2T Inhibits Osteosarcoma Cell Proliferation, Migration, and Invasion by Suppressing the PI3K/Akt Signaling Pathway. Oncology Research, 2016, 24, 361-369.	0.6	50

#	Article	IF	Citations
3426	miR-2861 acts as a tumor suppressor via targeting EGFR/AKT2/CCND1 pathway in cervical cancer induced by human papillomavirus virus 16 E6. Scientific Reports, 2016, 6, 28968.	1.6	29
3427	Polysaccharide isolated from the liquid culture broth of Inonotus obliquus suppresses invasion of B16-F10 melanoma cells via AKT/NF-Î²B signaling pathway. Molecular Medicine Reports, 2016, 14, 4429-4435.	1.1	12
3428	Membrane Polar Lipids. , 2016, , 63-87.		9
3429	Effect of hypoxia on chemosensitivity to 5-fluorouracil in SH-SY5Y neuroblastoma cells. Bioscience Horizons, 2016, 9, hzw005.	0.6	5
3430	Autocrine MCP-1/CCR2 signaling stimulates proliferation and migration of renal carcinoma cells. Oncology Letters, 2016, 12, 2201-2209.	0.8	23
3431	Novel roles for class II Phosphoinositide 3-Kinase C2Î² in signalling pathways involved in prostate cancer cell invasion. Scientific Reports, 2016, 6, 23277.	1.6	22
3432	Studies on deaf mobile application. AIP Conference Proceedings, 2016, , .	0.3	3
3433	Î±-Lipoic acid sensitizes lung cancer cells to chemotherapeutic agents and anoikis via integrin Î²1/Î²3 downregulation. International Journal of Oncology, 2016, 49, 1445-1456.	1.4	28
3434	GSK-3Î² inhibitor attenuates urinary albumin excretion in type 2 diabetic db/db mice, and delays epithelial-to-mesenchymal transition in mouse kidneys and podocytes. Molecular Medicine Reports, 2016, 14, 1771-1784.	1.1	19
3435	<scp>mTOR</scp> pathway protein immunoexpression as a prognostic factor for survival in head and neck cancer patients: a systematic review and metaâ€analysis. Journal of Oral Pathology and Medicine, 2016, 45, 319-328.	1.4	29
3436	The Akt/<scp>mTOR</scp> pathway is activated in verrucous carcinoma of the oral cavity. Journal of Oral Pathology and Medicine, 2016, 45, 581-585.	1.4	14
3437	Molecular Pathways: Targeting the PI3K Pathway in Cancerâ€"BET Inhibitors to the Rescue. Clinical Cancer Research, 2016, 22, 2605-2610.	3.2	37
3438	Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias. European Journal of Cancer, 2016, 63, 74-87.	1.3	13
3439	A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCIâ™9041). Investigational New Drugs, 2016, 34, 104-111.	1.2	17
3440	Circulating Omentin as a Novel Biomarker for Colorectal Cancer Risk: Data from the EPICâ€"Potsdam Cohort Study. Cancer Research, 2016, 76, 3862-3871.	0.4	41
3441	Establishment and characterization of a novel ovarian clear cell carcinoma cell line, TU-OC-2, with loss of ARID1A expression. Human Cell, 2016, 29, 181-187.	1.2	6
3442	A Common Variant at the 14q32 Endometrial Cancer Risk Locus Activates AKT1 through YY1 Binding. American Journal of Human Genetics, 2016, 98, 1159-1169.	2.6	32
3443	Your neighbours matter â€“ non-autonomous control of apoptosis in development and disease. Cell Death and Differentiation, 2016, 23, 1110-1118.	5.0	32

#	Article	IF	Citations
3444	miR-152 as a tumor suppressor microRNA: Target recognition and regulation in cancer. Oncology Letters, 2016, 11, 3911-3916.	0.8	61
3445	New structural and functional insight into the regulation of Ras. Seminars in Cell and Developmental Biology, 2016, 58, 70-78.	2.3	22
3446	Interaction between hypoxia, AKT and HIF-1 signaling in HNSCC and NSCLC: implications for future treatment strategies. Future Science OA, 2016, 2, FSO84.	0.9	25
3447	Phospho-Inositol-3-Kinase Activity and Dysregulation in Pediatric Leukemia and Lymphoma. Cancer Drug Discovery and Development, 2016, , 181-229.	0.2	0
3448	Histamine H2 Receptor in Blood Cells: A Suitable Target for the Treatment of Acute Myeloid Leukemia. Handbook of Experimental Pharmacology, 2016, 241, 141-160.	0.9	11
3449	Novel Anticancer Agents Based on Targeting the Trimer Interface of the PRL Phosphatase. Cancer Research, 2016, 76, 4805-4815.	0.4	40
3451	Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management. Oncologist, 2016, 21, 855-860.	1.9	48
3452	Role of a polyphenol-enriched preparation on chemoprevention of mammary carcinoma through cancer stem cells and inflammatory pathways modulation. Journal of Translational Medicine, 2016, 14, 13.	1.8	51
3453	PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma. Journal of Translational Medicine, 2016, 14, 67.	1.8	42
3454	Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 947-957.	1.5	23
3455	Phosphatidylinositol 3-Kinase. Pancreas, 2016, 45, 21-31.	0.5	11
3456	Inhibiting DX2-p14/ARF Interaction Exerts Antitumor Effects in Lung Cancer and Delays Tumor Progression. Cancer Research, 2016, 76, 4791-4804.	0.4	28
3457	IntegrinÎ²1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas. Tumor Biology, 2016, 37, 12315-12327.	0.8	14
3458	Allicin inhibits oxidative stress-induced mitochondrial dysfunction and apoptosis by promoting PI3K/AKT and CREB/ERK signaling in osteoblast cells. Experimental and Therapeutic Medicine, 2016, 11, 2553-2560.	0.8	56
3459	Systematic tracking of coordinated differential network motifs identifies novel disease-related genes by integrating multiple data. Neurocomputing, 2016, 206, 3-12.	3.5	4
3461	Knockdown of EHF inhibited the proliferation, invasion and tumorigenesis of ovarian cancer cells. Molecular Carcinogenesis, 2016, 55, 1048-1059.	1.3	31
3462	Suppression of phosphoâ€p85Î±â€“GTPâ€Rac1 lipid raft interaction by bichalcone analog attenuates cancer cell invasion. Molecular Carcinogenesis, 2016, 55, 2106-2120.	1.3	7
3463	Palmitoylethanolamide Exerts Antiproliferative Effect and Downregulates VEGF Signaling in Caco-2 Human Colon Carcinoma Cell Line Through a Selective PPAR-Î±-Dependent Inhibition of Akt/mTOR Pathway. Phytotherapy Research, 2016, 30, 963-970.	2.8	25

#	Article	IF	Citations
3464	Membrane-associated Ras dimers are isoform-specific: K-Ras dimers differ from H-Ras dimers. Biochemical Journal, 2016, 473, 1719-1732.	1.7	92
3465	Neurological Complications of Systemic Cancer and Antineoplastic Therapy. , 0, , .		3
3466	Exogenous midkine administration prevents cardiac remodeling in pacing-induced congestive heart failure of rabbits. Heart and Vessels, 2016, 31, 96-104.	0.5	10
3467	Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma. Bioorganic and Medicinal Chemistry, 2016, 24, 957-966.	1.4	13
3468	Emerging Approaches for Targeting Metabolic Vulnerabilities in Malignant Glioma. Current Neurology and Neuroscience Reports, 2016, 16, 17.	2.0	15
3469	A novel curcumin derivative increases the cytotoxicity of raloxifene in estrogen receptor-negative breast cancer cell lines. International Journal of Oncology, 2016, 48, 385-398.	1.4	11
3470	A headlight on liquid biopsies: a challenging tool for breast cancer management. Tumor Biology, 2016, 37, 4263-4273.	0.8	18
3471	EMC6/TMEM93 suppresses glioblastoma proliferation by modulating autophagy. Cell Death and Disease, 2016, 7, e2043-e2043.	2.7	37
3472	Systemic Codelivery of a Homoserine Derived Ceramide Analogue and Curcumin to Tumor Vasculature Inhibits Mouse Tumor Growth. Molecular Pharmaceutics, 2016, 13, 404-419.	2.3	17
3473	Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase. Molecular Pharmaceutics, 2016, 13, 784-794.	2.3	29
3474	PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives. European Journal of Medicinal Chemistry, 2016, 109, 314-341.	2.6	452
3475	TLR signalling affects sperm mitochondrial function and motility via phosphatidylinositol 3-kinase and glycogen synthase kinase-3Î±. Cellular Signalling, 2016, 28, 148-156.	1.7	34
3476	A study on promoter methylation of PTEN in sporadic breast cancer patients from North India. Breast Cancer, 2016, 23, 922-931.	1.3	13
3477	The mTOR Pathway and Aging. , 2016, , 55-81.		3
3478	The anti-ovarian cancer activity by WYE-132, a mTORC1/2 dual inhibitor. Tumor Biology, 2016, 37, 1327-1336.	0.8	25
3479	NAC selectively inhibit cancer telomerase activity: A higher redox homeostasis threshold exists in cancer cells. Redox Biology, 2016, 8, 91-97.	3.9	42
3480	High constitutive Akt2 activity in U937 promonocytes: effective reduction of Akt2 phosphorylation by the histamine H2-receptor and the Î²2-adrenergic receptor. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 87-101.	1.4	12
3481	Increased Expression of Phosphatidylinositol 3-Kinase p110Î± and Gene Amplification of PIK3CA in Nasopharyngeal Carcinoma. Pathology and Oncology Research, 2016, 22, 413-419.	0.9	6

#	Article	IF	Citations
3482	Combination of mTOR Inhibitors Augments Potency while Activating PI3K Signaling in Pituitary Tumors. Neuroendocrinology, 2016, 103, 592-604.	1.2	3
3483	PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas. Molecular Diagnosis and Therapy, 2016, 20, 13-26.	1.6	66
3484	Beyond ion-conduction: Channel-dependent and -independent roles of TRP channels during development and tissue homeostasis. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 1436-1446.	1.9	33
3485	Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras. Leukemia, 2016, 30, 1335-1343.	3.3	33
3486	InÂvitro antiproliferative activity of 2,3-dihydroxy-9,10-anthraquinone induced apoptosis against COLO320Âcells through cytochrome c release caspase mediated pathway with PI3K/AKT and COX-2 inhibition. Chemico-Biological Interactions, 2016, 249, 23-35.	1.7	12
3487	Asymmetric Dimethylarginine Stimulates Akt1 Phosphorylation via Heat Shock Protein 70â€“Facilitated Carboxyl-Terminal Modulator Protein Degradation in Pulmonary Arterial Endothelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2016, 55, 275-287.	1.4	8
3488	miRâ€490â€5p suppresses tumour growth in renal cell carcinoma through targeting PIK3CA. Biology of the Cell, 2016, 108, 41-50.	0.7	56
3489	Polymorphisms in the <scp>AKT</scp>1 and <scp>AKT</scp>2 genes and oesophageal squamous cell carcinoma risk in an Eastern Chinese population. Journal of Cellular and Molecular Medicine, 2016, 20, 666-677.	1.6	31
3490	Treatment with an activator of hypoxia-inducible factor 1, DMOG provides neuroprotection after traumatic brain injury. Neuropharmacology, 2016, 107, 79-88.	2.0	40
3491	Next-generation molecular diagnostics. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 121-130.	1.0	1
3492	Identification of PRKDC (Protein Kinase, DNA-Activated, Catalytic Polypeptide) as an essential gene for colorectal cancer (CRCs) cells. Gene, 2016, 584, 90-96.	1.0	31
3493	Pharmacological modulation of oncogenic Ras by natural products and their derivatives: Renewed hope in the discovery of novel anti-Ras drugs. , 2016, 162, 35-57.		16
3494	Enhancement of tumor cell susceptibility to natural killer cell activity through inhibition of the PI3K signaling pathway. Cancer Immunology, Immunotherapy, 2016, 65, 355-366.	2.0	13
3495	Codelivery of Doxorubicin and shAkt1 by Poly(ethylenimine)â€“Glycyrrhetinic Acid Nanoparticles To Induce Autophagy-Mediated Liver Cancer Combination Therapy. Molecular Pharmaceutics, 2016, 13, 1298-1307.	2.3	49
3496	Overexpression of Insulin-like Growth Factor-1 Receptor Is Associated With Penile Cancer Progression. Urology, 2016, 92, 51-56.	0.5	9
3498	Cinnamaldehyde affects the biological behavior of human colorectal cancer cells and induces apoptosis via inhibition of the PI3K/Akt signaling pathway. Oncology Reports, 2016, 35, 1501-1510.	1.2	33
3499	Natural Agents Used in Chemoprevention of Aerodigestive and GI Cancers. Current Pharmacology Reports, 2016, 2, 11-20.	1.5	7
3500	PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nature Medicine, 2016, 22, 379-387.	15.2	94

#	Article	IF	Citations
3501	Radiotherapy diagnostic biomarkers in radioresistant human H460 lung cancer stem-like cells. Cancer Biology and Therapy, 2016, 17, 208-218.	1.5	32
3502	Overexpression of KiSS-1 reduces colorectal cancer cell invasion by downregulating MMP-9 via blocking PI3K/Akt/NF-ÎºB signal pathway. International Journal of Oncology, 2016, 48, 1391-1398.	1.4	51
3503	Nonalcoholic fatty liver disease and hepatocellular carcinoma. Metabolism: Clinical and Experimental, 2016, 65, 1151-1160.	1.5	143
3504	The Role of Metallothioneins in Carcinogenesis. Advances in Anatomy, Embryology and Cell Biology, 2016, , 29-63.	1.0	5
3505	Clinical Trial of Oral Nelfinavir before and during Radiation Therapy for Advanced Rectal Cancer. Clinical Cancer Research, 2016, 22, 1922-1931.	3.2	30
3506	Principles of Cancer Genetics. , 2016, , .		12
3507	Notch-1 signaling activates NF-ÎºB in human breast carcinoma MDA-MB-231 cells via PP2A-dependent AKT pathway. Medical Oncology, 2016, 33, 33.	1.2	41
3508	PIK3C2A is a gene-specific target of microRNA-518a-5p in imatinib mesylate-resistant gastrointestinal stromal tumor. Laboratory Investigation, 2016, 96, 652-660.	1.7	35
3509	Hyperoside induces both autophagy and apoptosis in non-small cell lung cancer cells in vitro. Acta Pharmacologica Sinica, 2016, 37, 505-518.	2.8	50
3510	Cancer Gene Pathways. , 2016, , 203-270.		2
3511	Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells. Tumor Biology, 2016, 37, 10257-10267.	0.8	50
3512	Combination Nanopreparations of a Novel Proapoptotic Drug â€“ NCL-240, TRAIL and siRNA. Pharmaceutical Research, 2016, 33, 1587-1601.	1.7	13
3513	Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Annals of Oncology, 2016, 27, 409-416.	0.6	597
3514	Anti-tumoral effect of arsenic compound, sodium metaarsenite (KML001), in non-Hodgkinâ€™s lymphoma: an in vitro and in vivo study. Investigational New Drugs, 2016, 34, 1-14.	1.2	15
3515	Mg++ requirement for MtHK binding, and Mg++ stabilization of mitochondrial membranes via activation of MtHK & MtCK and promotion of mitochondrial permeability transition pore closure: A hypothesis on mechanisms underlying Mg++â€™s antioxidant and cytoprotective effects. Gene, 2016, 581, 1-13.	1.0	20
3516	The Rational Design of Selective Benzoxazepin Inhibitors of the Î±-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)prop (GDC-0326). Journal of Medicinal Chemistry, 2016, 59, 985-1002.	2.9	87
3517	Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development. Advances in Experimental Medicine and Biology, 2016, 890, 1-23.	0.8	7
3518	Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino- N -(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents. European Journal of Medicinal Chemistry, 2016, 108, 644-654.	2.6	28

#	Article	IF	Citations
3519	Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways. , 2016, 158, 71-90.		166
3520	SZC015, a synthetic oleanolic acid derivative, induces both apoptosis and autophagy in MCF-7 breast cancer cells. Chemico-Biological Interactions, 2016, 244, 94-104.	1.7	48
3521	Inhibition of phospholipaseD2 increases hypoxia-induced human colon cancer cell apoptosis through inactivating of the PI3K/AKT signaling pathway. Tumor Biology, 2016, 37, 6155-6168.	0.8	11
3522	Regulation of tumorigenic Wnt signaling by cyclooxygenase-2, 5-lipoxygenase and their pharmacological inhibitors: A basis for novel drugs targeting cancer cells?. , 2016, 157, 43-64.		36
3523	Emerging strategies for targeting PI3K in gynecologic cancer. Gynecologic Oncology, 2016, 140, 333-344.	0.6	21
3524	Current perspectives of molecular pathways involved in chronic inflammation-mediated breast cancer. Biochemical and Biophysical Research Communications, 2016, 472, 401-409.	1.0	47
3525	Genome Integrity in Aging: Human Syndromes, Mouse Models, and Therapeutic Options. Annual Review of Pharmacology and Toxicology, 2016, 56, 427-445.	4.2	94
3526	Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3Kâ€“AKTâ€“mTOR Pathway Inhibitors. Clinical Cancer Research, 2016, 22, 1018-1027.	3.2	69
3527	Glucose-regulated protein 94 mediates cancer progression via AKT and eNOS in hepatocellular carcinoma. Tumor Biology, 2016, 37, 4295-4304.	0.8	25
3528	Preclinical evaluation of perifosine as a potential promising anti-rhabdomyosarcoma agent. Tumor Biology, 2016, 37, 1025-1033.	0.8	8
3529	Signaling mechanisms of resistance to EGFR- and Anti-Angiogenic Inhibitors cancer. Critical Reviews in Oncology/Hematology, 2016, 97, 85-95.	2.0	19
3530	Overexpression of acylglycerol kinase is associated with poorer prognosis and lymph node metastasis in nasopharyngeal carcinoma. Tumor Biology, 2016, 37, 3349-3357.	0.8	14
3531	A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections. Critical Reviews in Oncology/Hematology, 2016, 97, 275-290.	2.0	73
3532	ML-7 amplifies the quinocetone-induced cell death through akt and MAPK-mediated apoptosis on HepG2 cell line. Toxicology Mechanisms and Methods, 2016, 26, 11-21.	1.3	4
3533	Simultaneous Targeting of Bladder Tumor Growth, Survival, and Epithelial-to-Mesenchymal Transition with a Novel Therapeutic Combination of Acetazolamide (AZ) and Sulforaphane (SFN). Targeted Oncology, 2016, 11, 209-227.	1.7	43
3534	Suppression of SHIP2 contributes to tumorigenesis and proliferation of gastric cancer cells via activation of Akt. Journal of Gastroenterology, 2016, 51, 230-240.	2.3	38
3535	TNIK serves as a novel biomarker associated with poor prognosis in patients with pancreatic cancer. Tumor Biology, 2016, 37, 1035-1040.	0.8	14
3536	Anti-tumour-promoting and thermal-induced protein denaturation inhibitory activities of Î²-sitosterol and lupeol isolated from Diospyros lotus L.. Natural Product Research, 2016, 30, 1205-1207.	1.0	21

#	Article	IF	Citations
3537	Loss of fatty acid synthase suppresses the malignant phenotype of colorectal cancer cells by down-regulating energy metabolism and mTOR signaling pathway. Journal of Cancer Research and Clinical Oncology, 2016, 142, 59-72.	1.2	31
3538	Structural basis and energy landscape of apigenin-induced cancer cell apoptosis mechanism in PI3K/Akt pathway. Molecular Simulation, 2016, 42, 138-148.	0.9	3
3539	Modulation of inflammation by autophagy: Consequences for human disease. Autophagy, 2016, 12, 245-260.	4.3	287
3540	Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer. Oncogene, 2016, 35, 2186-2196.	2.6	26
3541	Twist as a new prognostic marker in hematological malignancies. Clinical and Translational Oncology, 2016, 18, 113-124.	1.2	19
3542	Deciphering the impact of somatic mutations in exon 20 and exon 9 ofPIK3CAgene in breast tumors among Indian women through molecular dynamics approach. Journal of Biomolecular Structure and Dynamics, 2016, 34, 29-41.	2.0	28
3543	Toxicity study of ochratoxin A using HEK293 and HepG2 cell lines based on microRNA profiling. Human and Experimental Toxicology, 2017, 36, 8-22.	1.1	23
3544	Phosphorylated Akt Expression as a Favorable Prognostic Factor for Patients Undergoing Curative Resection and Adjuvant Chemoradiotherapy for Proximal Extrahepatic Bile Duct Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 158-162.	0.6	1
3545	Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 111.e15-111.e23.	0.8	8
3546	Pseudorabies virus infection inhibits autophagy in permissive cells in vitro. Scientific Reports, 2017, 7, 39964.	1.6	28
3547	Deptor: not only a mTOR inhibitor. Journal of Experimental and Clinical Cancer Research, 2017, 36, 12.	3.5	64
3548	Over expression of proteins that alter the intracellular signaling pathways in the cytoplasm of the liver cells forming Mallory-Denk bodies. Experimental and Molecular Pathology, 2017, 102, 106-114.	0.9	12
3549	Proteomics analyses of prostate cancer cells reveal cellular pathways associated with androgen resistance. Proteomics, 2017, 17, 1600228.	1.3	18
3550	miR-143 inhibits bladder cancer cell proliferation and enhances their sensitivity to gemcitabine by repressing IGF-1R signaling. Oncology Letters, 2017, 13, 435-440.	0.8	51
3551	The LINK-A lncRNA interacts with PtdIns(3,4,5)P3 toÂhyperactivate AKTÂand confer resistance to AKTÂinhibitors. Nature Cell Biology, 2017, 19, 238-251.	4.6	201
3553	NOS1-, NOS3-, PIK3CA-, and MAPK-pathways in skin following radiation therapy. Biomarker Research, 2017, 5, 3.	2.8	1
3554	A Systematic Evaluation of Methods for Tailoring Genome-Scale Metabolic Models. Cell Systems, 2017, 4, 318-329.e6.	2.9	178
3555	PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials. , 2017, 175, 91-106.		167

#	Article	IF	Citations
3556	Activating Akt1 mutations alter DNA double strand break repair and radiosensitivity. Scientific Reports, 2017, 7, 42700.	1.6	32
3557	<scp>AKT</scp>â€phosphorylated <scp>FOXO</scp>1 suppresses <scp>ERK</scp> activation and chemoresistance by disrupting <scp>IQGAP</scp>1â€<scp>MAPK</scp> interaction. EMBO Journal, 2017, 36, 995-1010.	3.5	101
3558	Major Physiological Signaling Pathways in the Regulation of Cell Proliferation and Survival. Handbook of Experimental Pharmacology, 2017, 249, 13-30.	0.9	8
3559	MicroRNA-185 induces potent autophagy via AKT signaling in hepatocellular carcinoma. Tumor Biology, 2017, 39, 101042831769431.	0.8	28
3560	Association between high expression of phosphorylated Akt and mammalian target of rapamycin and improved survival in salivary gland adenoid cystic carcinoma. Head and Neck, 2017, 39, 1145-1154.	0.9	13
3561	Nuclear Factor of Î°B1 Is a Key Regulator for the Transcriptional Activation of Milk Synthesis in Bovine Mammary Epithelial Cells. DNA and Cell Biology, 2017, 36, 295-302.	0.9	29
3562	Brainâ€derived neurotrophic factor improves proliferation of endometrial epithelial cells by inhibition of endoplasmic reticulum stress during early pregnancy. Journal of Cellular Physiology, 2017, 232, 3641-3651.	2.0	19
3563	Pseudolaric acid B inhibits gastric cancer cell metastasis in vitro and in haematogenous dissemination model through PI3K/AKT, ERK1/2 and mitochondria-mediated apoptosis pathways. Experimental Cell Research, 2017, 352, 34-44.	1.2	19
3564	MFN2 suppresses cancer progression through inhibition of mTORC2/Akt signaling. Scientific Reports, 2017, 7, 41718.	1.6	85
3565	CXCL12-induced macropinocytosis modulates two distinct pathways to activate mTORC1 in macrophages. Journal of Leukocyte Biology, 2017, 101, 683-692.	1.5	37
3566	A Systems Perspective of Signalling Networks in Hostâ€“Pathogen Interactions. Journal of the Indian Institute of Science, 2017, 97, 41-57.	0.9	0
3567	Nectin-4 co-stimulates the prolactin receptor by interacting with SOCS1 and inhibiting its activity on the JAK2-STAT5a signaling pathway. Journal of Biological Chemistry, 2017, 292, 6895-6909.	1.6	19
3568	The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients. Journal of Leukocyte Biology, 2017, 102, 381-391.	1.5	50
3569	Polyamine-RNA-membrane interactions: From the past to the future in biology. Colloids and Surfaces B: Biointerfaces, 2017, 155, 173-181.	2.5	3
3570	Aberrant low expression of p85Î± in stromal fibroblasts promotes breast cancer cell metastasis through exosome-mediated paracrine Wnt10b. Oncogene, 2017, 36, 4692-4705.	2.6	100
3571	Metabolomic characterisation of the effects of oncogenic PIK3CA transformation in a breast epithelial cell line. Scientific Reports, 2017, 7, 46079.	1.6	23
3572	RhoA/ROCK pathway inhibition by fasudil suppresses the vasculogenic mimicry of U2OS osteosarcoma cells in vitro. Anti-Cancer Drugs, 2017, 28, 514-521.	0.7	20
3573	Prediction of a highly deleterious mutation E17K in AKT-1 gene: An in silico approach. Biochemistry and Biophysics Reports, 2017, 10, 260-266.	0.7	7

#	Article	IF	Citations
3574	Overexpression of N-cadherin and Î²-catenin correlates with poor prognosis in patients with nasopharyngeal carcinoma. Oncology Letters, 2017, 13, 1725-1730.	0.8	23
3575	Novel pathogenesis: regulation of apoptosis by Apelin/APJ system. Acta Biochimica Et Biophysica Sinica, 2017, 49, 471-478.	0.9	29
3576	AKT. , 2017, , 3-12.		0
3577	Effect of Momordica charantia protein on proliferation, apoptosis and the AKT signal transduction pathway in the human endometrial carcinoma Ishikawa H cell line in vitro. Oncology Letters, 2017, 13, 3032-3038.	0.8	6
3578	Control of Tumor Initiation by NKG2D Naturally Expressed on Ovarian Cancer Cells. Neoplasia, 2017, 19, 471-482.	2.3	21
3579	Deoxypodophyllotoxin induces cytoprotective autophagy against apoptosis via inhibition of PI3K/AKT/mTOR pathway in osteosarcoma U2OS cells. Pharmacological Reports, 2017, 69, 878-884.	1.5	35
3580	FoxO1 Promotes Mitophagy in the Podocytes of Diabetic Male Mice via the PINK1/Parkin Pathway. Endocrinology, 2017, 158, 2155-2167.	1.4	109
3581	Discovery of a novel aminopyrazine series as selective PI3KÎ± inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3030-3035.	1.0	6
3582	Clinicopathological significance of ROCK1 and PIK3CA expression in nasopharyngeal carcinoma. Experimental and Therapeutic Medicine, 2017, 13, 1064-1068.	0.8	8
3583	TCRP1 promotes NIH/3T3 cell transformation by over-activating PDK1 and AKT1. Oncogenesis, 2017, 6, e323-e323.	2.1	12
3584	New agents for endocrine resistance in breast cancer. Breast, 2017, 34, 1-11.	0.9	22
3586	Heat shock protein 22 (HSPB8) reduces the migration of hepatocellular carcinoma cells through the suppression of the phosphoinositide 3-kinase (PI3K)/AKT pathway. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 1629-1639.	1.8	26
3587	Salinomycin acts through reducing AKT-dependent thymidylate synthase expression to enhance erlotinib-induced cytotoxicity in human lung cancer cells. Experimental Cell Research, 2017, 357, 59-66.	1.2	9
3588	Establishment and characterization of a novel uterine carcinosarcoma cell line, TU-ECS-1, with mutations of TP53 and KRAS. Human Cell, 2017, 30, 140-148.	1.2	3
3589	8-methoxypsoralen reduces AKT phosphorylation, induces intrinsic and extrinsic apoptotic pathways, and suppresses cell growth of SK-N-AS neuroblastoma and SW620 metastatic colon cancer cells. Journal of Ethnopharmacology, 2017, 207, 19-29.	2.0	32
3590	Casein Kinase II (CK2), Glycogen Synthase Kinase-3 (GSK-3) and Ikaros mediated regulation of leukemia. Advances in Biological Regulation, 2017, 65, 16-25.	1.4	21
3591	MCM7 amplification and overexpression promote cell proliferation, colony formation and migration in esophageal squamous cell carcinoma by activating the AKT1/mTOR signaling pathway. Oncology Reports, 2017, 37, 3590-3596.	1.2	34
3592	PRKDC regulates chemosensitivity and is a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients. Oncology Reports, 2017, 37, 3536-3542.	1.2	31

#	Article	IF	Citations
3593	CRISPR/Cas9-mediated p53 and Pten dual mutation accelerates hepatocarcinogenesis in adult hepatitis B virus transgenic mice. Scientific Reports, 2017, 7, 2796.	1.6	44
3594	Argininosuccinate synthase 1 is an intrinsic Akt repressor transactivated by p53. Science Advances, 2017, 3, e1603204.	4.7	40
3595	PRMT8 Controls the Pluripotency and Mesodermal Fate of Human Embryonic Stem Cells By Enhancing the PI3K/AKT/SOX2 Axis. Stem Cells, 2017, 35, 2037-2049.	1.4	31
3598	FUSâ€“DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma. Clinical Cancer Research, 2017, 23, 6227-6238.	3.2	40
3599	The mTOR Substrate S6 Kinase 1 (S6K1) Is a Negative Regulator of Axon Regeneration and a Potential Drug Target for Central Nervous System Injury. Journal of Neuroscience, 2017, 37, 7079-7095.	1.7	77
3600	<scp>SET</scp>/I2<scp>PP</scp>2A overexpression induces phenotypic, molecular, and metabolic alterations in an oral keratinocyte cell line. FEBS Journal, 2017, 284, 2774-2785.	2.2	8
3601	Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases. Clinical Cancer Research, 2017, 23, 5044-5054.	3.2	54
3602	An overall review of targeted therapy in solid cancers. Current Medicine Research and Practice, 2017, 7, 99-105.	0.1	9
3603	Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. Cancer, 2017, 123, 2118-2129.	2.0	121
3604	ASK family and cancer. Advances in Biological Regulation, 2017, 66, 72-84.	1.4	25
3605	Optical control of membrane tethering and interorganellar communication at nanoscales. Chemical Science, 2017, 8, 5275-5281.	3.7	39
3606	Genetic and epigenetic markers in colorectal cancer screening: recent advances. Expert Review of Molecular Diagnostics, 2017, 17, 665-685.	1.5	22
3607	Evaluation of PIK3CA mutations as a biomarker in Chinese breast carcinomas from Western China. Cancer Biomarkers, 2017, 19, 85-92.	0.8	12
3608	Oncogenic Roles of the PI3K/AKT/mTOR Axis. Current Topics in Microbiology and Immunology, 2017, 407, 153-189.	0.7	242
3609	TRIM59 facilitates the proliferation of colorectal cancer and promotes metastasis via the PI3K/AKT pathway. Oncology Reports, 2017, 38, 43-52.	1.2	54
3610	Precision Medicine in Gynecology and Obstetrics. Comprehensive Gynecology and Obstetrics, 2017, , .	0.0	1
3611	Polysaccharides isolated from liquid culture broth of Inonotus obliquus inhibit the invasion of human non-small cell lung carcinoma cells. Biotechnology and Bioprocess Engineering, 2017, 22, 45-51.	1.4	11
3612	Anticancer effects of oleuropein. BioFactors, 2017, 43, 517-528.	2.6	76

#	Article	IF	Citations
3613	USP49 negatively regulates tumorigenesis and chemoresistance through FKBP51â€AKT signaling. EMBO Journal, 2017, 36, 1434-1446.	3.5	72
3614	Generation of tricyclic imidazo[1,2- a]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2536-2543.	1.0	10
3615	Angiomotin-like 2 interacts with and negatively regulates AKT. Oncogene, 2017, 36, 4662-4669.	2.6	10
3616	Cool-associated Tyrosine-phosphorylated Protein 1 Is Required for the Anchorage-independent Growth of Cervical Carcinoma Cells by Binding Paxillin and Promoting AKT Activation. Journal of Biological Chemistry, 2017, 292, 3947-3957.	1.6	4
3617	A systematic review and pooled analysis of retrospective series of eribulin in metastatic breast cancer. Anti-Cancer Drugs, 2017, 28, 557-564.	0.7	16
3618	Assessment of Olea europaea L. fruit extracts: Phytochemical characterization and anticancer pathway investigation. Biomedicine and Pharmacotherapy, 2017, 90, 179-186.	2.5	28
3619	Targeted radionuclide therapy for lung cancer with iodine-131-labeled peptide in a nude-mouse model. Anti-Cancer Drugs, 2017, 28, 480-488.	0.7	3
3620	A nomogram to predict 5-fluorouracil toxicity. Anti-Cancer Drugs, 2017, 28, 551-556.	0.7	10
3621	Protein kinase B. Anti-Cancer Drugs, 2017, 28, 569-580.	0.7	26
3622	Adriamycin in combination with dexamethasone and octreotide lacks activity on the treatment of a 4T1 metastatic breast cancer model. Anti-Cancer Drugs, 2017, 28, 489-502.	0.7	1
3624	Nephronectin plays critical roles in Sox2 expression and proliferation in dental epithelial stem cells via EGF-like repeat domains. Scientific Reports, 2017, 7, 45181.	1.6	34
3625	Phosphatidylinositol 3-kinase regulatory subunit 1 and phosphatase and tensin homolog as therapeutic targets in breast cancer. Tumor Biology, 2017, 39, 101042831769552.	0.8	6
3626	Expression of Clonorchis sinensis GIIIsPLA2 protein in baculovirus-infected insect cells and its overexpression facilitating epithelial-mesenchymal transition in Huh7 cells via AKT pathway. Parasitology Research, 2017, 116, 1307-1316.	0.6	5
3627	A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. Investigational New Drugs, 2017, 35, 742-750.	1.2	10
3628	Morin Inhibits Proliferation, Migration, and Invasion of Bladder Cancer EJ Cells via Modulation of Signaling Pathways, Cell Cycle Regulators, and Transcription Factorâ€Mediated MMPâ€9 Expression. Drug Development Research, 2017, 78, 81-90.	1.4	25
3629	Treatment with low-dose sorafenib in combination with a novel benzimidazole derivative bearing a pyrolidine side chain provides synergistic anti-proliferative effects against human liver cancer. RSC Advances, 2017, 7, 16253-16263.	1.7	8
3630	Silica-based nanoparticles for therapeutic protein delivery. Journal of Materials Chemistry B, 2017, 5, 3241-3252.	2.9	65
3631	Determinants of Organotropic Metastasis. Annual Review of Cancer Biology, 2017, 1, 403-423.	2.3	25

#	Article	IF	Citations
3632	Targeting the AKT/cyclin D1 pathway to overcome intrinsic and acquired radioresistance of tumors for effective radiotherapy. International Journal of Radiation Biology, 2017, 93, 381-385.	1.0	25
3633	Suppression of protein tyrosine phosphatase PTPN22 gene induces apoptosis in T-cell leukemia cell line (Jurkat) through the AKT and ERK pathways. Biomedicine and Pharmacotherapy, 2017, 86, 41-47.	2.5	17
3634	Inhibitory potential of flavonoids on PtdIns(3,4,5)P3 binding with the phosphoinositide-dependent kinase 1 pleckstrin homology domain. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 420-426.	1.0	4
3635	LncRNA NEAT1 Impacts Cell Proliferation and Apoptosis of Colorectal Cancer via Regulation of Akt Signaling. Pathology and Oncology Research, 2017, 23, 651-656.	0.9	78
3636	Ex Vivo Engineering of the Tumor Microenvironment. Cancer Drug Discovery and Development, 2017, , .	0.2	4
3637	Advancing Techniques and Insights in Circulating Tumor Cell (CTC) Research. Cancer Drug Discovery and Development, 2017, , 71-94.	0.2	2
3638	T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment. Journal of the National Cancer Institute, 2017, 109, djw248.	3.0	28
3639	HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation. Cellular Oncology (Dordrecht), 2017, 40, 133-144.	2.1	51
3640	Irisin suppresses the migration, proliferation, and invasion of lung cancer cells via inhibition of epithelial-to-mesenchymal transition. Biochemical and Biophysical Research Communications, 2017, 485, 598-605.	1.0	76
3641	Quantitative structural characterization of phosphatidylinositol phosphates from biological samples. Journal of Lipid Research, 2017, 58, 469-478.	2.0	16
3642	An update on the implications of cyclin D1 in oral carcinogenesis. Oral Diseases, 2017, 23, 897-912.	1.5	74
3643	Effect of silencing the T-Box transcription factor TBX2 in prostate cancer PC3 and LNCaP cells. Molecular Medicine Reports, 2017, 16, 6050-6058.	1.1	15
3644	Novel ATPâ€competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Cancer Medicine, 2017, 6, 2646-2659.	1.3	42
3645	Use of multitarget tyrosine kinase inhibitors to attenuate platelet-derived growth factor signalling in lung disease. European Respiratory Review, 2017, 26, 170061.	3.0	13
3646	S-Nitrosylation inhibits the kinase activity of tomato phosphoinositide-dependent kinase 1 (PDK1). Journal of Biological Chemistry, 2017, 292, 19743-19751.	1.6	22
3647	AKT2 is involved in the IL-17A-mediated promotion of differentiation and calcification of murine preosteoblastic MC3T3-E1 cells. Molecular Medicine Reports, 2017, 16, 5833-5840.	1.1	6
3648	Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia. Expert Opinion on Investigational Drugs, 2017, 26, 1249-1265.	1.9	31
3649	Cyanidin-3-O-glucoside inhibits the UVB-induced ROS/COX-2 pathway in HaCaT cells. Journal of Photochemistry and Photobiology B: Biology, 2017, 177, 24-31.	1.7	55

#	Article	IF	Citations
3650	Rituximab effectively reverses Tyrosine kinase inhibitors (TKIs) resistance through inhibiting the accumulation of rictor on mitochondria-associated ER-membrane (MAM). Cancer Biomarkers, 2017, 20, 581-588.	0.8	4
3651	TGX-221 inhibits proliferation and induces apoptosis in human glioblastoma cells. Oncology Reports, 2017, 38, 2836-2842.	1.2	15
3652	Mechanism of apoptosis involved in gastric mucosal lesions in Tibetans with high-altitude polycythemia. Experimental and Therapeutic Medicine, 2017, 14, 3780-3787.	0.8	7
3653	Targeting energy metabolism of cancer cells: Combined administration of NCL-240 and 2-DG. International Journal of Pharmaceutics, 2017, 532, 149-156.	2.6	15
3654	Novel pan PI3K inhibitor-induced apoptosis in APL cells correlates with suppression of telomerase: An emerging mechanism of action of BKM120. International Journal of Biochemistry and Cell Biology, 2017, 91, 1-8.	1.2	14
3655	Esculetin exerts antitumor effect on human gastric cancer cells through IGF-1/PI3K/Akt signaling pathway. European Journal of Pharmacology, 2017, 814, 207-215.	1.7	46
3656	Lung Endothelial MicroRNA-1 Regulates Tumor Growth and Angiogenesis. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1443-1455.	2.5	31
3657	Gold-chrysophanol nanoparticles suppress human prostate cancer progression through inactivating AKT expression and inducing apoptosis and ROS generation in vitro and in vivo. International Journal of Oncology, 2017, 51, 1089-1103.	1.4	26
3658	Altered Adipose-Derived Stem Cell Characteristics in Macrodactyly. Scientific Reports, 2017, 7, 11090.	1.6	6
3659	A Split-Abl Kinase for Direct Activation in Cells. Cell Chemical Biology, 2017, 24, 1250-1258.e4.	2.5	12
3660	Synthesis and biological evaluation of sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474. Bioorganic and Medicinal Chemistry, 2017, 25, 5859-5874.	1.4	14
3661	Regulation of HGF-induced hepatocyte proliferation by the small GTPase Arf6 through the PIP2-producing enzyme PIP5K1A. Scientific Reports, 2017, 7, 9438.	1.6	14
3662	Nectin-like molecule-4/cell adhesion molecule 4 inhibits the ligand-induced dimerization of ErbB3 with ErbB2. Scientific Reports, 2017, 7, 11375.	1.6	6
3663	RasGRP3 controls cell proliferation and migration in papillary thyroid cancer by regulating the Akt-MDM2 pathway. Gene, 2017, 633, 35-41.	1.0	13
3664	Role of GSK-3Î² in Regulation of Canonical Wnt/Î²-catenin Signaling and PI3-K/Akt Oncogenic Pathway in Colon Cancer. Cancer Investigation, 2017, 35, 473-483.	0.6	39
3665	P-Rex1 and P-Rex2 RacGEFs and cancer. Biochemical Society Transactions, 2017, 45, 963-977.	1.6	44
3666	Inhibition of Human Class I vs Class III Phosphatidylinositol 3â€²-Kinases. Biochemistry, 2017, 56, 4326-4334.	1.2	7
3667	Phosphorylated ribosomal protein S6 correlation with p21 expression and inverse association with tumor size in oral squamous cell carcinoma. Head and Neck, 2017, 39, 1876-1887.	0.9	9

#	Article	IF	Citations
3668	Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. Gynecologic Oncology, 2017, 147, 145-152.	0.6	18
3669	Safety, tolerabilityÂand antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study. European Journal of Cancer, 2017, 83, 194-202.	1.3	14
3670	Discovery of a Novel Series of 7-Azaindole Scaffold Derivatives as PI3K Inhibitors with Potent Activity. ACS Medicinal Chemistry Letters, 2017, 8, 875-880.	1.3	28
3671	Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2- a]pyridine and quinazolin-4(3H)-one derivatives as PI3KÎ± inhibitors. European Journal of Medicinal Chemistry, 2017, 139, 95-106.	2.6	38
3672	Glycogen synthase kinase-3 inhibition sensitizes human induced pluripotent stem cells to thiol-containing antioxidants induced apoptosis. Stem Cell Research, 2017, 23, 182-187.	0.3	11
3673	In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor. Anti-Cancer Drugs, 2017, 28, 503-513.	0.7	21
3674	The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer. Clinical Cancer Research, 2017, 23, 6580-6591.	3.2	43
3675	Cancer-promoting mechanisms of tumor-associated neutrophils. American Journal of Surgery, 2017, 214, 938-944.	0.9	95
3676	Silencing of Glut1 induces chemoresistance via modulation of Akt/GSK-3Î²/Î²-catenin/survivin signaling pathway in breast cancer cells. Archives of Biochemistry and Biophysics, 2017, 636, 110-122.	1.4	30
3677	TRIM11 Upregulation Contributes to Proliferation, Invasion, and EMT of Hepatocellular Carcinoma Cells. Oncology Research, 2017, 25, 691-699.	0.6	36
3678	Expression of <scp>CPPED</scp>1 in human trophoblasts is associated with timing of term birth. Journal of Cellular and Molecular Medicine, 2018, 22, 968-981.	1.6	10
3679	Resistance to Targeted Therapies in Breast Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2017, , .	0.1	1
3681	EGFR Resistance. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 103-116.	0.1	0
3682	Suppression of microRNA-130b inhibits glioma cell proliferation and invasion, and induces apoptosis by PTEN/AKT signaling. International Journal of Molecular Medicine, 2018, 41, 284-292.	1.8	22
3683	ADAMTS9 is Silenced by Epigenetic Disruption in Colorectal Cancer and Inhibits Cell Growth and Metastasis by Regulating Akt/p53 Signaling. Cellular Physiology and Biochemistry, 2017, 44, 1370-1380.	1.1	27
3684	Oxymatrine protects against DSS-induced colitis via inhibiting the PI3K/AKT signaling pathway. International Immunopharmacology, 2017, 53, 149-157.	1.7	71
3685	Phosphorylated AKT expression in tumorâ€‘adjacent normal tissue is associated with poor prognosis in patients with hepatocellular carcinoma. Oncology Letters, 2017, 14, 7461-7466.	0.8	3
3686	PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohort. Lung Cancer, 2017, 112, 96-101.	0.9	17

#	Article	IF	Citations
3687	miR-124 Inhibits Lung Tumorigenesis Induced by K-ras Mutation and NNK. Molecular Therapy - Nucleic Acids, 2017, 9, 145-154.	2.3	23
3688	The down-regulation of TAPP2 inhibits the migration of esophageal squamous cell carcinoma and predicts favorable outcome. Pathology Research and Practice, 2017, 213, 1556-1562.	1.0	2
3689	SGK2 promotes hepatocellular carcinoma progression and mediates GSK-3Î²/Î²-catenin signaling in HCC cells. Tumor Biology, 2017, 39, 101042831770040.	0.8	19
3690	Kinase activity ranking using phosphoproteomics data (KARP) quantifies the contribution of protein kinases to the regulation of cell viability. Molecular and Cellular Proteomics, 2017, 16, 1694-1704.	2.5	18
3691	Tumor suppressor Pdcd4 attenuates Sin1 translation to inhibit invasion in colon carcinoma. Oncogene, 2017, 36, 6225-6234.	2.6	47
3692	Feedback autophagy activation as a key resistance factor of Ku-0060648 in colorectal cancer cells. Biochemical and Biophysical Research Communications, 2017, 490, 1244-1249.	1.0	7
3694	Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer. Molecular and Clinical Oncology, 2017, 7, 27-31.	0.4	15
3695	Anti-colon cancer activity of Murraya koenigii leaves is due to constituent murrayazoline and O-methylmurrayamine A induced mTOR/AKT downregulation and mitochondrial apoptosis. Biomedicine and Pharmacotherapy, 2017, 93, 510-521.	2.5	33
3696	Redox-dependent activation of PI3-kinase is involved in growth-factor- induced proliferation of fibroblasts. Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology, 2017, 11, 17-23.	0.3	0
3697	Wild carrot pentane-based fractions suppress proliferation of human HaCaT keratinocytes and protect against chemically-induced skin cancer. BMC Complementary and Alternative Medicine, 2017, 17, 36.	3.7	10
3698	DNA methylation-based chromatin compartments and ChIP-seq profiles reveal transcriptional drivers of prostate carcinogenesis. Genome Medicine, 2017, 9, 54.	3.6	17
3699	Kinase-driven metabolic signalling as a predictor of response to carboplatinâ€“paclitaxel adjuvant treatment in advanced ovarian cancers. British Journal of Cancer, 2017, 117, 494-502.	2.9	10
3700	The Emerging Role of TRAF7 in Tumor Development. Journal of Cellular Physiology, 2017, 232, 1233-1238.	2.0	68
3701	Protective effect of Î±-lipoic acid against antimycin A cytotoxicity in MC3T3-E1 osteoblastic cells. Cell Stress and Chaperones, 2017, 22, 5-13.	1.2	5
3702	Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR. Cancer Letters, 2017, 384, 27-38.	3.2	19
3703	Neomorphic mutations create therapeutic challenges in cancer. Oncogene, 2017, 36, 1607-1618.	2.6	24
3704	Analysis of genes involved in the PI3K/Akt pathway in radiation- and MNU-induced rat mammary carcinomas. Journal of Radiation Research, 2017, 58, 183-194.	0.8	9
3705	Drug resistance and cancer stem cells: the shared but distinct roles of hypoxiaâ€inducible factors <scp>HIF</scp>1Î± and <scp>HIF</scp>2Î±. Clinical and Experimental Pharmacology and Physiology, 2017, 44, 153-161.	0.9	91

#	Article	IF	Citations
3706	Determination of MLN0128, an investigational antineoplastic agent, in human plasma by LCâ€“MS/MS. Biomedical Chromatography, 2017, 31, e3818.	0.8	1
3707	UBE2S, a novel substrate of Akt1, associates with Ku70 and regulates DNA repair and glioblastoma multiforme resistance to chemotherapy. Oncogene, 2017, 36, 1145-1156.	2.6	46
3708	CXCR6 promotes tumor cell proliferation and metastasis in osteosarcoma through the Akt pathway. Cellular Immunology, 2017, 311, 80-85.	1.4	11
3709	Antitumoral Effects of D-Fraction fromGrifola Frondosa(Maitake) Mushroom in Breast Cancer. Nutrition and Cancer, 2017, 69, 29-43.	0.9	24
3710	Claudin-5, -7, and -18 suppress proliferation mediated by inhibition of phosphorylation of Akt in human lung squamous cell carcinoma. Biochimica Et Biophysica Acta - Molecular Cell Research, 2017, 1864, 293-302.	1.9	43
3711	S100A11 promotes human pancreatic cancer PANCâ€1 cell proliferation and is involved in the PI3K/AKT signaling pathway. Oncology Letters, 2018, 15, 175-182.	0.8	23
3712	Proteomic changes of CD4+/CD25+/forkhead box p3+ regulatory T cells in a 30â€day rat model of sepsis survival. Experimental and Therapeutic Medicine, 2017, 14, 5619-5628.	0.8	1
3713	Aqueous extract of Cordyceps sinensis potentiates the antitumor effect of DDP and attenuates therapy-associated toxicity in non-small cell lung cancer via ÎºBÎ±/NFÎºB and AKT/MMP2/MMP9 pathways. RSC Advances, 2017, 7, 37743-37754.	1.7	10
3714	The potential of emerging therapeutics for epithelioid sarcoma. Expert Opinion on Orphan Drugs, 2017, 5, 983-989.	0.5	2
3715	<i>Quisqualis indica</i> Improves Benign Prostatic Hyperplasia by Regulating Prostate Cell Proliferation and Apoptosis. Biological and Pharmaceutical Bulletin, 2017, 40, 2125-2133.	0.6	28
3716	Gelsolin regulates proliferation, apoptosis and invasion in NK/T-cell lymphoma cells. Biology Open, 2018, 7, .	0.6	8
3717	MicroRNAâ€1 inhibits tumorigenicity of esophageal squamous cell carcinoma and enhances sensitivity to gefitinib. Oncology Letters, 2017, 15, 963-971.	0.8	10
3718	PI3K/AKT/Afadin signaling pathway contributes to pathological vascularization in glioblastomas. Oncology Letters, 2018, 15, 1893-1899.	0.8	8
3719	New agents for the management of resistant metastatic breast cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 1815-1831.	0.9	5
3720	3D QSAR and HQSAR analysis of protein kinase B (PKB/Akt) inhibitors using various alignment methods. Arabian Journal of Chemistry, 2017, 10, S2182-S2195.	2.3	6
3721	Interaction of Epstein-Barr virus genes with human gastric carcinoma transcriptome. Oncotarget, 2017, 8, 38399-38412.	0.8	11
3722	Genetic Polymorphisms of Insulin-Like Growth Factor 1 Are Associated with Osteosarcoma Risk and Prognosis. Medical Science Monitor, 2017, 23, 5892-5898.	0.5	17
3723	Activation of Akt by SC79 protects myocardiocytes from oxygen and glucose deprivation (OGD)/re-oxygenation. Oncotarget, 2017, 8, 14978-14987.	0.8	40

#	Article	IF	Citations
3724	Azelaic Acid Exerts Antileukemic Activity in Acute Myeloid Leukemia. Frontiers in Pharmacology, 2017, 8, 359.	1.6	21
3725	Kaempferia parviflora Extract Exhibits Anti-cancer Activity against HeLa Cervical Cancer Cells. Frontiers in Pharmacology, 2017, 8, 630.	1.6	32
3726	Astrocytic Expression of CTMP Following an Excitotoxic Lesion in the Mouse Hippocampus. Experimental Neurobiology, 2017, 26, 25-32.	0.7	4
3727	Metabotropic glutamate receptors as a new therapeutic target for malignant gliomas. Oncotarget, 2017, 8, 22279-22298.	0.8	38
3728	Silencing of LIM and SH3 Protein 1 (LASP-1) Inhibits Thyroid Cancer Cell Proliferation and Invasion. Oncology Research, 2017, 25, 879-886.	0.6	3
3729	Akt1 Stimulates Homologous Recombination Repair of DNA Double-Strand Breaks in a Rad51-Dependent Manner. International Journal of Molecular Sciences, 2017, 18, 2473.	1.8	34
3730	Effect of electroacupuncture at Ximen (PC 4) and Hegu (LI 4) on expression of Akt in rats with myocardial ischemia-reperfusion injury. Journal of Traditional Chinese Medicine = Chung I Tsa Chih Ying Wen Pan / Sponsored By All-China Association of Traditional Chinese Medicine, Academy of Traditional Chinese Medicine, 2017, 37, 835-840.	0.4	1
3731	Liver Protective Effects of Extra Virgin Olive Oil: Interaction between Its Chemical Composition and the Cell-signaling Pathways Involved in Protection. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2017, 18, 75-84.	0.6	62
3732	The Interplay between Oncogenic Signaling Networks and Mitochondrial Dynamics. Antioxidants, 2017, 6, 33.	2.2	31
3733	PI3K Signaling in Tissue Hyper-Proliferation: From Overgrowth Syndromes to Kidney Cysts. Cancers, 2017, 9, 30.	1.7	29
3734	AR Signaling and the PI3K Pathway in Prostate Cancer. Cancers, 2017, 9, 34.	1.7	118
3735	Phosphoinositide 3-Kinase-Dependent Signalling Pathways in Cutaneous Squamous Cell Carcinomas. Cancers, 2017, 9, 86.	1.7	28
3736	The PI3KÎ´ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL. Cancers, 2017, 9, 121.	1.7	14
3737	Lamin B Receptor: Interplay between Structure, Function and Localization. Cells, 2017, 6, 28.	1.8	42
3738	Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?. International Journal of Molecular Sciences, 2017, 18, 85.	1.8	25
3739	Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer. International Journal of Molecular Sciences, 2017, 18, 367.	1.8	268
3740	EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment. International Journal of Molecular Sciences, 2017, 18, 1295.	1.8	91
3741	Anticancer potential of novel curcumin analogs towards castrate-resistant prostate cancer. International Journal of Oncology, 2018, 52, 579-588.	1.4	16

#	Article	IF	Citations
3742	Distinct Akt phosphorylation states are required for insulin regulated Glut4 and Glut1-mediated glucose uptake. ELife, 2017, 6, .	2.8	121
3743	Sonic Hedgehog Signaling in Thyroid Cancer. Frontiers in Endocrinology, 2017, 8, 284.	1.5	19
3744	Ataxia-Telangiectasia Mutated Modulation of Carbon Metabolism in Cancer. Frontiers in Oncology, 2017, 7, 291.	1.3	36
3745	The Role of Epidermal Growth Factor Receptor in the Management of Gastrointestinal Carcinomas: Present Status and Future Perspectives. Current Pharmaceutical Design, 2017, 23, 2314-2320.	0.9	10
3746	AIM2 regulates viability and apoptosis in human colorectal cancer cells via the PI3K/Akt pathway. OncoTargets and Therapy, 2017, Volume 10, 811-817.	1.0	39
3747	Identification of Linkages between EDCs in Personal Care Products and Breast Cancer through Data Integration Combined with Gene Network Analysis. International Journal of Environmental Research and Public Health, 2017, 14, 1158.	1.2	6
3748	Evolving Cancer Classification in the Era of Personalized Medicine: A Primer for Radiologists. Korean Journal of Radiology, 2017, 18, 6.	1.5	12
3749	HSPA6 augments garlic extract-induced inhibition of proliferation, migration, and invasion of bladder cancer EJ cells; Implication for cell cycle dysregulation, signaling pathway alteration, and transcription factor-associated MMP-9 regulation. PLoS ONE, 2017, 12, e0171860.	1.1	39
3750	Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer. PLoS ONE, 2017, 12, e0180192.	1.1	27
3751	Inferring gene and protein interactions using PubMed citations and consensus Bayesian networks. PLoS ONE, 2017, 12, e0186004.	1.1	11
3752	Downregulation of Ubiquitin-Specific Protease 22 Inhibits Proliferation, Invasion, and Epithelialâ€Mesenchymal Transition in Osteosarcoma Cells. Oncology Research, 2017, 25, 743-751.	0.6	19
3753	Regulation of Ras signaling and function by plasma membrane microdomains. BioScience Trends, 2017, 11, 23-40.	1.1	13
3754	Prognostic implications of the phosphatidylinositol 3-kinase/Akt signaling pathway in oral squamous cell carcinoma: overexpression of p-mTOR indicates an adverse prognosis. Applied Cancer Research, 2017, 37, .	1.0	13
3755	Using machine learning algorithms to identify genes essential for cell survival. BMC Bioinformatics, 2017, 18, 397.	1.2	5
3756	Molecular challenges of neuroendocrine tumors (Review). Oncology Letters, 2017, 15, 2715-2725.	0.8	13
3757	Vernodalol mediates antitumor effects in acute promyelocytic leukemia cells. Oncology Letters, 2017, 15, 2227-2235.	0.8	3
3758	STMN1, a prognostic predictor of esophageal squamous cell carcinoma, is a marker of the activation of the PI3K pathway. Oncology Reports, 2018, 39, 834-842.	1.2	8
3759	Correlation of NEDD4-1 and PTEN expression with the invasive capacity of pituitary adenomas. Molecular and Clinical Oncology, 2017, 6, 96-100.	0.4	3

#	Article	IF	Citations
3760	Silver nanoparticles coupled to anti-EGFR antibodies sensitize nasopharyngeal carcinoma cells to irradiation. Molecular Medicine Reports, 2017, 16, 9005-9010.	1.1	15
3761	Cooperative oncogenic effect and cell signaling crosstalk of co-occurring HER2 and mutant PIK3CA in mammary epithelial cells. International Journal of Oncology, 2017, 51, 1320-1330.	1.4	5
3762	VEGF-Mediated Signal Transduction in Tumor Angiogenesis. , 0, , .		3
3763	A novel RON splice variant lacking exon 2 activates the PI3K/AKT pathway via PTEN phosphorylation in colorectal carcinoma cells. Oncotarget, 2017, 8, 39101-39116.	0.8	18
3764	Analysis of miRNA profiles identified miR-196a as a crucial mediator of aberrant PI3K/AKT signaling in lung cancer cells. Oncotarget, 2017, 8, 19172-19191.	0.8	32
3765	Function of miR-152 as a Tumor Suppressor in Human Breast Cancer by Targeting PIK3CA. Oncology Research, 2017, 25, 1363-1371.	0.6	42
3766	Papillomaviruses: a systematic review. Genetics and Molecular Biology, 2017, 40, 1-21.	0.6	51
3767	A systematic study of Girdin on cell proliferation, migration and angiogenesis in different breast cancer subtypes. Molecular Medicine Reports, 2017, 16, 3351-3356.	1.1	9
3768	Molecular biology of human epidermal receptors, signaling pathways and targeted therapy against cancers: new evidences and old challenges. Brazilian Journal of Pharmaceutical Sciences, 2017, 53, .	1.2	22
3769	miR-202 Suppresses Cell Proliferation by Targeting FOXR2 in Endometrial Adenocarcinoma. Disease Markers, 2017, 2017, 1-8.	0.6	25
3770	Prognostic implications of phosphatidylinositol 3-kinase/AKT signaling pathway activation in gastric carcinomas. Archives of Medical Science, 2017, 6, 1262-1268.	0.4	10
3771	ANTITUMOR AND APOPTOTIC EFFECTS OF CUCURBITACIN A IN A-549 LUNG CARCINOMA CELLS IS MEDIATED VIA G2/M CELL CYCLE ARREST AND M-TOR/PI3K/AKT SIGNALLING PATHWAY.. Tropical Journal of Obstetrics and Gynaecology, 2017, 14, 75-82.	0.3	10
3772	IN SILICO DOCKING STUDIES ON KAEMPFERITRIN WITH DIVERSE INFLAMMATORY AND APOPTOTIC PROTEINS FUNCTIONAL APPROACH TOWARDS THE COLON CANCER. International Journal of Pharmacy and Pharmaceutical Sciences, 2017, 9, 199.	0.3	10
3773	AKT Inhibition in Solid Tumors With AKT1 Mutations. Journal of Clinical Oncology, 2017, 35, 2251-2259.	0.8	240
3774	Alteration of Akt, p-Akt, ERK, and p-ERK Proteins Expression in the Kidney of Hypokalemic Rat. Korean Journal of Physical Anthropology, 2017, 30, 87.	0.2	1
3775	Na+/H+ exchanger 1 has tumor suppressive activity and prognostic value in esophageal squamous cell carcinoma. Oncotarget, 2017, 8, 2209-2223.	0.8	20
3776	The miR-93 promotes proliferation by directly targeting PDCD4 in hepatocellular carcinoma. Neoplasma, 2017, 64, 770-777.	0.7	17
3777	LncRNA260-specific siRNA targeting IL28RA gene inhibit cardiomyocytes hypoxic/reoxygenation injury. Journal of Thoracic Disease, 2017, 9, 2447-2460.	0.6	4

#	Article	IF	Citations
3778	Molecular genetics of meningiomas: Building the roadmap towards personalized therapy. Neurochirurgie, 2018, 64, 22-28.	0.6	23
3779	Mutational Analysis of AKT1 and PIK3CA in Intraductal Papillomas of the Breast with Special Reference to Cellular Components. American Journal of Pathology, 2018, 188, 1106-1112.	1.9	14
3780	LZTS2 inhibits PI3K/AKT activation and radioresistance in nasopharyngeal carcinoma by interacting with p85. Cancer Letters, 2018, 420, 38-48.	3.2	46
3781	Cholesterol Depletion by TASIN-1 Induces Apoptotic Cell Death through the ER Stress/ROS/JNK Signaling in Colon Cancer Cells. Molecular Cancer Therapeutics, 2018, 17, 943-951.	1.9	27
3782	An <scp>FGFR</scp> 3/ <scp>MYC</scp> positive feedback loop provides new opportunities for targeted therapies in bladder cancers. EMBO Molecular Medicine, 2018, 10, .	3.3	54
3783	The Expression and Prognostic Impact of the PI3K/AKT/mTOR Signaling Pathway in Advanced Esophageal Squamous Cell Carcinoma. Technology in Cancer Research and Treatment, 2018, 17, 153303381875877.	0.8	31
3784	Discovery of Pyridopyrimidinones as Potent and Orally Active Dual Inhibitors of PI3K/mTOR. ACS Medicinal Chemistry Letters, 2018, 9, 256-261.	1.3	13
3785	BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers. Drugs, 2018, 78, 549-566.	4.9	95
3786	Phosphorylation of PI3K regulatory subunit p85 contributes to resistance against PI3K inhibitors in radioresistant head and neck cancer. Oral Oncology, 2018, 78, 56-63.	0.8	23
3787	Sensitization of tumor cells to chemotherapy by natural products: A systematic review of preclinical data and molecular mechanisms. FÃ¬toterapÃ¬Ã¢, 2018, 129, 383-400.	1.1	72
3788	Potential tumor suppressing role of microRNA-545 in epithelial ovarian cancer. Oncology Letters, 2018, 15, 6386-6392.	0.8	15
3789	AKT as a key target for growth promoting functions of neutral ceramidase in colon cancer cells. Oncogene, 2018, 37, 3852-3863.	2.6	27
3790	Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience. Therapeutic Advances in Urology, 2018, 10, 109-123.	0.9	27
3791	EGFR-Phosphorylated Platelet Isoform of Phosphofructokinase 1 Promotes PI3K Activation. Molecular Cell, 2018, 70, 197-210.e7.	4.5	116
3792	Too many targets, not enough patients: rethinking neuroblastoma clinical trials. Nature Reviews Cancer, 2018, 18, 389-400.	12.8	67
3793	Lithium, a classic drug in psychiatry, improves nilotinib-mediated antileukemic effects. Biomedicine and Pharmacotherapy, 2018, 99, 237-244.	2.5	2
3794	Oxyresveratrol prevents lipopolysaccharide/d-galactosamine-induced acute liver injury in mice. International Immunopharmacology, 2018, 56, 105-112.	1.7	37
3795	Distinct roles for phosphoinositide 3-kinases Î³ and Î´ in malignant B cell migration. Leukemia, 2018, 32, 1958-1969.	3.3	40

#	Article	IF	Citations
3796	Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. Cancer Research, 2018, 78, 2383-2395.	0.4	31
3797	Sphingadienes show therapeutic efficacy in neuroblastoma in vitro and in vivo by targeting the AKT signaling pathway. Investigational New Drugs, 2018, 36, 743-754.	1.2	13
3798	AMPKâ€“Akt Double-Negative Feedback Loop in Breast Cancer Cells Regulates Their Adaptation to Matrix Deprivation. Cancer Research, 2018, 78, 1497-1510.	0.4	57
3799	Effect of Akt activation and experimental pharmacological inhibition on responses to neoadjuvant chemoradiotherapy in rectal cancer. British Journal of Surgery, 2018, 105, e192-e203.	0.1	20
3800	Short-term heat stress altered metabolism and insulin signaling in skeletal muscle. Journal of Animal Science, 2018, 96, 154-167.	0.2	17
3801	Fluoxetine Inhibits Natural Decay of Long-Term Memory via Akt/GSK-3Î² Signaling. Molecular Neurobiology, 2018, 55, 7453-7462.	1.9	14
3802	Nuclear Phosphatidylinositol-Phosphate Type I Kinase Î±-Coupled Star-PAP Polyadenylation Regulates Cell Invasion. Molecular and Cellular Biology, 2018, 38, .	1.1	9
3803	Comparative transcriptomic analysis of skeletal muscle tissue during prenatal stages in Tongcheng and Yorkshire pig using RNA-seq. Functional and Integrative Genomics, 2018, 18, 195-209.	1.4	20
3804	Combinatorial Effect of Abiraterone Acetate and NVP-BEZ235 on Prostate Tumor Progression in Rats. Hormones and Cancer, 2018, 9, 175-187.	4.9	6
3805	Discovery of new thienopyrimidine derivatives as potent and orally efficacious phosphoinositide 3-kinase inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 637-646.	1.4	5
3806	Analyzing the Genetic Spectrum of Vascular Anomalies with Overgrowth viaÂCancer Genomics. Journal of Investigative Dermatology, 2018, 138, 957-967.	0.3	45
3807	Marine fish oil is more potent than plant-based n-3 polyunsaturated fatty acids in the prevention of mammary tumors. Journal of Nutritional Biochemistry, 2018, 55, 41-52.	1.9	23
3808	Pharmacological targeting of HSP90 with 17-AAG induces apoptosis of myogenic cells through activation of the intrinsic pathway. Molecular and Cellular Biochemistry, 2018, 445, 45-58.	1.4	12
3809	PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise. Leukemia and Lymphoma, 2018, 59, 2524-2534.	0.6	54
3810	A review of computational approaches for analysis of hepatitis C virus-mediated liver diseases. Briefings in Functional Genomics, 2018, 17, 428-440.	1.3	3
3811	Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs. Cancer Cell International, 2018, 18, 69.	1.8	32
3812	Smoking is predictive of poorer distant metastasis-free and progression free-survival in soft tissue sarcoma patients treated with pre-operative radiotherapy or chemoradiotherapy. Clinical Sarcoma Research, 2018, 8, 7.	2.3	9
3813	Differential regulation of the pro-inflammatory biomarker, YKL-40/CHI3L1, by PTEN/Phosphoinositide 3-kinase and JAK2/STAT3 pathways in glioblastoma. Cancer Letters, 2018, 429, 54-65.	3.2	21

#	Article	IF	Citations
3814	Pathologic significance of AKT, mTOR, and GSK3Î² proteins in oral squamous cell carcinoma-affected patients. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 983-997.	1.4	25
3815	Tributyltin reduces the levels of serum adiponectin and activity of AKT and induces metabolic syndrome in male mice. Environmental Toxicology, 2018, 33, 752-758.	2.1	8
3816	Targeting AKT with Oridonin Inhibits Growth of Esophageal Squamous Cell Carcinoma In Vitro and Patient-Derived Xenografts In Vivo. Molecular Cancer Therapeutics, 2018, 17, 1540-1553.	1.9	69
3817	An Autopsy Case of Pulmonary Tumor Thrombotic Microangiopathy Due to Rapidly Progressing Colon Cancer in a Patient with Type 2 Diabetes. Internal Medicine, 2018, 57, 2533-2539.	0.3	2
3818	The coâ€'treatment of metformin with flavone synergistically induces apoptosis through inhibition of PI3K/AKT pathway in breast cancer cells. Oncology Letters, 2018, 15, 5952-5958.	0.8	17
3819	Lycium barbarum Polysaccharide Promotes Nigrostriatal Dopamine Function by Modulating PTEN/AKT/mTOR Pathway in a Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Murine Model of Parkinsonâ€™s Disease. Neurochemical Research, 2018, 43, 938-947.	1.6	15
3820	Genetic defects in SAPK signalling, chromatin regulation, vesicle transport and CoA-related lipid metabolism are rescued by rapamycin in fission yeast. Open Biology, 2018, 8, .	1.5	4
3821	Itraconazole-Induced Inhibition on Human Esophageal Cancer Cell Growth Requires AMPK Activation. Molecular Cancer Therapeutics, 2018, 17, 1229-1239.	1.9	31
3822	An update on treatment for post-menopausal metastatic breast cancer in elderly patients. Expert Opinion on Pharmacotherapy, 2018, 19, 597-609.	0.9	1
3823	In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS). Neurogenetics, 2018, 19, 77-91.	0.7	65
3824	40 YEARS OF IGF1: IGF1 receptor signaling pathways. Journal of Molecular Endocrinology, 2018, 61, T69-T86.	1.1	257
3825	BCL6B suppresses proliferation and migration of colorectal carcinoma cells through inhibition of the PI3K/AKT signaling pathway. International Journal of Molecular Medicine, 2018, 41, 2660-2668.	1.8	10
3826	The Effect of miR-200c Inhibition on Chemosensitivity (5- FluoroUracil) in Colorectal Cancer. Pathology and Oncology Research, 2018, 24, 145-151.	0.9	33
3827	Nuclear phosphoinositide regulation of chromatin. Journal of Cellular Physiology, 2018, 233, 107-123.	2.0	39
3828	The chemopreventive and anticancer potential against colorectal cancer of polyphenol-rich fruit extracts. Food Reviews International, 2018, 34, 390-409.	4.3	10
3829	Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression. Seminars in Cancer Biology, 2018, 48, 36-52.	4.3	181
3830	A phase Ib study of everolimus combined with metformin for patients with advanced cancer. Investigational New Drugs, 2018, 36, 53-61.	1.2	15
3831	Resveratrol Attenuates the Cytotoxicity Induced by Amyloid-Î²1â€"42 in PC12 Cells by Upregulating Heme Oxygenase-1 via the PI3K/Akt/Nrf2 Pathway. Neurochemical Research, 2018, 43, 297-305.	1.6	75

#	Article	IF	Citations
3832	The PI3K/AKT signaling pathway: Associations of miRNAs with dysregulated gene expression in colorectal cancer. Molecular Carcinogenesis, 2018, 57, 243-261.	1.3	83
3833	Direct pharmacological Akt activation rescues Alzheimer's disease like memory impairments and aberrant synaptic plasticity. Neuropharmacology, 2018, 128, 282-292.	2.0	66
3834	Post-autologous transplant maintenance therapies in lymphoma: current state and future directions. Bone Marrow Transplantation, 2018, 53, 11-21.	1.3	2
3835	An Akt3 Splice Variant Lacking the Serine 472 Phosphorylation Site Promotes Apoptosis and Suppresses Mammary Tumorigenesis. Cancer Research, 2018, 78, 103-114.	0.4	13
3836	Identification of WEE1 as a target to make AKT inhibition more effective in melanoma. Cancer Biology and Therapy, 2018, 19, 53-62.	1.5	12
3837	The Regulation of NRF2 by Nutrient-Responsive Signaling and Its Role in Anabolic Cancer Metabolism. Antioxidants and Redox Signaling, 2018, 29, 1774-1791.	2.5	54
3838	Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study. Targeted Oncology, 2018, 13, 81-87.	1.7	8
3839	JAK3 and PI3K mediate bovine Interferonâ€τau stimulated gene expression in the blood neutrophils. Journal of Cellular Physiology, 2018, 233, 4885-4894.	2.0	9
3840	Stage-dependent therapeutic efficacy in PI3K/mTOR-driven squamous cell carcinoma of the skin. Cell Death and Differentiation, 2018, 25, 1146-1159.	5.0	31
3841	PI3K inhibitors IC87114 inhibits the migration and invasion of thyroid cancer cell in vitro and in vivo. Journal of Cellular Biochemistry, 2018, 119, 4097-4102.	1.2	3
3842	Biomaterialsâ€Based Approaches to Tumor Spheroid and Organoid Modeling. Advanced Healthcare Materials, 2018, 7, e1700980.	3.9	96
3843	Nectin-4 promotes gastric cancer progression via the PI3K/AKT signaling pathway. Human Pathology, 2018, 72, 107-116.	1.1	37
3844	Lipid rafts disruption induces apoptosis by attenuating expression of LRP6 and survivin in triple negative breast cancer. Biomedicine and Pharmacotherapy, 2018, 97, 359-368.	2.5	40
3845	Calmodulin and IQGAP1 activation of PI3KÎ± and Akt in KRAS, HRAS and NRAS-driven cancers. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 2304-2314.	1.8	16
3846	Prostate cancer health disparities: An immuno-biological perspective. Cancer Letters, 2018, 414, 153-165.	3.2	17
3847	Determination of ZSTK474, a novel Pan PI3K inhibitor in mouse plasma by LCâ€“MS/MS and its application to Pharmacokinetics. Journal of Pharmaceutical and Biomedical Analysis, 2018, 149, 387-393.	1.4	9
3848	Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example. Molecular Cancer Therapeutics, 2018, 17, 355-367.	1.9	27
3849	Exploring prognostic genes in ovarian cancer stage-related coexpression network modules. Medicine (United States), 2018, 97, e11895.	0.4	11

#	Article	IF	Citations
3850	CLCA4 inhibits cell proliferation and invasion of hepatocellular carcinoma by suppressing epithelial-mesenchymal transition via PI3K/AKT signaling. Aging, 2018, 10, 2570-2584.	1.4	46
3851	Novel targeting approaches and signaling pathways of colorectal cancer: An insight. World Journal of Gastroenterology, 2018, 24, 4428-4435.	1.4	64
3852	MicroRNA-126 regulates the phosphatidylinositol-3 kinase (PI3K)/protein kinase B (AKT) pathway in SLK cells in vitro and the expression of its pathway members in Kaposi's sarcoma tissue. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.4	4
3853	Protective effects of PI3KCG gene on acute myocardial infarction. Journal of Thoracic Disease, 2018, 10, 941-953.	0.6	6
3854	A DR4 capturer with AKT siRNA for the synergetic enhancement of death receptor-mediated apoptosis. Chemical Communications, 2018, 54, 13439-13442.	2.2	3
3855	Hematopoietic Stem Cell Molecular Targets and Factors Essential for Hematopoiesis. Journal of Stem Cell Research & Therapy, 2018, 8, .	0.3	8
3856	Lithium-containing biomaterials inhibit osteoclastogenesis of macrophagesin vitroand osteolysisin vivo. Journal of Materials Chemistry B, 2018, 6, 8115-8126.	2.9	17
3857	miR-182 and miR-183 Promote Cell Proliferation and Invasion by Targeting FOXO1 in Mesothelioma. Frontiers in Oncology, 2018, 8, 446.	1.3	45
3858	The critical role of AMPK in driving Akt activation under stress, tumorigenesis and drug resistance. Nature Communications, 2018, 9, 4728.	5.8	125
3859	Gene prioritization, communality analysis, networking and metabolic integrated pathway to better understand breast cancer pathogenesis. Scientific Reports, 2018, 8, 16679.	1.6	29
3860	Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer. Expert Opinion on Emerging Drugs, 2018, 23, 271-282.	1.0	15
3861	The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the Î²-catenin/SIRT3 signaling pathway in cervical cancer. Journal of Hematology and Oncology, 2018, 11, 139.	6.9	65
3862	Oleuropein, the Main Polyphenol of Olea europaea Leaf Extract, Has an Anti-Cancer Effect on Human BRAF Melanoma Cells and Potentiates the Cytotoxicity of Current Chemotherapies. Nutrients, 2018, 10, 1950.	1.7	79
3863	Role and regulation of proapoptotic Bax in oral squamous cell carcinoma and drug resistance. Head and Neck, 2019, 41, 185-197.	0.9	37
3864	Long Noncoding RNAs. Advances in Clinical Chemistry, 2018, 87, 1-36.	1.8	58
3865	Induction of cytotoxicity and apoptosis in FLT3 mutant expressing cells using novel pyrimido cyanoacrylates and quinoline derivatives. Biomedicine and Pharmacotherapy, 2018, 108, 893-905.	2.5	3
3866	CYP24A1 depletion facilitates the antitumor effect of vitamin D3 on thyroid cancer cells. Experimental and Therapeutic Medicine, 2018, 16, 2821-2830.	0.8	14
3867	Effects of metformin on the PI3K/AKT/FOXO1 pathway in anaplastic thyroid Cancer cell lines. DARU, Journal of Pharmaceutical Sciences, 2018, 26, 93-103.	0.9	31

#	Article	IF	Citations
3868	Diversity in human placental microvascular endothelial cells and macrovascular endothelial cells. Cytokine, 2018, 111, 287-294.	1.4	10
3869	Aurantoside C Targets and Induces Apoptosis in Triple Negative Breast Cancer Cells. Marine Drugs, 2018, 16, 361.	2.2	19
3870	Reduced menin expression impairs rapamycin effects as evidenced by an increase in mTORC2 signaling and cell migration. Cell Communication and Signaling, 2018, 16, 64.	2.7	13
3871	Resibufogenin suppresses transforming growth factorâ€Î²â€activated kinase 1â€mediated nuclear factorâ€ºB activity through protein kinase Câ€dependent inhibition of glycogen synthase kinase 3. Cancer Science, 2018, 109, 3611-3622.	1.7	18
3872	High throughput small RNA and transcriptome sequencing reveal capacitation-related microRNAs and mRNA in boar sperm. BMC Genomics, 2018, 19, 736.	1.2	33
3873	Focal adhesion kinase promotes progression and predicts poor clinical outcomes in patients with osteosarcoma. Oncology Letters, 2018, 15, 6225-6232.	0.8	12
3874	Immune Evasion Strategies. , 2018, , .		2
3875	Downregulation of RNF138 inhibits cellular proliferation, migration, invasion and EMT in glioma cells via suppression of the Erk signaling pathway. Oncology Reports, 2018, 40, 3285-3296.	1.2	18
3876	Abnormal activation of the Akt signaling pathway in adenoid cystic carcinoma. European Archives of Oto-Rhino-Laryngology, 2018, 275, 3039-3047.	0.8	5
3877	Effects of non-steroidal anti-inflammatory drug-activated gene-1 on Ganoderma lucidum polysaccharides-induced apoptosis of human prostate cancer PC-3 cells. International Journal of Oncology, 2018, 53, 2356-2368.	1.4	14
3878	Appropriate Sequence for Afatinib and Cisplatin Combination Improves Anticancer Activity in Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology, 2018, 8, 432.	1.3	12
3879	RIT1 suppresses esophageal squamous cell carcinoma growth and metastasis and predicts good prognosis. Cell Death and Disease, 2018, 9, 1085.	2.7	14
3880	Advancing therapies in metastatic castration-resistant prostate cancer. Expert Opinion on Pharmacotherapy, 2018, 19, 1797-1804.	0.9	23
3881	Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis. Clinics, 2018, 73, e566s.	0.6	35
3882	Modulation of G6PD affects bladder cancer via ROS accumulation and the AKT pathway in vitro. International Journal of Oncology, 2018, 53, 1703-1712.	1.4	61
3883	Inhibition of Prostate Cancer DU-145 Cells Proliferation by Anthopleura anjunae Oligopeptide (YVPGP) via PI3K/AKT/mTOR Signaling Pathway. Marine Drugs, 2018, 16, 325.	2.2	32
3884	Overcoming chemoresistance in pancreatic cancer cells: role of the bitter taste receptor T2R10. Journal of Cancer, 2018, 9, 711-725.	1.2	32
3885	Cerium Oxide Nanoparticles Sensitize Pancreatic Cancer to Radiation Therapy through Oxidative Activation of the JNK Apoptotic Pathway. Cancers, 2018, 10, 303.	1.7	33

#	Article	IF	Citations
3886	Phytoestrogens and breast cancer: In vitro anticancer activities of isoflavones, lignans, coumestans, stilbenes and their analogs and derivatives. Biomedicine and Pharmacotherapy, 2018, 107, 1648-1666.	2.5	93
3887	S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib. Cellular Physiology and Biochemistry, 2018, 49, 1184-1203.	1.1	18
3888	Signaling Pathways Targeted by Protozoan Parasites to Inhibit Apoptosis. , 2018, , .		2
3889	Synthesis, biological evaluation and structure-activity relationship of a novel class of PI3KÎ± H1047R mutant inhibitors. European Journal of Medicinal Chemistry, 2018, 158, 707-719.	2.6	10
3890	Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Research and Treatment, 2018, 172, 713-723.	1.1	78
3891	Signaling pathways and steroid receptors modulating estrogen receptor Î± function in breast cancer. Genes and Development, 2018, 32, 1141-1154.	2.7	107
3892	Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy. PLoS ONE, 2018, 13, e0193849.	1.1	14
3893	EGF upregulates RFPL3 and hTERT via the MEK signaling pathway in nonâ€‘small cell lung cancer cells. Oncology Reports, 2018, 40, 29-38.	1.2	10
3894	The Intestinotrophic Effects of Glucagon-Like Peptide-2 in Relation to Intestinal Neoplasia. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2827-2837.	1.8	9
3895	Deciphering the cells of origin of squamous cell carcinomas. Nature Reviews Cancer, 2018, 18, 549-561.	12.8	171
3896	The role of Pdcd4 in tumour suppression and protein translation. Biology of the Cell, 2018, 110, 169-177.	0.7	62
3897	Preclinical evaluation of novel PI3K/mTOR dual inhibitor SN202 as potential anti-renal cancer agent. Cancer Biology and Therapy, 2018, 19, 1015-1022.	1.5	5
3898	Functional link between plasma membrane spatiotemporal dynamics, cancer biology, and dietary membrane-altering agents. Cancer and Metastasis Reviews, 2018, 37, 519-544.	2.7	33
3899	The Antiarrhythmic Drug, Amiodarone, Decreases AKT Activity and Sensitizes Human Acute Myeloid Leukemia Cells to Apoptosis by ABT-263. American Journal of the Medical Sciences, 2018, 355, 488-496.	0.4	4
3900	Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. Oncogene, 2018, 37, 4639-4661.	2.6	219
3901	Noncoding RNA Alterations in Cancer Molecular Pathways. , 2018, , 247-268.		0
3902	CHP2 Promotes Cell Proliferation in Breast Cancer via Suppression of FOXO3a. Molecular Cancer Research, 2018, 16, 1512-1522.	1.5	12
3903	Ellagic acid prevents dementia through modulation of PI3-kinase-endothelial nitric oxide synthase signalling in streptozotocin-treated rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 2018, 391, 987-1001.	1.4	12

#	Article	IF	Citations
3904	Pharmacophore modeling for identification of anti-IGF-1R drugs and in-vitro validation of fulvestrant as a potential inhibitor. PLoS ONE, 2018, 13, e0196312.	1.1	7
3905	Additive effects of the combined expression of soluble forms of GAS1 and PTEN inhibiting glioblastoma growth. Gene Therapy, 2018, 25, 439-449.	2.3	19
3906	Regulation of Tumor Progression by Programmed Necrosis. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-28.	1.9	140
3907	RTN4 Knockdown Dysregulates the AKT Pathway, Destabilizes the Cytoskeleton, and Enhances Paclitaxel-Induced Cytotoxicity in Cancers. Molecular Therapy, 2018, 26, 2019-2033.	3.7	29
3908	MicroRNAâ€21 and microRNAâ€214 play important role in reproduction regulation during porcine estrous. Animal Science Journal, 2018, 89, 1398-1405.	0.6	8
3909	Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting. Endocrine, 2018, 62, 663-680.	1.1	9
3910	Overcoming Endocrine Resistance in Hormone Receptorâ€“Positive Breast Cancer. Current Oncology, 2018, 25, 18-27.	0.9	96
3911	Essential Oil Derived From Eupatorium adenophorum Spreng. Mediates Anticancer Effect by Inhibiting STAT3 and AKT Activation to Induce Apoptosis in Hepatocellular Carcinoma. Frontiers in Pharmacology, 2018, 9, 483.	1.6	32
3912	Cornel Iridoid Glycoside Inhibits Tau Hyperphosphorylation via Regulating Cross-Talk Between GSK-3Î² and PP2A Signaling. Frontiers in Pharmacology, 2018, 9, 682.	1.6	27
3913	The tumor suppressor role of microRNAâ€‘338â€‘3p in renal cell carcinoma. Oncology Letters, 2018, 16, 2195-2200.	0.8	8
3914	Increased megalin expression in early type 2 diabetes: role of insulin-signaling pathways. American Journal of Physiology - Renal Physiology, 2018, 315, F1191-F1207.	1.3	22
3915	miR-342-3p suppresses hepatocellular carcinoma proliferation through inhibition of IGF-1R-mediated Warburg effect. OncoTargets and Therapy, 2018, Volume 11, 1643-1653.	1.0	62
3916	Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date. Breast Cancer: Targets and Therapy, 2018, Volume 10, 23-29.	1.0	15
3917	Synthesis and PI 3-Kinase Inhibition Activity of Some Novel 2,4,6-Trisubstituted 1,3,5-Triazines. Molecules, 2018, 23, 1628.	1.7	2
3918	Mechanism of Yanghe Pingchuan granules treatment for airway remodeling in asthma. Drug Design, Development and Therapy, 2018, Volume 12, 1941-1951.	2.0	18
3919	Potential therapeutic targets for growth arrest of colorectal cancer cells exposed to PTHrP. Molecular and Cellular Endocrinology, 2018, 478, 32-44.	1.6	9
3921	Î²-1,3/1,4-Glucan Lichenan from Cetraria islandica (L.) ACH. induces cellular differentiation of human keratinocytes. FÃ¬toterapÃ¬Ã¢, 2018, 129, 226-236.	1.1	16
3922	PTEN: Tumor Suppressor and Metabolic Regulator. Frontiers in Endocrinology, 2018, 9, 338.	1.5	365

#	Article	IF	Citations
3923	Inhibitory effect of Au@Pt-NSs on proliferation, migration, and invasion of EJ bladder carcinoma cells: involvement of cell cycle regulators, signaling pathways, and transcription factor-mediated MMP-9 expression. International Journal of Nanomedicine, 2018, Volume 13, 3295-3310.	3.3	7
3924	An FRMD4B variant suppresses dysplastic photoreceptor lesions in models of enhanced S-cone syndrome and of Nrl deficiency. Human Molecular Genetics, 2018, 27, 3340-3352.	1.4	6
3925	Phosphoinositide 3-Kinase/Akt Signaling and Redox Metabolism in Cancer. Frontiers in Oncology, 2018, 8, 160.	1.3	283
3926	New Insights into Protein Kinase B/Akt Signaling: Role of Localized Akt Activation and Compartment-Specific Target Proteins for the Cellular Radiation Response. Cancers, 2018, 10, 78.	1.7	90
3927	MiR-99b-5p and miR-203a-3p Function as Tumor Suppressors by Targeting IGF-1R in Gastric Cancer. Scientific Reports, 2018, 8, 10119.	1.6	64
3928	Hesperetin inhibits Eca-109 cell proliferation and invasion by suppressing the PI3K/AKT signaling pathway and synergistically enhances the anti-tumor effect of 5-fluorouracil on esophageal cancer in vitro and in vivo. RSC Advances, 2018, 8, 24434-24443.	1.7	14
3929	Progress in targeted therapy for breast cancer. Chronic Diseases and Translational Medicine, 2018, 4, 164-175.	0.9	31
3930	Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism. International Journal of Molecular Sciences, 2018, 19, 382.	1.8	20
3931	Apoptosis: Activation and Inhibition in Health and Disease. Medical Sciences (Basel, Switzerland), 2018, 6, 54.	1.3	14
3932	EGFR: How Important Is EGFR Mutation Status in the Management of Lung Cancer?. Respiratory Disease Series, 2018, , 275-293.	0.1	0
3933	In vitro effects of PI3K/mTOR inhibition in canine hemangiosarcoma. PLoS ONE, 2018, 13, e0200634.	1.1	12
3934	Status of KRAS in iPSCs Impacts upon Self-Renewal and DifferentiationÂPropensity. Stem Cell Reports, 2018, 11, 380-394.	2.3	27
3935	<scp>PIK</scp>3<scp>CA</scp> c.3140A>G mutation in a patient with suspected Proteus Syndrome: a case report. Clinical Case Reports (discontinued), 2018, 6, 1358-1363.	0.2	4
3936	Hallmarks of Cancer in the Reading Room: A Guide for Radiologists. American Journal of Roentgenology, 2018, 211, 470-484.	1.0	6
3937	Novel Approaches in WaldenstrÃ¶m Macroglobulinemia. Hematology/Oncology Clinics of North America, 2018, 32, 875-890.	0.9	4
3938	Sleeping Beauty and the Microenvironment Enchantment: Microenvironmental Regulation of the Proliferation-Quiescence Decision in Normal Tissues and in Cancer Development. Frontiers in Cell and Developmental Biology, 2018, 6, 59.	1.8	43
3939	TIPE3 differentially modulates proliferation and migration of human non-small-cell lung cancer cells via distinct subcellular location. BMC Cancer, 2018, 18, 260.	1.1	16
3940	AZGP1 inhibits soft tissue sarcoma cells invasion and migration. BMC Cancer, 2018, 18, 89.	1.1	12

#	Article	IF	Citations
3941	Protein arginine methylation: an emerging regulator of the cell cycle. Cell Division, 2018, 13, 3.	1.1	70
3942	Biological function of Lemur tyrosine kinase 2 (LMTK2): implications in neurodegeneration. Molecular Brain, 2018, 11, 20.	1.3	25
3943	Expression of factors and key components associated with the PI3K signaling pathway in colon cancer. Oncology Letters, 2018, 15, 5465-5472.	0.8	8
3944	The role of mTOR in ovarian Neoplasms, polycystic ovary syndrome, and ovarian aging. Clinical Anatomy, 2018, 31, 891-898.	1.5	36
3945	Peanut (Arachis hypogaea L.): A Prospective Legume Crop to Offer Multiple Health Benefits Under Changing Climate. Comprehensive Reviews in Food Science and Food Safety, 2018, 17, 1325-1338.	5.9	58
3946	SUMOylation regulates germinal vesicle breakdown and the Akt/PKB pathway during mouse oocyte maturation. American Journal of Physiology - Cell Physiology, 2018, 315, C115-C121.	2.1	13
3947	CASTOR1 suppresses the progression of lung adenocarcinoma and predicts poor prognosis. Journal of Cellular Biochemistry, 2018, 119, 10186-10194.	1.2	6
3948	Emerging roles of long non-coding RNAs in tumor metabolism. Journal of Hematology and Oncology, 2018, 11, 106.	6.9	72
3949	RKIP: A Key Regulator in Tumor Metastasis Initiation and Resistance to Apoptosis: Therapeutic Targeting and Impact. Cancers, 2018, 10, 287.	1.7	53
3950	The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1870, 185-197.	3.3	40
3951	m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nature Cell Biology, 2018, 20, 1074-1083.	4.6	592
3952	Functional miRNAs in breast cancer drug resistance. OncoTargets and Therapy, 2018, Volume 11, 1529-1541.	1.0	89
3953	A national, multicenter, non-interventional, observational study on treatment patterns in patients with metastatic renal cell carcinoma in Turkey – NOTES study. OncoTargets and Therapy, 2018, Volume 11, 1223-1228.	1.0	3
3954	Midazolam activates caspase, MAPKs and endoplasmic reticulum stress pathways, and inhibits cell cycle and Akt pathway, to induce apoptosis in TM3 mouse Leydig progenitor cells. OncoTargets and Therapy, 2018, Volume 11, 1475-1490.	1.0	9
3955	Alternative polyadenylation confersÂPtenmRNAs stability and resistance to microRNAs. Nucleic Acids Research, 2018, 46, 10340-10352.	6.5	29
3956	Anthocyanins from Hibiscus sabdariffa calyx attenuate in vitro and in vivo melanoma cancer metastasis. Journal of Functional Foods, 2018, 48, 614-631.	1.6	37
3957	DNA methylation signatures of pulmonary arterial smooth muscle cells in chronic thromboembolic pulmonary hypertension. Physiological Genomics, 2018, 50, 313-322.	1.0	23
3958	Molecular Basis of Diseases of the Gastrointestinal Tract. , 2018, , 387-415.		1

#	Article	IF	Citations
3959	The effect of â€œNutramilTM Complex,â€•food for special medical purpose, on breast and prostate carcinoma cells. PLoS ONE, 2018, 13, e0192860.	1.1	0
3960	Galangin Induces Apoptosis in MCF-7 Human Breast Cancer Cells Through Mitochondrial Pathway and Phosphatidylinositol 3-Kinase/Akt Inhibition. Pharmacology, 2018, 102, 58-66.	0.9	44
3961	Pharmacological inactivation of the PI3K p110Î´ prevents breast tumour progression by targeting cancer cells and macrophages. Cell Death and Disease, 2018, 9, 678.	2.7	37
3962	Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-Kinase Inhibitors for Cancer Treatment. Journal of Medicinal Chemistry, 2018, 61, 6087-6109.	2.9	30
3963	TRPV4 promotes the migration and invasion of glioma cells via AKT/Rac1 signaling. Biochemical and Biophysical Research Communications, 2018, 503, 876-881.	1.0	31
3964	PIK3CA mutations in colorectal and breast cancer: impact on oncogenesis and response to nonsteroidal anti-inflammatory drugs. , 2019, , 123-144.		2
3965	A new medermycin analog from the marine-derived actinomycetes Streptomyces sp. ZS-A45. Journal of Asian Natural Products Research, 2019, 21, 826-831.	0.7	7
3966	MUC13 promotes the development of colitis-associated colorectal tumors via Î²-catenin activity. Oncogene, 2019, 38, 7294-7310.	2.6	28
3967	Nimbolide Represses the Proliferation, Migration, and Invasion of Bladder Carcinoma Cells via Chk2-Mediated G2/M Phase Cell Cycle Arrest, Altered Signaling Pathways, and Reduced Transcription Factors-Associated MMP-9 Expression. Evidence-based Complementary and Alternative Medicine, 2019, 2019, 1-12.	0.5	14
3968	Everolimus Nanoformulation in Biological Nanoparticles Increases Drug Responsiveness in Resistant and Low-Responsive Breast Cancer Cell Lines. Pharmaceutics, 2019, 11, 384.	2.0	18
3969	Triacanthine exerts antitumor effects on bladder cancer in vitro and in vivo. Phytomedicine, 2019, 64, 153069.	2.3	22
3970	Electromagnetic fields alter the motility of metastatic breast cancer cells. Communications Biology, 2019, 2, 303.	2.0	24
3971	mTOR and other effector kinase signals that impact T cell function and activity. Immunological Reviews, 2019, 291, 134-153.	2.8	53
3972	Clinicopathological and biological analysis of PIK3CA mutation and amplification in cervical carcinomas. Experimental and Therapeutic Medicine, 2019, 18, 2278-2284.	0.8	8
3973	The ubiquitination ligase SMURF2 reduces aerobic glycolysis and colorectal cancer cell proliferation by promoting ChREBP ubiquitination and degradation. Journal of Biological Chemistry, 2019, 294, 14745-14756.	1.6	27
3974	Development of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates bearing sulfonylpiperazine as antitumor inhibitors targeting PI3KÎ±. European Journal of Medicinal Chemistry, 2019, 182, 111630.	2.6	8
3975	Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma. Oncogene, 2019, 38, 7035-7045.	2.6	55
3976	A Novel Splice Variant of the Masculinizing Gene Masc with piRNA-Cleavage-Site Defect Functions in Female External Genital Development in the Silkworm, Bombyx mori. Biomolecules, 2019, 9, 318.	1.8	13

#	Article	IF	Citations
3977	The Ig superfamily protein PTGFRN coordinates survival signaling in glioblastoma multiforme. Cancer Letters, 2019, 462, 33-42.	3.2	26
3978	Scavenger Receptor Class B Type 1 (SR-B1) being a Potential Biomarker for the Diagnosis of Liposarcoma and Associated with the Degree of Differentiation of Liposarcomas. Journal of Cancer, 2019, 10, 4326-4332.	1.2	1
3979	Mechanosensitive ion channel Piezo1 promotes prostate cancer development through the activation of the Akt/mTOR pathway and acceleration of cell cycle. International Journal of Oncology, 2019, 55, 629-644.	1.4	55
3980	Mechanisms of resistance to a PI3K inhibitor in gastrointestinal stromal tumors: an omic approach to identify novel druggable targets . Cancer Management and Research, 2019, Volume 11, 6229-6244.	0.9	2
3981	Hyperinsulinemia promotes aberrant histone acetylation in triple-negative breast cancer. Epigenetics and Chromatin, 2019, 12, 44.	1.8	23
3982	EXOSC5 as a Novel Prognostic Marker Promotes Proliferation of Colorectal Cancer via Activating the ERK and AKT Pathways. Frontiers in Oncology, 2019, 9, 643.	1.3	24
3983	Emerging roles of exosomal miRNAs in breast cancer drug resistance. IUBMB Life, 2019, 71, 1672-1684.	1.5	26
3984	The effect of hydroethanolic extract of Matricaria chamomilla on the reproductive system of male rats exposed to formaldehyde. Andrologia, 2019, 51, e13362.	1.0	11
3985	Possible predisposition for colorectal carcinogenesis due to altered gene expressions in normal appearing mucosa from patients with colorectal neoplasia. BMC Cancer, 2019, 19, 643.	1.1	4
3986	Potential proapoptotic phytochemical agents for the treatment and prevention of colorectal cancer (Review). Oncology Letters, 2019, 18, 487-498.	0.8	24
3987	Transcriptome profiling of cervical cancer cells acquired resistance to cisplatin by deep sequencing. Artificial Cells, Nanomedicine and Biotechnology, 2019, 47, 2820-2829.	1.9	16
3988	Cleavage and polyadenylation specific factor 4 promotes colon cancer progression by transcriptionally activating hTERT. Biochimica Et Biophysica Acta - Molecular Cell Research, 2019, 1866, 1533-1543.	1.9	11
3989	Contribution of hepatitis B virus X protein-induced aberrant microRNA expression to hepatocellular carcinoma pathogenesis. Turkish Journal of Biology, 2019, 43, 113-123.	2.1	3
3990	Discovery of 4-Methylquinazoline Based PI3K Inhibitors for the Potential Treatment of Idiopathic Pulmonary Fibrosis. Journal of Medicinal Chemistry, 2019, 62, 8873-8879.	2.9	19
3991	Dual PI3K/mTOR Inhibitor, XL765, suppresses glioblastoma growth by inducing ER stress-dependent apoptosis . OncoTargets and Therapy, 2019, Volume 12, 5415-5424.	1.0	20
3992	Recent Findings in the Regulation of Programmed Death Ligand 1 Expression. Frontiers in Immunology, 2019, 10, 1337.	2.2	85
3993	Curcumin Induces Apoptotic Cell Death via Inhibition of PI3-Kinase/AKT Pathway in B-Precursor Acute Lymphoblastic Leukemia. Frontiers in Oncology, 2019, 9, 484.	1.3	56
3994	Isoform-Specific Role of Akt in Oral Squamous Cell Carcinoma. Biomolecules, 2019, 9, 253.	1.8	38

#	Article	IF	Citations
3995	The Inhibition on MDFIC and PI3K/AKT Pathway Caused by miR-146b-3p Triggers Suppression of Myoblast Proliferation and Differentiation and Promotion of Apoptosis. Cells, 2019, 8, 656.	1.8	35
3996	S100B Protein Stimulates Proliferation and Angiogenic Mediators Release through RAGE/pAkt/mTOR Pathway in Human Colon Adenocarcinoma Caco-2 Cells. International Journal of Molecular Sciences, 2019, 20, 3240.	1.8	25
3997	Interleukin-6 mediates resistance to PI3K-pathwayâ€“targeted therapy in lymphoma. BMC Cancer, 2019, 19, 936.	1.1	34
3998	The Modulatory Properties of Astragalus membranaceus Treatment on Triple-Negative Breast Cancer: An Integrated Pharmacological Method. Frontiers in Pharmacology, 2019, 10, 1171.	1.6	32
3999	USP13 serves as a tumor suppressor via the PTEN/AKT pathway in oral squamous cell carcinoma . Cancer Management and Research, 2019, Volume 11, 9175-9183.	0.9	27
4000	Akt Pathway Inhibition of the Solenopsin Analog, 2-Dodecylsulfanyl-1,-4,-5,-6-tetrahydropyrimidine. Anticancer Research, 2019, 39, 5329-5338.	0.5	8
4001	Functional validation of metabolic genes that distinguish Gleason 3 from Gleason 4 prostate cancer foci. Prostate, 2019, 79, 1777-1788.	1.2	7
4002	A computational approach for investigating the mutational landscape of RAC-alpha serine/threonine-protein kinase (AKT1) and screening inhibitors against the oncogenic E17K mutation causing breast cancer. Computers in Biology and Medicine, 2019, 115, 103513.	3.9	14
4003	Icariin promotes angiogenesis in glucocorticoidâ€induced osteonecrosis of femoral heads: In vitro and in vivo studies. Journal of Cellular and Molecular Medicine, 2019, 23, 7320-7330.	1.6	35
4004	A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor. Journal of Medicinal Chemistry, 2019, 62, 8609-8630.	2.9	24
4005	Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia. Future Oncology, 2019, 15, 2227-2239.	1.1	13
4006	Wnt Signaling Pathways in Keratinocyte Carcinomas. Cancers, 2019, 11, 1216.	1.7	27
4007	A Radiogenomic Approach for Decoding Molecular Mechanisms Underlying Tumor Progression in Prostate Cancer. Cancers, 2019, 11, 1293.	1.7	19
4008	Antiproliferative and proâ€apoptotic effects of Cyclocaryaï¿½paliurus polysaccharide and Xâ€ray irradiation combination on SW480 colorectal cancer cells. Molecular Medicine Reports, 2019, 20, 3535-3542.	1.1	3
4009	Tie2â€“FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in Glioblastoma. Cancer Research, 2019, 79, 5088-5101.	0.4	17
4010	The Possible Interactions and Therapeutic Roles of Lithium Chloride and Midkine on Cancer Treatment. Critical Reviews in Oncogenesis, 2019, 24, 35-45.	0.2	6
4011	A novel tumor suppressor protein encoded by circular AKT3 RNA inhibits glioblastoma tumorigenicity by competing with active phosphoinositide-dependent Kinase-1. Molecular Cancer, 2019, 18, 131.	7.9	205
4012	Phosphoinositide 3-kinase Î´ inactivation prevents vitreous-induced activation of AKT/MDM2/p53 and migration of retinal pigment epithelial cells. Journal of Biological Chemistry, 2019, 294, 15408-15417.	1.6	14

#	Article	IF	Citations
4013	PTEN Genetic and Epigenetic Alterations Define Distinct Subgroups in North Indian Breast Cancer Patients. Asian Pacific Journal of Cancer Prevention, 2019, 20, 269-276.	0.5	11
4014	Development of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates containing piperazine as inhibitors of PI3KÎ±. Bioorganic Chemistry, 2019, 92, 103238.	2.0	7
4015	Chinese Herbal Medicine Ganoderma tsugae Displays Potential Anti-Cancer Efficacy on Metastatic Prostate Cancer Cells. International Journal of Molecular Sciences, 2019, 20, 4418.	1.8	13
4016	Mechanical stretch promotes tumoricidal M1 polarization via the FAK/NFâ€ÎºB signaling pathway. FASEB Journal, 2019, 33, 13254-13266.	0.2	30
4017	New advances in targeting aberrant signaling pathways in T-cell acute lymphoblastic leukemia. Advances in Biological Regulation, 2019, 74, 100649.	1.4	17
4018	Duplicitous Dispositions of Micro-RNAs (miRs) in Breast Cancer. , 0, , .		0
4019	Tumour-specific Causal Inference Discovers Distinct Disease Mechanisms Underlying Cancer Subtypes. Scientific Reports, 2019, 9, 13225.	1.6	3
4020	TRIM59: A membrane protein expressed on Bacillus Calmette-GuÃ©rin-activated macrophages that induces apoptosis of fibrosarcoma cells by direct contact. Experimental Cell Research, 2019, 384, 111590.	1.2	5
4021	Uric acid and sphingomyelin enhance autophagy in iPS cell-originated cardiomyocytes through lncRNA MEG3/miR-7-5p/EGFR axis. Artificial Cells, Nanomedicine and Biotechnology, 2019, 47, 3774-3785.	1.9	15
4022	Mutation profiling of cancer drivers in Brazilian colorectal cancer. Scientific Reports, 2019, 9, 13687.	1.6	31
4023	Carnosine exerts antitumor activity against bladder cancers in vitro and in vivo via suppression of angiogenesis. Journal of Nutritional Biochemistry, 2019, 74, 108230.	1.9	10
4024	Therapeutic potential of PI3K signaling in distinct entities of B-cell lymphoma. Expert Review of Hematology, 2019, 12, 1053-1062.	1.0	14
4025	Inhibition of AKT signalling by benzoxazine derivative LTUR6 through the modulation of downstream kinases. Investigational New Drugs, 2019, 37, 779-783.	1.2	1
4026	Phosphorylated Progesterone Receptor Isoforms Mediate Opposing Stem Cell and Proliferative Breast Cancer Cell Fates. Endocrinology, 2019, 160, 430-446.	1.4	40
4027	A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer. Gynecologic Oncology, 2019, 153, 135-148.	0.6	45
4028	New roles for B cell receptor associated kinases: when the B cell is not the target. Leukemia, 2019, 33, 576-587.	3.3	26
4029	Antiproliferative and apoptotic activity of glycyrrhizinic acid in MCF-7 human breast cancer cells and evaluation of its effect on cell cycle, cell migration and m-TOR/PI3K/Akt signalling pathway. Archives of Medical Science, 2019, 15, 174-182.	0.4	14
4030	Solid stress-induced migration is mediated by GDF15 through Akt pathway activation in pancreatic cancer cells. Scientific Reports, 2019, 9, 978.	1.6	57

#	Article	IF	Citations
4031	Comprehensive bioinformation analysis of methylated and differentially expressed genes in esophageal squamous cell carcinoma. Molecular Omics, 2019, 15, 88-100.	1.4	9
4032	Synthesis and Evaluation of Imidazo[1,2â€a]pyridine Analogues of the ZSTK474 Class of Phosphatidylinositol 3â€Kinase Inhibitors. Chemistry - an Asian Journal, 2019, 14, 1249-1261.	1.7	9
4033	Monitoring flux in signalling pathways through measurements of 4EBP1-mediated eIF4F complex assembly. BMC Biology, 2019, 17, 40.	1.7	11
4034	Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases. Journal of Medicinal Chemistry, 2019, 62, 6992-7014.	2.9	58
4035	Focus on the glycerophosphocholine pathway in choline phospholipid metabolism of cancer. NMR in Biomedicine, 2019, 32, e4112.	1.6	89
4036	Insights into the effect on silkworm (Bombyx mori) cocooning and its potential mechanisms following non-lethal dose tebuconazole exposure. Chemosphere, 2019, 234, 338-345.	4.2	11
4037	Target identification, screening and in vivo evaluation of pyrrolone-fused benzosuberene compounds against human epilepsy using Zebrafish model of pentylenetetrazol-induced seizures. Scientific Reports, 2019, 9, 7904.	1.6	58
4038	Identification of TC2N as a novel promising suppressor of PI3K-AKT signaling in breast cancer. Cell Death and Disease, 2019, 10, 424.	2.7	17
4039	The Natural Product Butylcycloheptyl Prodiginine Binds Pre-miR-21, Inhibits Dicer-Mediated Processing of Pre-miR-21, and Blocks Cellular Proliferation. Cell Chemical Biology, 2019, 26, 1133-1142.e4.	2.5	30
4040	Antiviral Therapy for AECHB and Severe Hepatitis B (Liver Failure). , 2019, , 371-455.		0
4041	Macropinosomes as units of signal transduction. Philosophical Transactions of the Royal Society B: Biological Sciences, 2019, 374, 20180157.	1.8	33
4042	2â€²,4â€²-Dihydroxy-6â€²-methoxy-3â€²,5â€²-dimethylchalcone induced apoptosis and G1 cell cycle arrest through PI3K/AKT pathway in BEL-7402/5-FU cells. Food and Chemical Toxicology, 2019, 131, 110533.	1.8	19
4043	A novel lncRNA n384546 promotes thyroid papillary cancer progression and metastasis by acting as a competing endogenous RNA of miR-145-5p to regulate AKT3. Cell Death and Disease, 2019, 10, 433.	2.7	53
4044	Bioinformatics Analysis of Stromal Molecular Signatures Associated with Breast and Prostate Cancer. Journal of Computational Biology, 2019, 26, 1130-1139.	0.8	12
4045	In vitro and in vivo Induction of p53-Dependent Apoptosis by Extract of Euryale ferox Salisb in A549 Human Caucasian Lung Carcinoma Cancer Cells Is Mediated Through Akt Signaling Pathway. Frontiers in Oncology, 2019, 9, 406.	1.3	25
4046	N6-methyladenosine modifications: interactions with novel RNA-binding proteins and roles in signal transduction. RNA Biology, 2019, 16, 991-1000.	1.5	49
4048	As a downstream target of the AKT pathway, NPTX1 inhibits proliferation and promotes apoptosis in hepatocellular carcinoma. Bioscience Reports, 2019, 39, .	1.1	13
4050	Alpha7 nAChR Expression Is Correlated with Arthritis Development and Inhibited by Sinomenine in Adjuvant-Induced Arthritic Rats. Evidence-based Complementary and Alternative Medicine, 2019, 2019, 1-11.	0.5	13

#	Article	IF	Citations
4051	A genetic variant in PIK3R1 is associated with pancreatic cancer survival in the Chinese population. Cancer Medicine, 2019, 8, 3575-3582.	1.3	9
4052	Hydroxysafflor yellow A inhibited lipopolysaccharideâ€induced nonâ€small cell lung cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT/mTOR and ERK/MAPK signaling pathways. Thoracic Cancer, 2019, 10, 1319-1333.	0.8	42
4053	SOX9 Stem-Cell Factor: Clinical and Functional Relevance in Cancer. Journal of Oncology, 2019, 2019, 1-16.	0.6	61
4054	Oncogenic Signaling in Tumorigenesis and Applications of siRNA Nanotherapeutics in Breast Cancer. Cancers, 2019, 11, 632.	1.7	26
4055	Neutrophil Immunomodulatory Activity of Natural Organosulfur Compounds. Molecules, 2019, 24, 1809.	1.7	40
4056	Emergency Surgical Management of Colorectal Cancer. Hot Topics in Acute Care Surgery and Trauma, 2019, , .	0.1	2
4057	Modulation of cancer cell signaling by long noncoding RNAs. Journal of Cellular Biochemistry, 2019, 120, 12224-12246.	1.2	20
4058	Excessive miR-25-3p maturation via N6-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression. Nature Communications, 2019, 10, 1858.	5.8	242
4059	CD164 regulates proliferation, progression, and invasion of human glioblastoma cells. Oncotarget, 2019, 10, 2041-2054.	0.8	9
4060	Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma. Cells, 2019, 8, 350.	1.8	26
4061	Signaling pathways involved in regulating apoptosis induction in host cells upon PRRSV infection. Virus Genes, 2019, 55, 433-439.	0.7	9
4062	Design, synthesis and biological evaluation of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates containing sulfonamido as potential PI3KÎ± inhibitors. Bioorganic and Medicinal Chemistry, 2019, 27, 2261-2267.	1.4	8
4063	Upstream signaling events leading to elevated production of pro-survival nitric oxide in photodynamically-challenged glioblastoma cells. Free Radical Biology and Medicine, 2019, 137, 37-45.	1.3	24
4064	Development and characterisation of acquired radioresistant breast cancer cell lines. Radiation Oncology, 2019, 14, 64.	1.2	72
4065	Efficacy of combination therapy with zoledronic acid and cetuximab for unresectable rectal cancer with bone metastases: A case report. Molecular and Clinical Oncology, 2019, 10, 571-574.	0.4	3
4066	The Caspase-3/PKCÎ´/Akt/VEGF-A Signaling Pathway Mediates Tumor Repopulation during Radiotherapy. Clinical Cancer Research, 2019, 25, 3732-3743.	3.2	31
4067	DRAM1 regulates autophagy and cell proliferation via inhibition of the phosphoinositide 3-kinase-Akt-mTOR-ribosomal protein S6 pathway. Cell Communication and Signaling, 2019, 17, 28.	2.7	35
4068	Partial agonistic effect of cetuximab on epidermal growth factor receptor and Src kinase activation in tripleâ€negative breast cancer cell lines. International Journal of Oncology, 2019, 54, 1345-1356.	1.4	8

#	Article	IF	Citations
4069	The relation between PI3K/AKT signalling pathway and cancer. Gene, 2019, 698, 120-128.	1.0	331
4070	Role of cytoplasmic lncRNAs in regulating cancer signaling pathways. Journal of Zhejiang University: Science B, 2019, 20, 1-8.	1.3	35
4071	Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer. Cancer Research, 2019, 79, 2367-2378.	0.4	60
4072	The kinetics of folding of the NSH2 domain from p85. Scientific Reports, 2019, 9, 4058.	1.6	9
4073	Bee Venom and Its Peptide Component Melittin Suppress Growth and Migration of Melanoma Cells via Inhibition of PI3K/AKT/mTOR and MAPK Pathways. Molecules, 2019, 24, 929.	1.7	51
4074	Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusionâ€“Driven Cancer. Cancer Discovery, 2019, 9, 605-616.	7.7	11
4075	Greensporone A, a Fungal Secondary Metabolite Suppressed Constitutively Activated AKT via ROS Generation and Induced Apoptosis in Leukemic Cell Lines. Biomolecules, 2019, 9, 126.	1.8	13
4076	High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions. Cell Reports, 2019, 27, 631-647.e5.	2.9	9
4077	Delivering Combination Chemotherapies and Targeting Oncogenic Pathways via Polymeric Drug Delivery Systems. Polymers, 2019, 11, 630.	2.0	26
4078	CD47 Promotes Human Glioblastoma Invasion Through Activation of the PI3K/Akt Pathway. Oncology Research, 2019, 27, 415-422.	0.6	28
4079	CuS Nanoparticles as a Photodynamic Nanoswitch for Abrogating Bypass Signaling To Overcome Gefitinib Resistance. Nano Letters, 2019, 19, 3344-3352.	4.5	42
4080	Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression. Cell Death and Disease, 2019, 10, 322.	2.7	42
4081	Population genomics of rapidly invading lionfish in the Caribbean reveals signals of range expansion in the absence of spatial population structure. Ecology and Evolution, 2019, 9, 3306-3320.	0.8	24
4082	CD28 Signaling Controls MetabolicÂFitness of Pathogenic T Cells in Medium and LargeÂVesselÂVasculitis. Journal of the American College of Cardiology, 2019, 73, 1811-1823.	1.2	30
4083	Chaperone-mediated autophagy degradation of IGF-1RÎ² induced by NVP-AUY922 in pancreatic cancer. Cellular and Molecular Life Sciences, 2019, 76, 3433-3447.	2.4	15
4084	Cancer drug development: The missing links. Experimental Biology and Medicine, 2019, 244, 663-689.	1.1	72
4085	Metabolic regulation of cell growth and proliferation. Nature Reviews Molecular Cell Biology, 2019, 20, 436-450.	16.1	577
4086	Overexpression of TRIM26 suppresses the proliferation, metastasis, and glycolysis in papillary thyroid carcinoma cells. Journal of Cellular Physiology, 2019, 234, 19019-19027.	2.0	23

#	Article	IF	Citations
4087	Guajadial reverses multidrug resistance by inhibiting ABC transporter expression and suppressing the PI3K/Akt pathway in drug-resistant breast cancer cells. Chemico-Biological Interactions, 2019, 305, 98-104.	1.7	21
4088	The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma. Magnetic Resonance in Medicine, 2019, 81, 3798-3807.	1.9	13
4089	mTORC1 inhibitor RAD001 (everolimus) enhances non-small cell lung cancer cell radiosensitivity in vitro via suppressing epithelialâ€“mesenchymal transition. Acta Pharmacologica Sinica, 2019, 40, 1085-1094.	2.8	14
4090	Curcumin regulates the miR-21/PTEN/Akt pathway and acts in synergy with PD98059 to induce apoptosis of human gastric cancer MGC-803 cells. Journal of International Medical Research, 2019, 47, 1288-1297.	0.4	47
4091	Pyranocarbazole derivatives as potent anti-cancer agents triggering tubulin polymerization stabilization induced activation of caspase-dependent apoptosis and downregulation of Akt/mTOR in breast cancer cells. European Journal of Medicinal Chemistry, 2019, 167, 226-244.	2.6	24
4092	The Secret Life of Translation Initiation in Prostate Cancer. Frontiers in Genetics, 2019, 10, 14.	1.1	14
4093	MicroRNAâ€‘9â€‘5p downregulates Klf4 and influences the progression of hepatocellular carcinoma via the AKT signaling pathway. International Journal of Molecular Medicine, 2019, 43, 1417-1429.	1.8	13
4094	Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma. Molecular Cancer Therapeutics, 2019, 18, 834-844.	1.9	28
4095	Homeostatic Model Assessment of Insulin Resistance for Predicting the Recurrence of Hepatocellular Carcinoma after Curative Treatment. International Journal of Molecular Sciences, 2019, 20, 605.	1.8	18
4096	Synthesis and biological evaluation of solubilized sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474. Bioorganic and Medicinal Chemistry, 2019, 27, 1529-1545.	1.4	12
4097	Prostate Cancer Gene Regulatory Network Inferred from RNA-Seq Data. Current Genomics, 2019, 20, 38-48.	0.7	12
4098	The pan-cancer analysis of gain-of-functional mutations to identify the common oncogenic signatures in multiple cancers. Gene, 2019, 697, 57-66.	1.0	2
4099	Multiple Signal Pathways Involved in Crocetin-Induced Apoptosis in KYSE-150 Cells. Pharmacology, 2019, 103, 263-272.	0.9	20
4100	MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate. Acta Pharmaceutica Sinica B, 2019, 9, 1021-1034.	5.7	27
4101	Molecular Profiling Establishes Genetic Features Predictive of the Efficacy of the p110Î² Inhibitor KIN-193. Cancer Research, 2019, 79, 4524-4531.	0.4	7
4102	Silencing Of MAGI1 Promotes The Proliferation And Inhibits Apoptosis Of Glioma Cells Via The Wnt/Î²-Catenin And PTEN/AKT Signaling Pathways . OncoTargets and Therapy, 2019, Volume 12, 9639-9650.	1.0	10
4103	The Prevalence of PIK3CA Biomarker in Tumor Microenvironment of Human non-small Cell Lung Cancer. Journal of Physics: Conference Series, 2019, 1294, 062112.	0.3	0
4105	Metabolic gene alterations impact the clinical aggressiveness and drug responses of 32 human cancers. Communications Biology, 2019, 2, 414.	2.0	55

#	Article	IF	Citations
4106	Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy. Seminars in Cancer Biology, 2022, 80, 1-17.	4.3	270
4107	Treatment with a new benzimidazole derivative bearing a pyrrolidine side chain overcomes sorafenib resistance in hepatocellular carcinoma. Scientific Reports, 2019, 9, 17259.	1.6	23
4108	Sinulariolide Inhibits Gastric Cancer Cell Migration and Invasion through Downregulation of the EMT Process and Suppression of FAK/PI3K/AKT/mTOR and MAPKs Signaling Pathways. Marine Drugs, 2019, 17, 668.	2.2	40
4109	The impact of RASopathy-associated mutations on CNS development in mice and humans. Molecular Brain, 2019, 12, 96.	1.3	30
4110	Knockdown of lncRNA TDRG1 Inhibits Tumorigenesis in Endometrial Carcinoma Through the PI3K/AKT/mTOR Pathway . OncoTargets and Therapy, 2019, Volume 12, 10863-10872.	1.0	5
4111	Traditional Serrated Pathwayâ€“associated Colorectal Carcinoma. American Journal of Surgical Pathology, 2019, 43, 1042-1051.	2.1	7
4112	CSNK2A1 Promotes Gastric Cancer Invasion Through the PI3K-Akt-mTOR Signaling Pathway . Cancer Management and Research, 2019, Volume 11, 10135-10143.	0.9	24
4113	Identification of Distinct Prognostic Groups: Implications for Patient Selection to Targeted Therapies Among Anti-Endocrine Therapyâ€“Resistant Early Breast Cancers. JCO Precision Oncology, 2019, 3, 1-13.	1.5	0
4114	Prioritization of Therapy Options for a Patient With High Tumor Mutation Burden and Microsatellite Instability but No Clinical Benefit From Immunotherapy. JCO Precision Oncology, 2019, 3, 1-7.	1.5	1
4115	Elucidation of interaction mechanism of ellagic acid to the integrin linked kinase. International Journal of Biological Macromolecules, 2019, 122, 1297-1304.	3.6	38
4116	PI3k/AKT signaling pathway: Erythropoiesis and beyond. Journal of Cellular Physiology, 2019, 234, 2373-2385.	2.0	192
4117	A New Patient-Derived Metastatic Glioblastoma Cell Line: Characterisation and Response to Sodium Selenite Anticancer Agent. Cancers, 2019, 11, 12.	1.7	22
4118	NGF increases FGF2 expression and promotes endothelial cell migration and tube formation through PI3K/Akt and ERK/MAPK pathways in human chondrocytes. Osteoarthritis and Cartilage, 2019, 27, 526-534.	0.6	39
4119	Convergent Synthesis of PI3K Inhibitor GDC-0908 Featuring Palladium-Catalyzed Direct Câ€“H Arylation toward Dihydrobenzothienooxepines. Journal of Organic Chemistry, 2019, 84, 4796-4802.	1.7	10
4120	Nicotine exposure induces the proliferation of oral cancer cells through the Î±7 subunit of the nicotinic acetylcholine receptor. Biochemical and Biophysical Research Communications, 2019, 509, 514-520.	1.0	16
4121	Bound polyphenol extracted from jujube pulp triggers mitochondria-mediated apoptosis and cell cycle arrest of HepG2 cell in vitro and in vivo. Journal of Functional Foods, 2019, 53, 187-196.	1.6	9
4122	Neuronal calcium sensor 1 (NCS1) promotes motility and metastatic spread of breast cancer cells in vitro and in vivo. FASEB Journal, 2019, 33, 4802-4813.	0.2	14
4123	Inhibition of stearoyl CoA desaturaseâ€1 activity suppresses tumour progression and improves prognosis in human bladder cancer. Journal of Cellular and Molecular Medicine, 2019, 23, 2064-2076.	1.6	42

#	Article	IF	Citations
4124	Genetic alteration of Exon 5 of the PTEN gene in Indian patients with ameloblastoma. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2019, 127, 225-230.	0.2	4
4125	<scp>FAM</scp>134B induces tumorigenesis and epithelialâ€toâ€mesenchymal transition via Akt signaling in hepatocellular carcinoma. Molecular Oncology, 2019, 13, 792-810.	2.1	22
4126	Integrated analysis of pseudogene RP11-564D11.3 expression and its potential roles in hepatocellular carcinoma. Epigenomics, 2019, 11, 267-280.	1.0	17
4127	[1â€“9-NÎ±C]-linusorb B2 and [1â€“9-NÎ±C]-linusorb B3 isolated from flaxseed induce G1 cell cycle arrest on SGC-7901 cells by modulating the AKT/JNK signaling pathway. Journal of Functional Foods, 2019, 52, 332-339.	1.6	14
4128	KIAA1199 promotes invasion and migration in non-small-cell lung cancer (NSCLC) via PI3K-Akt mediated EMT. Journal of Molecular Medicine, 2019, 97, 127-140.	1.7	34
4129	PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma. Clinical Cancer Research, 2019, 25, 334-345.	3.2	17
4130	A controlled trial of HNSCC patientâ€derived xenografts reveals broad efficacy of PI3KÎ± inhibition in controlling tumor growth. International Journal of Cancer, 2019, 145, 2100-2106.	2.3	17
4131	High Glucose Represses the Anti-Proliferative and Pro-Apoptotic Effect of Metformin in Triple Negative Breast Cancer Cells. Biomolecules, 2019, 9, 16.	1.8	39
4132	Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology. Drug Safety, 2019, 42, 247-262.	1.4	66
4133	Phosvitin and its hydrolysate promote differentiation and inhibit TNF-É‘ induced inflammation in MC3T3-E1 cells via ERK and AKT pathways. Journal of Functional Foods, 2019, 53, 259-265.	1.6	3
4134	Annatto (Bixa orellana) Î´-TCT Supplementation Protection against Embryonic Malformations through Alterations in PI3K/Akt-Cyclin D1 Pathway. Biomolecules, 2019, 9, 19.	1.8	1
4135	Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma. Oncogene, 2019, 38, 1802-1814.	2.6	17
4136	Role of PI3K/Akt on migration and invasion of MCF10A cells treated with extracellular vesicles from MDA-MB-231 cells stimulated with linoleic acid. Journal of Cell Communication and Signaling, 2019, 13, 235-244.	1.8	13
4137	Theaflavin and epigallocatechinâ€3â€gallate synergistically induce apoptosis through inhibition of PI3K/Akt signaling upon depolymerizing microtubules in HeLa cells. Journal of Cellular Biochemistry, 2019, 120, 5987-6003.	1.2	20
4138	The diacylglycerol kinase Î± (DGKÎ±)/Akt/NF-ÎºB feedforward loop promotes esophageal squamous cell carcinoma (ESCC) progression via FAK-dependent and FAK-independent manner. Oncogene, 2019, 38, 2533-2550.	2.6	27
4139	Role of PI3K/AKT/mTOR in Cancer Signaling. , 2019, , 263-270.		12
4140	p110Î± and p110Î² isoforms of PI3K are involved in protection against H2O2 induced oxidative stress in cancer cells. Breast Cancer, 2019, 26, 378-385.	1.3	1
4141	Developing Hispolon-based novel anticancer therapeutics against human (NF-ÎºÎ²) using in silico approach of modelling, docking and protein dynamics. Journal of Biomolecular Structure and Dynamics, 2019, 37, 3947-3967.	2.0	14

#	Article	IF	Citations
4142	Extracellular Matrix Degradation Products Downregulate Neoplastic Esophageal Cell Phenotype. Tissue Engineering - Part A, 2019, 25, 487-498.	1.6	6
4143	Targeted therapies in pancreatic cancer: Promises and failures. Journal of Cellular Biochemistry, 2019, 120, 2726-2741.	1.2	17
4144	Absorption, distribution, metabolism, and excretion of mTOR kinase inhibitor CC-223 in rats, dogs, and humans. Xenobiotica, 2019, 49, 43-53.	0.5	2
4145	A Deregulated PI3K-AKT Signaling Pathway in Patients with Colorectal Cancer. Journal of Gastrointestinal Cancer, 2019, 50, 35-41.	0.6	40
4146	Assessment of drugâ€“drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase. Xenobiotica, 2019, 49, 54-70.	0.5	1
4147	In Silico Design and Experimental Validation of Combination Therapy for Pancreatic Cancer. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2020, 17, 1010-1018.	1.9	12
4148	Over expression of PI3K-AkT reduces apoptosis and increases prostate size in benign prostatic hyperplasia. Aging Male, 2020, 23, 440-446.	0.9	18
4149	Dietary phytochemicals in colorectal cancer prevention and treatment: A focus on the molecular mechanisms involved. Biotechnology Advances, 2020, 38, 107322.	6.0	112
4150	Intracellular Signaling. , 2020, , 24-46.e12.		0
4151	Genetic alterations in cell cycle regulation-associated genes may promote primary progression of gastrointestinal stromal tumors. Laboratory Investigation, 2020, 100, 426-437.	1.7	6
4152	MiR-337â€“3p suppresses proliferation of epithelial ovarian cancer by targeting PIK3CA and PIK3CB. Cancer Letters, 2020, 469, 54-67.	3.2	45
4153	Treatment of Pituitary and Other Tumours with Cabergoline: New Mechanisms and Potential Broader Applications. Neuroendocrinology, 2020, 110, 477-488.	1.2	23
4154	The Genetics and Mechanisms of T-Cell Acute Lymphoblastic Leukemia. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a035246.	2.9	23
4155	The NEDD4â€‘1 E3 ubiquitin ligase: A potential molecular target for bortezomib sensitivity in multiple myeloma. International Journal of Cancer, 2020, 146, 1963-1978.	2.3	24
4157	CELF2 suppresses non-small cell lung carcinoma growth by inhibiting the PREX2-PTEN interaction. Carcinogenesis, 2020, 41, 377-389.	1.3	35
4158	Emerging roles of aerobic glycolysis in breast cancer. Clinical and Translational Oncology, 2020, 22, 631-646.	1.2	140
4159	Melatonin: A promising agent targeting leukemia. Journal of Cellular Biochemistry, 2020, 121, 2730-2738.	1.2	17
4160	Biological regulation of diacylglycerol kinases in normal and neoplastic tissues: New opportunities for cancer immunotherapy. Advances in Biological Regulation, 2020, 75, 100663.	1.4	12

#	Article	IF	Citations
4161	At a glance: A history of autophagy and cancer. Seminars in Cancer Biology, 2020, 66, 3-11.	4.3	70
4163	Derlin-1 functions as a growth promoter in breast cancer. Biological Chemistry, 2020, 401, 377-387.	1.2	9
4164	Activated hepatic stellate cells promote angiogenesis in hepatocellular carcinoma by secreting angiopoietinâ€1. Journal of Cellular Biochemistry, 2020, 121, 1441-1451.	1.2	23
4165	Design, synthesis and 3D-QSAR analysis of novel thiopyranopyrimidine derivatives as potential antitumor agents inhibiting A549 and Hela cancer cells. European Journal of Medicinal Chemistry, 2020, 185, 111809.	2.6	20
4166	Himachalol induces apoptosis in B16-F10 murine melanoma cells and protects against skin carcinogenesis. Journal of Ethnopharmacology, 2020, 253, 112545.	2.0	14
4167	A modified carbon paste electrode based on Fe3O4@multi-walled carbon nanotubes@polyacrylonitrile nanofibers for determination of imatinib anticancer drug. Journal of Applied Electrochemistry, 2020, 50, 281-294.	1.5	35
4168	Celastrol-Loaded Galactosylated Liposomes Effectively Inhibit AKT/c-Met-Triggered Rapid Hepatocarcinogenesis in Mice. Molecular Pharmaceutics, 2020, 17, 738-747.	2.3	30
4169	Triterpenoids from Liquidambar Fructus induced cell apoptosis via a PI3K-AKT related signal pathway in SMMC7721 cancer cells. Phytochemistry, 2020, 171, 112228.	1.4	10
4170	IGFBP-2 in cervical cancer development. Experimental and Molecular Pathology, 2020, 113, 104362.	0.9	5
4171	Heterobifunctional Molecules Induce Dephosphorylation of Kinasesâ€“A Proof of Concept Study. Journal of Medicinal Chemistry, 2020, 63, 2807-2813.	2.9	88
4172	Methyl lucidone induces apoptosis and G2/M phase arrest via the PI3K/Akt/NF-ÎºB pathway in ovarian cancer cells. Pharmaceutical Biology, 2020, 58, 51-59.	1.3	18
4173	Maximum Entropy Framework for Predictive Inference of Cell Population Heterogeneity and Responses in Signaling Networks. Cell Systems, 2020, 10, 204-212.e8.	2.9	26
4174	Microcystinâ€LR exposure disrupts the insulin signaling pathway in C2C12 mice muscle cell line. Environmental Toxicology, 2020, 35, 194-202.	2.1	5
4175	Gene network analysis reveals a core set of genes involved in the immune response of Japanese flounder (Paralichthys olivaceus) against Vibrio anguillarum infection. Fish and Shellfish Immunology, 2020, 98, 800-809.	1.6	33
4176	Identification of the key differentially expressed genes and pathways involved in neutrophilia. Innate Immunity, 2020, 26, 270-284.	1.1	1
4177	Phosphotyrosine isosteres: past, present and future. Organic and Biomolecular Chemistry, 2020, 18, 583-605.	1.5	18
4178	Combination of KRAS gene silencing and PI3K inhibition for ovarian cancer treatment. Journal of Controlled Release, 2020, 318, 98-108.	4.8	27
4179	A First-in-human Study of Tenalisib (RP6530), a Dual PI3K Î´/Î³ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 78-86.	0.2	19

#	Article	IF	Citations
4180	A ketogenic diet combined with melatonin overcomes cisplatin and vincristine drug resistance in breast carcinoma syngraft. Nutrition, 2020, 72, 110659.	1.1	31
4181	Effects of Gangliosides on Spermatozoa, Oocytes, and Preimplantation Embryos. International Journal of Molecular Sciences, 2020, 21, 106.	1.8	10
4182	Coexpression of Matrix Metalloproteinase-7 and Tissue Inhibitor of Metalloproteinase-1 as a Prognostic Biomarker in Gastric Cancer. Disease Markers, 2020, 2020, 1-10.	0.6	7
4183	Effect of AKT1 (p. E17K) Hotspot Mutation on Malignant Tumorigenesis and Prognosis. Frontiers in Cell and Developmental Biology, 2020, 8, 573599.	1.8	26
4184	piR-001773 and piR-017184 promote prostate cancer progression by interacting with PCDH9. Cellular Signalling, 2020, 76, 109780.	1.7	14
4185	Prospects of tangeretin as a modulator of cancer targets/pathways. Pharmacological Research, 2020, 161, 105202.	3.1	36
4186	Amiodaroneâ€™s major metabolite, desethylamiodarone inhibits proliferation of B16-F10 melanoma cells and limits lung metastasis formation in an in vivo experimental model. PLoS ONE, 2020, 15, e0239088.	1.1	4
4187	Increased cancer mortality among Japanese individuals with hyperinsulinemia. Metabolism Open, 2020, 7, 100048.	1.4	5
4188	PTPN13 acts as a tumor suppressor in clear cell renal cell carcinoma by inactivating Akt signaling. Experimental Cell Research, 2020, 396, 112286.	1.2	9
4189	Mir-20a-5p induced WTX deficiency promotes gastric cancer progressions through regulating PI3K/AKT signaling pathway. Journal of Experimental and Clinical Cancer Research, 2020, 39, 212.	3.5	33
4190	Spermidine-induced improvement of memory consolidation involves PI3K/Akt signaling pathway. Brain Research Bulletin, 2020, 164, 208-213.	1.4	6
4191	Discovery and SAR of Novel Disubstituted Quinazolines as Dual PI3Kalpha/mTOR Inhibitors Targeting Breast Cancer. ACS Medicinal Chemistry Letters, 2020, 11, 2156-2164.	1.3	8
4192	AKT-induced lncRNA VAL promotes EMT-independent metastasis through diminishing Trim16-dependent Vimentin degradation. Nature Communications, 2020, 11, 5127.	5.8	71
4193	The overexpression of AUF1 in colorectal cancer predicts a poor prognosis and promotes cancer progression by activating ERK and AKT pathways. Cancer Medicine, 2020, 9, 8612-8623.	1.3	18
4194	Long noncoding RNA HOTAIR promotes breast cancer development by targeting ZEB1 via sponging miR-601. Cancer Cell International, 2020, 20, 320.	1.8	25
4195	Chemical strategies to overcome resistance against targeted anticancer therapeutics. Nature Chemical Biology, 2020, 16, 817-825.	3.9	41
4196	Marine compounds targeting the PI3K/Akt signaling pathway in cancer therapy. Biomedicine and Pharmacotherapy, 2020, 129, 110484.	2.5	33
4197	Proliferative Classification of Intracranially Injected HER2-positive Breast Cancer Cell Lines. Cancers, 2020, 12, 1811.	1.7	20

#	Article	IF	Citations
4198	Role of Phytochemicals in Modulating Signaling Cascades in Cancer Cells. , 2020, , 11-45.		1
4199	Insulin Promotes Mitochondrial Respiration and Survival through PI3K/AKT/GSK3 Pathway in Human Embryonic Stem Cells. Stem Cell Reports, 2020, 15, 1362-1376.	2.3	21
4200	A New Twist in Protein Kinase B/Akt Signaling: Role of Altered Cancer Cell Metabolism in Akt-Mediated Therapy Resistance. International Journal of Molecular Sciences, 2020, 21, 8563.	1.8	17
4201	Vascular endothelial growth factor encoded by Parapoxviruses can regulate metabolism and survival of triple negative breast cancer cells. Cell Death and Disease, 2020, 11, 996.	2.7	4
4202	Unveiling role of sphingosine-1-phosphate receptor 2 as a brake of epithelial stem cell proliferation and a tumor suppressor in colorectal cancer. Journal of Experimental and Clinical Cancer Research, 2020, 39, 253.	3.5	20
4203	ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1â€“SHP2 Signaling Pathway in Non-Small Cell Lung Cancer. Frontiers in Immunology, 2020, 11, 527750.	2.2	7
4204	Molecular Modeling, Synthesis and Biological Evaluation of N-Phenyl-4-Hydroxy-6-Methyl-2-Quinolone-3-CarboxAmides as Anticancer Agents. Molecules, 2020, 25, 5348.	1.7	8
4205	Biomarkers in Her2- Positive Disease. Breast Care, 2020, 15, 586-593.	0.8	8
4206	The Immunostimulative Effect and Mechanisms of a Novel Mouse Anti-Human PD-1 Monoclonal Antibody on Jurkat Lymphocytic Cells Cocultured with Hepatoma Cells . OncoTargets and Therapy, 2020, Volume 13, 12225-12241.	1.0	5
4207	PIK3CA Is Regulated by CUX1, Promotes Cell Growth and Metastasis in Bladder Cancer via Activating Epithelial-Mesenchymal Transition. Frontiers in Oncology, 2020, 10, 536072.	1.3	8
4208	Endocrine-Disrupting Chemicalsâ€™ (EDCs) Effects on Tumour Microenvironment and Cancer Progression: Emerging Contribution of RACK1. International Journal of Molecular Sciences, 2020, 21, 9229.	1.8	30
4209	Activation of protein kinase B by WNT4 as a regulator of uterine leiomyoma stem cell function. Fertility and Sterility, 2020, 114, 1339-1349.	0.5	12
4210	Identification of CDCA8, DSN1 and BIRC5 in Regulating Cell Cycle and Apoptosis in Osteosarcoma Using Bioinformatics and Cell Biology. Technology in Cancer Research and Treatment, 2020, 19, 153303382096560.	0.8	9
4211	Paclitaxel-Loaded Colloidal Silica and TPGS-Based Solid Self-Emulsifying System Interferes Akt/mTOR Pathway in MDA-MB-231 and Demonstrates Anti-tumor Effect in Syngeneic Mammary Tumors. AAPS PharmSciTech, 2020, 21, 313.	1.5	8
4212	Increased PIP3 activity blocks nanoparticle mRNA delivery. Science Advances, 2020, 6, eaba5672.	4.7	16
4213	In Vitro and In Vivo Antitumor Efficacy of Hizikia fusiforme Celluclast Extract against Bladder Cancer. Nutrients, 2020, 12, 2159.	1.7	6
4214	Comparative Analysis of the Development of Acquired Radioresistance in Canine and Human Mammary Cancer Cell Lines. Frontiers in Veterinary Science, 2020, 7, 439.	0.9	8
4215	FLCN Regulates HIF2Î± Nuclear Import and Proliferation of Clear Cell Renal Cell Carcinoma. Frontiers in Molecular Biosciences, 2020, 7, 121.	1.6	4

#	Article	IF	Citations
4216	Ribosomes as a nexus between translation and cancer progression: Focus on ribosomal Receptor for Activated C Kinase 1 (RACK1) in breast cancer. British Journal of Pharmacology, 2022, 179, 2813-2828.	2.7	17
4217	Differential Modulation of the Phospholipidome of Proinflammatory Human Macrophages by the Flavonoids Quercetin, Naringin and Naringenin. Molecules, 2020, 25, 3460.	1.7	7
4218	Evaluation of significant gene expression changes in congenital and acquired cholesteatoma. Molecular Biology Reports, 2020, 47, 6127-6133.	1.0	6
4219	Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma. Expert Opinion on Drug Safety, 2020, 19, 1105-1120.	1.0	6
4220	A high-throughput drug combination screen identifies an anti-glioma synergism between TH588 and PI3K inhibitors. Cancer Cell International, 2020, 20, 337.	1.8	5
4221	In Vitro Evaluation of the Neuroprotective Effect ofPanax notoginsengSaponins by Activating the EGFR/PI3K/AKT Pathway. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-11.	0.5	8
4222	p53-R273H promotes cancer cell migration via upregulation of neuraminidase-1. Journal of Cancer, 2020, 11, 6874-6882.	1.2	15
4223	Triterpenoid Saponin AG8 from Ardisia gigantifolia stapf. Induces Triple Negative Breast Cancer Cells Apoptosis through Oxidative Stress Pathway. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-11.	1.9	9
4224	Clinicopathological significance of VEGF and pAkt expressions in oral squamous cell carcinoma. International Journal of Transgender Health, 2020, 13, 507-515.	1.1	3
4225	Integrin-Ligand Interactions in Inflammation, Cancer, and Metabolic Disease: Insights Into the Multifaceted Roles of an Emerging Ligand Irisin. Frontiers in Cell and Developmental Biology, 2020, 8, 588066.	1.8	41
4227	Metabolic heterogeneity in cancer: An overview and therapeutic implications. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188421.	3.3	26
4228	Modulation of complement activation by pentraxin-3 in prostate cancer. Scientific Reports, 2020, 10, 18400.	1.6	15
4229	Variants in multiple genes are associated with esophageal cancer risk in a Chinese Han population: A caseâ€“control study. Journal of Gene Medicine, 2020, 22, e3266.	1.4	3
4230	Combination Therapy with Cinnamaldehyde and Hyperthermia Induces Apoptosis of A549 Non-Small Cell Lung Carcinoma Cells via Regulation of Reactive Oxygen Species and Mitogen-Activated Protein Kinase Family. International Journal of Molecular Sciences, 2020, 21, 6229.	1.8	17
4231	Transcriptome sequencing identifies genes associated with invasion of ovarian cancer. Journal of International Medical Research, 2020, 48, 030006052095091.	0.4	9
4232	The Natural Product Fucoidan Inhibits Proliferation and Induces Apoptosis of Human Ovarian Cancer Cells: Focus on the PI3K/Akt Signaling Pathway . Cancer Management and Research, 2020, Volume 12, 6195-6207.	0.9	16
4233	Role and mechanism of autophagyâ€regulating factors in tumorigenesis and drug resistance. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 193-208.	0.7	69
4234	Single-cell Sequencing and Methylation. Advances in Experimental Medicine and Biology, 2020, , .	0.8	4

#	Article	IF	Citations
4235	Myosin XVI in the Nervous System. Cells, 2020, 9, 1903.	1.8	5
4236	PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer. Scientific Reports, 2020, 10, 12308.	1.6	20
4237	Antiproliferative and Pro-Apoptotic Effect of Uvaol in Human Hepatocarcinoma HepG2 Cells by Affecting G0/G1 Cell Cycle Arrest, ROS Production and AKT/PI3K Signaling Pathway. Molecules, 2020, 25, 4254.	1.7	17
4238	Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity. Acta Pharmacologica Sinica, 2020, 41, 1395-1402.	2.8	32
4239	Shikonin inhibits growth, invasion and glycolysis of nasopharyngeal carcinoma cells through inactivating the phosphatidylinositol 3 kinase/AKT signal pathway. Anti-Cancer Drugs, 2020, 31, 932-941.	0.7	11
4240	MiR-325 Promotes Oxaliplatin-Induced Cytotoxicity Against Colorectal Cancer Through the HSPA12B/PI3K/AKT/Bcl-2 Pathway. Digestive Diseases and Sciences, 2021, 66, 2651-2660.	1.1	12
4241	A bibliometric analysis of highly cited Phosphoinositide 3-Kinase (PI3K) research papers. Collnet Journal of Scientometrics and Information Management, 2020, 14, 37-54.	0.4	0
4242	Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models. Cancers, 2020, 12, 3857.	1.7	8
4243	Novel Carborane Compounds Based on Cyclooxygenaseâ€2 Inhibitors for Effective Boron Neutron Capture Therapy of Tongue Squamous Cell Carcinoma. ChemistrySelect, 2020, 5, 14652-14660.	0.7	6
4244	Resveratrol, curcumin, paclitaxel and miRNAs mediated regulation of PI3K/Akt/mTOR pathway: go four better to treat bladder cancer. Cancer Cell International, 2020, 20, 560.	1.8	39
4245	Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway. Journal of Experimental and Clinical Cancer Research, 2020, 39, 278.	3.5	27
4246	Anti-neoplastic Potential of Flavonoids and Polysaccharide Phytochemicals in Glioblastoma. Molecules, 2020, 25, 4895.	1.7	22
4247	Therapeutic potential and molecular mechanisms of mycophenolic acid as an anticancer agent. European Journal of Pharmacology, 2020, 887, 173580.	1.7	22
4248	The algal polysaccharide ulvan suppresses growth of hepatoma cells. Food Frontiers, 2020, 1, 83-101.	3.7	32
4249	Role of microRNAs in epidermal growth factor receptor signaling pathway in cervical cancer. Molecular Biology Reports, 2020, 47, 4553-4568.	1.0	15
4250	Vitamin K2 promotes PI3K/AKT/HIF-1Î±-mediated glycolysis that leads to AMPK-dependent autophagic cell death in bladder cancer cells. Scientific Reports, 2020, 10, 7714.	1.6	44
4251	Effects of partial fish meal replacement with two fermented soybean meals on the growth of and protein metabolism in the Chinese mitten crab (Eriocheir sinensis). Aquaculture Reports, 2020, 17, 100328.	0.7	12
4252	The therapeutic value of SC66 in human renal cell carcinoma cells. Cell Death and Disease, 2020, 11, 353.	2.7	17

#	Article	IF	Citations
4253	TRAF4 knockdown triggers synergistic lethality with simultaneous PARP1 inhibition in endometrial cancer. Human Cell, 2020, 33, 801-809.	1.2	2
4254	Long noncoding RNA MALAT1 inhibits the apoptosis and autophagy of hepatocellular carcinoma cell by targeting the microRNA-146a/PI3K/Akt/mTOR axis. Cancer Cell International, 2020, 20, 165.	1.8	48
4255	Activation PDGFR-Î±/AKT Mediated Signaling Pathways in Oral Squamous Cell Carcinoma by Mesenchymal Stem/Stromal Cells Promotes Anti-apoptosis and Decreased Sensitivity to Cisplatin. Frontiers in Oncology, 2020, 10, 552.	1.3	11
4256	Novel PI3K/Akt/mTOR pathway inhibitors plus radiotherapy: Strategy for non-small cell lung cancer with mutant RAS gene. Life Sciences, 2020, 255, 117816.	2.0	18
4257	Anti-angiogenic activity of ShengMaBieJia decoction inÂvitro and in acute myeloid leukaemia tumour-bearing mouse models. Pharmaceutical Biology, 2020, 58, 454-464.	1.3	4
4258	p53-PHLDA3-Akt Network: The Key Regulators of Neuroendocrine Tumorigenesis. International Journal of Molecular Sciences, 2020, 21, 4098.	1.8	18
4259	Enhancer-Driven lncRNA BDNF-AS Induces Endocrine Resistance and Malignant Progression of Breast Cancer through the RNH1/TRIM21/mTOR Cascade. Cell Reports, 2020, 31, 107753.	2.9	52
4260	Engineered exosome for NIR-triggered drug delivery and superior synergistic chemo-phototherapy in a glioma model. Applied Materials Today, 2020, 20, 100723.	2.3	14
4261	CPPED1-targeting microRNA-371a-5p expression in human placenta associates with spontaneous delivery. PLoS ONE, 2020, 15, e0234403.	1.1	2
4262	SGK2 is overexpressed in colon cancer and promotes epithelial-mesenchymal transition in colon cancer cells. European Journal of Surgical Oncology, 2020, 46, 1912-1917.	0.5	3
4263	BIF-1 inhibits both mitochondrial and glycolytic ATP production: its downregulation promotes melanoma growth. Oncogene, 2020, 39, 4944-4955.	2.6	5
4264	PIK3CA mutation profiling in Vietnamese patients with breast cancer. Meta Gene, 2020, 25, 100709.	0.3	0
4265	Mechanisms of activation and key roles of SGK3 under physiological conditions and in prostate and breast cancer.. Current Signal Transduction Therapy, 2020, 15, .	0.3	0
4266	Combined p53- and PTEN-deficiency activates expression of mesenchyme homeobox 1 (MEOX1) required for growth of triple-negative breast cancer. Journal of Biological Chemistry, 2020, 295, 12188-12202.	1.6	16
4267	Poor Prognoses of Young Hepatocellular Carcinoma Patients with Microvascular Invasion: A Propensity Score Matching Cohort Study. Gastroenterology Research and Practice, 2020, 2020, 1-8.	0.7	3
4268	Aspirin and the chemoprevention of cancers: A mathematical and evolutionary dynamics perspective. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2020, 12, e1487.	6.6	5
4269	Silencing of HOXB9 suppresses cellular proliferation, angiogenesis, migration and invasion of prostate cancer cells. Journal of Biosciences, 2020, 45, 1.	0.5	8
4270	Celastrol Suppresses Glioma Vasculogenic Mimicry Formation and Angiogenesis by Blocking the PI3K/Akt/mTOR Signaling Pathway. Frontiers in Pharmacology, 2020, 11, 25.	1.6	81

#	Article	IF	Citations
4271	Circumventing AKT-Associated Radioresistance in Oral Cancer by Novel Nanoparticle-Encapsulated Capivasertib. Cells, 2020, 9, 533.	1.8	22
4272	ZnO Nanoparticles Induced Caspase-Dependent Apoptosis in Gingival Squamous Cell Carcinoma through Mitochondrial Dysfunction and p70S6K Signaling Pathway. International Journal of Molecular Sciences, 2020, 21, 1612.	1.8	54
4273	Systematic Development and Optimization of Inhalable Pirfenidone Liposomes for Non-Small Cell Lung Cancer Treatment. Pharmaceutics, 2020, 12, 206.	2.0	53
4274	Mechanism of Anti-Cancer Activity of Curcumin on Androgen-Dependent and Androgen-Independent Prostate Cancer. Nutrients, 2020, 12, 679.	1.7	58
4275	Recent researches for dual Aurora target inhibitors in antitumor field. European Journal of Medicinal Chemistry, 2020, 203, 112498.	2.6	1
4276	Impaired Autophagy Flux is Associated with Proinflammatory Microglia Activation Following Japanese Encephalitis Virus Infection. Neurochemical Research, 2020, 45, 2184-2195.	1.6	15
4277	Osteoclast Signal Transduction During Bone Metastasis Formation. Frontiers in Cell and Developmental Biology, 2020, 8, 507.	1.8	53
4278	Potential of Tyrosine Kinase Receptor TIE-1 as Novel Therapeutic Target in High-PI3K-Expressing Ovarian Cancer. Cancers, 2020, 12, 1705.	1.7	2
4279	Molecular genetics of meningiomas. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2020, 169, 101-119.	1.0	5
4280	Antitumor activity and safety of sirolimus for solid tumors with PIK3CA mutations: A multicenter, open-label, prospective single-arm study (KM 02-01, KCSG UN17-16). Translational Cancer Research, 2020, 9, 3222-3230.	0.4	3
4281	PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer. Gynecologic Oncology, 2020, 158, 776-784.	0.6	15
4282	A Polyphenol-Rich Extract From Muscadine Grapes Inhibits Triple-Negative Breast Tumor Growth. Integrative Cancer Therapies, 2020, 19, 153473542091744.	0.8	13
4283	From Orai to E-Cadherin: Subversion of Calcium Trafficking in Cancer to Drive Proliferation, Anoikis-Resistance, and Metastasis. Biomedicines, 2020, 8, 169.	1.4	11
4284	Adiponectin Reduces Embryonic Loss Rate and Ameliorates Trophoblast Apoptosis in Early Pregnancy of Mice with Polycystic Ovary Syndrome by Affecting the AMPK/PI3K/Akt/FoxO3a Signaling Pathway. Reproductive Sciences, 2020, 27, 2232-2241.	1.1	9
4285	In vivo modeling of the EGFR family in breast cancer progression and therapeutic approaches. Advances in Cancer Research, 2020, 147, 189-228.	1.9	7
4286	EPS8 phosphorylation by Src modulates its oncogenic functions. British Journal of Cancer, 2020, 123, 1078-1088.	2.9	2
4287	RIP1 Is a Novel Component of Î³-ionizing Radiation-Induced Invasion of Non-Small Cell Lung Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 4584.	1.8	6
4288	Quercetin suppresses the migration of hepatocellular carcinoma cells stimulated by hepatocyte growth factor or transforming growth factor-Î±: Attenuation of AKT signaling pathway. Archives of Biochemistry and Biophysics, 2020, 682, 108296.	1.4	22

#	Article	IF	Citations
4289	miR-485-5p/HSP90 axis blocks Akt1 phosphorylation to suppress osteosarcoma cell proliferation and migration via PI3K/AKT pathway. Journal of Physiology and Biochemistry, 2020, 76, 279-290.	1.3	28
4290	Strategy of Hepatic Metabolic Defects Induced by beclin1 Heterozygosity in Adult Zebrafish. International Journal of Molecular Sciences, 2020, 21, 1533.	1.8	7
4291	Loss of 5â€²-Methylthioadenosine Phosphorylase (MTAP) is Frequent in High-Grade Gliomas; Nevertheless, it is Not Associated with Higher Tumor Aggressiveness. Cells, 2020, 9, 492.	1.8	19
4292	MicroRNA-4316 inhibits gastric cancer proliferation and migration via directly targeting VEGF-A. Cancer Cell International, 2020, 20, 62.	1.8	11
4293	The CUL4B-miR-372/373-PIK3CA-AKT axis regulates metastasis in bladder cancer. Oncogene, 2020, 39, 3588-3603.	2.6	24
4294	Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 3028-3046.	2.9	50
4295	Dynamic Behavior of p53 Driven by Delay and a Microrna-34a-Mediated Feedback Loop. International Journal of Molecular Sciences, 2020, 21, 1271.	1.8	5
4296	Comparative Analysis and Molecular Evolution of Class I PI3K Regulatory Subunit p85Î± Reveal the Structural Similarity Between nSH2 and cSH2 Domains. International Journal of Peptide Research and Therapeutics, 2020, 26, 2555-2569.	0.9	0
4297	Sulfhydration of AKT triggers Tau-phosphorylation by activating glycogen synthase kinase 3Î² in Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 4418-4427.	3.3	34
4298	KIF2A promotes the progression via AKT signaling pathway and is upregulated by transcription factor ETV4 in human gastric cancer. Biomedicine and Pharmacotherapy, 2020, 125, 109840.	2.5	26
4299	Expression of inositol polyphosphate 4â€phosphatase type II and the prognosis of oral squamous cell carcinoma. European Journal of Oral Sciences, 2020, 128, 37-45.	0.7	1
4300	Introduction of Somatic Mutation in MED12 Induces Wnt4/Î²-Catenin and Disrupts Autophagy in Human Uterine Myometrial Cell. Reproductive Sciences, 2020, 27, 823-832.	1.1	35
4301	Oncogenic K-Ras4B Dimerization Enhances Downstream Mitogen-activated Protein Kinase Signaling. Journal of Molecular Biology, 2020, 432, 1199-1215.	2.0	16
4302	Genome sequencing analysis of a family with a child displaying severe abdominal distention and recurrent hypoglycemia. Molecular Genetics & Genomic Medicine, 2020, 8, e1130.	0.6	5
4303	Chloride Ion Transport by PITENINs across the Phospholipid Bilayers of Vesicles and Cells. ACS Applied Bio Materials, 2020, 3, 935-944.	2.3	13
4304	Targeting Glucose Transporters for Breast Cancer Therapy: The Effect of Natural and Synthetic Compounds. Cancers, 2020, 12, 154.	1.7	79
4305	Airborne Particulate Matter (PM10) Inhibits Apoptosis through PI3K/AKT/FoxO3a Pathway in Lung Epithelial Cells: The Role of a Second Oxidant Stimulus. International Journal of Molecular Sciences, 2020, 21, 473.	1.8	7
4306	CD74 Signaling Links Inflammation to Intestinal Epithelial Cell Regeneration and Promotes Mucosal Healing. Cellular and Molecular Gastroenterology and Hepatology, 2020, 10, 101-112.	2.3	37

#	Article	IF	Citations
4307	Circular RNA circHIAT1 inhibits proliferation and epithelialâ€•mesenchymal transition of gastric cancer cell lines through downregulation of miRâ€21. Journal of Biochemical and Molecular Toxicology, 2020, 34, e22458.	1.4	24
4308	Neuroprotective Effects of Deuterium-Depleted Water (DDW) Against H2O2-Induced Oxidative Stress in Differentiated PC12 Cells Through the PI3K/Akt Signaling Pathway. Neurochemical Research, 2020, 45, 1034-1044.	1.6	16
4309	Cross-Cancer Pleiotropic Analysis Reveals Novel Susceptibility Loci for Lung Cancer. Frontiers in Oncology, 2019, 9, 1492.	1.3	6
4310	Monomeric Targeted Protein Degraders. Journal of Medicinal Chemistry, 2020, 63, 11330-11361.	2.9	48
4311	Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target?. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118731.	1.9	51
4312	Synthesis and anticancer evaluation of novel 1H-benzo[d]imidazole derivatives of dehydroabietic acid as PI3KÎ± inhibitors. Bioorganic Chemistry, 2020, 100, 103845.	2.0	20
4313	Design, synthesis and antiproliferative activity evaluation of a series of pyrrolo[2,1-f][1,2,4]triazine derivatives. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127194.	1.0	12
4314	Microbiota-derived SSL6 enhances the sensitivity of hepatocellular carcinoma to sorafenib by down-regulating glycolysis. Cancer Letters, 2020, 481, 32-44.	3.2	15
4315	Structural elucidation of phosphatidylcholines from tissue using electron induced dissociation. International Journal of Mass Spectrometry, 2020, 452, 116338.	0.7	32
4316	Gain of function mutant p53 protein activates AKT through the Rac1 signaling to promote tumorigenesis. Cell Cycle, 2020, 19, 1338-1351.	1.3	18
4317	Low-dose interleukin-2 alleviates dextran sodium sulfate-induced colitis in mice by recovering intestinal integrity and inhibiting AKT-dependent pathways. Theranostics, 2020, 10, 5048-5063.	4.6	38
4318	Identification of lipid biomarkers of metastatic potential and gene expression (HER2/p53) in human breast cancer cell cultures using ambient mass spectrometry. Analytical and Bioanalytical Chemistry, 2020, 412, 2949-2961.	1.9	7
4319	Cancer of Unknown Primary Site: Real Entity or Misdiagnosed Disease?. Journal of Cancer, 2020, 11, 3919-3931.	1.2	14
4320	Neuronal Calcium Sensor 1 is upâ€regulated in response to stress to promote cell survival and motility in cancer cells. Molecular Oncology, 2020, 14, 1134-1151.	2.1	17
4321	Translatable circRNAs and lncRNAs: Driving mechanisms and functions of their translation products. Cancer Letters, 2020, 483, 59-65.	3.2	73
4322	Virtual docking screening and QSAR studies to explore AKT and mTOR inhibitors acting on PI3K in cancers. Wspolczesna Onkologia, 2020, 24, 5-12.	0.7	1
4323	Design, synthesis and biological activity of novel 2,3,4,5-tetra-substituted thiophene derivatives as PI3KÎ± inhibitors with potent antitumor activity. European Journal of Medicinal Chemistry, 2020, 197, 112309.	2.6	8
4324	The mTOR inhibitor manassantin B reveals a crucial role of mTORC2 signaling in Epstein-Barr virus reactivation. Journal of Biological Chemistry, 2020, 295, 7431-7441.	1.6	12

#	Article	IF	Citations
4325	Molecular and Cellular Mechanisms for PRRSV Pathogenesis and Host Response to Infection. Virus Research, 2020, 286, 197980.	1.1	57
4326	Duvelisib for the treatment of chronic lymphocytic leukemia. Expert Opinion on Pharmacotherapy, 2020, 21, 1299-1309.	0.9	13
4327	N⁶-methyladenosine mRNA methylation of PIK3CB regulates AKT signalling to promote PTEN-deficient pancreatic cancer progression. Gut, 2020, 69, 2180-2192.	6.1	52
4328	PTPN3 Inhibits the Growth and Metastasis of Clear Cell Renal Cell Carcinoma via Inhibition of PI3K/AKT Signaling. Molecular Cancer Research, 2020, 18, 903-912.	1.5	17
4329	New insights into the cellular activities of Fndc5/Irisin and its signaling pathways. Cell and Bioscience, 2020, 10, 51.	2.1	80
4330	Down-regulation of USP8 Inhibits Cholangiocarcinoma Cell Proliferation and Invasion . Cancer Management and Research, 2020, Volume 12, 2185-2194.	0.9	16
4331	Lightâ€emitting diode irradiation induces AKT/mTORâ€mediated apoptosis in human pancreatic cancer cells and xenograft mouse model. Journal of Cellular Physiology, 2021, 236, 1362-1374.	2.0	9
4332	In situ probing changes in fattyâ€acyl chain length and desaturation of lipids in cancerous areas using mass spectrometry imaging. Journal of Mass Spectrometry, 2021, 56, e4621.	0.7	5
4333	Blockage of PAK1 alleviates the proliferation and invasion of NSCLC cells via inhibiting ERK and AKT signaling activity. Clinical and Translational Oncology, 2021, 23, 892-901.	1.2	11
4334	Discovery of new thieno[2,3-d]pyrimidine and thiazolo[5,4-d]pyrimidine derivatives as orally active phosphoinositide 3-kinase inhibitors. Bioorganic and Medicinal Chemistry, 2021, 29, 115890.	1.4	12
4335	Structural basis for tailor-made selective PI3K Î±/Î² inhibitors: a computational perspective. New Journal of Chemistry, 2021, 45, 373-382.	1.4	4
4336	The Promising Effects of Astaxanthin on Lung Diseases. Advances in Nutrition, 2021, 12, 850-864.	2.9	19
4337	Gynecologic cancers and non-coding RNAs: Epigenetic regulators with emerging roles. Critical Reviews in Oncology/Hematology, 2021, 157, 103192.	2.0	85
4338	Radiation-induced IL-1Î² expression and secretion promote cancer cell migration/invasion via activation of the NF-ÎºBâ€“RIP1 pathway. Biochemical and Biophysical Research Communications, 2021, 534, 973-979.	1.0	10
4339	Discovery of 2-(5-(quinolin-6-yl)-1,3,4-oxadiazol-2-yl)acetamide derivatives as novel PI3KÎ± inhibitors via docking-based virtual screening. Bioorganic and Medicinal Chemistry, 2021, 29, 115863.	1.4	5
4340	Capilliposide B blocks VEGF-induced angiogenesis in vitro in primary human retinal microvascular endothelial cells. Biomedicine and Pharmacotherapy, 2021, 133, 110999.	2.5	12
4341	CDX2 inhibits epithelialâ€“mesenchymal transition in colorectal cancer by modulation of Snail expression and Î²-catenin stabilisation via transactivation of PTEN expression. British Journal of Cancer, 2021, 124, 270-280.	2.9	20
4342	Dithiolation indolizine exerts viability suppression effects on A549 cells via triggering intrinsic apoptotic pathways and inducing G2/M phase arrest. Biomedicine and Pharmacotherapy, 2021, 133, 110961.	2.5	12

#	Article	IF	Citations
4343	Durable Clinical Activity to the AKT Inhibitor Ipatasertib in a Heavily Pretreated Patient With an AKT1 E17K Mutant Metastatic Breast Cancer. Clinical Breast Cancer, 2021, 21, e150-e153.	1.1	7
4344	The role and therapeutic implications of PI3K signaling pathway in cancer. Journal of Surgical Oncology, 2021, 123, 39-41.	0.8	6
4345	Alpelisib in the treatment of metastatic HR+ breast cancer with PIK3CA mutations. Future Oncology, 2021, 17, 13-36.	1.1	9
4346	Mutant Allele Imbalance in Cancer. Annual Review of Cancer Biology, 2021, 5, 221-234.	2.3	2
4347	How selective are clinical CDK4/6 inhibitors?. Medicinal Research Reviews, 2021, 41, 1578-1598.	5.0	15
4348	EnDuo, a novel derivative of Endostar, inhibits the migration of colon cancer cells, suppresses matrix metalloproteinase-2/9 expression and impedes AKT/ERK activation. Biomedicine and Pharmacotherapy, 2021, 134, 111136.	2.5	9
4349	Genistein inhibits radiation-induced invasion and migration of glioblastoma cells by blocking the DNA-PKcs/Akt2/Rac1 signaling pathway. Radiotherapy and Oncology, 2021, 155, 93-104.	0.3	12
4350	Identification of methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamat (CYH33) as an orally bioavailable, highly potent, PI3K alpha inhibitor for the treatment of advanced solid tumors. European Journal of Medicinal Chemistry, 2021, 209, 112913.	2.6	20
4351	An evaluation of the effects of probiotics on tumoral necrosis factor (TNF-Î±) signaling and gene expression. Cytokine and Growth Factor Reviews, 2021, 57, 27-38.	3.2	31
4352	Mutation landscape of TSC1/TSC2 in Chinese patients with tuberous sclerosis complex. Journal of Human Genetics, 2021, 66, 227-236.	1.1	6
4353	Metformin and an insulin/IGF-1 receptor inhibitor are synergistic in blocking growth of triple-negative breast cancer. Breast Cancer Research and Treatment, 2021, 185, 73-84.	1.1	16
4354	lncRNA ZNF667â€AS1 (NR_036521.1) inhibits the progression of colorectal cancer via regulating ANK2/JAK2 expression. Journal of Cellular Physiology, 2021, 236, 2178-2193.	2.0	22
4355	Wikstromol from Wikstroemia indica induces apoptosis and suppresses migration of MDA-MB-231 cells via inhibiting PI3K/Akt pathway. Journal of Natural Medicines, 2021, 75, 178-185.	1.1	7
4356	INSL4 as prognostic marker for proliferation and invasiveness in Non-Small-Cell Lung Cancer. Journal of Cancer, 2021, 12, 3781-3795.	1.2	8
4357	Morroniside promotes the osteogenesis by activating PI3K/Akt/mTOR signaling. Bioscience, Biotechnology and Biochemistry, 2021, 85, 332-339.	0.6	20
4359	Biomarkers predicting the response to chemotherapy and the prognosis in patients with esophageal squamous cell carcinoma. General Thoracic and Cardiovascular Surgery, 2021, 69, 525-533.	0.4	4
4360	Predictive Systems Biomarkers of Response to Immune Checkpoint Inhibitors. SSRN Electronic Journal, 0, , .	0.4	0
4361	Cytotoxicity of oleanane type triterpene from leaf extract of Pterospermum acerifolium (in vitro) and theoretical investigation of inhibitory signaling pathway. Chinese Herbal Medicines, 2021, 13, 124-130.	1.2	3

#	Article	IF	Citations
4362	Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer. , 2021, 4, 573-595.		17
4363	Cx43 deficiency confers EMT-mediated tamoxifen resistance to breast cancer via c-Src/PI3K/Akt pathway. International Journal of Biological Sciences, 2021, 17, 2380-2398.	2.6	18
4364	Regulation of the Small GTPase Ras and Its Relevance to Human Disease. Methods in Molecular Biology, 2021, 2262, 19-43.	0.4	4
4365	Mechanisms of Cetuximab Resistance and How to Overcome It. , 2021, , 21-51.		1
4366	Role of selected phytochemicals on gynecological cancers. , 2021, , 1-30.		0
4367	Proinflammatory Signaling Pathways and Genomic Signatures in Head and NeckÂCancers. , 2021, , 143-184.		2
4368	Structurally diverse diterpenoid alkaloids from the lateral roots of Aconitum carmichaelii Debx. and their anti-tumor activities based on in vitro systematic evaluation and network pharmacology analysis. RSC Advances, 2021, 11, 26594-26606.	1.7	6
4369	Comparing mTOR inhibitor Rapamycin with Torin-2 within the RIST molecular-targeted regimen in neuroblastoma cells. International Journal of Medical Sciences, 2021, 18, 137-149.	1.1	9
4370	Lipid metabolism in cancer: A systematic review. Journal of Carcinogenesis, 2021, 20, 4.	2.5	37
4371	Metabolic Reprogramming and the Control of Anoikis Resistance in Cancer. , 2021, , 17-50.		0
4372	Peptide and protein assays using customizable bio-affinity arrays combined with ambient ionization mass spectrometry. Chemical Science, 2021, 12, 10810-10816.	3.7	5
4373	Co-overexpression of RIOK1 and AKT1 as a prognostic risk factor in glioma. Journal of Cancer, 2021, 12, 5745-5752.	1.2	4
4374	Signaling Pathway Mediating Myeloma Cell Growth and Survival. Cancers, 2021, 13, 216.	1.7	36
4375	Oscillatory Behaviors of Delayed p53 Regulatory Network with microRNA 192 in DNA Damage Response. International Journal of Bifurcation and Chaos in Applied Sciences and Engineering, 2021, 31, 2150020.	0.7	2
4376	Redox Regulation of PTEN by Peroxiredoxins. Antioxidants, 2021, 10, 302.	2.2	22
4377	Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis. Molecular Cell, 2021, 81, 708-723.e5.	4.5	51
4379	Dual PI3K/mTOR inhibitor NVPâ€'BEZ235 decreases theÂproliferation of doxorubicinâ€'resistant K562 cells. Molecular Medicine Reports, 2021, 23, .	1.1	6
4380	Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance. International Journal of Molecular Sciences, 2021, 22, 2100.	1.8	13

#	Article	IF	Citations
4381	Clinical characteristics of 93 cases of isolated macrodactyly of the foot in children. Journal of Orthopaedic Surgery and Research, 2021, 16, 121.	0.9	4
4382	Antioxidative Stress: Inhibiting Reactive Oxygen Species Production as a Cause of Radioresistance and Chemoresistance. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-16.	1.9	14
4383	Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor. JAMA Oncology, 2021, 7, 271.	3.4	49
4384	Pyrvinium pamoate inhibits cell proliferation through ROS-mediated AKT-dependent signaling pathway in colorectal cancer. Medical Oncology, 2021, 38, 21.	1.2	6
4385	LncRNA-SNHG16 promotes proliferation and migration of acute myeloid leukemia cells via PTEN/PI3K/AKT axis through suppressing CELF2 protein. Journal of Biosciences, 2021, 46, 1.	0.5	11
4386	Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme. International Journal of Molecular Sciences, 2021, 22, 1831.	1.8	37
4387	Metformin and asarone inhibit HepG2 cell proliferation in a high glucose environment by regulating AMPK and Akt signaling pathway. Future Journal of Pharmaceutical Sciences, 2021, 7, .	1.1	6
4388	Diallyl thiosulfinate enhanced the anti-cancer activity of dexamethasone in the side population cells of multiple myeloma by promoting miR-127-3p and deactivating the PI3K/AKT signaling pathway. BMC Cancer, 2021, 21, 125.	1.1	16
4389	Compound C, a Broad Kinase Inhibitor Alters Metabolic Fingerprinting of Extra Cellular Matrix Detached Cancer Cells. Frontiers in Oncology, 2021, 11, 612778.	1.3	13
4390	SOX2 enhances cell survival and induces resistance to apoptosis under serum starvation conditions through the AKT/GSKâ€˜3Î² signaling pathway in esophageal squamous cell carcinoma. Oncology Letters, 2021, 21, 269.	0.8	2
4391	Thyroid Carcinoma: Phenotypic Features, Underlying Biology and Potential Relevance for Targeting Therapy. International Journal of Molecular Sciences, 2021, 22, 1950.	1.8	40
4392	MicroRNA-552 expression in colorectal cancer and its clinicopathological significance. Journal of Pathology and Translational Medicine, 2021, 55, 125-131.	0.4	2
4393	Clinicopathological and Molecular Features of Colorectal Cancer Patients With Mucinous and Non-Mucinous Adenocarcinoma. Frontiers in Oncology, 2021, 11, 620146.	1.3	12
4394	PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Frontiers in Oncology, 2021, 11, 644737.	1.3	70
4395	Non-Alcoholic Fatty Liver Disease Progression to Non-Alcoholic Steatohepatitis-Related Primary Liver Cancer. , 0, , 55-76.		2
4396	Pharmacology of apocynin: a natural acetophenone. Drug Metabolism Reviews, 2021, 53, 542-562.	1.5	32
4397	The Role of the Ubiquitin Proteasome System in Glioma: Analysis Emphasizing the Main Molecular Players and Therapeutic Strategies Identified in Glioblastoma Multiforme. Molecular Neurobiology, 2021, 58, 3252-3269.	1.9	27
4398	A systematic review and meta-analysis of the prevalence of therapeutic targets in cervical cancer. Ecancermedicalscience, 2021, 15, 1200.	0.6	3

#	Article	IF	Citations
4399	Novel targeted agents for follicular lymphoma. Annals of Lymphoma, 0, 5, 3-3.	4.5	1
4400	T cells: a dedicated effector kinase pathways for every trait?. Biochemical Journal, 2021, 478, 1303-1307.	1.7	0
4401	Downregulation of TAF9B by miR-7-5p Inhibits the Progression of Osteosarcoma. OncoTargets and Therapy, 2021, Volume 14, 2917-2927.	1.0	5
4402	How can we turn the PI3K/AKT/mTOR pathway down? Insights into inhibition and treatment of cancer. Expert Review of Anticancer Therapy, 2021, 21, 605-619.	1.1	23
4403	Investigation of the expression levels of CPEB4, APC, TRIP13, EIF2S3, EIF4A1, IFNg, PIK3CA and CTNNB1 genes in different stage colorectal tumors. Turkish Journal of Medical Sciences, 2021, 51, 661-674.	0.4	8
4404	The Role of NRF2/KEAP1 Signaling Pathway in Cancer Metabolism. International Journal of Molecular Sciences, 2021, 22, 4376.	1.8	58
4405	MiRNA-138â€“5p: A strong tumor suppressor targeting PD-L-1 inhibits proliferation and motility of breast cancer cells and induces apoptosis. European Journal of Pharmacology, 2021, 896, 173933.	1.7	21
4406	Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFRâ€targeting agents to treat head and neck squamous cell carcinoma. Medicinal Research Reviews, 2022, 42, 112-155.	5.0	24
4407	GDC-0326 Enhances the Effects of 5-Fu in Colorectal Cancer Cells by Inducing Necroptotic Death. OncoTargets and Therapy, 2021, Volume 14, 2519-2530.	1.0	7
4408	Inhibitory effects of terrein on lung cancer cell metastasis and angiogenesis. Oncology Reports, 2021, 45, .	1.2	7
4409	Structural insights of oxindole based kinase inhibitors as anticancer agents: Recent advances. European Journal of Medicinal Chemistry, 2021, 216, 113334.	2.6	58
4411	Recent Updates on the Involvement of PI3K/AKT/mTOR Molecular Cascade in the Pathogenesis of Hyperproliferative Skin Disorders. Frontiers in Medicine, 2021, 8, 665647.	1.2	45
4412	Inhibited effect of an RGD peptide hydrogel on the expression of Î²1â€integrin, FAK , and Akt in Tenon's capsule fibroblasts. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2021, 109, 1857-1865.	1.6	5
4413	DDX54 Plays a Cancerous Role Through Activating P65 and AKT Signaling Pathway in Colorectal Cancer. Frontiers in Oncology, 2021, 11, 650360.	1.3	7
4414	The Anticancer Effects of Flavonoids through miRNAs Modulations in Triple-Negative Breast Cancer. Nutrients, 2021, 13, 1212.	1.7	27
4415	Detection of loci exhibiting pleiotropic effects on body weight and egg number in female broilers. Scientific Reports, 2021, 11, 7441.	1.6	6
4416	A narrative review of urinary phospholipids: from biochemical aspect towards clinical application. Translational Andrology and Urology, 2021, 10, 1829-1849.	0.6	4
4417	New derivatives of sulfonylhydrazone as potential antitumor agents: Design, synthesis and cheminformatics evaluation. Acta Pharmaceutica, 2021, 71, 545-565.	0.9	1

#	Article	IF	Citations
4418	Resveratrol Attenuates the Proliferation of Prostatic Stromal Cells in Benign Prostatic Hyperplasia by Regulating Cell Cycle Progression, Apoptosis, Signaling Pathways, BPH Markers, and NF-Ïº B Activity. International Journal of Molecular Sciences, 2021, 22, 5969.	1.8	4
4420	Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016â€“2020). Expert Opinion on Therapeutic Patents, 2021, 31, 877-892.	2.4	27
4421	MTHFD2 facilitates breast cancer cell proliferation via the AKT signaling pathway. Experimental and Therapeutic Medicine, 2021, 22, 703.	0.8	23
4422	Distribution of genetic alterations in high-risk early-stage cervical cancer patients treated with postoperative radiation therapy. Scientific Reports, 2021, 11, 10567.	1.6	7
4423	Combining Radiation Therapy with ALK Inhibitors in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (NSCLC): A Clinical and Preclinical Overview. Cancers, 2021, 13, 2394.	1.7	6
4424	Epithelial-to-Mesenchymal Transition in the Light of Plasticity and Hybrid E/M States. Journal of Clinical Medicine, 2021, 10, 2403.	1.0	30
4425	Targeting RTK-PI3K-mTOR Axis in Gliomas: An Update. International Journal of Molecular Sciences, 2021, 22, 4899.	1.8	69
4427	MicroRNA-2053 involves in the progression of esophageal cancer by targeting KIF3C. Cell Cycle, 2021, 20, 1163-1172.	1.3	6
4428	Research progress on FASN and MGLL in the regulation of abnormal lipid metabolism and the relationship between tumor invasion and metastasis. Frontiers of Medicine, 2021, 15, 649-656.	1.5	40
4429	Detection of PIK3CA Gene Mutation in Head and Neck Squamous Cell Carcinoma Using Droplet Digital PCR and RT-qPCR. Biomolecules, 2021, 11, 818.	1.8	6
4430	The cardioprotective effects of hydrogen sulfide by targeting endoplasmic reticulum stress and the Nrf2 signaling pathway: A review. BioFactors, 2021, 47, 701-712.	2.6	13
4431	Unlocking the Mechanisms of Cutaneous Adverse Drug Reactions: Activation of the Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway by EGFR Inhibitors Triggers Keratinocyte Differentiation and Polarization of Epidermal Immune Responses. JID Innovations, 2021, 1, 100009.	1.2	2
4432	Exploring polyps to colon carcinoma voyage: can blocking the crossroad halt the sequence?. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2199-2207.	1.2	5
4433	Integrated Transcriptomic and Proteomic Analysis Reveals Up-Regulation of Apoptosis and Small Heat Shock Proteins in Lens of Rats Under Low Temperature. Frontiers in Physiology, 2021, 12, 683056.	1.3	4
4434	Case Report: A Frameshift Mutation in MSH2 Exon 2 in a Kidney Recipient With Muirâ€“Torre Syndrome. Frontiers in Oncology, 2021, 11, 681780.	1.3	0
4435	Role of Long Non-Coding RNA Polymorphisms in Cancer Chemotherapeutic Response. Journal of Personalized Medicine, 2021, 11, 513.	1.1	6
4436	NoRCE: non-coding RNA sets cis enrichment tool. BMC Bioinformatics, 2021, 22, 294.	1.2	4
4437	The Enhanced Efficacy of Intracellular Delivery of Doxorubicin/C6-Ceramide Combination Mediated by the F3 Peptide/Nucleolin System Is Supported by the Downregulation of the PI3K/Akt Pathway. Cancers, 2021, 13, 3052.	1.7	7

#	Article	IF	Citations
4438	Spleen tyrosine kinase (SYK) inhibitor PRT062607 protects against ovariectomy-induced bone loss and breast cancer-induced bone destruction. Biochemical Pharmacology, 2021, 188, 114579.	2.0	4
4439	PHLPP2 gene L1016S (rs61733127) and PIK3R1 gene Met326Ile (rs3730089) polymorphisms are associated with the risk of colon and breast cancers. Nucleosides, Nucleotides and Nucleic Acids, 2021, 40, 767-778.	0.4	1
4440	Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth. Nature Chemical Biology, 2021, 17, 1065-1074.	3.9	33
4441	Target identification for small-molecule discovery in the FOXO3a tumor-suppressor pathway using a biodiverse peptide library. Cell Chemical Biology, 2021, 28, 1602-1615.e9.	2.5	6
4442	Combined Inhibition of Akt and mTOR Is Effective Against Non-Hodgkin Lymphomas. Frontiers in Oncology, 2021, 11, 670275.	1.3	4
4443	The nonreceptor tyrosine kinase SRMS inhibits autophagy and promotes tumor growth by phosphorylating the scaffolding protein FKBP51. PLoS Biology, 2021, 19, e3001281.	2.6	7
4444	The role of GSK3 in metabolic pathway perturbations in cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 119059.	1.9	20
4445	Multiâ€ancestral origin of intestinal tumors: Impact on growth, progression, and drug efficacy. Cancer Reports, 2022, 5, e1459.	0.6	2
4446	Current Understanding and Management of Intraductal Carcinoma of the Prostate. Current Oncology Reports, 2021, 23, 110.	1.8	1
4447	Downregulation of ATXN3 Enhances the Sensitivity to AKT Inhibitors (Perifosine or MK-2206), but Decreases the Sensitivity to Chemotherapeutic Drugs (Etoposide or Cisplatin) in Neuroblastoma Cells. Frontiers in Oncology, 2021, 11, 686898.	1.3	3
4448	Oleuropin controls miR-194/XIST/PD-L1 loop in triple negative breast cancer: New role of nutri-epigenetics in immune-oncology. Life Sciences, 2021, 277, 119353.	2.0	17
4449	iTRAQâ€based quantitative proteomic analysis of haemocyte proteins from crayfish (<i>Procambarus) Tj ETQq1 1 0.784314 rgBT /Ov 1661-1668.	0.9	4
4450	Polycystinâ€1 regulates cardiomyocyte mitophagy. FASEB Journal, 2021, 35, e21796.	0.2	6
4451	The Genomic Landscape of Actinic Keratosis. Journal of Investigative Dermatology, 2021, 141, 1664-1674.e7.	0.3	34
4452	p55PIK deficiency and its NH₂-terminal derivative inhibit inflammation and emphysema in COPD mouse model. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L159-L173.	1.3	4
4453	Tacrolimus inhibits insulin release and promotes apoptosis of Min6 cells through the inhibition of the PI3K/Akt/mTOR pathway. Molecular Medicine Reports, 2021, 24, .	1.1	11
4454	Biomarkers and cell-based models to predict the outcome of neoadjuvant therapy for rectal cancer patients. Biomarker Research, 2021, 9, 60.	2.8	12
4455	Knockdown circ_0040414 inhibits inflammation, apoptosis and promotes the proliferation of cardiomyocytes via miRâ€186â€5p/PTEN/AKT axis in chronic heart failure. Cell Biology International, 2021, 45, 2304-2315.	1.4	4

#	Article	IF	Citations
4456	The Chlamydia psittaci Inclusion Membrane Protein 0556 Inhibits Human Neutrophils Apoptosis Through PI3K/AKT and NF-Î¹B Signaling Pathways. Frontiers in Immunology, 2021, 12, 694573.	2.2	6
4457	DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. Gynecologic Oncology, 2021, 163, 334-341.	0.6	10
4458	Two Types of Mouse Models for Sarcopenia Research: Senescence Acceleration and Genetic Modification Models. Journal of Bone Metabolism, 2021, 28, 179-191.	0.5	6
4459	Differential effects of phenolic extracts from redâ€fleshed apple peels and flesh induced G1 cell cycle arrest and apoptosis in human breast cancer MDAâ€MBâ€231 cells. Journal of Food Science, 2021, 86, 4209-4222.	1.5	5
4460	A Comprehensive Genomic Analysis Constructs miRNAâ€“mRNA Interaction Network in Hepatoblastoma. Frontiers in Cell and Developmental Biology, 2021, 9, 655703.	1.8	2
4461	Interpretable systems biomarkers predict response to immune-checkpoint inhibitors. Patterns, 2021, 2, 100293.	3.1	47
4462	Keratin 8/18 Regulate the Akt Signaling Pathway. International Journal of Molecular Sciences, 2021, 22, 9227.	1.8	3
4463	Sclerosing Polycystic Adenoma: Conclusive Clinical and Molecular Evidence of Its Neoplastic Nature. Head and Neck Pathology, 2022, 16, 416-426.	1.3	10
4464	Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu. Gynecologic Oncology, 2021, 163, 93-99.	0.6	14
4465	Secretory NPC2 Protein-Mediated Free Cholesterol Levels Were Correlated with the Sorafenib Response in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2021, 22, 8567.	1.8	8
4466	Itraconazole Exerts Its Antitumor Effect in Esophageal Cancer By Suppressing the HER2/AKT Signaling Pathway. Molecular Cancer Therapeutics, 2021, 20, 1904-1915.	1.9	15
4467	The emerging roles of dual-specificity phosphatases and their specific characteristics in human cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188562.	3.3	13
4468	Chalcomoracin prevents vitreousâ€induced activation of AKT and migration of retinal pigment epithelial cells. Journal of Cellular and Molecular Medicine, 2021, 25, 9102-9111.	1.6	3
4469	Transduced Tat-PRAS40 prevents dopaminergic neuronal cell death through ROS inhibition and interaction with 14-3-3Ïƒ protein. Free Radical Biology and Medicine, 2021, 172, 418-429.	1.3	7
4470	Nicotinic acetylcholine receptors in chemotherapeutic drugs resistance: An emerging targeting candidate. Life Sciences, 2021, 278, 119557.	2.0	10
4471	Urinary exosomes-based Engineered Nanovectors for Homologously Targeted Chemo-Chemodynamic Prostate Cancer Therapy via abrogating EGFR/AKT/NF-κB/IκB signaling. Biomaterials, 2021, 275, 120946.	5.7	65
4472	Cooperation between liver-specific mutations of pten and tp53 genetically induces hepatocarcinogenesis in zebrafish. Journal of Experimental and Clinical Cancer Research, 2021, 40, 262.	3.5	2
4473	NSUN2-mediated RNA 5-methylcytosine promotes esophageal squamous cell carcinoma progression via LIN28B-dependent GRB2 mRNA stabilization. Oncogene, 2021, 40, 5814-5828.	2.6	59

#	Article	IF	Citations
4474	Trigoxyphin L Induces Apoptosis of Human Retinoblastoma Y79 Cells via PI3K/AKT/NF-ÎºB Pathway. International Journal of Pharmacology, 2021, 17, 420-427.	0.1	1
4475	p52Shc regulates the sustainability of ERK activation in a RAF-independent manner. Molecular Biology of the Cell, 2021, 32, 1838-1848.	0.9	3
4476	Fish oil supplementation increases expression of mammary tumor apoptosis mediators and reduces inflammation in an obesity-associated HER-2 breast cancer model. Journal of Nutritional Biochemistry, 2021, 95, 108763.	1.9	9
4478	Cell polarity and cell adhesion associated gene expression differences between invasive micropapillary and no special type breast carcinomas and their prognostic significance. Scientific Reports, 2021, 11, 18484.	1.6	2
4479	Oxysterol binding protein-like 3 (OSBPL3) is a novel driver gene that promotes tumor growth in part through R-Ras/Akt signaling in gastric cancer. Scientific Reports, 2021, 11, 19178.	1.6	10
4480	Glucose Metabolism and Glucose Transporters in Breast Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 728759.	1.8	69
4481	A Preclinical Investigation of GBM-N019 as a Potential Inhibitor of Glioblastoma via Exosomal mTOR/CDK6/STAT3 Signaling. Cells, 2021, 10, 2391.	1.8	2
4482	High temperature requirement A1 in cancer: biomarker and therapeutic target. Cancer Cell International, 2021, 21, 513.	1.8	4
4483	Obesity and Postmenopausal Hormone Receptor-positive Breast Cancer: Epidemiology and Mechanisms. Endocrinology, 2021, 162, .	1.4	15
4484	Comparative genomic analysis of esophageal squamous cell carcinoma and adenocarcinoma: New opportunities towards molecularly targeted therapy. Acta Pharmaceutica Sinica B, 2022, 12, 1054-1067.	5.7	16
4485	Out of Control: The Role of the Ubiquitin Proteasome System in Skeletal Muscle during Inflammation. Biomolecules, 2021, 11, 1327.	1.8	37
4486	Design, Synthesis and SAR in 2,4,7-Trisubstituted Pyrido[3,2-d]Pyrimidine Series as Novel PI3K/mTOR Inhibitors. Molecules, 2021, 26, 5349.	1.7	0
4487	The Breast Tumor Microenvironment: A Key Player in Metastatic Spread. Cancers, 2021, 13, 4798.	1.7	26
4488	Synthesis and Biological Evaluation of (S)-2-(Substituted) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 227 Td (arylmethyl)-1-oxo-1,2 Effect against PTEN-Deficient MDA-MB-468 Cells. Pharmaceuticals, 2021, 14, 974.	1.7	1
4489	Molecular mechanisms underlying curcumin-mediated microRNA regulation in carcinogenesis; Focused on gastrointestinal cancers. Biomedicine and Pharmacotherapy, 2021, 141, 111849.	2.5	15
4490	Case Report and Literature Review: Pulmonary Sclerosing Pneumocytoma With Multiple Metastases Harboring AKT1 E17K Somatic Mutation and TP53 C176Y Germline Mutation. Frontiers in Medicine, 2021, 8, 655574.	1.2	2
4491	SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway. Neoplasia, 2021, 23, 1037-1047.	2.3	12
4492	Integrin alpha 6 as a stemness driver is a novel promising target for HPV (+) head and neck squamous cell carcinoma. Experimental Cell Research, 2021, 407, 112815.	1.2	6

#	Article	IF	Citations
4493	A protein interaction landscape of breast cancer. Science, 2021, 374, eabf3066.	6.0	66
4494	PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers. ESMO Open, 2021, 6, 100230.	2.0	15
4495	PI3K/mTOR dual-inhibition with VS-5584 enhances anti-leukemic efficacy of ponatinib in blasts and Ph-negative LSCs of chronic myeloid leukemia. European Journal of Pharmacology, 2021, 910, 174446.	1.7	8
4496	Bioisosteric replacements of the indole moiety for the development of a potent and selective PI3KÎ´ inhibitor: Design, synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2021, 223, 113661.	2.6	10
4497	A Novel Cyclic Pentadepsipeptide, N-Methylsansalvamide, Suppresses Angiogenic Responses and Exhibits Antitumor Efficacy against Bladder Cancer. Cancers, 2021, 13, 191.	1.7	6
4498	Antineoplastic Activity of an Old Natural Antidiabetic Biguanoid on the Human Thyroid Carcinoma Cell Line. Anti-Cancer Agents in Medicinal Chemistry, 2021, 21, .	0.9	1
4499	Hormone Resistance. Advances in Experimental Medicine and Biology, 2021, 1187, 391-401.	0.8	1
4500	Carotenoids as Anticancer Agents. , 2021, , 475-512.		3
4501	A Reductionist Approach Using Primary and Metastatic Cellâ€“Derived Extracellular Vesicles Reveals Hub Proteins Associated with Oral Cancer Prognosis. Molecular and Cellular Proteomics, 2021, 20, 100118.	2.5	12
4502	TRIM37 overexpression is associated with chemoresistance in hepatocellular carcinoma via activating the AKT signaling pathway. International Journal of Clinical Oncology, 2021, 26, 532-542.	1.0	16
4506	SV40-Mediated Oncogenesis. , 2005, , 34-59.		3
4507	The p53 Network. , 2005, , 1-23.		2
4508	Cell survival signaling during apoptosis: Implications in drug resistance and anti-cancer therapeutic development. , 2005, 63, 115-145.		1
4509	Molecular Neurobiology of Retinal Degeneration. , 2007, , 47-92.		2
4510	Overcoming Therapeutic Resistance in Malignant Gliomas: Current Practices and Future Directions. Cancer Treatment and Research, 2008, , 169-185.	0.2	7
4511	Hormone Refractory Prostate Cancer: Lessons Learned from the PTEN Prostate Cancer Model. Advances in Experimental Medicine and Biology, 2008, 617, 87-95.	0.8	7
4512	Cancer Genetics of Human Gastric Adenocarcinoma. , 2009, , 251-283.		2
4514	Novel Approaches for Chemosensitization of Breast Cancer Cells: The E1A Story. Advances in Experimental Medicine and Biology, 2007, 608, 144-169.	0.8	21

#	Article	IF	Citations
4515	Molecular Biology of Malignant Melanoma. Advances in Experimental Medicine and Biology, 2008, 624, 252-264.	0.8	7
4516	Mitochondria as Targets for Cancer Therapy. , 2009, , 211-249.		1
4517	Tumor Suppressor Genes. Cancer Treatment and Research, 2009, 149, 109-129.	0.2	3
4518	Drugging the Hsp90 molecular chaperone machine for cancer treatment. , 2007, , 295-330.		1
4519	Signal Transduction Pathways as Therapeutic Targets in Cancer Therapy. , 2010, , 37-83.		2
4520	Genetic Instability and Chronic Inflammation in Gastrointestinal Cancers. , 2010, , 351-397.		1
4521	Crosstalk Between Mitogen-Activated Protein Kinase and Phosphoinositide-3 Kinase Signaling Pathways in Development and Disease. Systems Biology, 2010, , 505-529.	0.1	1
4522	Cancer Treatment Strategies Targeting Sphingolipid Metabolism. Advances in Experimental Medicine and Biology, 2010, 688, 185-205.	0.8	114
4523	Targeting the AKT Pathway in Ovarian Cancer. , 2011, , 73-94.		3
4524	Hypoxia and High Altitude. Advances in Experimental Medicine and Biology, 2003, 543, 89-115.	0.8	53
4525	The Role of GPR55 in Cancer. , 2013, , 115-133.		1
4526	The PI3K Pathway in Colorectal Cancers. , 2013, , 157-199.		1
4527	Inhibition of Glycolysis as a Therapeutic Strategy in Acute Myeloid Leukemias. , 2015, , 709-723.		1
4528	The PI3K-AKT Pathway in Melanoma. , 2016, , 165-180.		3
4529	Emerging Molecular Therapies. , 2004, , 569-606.		3
4530	Molecular Determinants of Intrinsic Multidrug Resistance in Cancer Cells and Tumors. , 2006, , 241-260.		2
4531	Crosstalk Between COX-2 and EGFR: A Potential Therapeutic Opportunity. , 2008, , 325-339.		2
4532	mTOR Signaling in Angiogenesis. , 2009, , 49-74.		1

#	Article	IF	Citations
4533	Androgen Action During Prostate Carcinogenesis. Methods in Molecular Biology, 2011, 776, 25-44.	0.4	37
4534	The Role of Akt Pathway Signaling in Glucose Metabolism and Metabolic Oxidative Stress. , 2012, , 21-46.		15
4535	Hepatoblastoma: New Insights into the Biology of Embryonal Tumors of the Liver. , 2012, , 243-258.		2
4536	COX-2 Signaling in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1277, 87-104.	0.8	17
4537	Uristatin Anti-inflammatory Cellular Signaling. , 2015, , 171-190.		1
4538	Biomarkers for Individualized Oral Cancer Therapy. , 2015, , 43-60.		1
4539	Resistance to PI3K Pathway Inhibition. Cancer Drug Discovery and Development, 2016, , 125-147.	0.2	2
4540	The Mammalian Target of Rapamycin Kinase and Tumor Growth Inhibition. , 2007, 172, 99-124.		33
4541	The Ras Signalling Pathway as a Target in Cancer Therapy. , 2007, 172, 125-153.		9
4542	Resistance to Chemotherapy in Ovarian Carcinoma. Recent Results in Cancer Research, 2007, 176, 51-60.	1.8	23
4543	Role of Signaling Pathway Modification. Medical Radiology, 2003, , 157-178.	0.0	1
4544	Metabolic Fluxes in Cancer Metabolism. , 2015, , 315-348.		5
4545	Regulation of Second Messenger Systems and Intracellular Pathways. , 2010, , 61-73.		5
4547	Gynecologic Cancers. , 2014, , 645-656.		1
4548	PI3K Isoform-Selective Inhibitors in Cancer. Advances in Experimental Medicine and Biology, 2020, 1255, 165-173.	0.8	7
4549	Phosphatidylinositol Bisphosphate and Trisphosphate. , 2004, , 266-271.		1
4550	Molecular Basis of Diseases of the Gastrointestinal Tract. , 2009, , 365-393.		2
4551	Progressing from Gene Mutations to Cancer. , 2008, , 207-222.		3

#	Article	IF	Citations
4552	Treatment of Castration-Resistant Prostate Cancer. , 2012, , 2954-2971.e4.		3
4553	Epidermal growth factor receptor pathway inhibitors. Cancer Chemotherapy and Biological Response Modifiers, 2005, 22, 205-223.	0.5	14
4554	Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases. Modern Pathology, 2004, 17, 15-21.	2.9	5
4555	Therapeutic approaches to the modulation of apoptosis. Essays in Biochemistry, 2003, 39, 131-153.	2.1	13
4556	Lnc GNG12-AS1 knockdown suppresses glioma progression through the AKT/GSK-3Î²/Î²-catenin pathway. Bioscience Reports, 2020, 40, .	1.1	13
4557	Inhibitors in AKTion: ATP-competitive vs allosteric. Biochemical Society Transactions, 2020, 48, 933-943.	1.6	27
4558	p110Î´ PI3K as a therapeutic target of solid tumours. Clinical Science, 2020, 134, 1377-1397.	1.8	15
4560	Targeting mTOR Signaling for Lung Cancer Therapy. Journal of Thoracic Oncology, 2006, 1, 109-111.	0.5	17
4561	A PI3K inhibitor-induced growth inhibition of cancer cells is linked to MEK-ERK pathway. Anti-Cancer Drugs, 2021, 32, 517-525.	0.7	4
4565	Other New Targets. International Journal of Gynecological Cancer, 2009, 19, S49-S54.	1.2	5
4566	Promising Molecular Targets for Design of Antitumor Drugs Based on Ras Protein Signaling Cascades. Russian Journal of Bioorganic Chemistry, 2020, 46, 891-902.	0.3	2
4568	Progesterone Induces NFÎºB DNA Binding Activity through a PI3K/Akt-Dependent Pathway in MCF-7 Breast Cancer Cells. Cancer Research Journal, 2014, 2, 63.	0.0	3
4569	Cell Migration Induced by Native Type IV Collagen Requires PI3K/Akt2 and EGFR Activity in MDA-MB-231 Breast Cancer Cells. Cancer Research Journal, 2015, 3, 52.	0.0	1
4570	Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. Journal of Clinical Investigation, 2005, 115, 959-968.	3.9	264
4571	Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. Journal of Clinical Investigation, 2005, 115, 959-968.	3.9	454
4572	Defects in secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2. Journal of Clinical Investigation, 2004, 113, 441-450.	3.9	101
4573	The survival kinases Akt and Pim as potential pharmacological targets. Journal of Clinical Investigation, 2005, 115, 2618-2624.	3.9	356
4574	New molecularly targeted therapies for lung cancer. Journal of Clinical Investigation, 2007, 117, 2740-2750.	3.9	180

#	Article	IF	Citations
4575	PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. Journal of Clinical Investigation, 2008, 118, 3762-3774.	3.9	403
4576	Constitutively active Akt1 expression in mouse pancreas requires S6 kinase 1 for insulinoma formation. Journal of Clinical Investigation, 2008, 118, 3629-3638.	3.9	60
4577	The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. Journal of Clinical Investigation, 2009, 119, 3626-3636.	3.9	365
4578	CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. Journal of Clinical Investigation, 2010, 120, 485-497.	3.9	658
4579	Developmental stage determines estrogen receptor alpha expression and non-genomic mechanisms that control IGF-1 signaling and mammary proliferation in mice. Journal of Clinical Investigation, 2012, 122, 192-204.	3.9	28
4580	Gankyrin plays an essential role in Ras-induced tumorigenesis through regulation of the RhoA/ROCK pathway in mammalian cells. Journal of Clinical Investigation, 2010, 120, 2829-2841.	3.9	61
4581	Ceramides as modulators of cellular and whole-body metabolism. Journal of Clinical Investigation, 2011, 121, 4222-4230.	3.9	350
4582	Modulation of Cell Signal Transduction by Tea and Ginger. Oxidative Stress and Disease, 2008, , .	0.3	1
4583	Reactive Oxygen Species in the Activation and Regulation of Intracellular Signaling Events. Lung Biology in Health and Disease, 2004, , 59-90.	0.1	2
4584	Insulin-Like Growth Factor 1 (IGF1) Pathway Member Polymorphisms Are Associated with Risk and Prognosis of Chondrosarcoma. Medical Science Monitor, 2020, 26, e923853.	0.5	1
4585	Using Molecular Markers to Guide Therapy of Metastatic Colorectal Cancer. The Journal of Oncopathology, 2013, 1, 21-29.	0.1	1
4586	Effect of Orostachys japonicus on Apoptosis and Autophagy in Human monocytic leukemia Cell line THP-1 via Inhibition of NF-Î²B and Phosphorylation of p38 MAPK. Journal of Korean Medicine, 2019, 40, 35-50.	0.1	1
4587	Asymmetric PTEN Distribution Regulated by Spatial Heterogeneity in Membrane-Binding State Transitions. PLoS Computational Biology, 2013, 9, e1002862.	1.5	20
4588	Transcriptional Regulation of PIK3CA Oncogene by NF-ÎºB in Ovarian Cancer Microenvironment. PLoS ONE, 2008, 3, e1758.	1.1	41
4589	Selective Deletion of PTEN in Dopamine Neurons Leads to Trophic Effects and Adaptation of Striatal Medium Spiny Projecting Neurons. PLoS ONE, 2009, 4, e7027.	1.1	46
4590	N-Cadherin Negatively Regulates Osteoblast Proliferation and Survival by Antagonizing Wnt, ERK and PI3K/Akt Signalling. PLoS ONE, 2009, 4, e8284.	1.1	67
4591	The Expression Level of CB1 and CB2 Receptors Determines Their Efficacy at Inducing Apoptosis in Astrocytomas. PLoS ONE, 2010, 5, e8702.	1.1	75
4592	Analysis of the Molecular Networks in Androgen Dependent and Independent Prostate Cancer Revealed Fragile and Robust Subsystems. PLoS ONE, 2010, 5, e8864.	1.1	31

#	Article	IF	Citations
4593	Casein Kinase 2 Dependent Phosphorylation of Neprilysin Regulates Receptor Tyrosine Kinase Signaling to Akt. PLoS ONE, 2010, 5, e13134.	1.1	22
4594	MYC Cooperates with AKT in Prostate Tumorigenesis and Alters Sensitivity to mTOR Inhibitors. PLoS ONE, 2011, 6, e17449.	1.1	77
4595	ROCK Inhibitor Y-27632 Suppresses Dissociation-Induced Apoptosis of Murine Prostate Stem/Progenitor Cells and Increases Their Cloning Efficiency. PLoS ONE, 2011, 6, e18271.	1.1	74
4596	Autotaxin and LPA Receptors Represent Potential Molecular Targets for the Radiosensitization of Murine Glioma through Effects on Tumor Vasculature. PLoS ONE, 2011, 6, e22182.	1.1	55
4597	PI3K-Dependent GSK3ÃŸ(Ser9)-Phosphorylation Is Implicated in the Intestinal Epithelial Cell Wound-Healing Response. PLoS ONE, 2011, 6, e26340.	1.1	37
4598	Constitutive MAP Kinase Activation in Hematopoietic Stem Cells Induces a Myeloproliferative Disorder. PLoS ONE, 2011, 6, e28350.	1.1	21
4599	Transient mTOR Inhibition Facilitates Continuous Growth of Liver Tumors by Modulating the Maintenance of CD133+ Cell Populations. PLoS ONE, 2011, 6, e28405.	1.1	44
4600	3, 3â€²-Diindolylmethane Exhibits Antileukemic Activity In Vitro and In Vivo through a Akt-Dependent Process. PLoS ONE, 2012, 7, e31783.	1.1	24
4601	Efficacy of a Non-Hypercalcemic Vitamin-D2 Derived Anti-Cancer Agent (MT19c) and Inhibition of Fatty Acid Synthesis in an Ovarian Cancer Xenograft Model. PLoS ONE, 2012, 7, e34443.	1.1	16
4602	Antagonist Effect of Triptolide on AKT Activation by Truncated Retinoid X Receptor-alpha. PLoS ONE, 2012, 7, e35722.	1.1	18
4603	Grape Proanthocyanidin Inhibit Pancreatic Cancer Cell Growth In Vitro and In Vivo through Induction of Apoptosis and by Targeting the PI3K/Akt Pathway. PLoS ONE, 2012, 7, e43064.	1.1	70
4604	Multiple Analyses of G-Protein Coupled Receptor (GPCR) Expression in the Development of Gefitinib-Resistance in Transforming Non-Small-Cell Lung Cancer. PLoS ONE, 2012, 7, e44368.	1.1	40
4605	Modulators of Sensitivity and Resistance to Inhibition of PI3K Identified in a Pharmacogenomic Screen of the NCI-60 Human Tumor Cell Line Collection. PLoS ONE, 2012, 7, e46518.	1.1	42
4606	Erioflorin Stabilizes the Tumor Suppressor Pdcd4 by Inhibiting Its Interaction with the E3-ligase Î²-TrCP1. PLoS ONE, 2012, 7, e46567.	1.1	48
4607	Measurement of Phospholipids May Improve Diagnostic Accuracy in Ovarian Cancer. PLoS ONE, 2012, 7, e46846.	1.1	19
4608	Identification of Global Alteration of Translational Regulation in Glioma In Vivo. PLoS ONE, 2012, 7, e46965.	1.1	21
4609	Solution Structure of the Oncogenic MIEN1 Protein Reveals a Thioredoxin-Like Fold with a Redox-Active Motif. PLoS ONE, 2012, 7, e52292.	1.1	12
4610	Green Tea Polyphenols Induce p53-Dependent and p53-Independent Apoptosis in Prostate Cancer Cells through Two Distinct Mechanisms. PLoS ONE, 2012, 7, e52572.	1.1	45

#	Article	IF	Citations
4611	Analysis of Gene Expression Profiling in Meningioma: Deregulated Signaling Pathways Associated with Meningioma and EGFL6 Overexpression in Benign Meningioma Tissue and Serum. PLoS ONE, 2012, 7, e52707.	1.1	64
4612	Activity of the Heat Shock Protein 90 Inhibitor Ganetespib in Melanoma. PLoS ONE, 2013, 8, e56134.	1.1	35
4613	Simvastatin Inhibits Renal Cancer Cell Growth and Metastasis via AKT/mTOR, ERK and JAK2/STAT3 Pathway. PLoS ONE, 2013, 8, e62823.	1.1	121
4614	Polymorphisms in the mTOR Gene and Risk of Sporadic Prostate Cancer in an Eastern Chinese Population. PLoS ONE, 2013, 8, e71968.	1.1	31
4615	BAD Dephosphorylation and Decreased Expression of MCL-1 Induce Rapid Apoptosis in Prostate Cancer Cells. PLoS ONE, 2013, 8, e74561.	1.1	20
4616	Eukaryotic Initiation Factor 2Î± - a Downstream Effector of Mammalian Target of Rapamycin - Modulates DNA Repair and Cancer Response to Treatment. PLoS ONE, 2013, 8, e77260.	1.1	14
4617	NETRIN-4 Protects Glioblastoma Cells FROM Temozolomide Induced Senescence. PLoS ONE, 2013, 8, e80363.	1.1	20
4618	Trans-Homophilic Interaction of CADM1 Activates PI3K by Forming a Complex with MAGuK-Family Proteins MPP3 and Dlg. PLoS ONE, 2014, 9, e82894.	1.1	34
4619	Genetic Polymorphisms in IGF-I and IGFBP-3 Are Associated with Prostate Cancer in the Chinese Population. PLoS ONE, 2014, 9, e85609.	1.1	18
4620	Meloxicam Executes Its Antitumor Effects against Hepatocellular Carcinoma in COX-2- Dependent and -Independent Pathways. PLoS ONE, 2014, 9, e92864.	1.1	44
4621	Association of mTOR Polymorphisms with Cancer Risk and Clinical Outcomes: A Meta-Analysis. PLoS ONE, 2014, 9, e97085.	1.1	22
4622	Caffeic Acid Derivatives Inhibit the Growth of Colon Cancer: Involvement of the PI3-K/Akt and AMPK Signaling Pathways. PLoS ONE, 2014, 9, e99631.	1.1	84
4623	Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. PLoS ONE, 2015, 10, e0136155.	1.1	39
4624	Colon Cancer Tumorigenesis Initiated by the H1047R Mutant PI3K. PLoS ONE, 2016, 11, e0148730.	1.1	17
4625	Hepatitis C Virus Protein Interaction Network Analysis Based on Hepatocellular Carcinoma. PLoS ONE, 2016, 11, e0153882.	1.1	9
4626	EGFR Activation Leads to Cell Death Independent of PI3K/AKT/mTOR in an AD293 Cell Line. PLoS ONE, 2016, 11, e0155230.	1.1	31
4627	Down-Regulation of AKT Signalling by Ursolic Acid Induces Intrinsic Apoptosis and Sensitization to Doxorubicin in Soft Tissue Sarcoma. PLoS ONE, 2016, 11, e0155946.	1.1	11
4628	Sam68 Mediates the Activation of Insulin and Leptin Signalling in Breast Cancer Cells. PLoS ONE, 2016, 11, e0158218.	1.1	13

#	Article	IF	Citations
4629	Small Molecular TRAIL Inducer ONC201 Induces Death in Lung Cancer Cells: A Preclinical Study. PLoS ONE, 2016, 11, e0162133.	1.1	17
4630	Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy. PLoS ONE, 2016, 11, e0163011.	1.1	14
4631	Phosphorylated Mammalian Target of Rapamycin p-mTOR Is a Favorable Prognostic Factor than mTOR in Gastric Cancer. PLoS ONE, 2016, 11, e0168085.	1.1	16
4632	AT7867 Inhibits Human Colorectal Cancer Cells via AKT-Dependent and AKT-Independent Mechanisms. PLoS ONE, 2017, 12, e0169585.	1.1	16
4633	Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies. PLoS ONE, 2017, 12, e0179510.	1.1	12
4634	miR-182 aids in receptive endometrium development in dairy goats by down-regulating PTN expression. PLoS ONE, 2017, 12, e0179783.	1.1	14
4635	Involvement of the phosphoinositide 3-kinase/Akt signaling pathway in the resistance to therapeutic treatments of human leukemias. Histology and Histopathology, 2005, 20, 239-52.	0.5	23
4636	New determinates of disease progression and outcome in metastatic ovarian carcinoma. Histology and Histopathology, 2010, 25, 1591-609.	0.5	20
4637	New insights into 4E-BP1-regulated translation in cancer progression and metastasis. Cancer Cell & Microenvironment, 2014, 1, .	0.8	12
4638	Exogenous c-Myc Blocks Differentiation and Improves Expansion of Human Erythroblasts In vitro. International Journal of Stem Cells, 2014, 7, 153-157.	0.8	7
4639	PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer. Endocrine-Related Cancer, 2019, 26, 471-482.	1.6	17
4640	Platinum-resistance and AKT Over-expression in Ovarian Cancer. International Journal of Gynecology & Clinical Practices, 2015, 2, .	0.1	2
4641	The Role of Skp2 and its Substrate CDKN1B (p27) in Colorectal Cancer. Journal of Gastrointestinal and Liver Diseases, 2020, 24, 225-234.	0.5	61
4642	Steroid Hormone Intervenes in the Endometrial Tumorigenesis of Pten Ablation. Journal of Cancer Prevention, 2013, 18, 313-321.	0.8	10
4643	Association of polymorphisms of PTEN, AKT1, PI3K, AR, and AMACR genes in patients with prostate cancer. Genetics and Molecular Biology, 2020, 43, e20180329.	0.6	11
4644	Molecular Mechanisms of Apoptosis in Prostate Cancer. Critical Reviews in Oncogenesis, 2007, 13, 1-38.	0.2	11
4645	Aberrant Receptor Signaling and Trafficking as Mechanisms in Oncogenesis. Critical Reviews in Oncogenesis, 2007, 13, 39-74.	0.2	42
4646	Chronic Chlorpyrifos Exposure Does Not Promote Prostate Cancer in Prostate Specific PTEN Mutant Mice. Journal of Environmental Pathology, Toxicology and Oncology, 2013, 32, 29-39.	0.6	5

#	Article	IF	Citations
4647	Association between single nucleotide polymorphisms in the PI3K/AKT/mTOR pathway and bladder cancer risk in a sample of Iranian population. EXCLI Journal, 2018, 17, 3-13.	0.5	14
4648	Epidermal growth factor and aging: A signaling molecule reveals a new eye opening function. Aging, 2011, 3, 896-905.	1.4	25
4649	Long non-coding RNA NNT-AS1 promotes cholangiocarcinoma cells proliferation and epithelial-to-mesenchymal transition through down-regulating miR-203. Aging, 2020, 12, 2333-2346.	1.4	16
4650	Inhibition of miR-19a partially reversed the resistance of colorectal cancer to oxaliplatin via PTEN/PI3K/AKT pathway. Aging, 2020, 12, 5640-5650.	1.4	22
4651	Resveratrol inhibits the malignant progression of hepatocellular carcinoma via MARCH1-induced regulation of PTEN/AKT signaling. Aging, 2020, 12, 11717-11731.	1.4	21
4652	Active Î²-catenin is regulated by the PTEN/PI3 kinase pathway: a role for protein phosphatase PP2A. Genes and Cancer, 2017, 7, 368-382.	0.6	34
4653	IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin. Oncotarget, 2016, 7, 56826-56841.	0.8	24
4654	GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K/AKT pathways. Oncotarget, 2017, 8, 87002-87015.	0.8	16
4655	Endoplasmic reticulum-Golgi intermediate compartment protein 3 knockdown suppresses lung cancer through endoplasmic reticulum stress-induced autophagy. Oncotarget, 2016, 7, 65335-65347.	0.8	22
4656	Application of pharmacologically induced transcriptomic profiles to interrogate PI3K-Akt-mTOR pathway activity associated with cancer patient prognosis. Oncotarget, 2016, 7, 84142-84154.	0.8	5
4657	MiR-155 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells through the activation of PI3K/SGK3/Î²-catenin signaling pathways. Oncotarget, 2016, 7, 66051-66060.	0.8	27
4658	MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway. Oncotarget, 2016, 7, 73188-73199.	0.8	51
4659	Distinct biological effects of low-dose radiation on normal and cancerous human lung cells are mediated by ATM signaling. Oncotarget, 2016, 7, 71856-71872.	0.8	20
4660	Identification of DNA-PKcs as a primary resistance factor of salinomycin in osteosarcoma cells. Oncotarget, 2016, 7, 79417-79427.	0.8	30
4661	Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells. Oncotarget, 2017, 8, 5003-5015.	0.8	16
4662	Transcription factor HBP1 is a direct anti-cancer target of transcription factor FOXO1 in invasive oral cancer. Oncotarget, 2017, 8, 14537-14548.	0.8	12
4663	Loss of PFKFB4 induces cell death in mitotically arrested ovarian cancer cells. Oncotarget, 2017, 8, 17960-17980.	0.8	23
4664	USP22 knockdown enhanced chemosensitivity of hepatocellular carcinoma cells to 5-Fu by up-regulation of Smad4 and suppression of Akt. Oncotarget, 2017, 8, 24728-24740.	0.8	23

#	Article	IF	Citations
4665	WNT signaling and distant metastasis in colon cancer through transcriptional activity of nuclear Î²-Catenin depend on active PI3K signaling. Oncotarget, 2014, 5, 2999-3011.	0.8	51
4666	Hypoxia-induced PLOD2 promotes proliferation, migration and invasion via PI3K/Akt signaling in glioma. Oncotarget, 2017, 8, 41947-41962.	0.8	76
4667	Ulk1 over-expression in human gastric cancer is correlated with patients' T classification and cancer relapse. Oncotarget, 2017, 8, 33704-33712.	0.8	21
4668	Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3KÎ±, in comparison to established pan PI3K inhibitors. Oncotarget, 2017, 8, 47725-47740.	0.8	11
4669	Prognostic significance of HER3 in patients with malignant solid tumors. Oncotarget, 2017, 8, 67140-67151.	0.8	29
4670	IGF-1R, a target of let-7b, mediates crosstalk between IRS-2/Akt and MAPK pathways to promote proliferation of oral squamous cell carcinoma. Oncotarget, 2014, 5, 2562-2574.	0.8	44
4671	Regulation of human glioblastoma cell death by combined treatment of cannabidiol, Î³-radiation and small molecule inhibitors of cell signaling pathways. Oncotarget, 2017, 8, 74068-74095.	0.8	34
4672	The EF-hand calcium-binding protein tescalcin is a potential oncotarget in colorectal cancer. Oncotarget, 2014, 5, 2149-2160.	0.8	28
4673	Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma. Oncotarget, 2014, 5, 2635-2647.	0.8	77
4674	PIK3CA mutations are associated with increased tumor aggressiveness and Akt activation in gastric cancer. Oncotarget, 2017, 8, 90948-90958.	0.8	37
4675	Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia. Oncotarget, 2010, 1, 578-582.	0.8	30
4676	Breast cancer suppression by aplysin is associated with inhibition of PI3K/AKT/FOXO3a pathway. Oncotarget, 2017, 8, 63923-63934.	0.8	18
4677	PIK3CAH1047R-induced paradoxical ERK activation results in resistance to BRAFV600E specific inhibitors in BRAFV600E PIK3CAH1047R double mutant thyroid tumors. Oncotarget, 2017, 8, 103207-103222.	0.8	18
4678	Autophagy inhibition sensitizes LY3023414-induced anti-glioma cell activity in vitro and in vivo. Oncotarget, 2017, 8, 98964-98973.	0.8	8
4679	Targeting DYRK1B suppresses the proliferation and migration of liposarcoma cells. Oncotarget, 2018, 9, 13154-13166.	0.8	13
4680	FOXO3 induces ubiquitylation of AKT through MUL1 regulation. Oncotarget, 2017, 8, 110474-110489.	0.8	16
4681	Expression of HNF4G and its potential functions in lung cancer. Oncotarget, 2018, 9, 18018-18028.	0.8	26
4682	GRAM domain-containing protein 1B (GRAMD1B), a novel component of the JAK/STAT signaling pathway, functions in gastric carcinogenesis. Oncotarget, 2017, 8, 115370-115383.	0.8	13

#	Article	IF	Citations
4683	Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors. Oncotarget, 2014, 5, 8544-8557.	0.8	56
4684	Germline polymorphism of interferon-lambda3 is clinically associated with progression of renal cell carcinoma. Oncotarget, 2018, 9, 4188-4199.	0.8	1
4685	Association between PIK3CA alteration and prognosis of gastric cancer patients: a meta-analysis. Oncotarget, 2018, 9, 7651-7659.	0.8	14
4686	HS-133, a novel fluorescent phosphatidylinositol 3-kinase inhibitor as a potential imaging and anticancer agent for targeted therapy. Oncotarget, 2014, 5, 10180-10197.	0.8	5
4687	Transformation of mouse T cells requires MYC and AKT activity in conjunction with inhibition of intrinsic apoptosis. Oncotarget, 2018, 9, 21396-21410.	0.8	7
4688	Simultaneous targeting of PI3KÎ´ and a PI3KÎ´-dependent MEK1/2-Erk1/2 pathway for therapy in pediatric B-cell acute lymphoblastic leukemia. Oncotarget, 2014, 5, 10732-10744.	0.8	12
4689	CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128. Oncotarget, 2018, 9, 26032-26045.	0.8	26
4690	Targeted therapies for advanced non-small cell lung cancer. Oncotarget, 2018, 9, 37589-37607.	0.8	52
4691	PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer. Oncotarget, 2019, 10, 3667-3680.	0.8	6
4692	PLAC1 is essential for FGF7/FGFRIIIb-induced Akt-mediated cancer cell proliferation. Oncotarget, 2020, 11, 1862-1875.	0.8	7
4693	RNA sequencing analyses reveal differentially expressed genes and pathways as Notch2 targets in B-cell lymphoma. Oncotarget, 2020, 11, 4527-4540.	0.8	3
4694	Evi1 forms a bridge between the epigenetic machinery and signaling pathways. Oncotarget, 2011, 2, 575-586.	0.8	32
4695	Adhesion glycoprotein CD44 functions as an upstream regulator of a network connecting ERK, AKT and Hippo-YAP pathways in cancer progression. Oncotarget, 2015, 6, 2951-2965.	0.8	55
4696	PI3K inhibition synergizes with glucocorticoids but antagonizes with methotrexate in T-cell acute lymphoblastic leukemia. Oncotarget, 2015, 6, 13105-13118.	0.8	30
4697	PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget, 2011, 2, 984-996.	0.8	85
4698	PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling. Oncotarget, 2018, 9, 24914-24926.	0.8	24
4699	Mitochondrial p53 phosphorylation induces Bak-mediated and caspase-independent cell death. Oncotarget, 2015, 6, 17192-17205.	0.8	29
4700	AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis. Oncotarget, 2015, 6, 13962-13977.	0.8	54

#	Article	IF	Citations
4701	COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPÎ² pathway and PDK1 stabilization. Oncotarget, 2015, 6, 23748-23763.	0.8	84
4702	Cyclooxygenase-2 in tumor-associated macrophages promotes breast cancer cell survival by triggering a positive-feedback loop between macrophages and cancer cells. Oncotarget, 2015, 6, 29637-29650.	0.8	65
4703	New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?. Oncotarget, 2015, 6, 24780-24796.	0.8	77
4704	Non-thermal plasma induces AKT degradation through turn-on the MUL1 E3 ligase in head and neck cancer. Oncotarget, 2015, 6, 33382-33396.	0.8	50
4705	The promise of anti-ErbB3 monoclonals as new cancer therapeutics. Oncotarget, 2012, 3, 744-758.	0.8	75
4706	Ack1 overexpression promotes metastasis and indicates poor prognosis of hepatocellular carcinoma. Oncotarget, 2015, 6, 40622-40641.	0.8	37
4707	Epigenetic silencing of tumor suppressor miR-3151 contributes to Chinese chronic lymphocytic leukemia by constitutive activation of MADD/ERK and PIK3R2/AKT signaling pathways. Oncotarget, 2015, 6, 44422-44436.	0.8	21
4708	DAB2IP in cancer. Oncotarget, 2016, 7, 3766-3776.	0.8	50
4709	Mitochondrial reactive oxygen species perturb AKT/cyclin D1 cell cycle signaling via oxidative inactivation of PP2A in lowdose irradiated human fibroblasts. Oncotarget, 2016, 7, 3559-3570.	0.8	50
4710	Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells. Oncotarget, 2016, 7, 7297-7306.	0.8	29
4711	Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells. Oncotarget, 2016, 7, 35753-35767.	0.8	46
4712	Withaferin-A suppress AKT induced tumor growth in colorectal cancer cells. Oncotarget, 2016, 7, 13854-13864.	0.8	39
4713	Argon protects against hypoxic-ischemic brain injury in neonatal rats through activation of nuclear factor (erythroid-derived 2)-like 2. Oncotarget, 2016, 7, 25640-25651.	0.8	54
4714	Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+PTENâ^' glioblastoma in vivo. Oncotarget, 2016, 7, 24752-24765.	0.8	13
4715	Matrix stiffness-mediated effects on stemness characteristics occurring in HCC cells. Oncotarget, 2016, 7, 32221-32231.	0.8	81
4716	mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma. Oncotarget, 2016, 7, 32916-32924.	0.8	14
4717	Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas. Oncotarget, 2016, 7, 29780-29793.	0.8	64
4718	EGR1 mediates miR-203a suppress the hepatocellular carcinoma cells progression by targeting HOXD3 through EGFR signaling pathway. Oncotarget, 2016, 7, 45302-45316.	0.8	39

#	Article	IF	Citations
4719	AB044. AGE/RAGE/Akt pathway contributes to prostate cancer cell proliferation by promoting Rb phosphorylation and degradation. Translational Andrology and Urology, 2016, 5, AB044-AB044.	0.6	7
4720	Metabolism of Rhaponticin and Activities of its Metabolite, Rhapontigenin: A Review. Current Medicinal Chemistry, 2020, 27, 3168-3186.	1.2	10
4721	Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis. Current Pharmaceutical Design, 2017, 23, 4226-4246.	0.9	38
4722	Exploring Dysregulated Signaling Pathways in Cancer. Current Pharmaceutical Design, 2020, 26, 429-445.	0.9	18
4723	Modulation of Signaling Enhances the Efficacy of the Combination of Satraplatin and Erlotinib. Current Drug Targets, 2014, 15, 1312-1321.	1.0	6
4724	Recent Advancements in Small Molecule Inhibitors of Insulinâ€“like Growth Factor-1 Receptor (IGF-1R) Tyrosine Kinase as Anticancer agents. Mini-Reviews in Medicinal Chemistry, 2013, 13, 653-681.	1.1	29
4725	Roles of EGFR, PI3K, AKT, and mTOR in Heavy Metal-Induced Cancer. Current Cancer Drug Targets, 2013, 13, 252-266.	0.8	52
4726	Antiproliferative Effect of HSP90 Inhibitor Y306zh Against Pancreatic Cancer is Mediated by Interruption of AKT and MAPK Signaling Pathways. Current Cancer Drug Targets, 2014, 14, 671-683.	0.8	18
4727	The Use of Conformational Restriction in Medicinal Chemistry. Current Topics in Medicinal Chemistry, 2019, 19, 1712-1733.	1.0	26
4728	Targeting Mutant KRAS for Anticancer Therapy. Current Topics in Medicinal Chemistry, 2019, 19, 2098-2113.	1.0	12
4729	Akt Pathway Inhibitors. Current Topics in Medicinal Chemistry, 2020, 20, 883-900.	1.0	58
4730	Ligand-Based Drug Design: Synthesis and Biological Evaluation of Substituted Benzoin Derivatives as Potential Antitumor Agents. Medicinal Chemistry, 2019, 15, 417-429.	0.7	8
4731	Recent Progress and Development of Small Molecule Kinase Inhibitors for the Treatment of Breast Cancer. Current Enzyme Inhibition, 2020, 16, 4-19.	0.3	3
4732	The Membrane-targeted Alkylphosphocholine Erufosine Interferes with Survival Signals from the Extracellular Matrix. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 578-591.	0.9	6
4733	Structure-Based Design: Synthesis, X-ray Crystallography, and Biological Evaluation of N-Substituted-4-Hydroxy-2-Quinolone-3-Carboxamides as Potential Cytotoxic Agents. Anti-Cancer Agents in Medicinal Chemistry, 2018, 18, 263-276.	0.9	20
4734	Structural Studies of the Complex Between Akt-in and the Akt2-PH Domain Suggest that the Peptide Acts as an Allosteric Inhibitor of the Akt Kinase. The Open Spectroscopy Journal, 2009, 3, 65-76.	1.0	1
4735	Radiation Induced Non-targeted Response: Mechanism and Potential Clinical Implications. Current Molecular Pharmacology, 2011, 4, 96-105.	0.7	190
4736	PIK3CA mutations in HER2-positive Breast Cancer Patients; Frequency and Clinicopathological Perspective in Egyptian Patients. Asian Pacific Journal of Cancer Prevention, 2017, 18, 57-64.	0.5	8

#	Article	IF	Citations
4737	Dysregulation of Glucose Metabolism by Oncogenes and Tumor Suppressors in Cancer Cells. Asian Pacific Journal of Cancer Prevention, 2018, 19, 2377-2390.	0.5	46
4738	The miRNAbantamregulates growth and tumorigenesis by repressing the cell cycle regulatortribbles. Life Science Alliance, 2019, 2, e201900381.	1.3	12
4739	CDKL3 promotes osteosarcoma progression by activating Akt/PKB. Life Science Alliance, 2020, 3, e202000648.	1.3	7
4740	Nti-EGFR monoclonal antibody in cancer treatment: in vitro and in vivo evidence. Frontiers in Bioscience - Landmark, 2011, 16, 1973.	3.0	7
4741	Magnolol Affects Cellular Proliferation, Polyamine Biosynthesis and Catabolism-Linked Protein Expression and Associated Cellular Signaling Pathways in Human Prostate Cancer Cells in vitro. Functional Foods in Health and Disease, 2015, 5, 17.	0.3	6
4742	Successful Sirolimus Treatment for Korean Patients with Activated Phosphoinositide 3-kinase Î´ Syndrome 1: the First Case Series in Korea. Yonsei Medical Journal, 2020, 61, 542.	0.9	8
4744	Characterization and Childhood Tumor Risk Assessment of Genetic and Epigenetic Syndromes Associated With Lateralized Overgrowth. Frontiers in Pediatrics, 2020, 8, 613260.	0.9	14
4745	Radiosensitising Cancer Using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or Mammalian Target of Rapamycin (mTOR) Inhibitors. Cancers, 2020, 12, 1278.	1.7	45
4746	Targeting Protein Kinase C Downstream of Growth Factor and Adhesion Signalling. Cancers, 2015, 7, 1271-1291.	1.7	17
4747	N-phenyl-6-chloro-4-hydroxy-2-quinolone-3-carboxamides: Molecular Docking, Synthesis, and Biological Investigation as Anticancer Agents. Molecules, 2021, 26, 73.	1.7	11
4748	A Novel Approach against Vascular Intimal Hyperplasia Through the Suppression of Girdin. Annals of Vascular Diseases, 2015, 8, 69-73.	0.2	12
4749	Overexpression of Serum and Glucocorticoid-regulated Kinase 2Î±Inhibits Proliferation of Liver Cancer Cell Line BEL7402 <I>via</I> Wnt/Î²-Catenin Signal Pathway*. Progress in Biochemistry and Biophysics, 2010, 37, 496-502.	0.3	1
4750	SMAD-4 Cooperates with TGF-Î² to Enhance PTEN Expression Upon The Inhibition of RAS/ERK Pathway in Gastric Carcinoma Cells*. Progress in Biochemistry and Biophysics, 2011, 38, 543-550.	0.3	1
4751	Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma. , 2020, 1, 53-70.		5
4752	Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice. World Journal of Gastroenterology, 2009, 15, 1943.	1.4	52
4753	Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: A pilot study. World Journal of Gastroenterology, 2009, 15, 4278.	1.4	3
4754	Exploiting novel molecular targets in gastrointestinal cancers. World Journal of Gastroenterology, 2007, 13, 5845.	1.4	16
4755	Up-regulation of PIK3CA promotes metastasis in gastric carcinoma. World Journal of Gastroenterology, 2010, 16, 4986.	1.4	53

#	Article	IF	Citations
4756	RNAi knockdown of PIK3CA preferentially inhibits invasion of mutant PIK3CA cells. World Journal of Gastroenterology, 2011, 17, 3700.	1.4	14
4757	Development of systemic therapy for hepatocellular carcinoma at 2013: Updates and insights. World Journal of Gastroenterology, 2014, 20, 3135.	1.4	13
4758	Targeting mTOR network in colorectal cancer therapy. World Journal of Gastroenterology, 2014, 20, 4178.	1.4	85
4759	Elevated estrogen receptor Î² expression in triple negative breast cancer cells is associated with sensitivity to doxorubicin by inhibiting the PI3K/AKT/mTOR signaling pathway. Experimental and Therapeutic Medicine, 2020, 20, 1630-1636.	0.8	13
4760	Knockdown of ROS1 gene sensitizes breast tumor growth to doxorubicin in a syngeneic mouse model. International Journal of Oncology, 2016, 48, 2359-2366.	1.4	28
4761	Prognostic genes of melanoma identified by weighted gene coâ€'expression network analysis and drug repositioning using a networkâ€'based method. Oncology Letters, 2019, 18, 6066-6078.	0.8	9
4762	Downregulation of FHL1 protein in glioma inhibits tumor growth through PI3K/AKT signaling. Oncology Letters, 2020, 19, 3781-3788.	0.8	4
4763	Low PTEN expression and overexpression of phosphorylated Akt^{Ser473} and Akt^{Thr308} are associated with poor overall survival in upper tract urothelial carcinoma. Oncology Letters, 2020, 20, 1-1.	0.8	2
4764	MicroRNAâ€'15aâ€'5p promotes the proliferation and invasion of T98G glioblastoma cells via targeting cell adhesion molecule 1. Oncology Letters, 2020, 21, 103.	0.8	3
4765	Cholinergic Î±5 nicotinic receptor is involved in the proliferation and invasion of human prostate cancer cells. Oncology Reports, 2020, 43, 159-168.	1.2	7
4766	Icotinib Enhances Bufalin-Induced Apoptosis via the Suppression of PI3K/Akt Signaling Pathway in Human Colon Cancer Cells. International Journal of Pharmacology, 2015, 11, 910-919.	0.1	1
4767	A structural model of the VEGF signalling pathway: Emergence of robustness and redundancy properties. Mathematical Biosciences and Engineering, 2013, 10, 167-184.	1.0	3
4768	Construction of a recombinant lentivirus containing human microRNA-7-3 and its inhibitory effects on glioma proliferation. Neural Regeneration Research, 2012, 7, 2144-50.	1.6	6
4769	Molecular biology of lung cancer. Journal of Thoracic Disease, 2013, 5 Suppl 5, S479-90.	0.6	173
4770	Current status of novel agents in advanced gastroesophageal adenocarcinoma. Journal of Gastrointestinal Oncology, 2015, 6, 60-74.	0.6	19
4771	AKT expression is associated with degree of pathologic response in adenocarcinoma of the esophagus treated with neoadjuvant therapy. Journal of Gastrointestinal Oncology, 2016, 7, 158-65.	0.6	10
4772	Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer. Translational Lung Cancer Research, 2015, 4, 165-76.	1.3	103
4773	Androgen receptor-mediated non-genomic regulation of prostate cancer cell proliferation. Translational Andrology and Urology, 2013, 2, 187-96.	0.6	70

#	Article	IF	Citations
4774	The Cholesterol-Binding Antibiotic Nystatin Induces Expression of Macrophage Inflammatory Protein-1 in Macrophages. Biomolecules and Therapeutics, 2013, 21, 42-48.	1.1	18
4775	Peptidoglycan Up-Regulates CXCL8 Expression via Multiple Pathways in Monocytes/Macrophages. Biomolecules and Therapeutics, 2015, 23, 564-570.	1.1	15
4776	Gomisin G Suppresses the Growth of Colon Cancer Cells by Attenuation of AKT Phosphorylation and Arrest of Cell Cycle Progression. Biomolecules and Therapeutics, 2019, 27, 210-215.	1.1	9
4777	Effects of Insulin-Like Growth Factor 1 on Muscle Atrophy and Motor Function in Rats with Brain Ischemia. Chinese Journal of Physiology, 2010, 53, 337-348.	0.4	13
4779	Targeting the AKT pathway: Repositioning HIV protease inhibitors as radiosensitizers. Indian Journal of Medical Research, 2016, 143, 145.	0.4	13
4780	Allele frequencies of the epidermal growth factor receptors polymorphism r521k in colorectal cancer patients and healthy subjects indicate a risk-reducing effect of k521 in Syrian population. North American Journal of Medical Sciences, 2013, 5, 202.	1.7	5
4781	Roles of p63 in Epidermal Development and Tumorigenesis. Biomedical Journal, 2012, 35, 457.	1.4	21
4782	Role of phosphatase and tensin homolog in pathogenesis of ameloblastoma: An immunohistochemical study. Journal of Cancer Research and Therapeutics, 2020, 16, 513.	0.3	3
4783	Pneumonitis After Precision Oncology Therapies: A Concise Review. Journal of Immunotherapy and Precision Oncology, 2018, 1, 26-37.	0.6	5
4784	Prognostic Value of Phosphorylated Akt and Survivin Expression in Gastric Adenocarcinoma. Korean Journal of Pathology, 2010, 44, 252.	1.2	3
4785	A Novel, Potent, Small Molecule AKT Inhibitor Exhibits Efficacy against Lung Cancer Cells In Vitro. Cancer Research and Treatment, 2015, 47, 913-920.	1.3	6
4786	Synergistic Effect of COX-2 Inhibitor on Paclitaxel-Induced Apoptosis in the Human Ovarian Cancer Cell Line OVCAR-3. Cancer Research and Treatment, 2014, 46, 81-92.	1.3	24
4787	Pan-Pim Kinase Inhibitor AZD1208 Suppresses Tumor Growth and Synergistically Interacts with Akt Inhibition in Gastric Cancer Cells. Cancer Research and Treatment, 2019, 51, 451-463.	1.3	12
4788	Resveratrol inhibits mTOR signaling by targeting DEPTOR. Communicative and Integrative Biology, 2011, 4, 382-4.	0.6	14
4789	MTA1 Aids the AKT Pathway by Inhibiting Expression of a Key Regulator, PTEN. Journal of Cancer Science & Therapy, 2010, 02, .	1.7	7
4790	Dual Differential Roles of Cancerous Immunoglobulins as Suggested by Interactions with Human Serum Proteins. Journal of Clinical & Cellular Immunology, 2015, 06, .	1.5	1
4791	Metformin- A Promising Agent for Chemoprevention in BRCA1 Carriers. Hereditary Genetics: Current Research, 2012, 01, .	0.1	2
4792	Cancer Treatment Strategies. , 0, , .		1

#	Article	IF	Citations
4793	The Effect of Antineoplastons A10 and AS2-1 and Metabolites of Sodium Phenylbutyrate on Gene Expression in Glioblastoma Multiforme. Journal of Cancer Therapy, 2014, 05, 929-945.	0.1	14
4794	Linking stemness with colorectal cancer initiation, progression, and therapy. World Journal of Stem Cells, 2019, 11, 519-534.	1.3	13
4795	Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action. World Journal of Biological Chemistry, 2010, 1, 209.	1.7	43
4796	The Effect of Helicobacter pylori on Epidermal Growth Factor Receptor-Induced Signal Transduction and the Preventive Effect of Celecoxib in Gastric Cancer Cells. Gut and Liver, 2013, 7, 552-559.	1.4	22
4797	LETM1 Promotes Gastric Cancer Cell Proliferation, Migration, and Invasion via the PI3K/Akt Signaling Pathway. Journal of Gastric Cancer, 2020, 20, 139.	0.9	10
4798	The potential role of Akt phosphorylation in human cancers. International Journal of Biological Markers, 2008, 23, 1-9.	0.7	100
4799	Role of Akt signaling in resistance to DNA-targeted therapy. World Journal of Clinical Oncology, 2016, 7, 352.	0.9	48
4800	Snail Switches 5-FU-induced Apoptosis to Necrosis through Akt/PKB Activation and p53 Down-regulation. Journal of Life Science, 2012, 22, 1018-1023.	0.2	2
4801	Identification of a Novel Human Lysophosphatidic Acid Acyltransferase, LPAAT-theta, Which Activates mTOR Pathway. BMB Reports, 2006, 39, 626-635.	1.1	37
4802	Heat shock protein 90Î² inhibits apoptosis of intestinal epithelial cells induced by hypoxia through stabilizing phosphorylated Akt. BMB Reports, 2013, 46, 47-52.	1.1	14
4803	YAC tripeptide of epidermal growth factor promotes the proliferation of HaCaT keratinocytes through activation of EGFR. BMB Reports, 2014, 47, 581-586.	1.1	6
4804	Antineoplastic effects of mammalian target of rapamycine inhibitors. World Journal of Transplantation, 2012, 2, 74.	0.6	12
4805	Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. Chinese Journal of Cancer, 2011, 30, 5-12.	4.9	116
4806	Vitamin K2 as a Chemotherapeutic Agent for Treating Ovarian Cancer. , 0, , .		1
4807	Novel Therapeutic Targets for Hepatocellular Carcinoma Treatment. , 0, , .		1
4808	Discovery and Evaluation of Polymorphisms in theAKT2andAKT3Promoter Regions for Risk of Korean Lung Cancer. Genomics and Informatics, 2012, 10, 167.	0.4	8
4809	Second Messenger Systems in Human Gliomas. Archives of Pathology and Laboratory Medicine, 2007, 131, 1585-1590.	1.2	33
4810	Anaplastic Large Cell Lymphoma: Twenty-Five Years of Discovery. Archives of Pathology and Laboratory Medicine, 2011, 135, 19-43.	1.2	98

#	Article	IF	Citations
4811	MicroRNA 100: a context dependent miRNA in prostate cancer. Clinics, 2013, 68, 797-802.	0.6	40
4812	Oncogenesis and the Clinical Significance of K-ras in Pancreatic Adenocarcinoma. Asian Pacific Journal of Cancer Prevention, 2013, 14, 2699-2701.	0.5	5
4813	Phosphatidylinositol 3-kinase (PI3KCA) Oncogene Mutation Analysis and Gene Expression Profiling in Primary Breast Cancer Patients. Asian Pacific Journal of Cancer Prevention, 2013, 14, 5067-5072.	0.5	17
4814	PIK3CA and AKT Gene Polymorphisms in Susceptibility to Osteosarcoma in a Chinese Population. Asian Pacific Journal of Cancer Prevention, 2013, 14, 5117-5122.	0.5	28
4815	Review of the Molecular Pathogenesis of Osteosarcoma. Asian Pacific Journal of Cancer Prevention, 2014, 15, 5967-5976.	0.5	120
4816	The mTOR Signalling Pathway in Cancer and the Potential mTOR Inhibitory Activities of Natural Phytochemicals. Asian Pacific Journal of Cancer Prevention, 2014, 15, 6463-6475.	0.5	38
4817	Sensitization of Cervical Carcinoma Cells to Paclitaxel by an IPP5 Active Mutant. Asian Pacific Journal of Cancer Prevention, 2014, 15, 8337-8343.	0.5	3
4818	Novel Insight into the Structural Requirements of P70S6K Inhibition Using Group-based Quantitative Structure Activity Relationship (GQSAR). Journal of Applied Pharmaceutical Science, 0, , .	0.7	2
4819	Hepatitis B virus X protein accelerates the development of hepatoma. Cancer Biology and Medicine, 2014, 11, 182-90.	1.4	73
4820	Rac1-mediated membrane raft localization of PI3K/p110Î² is required for its activation by GPCRs or PTEN loss. ELife, 2016, 5, .	2.8	25
4821	Palmitoylated SCP1 is targeted to the plasma membrane and negatively regulates angiogenesis. ELife, 2017, 6, .	2.8	15
4822	Affimer proteins are versatile and renewable affinity reagents. ELife, 2017, 6, .	2.8	151
4823	Mutationally-activated PI3â€™-kinase-Î± promotes de-differentiation of lung tumors initiated by the BRAFV600E oncoprotein kinase. ELife, 2019, 8, .	2.8	18
4824	Formal modeling and analysis of ER-Î±associated Biological Regulatory Network in breast cancer. PeerJ, 2016, 4, e2542.	0.9	6
4825	Case Report: Targeted Therapy for Metastatic Solid Pseudopapillary Neoplasm of the Pancreas With CTNNB1 and PTEN Mutations. Frontiers in Oncology, 2021, 11, 729151.	1.3	5
4826	Small molecules with huge impacts: the role of miRNA-regulated PI3K pathway in human malignancies. Molecular Biology Reports, 2021, 48, 8045-8059.	1.0	2
4827	Research Progress on Circular RNA in Glioma. Frontiers in Oncology, 2021, 11, 705059.	1.3	3
4828	Playing the Devilâ€™s Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? â€“ ie Strategies to Revert Resistance to mTOR Inhibitors. Cancer Management and Research, 2021, Volume 13, 7623-7636.	0.9	6

#	Article	IF	Citations
4829	Knockdown of DIAPH3 Inhibits the Proliferation of Cervical Cancer Cells through Inactivating mTOR Signaling Pathway. Journal of Oncology, 2021, 2021, 1-16.	0.6	8
4830	WISP3 suppresses ESCC progression by inhibiting the IGF-2-IGF1R-AKT signaling cascade. Experimental Cell Research, 2021, 409, 112871.	1.2	1
4831	Development of anti-breast cancer PI3K inhibitors based on 7-azaindole derivatives through scaffold hopping: Design, synthesis and in vitro biological evaluation. Bioorganic Chemistry, 2021, 117, 105405.	2.0	8
4833	Genetische Grundlagen der Kanzerogenese. , 2004, , 75-145.		1
4834	Phosphoinositide 3-Kinase. , 2004, , 281-286.		0
4835	Protein Kinase B. , 2004, , 516-522.		1
4836	Molecular Mechanisms of Hepatocellular Carcinoma. , 2005, , 23-57.		0
4837	Vitamin E Analogs as Anticancer Agents. Nutrition and Disease Prevention, 2005, , .	0.1	0
4839	Cellular Oncogenes and Carcinogenesis. , 2005, , 103-129.		0
4840	Resveratrol as Inhibitor of Cell Survival Signal Transduction. Oxidative Stress and Disease, 2005, , 105-117.	0.3	0
4841	Comparison of the Effects of Ras Effector Mutants and Ras Effectors on Transformed and Tumorigenic Growth of Human and Rodent Cells. , 2006, , 257-272.		0
4842	Integration of stimulatory and inhibitory signals in pituitary tumor cells through the PI3 kinase pathway. Experimental and Clinical Endocrinology and Diabetes, 2006, 114, .	0.6	0
4843	Bcr-Abl and Signal Transduction. , 2007, , 15-35.		0
4844	Inhibition of the PI3K-Akt Signaling Pathway Reduces Tumor Necrosis Factor-? Production in Response to Titanium Particles in Vitro. Journal of Bone and Joint Surgery - Series A, 2007, 89, 1019-1027.	1.4	0
4845	HER2 Inhibition and Clinical Achievements. , 2007, , 57-66.		0
4846	Promising New Agents in Phase I and II Clinical Trials in Multiple Myeloma. Translational Medicine Series, 2007, , 211-242.	0.0	0
4847	Physiology of erythropoiesis. , 2008, , 1-66.		0
4848	Profilin. , 2008, , 200-217.		0

#	Article	IF	Citations
4849	Therapeutic Strategies that Target the HIF System. , 2008, , 359-373.		0
4850	Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways. , 2008, , 317-365.		0
4851	Genetics of Pten Hamartoma Tumor Syndrome (PHTS). , 2008, , 483-489.		0
4852	Chemo-Immunosensitization of Resistant B-NHL as a Result of Rituximab (anti-CD20 mAb)-Mediated Inhibition of Cell Survival Signaling Pathways. , 2008, , 29-39.		1
4853	Molecular Signaling Pathways in Pancreatic Cancer. , 2008, , 181-228.		0
4854	PIK3CA Gene Alterations in Human Cancers. , 2009, , 1-20.		0
4855	Molecular Neurooncology and Neoangiogenesis of Malignant Gliomas. , 2009, , 23-55.		0
4856	Signal Transduction Inhibitors in the Treatment of Breast Cancer. , 2009, , 177-201.		0
4857	Future Directions: New Targets. , 2009, , 267-283.		0
4858	The Role of Autophagy and Apoptosis in the Drug Resistance of Cancer. , 2009, , 53-71.		3
4859	Tumor Growth and Cell Proliferation. Medical Radiology, 2009, , 19-37.	0.0	0
4860	STOP AKTING TO TREAT ENDOCRINE TUMOURS. Acta Endocrinologica, 2009, 5, 131-142.	0.1	0
4861	mTOR Signaling in Glioblastoma: Lessons Learned from Bench to Bedside. , 2009, , 99-111.		0
4862	Radiosensitizers in Neurooncology. , 2009, , 987-1005.		0
4863	Lycopene and Down-regulation of Cyclin D1, pAKT and pBad. , 2009, , 133-158.		0
4864	Update on Diagnostic Practice: Tumors of the Nervous System. Archives of Pathology and Laboratory Medicine, 2009, 133, 1062-1077.	1.2	18
4865	Somatic Molecular Genetics of Prostate Cancer. , 2010, , 143-180.		1
4866	Implication of PI3K-dependent HSP27 and p53 expression in mild heat shock-triggered switch of metabolic stress-induced necrosis to apoptosis in A549 cells. International Journal of Oncology, 2009, 36, .	1.4	2

#	Article	IF	Citations
4867	Genetische Grundlagen der Kanzerogenese. , 2010, , 67-127.		0
4868	Molecular Mechanisms Linking Adiponectin Receptor Signalling and Cancer. The Open Obesity Journal, 2010, 2, 43-49.	0.1	3
4869	Cell Biology of Prostate Cancer and Molecular Targets. , 2010, , 1-24.		0
4870	Transgenic and Knockout Mouse Models of Liver Cancer. , 2010, , 163-188.		0
4873	Targeting UVB Mediated Signal Transduction Pathways for the Chemoprevention of Squamous Cell Carcinoma. , 2011, , 335-363.		0
4874	Effects and Therapeutic Potential of Targeting Dysregulated Signaling Axes in Squamous Cell Carcinoma: Another Kinase of Transcription and Mammalian Target of Rapamycin. , 2011, , 383-405.		0
4875	Age-Related Changes in the Molecular Regulation of Skeletal Muscle Mass. , 2011, , 207-221.		0
4876	No Association between PIK3CA Polymorphism and Lung Cancer Risk in the Korean Population. Genomics and Informatics, 2010, 8, 194-200.	0.4	1
4877	Cancer Stem Cells in Ovarian Cancer. , 2011, , 151-176.		0
4878	PIK3CA. , 2011, , 2892-2894.		0
4879	Rapamycin. , 2011, , 3173-3175.		0
4881	Molecular Targeted Drug Delivery Radiotherapy. , 2011, , 187-200.		0
4882	Prostate Cancer Molecularly Targeted Therapies. , 2011, , 3040-3046.		0
4883	Walking on the Molecular Pathway: m-TOR Inhibition in the Liver Transplant Setting. The Open Transplantation Journal, 2011, 5, 35-43.	0.1	0
4884	Genetic and Epigenetic Alterations in the MAP Kinase and PI3K/Akt Pathways in Thyroid Cancer. , 2011, , 27-38.		0
4885	Changing the Nature of Melanoma Cells by Manipulation of Ganglioside Expression. , 0, , .		1
4886	Ovarian/Primary Peritoneal Carcinoma. , 2012, , 167-203.		0
4887	Molecular Targets and Subtypes in Melanoma. , 2012, , 3-15.		0

#	Article	IF	Citations
4889	Apoptotic Pathways upon Arsenite Treatment. , 2012, , 149-187.		0
4890	The Role of ErbB Receptors in Endometrial Cancer. , 0, , .		5
4892	Molecular Targets of Benzyl Isothiocyanates in Pancreatic Cancer. , 0, , .		0
4893	Iris Nertschinskia Ethanol Extract Differentially Induces Cytotoxicity in Human Breast Cancer Cells Depending on AKT1/2 Activity. Asian Pacific Journal of Cancer Prevention, 2012, 13, 6511-6516.	0.5	4
4894	Chemotherapy and Novel Systemic Approaches in the Treatment of Metastatic Castration Resistant Prostate Cancer. , 2013, , 901-923.		0
4895	Molecular Pathology of Inflammatory Bowel Disease-Associated Neoplasia. Molecular Pathology Library, 2013, , 173-178.	0.1	0
4896	Molecular investigation of breast cancer. , 2013, , 286-304.		0
4897	AKT. , 2013, , 1-10.		0
4898	Prerequisite Genetic Traits for Metastasis. , 2013, , 403-444.		0
4899	Phospholipids | Phosphatidylinositol Bisphosphate and Trisphosphate. , 2013, , 552-556.		0
4900	Phosphatidylinositol Bisphosphate and Trisphosphate. , 2013, , 451-455.		0
4901	Tumor Resistance to Antibody-Mediated Immunotherapy and Reversal of Resistance: Rituximab as Prototype. Resistance To Targeted Anti-cancer Therapeutics, 2013, , 93-124.	0.1	0
4902	Cell Cycle Control and Growth Factor Systems in Metastasis. , 2013, , 57-78.		0
4903	Molecular Pathology of Melanocytic Skin Cancer. , 2014, , 59-74.		0
4904	New Perspectives in Chemoresistant Ovarian Cancer. , 2013, , 299-330.		0
4906	Inhibiting the Phosphoinositide 3-Kinase/AKT/Mammalian Target of Rapamycin Pathway. , 2013, , 81-114.		0
4909	Personalized prostate cancer therapy based on systems analysis of the apoptosis regulatory network. Asian Journal of Andrology, 2015, 17, 471.	0.8	3
4910	Molecular Testing in Prostate Cancer. , 2014, , 277-300.		0

#	Article	IF	Citations
4911	Intracellular Signaling. , 2014, , 22-39.e8.		1
4912	Note on Three Classes of Data Grid Operations. Journal of Computer and Communications, 2014, 02, 1-6.	0.6	1
4913	Pathogenic Mechanisms of Pulmonary Hypertension. , 2014, , 1-32.		0
4914	ErbB Receptors and ErbB Targeted Therapies in Endometrial Cancer. Journal of Cancer Therapy, 2014, 05, 483-492.	0.1	2
4915	Strategies in Patients with Other Molecular Alterations. , 2015, , 187-202.		0
4916	Genomic Applications in Pulmonary Malignancies. , 2015, , 383-413.		0
4917	Novel Targets for Future Medical Treatments. , 2015, , 145-162.		0
4918	Muscle Metabolism, Nutrition, and Functional Status in Older Adults. , 2015, , 113-124.		0
4920	Effect of BMI1 Knockdown on Cell Proliferation, Apoptosis, Invasiveness, and Migration of U251 Glioma Cells. Korean Journal of Physical Anthropology, 2015, 28, 69.	0.2	0
4921	Rapamycin. , 2015, , 1-4.		0
4922	Transforming Growth Factor-beta Superfamily in Meningiomas: Targets for Novel Therapy in eningiomas. International Journal of Neuropathology, 0, , .	0.0	0
4923	Response of Subcutaneous Xenografts of Endometrial Cancer in Nude Mice to Inhibitors of Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase (MAPK) Pathways: An Effective Therapeutic Strategy for Endometrial Cancer. Journal of Cancer Therapy, 2015, 06, 1083-1092.	0.1	1
4924	Pathogenic Mechanisms of Pulmonary Hypertension. , 2015, , 4079-4104.		0
4925	Critical Roles of the AKT Substrate Girdin in Disease Initiation and Progression. , 2015, , 233-250.		0
4926	Targeted Therapies for Gastric Cancer. Current Clinical Pathology, 2015, , 103-126.	0.0	0
4927	Molecular Mechanisms, Expression and Clinical Role of ErbB Receptors in Endometrial Cancer. International Journal of Clinical Therapeutics and Diagnosis, 0, , 28-32.	0.0	0
4928	KANSER TEDAVÄ°SÄ°NDE mTOR Ä°NHÄ°BÄ°TÃ–RLERÄ°. Marmara Pharmaceutical Journal, 2015, 19, 290.	0.5	1
4929	Decreased Activity in Neuropathic Pain Form and Gene Expression of Cyclin-Dependent Kinase5 and Glycogen Synthase Kinase-3 Beta in Soleus Muscle of Wistar Male Rats. Iranian Red Crescent Medical Journal, 2015, 17, e23324.	0.5	2

#	Article	IF	Citations
4932	Regulation of Cellular Signalling by Thioredoxin. , 2015, , 255-274.		0
4933	Anticarcinogenic Effect of S-allylcysteine (SAC). Journal of Life Science, 2015, 25, 1331-1337.	0.2	0
4934	Sinulariolide suppress human hepatocellular carcinoma cell migration and invasion by inhibiting matrix metalloproteinase-2/-9 through MAPKs and PI3K/Akt signaling pathways. Planta Medica, 2015, 81, .	0.7	1
4936	PTEN at 18: Still Growing. Methods in Molecular Biology, 2016, 1388, 13-19.	0.4	2
4937	Neoangiogenesis control in oncology: mechanisms and prospects of practical application. Regional Blood Circulation and Microcirculation, 2015, 14, 11-17.	0.1	0
4938	Application of molecular targeted therapy for refractory metastatic thyroid cancers. Integrative Cancer Science and Therapeutics, 2016, 3, 489-494.	0.1	0
4939	Combination Therapies Targeting the PI3K/AKT/mTOR Pathways. Cancer Drug Discovery and Development, 2016, , 151-180.	0.2	0
4940	Rapamycin. , 2016, , 3908-3911.		0
4941	Prostate Cancer Molecularly Targeted Therapies. , 2016, , 3766-3772.		0
4942	The mTOR signalling pathways in the pathogenesis and treatment of neuroendocrine tumours. OnCOReview, 2016, 6, 37-42.	0.1	0
4943	Simple Sequence Mutations. , 2017, , 217-230.		0
4944	PIK3CA. , 2017, , 3584-3586.		0
4945	Hypoxia-Inducible Factor (HIF)-1Î± and Its Regulation in Pancreatic Cancer. , 2017, , 371-378.		1
4946	Signal Transduction and Targeted Therapy for Gynecologic Cancer. Comprehensive Gynecology and Obstetrics, 2017, , 23-67.	0.0	0
4947	Molecular Pathogenesis of Prostate Cancer. , 2017, , 171-189.		0
4948	Molecular mechanisms of neoplasia. Annales Academiae Medicae Silesiensis, 2017, 71, 225-245.	0.1	0
4951	Wachstumsfaktoren unter besonderer BerÃ¼cksichtigung des muskuloskelettalen Systems. , 2018, , 171-228.		0
4952	Description of Hemoproteins and Elemental Homeostasis in Brain Tumors. Journal of Biosciences and Medicines, 2018, 06, 89-96.	0.1	0

#	Article	IF	Citations
4953	Annatto (Bixa orellana) Î´-TCT supplementation protected against embryonic DNA damages through alterations in PI3K/ Akt-Cyclin D1 pathway. International Journal for Vitamin and Nutrition Research, 2018, 88, 16-26.	0.6	0
4955	Fatty Acids of CLA-enriched Egg Yolks Can Induce Mitochondrial Pathway of Apoptosis in MCF-7 Breast Cancer Cells. Anticancer Research, 2018, 38, 2861-2870.	0.5	3
4958	Regulatory Pathway of Ion-Transporter Genes through Nrf2 Transcription Factor in Hypokalemic Condition. Anatomy & Biological Anthropology, 2019, 32, 141.	0.1	0
4959	Study of the association of phosphatase and tensin homolog and p27 expressions in endometrial hyperplasia and carcinoma. Journal of Microscopy and Ultrastructure, 2019, 7, 109.	0.1	1
4960	Future Perspectives in Colorectal Cancer Treatments. Hot Topics in Acute Care Surgery and Trauma, 2019, , 267-283.	0.1	0
4961	Skin Cancer Prevention. , 2019, , 405-472.		0
4962	Role of Heat Shock Protein 90 in Mammary Tumorigenesis. Heat Shock Proteins, 2019, , 103-124.	0.2	0
4965	Molecular Mechanisms of Insulin Resistance. Contemporary Endocrinology, 2020, , 55-66.	0.3	3
4966	Novel and Emerging Chemotherapeutic Agents in Head and Neck Cancer. , 2020, , 117-128.		0
4967	Analysis of circular RNAâ€˜associated competing endogenous RNA network in breast cancer. Oncology Letters, 2020, 19, 1619-1634.	0.8	3
4968	Long Non-coding RNAs and Cancer Cellsâ€™ Drug Resistance: An Unexpected Connection. RNA Technologies, 2020, , 167-198.	0.2	1
4969	Propofol induces apoptosis by activating caspases and the MAPK pathways, and inhibiting the Akt pathway in TM3 mouse Leydig stem/progenitor cells. International Journal of Molecular Medicine, 2020, 46, 439-448.	1.8	5
4971	The biology of Epidermal Growth Factor Receptor (EGFR) from regulating cell cycle to promoting carcinogenesis: the state of art including treatment options. Annals of Cytology and Pathology, 2020, 5, 048-053.	0.3	3
4972	Novel antibodyâ€“drug conjugates: current and future roles in gynecologic oncology. Current Opinion in Obstetrics and Gynecology, 2021, 33, 26-33.	0.9	1
4974	Targeting USP11 may alleviate radiation-induced pulmonary fibrosis by regulating endothelium tight junction. International Journal of Radiation Biology, 2022, 98, 30-40.	1.0	5
4975	RGD engineered dendrimer nanotherapeutic as an emerging targeted approach in cancer therapy. Journal of Controlled Release, 2021, 340, 221-242.	4.8	62
4976	TRPC6, a therapeutic target for pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L1161-L1182.	1.3	22
4977	The role of PI3'â€lipid signalling in melanoma initiation, progression and maintenance. Experimental Dermatology, 2022, 31, 43-56.	1.4	7

#	Article	IF	Citations
4978	4E-BP1^{Thr46} Phosphorylation Association with Poor Prognosis in Quantitative Phosphoproteomics of Portal Vein Tumor Thrombus Revealed that 4E-BP1Thr46 Phosphorylation is Associated with Poor Prognosis in HCC . Cancer Management and Research, 2020, Volume 12, 103-115.	0.9	5
4979	Role of Phytochemicals on Growth and Metastasis of GI Cancer. , 2020, , 35-50.		0
4980	Negative effects of tumor cell nitric oxide on anti-glioblastoma photodynamic therapy. Journal of Cancer Metastasis and Treatment, 2020, 2020, .	0.5	1
4981	Endoplasmic Reticulum Stress and Autophagy in Cancer. , 2020, , 355-402.		0
4982	Role of c-Met/HGF Axis in Altered Cancer Metabolism. , 2020, , 89-102.		1
4983	Purine and Pyrimidine-Linked Enzymes and Genes are Strongly Responsible for the Development of Tumors, Particularly Glioblastoma Multiforme. Computational Molecular Bioscience, 2020, 10, 73-80.	0.6	0
4984	The effect of Lactobacillus brevis on Apoptosis and casp (casp8, casp3) gene Expression in HeLa Cancer Cells. Iranian Journal of Medical Microbiology, 2020, 14, 84-100.	0.1	1
4985	Kaempferol sensitizes cell proliferation inhibition in oxaliplatin-resistant colon cancer cells. Archives of Pharmacal Research, 2021, 44, 1091-1108.	2.7	19
4986	PI3Kinase Inhibition in Hormone Receptor-Positive Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 11878.	1.8	1
4987	Echinacea purpurea suppresses the cell survival and metastasis of hepatocellular carcinoma through regulating the PI3K/Akt pathway. International Journal of Biochemistry and Cell Biology, 2022, 142, 106115.	1.2	7
4988	Ponatinib miRNA ifadelerini dÃ¼zenleyerek meme kanseri hÃ¼crelerini hedefler. UludaÄŸ Ãœniversitesi TÄ±p FakÃ¼ltesi Dergisi, 0, , .	0.2	0
4991	Cell Death and Transcription. , 2006, , 431-444.		0
4993	Neuroprotective Effects of Trophic Factors and Natural Products: Involvement of Multiple Intracellular Kinases. , 2008, , 291-296.		0
4994	Small-molecule Hsp90 Inhibitors: Applications in Cancer and Neurodegenerative diseases. , 2007, , 275-294.		0
4995	Non-Small Cell Lung Carcinoma: EGFR Gene Mutations and Response to Gefitinib. , 2008, , 291-306.		0
4996	Roles of Negative and Positive Growth Regulators in Nasopharyngeal Carcinoma. , 2009, , 273-294.		0
4997	Altered Signal Transduction in Melanoma. , 2006, , 119-147.		0
4998	Signaling Modules in Glial Tumors and Implications for Molecular Therapy. , 2006, , 389-417.		0

#	Article	IF	Citations
4999	Molecular Mechanisms of Insulin Resistance. , 2008, , 95-108.		0
5000	Chemo- and Radiosensitization Through Inhibition of PI3K/Akt Signaling. , 2007, , 313-334.		1
5001	How to Define Treatment Success or Failure if Tumors Do Not Shrink. , 2008, , 657-674.		0
5003	Innovative Rational-Derived, Target-Based and Cytotoxic Therapies for Breast Cancer and Other Malignancies. , 2006, , 741-780.		0
5005	Nanotechnology Assisted Chemotherapy for Targeted Cancer Treatment: Recent Advances and Clinical Perspectives. Current Topics in Medicinal Chemistry, 2020, 20, 2442-2458.	1.0	7
5008	Enhancing Akt imaging through targeted reporter expression. Molecular Imaging, 2008, 7, 168-74.	0.7	5
5009	An EGFR and AKT Signaling Pathway was Identified with Mediation Model in Osteosarcomas Clinical Study. Biomarker Insights, 2007, 2, 469-76.	1.0	4
5010	The role of glucose metabolism and glucose-associated signalling in cancer. Perspectives in Medicinal Chemistry, 2008, 1, 64-82.	4.6	32
5011	Transgenic mice expressing constitutively active Akt in oral epithelium validate KLFA as a potential biomarker of head and neck squamous cell carcinoma. In Vivo, 2009, 23, 653-60.	0.6	8
5012	TRAIL-induced caspase/p38 activation is responsible for the increased catalytic and invasive activities of Akt. International Journal of Oncology, 2011, 38, 249-56.	3.9	5
5014	Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia. Oncotarget, 2010, 1, 578-82.	0.8	19
5015	Proliferation of retinal pigment epithelial cells induced by (R,R)-XY-10 and (S,S)-XY-10 and their action mechanisms. International Journal of Ophthalmology, 2010, 3, 9-13.	0.5	0
5017	Effects of intravitreal insulin and insulin signaling cascade inhibitors on emmetropization in the chick. Molecular Vision, 2012, 18, 2608-22.	1.1	14
5018	Non-invasive imaging of PI3K/Akt/mTOR signalling in cancer. American Journal of Nuclear Medicine and Molecular Imaging, 2012, 2, 418-31.	1.0	16
5019	Role of reactive oxygen species (ROS) in CDDO-Me-mediated growth inhibition and apoptosis in colorectal cancer cells. Journal of Experimental Therapeutics and Oncology, 2011, 9, 119-27.	0.5	14
5020	Role of mTOR inhibition in preventing resistance and restoring sensitivity to hormone-targeted and HER2-targeted therapies in breast cancer. Clinical Advances in Hematology and Oncology, 2013, 11, 217-24.	0.3	18
5021	Elevated expression of SHIP2 correlates with poor prognosis in non-small cell lung cancer. International Journal of Clinical and Experimental Pathology, 2013, 6, 2185-91.	0.5	26
5023	Telencephalin protects PAJU cells from amyloid beta protein-induced apoptosis by activating the ezrin/radixin/moesin protein family/phosphatidylinositol-3-kinase/protein kinase B pathway. Neural Regeneration Research, 2012, 7, 2189-98.	1.6	2

#	Article	IF	Citations
5024	Overexpression of GRIM-19, a mitochondrial respiratory chain complex I protein, suppresses hepatocellular carcinoma growth. International Journal of Clinical and Experimental Pathology, 2014, 7, 7497-507.	0.5	11
5025	RNA interference targeting enhancer of polycomb1 exerts anti-tumor effects in lung cancer. International Journal of Clinical and Experimental Pathology, 2015, 8, 361-7.	0.5	2
5026	Apoptosis prediction via inhibition of AKT signaling pathway by neogrifolin. International Journal of Clinical and Experimental Pathology, 2015, 8, 1154-64.	0.5	4
5027	AGE/RAGE/Akt pathway contributes to prostate cancer cell proliferation by promoting Rb phosphorylation and degradation. American Journal of Cancer Research, 2015, 5, 1741-50.	1.4	34
5028	MicroRNA-126 is down-regulated in human esophageal squamous cell carcinoma and inhibits the proliferation and migration in EC109 cell via PI3K/AKT signaling pathway. International Journal of Clinical and Experimental Pathology, 2015, 8, 4745-54.	0.5	17
5029	Expression of phospho-mTOR kinase is abundant in colorectal cancer and associated with left-sided tumor localization. International Journal of Clinical and Experimental Pathology, 2015, 8, 7009-15.	0.5	7
5031	Targeting the VEGF and PDGF signaling pathway in glioblastoma treatment. International Journal of Clinical and Experimental Pathology, 2015, 8, 7825-37.	0.5	22
5032	The role of Akt activation in the response to chemotherapy in pancreatic cancer. Anticancer Research, 2010, 30, 3279-89.	0.5	31
5033	The silence of p66(Shc) in HCT8 cells inhibits the viability via PI3K/AKT/Mdm-2/p53 signaling pathway. International Journal of Clinical and Experimental Pathology, 2015, 8, 9097-104.	0.5	2
5034	ING5 inhibits epithelial-mesenchymal transition in breast cancer by suppressing PI3K/Akt pathway. International Journal of Clinical and Experimental Medicine, 2015, 8, 15498-505.	1.3	20
5035	SASH1 inhibits proliferation and invasion of thyroid cancer cells through PI3K/Akt signaling pathway. International Journal of Clinical and Experimental Pathology, 2015, 8, 12276-83.	0.5	19
5036	BTG2 inhibits the proliferation and metastasis of osteosarcoma cells by suppressing the PI3K/AKT pathway. International Journal of Clinical and Experimental Pathology, 2015, 8, 12410-8.	0.5	23
5037	Knockdown of PFTK1 inhibits tumor cell proliferation, invasion and epithelial-to-mesenchymal transition in pancreatic cancer. International Journal of Clinical and Experimental Pathology, 2015, 8, 14005-12.	0.5	10
5038	Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL. International Journal of Clinical and Experimental Pathology, 2015, 8, 14875-84.	0.5	18
5039	A three gene-based risk score predicts prognosis of resected non-small-cell lung cancer. International Journal of Clinical and Experimental Pathology, 2015, 8, 16081-8.	0.5	4
5040	LY294002 induces differentiation and inhibits invasion of glioblastoma cells by targeting GSK-3beta and MMP. EXCLI Journal, 2012, 11, 68-77.	0.5	5
5041	Rapamycin inhibits prostate cancer cell growth through cyclin D1 and enhances the cytotoxic efficacy of cisplatin. American Journal of Cancer Research, 2016, 6, 1772-84.	1.4	8
5042	MicroRNA-184-mediated inhibition of tumour growth in an orthotopic murine model of neuroblastoma. Anticancer Research, 2010, 30, 4391-5.	0.5	41

#	Article	IF	Citations
5043	Oral squamous cell cancer protein-protein interaction network interpretation in comparison to esophageal adenocarcinoma. Gastroenterology and Hepatology From Bed To Bench, 2017, 10, 118-124.	0.6	20
5044	Combination of sorafenib and Valproic acid synergistically induces cell apoptosis and inhibits hepatocellular carcinoma growth via down-regulating Notch3 and pAkt. American Journal of Cancer Research, 2017, 7, 2503-2514.	1.4	13
5045	Evaluation of involved proteins in colon adenocarcinoma: an interactome analysis. Gastroenterology and Hepatology From Bed To Bench, 2017, 10, S129-S138.	0.6	6
5046	Preprogramming therapeutic response of PI3K/mTOR dual inhibitor via the regulation of EHMT2 and p27 in pancreatic cancer. American Journal of Cancer Research, 2018, 8, 1812-1822.	1.4	12
5047	The fundamental role of miR-10b in metastatic cancer. American Journal of Cancer Research, 2018, 8, 1674-1688.	1.4	35
5048	Monepantel considerably enhances the therapeutic potentials of PEGylated liposomal doxorubicin and gemcitabine in ovarian cancer: in vitro and in vivo studies. American Journal of Cancer Research, 2018, 8, 2064-2075.	1.4	4
5050	Euscaphic acid inhibits proliferation and promotes apoptosis of nasopharyngeal carcinoma cells by silencing the PI3K/AKT/mTOR signaling pathway. American Journal of Translational Research (discontinued), 2019, 11, 2090-2098.	0.0	8
5051	PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer. Oncotarget, 2019, 10, 3667-3680.	0.8	4
5052	Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer. American Journal of Cancer Research, 2019, 9, 2103-2119.	1.4	34
5053	Perifosine and vitamin D combination induces apoptotic and non-apoptotic cell death in endometrial cancer cells. EXCLI Journal, 2020, 19, 532-546.	0.5	7
5056	Î²Klotho, a direct target of miR-206, contributes to the growth of hepatoblastoma through augmenting PI3K/Akt/mTOR signaling. American Journal of Cancer Research, 2021, 11, 1982-2004.	1.4	2
5057	A modular strategy for the synthesis of marine originated meroterpenoid-type natural products. Organic and Biomolecular Chemistry, 2021, 19, 9439-9447.	1.5	2
5058	Silybum marianum total extract, silymarin and silibinin abate hepatocarcinogenesis and hepatocellular carcinoma growth via modulation of the HGF/c-Met, Wnt/Î²-catenin, and PI3K/Akt/mTOR signaling pathways. Biomedicine and Pharmacotherapy, 2022, 145, 112409.	2.5	27
5059	Targeting PI3K/Akt/mTOR Pathway by Different Flavonoids: A Cancer Chemopreventive Approach. International Journal of Molecular Sciences, 2021, 22, 12455.	1.8	29
5060	Contribution of endoplasmic reticulum stress, MAPK and PI3K/Akt pathways to the apoptotic death induced by a penicillin derivative in melanoma cells. Apoptosis: an International Journal on Programmed Cell Death, 2022, 27, 34-48.	2.2	4
5061	Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer Medicine. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 1517-1535.	0.4	9
5062	Ellagic acid as a potent anticancer drug: A comprehensive review on in vitro, in vivo, in silico, and drug delivery studies. Biotechnology and Applied Biochemistry, 2022, 69, 2323-2356.	1.4	17
5063	The effects of UVB irradiance on aberrant epidermal proliferation: Novel insights on how to improve currently available sunscreens. Life Sciences, 2022, 288, 120181.	2.0	0

#	Article	IF	Citations
5064	Combinational Anti-tumor Effects of Chemicals from Paeonia lutea Leaf Extract in Oral Squamous Cell Carcinoma Cells. Anticancer Research, 2021, 41, 6077-6086.	0.5	3
5065	Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance. Cell Death Discovery, 2021, 7, 359.	2.0	28
5066	Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer. Cancers, 2021, 13, 5748.	1.7	11
5067	Autophagy-related signaling pathways in non-small cell lung cancer. Molecular and Cellular Biochemistry, 2021, , 1.	1.4	8
5068	Modulating undruggable targets to overcome cancer therapy resistance. Drug Resistance Updates, 2022, 60, 100788.	6.5	15
5069	Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders. Journal of Medicinal Chemistry, 2021, 64, 18054-18081.	2.9	27
5070	TC2N: A Novel Vital Oncogene or Tumor Suppressor Gene In Cancers. Frontiers in Immunology, 2021, 12, 764749.	2.2	6
5071	Breast Health. , 2022, , 347-403.		0
5072	Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition. Npj Precision Oncology, 2021, 5, 99.	2.3	2
5073	Research on Kinases and Peripheral Nerve Injury Repair. Bioprocess, 2021, 11, 99-108.	0.1	0
5074	Synthesis and bioevaluation of diaryl urea derivatives as potential antitumor agents for the treatment of human colorectal cancer. European Journal of Medicinal Chemistry, 2022, 229, 114055.	2.6	12
5075	Comparative Transcriptome Analysis of Spleen Reveals Potential Regulation of Genes and Immune Pathways Following Administration of Aeromonas salmonicida subsp. masoucida Vaccine in Atlantic Salmon (Salmo salar). Marine Biotechnology, 2022, 24, 97-115.	1.1	6
5076	Involvement of Mitochondrial Mechanisms and Cyclooxygenase-2 Activation in the Effect of Desethylamiodarone on 4T1 Triple-Negative Breast Cancer Line. International Journal of Molecular Sciences, 2022, 23, 1544.	1.8	2
5079	DNA-PK promotes activation of the survival kinase AKT in response to DNA damage through an mTORC2-ECT2 pathway. Science Signaling, 2022, 15, eabh2290.	1.6	16
5080	Lasting Complete Clinical Response of a Recurring Cutaneous Squamous Cell Carcinoma With MEK Mutation and PIK3CA Amplification Achieved by Dual Trametinib and Metformin Therapy. JCO Precision Oncology, 2022, 6, e2100344.	1.5	1
5081	The Potential for Natural Products to Overcome Cancer Drug Resistance by Modulation of Epithelial-Mesenchymal Transition. Nutrition and Cancer, 2022, , 1-27.	0.9	2
5083	Eph/Ephrin-Based Protein Complexes: The Importance of cis Interactions in Guiding Cellular Processes. Frontiers in Molecular Biosciences, 2021, 8, 809364.	1.6	6
5084	Antineoplastic effects of erufosine on small cell and non-small cell lung cancer cells through induction of apoptosis and cell cycle arrest. Molecular Biology Reports, 2022, 49, 2963.	1.0	3

#	Article	IF	Citations
5085	Comparative expression analysis of dasatinib and ponatinib-regulated lncRNAs in chronic myeloid leukemia and their network analysis. Medical Oncology, 2022, 39, 29.	1.2	1
5086	Natural Products Modulate Cell Apoptosis: A Promising Way for the Treatment of Ulcerative Colitis. Frontiers in Pharmacology, 2022, 13, 806148.	1.6	15
5087	Hinokiflavone Inhibits Growth of Esophageal Squamous Cancer By Inducing Apoptosis via Regulation of the PI3K/AKT/mTOR Signaling Pathway. Frontiers in Oncology, 2022, 12, 833719.	1.3	6
5088	Inhibition of the Akt/PKB Kinase Increases Nav1.6-Mediated Currents and Neuronal Excitability in CA1 Hippocampal Pyramidal Neurons. International Journal of Molecular Sciences, 2022, 23, 1700.	1.8	7
5089	Genetic and Molecular Determinants of Lymphatic Malformations: Potential Targets for Therapy. Journal of Developmental Biology, 2022, 10, 11.	0.9	7
5090	Lessons from microRNA biology: Top key cellular drivers of Autosomal Dominant Polycystic Kidney Disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2022, 1868, 166358.	1.8	1
5091	Comprehensive Analysis of a Novel Lipid Metabolism-Related Gene Signature for Predicting the Prognosis and Immune Landscape in Uterine Corpus Endometrial Carcinoma. Journal of Oncology, 2022, 2022, 1-22.	0.6	2
5092	Tomatoes: An Extensive Review of the Associated Health Impacts of Tomatoes and Factors That Can Affect Their Cultivation. Biology, 2022, 11, 239.	1.3	48
5093	Anticancer potential of allicin: A review. Pharmacological Research, 2022, 177, 106118.	3.1	34
5094	Molecular pathogenesis of Cutaneous T cell Lymphoma: Role of chemokines, cytokines, and dysregulated signaling pathways. Seminars in Cancer Biology, 2022, 86, 382-399.	4.3	21
5095	Silencing of HOXB9 suppresses cellular proliferation, angiogenesis, migration and invasion of prostate cancer cells. Journal of Biosciences, 2020, 45, .	0.5	3
5096	Targeting the Endocannabinoid System: From the Need for New Therapies to the Development of a Promising Strategy. What About Pancreatic Cancer?. In Vivo, 2022, 36, 543-555.	0.6	2
5097	Structure-Based Rational Design Enables Discovery of a New Selective and Potent Akt Degrader with Improved Dermatologic Safety. SSRN Electronic Journal, 0, , .	0.4	0
5098	Biology and pathophysiology of central nervous system metastases. , 2022, , 55-78.		0
5099	PTEN Deletion in Adult Mice Induces Hypoinsulinemia With Concomitant Low Glucose Levels. Frontiers in Endocrinology, 2022, 13, 850214.	1.5	2
5100	Establishment of a Novel Mouse Hepatocellular Carcinoma Model for Dynamic Monitoring of Tumor Development by Bioluminescence Imaging. Frontiers in Oncology, 2022, 12, 794101.	1.3	7
5102	Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance. Cancers, 2022, 14, 958.	1.7	13
5103	Post-transplant Lymphoproliferative Disorder Following Cardiac Transplantation. Frontiers in Cardiovascular Medicine, 2022, 9, 787975.	1.1	11

#	Article	IF	Citations
5104	PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?. Frontiers in Oncology, 2022, 12, 819128.	1.3	135
5105	GNG2 acts as a tumor suppressor in breast cancer through stimulating MRAS signaling. Cell Death and Disease, 2022, 13, 260.	2.7	4
5106	FTO m6A Demethylase in Obesity and Cancer: Implications and Underlying Molecular Mechanisms. International Journal of Molecular Sciences, 2022, 23, 3800.	1.8	54
5107	Fyn and TOM1L1 are recruited to clathrin-coated pits and regulate Akt signaling. Journal of Cell Biology, 2022, 221, .	2.3	17
5108	Identification of co-expression hub genes for ferroptosis in kidney renal clear cell carcinoma based on weighted gene co-expression network analysis and The Cancer Genome Atlas clinical data. Scientific Reports, 2022, 12, 4821.	1.6	4
5109	Covalent Allosteric Inhibitors of Akt Generated Using a Click Fragment Approach. ChemMedChem, 2022, 17, .	1.6	3
5110	Clinical Oncogenomics and Personalized Medicine in Colorectal Cancer for the Surgeon: What We Need to Know and What the Future Holds. SN Comprehensive Clinical Medicine, 2022, 4, 1.	0.3	0
5111	Indoxyl sulfate- and P-cresol-induced monocyte adhesion and migration is mediated by integrin-linked kinase-dependent podosome formation. Experimental and Molecular Medicine, 2022, 54, 226-238.	3.2	8
5112	Pyrimidine-5-carbonitrile based potential anticancer agents as apoptosis inducers through PI3K/AKT axis inhibition in leukaemia K562. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 895-911.	2.5	10
5113	Quinazoline Based HDAC Dual Inhibitors as Potential Anti-Cancer Agents. Molecules, 2022, 27, 2294.	1.7	17
5114	Risk Factors for Occurrence and Relapse of Soft Tissue Sarcoma. Cancers, 2022, 14, 1273.	1.7	9
5115	Effects of H2O2 Treatment Combined With PI3K Inhibitor and MEK Inhibitor in AGS Cells: Oxidative Stress Outcomes in a Model of Gastric Cancer. Frontiers in Oncology, 2022, 12, 860760.	1.3	3
5116	The Effects of Sesquiterpene Lactones on the Differentiation of Human or Animal Cells Cultured In-Vitro: A Critical Systematic Review. Frontiers in Pharmacology, 2022, 13, 862446.	1.6	3
5117	How myo-inositol improves the physiological functions of aquatic animals: A review. Aquaculture, 2022, 553, 738118.	1.7	9
5118	Replacement of dietary fish meal with Clostridium autoethanogenum protein on growth performance, digestion, mTOR pathways and muscle quality of abalone Haliotis discus hannai. Aquaculture, 2022, 553, 738070.	1.7	15
5119	Activation of mitochondrial-associated apoptosis signaling pathway and inhibition of PI3K/Akt/mTOR signaling pathway by voacamine suppress breast cancer progression. Phytomedicine, 2022, 99, 154015.	2.3	23
5120	A novel lncRNA lnc-PPRL promotes pterygium development by activating PI3K/PDK1 signaling pathway. Experimental Eye Research, 2022, 219, 109034.	1.2	0
5121	Harnessing Reversed Allosteric Communication: A Novel Strategy for Allosteric Drug Discovery. Journal of Medicinal Chemistry, 2021, 64, 17728-17743.	2.9	29

#	Article	IF	Citations
5122	Revealing the Mechanism of Astragali Radix against Cancer-Related Fatigue by Network Pharmacology and Molecular Docking. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-10.	0.5	6
5123	Hippo Pathway in Regulating Drug Resistance of Glioblastoma. International Journal of Molecular Sciences, 2021, 22, 13431.	1.8	15
5124	La vÃa canÃ³nica PI3K/AKT/mTOR y sus alteraciones en cÃ¡ncer. Horizonte MÃ©dico, 2021, 21, e1547.	0.1	1
5125	Combination Therapy with PIK3R3-siRNA and EGFR-TKI Erlotinib Synergistically Suppresses Glioblastoma Cell Growth In Vitro. Asian Pacific Journal of Cancer Prevention, 2021, 22, 3993-4000.	0.5	4
5126	mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment. Frontiers in Immunology, 2021, 12, 774103.	2.2	57
5127	Distinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitors. Nature Communications, 2022, 13, 2057.	5.8	12
5128	QSAR analysis on a large and diverse set of potent phosphoinositide 3-kinase gamma (PI3KÎ³) inhibitors using MLR and ANN methods. Scientific Reports, 2022, 12, 6090.	1.6	9
5129	Computational study reveals substituted benzimidazole derivativesâ€™ binding selectivity to PI3KÎ´ and PI3KÎ³. Journal of Molecular Modeling, 2022, 28, 123.	0.8	2
5130	Biology of human stomach cancer. , 0, , 386-408.		0
5184	Methods Used to Study Alterations of Cell Signaling and Proliferation. , 0, , 277-289.		0
5186	Molecular Mechanisms of Resistance to Therapies Targeting the Epidermal Growth Factor Receptor. Clinical Cancer Research, 2005, 11, 397-405.	3.2	168
5187	FOXO transcriptional activity is associated with response to chemoradiation in EAC. Journal of Translational Medicine, 2022, 20, 183.	1.8	1
5188	BCR-ABL negative myeloproliferative neoplasia: a review of involved molecular mechanisms. Histology and Histopathology, 2015, 30, 151-61.	0.5	3
5194	Gene expression changes in the pituitary gland of rats exposed to electromagnetic pulses. Biomedical and Environmental Sciences, 2011, 24, 560-8.	0.2	2
5197	Common and differential features of liver and pancreatic cancers: molecular mechanism approach.. Gastroenterology and Hepatology From Bed To Bench, 2021, 14, S87-S93.	0.6	0
5198	The Molecular Mechanisms Involved in Suppressing Triple Negative Breast Cancer Using Natural Agents. Advances in Medical Diagnosis, Treatment, and Care, 2022, , 45-71.	0.1	0
5199	PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives. Cancers, 2022, 14, 2161.	1.7	15
5200	Prognostic Significance of HER3 Expression in Patients with Cervical Cancer. Cancers, 2022, 14, 2139.	1.7	3

#	Article	IF	Citations
5201	Î±-Linolenic Acid Suppresses Proliferation and Invasion in Osteosarcoma Cells via Inhibiting Fatty Acid Synthase. Molecules, 2022, 27, 2741.	1.7	14
5202	Kinases on Double Duty: A Review of UniProtKB Annotated Bifunctionality within the Kinome. Biomolecules, 2022, 12, 685.	1.8	0
5203	miRâ€‘382â€‘3p downregulation contributes to the carcinogenesis of lung adenocarcinoma by promoting AKT SUMOylation and phosphorylation. Experimental and Therapeutic Medicine, 2022, 24, .	0.8	4
5204	ZAP70 Activation Compensates for Loss of Class IA PI3K Isoforms Through Activation of the JAKâ€“STAT3 Pathway. Cancer Diagnosis & Prognosis, 2022, 2, 391-404.	0.3	4
5205	Sufentanil ameliorates oxygenâ€‘glucose deprivation/reoxygenationâ€‘induced endothelial barrier dysfunction in HCMECs via the PI3K/Akt signaling pathway. Experimental and Therapeutic Medicine, 2022, 24, .	0.8	3
5206	The diagnostic importance of pathogenic variants and variant coexistence determined by NGS-based liquid biopsy approach in patients with lung adenocarcinoma. Molecular and Cellular Probes, 2022, 64, 101819.	0.9	1
5207	Bone formation and bone repair: The roles and crosstalk of osteoinductive signaling pathways. Process Biochemistry, 2022, 118, 252-262.	1.8	5
5208	Involvement of the Chemokine Receptor CXCR4 and Its Ligand Stromal Cell-Derived Factor 1Î± in Breast Cancer Cell Migration Through Human Brain Microvascular Endothelial Cells. Molecular Cancer Research, 2004, 2, 327-338.	1.5	230
5209	Pyruvate Kinase M1 Suppresses Development and Progression of Prostate Adenocarcinoma. Cancer Research, 2022, 82, 2403-2416.	0.4	10
5210	Src kinase: An attractive therapeutic target for prostate cancer. , 2022, , 479-503.		0
5211	Design and Optimization of Thienopyrimidine Derivatives as Potent and Selective PI3KÎ´ Inhibitors for the Treatment of B-Cell Malignancies. Journal of Medicinal Chemistry, 2022, 65, 8011-8028.	2.9	7
5212	Genomic Evolution and Personalized Therapy of an Infantile Fibrosarcoma Harboring anNTRKOncogenic Fusion. JCO Precision Oncology, 2022, , .	1.5	4
5213	Î±-Mangostin suppresses proliferation and invasion in osteosarcoma cells via inhibiting fatty acid synthase. Journal of Functional Foods, 2022, 94, 105107.	1.6	1
5214	Structure-based rational design enables efficient discovery of a new selective and potent AKT PROTAC degrader. European Journal of Medicinal Chemistry, 2022, 238, 114459.	2.6	9
5215	What protein kinases are crucial for acantholysis and blister formation in pemphigus vulgaris? A systematic review. Journal of Cellular Physiology, 0, , .	2.0	4
5216	Design, Synthesis, and Biological Examination of Nâ€²Phenylâ€6â€fluoroâ€4â€hydroxyâ€2â€quinoloneâ€3â€carboxamides as Anticancer Agents. ChemistrySelect, 2022, 7, .		4
5217	Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015â€“2021). European Journal of Medicinal Chemistry, 2022, 238, 114498.	2.6	16
5218	Molecular Docking and Simulation Studies of Flavanone and its Derived Compounds on PI3K-AKT Pathway Targeting against Cancer. Current Drug Discovery Technologies, 2023, 20, .	0.6	2

#	Article	IF	Citations
5229	Inhibition of AKT induces p53/SIRT6/PARP1-dependent parthanatos to suppress tumor growth. Cell Communication and Signaling, 2022, 20, .	2.7	8
5230	RNF43 G659fs is an oncogenic colorectal cancer mutation and sensitizes tumor cells to PI3K/mTOR inhibition. Nature Communications, 2022, 13, .	5.8	18
5231	Emerging roles for lncRNA-NEAT1 in colorectal cancer. Cancer Cell International, 2022, 22, .	1.8	21
5232	Aggressive nonfunctioning pituitary neuroendocrine tumors. Brain Tumor Pathology, 2022, 39, 183-199.	1.1	5
5233	Adverse events in lymphoma patients treated with phosphoinositide 3 kinase Inhibitor in clinical trials: a meta-analysis. Annals of Hematology, 2022, 101, 1741-1753.	0.8	1
5234	Inhibition of Platelet-Derived Growth Factor Receptor Signaling Restricts the Growth of Human Breast Cancer in the Bone of Nude Mice. Clinical Cancer Research, 2005, 11, 306-314.	3.2	69
5235	The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Molecular Cancer Therapeutics, 2004, 3, 299-307.	1.9	110
5236	ATP8B2-Mediated Asymmetric Distribution of Plasmalogens Regulates Plasmalogen Homeostasis and Plays a Role in Intracellular Signaling. Frontiers in Molecular Biosciences, 0, 9, .	1.6	11
5237	The <scp>PI3K</scp>/<scp>AKT</scp> signalling pathway in inflammation, cell death and glial scar formation after traumatic spinal cord injury: Mechanisms and therapeutic opportunities. Cell Proliferation, 2022, 55, .	2.4	53
5238	Involvement of the PI3K/AKT Intracellular Signaling Pathway in the AntiCancer Activity of Hydroxytyrosol, a Polyphenol from Olea europaea, in Hematological Cells and Implication of HSP60 Levels in Its Anti-Inflammatory Activity. International Journal of Molecular Sciences, 2022, 23, 7053.	1.8	8
5239	Collagen XI Alpha 1 Chain, a Novel Therapeutic Target for Cancer Treatment. Frontiers in Oncology, 0, 12, .	1.3	5
5240	PRMT5 activates AKT via methylation to promote tumor metastasis. Nature Communications, 2022, 13, .	5.8	25
5241	Discovery, Optimization, and Evaluation of Potent and Selective PI3KÎ´Î³ Dual Inhibitors for the Treatment of B-cell Malignancies. Journal of Medicinal Chemistry, 2022, 65, 9893-9917.	2.9	2
5242	Long Non-coding RNAs Sponging MicroRNAs With Efficacy in Preclinical In Vivo Models of Esophageal Squamous Cell Cancer. Anticancer Research, 2022, 42, 3233-3249.	0.5	1
5243	NKX3.1 Expression in Salivary Gland â€œIntraductalâ€•Papillary Mucinous Neoplasm: A Low-Grade Subtype of Salivary Gland Mucinous Adenocarcinoma. Head and Neck Pathology, 2022, 16, 1114-1123.	1.3	9
5244	Glioblastoma: Current Status, Emerging Targets, and Recent Advances. Journal of Medicinal Chemistry, 2022, 65, 8596-8685.	2.9	29
5245	p-S6 as a Prognostic Biomarker in Canine Oral Squamous Cell Carcinoma. Biomolecules, 2022, 12, 935.	1.8	3
5246	Antiâ€‘oncogenic and proâ€‘myogenic action of the MKK6/p38/AKT axis induced by targeting MEK/ERK in embryonal rhabdomyosarcoma. Oncology Reports, 2022, 48, .	1.2	1

#	Article	IF	Citations
5247	AKT inhibition sensitizes EVI1 expressing colon cancer cells to irinotecan therapy by regulating the Akt/mTOR axis. Cellular Oncology (Dordrecht), 0, , .	2.1	3
5248	Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Molecular Cancer Therapeutics, 2004, 3, 1605-1613.	1.9	91
5249	Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Molecular Cancer Therapeutics, 2005, 4, 271-279.	1.9	148
5250	Non-electric bioelectrical analog strategy by a biophysical-driven nano-micro spatial anisotropic scaffold for regulating stem cell niche and tissue regeneration in a neuronal therapy. Bioactive Materials, 2023, 20, 319-338.	8.6	12
5252	Muscle metabolism in older adults. Russian Journal of Geriatric Medicine, 2022, , 96-102.	0.3	3
5253	Identification of Molecular Targets and Potential Mechanisms of Yinchen Wuling San Against Head and Neck Squamous Cell Carcinoma by Network Pharmacology and Molecular Docking. Frontiers in Genetics, 0, 13, .	1.1	3
5254	Ultraviolet Radiation Exposure and its Impacts on Cutaneous Phosphorylation Signaling in Carcinogenesis: Focusing on Protein Tyrosine Phosphatases^{â€}. Photochemistry and Photobiology, 2023, 99, 344-355.	1.3	1
5255	Research progress on RNAâ^'binding proteins in breast cancer. Frontiers in Oncology, 0, 12, .	1.3	7
5256	Loss of PTEN Expression, PIK3CA Mutations, and Breast Cancer Survival in the Nurses' Health Studies. Cancer Epidemiology Biomarkers and Prevention, 0, , .	1.1	0
5257	Walnut Prevents Cognitive Impairment by Regulating the Synaptic and Mitochondrial Dysfunction via JNK Signaling and Apoptosis Pathway in High-Fat Diet-Induced C57BL/6 Mice. Molecules, 2022, 27, 5316.	1.7	3
5258	Arsenic compounds activate <scp>MAPK</scp> and inhibit Akt pathways to induce apoptosis in <scp>MA</scp>â€10 mouse Leydig tumor cells. Cancer Medicine, 2023, 12, 3260-3275.	1.3	2
5259	Targeting the mTOR Pathway for the Prevention of ER-Negative Breast Cancer. Cancer Prevention Research, 2022, 15, 791-802.	0.7	3
5260	The role of ferroptosis in esophageal cancer. Cancer Cell International, 2022, 22, .	1.8	8
5261	Neurotransmitters: Potential Targets in Glioblastoma. Cancers, 2022, 14, 3970.	1.7	8
5262	The nature inspired peptide [T20K]-kalata B1 induces anti-tumor effects in anaplastic large cell lymphoma. Biomedicine and Pharmacotherapy, 2022, 153, 113486.	2.5	0
5264	Molecular pathways in periampullary cancer: An overview. Cellular Signalling, 2022, 100, 110461.	1.7	2
5265	Understanding the Molecular Kinetics in NSCLC Through Computational Method. , 2022, , 129-163.		0
5266	Role of Tumor-associated neutrophils in the breast tumor microenvironment. , 2022, , 171-194.		0

#	Article	IF	Citations
5267	Research Progress of VEGF, Adipokine and the Pathogenesis of Colorectal Cancer. World Journal of Cancer Research, 2022, 12, 161-166.	0.1	0
5268	The Role of TRAF7 in Tumorigenesis. World Journal of Cancer Research, 2022, 12, 188-198.	0.1	0
5269	EventPointer 3.0: flexible and accurate splicing analysis that includes studying the differential usage of protein-domains. NAR Genomics and Bioinformatics, 2022, 4, .	1.5	2
5270	Molecular Testing for Thyroid Nodules: The Experience at McGill University Teaching Hospitals in Canada. Cancers, 2022, 14, 4140.	1.7	14
5271	Potential of Kalanchoe pinnata as a Cancer Treatment Adjuvant and an Epigenetic Regulator. Molecules, 2022, 27, 6425.	1.7	7
5272	Exploring the recent trends in perturbing the cellular signaling pathways in cancer by natural products. Frontiers in Pharmacology, 0, 13, .	1.6	13
5273	Detection of breast cancer-related point-mutations using screen-printed and gold-plated electrochemical sensor arrays suitable for point-of-care applications. Talanta Open, 2022, 6, 100150.	1.7	7
5274	RAB3D, upregulated by aryl hydrocarbon receptor (AhR), promotes the progression of prostate cancer by activating the PI3K/AKT signaling pathway. Cell Biology International, 2022, 46, 2246-2256.	1.4	3
5275	PIK3CA Mutation is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer Patients. Cancer Research and Treatment, 2023, 55, 531-541.	1.3	5
5277	Tyk2 is a tumor suppressor in colorectal cancer. OncoImmunology, 2022, 11, .	2.1	1
5279	PTEN loss promotes Warburg effect and prostate cancer cell growth by inducing FBP1 degradation. Frontiers in Oncology, 0, 12, .	1.3	7
5280	Developing PI3K Inhibitors for Respiratory Diseases. Current Topics in Microbiology and Immunology, 2022, , 437-466.	0.7	0
5281	PI3K Isoforms in Cell Signalling and Innate Immune Cell Responses. Current Topics in Microbiology and Immunology, 2022, , 147-164.	0.7	2
5283	Signaling pathways and therapeutic interventions in gastric cancer. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	54
5284	Modulation of signaling cross-talk between pJNK and pAKT generates optimal apoptotic response. PLoS Computational Biology, 2022, 18, e1010626.	1.5	1
5285	Investigation of cytotoxic and apoptotic effects of disodium pentaborate decahydrate on ovarian cancer cells and assessment of gene profiling. , 2023, 40, .		3
5288	Short-chain L-3-hydroxyacyl-CoA dehydrogenase: A novel vital oncogene or tumor suppressor gene in cancers. Frontiers in Pharmacology, 0, 13, .	1.6	5
5289	PIK3CA-mutations in breast cancer. Breast Cancer Research and Treatment, 2022, 196, 483-493.	1.1	23

#	Article	IF	Citations
5290	KRAS, NRAS, BRAF, PIK3CA, and AKT1 signatures in colorectal cancer patients in south-eastern Romania. Medicine (United States), 2022, 101, e30979.	0.4	2
5291	Genetic variants in <scp>LKB1</scp>/<scp>AMPK</scp>/<scp>mTOR</scp> pathway are associated with clinical outcomes of chemotherapy in nonâ€small cell lung cancer. Thoracic Cancer, 2022, 13, 3322-3330.	0.8	3
5292	Decrotonylation of AKT1 promotes AKT1 phosphorylation and activation during myogenic differentiation. Journal of Advanced Research, 2023, 50, 117-133.	4.4	3
5293	Based on 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474), design, synthesis and biological evaluation of novel PI3Kl± selective inhibitors. Bioorganic Chemistry, 2023, 130, 106211.	2.0	6
5294	Gundelia tournefortii inhibits hepatocellular carcinoma progression by lowering gene expression of the cell cycle and hepatocyte proliferation in immunodeficient mice. Biomedicine and Pharmacotherapy, 2022, 156, 113885.	2.5	2
5295	Kaempferol tetrasaccharides restore skin atrophy via PDK1 inhibition in human skin cells and tissues: Bench and clinical studies. Biomedicine and Pharmacotherapy, 2022, 156, 113864.	2.5	4
5296	Targeting feedback activation of signaling transduction pathways to overcome drug resistance in cancer. Drug Resistance Updates, 2022, 65, 100884.	6.5	11
5297	Silencing of KNTC1 inhibits hepatocellular carcinoma cells progression via suppressing PI3K/Akt pathway. Cellular Signalling, 2023, 101, 110498.	1.7	7
5298	Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and Immunotherapy. Cancers, 2022, 14, 5520.	1.7	10
5299	PI3K signalling at the intersection of cardio-oncology networks: cardiac safety in the era of AI. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	0
5300	BCL-2 protein family: attractive targets for cancer therapy. Apoptosis: an International Journal on Programmed Cell Death, 2023, 28, 20-38.	2.2	64
5301	Potential role of the bitter taste receptor T2R14 in the prolonged survival and enhanced chemoresponsiveness induced by apigenin. International Journal of Oncology, 2022, 62, .	1.4	1
5302	Roles of N6-methyladenosine (m6A) modifications in gynecologic cancers: mechanisms and therapeutic targeting. Experimental Hematology and Oncology, 2022, 11, .	2.0	5
5305	Effect of Diammonium Glycyrrhizinate in Improving Focal Cerebral Ischemia-Reperfusion Injury in Rats Through Multiple Mechanisms. Dose-Response, 2022, 20, 155932582211427.	0.7	2
5306	Delivery of Active AKT1 to Human Cells. Cells, 2022, 11, 3834.	1.8	4
5307	GPR137 Inhibits Cell Proliferation and Promotes Neuronal Differentiation in the Neuro2a Cells. Neurochemical Research, 2023, 48, 996-1008.	1.6	1
5308	The importance of habitat in the tumor-associated Pten, Mtor, and Akt gene expressions and chromosomal aberrations for wild rats. , 0, , .		0
5309	NSCLC Cells Resistance to PI3K/mTOR Inhibitors Is Mediated by Delta-6 Fatty Acid Desaturase (FADS2). Cells, 2022, 11, 3719.	1.8	0

#	Article	IF	Citations
5310	Targeted Therapies in the Treatment of Uterine Serous Carcinoma. Current Treatment Options in Oncology, 2022, 23, 1804-1817.	1.3	3
5311	Genome-wide association analysis identifies a susceptibility locus for sporadic vestibular schwannoma at 9p21. Brain, 0, , .	3.7	1
5312	The multifaced role and therapeutic regulation of autophagy in ovarian cancer. Clinical and Translational Oncology, 2023, 25, 1207-1217.	1.2	1
5313	<i>PIK3CA</i>-mutated breast cancer: from research to clinical practice. Meditsinskiy Sovet, 2022, , 148-153.	0.1	0
5314	Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3KÎ±. Journal of Medicinal Chemistry, 2022, 65, 16589-16621.	2.9	23
5316	MiR-363 suppresses the tumor growth of natural killer/T-cell lymphoma via the SIRT6/PI3K/AKT axis. Annals of Translational Medicine, 2022, 10, 1276-1276.	0.7	1
5317	Dapagliflozin improves pancreatic islet function by attenuating microvascular endothelial dysfunction in type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2023, 39, .	1.7	1
5318	Recent Advances in Understanding the Roles of RNA Binding Proteins in Breast Cancer Pathogenesis. Advances in Clinical Medicine, 2022, 12, 11780-11786.	0.0	0
5319	Agent in Urgent Need of Clinical Practice: Corilagin. Mini-Reviews in Medicinal Chemistry, 2023, 23, 1642-1652.	1.1	3
5320	Molecular mechanisms on how FABP5 inhibitors promote apoptosisâ€induction sensitivity of prostate cancer cells. Cell Biology International, 2023, 47, 929-942.	1.4	3
5321	Laminin-332 Î²2 Monomeric Chain Promotes Adhesion and Migration of Hepatocellular Carcinoma Cells. Cancers, 2023, 15, 373.	1.7	2
5322	Development and validation of a GRGPI model for predicting the prognostic and treatment outcomes in head and neck squamous cell carcinoma. Frontiers in Oncology, 0, 12, .	1.3	1
5323	Absence of Scaffold Protein Tks4 Disrupts Several Signaling Pathways in Colon Cancer Cells. International Journal of Molecular Sciences, 2023, 24, 1310.	1.8	0
5324	MicroRNAs induced by Listeria monocytogenes and their role in cells. Microbial Pathogenesis, 2023, 175, 105997.	1.3	4
5325	Upregulation of LRRC8A by m⁵C modification-mediated mRNA stability suppresses apoptosis and facilitates tumorigenesis in cervical cancer. International Journal of Biological Sciences, 2023, 19, 691-704.	2.6	10
5326	Machine learning-based models for genomic predicting neoadjuvant chemotherapeutic sensitivity in cervical cancer. Biomedicine and Pharmacotherapy, 2023, 159, 114256.	2.5	3
5327	Synergistic therapeutic potential of alpelisib in cancers (excluding breast cancer): Preclinical and clinical evidences. Biomedicine and Pharmacotherapy, 2023, 159, 114183.	2.5	5
5328	circTAB2 inhibits lung cancer proliferation, migration and invasion by sponging miR-3142 to upregulate GLIS2. Apoptosis: an International Journal on Programmed Cell Death, 2023, 28, 471-484.	2.2	4

#	Article	IF	Citations
5329	Occult colon cancer with liver abscess and pancreatitis as the first manifestations: A case report. Medicine (United States), 2023, 102, e32654.	0.4	0
5330	Dietary Î²-Hydroxy-Î²-Methylbutyrate Supplementation Affects Growth Performance, Digestion, TOR Pathway, and Muscle Quality in Kuruma Shrimp (Marsupenaeus japonicas) Fed a Low Protein Diet. Aquaculture Nutrition, 2023, 2023, 1-17.	1.1	4
5331	Regulatory Mechanism on Anti-Glycolytic and Anti-Metastatic Activities Induced by Strobilanthes crispus in Breast Cancer, In Vitro. Pharmaceuticals, 2023, 16, 153.	1.7	2
5332	Synergistic effect of sorafenib with Platycladus orientalis (L) leaf extract on cervical cancer. Bioscience Journal, 0, 39, e39011.	0.4	0
5333	The Effect of Dietary n-3 Polyunsaturated Fatty Acids on Non-obese and Obesity-Associated Breast Cancer. , 2023, , .		0
5334	A spotlight on the interplay of signaling pathways and the role of miRNAs in osteosarcoma pathogenesis and therapeutic resistance. Pathology Research and Practice, 2023, 245, 154442.	1.0	2
5335	Familial CCM Genes Might Not Be Main Drivers for Pathogenesis of Sporadic CCMs-Genetic Similarity between Cancers and Vascular Malformations. Journal of Personalized Medicine, 2023, 13, 673.	1.1	3
5337	Design, synthesis and in vitro biological evaluation of 2-aminopyridine derivatives as novel PI3KÎ´ inhibitors for hematological cancer. Bioorganic and Medicinal Chemistry Letters, 2023, 82, 129152.	1.0	3
5338	Changes in HER3 expression profiles between primary and recurrent gynecological cancers. Cancer Cell International, 2023, 23, .	1.8	0
5339	Programmed death ligand 1 regulates epithelialâ€“mesenchymal transition and cancer stem cell phenotypes in hepatocellular carcinoma through the serum and glucocorticoid kinase 2/Î²â€catenin signaling pathway. Cancer Science, 2023, 114, 2265-2276.	1.7	2
5340	An in vitro carcinogenesis model for cervical cancer harboring episomal form of HPV16. PLoS ONE, 2023, 18, e0281069.	1.1	1
5341	Carcinoid Syndrome: Preclinical Models and Future Therapeutic Strategies. International Journal of Molecular Sciences, 2023, 24, 3610.	1.8	2
5342	Current Trends In Development Of Egfr Inhibitors As A Promising Anticancer Agents: Sar And Synthetic Studies From (2010-2020). Current Organic Chemistry, 2023, 27, .	0.9	0
5343	Transcriptomic Responses to Polymyxin B and Analogues in Human Kidney Tubular Cells. Antibiotics, 2023, 12, 415.	1.5	0
5344	PARP inhibitors in the treatment of ARID1A mutant ovarian clear cell cancer: PI3K/Akt1-dependent mechanism of synthetic lethality. Frontiers in Oncology, 0, 13, .	1.3	0
5345	The Relationship between PIK3CA Mutation and Hormone Receptor Positive and HER2 Negative Breast Cancer. Advances in Clinical Medicine, 2023, 13, 2724-2728.	0.0	0
5346	Chalcone-3 Inhibits the Proliferation of Human Breast Cancer MDA-MB-231 Cell Line. Asian Pacific Journal of Cancer Prevention, 2023, 24, 683-691.	0.5	2
5347	3-kinase Inhibitors for Treating Cancer and Other Diseases. Recent Patents on Anti-Cancer Drug Discovery, 2024, 19, 253-255.	0.8	0

#	Article	IF	Citations
5348	The role of isoflavones in augmenting the effects of radiotherapy. Frontiers in Oncology, 0, 12, .	1.3	2
5349	Cancer Biology. , 2023, , 1-30.		0
5350	Fenugreek (Trigonella foenum-graecum L.) modulates energy metabolism and anti-inflammatory response in obesity via combinatorial analysis. Natural Products Journal, 2023, 13, .	0.1	0
5351	Systemic treatment for unresectable hepatocellular carcinoma. World Journal of Gastroenterology, 0, 29, 1407-1424.	1.4	0
5352	Systemic treatment for unresectable hepatocellular carcinoma. World Journal of Gastroenterology, 0, 29, 1551-1568.	1.4	5
5353	Cross-cancer pleiotropic analysis identifies three novel genetic risk loci for colorectal cancer. Human Molecular Genetics, 2023, 32, 2093-2102.	1.4	3
5354	Total Flavonoids of Polygala fallax Hemsl Induce Apoptosis of Human Ectopic Endometrial Stromal Cells through PI3K/AKT/Bcl-2 Signaling Pathway. Gynecologic and Obstetric Investigation, 2023, 88, 197-213.	0.7	1
5356	Design, Synthesis, and Biological Evaluation of Sulfonamide Methoxypyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors. Pharmaceuticals, 2023, 16, 461.	1.7	1
5357	Short-term fasting and fasting mimicking diets combined with chemotherapy: a narrative review. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592311614.	1.4	4
5358	Characteristics of Metastatic and Nonmetastatic Pulmonary Sclerosing Pneumocytomas: A Clinicopathological Study of 68 Cases and 15 Reported Metastatic Cases. Laboratory Investigation, 2023, 103, 100135.	1.7	0
5359	Molecular Pathology of Lung Cancer. , 0, , .		0
5360	Anti-EGFR conjugated nanoparticles to deliver Alpelisib as targeted therapy for head and neck cancer. Cancer Nanotechnology, 2023, 14, .	1.9	0
5361	Comparison of different noble metal-based screen-printed sensors for detection of PIK3CA point-mutations as biomarker for circulating tumor DNA. Electrochimica Acta, 2023, 455, 142336.	2.6	3
5362	The targeted next-generation sequence revealed SMAD4, AKT1, and TP53 mutations from circulating cell-free DNA of breast cancer and its effect on protein structure â€“ A computational approach. Journal of Biomolecular Structure and Dynamics, 2023, 41, 15584-15597.	2.0	0
5363	Recent advances in targeted therapy for pancreatic adenocarcinoma. World Journal of Gastrointestinal Oncology, 0, 15, 571-595.	0.8	10
5364	Netrin-1 inducing antiapoptotic effect of acute myeloid leukemia cells in a concentration-dependent manner through the Unc-5 netrin receptor B-focal adhesion kinase axis. Cancer Biology and Therapy, 2023, 24, .	1.5	1
5365	Role of microRNAs in glycolysis in gynecological tumors (Review). International Journal of Oncology, 2023, 62, .	1.4	1
5367	Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. Npj Precision Oncology, 2023, 7, .	2.3	1

#	Article	IF	Citations
5368	The invariant chain <scp>CD74</scp> protein is a cell surface binding partner of <scp>TIMP</scp> â€1 in breast cancer cells. Molecular Oncology, 0, , .	2.1	1
5369	Cell Signaling Pathways in Cancer. , 2023, , 242-272.		0
5392	Receptor tyrosine kinases (RTKs). , 2023, , 117-185.		1
5397	The Mediator Complex Subunit 12 (MED-12) Gene and Uterine Fibroids: a Systematic Review. Reproductive Sciences, 0, , .	1.1	0
5418	Distal Onco-sphere: Organotrophic Metastasis. , 2023, , 351-369.		0
5423	Targeting immune checkpoints for cancer therapy. , 2023, , 95-134.		0
5431	Androgen Receptor Signaling: A Central and Evolving Theme in Prostate Cancer Treatment. , 2023, , 1-29.		0
5432	In the Pipeline: Emerging Therapy for MDS and MDS/MPN. , 2023, , 477-500.		0
5433	Dysregulation of cholesterol metabolism in cancer progression. Oncogene, 2023, 42, 3289-3302.	2.6	2
5463	Modes and mechanisms of action of potent cytotoxic plant-derived products from the flora of Africa. Advances in Botanical Research, 2024, , .	0.5	0
5470	Molecular Testing for Thyroid Nodules: The Experience at McGill University Teaching Hospitals in Canada. , 2023, , 675-683.		0